<SEC-DOCUMENT>0001213900-13-006378.txt : 20131114
<SEC-HEADER>0001213900-13-006378.hdr.sgml : 20131114
<ACCEPTANCE-DATETIME>20131114103519
ACCESSION NUMBER:		0001213900-13-006378
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131114
DATE AS OF CHANGE:		20131114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52446
		FILM NUMBER:		131217453

	BUSINESS ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		501 FIFTH AVENUE, 3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0913_actinium.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
    <title>f10q0913_actinium.htm</title>
    <!--Licensed to: Edgar Agents LLC-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="TEXT-INDENT: 0pt; DISPLAY: inline; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 7%; FONT-SIZE: 10pt; MARGIN-RIGHT: 7%">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="filing_1"><!--EFPlaceholder--></a><a name="doc_1_1"><!--EFPlaceholder--></a>UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Mark One)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">x&#160;</font> Quarterly Report PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarterly period ended<font style="DISPLAY: inline; FONT-WEIGHT: bold"> September 30, 2013</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">o&#160;</font> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the transition period from _______________________ &#160;to &#160;___________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number: &#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">000-52446</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">88-0378336</font></div>
</td>
</tr><tr>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Incorporation or Organization)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">501 Fifth Avenue, 3rd Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">New York, NY</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="28%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10017</font></div>
</td>
</tr><tr>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(646) 459-4201</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">x</font>&#160; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No<font style="DISPLAY: inline;" face="Wingdings"> o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">x</font>&#160; &#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No<font style="DISPLAY: inline;" face="Wingdings"> o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. &#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="58%">
<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> o</font></font></div>
</td>
<td align="left" valign="middle" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> o</font></font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="58%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="58%">
<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings"> o&#160;&#160;</font>(Do not check if a smaller reporting company)</font></div>
</td>
<td align="left" valign="middle" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).<font style="DISPLAY: inline;" face="Wingdings"> o</font> &#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">x</font> &#160;&#160;No</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">PROCEEDINGS DURING THE PRECEDING FIVE YEARS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.<font style="DISPLAY: inline;" face="Wingdings">&#160;o</font> &#160;&#160;Yes&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font> &#160;&#160;No</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">APPLICABLE ONLY TO CORPORATE ISSUERS:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of<font style="DISPLAY: inline; FONT-WEIGHT: bold"> November 12, 2013; 23,656,582</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: white" align="left" noshade size="2" width="100%">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-Q</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For period ended September 30, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INDEX</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<a name="part_1_2_1"><!--EFPlaceholder--></a><a name="item_1_3_1"><!--EFPlaceholder--></a></font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I-- FINANCIAL INFORMATION</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Statements (Unaudited)</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Quantitative and Qualitative Disclosures About Market Risk</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Controls and Procedures</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="2" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II-- OTHER INFORMATION</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal Proceedings</font></div>
</td>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 1A.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk Factors</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 2.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 3.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Defaults Upon Senior Securities</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mine Safety Disclosures</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 5.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other Information</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 6.</font></div>
</td>
<td align="left" valign="top" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibits</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" colspan="2" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>
</td>
<td valign="top" width="5%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I - FINANCIAL INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_2"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1. &#160;FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying financial statements have been prepared by the Company and are unaudited. &#160;In the opinion of management, all adjustments (which include&#160;all normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2013 and 2012 and for the periods then ended have been made. &#160;Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. &#160;It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s audited financial statements for the year ended December 31, 2012. &#160;The results of operations for the period ended September 30, 2013 are not necessarily indicative of the operating results for the full year.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company) </font></font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Balance Sheets</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Unaudited)</font></div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30, 2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31, 2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Assets</font></font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,990,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">167,143</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,043,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,785,812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net of accumulated depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,918</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4,049,981</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,788,822</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Liabilities and Stockholders' Equity</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,001</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">897,044</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses - related party</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">375,686</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,185</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Note payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">140,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,643,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,445,653</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,643,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments and contingencies</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders' Equity:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; 10,000,000 authorized</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0 shares issued and outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value; 100,000,000 shares authorized;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,656,582 and 21,391,665 shares issued and outstanding, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">236,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,916</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,005,177</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">56,675,182</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit accumulated during the development stage</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(60,637,414</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(55,743,463</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Stockholders' Equity</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">604,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,145,635</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities and Stockholders' Equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4,049,981</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5,788,822</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr></table>
</div>

<div align="left">&#160;</div>

<div style="TEXT-ALIGN: center">See accompanying notes to consolidated financial statements.</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Unaudited)</font></div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from June 13, 2000</font></font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended </font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended </font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></font></div>
</div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">778,232</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,677,301</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,373,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,723,459</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,793,719</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">830,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">722,037</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,730,233</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,520,221</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,235,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,608,962</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,399,450</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,107,555</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,244,109</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,845,697</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss from operations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,608,962</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,399,450</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,107,555</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,244,109</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(59,845,697</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,299</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(318,623</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,508</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(952,241</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,967,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">260,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value - derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">189,348</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(294,381</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">216,112</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(287,604</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">915,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total other income&#160;(expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">188,049</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(613,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">213,604</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,239,845</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(791,717</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1,420,913</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3,012,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(4,893,951</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(5,483,954</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(60,637,414</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net loss per common share&#160;&#160;- basic and diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.06</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3.76</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6.84</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted average number of common shares outstanding </font>- basic and diluted</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,601,895</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,401,711</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">801,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">See accompanying notes to consolidated financial statements.</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>
</div>

<div style="TEXT-ALIGN: center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidated Statements of Cash Flows</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(Unaudited)</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>
</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Period</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Nine</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">from June 13, 2000</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Months Ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Inception) to</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="62%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Operating Activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,893,951</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,483,954</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(60,637,414</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash provided by (used in) </font>operating activities:</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">284,371</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">312,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,336,407</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,262,462</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">554,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of debt discount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">678,116</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">900,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amortization of deferred financing costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">219,725</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">292,692</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gain on extinguishment of liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(260,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value&#160;derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,604</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(915,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 7pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in operating assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 7pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Increase) decrease in:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">114,143</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,386</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Increase (decrease) in:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(585,043</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">173,614</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">653,730</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 16pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 16pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued liabilities - related party</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">344,501</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">375,686</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash&#160;Used In Operating Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,947,969</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,795,480</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(49,350,627</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Investing Activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payment made for patent rights</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(823,689</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used In Investing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,823,689</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows From Financing Activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Borrowings on convertible debt, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">645,888</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160; Payments on note payable</font></font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(140,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(140,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sales of common stock, net of offering costs</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,191,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from the exercise of warrants for cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,467,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,467,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided By Financing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,327,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">57,164,379</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net change&#160;&#160;in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,628,606</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,137,129</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,990,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash at beginning of period</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,618,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,703,798</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash at end of period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3,990,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2,566,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3,990,063</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="62%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Supplemental disclosures of cash flow information:</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for interest</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">561</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,243</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" colspan="4" valign="bottom" width="73%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Supplemental disclosure of non-cash investing and financing activities:</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="11%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beneficial conversion feature discount</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">372,850</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with debt</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">377,150</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued with stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,087</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,985,238</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair value of warrants issued to the placement agent</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,044</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,170,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of notes payable and accrued interest to stock</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">981,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="62%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transfer from derivative liability classification to equity classification</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">600,880</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,832,204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center">See accompanying notes to consolidated&#160;financial statements.</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Formerly Cactus Ventures, Inc.)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A Development Stage Company)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes to Consolidated Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Basis of Presentation - Unaudited Interim Financial Information &#8211; </font>The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Impairment of Long-Lived Assets &#8211; </font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font><br>
&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 1</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 2</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Level 3</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative liabilities:</font></div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;At December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&#160;&#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,441,942 shares of the Company&#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 2 &#8211; Going Concern</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The ability of the Company to continue its operations is dependent on the successful execution of management's plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 3 &#8211; Property and Equipment</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Lives</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;5 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">162,384</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,162</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Furniture and fixture</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;7 years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,292</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">165,484</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">157,454</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font></div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(154,444 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(154,444 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss on disposition of equipment</font></div>
</td>
<td align="left" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="67%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,918</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Depreciation expense for the nine months ended September 30, 2013 and 2012 were $0 and&#160;$429 respectively.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 4 &#8211; Note Payable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&#160;is required&#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 5 &#8211; Derivatives</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fair Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,146,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,574,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reclassification to paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,130,536 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(600,880 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in fair value</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,015,802</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,757,966</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market value of common stock on measurement date (1)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.17</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjusted exercise price</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.48 - $0.81</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.50 - $2.475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk free interest rate (2)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.10% - 0.77</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.33</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrant lives in years</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4 months/5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0 days/4.22 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility (3)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125% - 161</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">139</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield (4)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Probability of stock offering in any period over 5 years (5)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25% - 40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The market value of common stock is based on an enterprise valuation.</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div>
</td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="96%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td valign="top" width="96%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 6 &#8211; Commitments and Contingencies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Contracts</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 16, 2013, the Company&#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&#160;and Director. Material terms of the Employment Agreement are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">a</font></div>
</td>
<td align="left" colspan="3" valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A base salary at an annual rate of $350,000, which will be re-evaluated upon the&#160;six month anniversary of the start date and reimbursement of certain expenses.</font></div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">b</font></div>
</td>
<td colspan="3" valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&#160;&#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary</font>.</font></div>
</div>
</td>
</tr><tr>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="68%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">c</font></div>
</td>
<td colspan="3" valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">An option to purchase common shares of the Company and restricted stock (the &#8220;Grant&#8221;).&#160;&#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&#160;&#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&#160;&#160;As of October 25, 2013, the option has not been granted by the Board.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">License and Research Agreements</font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a.&#160;&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4) Biological License Application filing with U.S. FDA</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5) First commercial sale</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6) after the first $10,000,000 in net sales</font></div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Milestones</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Payments</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval </font>for each licensed product</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2) upon the receipt of regulatory approval from the U.S. FDA for each </font>licensed product</font></div>
</div>
</td>
<td align="right" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,750,000</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;The Company is currently negotiating the 2013 agreement.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million.&#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;e.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">f.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&#160;&#160;The amount due of $79,623 was paid on July 10, 2012.</font></div>
</td>
</tr></table>
</div>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">g.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $19,749.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable.&#160;&#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">h.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">i.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase I/II clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.</font></div>
</td>
</tr><tr>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="93%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="right" valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">j.&#160;&#160; </font></div>
</td>
<td valign="top" width="93%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase I/II clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div>
</td>
</tr></table>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On&#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">.</font></div>
</div>

<div>
<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 7 &#8211; Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of the 2013 Stock Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Board approved the Company&#8217;s 2013 Stock Plan.&#160;&#160;The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Approval of the Equity Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Board approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of&#160;option activities:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="3" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,330,134</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.91</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">685,800</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cancellation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(49,950</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, September 30, 2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,280,184</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.17</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,609,035</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&#160;was $1,014,474.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Warrants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a summary of warrant activities:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="right">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number of</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise Price</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (in years)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, December 31, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12,770,636 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.97</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.48</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 6,114,768 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants exercised</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,304,910</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants expired</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,023,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.65</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding, September 30, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,441,942 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0. 77</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.09</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,611,403</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Note 8 &#8211; Subsequent Events</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management has evaluated subsequent events and has concluded no events warrant disclosure.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>
</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2. &#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORWARD-LOOKING STATEMENT NOTICE</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. &#160;For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. &#160;Without limiting the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;estimate&#8221; or &#8220;continue&#8221; or comparable terminology are intended to identify forward-looking statements. &#160;These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. &#160;These factors include but are not limited to economic conditions generally and in the industries in which we may participate; competition within our chosen industry, including competition from much larger competitors; technological advances and failure to successfully develop business relationships.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description of Business</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that&#160;was in the market for a merger with an appropriate operating company.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which Cactus Ventures, Inc. (now the Company) acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Cactus Ventures, Inc. common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock were exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Cactus common stock. As a result of the Share Exchange, the Company became a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments</font>.</font></div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">API, incorporated on June 13, 2000, is a biopharmaceutical company focused on the $50 billion market for cancer drugs. Our most advanced products are Actimab&#8482;-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab&#8482;-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. The Company is currently designing a trial which the Company intends to submit for registration approval in HSCT in the settings of refractory and relapsed acute myeloid leukemia in older patients. The Company is developing its cancer drugs using its expertise in radioimmunotherapy. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center, whose indirect subsidiary, Actinium Holdings Ltd., is a significant stockholder of the Company. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects. The Company intends to develop a number of products for different types of cancer and derive revenue from partnering relationships with large pharmaceutical companies and/or direct sales of its products in specialty markets in the U.S.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&#160;&#160;&#160;Effective April 18, 2013, the Company&#8217;s trading symbol is ATNM.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 25, 2013 in accordance with a Certificate of Ownership Merging Actinium Corporation into the Company, the Company merged into itself Actinium Corporation, and Actinium Corporation ceased to exist. As a result of the merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plan of Operation</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We develop drugs for treatment of cancer with intent to cure or significantly improve survival of the affected patients. As of now none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial operations in sales or marketing of our products. All our product candidates are under development. In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies like the Food and Drug Administration (FDA) in the United States and similar agencies elsewhere in the world.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our products under development are monoclonal antibodies labeled with radioisotopes. We have one program with an antibody labeled with a beta emitter and several programs based on a proprietary patent protected platform technology called alpha particle immunotherapy or APIT. Our APIT technology is based on attaching actinium 225 (Ac-225) or bismuth 213 (Bi-213) alpha emitting radioisotopes to monoclonal antibodies. Alpha emitting radioisotopes are unstable chemical elements that decay by releasing alpha particles. Alpha particles can kill any cell in whose immediate proximity they are released. Monoclonal antibodies are genetically engineered proteins that target specifically certain cells, and can target cancer cells. It is crucial for the success of our drug candidates to contain monoclonal antibodies that can successfully seek cancer cells and can kill them with the attached isotope while not harming nearby normal cells. We do not have technology and operational capabilities to develop and manufacture such monoclonal antibodies and we therefore rely on collaboration with third parties to gain access to such monoclonal antibodies. We have secured rights to two monoclonal antibodies, HuM195 (Lintuzumab), in 2003 through a collaborative licensing agreement with Abbott Laboratories and BC8 in 2012 with the Fred Hutchinson Cancer Research Center. We expect to negotiate collaborative agreements with other potential partners that would provide us with access to additional monoclonal antibodies. Establishing and maintaining such collaborative agreements is a key to our success as a company.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under our own sponsorship as well as activity at FHCRC, we have four product candidates in active clinical trials: Actimab&#8482;-A (HuM195-Ac-225), Iomab&#8482;-B (BC8-I-131), BC8-Y-90 and BC8-SA. At this time, the Company is actively pursuing development of Actimab&#8482;-A and Iomab&#8482;-B while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center.Actimab&#8482;-A is a combination of the monoclonal antibody we have in-licensed, Lintuzumab (HuM195), and the alpha emitting isotope actinium 225. Actimab&#8482;-A has shown promising results throughout preclinical development and an ongoing clinical trial started in 2006 in treating acute myeloid leukemia (AML) in the elderly. We have expanded the number of patients and number of clinical centers by commencing a new AML clinical trial which we have launched in 2012. This trial targets newly diagnosed AML patients over the age of 60. In order to conduct the trial we are engaged in funding, monitoring and quality assurance and control of the Lintuzumab antibody; procurement of actinium 225 isotope; funding, monitoring and quality assurance and control of the drug candidate Actimab&#8482;-A manufacturing and organizing and monitoring clinical trials. We estimate that the direct costs to completion of both parts of the ongoing Phase I/II trial will be approximately US $7.5 million. Iomab&#8482;-B is a combination of the in-licensed monoclonal antibody BC8 and the beta emitting radioisotope iodine 131. This construct has been extensively tested in Phase I and Phase II clinical trials in approximately 250 patients with different blood cancer indications who were in need of a hematopoietic stem cell transplantation (HSCT). Iomab&#8482;-B is used to condition the bone marrow of these patients by destroying blood cancer cells in their bone marrow and elsewhere thus allowing for a subsequent transplant containing healthy donor bone marrow stem cells. We have decided to develop this drug candidate by initially focusing on the patients over 55 with active acute myeloid leukemia in relapse and/or refractory to existing treatments. Our intention is to request the FDA in 2014 to allow us to enter into a pivotal trial with Iomab&#8482;-B. We estimate the direct costs of such a trial will be approximately US $15-20 million.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have primarily management position employees and consultants who direct, organize and monitor the activities described above through contractors. Much of the<font style="FONT-STYLE: italic; DISPLAY: inline"> &#160;&#160;in vivo</font> &#160;&#160;laboratory and clinical work contracted for by the Company has been conducted at Memorial Sloan-Kettering Cancer Center in New York. The Company has also made clinical trial arrangements with other-well known cancer centers. Our Actimab&#8482;-A drug candidate and its components are contract manufactured and maintained under our supervision by specialized contract manufacturers and suppliers in the U.S., including IsoTex Diagnostics, Oak Ridge National Laboratory, Pacific GMP, Fischer Bioservices, BioReliance and others.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a development stage company and have never generated revenue. Currently we do not have a stable recurring source of revenues sufficient to cover our operating costs. As of September 30, 2013, we had an accumulated deficit of $60.6 million. We incurred net losses of $4.9 million for the nine months ended September 30, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Opportunities, Challenges and Risks</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market for drugs for cancer treatment is a large market in need of novel products, in which successful products can command multibillion dollars in annual sales. A number of large pharmaceutical and biotechnology company regularly acquire products in development, with preference given to products in Phase II or later clinical trials. These&#160;transactions are typically structured to include an upfront payment that ranges from several million dollars to tens of million dollars or more and additional milestone payments tied to regulatory submissions and approvals and sales milestones. Our goal is to develop our product candidates through Phase II clinical trials or later and enter into partnership agreements with one or more large pharmaceutical and/or biotechnology companies or eventually commercialize some of our products ourselves or through other appropriate partnerships.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe our future success will be heavily dependent upon our ability to successfully conduct clinical trials and preclinical development of our drug candidates. This will in turn depend on our ability to continue our collaboration with Memorial Sloan-Kettering Cancer Center and our Clinical Advisory Board members plan to continue and expand other research and clinical trial collaborations. In addition, we will have to maintain sufficient supply of actinium 225 and successfully maintain and if and when needed replenish or obtain our reserves of monoclonal antibodies. We will have to maintain and improve manufacturing procedures we have developed for production of our drug candidates from the components that include the iodine 131 and actinium 225 isotopes, monoclonal antibodies and other materials. It is possible that despite our best efforts our clinical trials results may not meet regulatory requirements for approval. Despite our best efforts and regardless of the clinical trial, we may not be able to find&#160;a partner for our compounds. If our efforts are successful, we will be able to partner our development stage products on commercially favorable terms only if they enjoy appropriate patent coverage and/or considerable know-how and other protection that ensures market exclusivity. For that reason we intend to continue our efforts to maintain existing and generate new intellectual property. Intellectual property is a key factor in the success of our business as well as market exclusivity.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To achieve the goals discussed above we intend to continue to invest in research and development at high and constantly increasing rates thus incurring further losses until one or more of our products are sufficiently developed to partner them to large pharmaceutical and biotechnology companies.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations &#8211; Three Months Ended September 30, 2013 Compared to the Three Months Ended September 30, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the three months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">778,232</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,677,301</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">830,730</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">722,037</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,608,962</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,399,450</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,299</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">318,623</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Gain) loss on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(189,348)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">294,381</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other (income) expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(188,049)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">613,004</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,420,913</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,012,454</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded&#160;no commercial revenues for the three months ended September 30, 2013 and&#160;2012.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expense</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses decreased by $899,069 to $778,232 for the three months ended September 30, 2013 compared to $1,677,301 for the three months ended September 30, 2012. The decrease is primarily attributable to the Company conserving capital during the three months ended September 30, 2013.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overall, total general and administrative expenses increased by $108,693 to $830,730 for the three months ended September 30, 2013 compared to $722,037 for the three months ended September 30, 2012. The increase was largely attributable to increases in professional fees, financing related fees and the stock-based compensation incurred by the Company as discussed below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Expense</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other expenses&#160;decreased by $801,053 for the three months ended September 30, 2013 compared to the three months ended September 30, 2012. The&#160;decrease is primarily attributable a significant decrease in interest expense&#160;related to the amortization of the convertible debt discount and deferred financing costs related to the convertible debt and the gain on the change in fair value of the derivative liability.&#160;&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss decreased by $1,591,541 to $1,420,913 for the three months ended September 30, 2013 compared $3,012,454 for the three months ended September 30, 2012. The decrease was primarily due to the gain on the change in fair value of the derivative liability, a decrease in interest expense associated with the amortization of debt discount to interest expense and a significant decrease in research and development, offset by an increase in professional fees and payroll related expense.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations &#8211; Nine Months Ended September 30, 2013 Compared to the Nine Months Ended September 30, 2012</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth, for the periods indicated, data derived from our statements of operations:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development, net of reimbursements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,373,200</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,723,459</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,730,233</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,520,221</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,122</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">429</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,107,555</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,244,109</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other (income) expense:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,508</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">952,241</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Gain) loss on change in fair value of derivative liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(216,112</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287,604</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 45pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other (income) expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(213,604</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,239,845</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,893,951</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,483,954</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenues</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded&#160;no&#160;commercial revenues for the nine months ended September 30, 2013 and&#160;2012.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expense</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expenses decreased by $350,259 to $2,373,200 for the nine months ended September 30, 2013 compared to $2,723,459 for the nine months ended September 30, 2012. The decrease is primarily attributable to the Company conserving capital during the three months ended September 30, 2013.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overall, total general and administrative expenses increased by $1,210,012 to $2,730,233 for the nine months ended September 30, 2013 compared to $1,520,221 for the nine months ended September, 2012. The increase was largely attributable to increases in professional fees and&#160;financing related fees&#160;incurred by the Company as discussed below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other&#160;Expense</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other&#160;expense decreased by $1,453,449 for the nine months ended September 30, 2013 compared to the nine months ended September 30, 2012. The decrease is primarily attributable a decrease in interest expense&#160;related to the amortization of the convertible debt discount and deferred financing costs related to the convertible debt&#160;and an&#160;&#160;increase in the gain on the change in fair value of the derivative liability.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net loss decreased by $590,003 to $4,893,951&#160;for the nine months ended September 30, 2013 compared $5,483,954 for the nine months ended September 30, 2012. The decrease was primarily due to a decrease in interest expense associated with the amortization of debt discount to interest expense, a decrease in research and development and a gain from change in fair value of the derivative liability efforts and offset by an increase in professional fees and payroll related expense.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have financed our operations primarily through sales of the Company&#8217;s stock and the issuance of convertible promissory notes.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following tables sets forth selected cash flow information for the periods indicated:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the nine months ended</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">September 30,</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2013</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash used in operating activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,947,969</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,795,480</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash used in investing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(8,030</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,812</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash provided by financing activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,327,393</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">660,163</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net&#160;change in cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,628,606</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,137,129)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was $4,947,969 for the nine months ended September 30, 2013 compared to $3,795,480 used in operations for the same period in 2012. Cash used in operations increased due to the increase in spending related to preparations and eventual launch and conduct of a multicenter trial and an increase in spending related to professional fees combined with an increase in payroll-related expenses.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $3,327,393 for the nine months ended September 30, 2013 compared to net cash provided by financing activities of $660,163 for the same period in 2012. During the nine months ended September 30, 2013, the Company received proceeds from the exercise of warrants as more discussed below. During the nine months ended September 30, 2012, the Company received net proceeds of $660,163 from sale of its stock.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have experienced cumulative losses of $60,637,414 from inception (June 13, 2000) through&#160;September 30, 2013, and have stockholders' equity of $604,328 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Debt and Equity Offerings</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the&#160;second and third quarters&#160;2013 we issued shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.&#160;&#160;The warrants were exercised at $1.65 per share, resulting in gross proceeds of $3,467,393 for the Company.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company intends to increase funds available to continue our research and development efforts, which include material supply, manufacturing, clinical development and pre-clinical trials and working capital. In 2013, we expect cash needs of up to $2.9 million to finance research and development, which include material supply, manufacturing, clinical trials and pre-clinical trials and to cover our ongoing working capital needs.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To satisfy our research and development requirements beyond 2013, we are contemplating additional funding activities but we can give no assurances that these activities will be successful. In the event we do not meet our cash needs of $25,000,000, it may be necessary for us to delay the timing of various product development efforts.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Seasonality</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have a seasonal business cycle. Our revenues and operating results are generally derived evenly throughout the calendar year.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States. To prepare these consolidated&#160;financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities. These estimates also affect our expenses. Judgments must also be made about the disclosure of contingent liabilities. Actual results could be significantly different from these estimates. We believe that the following discussion addresses the accounting policies that are necessary to understand and evaluate our reported financial results.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivatives</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All derivatives are recorded at fair value and recorded on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of Financial Instruments</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#9679;&#160;&#160;&#160;&#160;&#160; Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Costs</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.7pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Share-Based Payments</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were various accounting standards and interpretations issued during 2013 and 2012, none of which are expected to have a material impact on the Company&#8217;s financial position, operations or cash flows.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Subsequent Events</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 36pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">On October 24, 2013, the Company&#8217;s board of directors appointed </font>Sandesh Seth as Chairman of the Board.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 8, 2013, the <font style="DISPLAY: inline">Company</font>&#8217;s board of directors appointed Richard I. Steinhart as a Director of the Company.&#160;&#160;The Board also named Mr. Steinhart as Chairman of the Board&#8217;s Audit Committee&#160;&#160;and a member of the Board&#8217;s Compensation Committee.</font></div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="item_1_3_4"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 3. &#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not required by smaller reporting companies.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><a name="item_1_3_5"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 4. &#160;CONTROLS AND PROCEDURES.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Evaluation of Disclosure Controls and Procedures.</font> &#160;We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8216;&#8216;Exchange Act&#8217;&#8217;). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based upon our evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are not effective, as of September 30, 2013, in ensuring that material information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms. <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The ineffective was due to the material weaknesses described in Management&#8217;s Report on Internal Control over Financial Reporting as reported in our Form 10-K for the year ended December 31, 2012.</font></font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Changes in Internal Control over Financial Reporting</font>. &#160;There were no changes in our system of internal controls over financial reporting during the period covered by this report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;<a name="part_1_2_3"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II &#8211; OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_6"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1A. &#160;RISK FACTORS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not Applicable to a smaller reporting company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="item_1_3_7"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 7.7pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 22, 2013, the Company closed on a share exchange agreement (the &#8220;Exchange Agreement&#8221;) with (i) Actinium Corporation, a Delaware corporation (&#8220;Actinium Corporation&#8221;), and (ii) the former shareholders of Actinium Corporation (the &#8220;Actinium Corporation Shareholders&#8221;), pursuant to which the Company acquired 24,052,702 additional shares of capital stock of Actinium Corporation from the Actinium Corporation Shareholders in exchange for the issuance of 8,009,550 additional shares of shares of common stock, par value $0.001 per share, of the Company (the &#8220;Common Stock&#8221;) to the Actinium Corporation Shareholders (the &#8220;Share Exchange&#8221;). The 24,052,702 shares of Common Stock constitute 38.2% of the issued and outstanding equity securities of Actinium Corporation.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The shares of common stock issued to the former shareholders of Actinium Corporation in connection with the Share Exchange were offered and sold in a private transaction in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D (&#8220;Regulation D&#8221;) promulgated under the Securities Act and Regulation S promulgated under the Securities Act. The Company made this determination based on the representations of the investors which included, in pertinent part, that each such investor was an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (the &#8220;Company&#8221;) filed in Delaware, the Company merged (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Merger</font>&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&#160;&#160;As of the September 30, 2013, the Company has acquired a total of 63,018,053, or 100%, of the issued and outstanding equity securities of Actinium Corporation.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The shares of common stock issued to the former shareholders of Actinium Corporation in connection with the Merger were offered and sold in a private transaction in reliance upon exemptions from registration pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D (&#8220;Regulation D&#8221;) promulgated under the Securities Act and Regulation S promulgated under the Securities Act. The Company made this determination based on the representations of the investors which included, in pertinent part, that each such investor was an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="item_1_3_8"><!--EFPlaceholder--></a>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><a name="item_1_3_9"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 4. MINE SAFETY DISCLOSURES</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><a name="item_1_3_10"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 5. OTHER INFORMATION.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><a name="item_1_3_11"><!--EFPlaceholder--></a><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 6. EXHIBITS</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">No.</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="67%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of Document</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Location</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.2</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Principal Financial and Accounting&#160;&#160;Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 4.4pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.INS</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Instance Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.SCH</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Taxonomy Extension Schema Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.CAL</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Taxonomy Calculation Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.DEF</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Taxonomy Extension Definition Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.LAB</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Taxonomy Label Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101.PRE</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">X&#160;&#160;XBRL Taxonomy Presentation Linkbase Document</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Attached</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* The Exhibit attached to this Form 10-Q shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<a name="part_1_2_4"><!--EFPlaceholder--></a></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 54pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ACTINIUM PHARMACEUTICALS, INC.</font></div>
</td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: November 14, 2013</font></div>
</td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer (Duly Authorized Officer, and Principal Executive Officer)</font></div>
</td>
<td align="left" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Sergio Traversa</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="35%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer (Duly Authorized Officer, and Principal Financial and Accounting Officer)</font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">27</font>

<div>
<hr style="COLOR: black" align="left" noshade size="2" width="100%">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0913ex31i_actinium.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
    <title>f10q0913ex31i_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF&#160;PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Kaushik Jo Dave, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financing reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceutical, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/<font style="FONT-STYLE: italic; DISPLAY: inline"> Kaushik J. Dave</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal&#160;Executive Officer)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">November 14, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0913ex31ii_actinium.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
    <title>f10q0913ex31ii_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF&#160;PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO SECTION 302 OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Sergio Traversa, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="74%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">c)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">d)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Disclosed in this report any change in the registrant&#8217;s internal control over financing reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td valign="top" width="74%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">b)</font></div>
</td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceutical, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/<font style="FONT-STYLE: italic; DISPLAY: inline"> Sergio Traversa</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal&#160;financial and Accounting Officer)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">November 14, 2013</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0913ex32i_actinium.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*
<TEXT>
<html>
<head>
    <title>f10q0913ex32i_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the&#160;Quarterly Report of Actinium Pharmaceuticals, Inc.&#160;(the &#8220;Company&#8221;) on Form 10-Q for the&#160;period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kaushik J. Dave,&#160;President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%">&#160;</td>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/<font style="FONT-STYLE: italic; DISPLAY: inline"> Kaushik J. Dave </font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Kaushik J. Dave</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">&#160;</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">&#160;</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Executive Officer)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">November 14, 2013</font><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0913ex32ii_actinium.htm
<DESCRIPTION>CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*
<TEXT>
<html>
<head>
    <title>f10q0913ex32ii_actinium.htm</title>
    <!--Licensed to: Edgar Agents-->
    <!--Document Created using EDGARizerAgent 5.4.5.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the&#160;Quarterly Report of Actinium Pharmaceuticals, Inc.&#160;(the &#8220;Company&#8221;) on Form 10-Q for the&#160;period ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Sergio Traversa,&#160;interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="40%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Actinium Pharmaceuticals, Inc.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/<font style="FONT-STYLE: italic; DISPLAY: inline"> Sergio </font></font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Traversa</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>
</td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sergio Traversa</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Principal Financial and Accounting Officer)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">November 14, 2013</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>fil-20130930.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.0.3.3 [11/14/2013 08:26:10 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<xbrli:xbrl xmlns:fil="http://cactusventuresinc.com/20130930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="fil-20130930.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of__12-Jun-2000">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2000-06-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2002-02-01
</xbrli:startDate>
<xbrli:endDate>
2002-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-01-01
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_14-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-06-14
</xbrli:startDate>
<xbrli:endDate>
2012-06-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Jun-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-19
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jul-2012_01-Aug-2012_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-28
</xbrli:startDate>
<xbrli:endDate>
2012-08-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05-Aug-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-05
</xbrli:startDate>
<xbrli:endDate>
2012-08-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_27-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-08-27
</xbrli:startDate>
<xbrli:endDate>
2012-08-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:JohnsHopkinsUniversityMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-09-25
</xbrli:startDate>
<xbrli:endDate>
2012-09-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fil:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:UniversityOfPennsylvaniaMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ClinicalTrialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-11-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_27-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-12-27
</xbrli:startDate>
<xbrli:endDate>
2012-12-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__31-Jan-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-03-01
</xbrli:startDate>
<xbrli:endDate>
2013-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">fil:ActiniumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01-Sep-2013_25-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AptivSolutionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:FredHutchinsonCancerResearchCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:LicenseAndSponsoredResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:RentalAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fil:OptionsAndWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:SeparationAndSettlementAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseSecondClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseThirdClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:BiologicalLicenseApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:FirstCommercialSaleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:PhaseFirstClinicalTrialOfLicensedProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:NewDrugApplicationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:MemorialSloanKetteringCancerCenterMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:ReceiptOfRegulatoryApprovalFromUSFdaMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:AbbottBiotherapeuticsCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">fil:AfterFirstNetSalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">fil:ProductDevelopmentAndPatentLicenseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fil:OakRidgeNationalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:ChiefExecutiveOfficerAndDirectorMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="fil:AgreementAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">fil:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenEquityIncentivePlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fil:TwoThousandThirteenStockPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13-Jun-2000_30-Sep-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-06-13
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of__12-Nov-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001388320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw6=c444c555cT{h>J==J:FEF1F67J18E<41E<5:15488;5G445I< -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="pures"><xbrli:measure>fil:pures</xbrli:measure></xbrli:unit>
<xbrli:unit id="Installment"><xbrli:measure>fil:Installment</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME__30-Sep-2013">Actinium Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME__30-Sep-2013">0001388320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME__30-Sep-2013">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME__30-Sep-2013">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_9ME__30-Sep-2013">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME__30-Sep-2013">2013-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME__30-Sep-2013">2013</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME__30-Sep-2013">Q3</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_9ME__30-Sep-2013">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of__12-Nov-2013" unitRef="shares" decimals="INF">23656582</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__12-Jun-2000" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2011" unitRef="USD" decimals="0">5703798</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__30-Jun-2012" unitRef="USD" decimals="0">4500572</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__30-Sep-2012" unitRef="USD" decimals="0">2566669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5618669</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3990063</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">167143</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">53000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5785812</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4043063</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3010</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">6918</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5788822</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4049981</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">897044</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">312001</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">31185</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">375686</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">140000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">4643187</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3445653</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">4643187</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">3445653</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">213916</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">236565</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">56675182</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">61005177</us-gaap:AdditionalPaidInCapital>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">55743463</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">60637414</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">1145635</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">604328</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">5788822</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4049981</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">21391665</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">23656582</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="INF">21391665</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="INF">23656582</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesRevenueNet contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">1677301</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">2723459</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">778232</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2373200</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">28793719</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">722037</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">1520221</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">830730</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2730233</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">27235208</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">112</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationAndAmortization contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationAndAmortization contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationAndAmortization>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4122</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1 contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-554308</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:OperatingExpenses contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">2399450</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">4244109</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">1608962</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">5107555</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">59845697</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-2399450</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-4244109</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">-1608962</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-5107555</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-59845697</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">318623</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">952241</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">1299</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">2508</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">1967215</us-gaap:InterestExpense>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_3ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">260000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-294381</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-287604</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">189348</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">216112</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">915498</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-613004</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-1239845</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">188049</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">213604</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-791717</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">-3012454</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-5483954</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">-1420913</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4893951</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-60637414</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__30-Sep-2012" unitRef="USD_per_Share" decimals="2">-3.76</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME__30-Sep-2012" unitRef="USD_per_Share" decimals="2">-6.84</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME__30-Sep-2013" unitRef="USD_per_Share" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME__30-Sep-2013" unitRef="USD_per_Share" decimals="2">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__30-Sep-2012" unitRef="shares" decimals="0">801799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME__30-Sep-2012" unitRef="shares" decimals="0">801799</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME__30-Sep-2013" unitRef="shares" decimals="0">23601895</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME__30-Sep-2013" unitRef="shares" decimals="0">22401711</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">312500</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2012_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">168000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">284371</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">6336407</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3262462</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">678116</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">900000</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">219725</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">292692</us-gaap:AmortizationOfFinancingCosts>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-287604</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">216112</fil:GainOnChangeInFairValueOfDerivatives>
<fil:GainOnChangeInFairValueOfDerivatives contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">915498</fil:GainOnChangeInFairValueOfDerivatives>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-14386</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-114143</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-87000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">173614</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-585043</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">653730</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">2100</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">344501</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">375686</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-3795480</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-4947969</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-49350627</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">1812</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">8030</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">823689</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-1812</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-8030</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">-3823689</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">645888</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">140000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">140000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">660163</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">53191098</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">3467393</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3467393</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">660163</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">3327393</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">57164379</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">-3137129</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-1628606</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">3990063</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">561</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">1243</us-gaap:IncomeTaxesPaid>
<us-gaap:InterestPaid contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">372850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithDebt contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">377150</fil:FairValueOfWarrantsIssuedWithDebt>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">318087</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedWithStock contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">5985238</fil:FairValueOfWarrantsIssuedWithStock>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">159044</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfWarrantsIssuedToPlacementAgent contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">2170282</fil:FairValueOfWarrantsIssuedToPlacementAgent>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_9ME__30-Sep-2013" unitRef="USD" xsi:nil="true"/>
<fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">981729</fil:ConversionOfNotesPayableAndAccruedInterestToCommonStock>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME__30-Sep-2012" unitRef="USD" xsi:nil="true"/>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">600880</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification contextRef="Context_Custom_13-Jun-2000_30-Sep-2013" unitRef="USD" decimals="0">4832204</fil:FairValueOfTransferFromLiabilityClassificationToEquityClassification>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 1 &amp;#8211; Description of Business and Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Nature of Business &amp;#8211;&lt;/font&gt; Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211; &lt;/font&gt;The accompanying unaudited
 interim
 consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Development Stage Company &amp;#8211;&lt;/font&gt; The Company is considered a development stage company and has had no commercial revenue to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Reclassification &amp;#8211;&lt;/font&gt; Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Impairment of Long-Lived Assets &amp;#8211; &lt;/font&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family:
 times new roman; font-size:
 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"
 colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability
 method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&amp;#160;&amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,441,942 shares of the Company&amp;#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase&amp;#160;1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt; The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Subsequent Events &amp;#8211;&lt;/font&gt; The Company&amp;#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
<fil:GoingConcernTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 2 &amp;#8211; Going Concern&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The ability of the Company to continue its operations is dependent on the successful execution of management's plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&amp;#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;&lt;/div&gt;</fil:GoingConcernTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 3 &amp;#8211; Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;162,384&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;3,100&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap"
 valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,292&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;165,484&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Loss on disposition of equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;(4,122&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6,918&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Depreciation expense for the&amp;#160;nine months ended September 30, 2013 and 2012 were $0,&amp;#160;and $429 respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="font: 13.63px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font size="2" style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 4 &amp;#8211; Note Payable&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="font: 13.63px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font size="2" style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&amp;#160;is required&amp;#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.&lt;/font&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 5 &amp;#8211; Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&amp;#8217;s common stock at prices below such warrants&amp;#8217; respective exercise prices and these provisions could result in modification of the warrants&amp;#8217; exercise price based on a variable that is not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221; option as defined under FASB ASC Topic No. 815 &amp;#8211; 40. The warrants granted in connection with the issuance of the Company&amp;#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &amp;#8220;Lower Price&amp;#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right:
 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Reclassification to paid in capital&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,130,536 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(600,880 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td width="76%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(216,112 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family:
 times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom:
 black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,015,802&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline;
 font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.17&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.48 - $0.81&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.50 - $2.475&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.33&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0 days/4.22 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times
 new;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;139&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25% - 40&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;Management determined the dividend yield to be 0% based upon its
 expectation that it will not pay dividends for the foreseeable future.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;
 &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Note 6 &amp;#8211; Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;Employment Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On September 16, 2013, the Company&amp;#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&amp;#160;and Director. Material terms of the Employment Agreement are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;div&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="3%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;a&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="74%" valign="top" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;A base salary at an annual rate of $350,000, which will be re-evaluated upon the&amp;#160;six month anniversary of the start date and reimbursement of certain expenses.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="2%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="68%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="3%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;b&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="74%" valign="top" colspan="3"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&amp;#160;&amp;#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="3%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="2%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="68%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="3%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;c&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="74%" valign="top" colspan="3"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;An option to purchase common shares of the Company and restricted stock (the &amp;#8220;Grant&amp;#8221;).&amp;#160;&amp;#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&amp;#160;&amp;#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&amp;#160;&amp;#160;As of October 25, 2013, the option has not been granted by the Board.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;div&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;"&gt;License and Research Agreements&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;a.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;
 display: block;"&gt;&lt;font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;"&gt;Abbott Biotherapeutics Corp &amp;#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display:
 block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&amp;#160;&amp;#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;b.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top" style="text-align: justify;"&gt;&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Memorial Sloan Kettering Cancer Center (MSKCC) &amp;#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent:
 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left"
 style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval&amp;#160;&lt;/font&gt;for each licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each&amp;#160;&lt;/font&gt;licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt;
 margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt;
 margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;c.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;Oak Ridge National Laboratory (ORNL) &amp;#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&amp;#160;&amp;#160;The Company is currently negotiating the 2013 agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;d.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&amp;#160;&amp;#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&amp;#160;&amp;#160;The down payment totaling $239,000 was paid in 2007 and 2012.&amp;#160;&amp;#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&amp;#160;&amp;#160;The total project is now estimated at approximately $2.2 million.&amp;#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;e.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&amp;#160;&amp;#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&amp;#160;&amp;#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&amp;#160;&amp;#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&amp;#160;&amp;#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&amp;#160;&amp;#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&amp;#160;&amp;#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&amp;#160;&amp;#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;f.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&amp;#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&amp;#160;&amp;#160;The amount due of $79,623 was paid on July 10, 2012.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;g.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&amp;#160;&amp;#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up
 fee of $19,749.&amp;#160;&amp;#160;During the clinical trial additional fees apply and will be invoiced when applicable.&amp;#160;&amp;#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%"
 valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;h.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&amp;#160;&amp;#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&amp;#160;&amp;#160;The estimated cost is based on treating 24 patients through 2013.&amp;#160;&amp;#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;i.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&amp;#160;&amp;#160;The Phase I/II clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="7%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;j.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&amp;#160;&amp;#160;The Phase I/II clinical trial will be conducted with Actinium 225.&amp;#160;&amp;#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&amp;#160;&amp;#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&amp;#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&amp;#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"&gt;&lt;div style="text-align: justify; text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;On&amp;#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012&lt;/font&gt;&lt;font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Note 7 &amp;#8211; Equity&lt;/font&gt;&lt;/div&gt;&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Approval of the 2013 Stock Plan&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The Board approved the Company&amp;#8217;s 2013 Stock Plan.&amp;#160;&amp;#160;The expiration date of the plan is September&amp;#160;&amp;#160;9, 2023&amp;#160;&amp;#160;and the total number of underlying shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Approval of the Equity Incentive Plan&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The Board approved the Company&amp;#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&amp;#160;&amp;#160;9, 2023&amp;#160;&amp;#160;and the total number of shares of the Company&amp;#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The following is a summary of&amp;#160;option activities:&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 align="left" valign="bottom"
 colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align:
 left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2,330,134&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.91&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"
 style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"
 style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;685,800&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Cancellation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(49,950&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman';
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;2,280,184&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.95&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;8.17&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1,609,035&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&amp;#160;was $1,014,474.&lt;/font&gt;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal;
 orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;The following is a summary of warrant activities:&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td
 nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div
 align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;12,770,636&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0.97&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;4.48&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160; 6,114,768&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(2,304,910&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Warrants expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;(1,023,784&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,441,942&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;0. 77&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;5.09&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;9,611,403&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;
 text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font size="2"&gt;During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.&lt;/font&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"&gt;Note 8 &amp;#8211; Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has evaluated subsequent events and has concluded no events warrant disclosure.&lt;/font&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BusinessCombinationsPolicy contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Nature of Business &amp;#8211;&lt;/font&gt; Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &amp;#8220;Company&amp;#8221;, &amp;#8220;Actinium&amp;#8221;, &amp;#8220;Cactus&amp;#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On December 28, 2012, the Company entered into a transaction (the &amp;#8220;Share Exchange&amp;#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&amp;#8220;API&amp;#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&amp;#160;&amp;#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &amp;#8220;Exchange Ratio&amp;#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&amp;#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&amp;#160;&amp;#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &amp;#8220;API&amp;#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&amp;#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&amp;#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&amp;#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&amp;#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&amp;#160;&amp;#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &amp;#8220;Merger&amp;#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&amp;#160;&amp;#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Basis of Presentation - Unaudited Interim Financial Information &amp;#8211; &lt;/font&gt;The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&amp;#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<fil:DevelopmentStageCompanyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Development Stage Company &amp;#8211;&lt;/font&gt; The Company is considered a development stage company and has had no commercial revenue to date.&lt;/font&gt;&lt;/div&gt;</fil:DevelopmentStageCompanyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Use of Estimates in Financial Statement Presentation &amp;#8211;&lt;/font&gt; The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Reclassification &amp;#8211;&lt;/font&gt; Certain prior period amounts have been reclassified to conform to current period presentation.&lt;/font&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Cash and Cash Equivalents &amp;#8211;&lt;/font&gt; The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&amp;#8217;s cash was deposited in one bank.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Property and Equipment &amp;#8211;&lt;/font&gt; Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Impairment of Long-Lived Assets &amp;#8211; &lt;/font&gt;Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&amp;#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Derivatives &amp;#8211;&lt;/font&gt; All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/font&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Fair Value of Financial Instruments &amp;#8211;&lt;/font&gt; Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1 Inputs &amp;#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2 Inputs &amp;#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3 Inputs &amp;#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.&lt;/font&gt;&lt;br /&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap"
 valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Income Taxes &amp;#8211;&lt;/font&gt; The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&amp;#8217;s assessment as to their realization.&lt;/font&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Research and Development Costs &amp;#8211;&lt;/font&gt; Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.&lt;/font&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Share-Based Payments &amp;#8211;&lt;/font&gt; The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&amp;#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.&lt;/font&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-weight: bold; display: inline;"&gt;Earnings (Loss) Per Common Share &amp;#8211;&lt;/font&gt; The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&amp;#160;&amp;#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase&amp;#160;2,280184 shares and warrants to purchase 9,441,942 shares of the Company&amp;#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&amp;#8217;s common stock have been excluded from the calculation.&lt;/font&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements &amp;#8211;&lt;/font&gt; The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.&lt;/font&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&lt;font style="display: inline; font-weight: bold;"&gt;Subsequent Events &amp;#8211;&lt;/font&gt; The Company&amp;#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.&lt;/font&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Derivative liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&amp;#160;At December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid;"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="10%" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;162,384&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;156,162&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Furniture and fixture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;7 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,100&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;1,292&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align:
 left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Total property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;165,484&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;157,454&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(154,444 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Loss on disposition of equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4,122&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%"
 nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;6,918&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,010&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;5,146,338&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;3,574,958&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Reclassification to paid in capital&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3,130,536 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%"
 valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(600,880 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td width="76%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Change in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(216,112 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Balance, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,015,802&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,757,966&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
<fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock contextRef="Context_9ME__30-Sep-2013">&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Market value of common stock on measurement date (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.17&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Adjusted exercise price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.48 - $0.81&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;1.50
 - $2.475&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Risk free interest rate (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.10% - 0.77&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.33&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Warrant lives in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;4 months/5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0 days/4.22 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected volatility (3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;125% - 161&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;139&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Expected dividend yield (4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="76%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Probability of stock offering in any period over 5 years (5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;25% - 40&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The market value of common stock is based on an enterprise valuation.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="4%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" width="4%" valign="top"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="96%" valign="top"&gt;&lt;div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fil:FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember">&lt;div align="left"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="right" width="7%" valign="top"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td width="93%" valign="top" style="text-align: justify;"&gt;&lt;div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;1) filing of an New Drug Application (&amp;#8220;NDA&amp;#8221;) or regulatory approval &lt;/font&gt;for each licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;(2) upon the receipt of regulatory approval from the U.S. FDA for each &lt;/font&gt;licensed product&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<fil:MilestonePaymentsMilestoneMethodTableTextBlock contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember">&lt;div style="text-indent: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(1) when Company initiates a Phase I Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(2) when Company initiates a Phase II Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(3) when Company initiates a Phase III Clinical Trial of a licensed product&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(4) Biological License Application filing with U.S. FDA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman;
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div
 align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,750,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(5) First commercial sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="88%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(6) after the first $10,000,000 in net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="9%" valign="bottom"&gt;&lt;div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fil:MilestonePaymentsMilestoneMethodTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">&lt;div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display:
 inline; font-family: times new roman; font-size:
 10pt;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" style="padding-bottom: 2px;"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"&gt;&lt;div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="3"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,330,134&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.96&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.91&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font
 style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom"
 style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;685,800&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Cancellation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;(49,950&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;2,280,184&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;0.95&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;8.17&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="right" width="1%" valign="bottom"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;1,609,035&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="display: inline; font-family: times new roman; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">&lt;div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;div align="right"&gt;&lt;table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display:
 inline;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align:
 left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"&gt;&lt;div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Outstanding, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;12,770,636 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom"
 style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%"
 valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;0.97&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;4.48&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160; 6,114,768 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;(2,304,910&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="#cceeff"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Warrants expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;(1,023,784&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;1.65&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display:
 inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%"
 valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr bgcolor="white"&gt;&lt;td align="left" width="52%" valign="bottom"&gt;&lt;div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;Outstanding, September 30, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;9,441,942 &lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;0. 77&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;5.09&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td align="left" width="1%" valign="bottom"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td width="9%" valign="bottom" style="text-align: right;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;9,611,403&lt;/font&gt;&lt;/td&gt;&lt;td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"&gt;&lt;font style="font-family: times new roman; font-size: 10pt; display: inline;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__31-Dec-2012_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of__30-Sep-2013_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<fil:PercentageOfOwnershipInterestToBeAcquired contextRef="Context_As_Of__28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">1.00</fil:PercentageOfOwnershipInterestToBeAcquired>
<fil:PercentageOfOwnershipInterestToBeAcquired contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="3">0.937</fil:PercentageOfOwnershipInterestToBeAcquired>
<fil:CommonStockIssuableInConsiderationForEquityInterestAcquisition contextRef="Context_Custom_27-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pure" decimals="2">0.99</fil:CommonStockIssuableInConsiderationForEquityInterestAcquisition>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">Seven years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_MachineryAndEquipmentMember">Five years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<fil:SharesExchangeRatio contextRef="Context_Custom_27-Dec-2012_28-Dec-2012_LegalEntityAxis_ActiniumMember" unitRef="pures" decimals="3">0.333</fil:SharesExchangeRatio>
<fil:SharesExchangeRatio contextRef="Context_Custom_01-Sep-2013_25-Sep-2013" unitRef="pures" decimals="3">0.333</fil:SharesExchangeRatio>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF">5861044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">1968829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertibleNotesPayableMember" unitRef="shares" decimals="INF">1152692</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">13831762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="INF">9441942</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME__30-Sep-2013_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_OptionsAndWarrantsMember" unitRef="shares" decimals="INF">2280184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<fil:TotalOfCommonStockShares contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">3970137</fil:TotalOfCommonStockShares>
<fil:ExchangedInCommonStockShares contextRef="Context_As_Of__25-Sep-2013_LegalEntityAxis_ActiniumMember" unitRef="shares" decimals="INF">1322055</fil:ExchangedInCommonStockShares>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">60637414</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">157454</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">156162</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">1292</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">165484</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">162384</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of__30-Sep-2013_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="USD" decimals="0">3100</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">154444</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">154444</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<fil:LossOnDispositionOfPropertyAndEquipment contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" xsi:nil="true"/>
<fil:LossOnDispositionOfPropertyAndEquipment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">4122</fil:LossOnDispositionOfPropertyAndEquipment>
<us-gaap:Depreciation contextRef="Context_9ME__30-Sep-2012" unitRef="USD" decimals="0">429</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">0</us-gaap:Depreciation>
<fil:KeymanInsurancePolicyPremium contextRef="Context_As_Of__28-Dec-2012" unitRef="USD" decimals="0">140000</fil:KeymanInsurancePolicyPremium>
<fil:InsurancePolicyDownPayment contextRef="Context_As_Of__31-Jan-2013" unitRef="USD" decimals="0">28000</fil:InsurancePolicyDownPayment>
<fil:InsurancePolicyInstallmentPayment contextRef="Context_As_Of__31-Jan-2013" unitRef="USD" decimals="0">12636</fil:InsurancePolicyInstallmentPayment>
<us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">103050</us-gaap:DebtInstrumentAnnualPrincipalPayment>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__31-Dec-2012" unitRef="shares" decimals="0">5146338</fil:DerivativeWarrantsUnits>
<fil:DerivativeWarrantsUnits contextRef="Context_As_Of__30-Sep-2013" unitRef="shares" decimals="0">2015802</fil:DerivativeWarrantsUnits>
<fil:DerivativeWarrantUnitsReclassificationToPaidInCapital contextRef="Context_9ME__30-Sep-2013" unitRef="shares" decimals="0">-3130536</fil:DerivativeWarrantUnitsReclassificationToPaidInCapital>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__31-Dec-2012" unitRef="USD" decimals="0">3574958</us-gaap:DerivativeFairValueOfDerivativeNet>
<us-gaap:DerivativeFairValueOfDerivativeNet contextRef="Context_As_Of__30-Sep-2013" unitRef="USD" decimals="0">2757966</us-gaap:DerivativeFairValueOfDerivativeNet>
<fil:DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-600880</fil:DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue>
<fil:ChangeInFairValueOfDerivativeWarrants contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">-216112</fil:ChangeInFairValueOfDerivativeWarrants>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__31-Dec-2012" unitRef="USD_per_Share" decimals="2" id="Footnote-1_1">1.17</fil:MarketValueOfCommonStockOnMeasurementDate>
<fil:MarketValueOfCommonStockOnMeasurementDate contextRef="Context_As_Of__30-Sep-2013" unitRef="USD_per_Share" decimals="2" id="Footnote-1_2">1.65</fil:MarketValueOfCommonStockOnMeasurementDate>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.81</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.48</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="3">2.475</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="pure" decimals="4" id="Footnote-2_1">0.0077</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="pure" decimals="4" id="Footnote-2_2">0.0010</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" decimals="4" id="Footnote-2_3">0.0033</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">P4M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember">P4Y2M19D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember">P0D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="pure" decimals="2" id="Footnote-3_1">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE__31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="pure" decimals="2" id="Footnote-3_2">1.25</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" decimals="2" id="Footnote-3_3">1.39</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE__31-Dec-2012" unitRef="pure" xsi:nil="true" id="Footnote-4_1"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME__30-Sep-2013" unitRef="pure" xsi:nil="true" id="Footnote-4_2"/>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_FYE__31-Dec-2012" unitRef="pure" decimals="2" id="Footnote-5_1">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="pure" decimals="2" id="Footnote-5_2">0.40</us-gaap:FairValueInputsProbabilityOfDefault>
<us-gaap:FairValueInputsProbabilityOfDefault contextRef="Context_9ME__30-Sep-2013_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="pure" decimals="2" id="Footnote-5_3">0.25</us-gaap:FairValueInputsProbabilityOfDefault>
<fil:DescriptionOfProbabilityOfStockOffering contextRef="Context_9ME__30-Sep-2013">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</fil:DescriptionOfProbabilityOfStockOffering>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseSecondClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseThirdClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_BiologicalLicenseApplicationMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_FirstCommercialSaleMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember" unitRef="USD" decimals="0">1500000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_PhaseFirstClinicalTrialOfLicensedProductMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_NewDrugApplicationMember" unitRef="USD" decimals="0">750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ReceiptOfRegulatoryApprovalFromUSFdaMember" unitRef="USD" decimals="0">1750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<fil:LongTermPurchaseCommitmentMilestonesPayment contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">7750000</fil:LongTermPurchaseCommitmentMilestonesPayment>
<us-gaap:OfficersCompensation contextRef="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember" unitRef="USD" decimals="0">350000</us-gaap:OfficersCompensation>
<fil:PerformanceObjectiveDescription contextRef="Context_9ME__30-Sep-2013_TitleOfIndividualAxis_ChiefExecutiveOfficerAndDirectorMember_AgreementAxis_EmploymentContractsMember">&lt;div&gt;Upon the attainment of such performance objectives, Dr. Dave shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.&lt;/div&gt;</fil:PerformanceObjectiveDescription>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember" unitRef="shares" decimals="INF">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">2750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<fil:OptionGrantedToPurchaseSharesAsSignOnBonus contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember" unitRef="shares" decimals="INF">100000</fil:OptionGrantedToPurchaseSharesAsSignOnBonus>
<fil:OptionGrantedToPurchaseSharesAsSignOnBonusDescription contextRef="Context_9ME__30-Sep-2013_AgreementAxis_EmploymentContractsMember_AwardTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_RestrictedStockMember">(C) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work. An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date</fil:OptionGrantedToPurchaseSharesAsSignOnBonusDescription>
<fil:PaymentOfLicenseFee contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">3000000</fil:PaymentOfLicenseFee>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_Custom_14-Jun-2012_15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="-6">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_AfterFirstNetSalesMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="USD" decimals="0">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember">We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember">Royalty payments of 2% of net sales will be due to FHCRC.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:DescriptionOfRoyaltyPaymentToRelatedParty contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</fil:DescriptionOfRoyaltyPaymentToRelatedParty>
<fil:RoyaltyOfNetSalesPercentage contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember" unitRef="pure" decimals="2">0.12</fil:RoyaltyOfNetSalesPercentage>
<fil:FirstCommercialSalePeriod contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AbbottBiotherapeuticsCorpMember_AgreementAxis_ProductDevelopmentAndPatentLicenseAgreementMember">P12Y6M</fil:FirstCommercialSalePeriod>
<us-gaap:TechnologyServicesCosts contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</us-gaap:TechnologyServicesCosts>
<us-gaap:MaintenanceCosts contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</us-gaap:MaintenanceCosts>
<fil:ResearchAndDevelopmentArrangement contextRef="Context_Custom_01-Feb-2002_28-Feb-2002_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_LicenseAgreementMember" unitRef="USD" decimals="0">50000</fil:ResearchAndDevelopmentArrangement>
<fil:PurchaseOfRadioactiveMaterial contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_OakRidgeNationalLaboratoryMember" unitRef="USD" decimals="0">233100</fil:PurchaseOfRadioactiveMaterial>
<fil:ProjectEstimatedCost contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">1859333</fil:ProjectEstimatedCost>
<fil:DownPaymentOfProjectEstimatedCostPercentage contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="pure" decimals="3">0.125</fil:DownPaymentOfProjectEstimatedCostPercentage>
<fil:DownPaymentForProject contextRef="Context_FYE__31-Dec-2007_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</fil:DownPaymentForProject>
<fil:DownPaymentForProject contextRef="Context_Custom_05-Aug-2012_06-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">1997732</fil:DownPaymentForProject>
<fil:DownPaymentForProject contextRef="Context_FYE__31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_AptivSolutionsMember" unitRef="USD" decimals="0">239000</fil:DownPaymentForProject>
<fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MaximumMember" unitRef="USD" decimals="-5">23500000</fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_MinimumMember" unitRef="USD" decimals="-5">13200000</fil:ClinicalTrialCostForApprovalForFoodAndDrugAdministration>
<fil:FundToRelatedPartyUnderAgreementForFirstTwoYear contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">150000</fil:FundToRelatedPartyUnderAgreementForFirstTwoYear>
<fil:FundToRelatedPartyUnderAgreementAfterYearTwo contextRef="Context_As_Of__15-Jun-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_LicenseAndSponsoredResearchAgreementMember" unitRef="USD" decimals="0">250000</fil:FundToRelatedPartyUnderAgreementAfterYearTwo>
<fil:NumberOfPatients contextRef="Context_Custom_27-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="Installment" decimals="INF">24</fil:NumberOfPatients>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31185</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31366</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">481204</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">38501</fil:AmountPaidToEachPatient>
<fil:AmountPaidToEachPatient contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">31771</fil:AmountPaidToEachPatient>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">79623</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">19749</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">33946</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">22847</fil:StartUpFeeForClinicalTrial>
<fil:StartUpFeeForClinicalTrial contextRef="Context_As_Of__21-Nov-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfPennsylvaniaMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">16000</fil:StartUpFeeForClinicalTrial>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__27-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_MemorialSloanKetteringCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2012-07-10</fil:StartUpDueCostPaidDate>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__19-Jul-2012_RelatedPartyTransactionsByRelatedPartyAxis_FredHutchinsonCancerResearchCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-09-30</fil:StartUpDueCostPaidDate>
<fil:StartUpDueCostPaidDate contextRef="Context_As_Of__28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember">2013-09-30</fil:StartUpDueCostPaidDate>
<fil:NonRefundableInstitutionalFee contextRef="Context_Custom_27-Aug-2012_28-Aug-2012_RelatedPartyTransactionsByRelatedPartyAxis_UniversityOfTexasMDAndersonCancerCenterMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">14500</fil:NonRefundableInstitutionalFee>
<fil:PharmacyFee contextRef="Context_Custom_25-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">2025</fil:PharmacyFee>
<fil:AmendmentProcessingFee contextRef="Context_Custom_25-Sep-2012_26-Sep-2012_RelatedPartyTransactionsByRelatedPartyAxis_JohnsHopkinsUniversityMember_AgreementAxis_ClinicalTrialAgreementMember" unitRef="USD" decimals="0">500</fil:AmendmentProcessingFee>
<fil:AgreementConsideration contextRef="Context_9ME__30-Sep-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember">The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.</fil:AgreementConsideration>
<fil:PerformanceBonusPayableUnderAgreementForService contextRef="Context_As_Of__28-Feb-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">60000</fil:PerformanceBonusPayableUnderAgreementForService>
<fil:NoticePeriodForTerminationOfAgreement contextRef="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">This agreement terminates on Decemeber 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</fil:NoticePeriodForTerminationOfAgreement>
<us-gaap:LeaseExpirationDate1 contextRef="Context_Custom_28-Jul-2012_01-Aug-2012_AgreementAxis_RentalAgreementMember">2013-12-31</us-gaap:LeaseExpirationDate1>
<fil:AgreementRenewalDescription contextRef="Context_9ME__30-Sep-2013_AgreementAxis_RentalAgreementMember">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.</fil:AgreementRenewalDescription>
<fil:PaymentOfAggregateAmount contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">125000</fil:PaymentOfAggregateAmount>
<fil:PaymentOfFinalInstallmentForServicesByCompany contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">125000</fil:PaymentOfFinalInstallmentForServicesByCompany>
<fil:PaymentOfPerformanceBonusForServicesByCompany contextRef="Context_Custom_01-Mar-2013_31-Mar-2013_RelatedPartyTransactionsByRelatedPartyAxis_ChiefExecutiveOfficerMember_AgreementAxis_SeparationAndSettlementAgreementMember" unitRef="USD" decimals="0">60000</fil:PaymentOfPerformanceBonusForServicesByCompany>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2330134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">12770636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2280184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">9441942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">-49950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">2304910</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">1023784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember">P8Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE__31-Dec-2012_AwardTypeAxis_WarrantMember">P4Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember">P8Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME__30-Sep-2013_AwardTypeAxis_WarrantMember">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">685800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__31-Dec-2012_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">6114768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">1609035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of__30-Sep-2013_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">9611403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenEquityIncentivePlanMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_9ME__30-Sep-2013_PlanNameAxis_TwoThousandThirteenStockPlanMember">2023-09-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<fil:UnrecognizedShareBasedCompensationExpense contextRef="Context_9ME__30-Sep-2013" unitRef="USD" decimals="0">1014474</fil:UnrecognizedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__30-Sep-2012" unitRef="USD" decimals="0">72100</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME__30-Sep-2013" unitRef="USD" decimals="0">95971</us-gaap:AllocatedShareBasedCompensationExpense>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_3" xlink:label="lab_Footnote-2_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_1" xlink:label="lab_Footnote-3_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_2" xlink:label="lab_Footnote-3_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_3" xlink:label="lab_Footnote-3_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_1" xlink:label="lab_Footnote-4_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-4_2" xlink:label="lab_Footnote-4_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-4" xlink:from="lab_Footnote-4_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_1" xlink:label="lab_Footnote-5_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_2" xlink:label="lab_Footnote-5_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-5_3" xlink:label="lab_Footnote-5_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-5" xlink:from="lab_Footnote-5_3"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">The market value of common stock is based on an enterprise valuation.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-3">For the year ended December 31, 2012, because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-4">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-5">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fil-20130930.xsd
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<schema targetNamespace="http://cactusventuresinc.com/20130930" elementFormDefault="qualified" xmlns:fil="http://cactusventuresinc.com/20130930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2013-01-31">
<annotation><appinfo>
<link:roleType roleURI="http://cactusventuresinc.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited" id="Consolidatedbalancesheetsunaudited">
<link:definition>002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunauditedparenthetical" id="Consolidatedbalancesheetsunauditedparenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited" id="Consolidatedstatementsofoperationsunaudited">
<link:definition>004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<link:definition>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Notes11" id="Notes11">
<link:definition>007 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>008 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayable" id="NotePayable">
<link:definition>009 - Disclosure - Note Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Derivatives" id="Derivatives">
<link:definition>010 - Disclosure - Derivatives</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>011 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/StockOptionPlan" id="StockOptionPlan">
<link:definition>012 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Notes13" id="Notes13">
<link:definition>013 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<link:definition>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<link:definition>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>016 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesTables" id="DerivativesTables">
<link:definition>017 - Disclosure - Derivatives (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>018 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EquityTables" id="EquityTables">
<link:definition>019 - Disclosure - Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" id="DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<link:definition>020 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" id="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/GoingconcernDetails" id="GoingconcernDetails">
<link:definition>022 - Disclosure - Going concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>023 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual" id="Propertyandequipmentdetailstesxtual">
<link:definition>024 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/NotePayableDetails" id="NotePayableDetails">
<link:definition>025 - Disclosure - Note Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetails" id="DerivativesDetails">
<link:definition>026 - Disclosure - Derivatives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetails1" id="DerivativesDetails1">
<link:definition>027 - Disclosure - Derivatives (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/DerivativesDetailsTextual" id="DerivativesDetailsTextual">
<link:definition>028 - Disclosure - Derivatives (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>029 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>030 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1" id="CommitmentsAndContingenciesDetailsTextual1">
<link:definition>031 - Disclosure - Commitments and Contingencies (Details Textual 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EquityDetails" id="EquityDetails">
<link:definition>032 - Disclosure - Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://cactusventuresinc.com/role/EquityDetailsTextual" id="EquityDetailsTextual">
<link:definition>033 - Disclosure - Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="fil-20130930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
<import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="fil_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainOnChangeInFairValueOfDerivatives" id="fil_GainOnChangeInFairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedWithDebt" id="fil_FairValueOfWarrantsIssuedWithDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedWithStock" id="fil_FairValueOfWarrantsIssuedWithStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssuedToPlacementAgent" id="fil_FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfNotesPayableAndAccruedInterestToCommonStock" id="fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfTransferFromLiabilityClassificationToEquityClassification" id="fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernAbstract" id="fil_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernTextBlock" id="fil_GoingConcernTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DevelopmentStageCompanyPolicyTextBlock" id="fil_DevelopmentStageCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" id="fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentsMilestoneMethodTable" id="fil_MilestonePaymentsMilestoneMethodTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AbbottBiotherapeuticsCorpMember" id="fil_AbbottBiotherapeuticsCorpMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MemorialSloanKetteringCancerCenterMember" id="fil_MemorialSloanKetteringCancerCenterMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentsMilestoneMethodLineItems" id="fil_MilestonePaymentsMilestoneMethodLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentsMilestoneMethodTableTextBlock" id="fil_MilestonePaymentsMilestoneMethodTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" id="fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ActiniumMember" id="fil_ActiniumMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsAndWarrantsMember" id="fil_OptionsAndWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" id="fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfOwnershipInterestToBeAcquired" id="fil_PercentageOfOwnershipInterestToBeAcquired" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuableInConsiderationForEquityInterestAcquisition" id="fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesExchangeRatio" id="fil_SharesExchangeRatio" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TotalOfCommonStockShares" id="fil_TotalOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExchangedInCommonStockShares" id="fil_ExchangedInCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernTextualAbstract" id="fil_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LossOnDispositionOfPropertyAndEquipment" id="fil_LossOnDispositionOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PropertyAndEquipmentTextualAbstract" id="fil_PropertyAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotePayableTextualAbstract" id="fil_NotePayableTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="KeymanInsurancePolicyPremium" id="fil_KeymanInsurancePolicyPremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InsurancePolicyDownPayment" id="fil_InsurancePolicyDownPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InsurancePolicyInstallmentPayment" id="fil_InsurancePolicyInstallmentPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" id="fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantsUnits" id="fil_DerivativeWarrantsUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantUnitsReclassificationToPaidInCapital" id="fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" id="fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfDerivativeWarrants" id="fil_ChangeInFairValueOfDerivativeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" id="fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketValueOfCommonStockOnMeasurementDate" id="fil_MarketValueOfCommonStockOnMeasurementDate" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DerivativesTextualAbstract" id="fil_DerivativesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfProbabilityOfStockOffering" id="fil_DescriptionOfProbabilityOfStockOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseFirstClinicalTrialOfLicensedProductMember" id="fil_PhaseFirstClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseSecondClinicalTrialOfLicensedProductMember" id="fil_PhaseSecondClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseThirdClinicalTrialOfLicensedProductMember" id="fil_PhaseThirdClinicalTrialOfLicensedProductMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BiologicalLicenseApplicationMember" id="fil_BiologicalLicenseApplicationMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSaleMember" id="fil_FirstCommercialSaleMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AfterFirstNetSalesMember" id="fil_AfterFirstNetSalesMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NewDrugApplicationMember" id="fil_NewDrugApplicationMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReceiptOfRegulatoryApprovalFromUSFdaMember" id="fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentAbstract" id="fil_MilestonePaymentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LongTermPurchaseCommitmentMilestonesPayment" id="fil_LongTermPurchaseCommitmentMilestonesPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTable" id="fil_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="ChiefExecutiveOfficerAndDirectorMember" id="fil_ChiefExecutiveOfficerAndDirectorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementAxis" id="fil_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="fil_AgreementDomain" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesLineItems" id="fil_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentsAndContingenciesTextualAbstract" id="fil_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BaseSalaryAndPerformanceBonusDescription" id="fil_BaseSalaryAndPerformanceBonusDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumReimbursementOfTravelExpenses" id="fil_MaximumReimbursementOfTravelExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReimbursementOfTravelExpensesDescription" id="fil_ReimbursementOfTravelExpensesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceObjectiveDescription" id="fil_PerformanceObjectiveDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionGrantedToPurchaseSharesAsSignOnBonus" id="fil_OptionGrantedToPurchaseSharesAsSignOnBonus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionGrantedToPurchaseSharesAsSignOnBonusDescription" id="fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockGrantPercentagesOne" id="fil_RestrictedStockGrantPercentagesOne" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockGrantPercentageTwo" id="fil_RestrictedStockGrantPercentageTwo" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RestrictedStockGrantDescription" id="fil_RestrictedStockGrantDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="VestingScheduleDescription" id="fil_VestingScheduleDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" id="fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmploymentTermUnderAgreement" id="fil_EmploymentTermUnderAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OakRidgeNationalLaboratoryMember" id="fil_OakRidgeNationalLaboratoryMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AptivSolutionsMember" id="fil_AptivSolutionsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FredHutchinsonCancerResearchCenterMember" id="fil_FredHutchinsonCancerResearchCenterMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" id="fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfTexasMDAndersonCancerCenterMember" id="fil_UniversityOfTexasMDAndersonCancerCenterMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JohnsHopkinsUniversityMember" id="fil_JohnsHopkinsUniversityMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaidlawAndCoMember" id="fil_LaidlawAndCoMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfPennsylvaniaMember" id="fil_UniversityOfPennsylvaniaMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JamessCapitalGroupMember" id="fil_JamessCapitalGroupMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProductDevelopmentAndPatentLicenseAgreementMember" id="fil_ProductDevelopmentAndPatentLicenseAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementMember" id="fil_LicenseAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAndSponsoredResearchAgreementMember" id="fil_LicenseAndSponsoredResearchAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialAgreementMember" id="fil_ClinicalTrialAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentAgreementMember" id="fil_PlacementAgentAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransactionManagementAgreementMember" id="fil_TransactionManagementAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RentalAgreementMember" id="fil_RentalAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeparationAndSettlementAgreementMember" id="fil_SeparationAndSettlementAgreementMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfLicenseFee" id="fil_PaymentOfLicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePaymentDate" id="fil_MilestonePaymentDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfRoyaltyPaymentToRelatedParty" id="fil_DescriptionOfRoyaltyPaymentToRelatedParty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyOfNetSalesPercentage" id="fil_RoyaltyOfNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstCommercialSalePeriod" id="fil_FirstCommercialSalePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ResearchAndDevelopmentArrangement" id="fil_ResearchAndDevelopmentArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfRadioactiveMaterial" id="fil_PurchaseOfRadioactiveMaterial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProjectEstimatedCost" id="fil_ProjectEstimatedCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentOfProjectEstimatedCostPercentage" id="fil_DownPaymentOfProjectEstimatedCostPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownPaymentForProject" id="fil_DownPaymentForProject" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialCostForApprovalForFoodAndDrugAdministration" id="fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementForFirstTwoYear" id="fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FundToRelatedPartyUnderAgreementAfterYearTwo" id="fil_FundToRelatedPartyUnderAgreementAfterYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfPatients" id="fil_NumberOfPatients" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPaidToEachPatient" id="fil_AmountPaidToEachPatient" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpFeeForClinicalTrial" id="fil_StartUpFeeForClinicalTrial" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StartUpDueCostPaidDate" id="fil_StartUpDueCostPaidDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodicFeeReceivedByManagementFirm" id="fil_PeriodicFeeReceivedByManagementFirm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFullyDilutedCapitalStockEqualToCommonStock" id="fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantExercisableNoticePeriodDescription" id="fil_WarrantExercisableNoticePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DescriptionOfSharesAvailabilityByExerciseOfWarrant" id="fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumAmountOfOutOfPocketExpenses" id="fil_MaximumAmountOfOutOfPocketExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NonRefundableInstitutionalFee" id="fil_NonRefundableInstitutionalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PharmacyFee" id="fil_PharmacyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmendmentProcessingFee" id="fil_AmendmentProcessingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementConsideration" id="fil_AgreementConsideration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmountPayableInInstallmentsUnderAgreement" id="fil_AmountPayableInInstallmentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfInstallments" id="fil_NumberOfInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceBonusPayableUnderAgreementForService" id="fil_PerformanceBonusPayableUnderAgreementForService" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTerminationOfAgreement" id="fil_NoticePeriodForTerminationOfAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementRenewalDescription" id="fil_AgreementRenewalDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfAggregateAmount" id="fil_PaymentOfAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfFinalInstallmentForServicesByCompany" id="fil_PaymentOfFinalInstallmentForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PaymentOfPerformanceBonusForServicesByCompany" id="fil_PaymentOfPerformanceBonusForServicesByCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandThirteenStockPlanMember" id="fil_TwoThousandThirteenStockPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TwoThousandThirteenEquityIncentivePlanMember" id="fil_TwoThousandThirteenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesDirectorsAndConsultantsMember" id="fil_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesAndConsultantsMember" id="fil_EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantsMember" id="fil_ConsultantsMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTextualAbstract" id="fil_EquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnrecognizedShareBasedCompensationExpense" id="fil_UnrecognizedShareBasedCompensationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>fil-20130930_cal.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedbalancesheetsunaudited" roleURI="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedstatementsofoperationsunaudited" roleURI="http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_fil_GainOnChangeInFairValueOfDerivatives"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_fil_GainOnChangeInFairValueOfDerivatives" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment" order="30" use="optional" weight="-1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>fil-20130930_def.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesTables" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityTables" roleURI="http://cactusventuresinc.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails1" roleURI="http://cactusventuresinc.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesDetails" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual1" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityDetails" roleURI="http://cactusventuresinc.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityDetailsTextual" roleURI="http://cactusventuresinc.com/role/EquityDetailsTextual"/>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_7" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_fil_ActiniumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_fil_ActiniumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_fil_OptionsAndWarrantsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_fil_OptionsAndWarrantsMember_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_fil_PercentageOfOwnershipInterestToBeAcquired_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_fil_PercentageOfOwnershipInterestToBeAcquired_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesExchangeRatio" xlink:label="loc_fil_SharesExchangeRatio_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_fil_SharesExchangeRatio_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TotalOfCommonStockShares" xlink:label="loc_fil_TotalOfCommonStockShares_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_fil_TotalOfCommonStockShares_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ExchangedInCommonStockShares" xlink:label="loc_fil_ExchangedInCommonStockShares_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_16" xlink:to="loc_fil_ExchangedInCommonStockShares_24" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0" xlink:to="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_fil_MarketValueOfCommonStockOnMeasurementDate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_fil_MarketValueOfCommonStockOnMeasurementDate_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_6" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_13" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_fil_BiologicalLicenseApplicationMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_BiologicalLicenseApplicationMember_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_fil_FirstCommercialSaleMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_FirstCommercialSaleMember_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_AfterFirstNetSalesMember_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_fil_NewDrugApplicationMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_NewDrugApplicationMember_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_fil_MilestonePaymentAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_0" xlink:to="loc_fil_MilestonePaymentAbstract_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_MilestonePaymentAbstract_16" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_17" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_6" xlink:to="loc_us-gaap_EmploymentContractsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_RestrictedStockMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_us-gaap_OfficersCompensation_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BaseSalaryAndPerformanceBonusDescription" xlink:label="loc_fil_BaseSalaryAndPerformanceBonusDescription_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_BaseSalaryAndPerformanceBonusDescription_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumReimbursementOfTravelExpenses" xlink:label="loc_fil_MaximumReimbursementOfTravelExpenses_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_MaximumReimbursementOfTravelExpenses_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReimbursementOfTravelExpensesDescription" xlink:label="loc_fil_ReimbursementOfTravelExpensesDescription_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_ReimbursementOfTravelExpensesDescription_19" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_fil_PerformanceObjectiveDescription_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_PerformanceObjectiveDescription_20" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_22" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_23" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentagesOne" xlink:label="loc_fil_RestrictedStockGrantPercentagesOne_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_RestrictedStockGrantPercentagesOne_24" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentageTwo" xlink:label="loc_fil_RestrictedStockGrantPercentageTwo_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_RestrictedStockGrantPercentageTwo_25" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantDescription" xlink:label="loc_fil_RestrictedStockGrantDescription_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_RestrictedStockGrantDescription_26" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_VestingScheduleDescription" xlink:label="loc_fil_VestingScheduleDescription_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_VestingScheduleDescription_27" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_28" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmploymentTermUnderAgreement" xlink:label="loc_fil_EmploymentTermUnderAgreement_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_15" xlink:to="loc_fil_EmploymentTermUnderAgreement_29" order="130" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_fil_OakRidgeNationalLaboratoryMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_OakRidgeNationalLaboratoryMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_fil_AptivSolutionsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AptivSolutionsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_fil_FredHutchinsonCancerResearchCenterMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_fil_JohnsHopkinsUniversityMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JohnsHopkinsUniversityMember_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCoMember_12" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_fil_UniversityOfPennsylvaniaMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfPennsylvaniaMember_13" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_14" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_15" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_AfterFirstNetSalesMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_fil_LicenseAgreementMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAgreementMember_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_fil_LicenseAndSponsoredResearchAgreementMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ClinicalTrialAgreementMember_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_fil_PlacementAgentAgreementMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_PlacementAgentAgreementMember_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_TransactionManagementAgreementMember_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_fil_RentalAgreementMember_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_RentalAgreementMember_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_29" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30" xlink:to="loc_us-gaap_RangeMember_31" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30" xlink:to="loc_us-gaap_RangeMember_31_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_31" xlink:to="loc_us-gaap_MaximumMember_32" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_31" xlink:to="loc_us-gaap_MinimumMember_33" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_fil_PaymentOfLicenseFee_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PaymentOfLicenseFee_35" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_36" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_37" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_fil_MilestonePaymentDate_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_MilestonePaymentDate_38" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_39" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_fil_RoyaltyOfNetSalesPercentage_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_RoyaltyOfNetSalesPercentage_40" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_fil_FirstCommercialSalePeriod_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_FirstCommercialSalePeriod_41" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_us-gaap_TechnologyServicesCosts_42" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_us-gaap_MaintenanceCosts_43" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_fil_ResearchAndDevelopmentArrangement_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_ResearchAndDevelopmentArrangement_44" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_fil_PurchaseOfRadioactiveMaterial_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PurchaseOfRadioactiveMaterial_45" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_fil_ProjectEstimatedCost_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_ProjectEstimatedCost_46" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_47" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_fil_DownPaymentForProject_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_DownPaymentForProject_48" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_49" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_50" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_51" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_us-gaap_RoyaltyExpense_52" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_NumberOfPatients_53" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_AmountPaidToEachPatient_54" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_StartUpFeeForClinicalTrial_55" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_StartUpDueCostPaidDate_56" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_57" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_58" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_fil_WarrantExercisableNoticePeriodDescription_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_WarrantExercisableNoticePeriodDescription_59" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_60" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_61" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_fil_NonRefundableInstitutionalFee_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_NonRefundableInstitutionalFee_62" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_fil_PharmacyFee_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PharmacyFee_63" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_fil_AmendmentProcessingFee_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_AmendmentProcessingFee_64" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_fil_AgreementConsideration_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_AgreementConsideration_65" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_fil_AmountPayableInInstallmentsUnderAgreement_66"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_AmountPayableInInstallmentsUnderAgreement_66" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_fil_NumberOfInstallments_67"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_NumberOfInstallments_67" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_fil_PerformanceBonusPayableUnderAgreementForService_68"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PerformanceBonusPayableUnderAgreementForService_68" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_fil_NoticePeriodForTerminationOfAgreement_69"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_NoticePeriodForTerminationOfAgreement_69" order="340" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_70"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_us-gaap_LeaseExpirationDate1_70" order="350" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_fil_AgreementRenewalDescription_71"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_AgreementRenewalDescription_71" order="360" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfAggregateAmount" xlink:label="loc_fil_PaymentOfAggregateAmount_72"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PaymentOfAggregateAmount_72" order="370" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_73"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_73" order="380" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_74"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_34" xlink:to="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_74" order="390" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_15" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_fil_TwoThousandThirteenStockPlanMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThirteenStockPlanMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_WarrantMember_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_fil_EmployeesDirectorsAndConsultantsMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_EmployeesDirectorsAndConsultantsMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_fil_EmployeesAndConsultantsMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_EmployeesAndConsultantsMember_17" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_fil_ConsultantsMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_ConsultantsMember_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_fil_EquityTextualAbstract_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_fil_EquityTextualAbstract_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_19" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_19" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fil_EquityTextualAbstract_19" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_24" order="40" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>fil-20130930_lab.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DocumentAndEntityInformationAbstract" xlink:label="loc_659926H556J3_fil_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DocumentAndEntityInformationAbstract" xlink:to="lab_871148J778L5_fil_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_K44K1GFGG78K9F35F361_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_EntityRegistrantName" xlink:to="lab_M66M3IHII90M1H57H583_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_659926H556J3_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_EntityCentralIndexKey" xlink:to="lab_871148J778L5_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_K44K1GFGG78K9F35F361_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_AmendmentFlag" xlink:to="lab_M66M3IHII90M1H57H583_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_659926H556J3_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_CurrentFiscalYearEndDate" xlink:to="lab_871148J778L5_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_K44K1GFGG78K9F35F361_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_DocumentType" xlink:to="lab_M66M3IHII90M1H57H583_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_659926H556J3_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_DocumentPeriodEndDate" xlink:to="lab_871148J778L5_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_K44K1GFGG78K9F35F361_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_DocumentFiscalYearFocus" xlink:to="lab_M66M3IHII90M1H57H583_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_659926H556J3_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_DocumentFiscalPeriodFocus" xlink:to="lab_871148J778L5_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_K44K1GFGG78K9F35F361_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_EntityFilerCategory" xlink:to="lab_M66M3IHII90M1H57H583_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_659926H556J3_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_871148J778L5_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_659926H556J3_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AssetsAbstract" xlink:to="lab_871148J778L5_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AssetsCurrentAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_659926H556J3_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_871148J778L5_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_659926H556J3_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AssetsCurrent" xlink:to="lab_871148J778L5_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net of accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_659926H556J3_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_Assets" xlink:to="lab_871148J778L5_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_659926H556J3_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_871148J778L5_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_659926H556J3_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_871148J778L5_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NotesPayableCurrent" xml:lang="en-US">Note Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NotesPayableCurrent" xml:lang="en-US">Note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NotesPayableCurrent" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_659926H556J3_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_871148J778L5_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_LiabilitiesCurrent" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_659926H556J3_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_Liabilities" xlink:to="lab_871148J778L5_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CommitmentsAndContingencies" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_659926H556J3_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_StockholdersEquityAbstract" xlink:to="lab_871148J778L5_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, 100,000,000 Shares .01 Par Authorized, 0 Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, 100,000,000 shares $.01 par authorized, 0 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 authorized 0 shares issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockValue" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_659926H556J3_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, 100,000,000 shares, $.01 par authorized, 11,155,008 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 23,656,582 and 21,391,665 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CommonStockValue" xlink:to="lab_871148J778L5_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Paid in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AdditionalPaidInCapital" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_659926H556J3_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during the development stage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_871148J778L5_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_StockholdersEquity" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_659926H556J3_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_871148J778L5_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_659926H556J3_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_871148J778L5_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PreferredStockSharesIssued" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_659926H556J3_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">No. of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_871148J778L5_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_659926H556J3_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_871148J778L5_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued in exchange of equity securities of company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CommonStockSharesIssued" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_659926H556J3_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_871148J778L5_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statements Of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeStatementAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_659926H556J3_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_SalesRevenueNet" xlink:to="lab_871148J778L5_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_OperatingExpensesAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_659926H556J3_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development, net of reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_659926H556J3_us-gaap_DepreciationAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DepreciationAndAmortization" xlink:to="lab_871148J778L5_us-gaap_DepreciationAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_GainLossOnDispositionOfAssets1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_GainLossOnDispositionOfAssets1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_659926H556J3_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_OperatingExpenses" xml:lang="en-US">Total expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_OperatingExpenses" xlink:to="lab_871148J778L5_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_OperatingIncomeLoss" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_659926H556J3_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_871148J778L5_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_InterestExpense" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_659926H556J3_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gains (Losses) On Extinguishment Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on extinguishment of liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_871148J778L5_us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) On Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Change in fair value - derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain/loss on change in fair value of the derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_659926H556J3_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Net Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_871148J778L5_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NetIncomeLoss" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_659926H556J3_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Loss Per Common Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_871148J778L5_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_659926H556J3_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_871148J778L5_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_659926H556J3_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_871148J778L5_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_659926H556J3_us-gaap_DepreciationDepletionAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_871148J778L5_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization Of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Add: amortization of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_659926H556J3_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization Of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_871148J778L5_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_K44K1GFGG78K9F35F361_fil_GainOnChangeInFairValueOfDerivatives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain On Change In Fair Value Of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Gain on change in fair value of the derivatives.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_GainOnChangeInFairValueOfDerivatives" xml:lang="en-US">Change in fair value derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_GainOnChangeInFairValueOfDerivatives" xlink:to="lab_M66M3IHII90M1H57H583_fil_GainOnChangeInFairValueOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_659926H556J3_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_871148J778L5_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">(Increase) decrease in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_659926H556J3_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_871148J778L5_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (Decrease) In Operating Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xml:lang="en-US">Increase (decrease) in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_659926H556J3_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_871148J778L5_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) In Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Accounts payable and accrued liabilities - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_659926H556J3_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments To Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payment made for patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_871148J778L5_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_659926H556J3_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Proceeds From Debt, Net Of Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US">Borrowings on convertible debt, net of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_871148J778L5_us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RepaymentsOfNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments Of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payments on note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_659926H556J3_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds From Issuance Of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Sales of Common stock, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from issuance of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_871148J778L5_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from the exercise of warrants for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_871148J778L5_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">INCREASE IN CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net change in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_659926H556J3_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_871148J778L5_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeTaxesPaid" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_659926H556J3_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_InterestPaid" xlink:to="lab_871148J778L5_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_659926H556J3_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_871148J778L5_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_K44K1GFGG78K9F35F361_fil_FairValueOfWarrantsIssuedWithDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair Value Of Warrants Issued With Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedWithDebt" xml:lang="en-US">Fair value of warrants issued with debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_FairValueOfWarrantsIssuedWithDebt" xlink:to="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedWithDebt"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_659926H556J3_fil_FairValueOfWarrantsIssuedWithStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair Value Of Warrants Issued With Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_FairValueOfWarrantsIssuedWithStock" xml:lang="en-US">Fair value of warrants issued with stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_FairValueOfWarrantsIssuedWithStock" xlink:to="lab_871148J778L5_fil_FairValueOfWarrantsIssuedWithStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_K44K1GFGG78K9F35F361_fil_FairValueOfWarrantsIssuedToPlacementAgent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair Value Of Warrants Issued To Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedToPlacementAgent" xml:lang="en-US">Fair value of warrants issued to the placement agent.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="lab_M66M3IHII90M1H57H583_fil_FairValueOfWarrantsIssuedToPlacementAgent"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_659926H556J3_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion Of Notes Payable and Accrued Interest To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xml:lang="en-US">Conversion of notes payable and accrued interest to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:to="lab_871148J778L5_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_K44K1GFGG78K9F35F361_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair Value Of Transfer From Liability Classification To Equity Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from derivative liability classification to equity classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Transfer from liability classification to equity classification, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xml:lang="en-US">Fair value of Transfer from liability classification to equity classification.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:to="lab_M66M3IHII90M1H57H583_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_659926H556J3_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_871148J778L5_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_659926H556J3_fil_GoingConcernAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_GoingConcernAbstract" xlink:to="lab_871148J778L5_fil_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_fil_GoingConcernTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_GoingConcernTextBlock" xml:lang="en-US">Going Concern assumption.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_GoingConcernTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_fil_GoingConcernTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_659926H556J3_us-gaap_DebtDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Note Payable [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DebtDisclosureAbstract" xlink:to="lab_871148J778L5_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Note Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_659926H556J3_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivatives [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_871148J778L5_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_659926H556J3_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_871148J778L5_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_659926H556J3_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_871148J778L5_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_659926H556J3_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_SubsequentEventsAbstract" xlink:to="lab_871148J778L5_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_659926H556J3_us-gaap_BusinessCombinationsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Nature of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_871148J778L5_us-gaap_BusinessCombinationsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis Of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation - Unaudited Interim Financial Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_659926H556J3_fil_DevelopmentStageCompanyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DevelopmentStageCompanyPolicyTextBlock" xlink:to="lab_871148J778L5_fil_DevelopmentStageCompanyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_659926H556J3_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates in Financial Statement Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_UseOfEstimates" xlink:to="lab_871148J778L5_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_659926H556J3_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_871148J778L5_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_659926H556J3_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_871148J778L5_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_659926H556J3_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_871148J778L5_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_659926H556J3_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_871148J778L5_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Share-Based Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_659926H556J3_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_871148J778L5_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_659926H556J3_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_871148J778L5_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured On Recurring and Nonrecurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Summary of set forth assets and liabilities measured at fair value on a recurring and non-recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule Of Derivative Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_659926H556J3_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair Value Of Derivative Warrants On Basis Of Valuation Model [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xml:lang="en-US">Fair value of derivative warrants on basis of valuation model.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:to="lab_871148J778L5_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentsMilestoneMethodTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone Payments Milestone Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone Payments Milestone Method [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTable" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentsMilestoneMethodTable" xlink:to="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_659926H556J3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_871148J778L5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RelatedPartyDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_659926H556J3_fil_AbbottBiotherapeuticsCorpMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott Biotherapeutics Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_AbbottBiotherapeuticsCorpMember" xml:lang="en-US">Abbott biotherapeutics corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_AbbottBiotherapeuticsCorpMember" xlink:to="lab_871148J778L5_fil_AbbottBiotherapeuticsCorpMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_MemorialSloanKetteringCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial Sloan Kettering Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">MSKCC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_MemorialSloanKetteringCancerCenterMember" xml:lang="en-US">Memorial sloan kettering cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_MemorialSloanKetteringCancerCenterMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_MemorialSloanKetteringCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_659926H556J3_fil_MilestonePaymentsMilestoneMethodLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone Payments Milestone Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone Payments Milestone Method [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_MilestonePaymentsMilestoneMethodLineItems" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_MilestonePaymentsMilestoneMethodLineItems" xlink:to="lab_871148J778L5_fil_MilestonePaymentsMilestoneMethodLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone Payments Milestone Method [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Summary of milestone payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xml:lang="en-US">Milestone payments milestone method.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:to="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentsMilestoneMethodTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_659926H556J3_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share-Based Compensation Arrangements By Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AwardTypeAxis" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_EmployeeStockOptionMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_659926H556J3_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_WarrantMember" xml:lang="en-US">A Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_WarrantMember" xlink:to="lab_871148J778L5_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_659926H556J3_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_871148J778L5_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_659926H556J3_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_871148J778L5_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_659926H556J3_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_871148J778L5_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_659926H556J3_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_871148J778L5_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_659926H556J3_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xml:lang="en-US">Summary Of Assets and Liabilities Measured At Fair Value On Recurring and Non Recurring Basis [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xml:lang="en-US">Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:to="lab_871148J778L5_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeLiabilities" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_659926H556J3_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Description of business and summary of significant accounting policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_K44K1GFGG78K9F35F361_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_dei_LegalEntityAxis" xlink:to="lab_M66M3IHII90M1H57H583_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_659926H556J3_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_dei_EntityDomain" xlink:to="lab_871148J778L5_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ActiniumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ActiniumMember" xml:lang="en-US">Actinium [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ActiniumMember" xml:lang="en-US">Actinium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ActiniumMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_ActiniumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_659926H556J3_us-gaap_MachineryAndEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_871148J778L5_us-gaap_MachineryAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FurnitureAndFixturesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FurnitureAndFixturesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_659926H556J3_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_871148J778L5_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_659926H556J3_fil_OptionsAndWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options And Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options and Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_OptionsAndWarrantsMember" xml:lang="en-US">Options and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_OptionsAndWarrantsMember" xlink:to="lab_871148J778L5_fil_OptionsAndWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_659926H556J3_us-gaap_ConvertibleNotesPayableMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_871148J778L5_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Description of business and summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_M66M3IHII90M1H57H583_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_659926H556J3_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description Of Business and Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Description of Business and Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_871148J778L5_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PercentageOfOwnershipInterestToBeAcquired"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage Of Ownership Interest To Be Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage of ownership interest to be acquired by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage of ownership interest to be acquired by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PercentageOfOwnershipInterestToBeAcquired" xml:lang="en-US">Percentage of ownership interest to be acquired by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PercentageOfOwnershipInterestToBeAcquired" xlink:to="lab_M66M3IHII90M1H57H583_fil_PercentageOfOwnershipInterestToBeAcquired"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_659926H556J3_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock Issuable In Consideration For Equity Interest Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xml:lang="en-US">Common Stock issuable in consideration for equity interest acquisition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:to="lab_871148J778L5_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesExchangeRatio" xlink:label="loc_659926H556J3_fil_SharesExchangeRatio"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_SharesExchangeRatio" xml:lang="en-US">Shares Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_SharesExchangeRatio" xml:lang="en-US">Shares received by each API shareholder of Actinium common stock for each API share exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_SharesExchangeRatio" xml:lang="en-US">Shares exchange ratio.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_SharesExchangeRatio" xlink:to="lab_871148J778L5_fil_SharesExchangeRatio"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially issuable shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TotalOfCommonStockShares" xlink:label="loc_659926H556J3_fil_TotalOfCommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_TotalOfCommonStockShares" xml:lang="en-US">Total Of Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_TotalOfCommonStockShares" xml:lang="en-US">Total of common stock shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_TotalOfCommonStockShares" xml:lang="en-US">Total of common stock shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_TotalOfCommonStockShares" xlink:to="lab_871148J778L5_fil_TotalOfCommonStockShares"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ExchangedInCommonStockShares" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ExchangedInCommonStockShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ExchangedInCommonStockShares" xml:lang="en-US">Exchanged In Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ExchangedInCommonStockShares" xml:lang="en-US">Common stock shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ExchangedInCommonStockShares" xlink:to="lab_M66M3IHII90M1H57H583_fil_ExchangedInCommonStockShares"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextualAbstract" xlink:label="loc_659926H556J3_fil_GoingConcernTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_GoingConcernTextualAbstract" xlink:to="lab_871148J778L5_fil_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_659926H556J3_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_871148J778L5_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_OfficeEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_OfficeEquipmentMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Property, Plant and Equipment, Net, By Type [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_871148J778L5_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Total property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_659926H556J3_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">(Less) Accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_871148J778L5_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_K44K1GFGG78K9F35F361_fil_LossOnDispositionOfPropertyAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss On Disposition Of Property and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss on disposition of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss on disposition of property and equipment.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_LossOnDispositionOfPropertyAndEquipment" xml:lang="en-US">Loss on disposition of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_LossOnDispositionOfPropertyAndEquipment" xlink:to="lab_M66M3IHII90M1H57H583_fil_LossOnDispositionOfPropertyAndEquipment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PropertyAndEquipmentTextualAbstract" xlink:label="loc_659926H556J3_fil_PropertyAndEquipmentTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PropertyAndEquipmentTextualAbstract" xml:lang="en-US">Property and Equipment (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PropertyAndEquipmentTextualAbstract" xlink:to="lab_871148J778L5_fil_PropertyAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_Depreciation" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NotePayableTextualAbstract" xlink:label="loc_659926H556J3_fil_NotePayableTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_NotePayableTextualAbstract" xml:lang="en-US">Note Payable Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_NotePayableTextualAbstract" xml:lang="en-US">Note Payable (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_NotePayableTextualAbstract" xlink:to="lab_871148J778L5_fil_NotePayableTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_KeymanInsurancePolicyPremium" xlink:label="loc_K44K1GFGG78K9F35F361_fil_KeymanInsurancePolicyPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_KeymanInsurancePolicyPremium" xml:lang="en-US">Keyman Insurance Policy Premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_KeymanInsurancePolicyPremium" xml:lang="en-US">Premium paid by company pursuant to premium finance agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_KeymanInsurancePolicyPremium" xml:lang="en-US">Company took a policy for its top management employee and mount of policy premium paid by company on behalf of its director and president.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_KeymanInsurancePolicyPremium" xlink:to="lab_M66M3IHII90M1H57H583_fil_KeymanInsurancePolicyPremium"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyDownPayment" xlink:label="loc_659926H556J3_fil_InsurancePolicyDownPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_InsurancePolicyDownPayment" xml:lang="en-US">Insurance Policy Down Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_InsurancePolicyDownPayment" xml:lang="en-US">Down payment under insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_InsurancePolicyDownPayment" xml:lang="en-US">Amount of down payment of insurance policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_InsurancePolicyDownPayment" xlink:to="lab_871148J778L5_fil_InsurancePolicyDownPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyInstallmentPayment" xlink:label="loc_K44K1GFGG78K9F35F361_fil_InsurancePolicyInstallmentPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Insurance Policy Installment Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Premium monthly installment for nine months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_InsurancePolicyInstallmentPayment" xml:lang="en-US">Amount of monthly installment payment of insurance policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_InsurancePolicyInstallmentPayment" xlink:to="lab_M66M3IHII90M1H57H583_fil_InsurancePolicyInstallmentPayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_659926H556J3_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Principal payment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_871148J778L5_us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule Of Derivative Warrant Instruments Activity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xml:lang="en-US">Schedule of derivative warrant instruments activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:to="lab_M66M3IHII90M1H57H583_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_659926H556J3_fil_DerivativeWarrantsUnits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative Warrants Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Total warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Beginning balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Balance, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DerivativeWarrantsUnits" xml:lang="en-US">Derivative warrants units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DerivativeWarrantsUnits" xlink:to="lab_871148J778L5_fil_DerivativeWarrantsUnits"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Derivative Warrant Units, Reclassification To Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Reclassification to paid in capital, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xml:lang="en-US">Reclassification to paid in capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:to="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_659926H556J3_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Derivative, Fair Value, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Beginning balance, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeFairValueOfDerivativeNet" xml:lang="en-US">Balance, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_871148J778L5_us-gaap_DerivativeFairValueOfDerivativeNet"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Derivative Warrant Units, Reclassification To Paid In Capital, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Reclassification to paid in capital, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xml:lang="en-US">Reclassification to paid in capital, fair value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:to="lab_M66M3IHII90M1H57H583_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_659926H556J3_fil_ChangeInFairValueOfDerivativeWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change In Fair Value Of Derivative Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ChangeInFairValueOfDerivativeWarrants" xml:lang="en-US">Change in fair value of derivative warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ChangeInFairValueOfDerivativeWarrants" xlink:to="lab_871148J778L5_fil_ChangeInFairValueOfDerivativeWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeTable" xml:lang="en-US">Derivative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_DerivativeTable" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_DerivativeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RangeMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_659926H556J3_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_MinimumMember" xlink:to="lab_871148J778L5_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_MaximumMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_659926H556J3_us-gaap_DerivativeLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_DerivativeLineItems" xml:lang="en-US">Derivative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_DerivativeLineItems" xlink:to="lab_871148J778L5_us-gaap_DerivativeLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary Of Fair Value Of Derivative Warrants On Basis Of Valuation Model [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xml:lang="en-US">Summary of fair values of derivative warrants on basis of valuation model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:to="lab_M66M3IHII90M1H57H583_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_659926H556J3_fil_MarketValueOfCommonStockOnMeasurementDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market Value Of Common Stock On Measurement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_MarketValueOfCommonStockOnMeasurementDate" xml:lang="en-US">Market value of common stock on measurement date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_MarketValueOfCommonStockOnMeasurementDate" xlink:to="lab_871148J778L5_fil_MarketValueOfCommonStockOnMeasurementDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Adjusted exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_659926H556J3_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_871148J778L5_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Term of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Warrant lives in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_659926H556J3_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_871148J778L5_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield (4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_659926H556J3_us-gaap_FairValueInputsProbabilityOfDefault"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Fair Value Inputs, Probability of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_FairValueInputsProbabilityOfDefault" xml:lang="en-US">Probability of stock offering in any period over 5 years (5)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="lab_871148J778L5_us-gaap_FairValueInputsProbabilityOfDefault"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativesTextualAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DerivativesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativesTextualAbstract" xml:lang="en-US">Derivatives Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DerivativesTextualAbstract" xml:lang="en-US">Derivatives textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DerivativesTextualAbstract" xlink:to="lab_M66M3IHII90M1H57H583_fil_DerivativesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_659926H556J3_fil_DescriptionOfProbabilityOfStockOffering"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description Of Probability Of Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DescriptionOfProbabilityOfStockOffering" xml:lang="en-US">Description of probability of stock offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DescriptionOfProbabilityOfStockOffering" xlink:to="lab_871148J778L5_fil_DescriptionOfProbabilityOfStockOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_LongTermPurchaseCommitmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-Term Purchase Commitment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentTable" xml:lang="en-US">Long-term Purchase Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_659926H556J3_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_659926H556J3_fil_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase First Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase I Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase first clinical trial of a licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:to="lab_871148J778L5_fil_PhaseFirstClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Second Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase II Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase second clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_PhaseSecondClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_659926H556J3_fil_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase Third Clinical Trial Of Licensed Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III Clinical Trial of a licensed product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xml:lang="en-US">Phase III clinical trial of licensed product.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:to="lab_871148J778L5_fil_PhaseThirdClinicalTrialOfLicensedProductMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_BiologicalLicenseApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological License Application filing with U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_BiologicalLicenseApplicationMember" xml:lang="en-US">Biological license application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_BiologicalLicenseApplicationMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_BiologicalLicenseApplicationMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_659926H556J3_fil_FirstCommercialSaleMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_FirstCommercialSaleMember" xml:lang="en-US">First Commercial Sale [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_FirstCommercialSaleMember" xml:lang="en-US">First commercial sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_FirstCommercialSaleMember" xlink:to="lab_871148J778L5_fil_FirstCommercialSaleMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_AfterFirstNetSalesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_AfterFirstNetSalesMember" xml:lang="en-US">After First Net Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_AfterFirstNetSalesMember" xml:lang="en-US">After first net sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_AfterFirstNetSalesMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_AfterFirstNetSalesMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_659926H556J3_fil_NewDrugApplicationMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_NewDrugApplicationMember" xml:lang="en-US">New Drug Application [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_NewDrugApplicationMember" xml:lang="en-US">New drug application.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_NewDrugApplicationMember" xlink:to="lab_871148J778L5_fil_NewDrugApplicationMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt Of Regulatory Approval From U S Fda [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of Regulatory Approval From U.S. FDA [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xml:lang="en-US">Receipt of regulatory approval from U.S. FDA.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_659926H556J3_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentLineItems" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_871148J778L5_us-gaap_LongTermPurchaseCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentAbstract" xml:lang="en-US">Milestone Payment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentAbstract" xml:lang="en-US">Summary of milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_MilestonePaymentAbstract" xlink:to="lab_M66M3IHII90M1H57H583_fil_MilestonePaymentAbstract"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_659926H556J3_fil_LongTermPurchaseCommitmentMilestonesPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long Term Purchase Commitment Milestones Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Milestones payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_LongTermPurchaseCommitmentMilestonesPayment" xml:lang="en-US">Long term purchase commitment milestones payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:to="lab_871148J778L5_fil_LongTermPurchaseCommitmentMilestonesPayment"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_K44K1GFGG78K9F35F361_fil_CommitmentsAndContingenciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_CommitmentsAndContingenciesTable" xlink:to="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_659926H556J3_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_TitleOfIndividualAxis" xlink:to="lab_871148J778L5_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_659926H556J3_fil_ChiefExecutiveOfficerAndDirectorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ChiefExecutiveOfficerAndDirectorMember" xml:lang="en-US">Chief Executive Officer And Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ChiefExecutiveOfficerAndDirectorMember" xml:lang="en-US">Highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ChiefExecutiveOfficerAndDirectorMember" xlink:to="lab_871148J778L5_fil_ChiefExecutiveOfficerAndDirectorMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_K44K1GFGG78K9F35F361_fil_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementAxis" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_AgreementAxis" xlink:to="lab_M66M3IHII90M1H57H583_fil_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_659926H556J3_fil_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_AgreementDomain" xml:lang="en-US">Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_AgreementDomain" xlink:to="lab_871148J778L5_fil_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_EmploymentContractsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EmploymentContractsMember" xml:lang="en-US">Employment Contracts [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_EmploymentContractsMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_EmploymentContractsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_659926H556J3_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_871148J778L5_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_EquityComponentDomain" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_659926H556J3_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_CommonStockMember" xlink:to="lab_871148J778L5_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RestrictedStockMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_659926H556J3_fil_CommitmentsAndContingenciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_CommitmentsAndContingenciesLineItems" xlink:to="lab_871148J778L5_fil_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_K44K1GFGG78K9F35F361_fil_CommitmentsAndContingenciesTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_M66M3IHII90M1H57H583_fil_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_659926H556J3_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_us-gaap_OfficersCompensation" xml:lang="en-US">Base salary at annual rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_OfficersCompensation" xlink:to="lab_871148J778L5_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BaseSalaryAndPerformanceBonusDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_BaseSalaryAndPerformanceBonusDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_BaseSalaryAndPerformanceBonusDescription" xml:lang="en-US">Base Salary And Performance Bonus Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_BaseSalaryAndPerformanceBonusDescription" xml:lang="en-US">Base salary and performance bonus, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_BaseSalaryAndPerformanceBonusDescription" xml:lang="en-US">Description relating to ceo and director base salary and performance bonus.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_BaseSalaryAndPerformanceBonusDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_BaseSalaryAndPerformanceBonusDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumReimbursementOfTravelExpenses" xlink:label="loc_659926H556J3_fil_MaximumReimbursementOfTravelExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_MaximumReimbursementOfTravelExpenses" xml:lang="en-US">Maximum Reimbursement Of Travel Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_MaximumReimbursementOfTravelExpenses" xml:lang="en-US">Maximum reimbursement for travel expenses per month</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_MaximumReimbursementOfTravelExpenses" xml:lang="en-US">Reimbursement made for Expenses incurred for travel during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_MaximumReimbursementOfTravelExpenses" xlink:to="lab_871148J778L5_fil_MaximumReimbursementOfTravelExpenses"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReimbursementOfTravelExpensesDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ReimbursementOfTravelExpensesDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReimbursementOfTravelExpensesDescription" xml:lang="en-US">Reimbursement Of Travel Expenses Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReimbursementOfTravelExpensesDescription" xml:lang="en-US">Reimbursement of travel expenses, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ReimbursementOfTravelExpensesDescription" xml:lang="en-US">Description of reimbursement of travel expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ReimbursementOfTravelExpensesDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_ReimbursementOfTravelExpensesDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_659926H556J3_fil_PerformanceObjectiveDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PerformanceObjectiveDescription" xml:lang="en-US">Performance Objective Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_fil_PerformanceObjectiveDescription" xml:lang="en-US">Performance objective, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PerformanceObjectiveDescription" xml:lang="en-US">Description regarding remuneration of CEO and director upon the attainment of performance objective.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PerformanceObjectiveDescription" xlink:to="lab_871148J778L5_fil_PerformanceObjectiveDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Common stock available for grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Options granted to purchase shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_659926H556J3_fil_OptionGrantedToPurchaseSharesAsSignOnBonus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option Granted To Purchase Shares As Sign On Bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option granted as sign on bonus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xml:lang="en-US">Option granted to purchase shares as sign on bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:to="lab_871148J778L5_fil_OptionGrantedToPurchaseSharesAsSignOnBonus"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option Granted To Purchase Shares As Sign On Bonus Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option granted as sign on bonus, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xml:lang="en-US">Option granted to purchase shares as sign on bonus description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentagesOne" xlink:label="loc_659926H556J3_fil_RestrictedStockGrantPercentagesOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantPercentagesOne" xml:lang="en-US">Restricted Stock Grant Percentages One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantPercentagesOne" xml:lang="en-US">Restricted stock grant percentages, One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantPercentagesOne" xml:lang="en-US">Restricted stock grant percentages one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_RestrictedStockGrantPercentagesOne" xlink:to="lab_871148J778L5_fil_RestrictedStockGrantPercentagesOne"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentageTwo" xlink:label="loc_K44K1GFGG78K9F35F361_fil_RestrictedStockGrantPercentageTwo"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_RestrictedStockGrantPercentageTwo" xml:lang="en-US">Restricted Stock Grant Percentage Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_RestrictedStockGrantPercentageTwo" xml:lang="en-US">Percentage of restricted stock granted, Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_RestrictedStockGrantPercentageTwo" xml:lang="en-US">Other Percentage of restricted stock granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_RestrictedStockGrantPercentageTwo" xlink:to="lab_M66M3IHII90M1H57H583_fil_RestrictedStockGrantPercentageTwo"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantDescription" xlink:label="loc_659926H556J3_fil_RestrictedStockGrantDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantDescription" xml:lang="en-US">Restricted Stock Grant Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantDescription" xml:lang="en-US">Restricted stock grant, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_RestrictedStockGrantDescription" xml:lang="en-US">Restricted stock grant, description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_RestrictedStockGrantDescription" xlink:to="lab_871148J778L5_fil_RestrictedStockGrantDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_VestingScheduleDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_VestingScheduleDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_VestingScheduleDescription" xml:lang="en-US">Vesting Schedule Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_VestingScheduleDescription" xml:lang="en-US">Vesting schedule, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_VestingScheduleDescription" xml:lang="en-US">Description relating to vesting schedule.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_VestingScheduleDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_VestingScheduleDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="loc_659926H556J3_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xml:lang="en-US">Options,Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award, options, expiration term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="lab_871148J778L5_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmploymentTermUnderAgreement" xlink:label="loc_K44K1GFGG78K9F35F361_fil_EmploymentTermUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_EmploymentTermUnderAgreement" xml:lang="en-US">Employment Term Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_EmploymentTermUnderAgreement" xml:lang="en-US">Term of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_EmploymentTermUnderAgreement" xlink:to="lab_M66M3IHII90M1H57H583_fil_EmploymentTermUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_659926H556J3_fil_OakRidgeNationalLaboratoryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak Ridge National Laboratory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_OakRidgeNationalLaboratoryMember" xml:lang="en-US">Oak ridge national laboratory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_OakRidgeNationalLaboratoryMember" xlink:to="lab_871148J778L5_fil_OakRidgeNationalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_AptivSolutionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv Solutions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_AptivSolutionsMember" xml:lang="en-US">Aptiv solutions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_AptivSolutionsMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_AptivSolutionsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_659926H556J3_fil_FredHutchinsonCancerResearchCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred Hutchinson Cancer Research Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_FredHutchinsonCancerResearchCenterMember" xml:lang="en-US">Fred hutchinson cancer research center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_FredHutchinsonCancerResearchCenterMember" xlink:to="lab_871148J778L5_fil_FredHutchinsonCancerResearchCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and Ii Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I/II Clinical Trial For Actimab In Elderly Acute Myeloid Leukemia [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xml:lang="en-US">Phase I and II clinical trial for actimab in elderly acute myeloid leukemia.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_659926H556J3_fil_UniversityOfTexasMDAndersonCancerCenterMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University Of Texas M D Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of Texas M.D. Anderson Cancer Center [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_UniversityOfTexasMDAndersonCancerCenterMember" xml:lang="en-US">University of texas M.D. anderson cancer center.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_871148J778L5_fil_UniversityOfTexasMDAndersonCancerCenterMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_JohnsHopkinsUniversityMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns Hopkins University [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_JohnsHopkinsUniversityMember" xml:lang="en-US">Johns hopkins university.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_JohnsHopkinsUniversityMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_JohnsHopkinsUniversityMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_659926H556J3_fil_LaidlawAndCoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw &amp; Co [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_LaidlawAndCoMember" xml:lang="en-US">Laidlaw and company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_LaidlawAndCoMember" xlink:to="lab_871148J778L5_fil_LaidlawAndCoMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_UniversityOfPennsylvaniaMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University Of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of Pennsylvania [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_UniversityOfPennsylvaniaMember" xml:lang="en-US">University of pennsylvania.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_UniversityOfPennsylvaniaMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_UniversityOfPennsylvaniaMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_659926H556J3_fil_JamessCapitalGroupMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess Capital Group LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_JamessCapitalGroupMember" xml:lang="en-US">Jamess capital group.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_JamessCapitalGroupMember" xlink:to="lab_871148J778L5_fil_JamessCapitalGroupMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Former CEO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_659926H556J3_fil_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product Development and Patent License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xml:lang="en-US">Product development and patent license agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:to="lab_871148J778L5_fil_ProductDevelopmentAndPatentLicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_LicenseAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_LicenseAgreementMember" xml:lang="en-US">License Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_LicenseAgreementMember" xml:lang="en-US">License agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_LicenseAgreementMember" xml:lang="en-US">License agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_LicenseAgreementMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_LicenseAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_659926H556J3_fil_LicenseAndSponsoredResearchAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and Sponsored Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">license and sponsored research agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_LicenseAndSponsoredResearchAgreementMember" xml:lang="en-US">License and sponsored research agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_LicenseAndSponsoredResearchAgreementMember" xlink:to="lab_871148J778L5_fil_LicenseAndSponsoredResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ClinicalTrialAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialAgreementMember" xml:lang="en-US">Clinical trial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ClinicalTrialAgreementMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_659926H556J3_fil_PlacementAgentAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement Agent Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PlacementAgentAgreementMember" xml:lang="en-US">Placement agent agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PlacementAgentAgreementMember" xlink:to="lab_871148J778L5_fil_PlacementAgentAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_TransactionManagementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction Management Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_TransactionManagementAgreementMember" xml:lang="en-US">Transaction management agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_TransactionManagementAgreementMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_TransactionManagementAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_659926H556J3_fil_RentalAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_RentalAgreementMember" xml:lang="en-US">Rental Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_RentalAgreementMember" xml:lang="en-US">Rental agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_RentalAgreementMember" xlink:to="lab_871148J778L5_fil_RentalAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_SeparationAndSettlementAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_SeparationAndSettlementAgreementMember" xml:lang="en-US">Separation and Settlement Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_SeparationAndSettlementAgreementMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_SeparationAndSettlementAgreementMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_659926H556J3_fil_PaymentOfLicenseFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PaymentOfLicenseFee" xml:lang="en-US">Payment Of License Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PaymentOfLicenseFee" xml:lang="en-US">License fee payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PaymentOfLicenseFee" xml:lang="en-US">License fee payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PaymentOfLicenseFee" xlink:to="lab_871148J778L5_fil_PaymentOfLicenseFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Net sales in milestones payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_659926H556J3_fil_MilestonePaymentDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_MilestonePaymentDate" xml:lang="en-US">Milestone Payment Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_MilestonePaymentDate" xml:lang="en-US">Milestone payment date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_MilestonePaymentDate" xml:lang="en-US">Milestone payment date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_MilestonePaymentDate" xlink:to="lab_871148J778L5_fil_MilestonePaymentDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description Of Royalty Payment To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xml:lang="en-US">Description of royalty payment to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:to="lab_M66M3IHII90M1H57H583_fil_DescriptionOfRoyaltyPaymentToRelatedParty"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_659926H556J3_fil_RoyaltyOfNetSalesPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty Of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of Net Sales Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_RoyaltyOfNetSalesPercentage" xml:lang="en-US">Royalty of net sales percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_RoyaltyOfNetSalesPercentage" xlink:to="lab_871148J778L5_fil_RoyaltyOfNetSalesPercentage"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_K44K1GFGG78K9F35F361_fil_FirstCommercialSalePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_FirstCommercialSalePeriod" xml:lang="en-US">First Commercial Sale Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_FirstCommercialSalePeriod" xml:lang="en-US">First commercial sale period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_FirstCommercialSalePeriod" xlink:to="lab_M66M3IHII90M1H57H583_fil_FirstCommercialSalePeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_659926H556J3_us-gaap_TechnologyServicesCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_TechnologyServicesCosts" xml:lang="en-US">Technology access fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_TechnologyServicesCosts" xlink:to="lab_871148J778L5_us-gaap_TechnologyServicesCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_MaintenanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_MaintenanceCosts" xml:lang="en-US">Maintenance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_MaintenanceCosts" xml:lang="en-US">Annual maintenance fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_MaintenanceCosts" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_MaintenanceCosts"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_659926H556J3_fil_ResearchAndDevelopmentArrangement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and Development Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Annual research funding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ResearchAndDevelopmentArrangement" xml:lang="en-US">Research and development arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ResearchAndDevelopmentArrangement" xlink:to="lab_871148J778L5_fil_ResearchAndDevelopmentArrangement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PurchaseOfRadioactiveMaterial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase Of Radioactive Material</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material used for research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PurchaseOfRadioactiveMaterial" xml:lang="en-US">Purchase of radioactive material.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PurchaseOfRadioactiveMaterial" xlink:to="lab_M66M3IHII90M1H57H583_fil_PurchaseOfRadioactiveMaterial"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_659926H556J3_fil_ProjectEstimatedCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_ProjectEstimatedCost" xml:lang="en-US">Project Estimated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost for clinical trials of drug Ac-225-HuM195</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_ProjectEstimatedCost" xml:lang="en-US">Project estimated cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_ProjectEstimatedCost" xlink:to="lab_871148J778L5_fil_ProjectEstimatedCost"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_K44K1GFGG78K9F35F361_fil_DownPaymentOfProjectEstimatedCostPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down Payment Of Project Estimated Cost Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Down payment of project estimated cost percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_DownPaymentOfProjectEstimatedCostPercentage" xml:lang="en-US">Percentage of total estimated project cost required for down payment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:to="lab_M66M3IHII90M1H57H583_fil_DownPaymentOfProjectEstimatedCostPercentage"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_659926H556J3_fil_DownPaymentForProject"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DownPaymentForProject" xml:lang="en-US">Down Payment For Project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DownPaymentForProject" xml:lang="en-US">Down payment for project</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DownPaymentForProject" xml:lang="en-US">Down payment for project.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DownPaymentForProject" xlink:to="lab_871148J778L5_fil_DownPaymentForProject"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical Trial Cost For Approval For Food and Drug Administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xml:lang="en-US">Clinical trial cost for approval of food and drug administration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:to="lab_M66M3IHII90M1H57H583_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_659926H556J3_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund To Related Party Under Agreement For First Two Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xml:lang="en-US">Fund to related party under agreement for first two Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:to="lab_871148J778L5_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_K44K1GFGG78K9F35F361_fil_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund To Related Party Under Agreement After Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xml:lang="en-US">Fund to related party under agreement after year two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:to="lab_M66M3IHII90M1H57H583_fil_FundToRelatedPartyUnderAgreementAfterYearTwo"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_659926H556J3_us-gaap_RoyaltyExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty payment for the commercial use of drugs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_RoyaltyExpense" xlink:to="lab_871148J778L5_us-gaap_RoyaltyExpense"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_K44K1GFGG78K9F35F361_fil_NumberOfPatients"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfPatients" xml:lang="en-US">Number Of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfPatients" xml:lang="en-US">Number of Patients enrolled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfPatients" xml:lang="en-US">Number of Patients</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfPatients" xml:lang="en-US">Number of patients.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_NumberOfPatients" xlink:to="lab_M66M3IHII90M1H57H583_fil_NumberOfPatients"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_659926H556J3_fil_AmountPaidToEachPatient"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount Paid To Each Patient</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount paid to each patient after Completing clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_AmountPaidToEachPatient" xml:lang="en-US">Amount to be paid for each Patient that has completed the clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_AmountPaidToEachPatient" xlink:to="lab_871148J778L5_fil_AmountPaidToEachPatient"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_K44K1GFGG78K9F35F361_fil_StartUpFeeForClinicalTrial"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start Up Fee For Clinical Trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_StartUpFeeForClinicalTrial" xml:lang="en-US">Start-up fee for clinical trial.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_StartUpFeeForClinicalTrial" xlink:to="lab_M66M3IHII90M1H57H583_fil_StartUpFeeForClinicalTrial"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_659926H556J3_fil_StartUpDueCostPaidDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start Up Due Cost Paid Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_871148J778L5_fil_StartUpDueCostPaidDate" xml:lang="en-US">Due date of start-up fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_StartUpDueCostPaidDate" xml:lang="en-US">Start-up due cost paid date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_StartUpDueCostPaidDate" xlink:to="lab_871148J778L5_fil_StartUpDueCostPaidDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PeriodicFeeReceivedByManagementFirm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic Fee Received By Management Firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Monthly fee received by management firm</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PeriodicFeeReceivedByManagementFirm" xml:lang="en-US">Periodic fee received by management firm.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PeriodicFeeReceivedByManagementFirm" xlink:to="lab_M66M3IHII90M1H57H583_fil_PeriodicFeeReceivedByManagementFirm"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_659926H556J3_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage Of Fully Diluted Capital Stock Equal To Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xml:lang="en-US">Percentage of fully diluted capital stock equal to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:to="lab_871148J778L5_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_WarrantExercisableNoticePeriodDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant Exercisable Notice Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_WarrantExercisableNoticePeriodDescription" xml:lang="en-US">Warrant exercisable notice period description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_WarrantExercisableNoticePeriodDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_WarrantExercisableNoticePeriodDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_659926H556J3_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description Of Shares Availability By Exercise Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of period of shares availability by exercise of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xml:lang="en-US">Description of shares availability by exercise of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:to="lab_871148J778L5_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_K44K1GFGG78K9F35F361_fil_MaximumAmountOfOutOfPocketExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum Amount Of Out Of Pocket Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_MaximumAmountOfOutOfPocketExpenses" xml:lang="en-US">Maximum amount of out of pocket expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_MaximumAmountOfOutOfPocketExpenses" xlink:to="lab_M66M3IHII90M1H57H583_fil_MaximumAmountOfOutOfPocketExpenses"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_659926H556J3_fil_NonRefundableInstitutionalFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non Refundable Institutional Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non-refundable institutional fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_NonRefundableInstitutionalFee" xml:lang="en-US">Non refundable institutional fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_NonRefundableInstitutionalFee" xlink:to="lab_871148J778L5_fil_NonRefundableInstitutionalFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PharmacyFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PharmacyFee" xml:lang="en-US">Pharmacy Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PharmacyFee" xml:lang="en-US">Annual pharmacy fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PharmacyFee" xml:lang="en-US">Pharmacy fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PharmacyFee" xlink:to="lab_M66M3IHII90M1H57H583_fil_PharmacyFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_659926H556J3_fil_AmendmentProcessingFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment Processing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_AmendmentProcessingFee" xml:lang="en-US">Amendment processing fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_AmendmentProcessingFee" xlink:to="lab_871148J778L5_fil_AmendmentProcessingFee"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_K44K1GFGG78K9F35F361_fil_AgreementConsideration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementConsideration" xml:lang="en-US">Agreement Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementConsideration" xml:lang="en-US">Consideration pursuant to agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementConsideration" xml:lang="en-US">Consideration under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_AgreementConsideration" xlink:to="lab_M66M3IHII90M1H57H583_fil_AgreementConsideration"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_659926H556J3_fil_AmountPayableInInstallmentsUnderAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount Payable In Installments Under Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount payable in installments under agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_AmountPayableInInstallmentsUnderAgreement" xml:lang="en-US">Amount payable in installments under agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_AmountPayableInInstallmentsUnderAgreement" xlink:to="lab_871148J778L5_fil_AmountPayableInInstallmentsUnderAgreement"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_K44K1GFGG78K9F35F361_fil_NumberOfInstallments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfInstallments" xml:lang="en-US">Number Of Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfInstallments" xml:lang="en-US">Number of installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_NumberOfInstallments" xml:lang="en-US">Number of installments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_NumberOfInstallments" xlink:to="lab_M66M3IHII90M1H57H583_fil_NumberOfInstallments"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_659926H556J3_fil_PerformanceBonusPayableUnderAgreementForService"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance Bonus Payable Under Agreement For Service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PerformanceBonusPayableUnderAgreementForService" xml:lang="en-US">Performance bonus payable under agreement for service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PerformanceBonusPayableUnderAgreementForService" xlink:to="lab_871148J778L5_fil_PerformanceBonusPayableUnderAgreementForService"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_K44K1GFGG78K9F35F361_fil_NoticePeriodForTerminationOfAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period For Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice period for termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_NoticePeriodForTerminationOfAgreement" xml:lang="en-US">Notice Period for termination of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_NoticePeriodForTerminationOfAgreement" xlink:to="lab_M66M3IHII90M1H57H583_fil_NoticePeriodForTerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_659926H556J3_us-gaap_LeaseExpirationDate1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Rent agreement termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_LeaseExpirationDate1" xlink:to="lab_871148J778L5_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_K44K1GFGG78K9F35F361_fil_AgreementRenewalDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementRenewalDescription" xml:lang="en-US">Agreement Renewal Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementRenewalDescription" xml:lang="en-US">Rental agreement renewal description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_AgreementRenewalDescription" xml:lang="en-US">Description regarding renewal of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_AgreementRenewalDescription" xlink:to="lab_M66M3IHII90M1H57H583_fil_AgreementRenewalDescription"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfAggregateAmount" xlink:label="loc_659926H556J3_fil_PaymentOfAggregateAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PaymentOfAggregateAmount" xml:lang="en-US">Payment Of Aggregate Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount in installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PaymentOfAggregateAmount" xml:lang="en-US">Payment of aggregate amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PaymentOfAggregateAmount" xlink:to="lab_871148J778L5_fil_PaymentOfAggregateAmount"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_K44K1GFGG78K9F35F361_fil_PaymentOfFinalInstallmentForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding Payment Of Final Installment For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_PaymentOfFinalInstallmentForServicesByCompany" xml:lang="en-US">Outstanding payment of final installment for services by company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:to="lab_M66M3IHII90M1H57H583_fil_PaymentOfFinalInstallmentForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_659926H556J3_fil_PaymentOfPerformanceBonusForServicesByCompany"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment Of Performance Bonus For Services By Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services by company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_PaymentOfPerformanceBonusForServicesByCompany" xml:lang="en-US">Payment of performance bonus for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:to="lab_871148J778L5_fil_PaymentOfPerformanceBonusForServicesByCompany"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of warrants activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Summary of stock option activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Units, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Cancellation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_659926H556J3_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_871148J778L5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_871148J778L5_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Warrants expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_871148J778L5_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_PlanNameAxis" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_659926H556J3_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_us-gaap_PlanNameDomain" xlink:to="lab_871148J778L5_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_TwoThousandThirteenStockPlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">Two Thousand Thirteen Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">2013 Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_TwoThousandThirteenStockPlanMember" xml:lang="en-US">Two thousand thirteen stock plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_TwoThousandThirteenStockPlanMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_TwoThousandThirteenStockPlanMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_659926H556J3_fil_TwoThousandThirteenEquityIncentivePlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Thirteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">2013 Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_TwoThousandThirteenEquityIncentivePlanMember" xml:lang="en-US">Two thousand thirteen equity incentive plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:to="lab_871148J778L5_fil_TwoThousandThirteenEquityIncentivePlanMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_EmployeesDirectorsAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, directors and consultants .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_659926H556J3_fil_EmployeesAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_EmployeesAndConsultantsMember" xlink:to="lab_871148J778L5_fil_EmployeesAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_K44K1GFGG78K9F35F361_fil_ConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_fil_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ConsultantsMember" xml:lang="en-US">Former Director and Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_fil_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M66M3IHII90M1H57H583_fil_ConsultantsMember" xml:lang="en-US">Consultants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_fil_ConsultantsMember" xlink:to="lab_M66M3IHII90M1H57H583_fil_ConsultantsMember"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_659926H556J3_fil_EquityTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_EquityTextualAbstract" xml:lang="en-US">Equity Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_EquityTextualAbstract" xml:lang="en-US">Equity (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_EquityTextualAbstract" xlink:to="lab_871148J778L5_fil_EquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_659926H556J3_fil_UnrecognizedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_871148J778L5_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized Share Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_871148J778L5_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized share based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_871148J778L5_fil_UnrecognizedShareBasedCompensationExpense" xml:lang="en-US">Unrecognized share based compensation expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_659926H556J3_fil_UnrecognizedShareBasedCompensationExpense" xlink:to="lab_871148J778L5_fil_UnrecognizedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_K44K1GFGG78K9F35F361_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Fair value of warrants recorded as stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M66M3IHII90M1H57H583_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recorded option expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K44K1GFGG78K9F35F361_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_M66M3IHII90M1H57H583_us-gaap_AllocatedShareBasedCompensationExpense"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>fil-20130930_pre.xml
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.6.8 on Thursday, November 14, 2013 08:29:30 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DocumentAndEntityInformation" roleURI="http://cactusventuresinc.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedbalancesheetsunaudited" roleURI="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedbalancesheetsunauditedparenthetical" roleURI="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunauditedparenthetical"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Consolidatedstatementsofoperationsunaudited" roleURI="http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies" roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Notes11" roleURI="http://cactusventuresinc.com/role/Notes11"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyAndEquipment" roleURI="http://cactusventuresinc.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayable" roleURI="http://cactusventuresinc.com/role/NotePayable"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Derivatives" roleURI="http://cactusventuresinc.com/role/Derivatives"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingencies" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#StockOptionPlan" roleURI="http://cactusventuresinc.com/role/StockOptionPlan"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Notes13" roleURI="http://cactusventuresinc.com/role/Notes13"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentTables" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesTables" roleURI="http://cactusventuresinc.com/role/DerivativesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesTables" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityTables" roleURI="http://cactusventuresinc.com/role/EquityTables"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#GoingconcernDetails" roleURI="http://cactusventuresinc.com/role/GoingconcernDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#PropertyandEquipmentDetails" roleURI="http://cactusventuresinc.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#Propertyandequipmentdetailstesxtual" roleURI="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#NotePayableDetails" roleURI="http://cactusventuresinc.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails" roleURI="http://cactusventuresinc.com/role/DerivativesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetails1" roleURI="http://cactusventuresinc.com/role/DerivativesDetails1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#DerivativesDetailsTextual" roleURI="http://cactusventuresinc.com/role/DerivativesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsandContingenciesDetails" roleURI="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#CommitmentsAndContingenciesDetailsTextual1" roleURI="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityDetails" roleURI="http://cactusventuresinc.com/role/EquityDetails"/>
<roleRef xlink:type="simple" xlink:href="fil-20130930.xsd#EquityDetailsTextual" roleURI="http://cactusventuresinc.com/role/EquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DocumentAndEntityInformationAbstract" xlink:label="loc_fil_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_NotesPayableCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_Liabilities_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_PreferredStockValue_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommonStockValue_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_AdditionalPaidInCapital_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquity_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedbalancesheetsunauditedparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_DepreciationAndAmortization_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InterestExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GainOnChangeInFairValueOfDerivatives" xlink:label="loc_fil_GainOnChangeInFairValueOfDerivatives_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_fil_GainOnChangeInFairValueOfDerivatives_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_IncomeTaxesPaid_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_InterestPaid_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithDebt" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithDebt_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithDebt_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedWithStock" xlink:label="loc_fil_FairValueOfWarrantsIssuedWithStock_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedWithStock_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfWarrantsIssuedToPlacementAgent_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock" xlink:label="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock_39" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification" xlink:label="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification_40" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Notes11">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_fil_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextBlock" xlink:label="loc_fil_GoingConcernTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernAbstract_0" xlink:to="loc_fil_GoingConcernTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Derivatives">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/StockOptionPlan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Notes13">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_fil_DevelopmentStageCompanyPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_fil_DevelopmentStageCompanyPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock" xlink:label="loc_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTable" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodLineItems" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodTable_1" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentsMilestoneMethodTableTextBlock" xlink:label="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentsMilestoneMethodLineItems_6" xlink:to="loc_fil_MilestonePaymentsMilestoneMethodTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract" xlink:label="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7" xlink:to="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract_8" xlink:to="loc_us-gaap_DerivativeLiabilities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ActiniumMember" xlink:label="loc_fil_ActiniumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_fil_ActiniumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_EmployeeStockOptionMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionsAndWarrantsMember" xlink:label="loc_fil_OptionsAndWarrantsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_fil_OptionsAndWarrantsMember_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_10" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems_16" xlink:to="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfOwnershipInterestToBeAcquired" xlink:label="loc_fil_PercentageOfOwnershipInterestToBeAcquired_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_fil_PercentageOfOwnershipInterestToBeAcquired_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition" xlink:label="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SharesExchangeRatio" xlink:label="loc_fil_SharesExchangeRatio_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_fil_SharesExchangeRatio_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TotalOfCommonStockShares" xlink:label="loc_fil_TotalOfCommonStockShares_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_fil_TotalOfCommonStockShares_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ExchangedInCommonStockShares" xlink:label="loc_fil_ExchangedInCommonStockShares_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract_17" xlink:to="loc_fil_ExchangedInCommonStockShares_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/GoingconcernDetails">
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernAbstract" xlink:label="loc_fil_GoingConcernAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_GoingConcernTextualAbstract" xlink:label="loc_fil_GoingConcernTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernAbstract_0" xlink:to="loc_fil_GoingConcernTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_GoingConcernTextualAbstract_1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LossOnDispositionOfPropertyAndEquipment" xlink:label="loc_fil_LossOnDispositionOfPropertyAndEquipment_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_fil_LossOnDispositionOfPropertyAndEquipment_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PropertyAndEquipmentTextualAbstract" xlink:label="loc_fil_PropertyAndEquipmentTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_fil_PropertyAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_PropertyAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NotePayableTextualAbstract" xlink:label="loc_fil_NotePayableTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_fil_NotePayableTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_KeymanInsurancePolicyPremium" xlink:label="loc_fil_KeymanInsurancePolicyPremium_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableTextualAbstract_1" xlink:to="loc_fil_KeymanInsurancePolicyPremium_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyDownPayment" xlink:label="loc_fil_InsurancePolicyDownPayment_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableTextualAbstract_1" xlink:to="loc_fil_InsurancePolicyDownPayment_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_InsurancePolicyInstallmentPayment" xlink:label="loc_fil_InsurancePolicyInstallmentPayment_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableTextualAbstract_1" xlink:to="loc_fil_InsurancePolicyInstallmentPayment_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableTextualAbstract_1" xlink:to="loc_us-gaap_NotesPayableCurrent_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_NotePayableTextualAbstract_1" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract" xlink:label="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_fil_DerivativeWarrantsUnits_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsUnits_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapital" xlink:label="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantsUnits" xlink:label="loc_fil_DerivativeWarrantsUnits_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantsUnits_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue" xlink:label="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChangeInFairValueOfDerivativeWarrants" xlink:label="loc_fil_ChangeInFairValueOfDerivativeWarrants_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_fil_ChangeInFairValueOfDerivativeWarrants_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract_1" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1" xlink:to="loc_us-gaap_DerivativeLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract" xlink:label="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_6" xlink:to="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MarketValueOfCommonStockOnMeasurementDate" xlink:label="loc_fil_MarketValueOfCommonStockOnMeasurementDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_fil_MarketValueOfCommonStockOnMeasurementDate_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:label="loc_us-gaap_FairValueInputsProbabilityOfDefault_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract_7" xlink:to="loc_us-gaap_FairValueInputsProbabilityOfDefault_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/DerivativesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DerivativesTextualAbstract" xlink:label="loc_fil_DerivativesTextualAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_fil_DerivativesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DerivativesTextualAbstract_1" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfProbabilityOfStockOffering" xlink:label="loc_fil_DescriptionOfProbabilityOfStockOffering_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_DerivativesTextualAbstract_1" xlink:to="loc_fil_DescriptionOfProbabilityOfStockOffering_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseSecondClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseSecondClinicalTrialOfLicensedProductMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseThirdClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_PhaseThirdClinicalTrialOfLicensedProductMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BiologicalLicenseApplicationMember" xlink:label="loc_fil_BiologicalLicenseApplicationMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_BiologicalLicenseApplicationMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSaleMember" xlink:label="loc_fil_FirstCommercialSaleMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_FirstCommercialSaleMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_AfterFirstNetSalesMember_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NewDrugApplicationMember" xlink:label="loc_fil_NewDrugApplicationMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_NewDrugApplicationMember_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReceiptOfRegulatoryApprovalFromUSFdaMember" xlink:label="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_7" xlink:to="loc_fil_ReceiptOfRegulatoryApprovalFromUSFdaMember_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentAbstract" xlink:label="loc_fil_MilestonePaymentAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_16" xlink:to="loc_fil_MilestonePaymentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_MilestonePaymentAbstract_17" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ChiefExecutiveOfficerAndDirectorMember" xlink:label="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_fil_ChiefExecutiveOfficerAndDirectorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementAxis_5" xlink:to="loc_fil_AgreementDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_6" xlink:to="loc_us-gaap_EmploymentContractsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_RestrictedStockMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_CommitmentsAndContingenciesLineItems_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_15" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_us-gaap_OfficersCompensation_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_BaseSalaryAndPerformanceBonusDescription" xlink:label="loc_fil_BaseSalaryAndPerformanceBonusDescription_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_BaseSalaryAndPerformanceBonusDescription_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumReimbursementOfTravelExpenses" xlink:label="loc_fil_MaximumReimbursementOfTravelExpenses_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_MaximumReimbursementOfTravelExpenses_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ReimbursementOfTravelExpensesDescription" xlink:label="loc_fil_ReimbursementOfTravelExpensesDescription_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_ReimbursementOfTravelExpensesDescription_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceObjectiveDescription" xlink:label="loc_fil_PerformanceObjectiveDescription_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_PerformanceObjectiveDescription_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonus" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonus_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription" xlink:label="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentagesOne" xlink:label="loc_fil_RestrictedStockGrantPercentagesOne_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_RestrictedStockGrantPercentagesOne_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantPercentageTwo" xlink:label="loc_fil_RestrictedStockGrantPercentageTwo_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_RestrictedStockGrantPercentageTwo_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RestrictedStockGrantDescription" xlink:label="loc_fil_RestrictedStockGrantDescription_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_RestrictedStockGrantDescription_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_VestingScheduleDescription" xlink:label="loc_fil_VestingScheduleDescription_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_VestingScheduleDescription_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:label="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmploymentTermUnderAgreement" xlink:label="loc_fil_EmploymentTermUnderAgreement_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_16" xlink:to="loc_fil_EmploymentTermUnderAgreement_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTable" xlink:label="loc_fil_CommitmentsAndContingenciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_fil_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AbbottBiotherapeuticsCorpMember" xlink:label="loc_fil_AbbottBiotherapeuticsCorpMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AbbottBiotherapeuticsCorpMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MemorialSloanKetteringCancerCenterMember" xlink:label="loc_fil_MemorialSloanKetteringCancerCenterMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_MemorialSloanKetteringCancerCenterMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_OakRidgeNationalLaboratoryMember" xlink:label="loc_fil_OakRidgeNationalLaboratoryMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_OakRidgeNationalLaboratoryMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AptivSolutionsMember" xlink:label="loc_fil_AptivSolutionsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_AptivSolutionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FredHutchinsonCancerResearchCenterMember" xlink:label="loc_fil_FredHutchinsonCancerResearchCenterMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_FredHutchinsonCancerResearchCenterMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember" xlink:label="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_PhaseIAndIiClinicalTrialForActimabInElderlyAcuteMyeloidLeukemiaMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfTexasMDAndersonCancerCenterMember" xlink:label="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfTexasMDAndersonCancerCenterMember_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JohnsHopkinsUniversityMember" xlink:label="loc_fil_JohnsHopkinsUniversityMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JohnsHopkinsUniversityMember_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LaidlawAndCoMember" xlink:label="loc_fil_LaidlawAndCoMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_LaidlawAndCoMember_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UniversityOfPennsylvaniaMember" xlink:label="loc_fil_UniversityOfPennsylvaniaMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_UniversityOfPennsylvaniaMember_13" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_JamessCapitalGroupMember" xlink:label="loc_fil_JamessCapitalGroupMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_fil_JamessCapitalGroupMember_14" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_15" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_16" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AfterFirstNetSalesMember" xlink:label="loc_fil_AfterFirstNetSalesMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_AfterFirstNetSalesMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PhaseFirstClinicalTrialOfLicensedProductMember" xlink:label="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_17" xlink:to="loc_fil_PhaseFirstClinicalTrialOfLicensedProductMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementAxis" xlink:label="loc_fil_AgreementAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_AgreementAxis_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementDomain" xlink:label="loc_fil_AgreementDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementAxis_20" xlink:to="loc_fil_AgreementDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProductDevelopmentAndPatentLicenseAgreementMember" xlink:label="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ProductDevelopmentAndPatentLicenseAgreementMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAgreementMember" xlink:label="loc_fil_LicenseAgreementMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAgreementMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LicenseAndSponsoredResearchAgreementMember" xlink:label="loc_fil_LicenseAndSponsoredResearchAgreementMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_LicenseAndSponsoredResearchAgreementMember_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialAgreementMember" xlink:label="loc_fil_ClinicalTrialAgreementMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_ClinicalTrialAgreementMember_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PlacementAgentAgreementMember" xlink:label="loc_fil_PlacementAgentAgreementMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_PlacementAgentAgreementMember_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TransactionManagementAgreementMember" xlink:label="loc_fil_TransactionManagementAgreementMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_TransactionManagementAgreementMember_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RentalAgreementMember" xlink:label="loc_fil_RentalAgreementMember_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_RentalAgreementMember_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_SeparationAndSettlementAgreementMember" xlink:label="loc_fil_SeparationAndSettlementAgreementMember_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_AgreementDomain_21" xlink:to="loc_fil_SeparationAndSettlementAgreementMember_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_30" xlink:to="loc_us-gaap_RangeMember_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_31" xlink:to="loc_us-gaap_MaximumMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_31" xlink:to="loc_us-gaap_MinimumMember_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesLineItems" xlink:label="loc_fil_CommitmentsAndContingenciesLineItems_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTable_1" xlink:to="loc_fil_CommitmentsAndContingenciesLineItems_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_fil_CommitmentsAndContingenciesTextualAbstract_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesLineItems_34" xlink:to="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfLicenseFee" xlink:label="loc_fil_PaymentOfLicenseFee_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PaymentOfLicenseFee_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_LongTermPurchaseCommitmentMilestonesPayment" xlink:label="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_LongTermPurchaseCommitmentMilestonesPayment_37" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_38" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MilestonePaymentDate" xlink:label="loc_fil_MilestonePaymentDate_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_MilestonePaymentDate_39" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfRoyaltyPaymentToRelatedParty" xlink:label="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_DescriptionOfRoyaltyPaymentToRelatedParty_40" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_RoyaltyOfNetSalesPercentage" xlink:label="loc_fil_RoyaltyOfNetSalesPercentage_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_RoyaltyOfNetSalesPercentage_41" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FirstCommercialSalePeriod" xlink:label="loc_fil_FirstCommercialSalePeriod_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_FirstCommercialSalePeriod_42" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TechnologyServicesCosts" xlink:label="loc_us-gaap_TechnologyServicesCosts_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_us-gaap_TechnologyServicesCosts_43" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaap_MaintenanceCosts_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_us-gaap_MaintenanceCosts_44" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ResearchAndDevelopmentArrangement" xlink:label="loc_fil_ResearchAndDevelopmentArrangement_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_ResearchAndDevelopmentArrangement_45" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PurchaseOfRadioactiveMaterial" xlink:label="loc_fil_PurchaseOfRadioactiveMaterial_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PurchaseOfRadioactiveMaterial_46" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ProjectEstimatedCost" xlink:label="loc_fil_ProjectEstimatedCost_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_ProjectEstimatedCost_47" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentOfProjectEstimatedCostPercentage" xlink:label="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_DownPaymentOfProjectEstimatedCostPercentage_48" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DownPaymentForProject" xlink:label="loc_fil_DownPaymentForProject_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_DownPaymentForProject_49" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration" xlink:label="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration_50" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementForFirstTwoYear" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear_51" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_FundToRelatedPartyUnderAgreementAfterYearTwo" xlink:label="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_FundToRelatedPartyUnderAgreementAfterYearTwo_52" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_us-gaap_RoyaltyExpense_53" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfPatients" xlink:label="loc_fil_NumberOfPatients_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_NumberOfPatients_54" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPaidToEachPatient" xlink:label="loc_fil_AmountPaidToEachPatient_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_AmountPaidToEachPatient_55" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpFeeForClinicalTrial" xlink:label="loc_fil_StartUpFeeForClinicalTrial_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_StartUpFeeForClinicalTrial_56" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_StartUpDueCostPaidDate" xlink:label="loc_fil_StartUpDueCostPaidDate_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_StartUpDueCostPaidDate_57" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PeriodicFeeReceivedByManagementFirm" xlink:label="loc_fil_PeriodicFeeReceivedByManagementFirm_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PeriodicFeeReceivedByManagementFirm_58" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock" xlink:label="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PercentageOfFullyDilutedCapitalStockEqualToCommonStock_59" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_WarrantExercisableNoticePeriodDescription" xlink:label="loc_fil_WarrantExercisableNoticePeriodDescription_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_WarrantExercisableNoticePeriodDescription_60" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant" xlink:label="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_DescriptionOfSharesAvailabilityByExerciseOfWarrant_61" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_MaximumAmountOfOutOfPocketExpenses" xlink:label="loc_fil_MaximumAmountOfOutOfPocketExpenses_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_MaximumAmountOfOutOfPocketExpenses_62" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NonRefundableInstitutionalFee" xlink:label="loc_fil_NonRefundableInstitutionalFee_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_NonRefundableInstitutionalFee_63" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PharmacyFee" xlink:label="loc_fil_PharmacyFee_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PharmacyFee_64" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmendmentProcessingFee" xlink:label="loc_fil_AmendmentProcessingFee_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_AmendmentProcessingFee_65" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementConsideration" xlink:label="loc_fil_AgreementConsideration_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_AgreementConsideration_66" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AmountPayableInInstallmentsUnderAgreement" xlink:label="loc_fil_AmountPayableInInstallmentsUnderAgreement_67"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_AmountPayableInInstallmentsUnderAgreement_67" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NumberOfInstallments" xlink:label="loc_fil_NumberOfInstallments_68"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_NumberOfInstallments_68" order="320" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PerformanceBonusPayableUnderAgreementForService" xlink:label="loc_fil_PerformanceBonusPayableUnderAgreementForService_69"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PerformanceBonusPayableUnderAgreementForService_69" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_NoticePeriodForTerminationOfAgreement" xlink:label="loc_fil_NoticePeriodForTerminationOfAgreement_70"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_NoticePeriodForTerminationOfAgreement_70" order="340" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_71"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_us-gaap_LeaseExpirationDate1_71" order="350" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_AgreementRenewalDescription" xlink:label="loc_fil_AgreementRenewalDescription_72"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_AgreementRenewalDescription_72" order="360" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfAggregateAmount" xlink:label="loc_fil_PaymentOfAggregateAmount_73"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PaymentOfAggregateAmount_73" order="370" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfFinalInstallmentForServicesByCompany" xlink:label="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_74"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PaymentOfFinalInstallmentForServicesByCompany_74" order="380" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_PaymentOfPerformanceBonusForServicesByCompany" xlink:label="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_75"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_CommitmentsAndContingenciesTextualAbstract_35" xlink:to="loc_fil_PaymentOfPerformanceBonusForServicesByCompany_75" order="390" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://cactusventuresinc.com/role/EquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenStockPlanMember" xlink:label="loc_fil_TwoThousandThirteenStockPlanMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThirteenStockPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_TwoThousandThirteenEquityIncentivePlanMember" xlink:label="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_fil_TwoThousandThirteenEquityIncentivePlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11" xlink:to="loc_us-gaap_WarrantMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_fil_EmployeesDirectorsAndConsultantsMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_EmployeesDirectorsAndConsultantsMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EmployeesAndConsultantsMember" xlink:label="loc_fil_EmployeesAndConsultantsMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_EmployeesAndConsultantsMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_ConsultantsMember" xlink:label="loc_fil_ConsultantsMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_fil_ConsultantsMember_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_EquityTextualAbstract" xlink:label="loc_fil_EquityTextualAbstract_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_19" xlink:to="loc_fil_EquityTextualAbstract_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="fil-20130930.xsd#fil_UnrecognizedShareBasedCompensationExpense" xlink:label="loc_fil_UnrecognizedShareBasedCompensationExpense_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_20" xlink:to="loc_fil_UnrecognizedShareBasedCompensationExpense_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_20" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fil_EquityTextualAbstract_20" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of derivative warrant instruments activity</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,146,338</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Reclassification to paid in capital</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,130,536 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">)</font></td><td align="right" width="1%"
 valign="bottom">&#160;</td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(600,880 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td width="76%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(216,112 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,015,802</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock', window );">Summary of fair values of derivative warrants on basis of valuation model</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.17</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.48 - $0.81</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;">1.50
 - $2.475</td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.33</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0 days/4.22 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">139</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">%</font></td><td width="1%" valign="bottom">&#160;</td><td width="1%" valign="bottom" style="text-align: left;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25% - 40</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants on basis of valuation model.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfDerivativeWarrantsOnBasisOfValuationModelTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41678-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!^3Q`*UP$``*@5```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/&
MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,84'^@Y&JZJ,
MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N
M);GWYIY2E^50"1=K`RK<F6I;"1^^VADU(IN+&5#>[?9HII4'Y3N^GD&&@T>8
MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@
MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A
M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD
M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E
M6,S*L9B58S$KQV)6CL6L'(M9.1:S<BQFY5C,RK&8-<%BU@2+61,L9DW^RZP^
M]&!`F\^_/Y1FS"]%C//K$MR97YXV0W]+SH4%^>9M:`S/#O!]]C&.T*>-K38N
M-(L63C^%7758[^Z8,`BL+V!?'K:5</O$T$J>'GC0`D+=>TJ0+=FTZ5F'7P``
M`/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N<F5L
M<R"B!`(HH``"````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````",DL].PS`,QN](O$/D^^IN2`BA
MI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#NBA!
ML3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T
M'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FRMS1-
M;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<3_3_
MMCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\#
M`%!+`P04``8`"````"$`FM$*B](!``"-%```&@`(`7AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````O)C-3L,P$(3O2+Q#Y#MU=UU*04U[04B]\O,`5N(V$6D2V>:G;X]5
M4*`2#)=H+Y'L*)O1V#M?G.7Z?=]DK\Z'NFMS19.IREQ;=&7=[G+U]'AWL5!9
MB+8M;=.U+E<'%]1Z=7ZVO'>-C>FA4-5]R%*5-N2JBK&_T3H4E=O;,.EZUZ8[
MV\[O;4Q#O].]+9[MSFF>3N?:_ZRA5B<ULTV9*[\IR:CL\="G5_]?O-MNZ\+=
M=L7+WK7QEW?HM\X_A\JYF(I:OW,Q5\-4T,<[9"9)L])_R$E^R,I9(#D\%Y;#
M<R1'>JW@4C%)>T/0F]F8<F+J,)<*?FWBXU`?KU#$U9@:AL[YUC%,?373%7*$
M6%@-,90C;0Y!=_A2V!V^1.X8\=[&S2UM#O*&I%.88`IS@K@HHWB*W.%K:3G7
M2(XT%6`>2V\<N&](W!KH#8\*S(%,:3/^\>7',[1OC#2M#*25-!T@'$A:#4$Y
M+,TJQJR2/C,P/#.844,G5-:[\B'Z=&(,W[UU,HW:BJ1A11!6)`TK@K`RTI%L
M8"1+)S(,9.F5@@M%TM80](:E8<405BQ]M&)XM#+2F6-@YIA1Z1GBH4D_Z8:O
MG,\QBF!I/`UTTB<_$5<?````__\#`%!+`P04``8`"````"$`):`@#28#``!B
M"@``#P```'AL+W=O<FMB;V]K+GAM;)2635/;,!"&[YWI?_#X7OP5*#`DS$#2
ME@ME)@&.&F$K1(,M&4G.Q[_ORF[,VC*>]N3(SK[:??=9V5?7^R+WMDQI+L74
MCTY"WV,BE1D7KU/_<?7CV[GO:4-%1G,IV-0_,.U?S[Y^N=I)]?8BY9L'`D)/
M_8TQY640Z'3#"JI/9,D$/%E+55`#2_4:Z%(QFND-8Z;(@S@,SX*"<N$W"I?J
M7S3D>LU3-I=I53!A&A'%<FH@?;WAI?9G5VN>LZ>F(H^6Y3TM(.]][GLYU6:1
M<<.RJ7\*2[ECG1NJ*F\JGL/3BR1,_&#6%OF@O(RM:96;%91W5`>_XDD<G]E_
M6BN>.-OICR"[]/;/7&1R9_\*UA[:50()[.I'SSPS&W@>AF%[[Q?CKQMSO`GR
M`=*O'81]ZJLGZO*.CA#H%%D(P\V!W(G&?2ZAA=;U.Z@L\CUUR>&'NLLBFSA6
MN0439<XS"A:1&YI3D3*RM*&:/$*C6I48J<3_IP()M#()DJG]_C29I8&<;,LU
MD6ORNV1(98)4)J/)=%5NJ48JX'UKS&E?9<YTJGAI*;/[WU2:"Z9U[?:R0BH)
M3J8&`Y?T4\)8$7`Y90K;:6%H-__>W_Q!P3`I:&C=V_>*E]8(O.D9"C_OA]]+
MP\@#/="7'+N6?$=!%_V@.5-\"U.UA7%'_8+#H,TS"OM!M[(HN&FZ9'.%0@T4
M#.<)[\I<8!F'P@64:`YHVPE,SL>V#F_+ZD6S]PH\(8NM102'=GAW&!OO*T9U
M@I&/',S&A2"V97Z"H8\<TH:;35:V>YW",&B10QKJWT`LQBUR>!MM(\&E8.XB
M![RFCP/;8_*B`?3&9@W<:ZVT)VK+!2QZI]EX3\"_5FB"N8X=()NQ39NQ)7-F
M*,]Q+V+,!BQZ>7S2T@$=C$;LP#JN@V&-,1RPZ"6$3X2A<C`>L4,H1FN@!LQ$
M\VK$)^!`,.EDCMF('32'PE=L;RH*K_>VG7&GG0Z7XWQWLL$'5>R0.B[4&7HL
ME#BDC@MAY$\Q\HE#ZM^1<]N28$1AT2.B&T=<2Q.,)BP@/JC]AN^0E.8I?"#9
MB_W"J*L+CI^'LS\```#__P,`4$L#!!0`!@`(````(0"'[3=0P@4``'45```8
M````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE)A9;^,V$,??"_0["'JW)9(Z
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MMF#.$!M=:O8-WP!+CP^'`A1PMVM-?MSK3V27$%\W'A]Z!_U3Y.^M]+?6GNOW
M7YKB\%M1Y>!MB!./P'-=OW#T^X$/P61C,3OI(_!'HQWR8_IZZ?ZLWW_-B].Y
M@W#;?$I67V`E^*F5!<\!D)Y^]+_?BT-WWNO,V=JNR0BU=>TY;[NDX'-U+7MM
MN[K\5T!D,"6,T,$(S!B,$+JEGDULYW]8<08K\'NTXGYU*X:0U;LC2KOT\:&I
MWS7(,=AX>TUYQI(=&![\,(B9/`,!RCC]Q/&][NH::&YA].W1]AZ,-_!T-B#!
M#<3'2#@BW-W<;#0.S&8)GA*/Q#@E$0/P<]J)8TYS#%`W203O2Q)')7R4*QD-
M!F)`-D@G>_TNPR7A*-N,EHAB)%X2JI%DB<Q&D#)V4QD?A325/3//[Y4$`K$D
MQ%:TKA+1*A&O$LD]`BF%K=Z((1_=Z^"N.0<8UA$(1%;*'(R$ZTBTCL3K2'(7
M07*A4-R0RT>5P%I82R`06&CRB!K852):)>)5(KE'(*50<R2E??UAYE1N^+=*
M@!4]@4"<OA:YKD>9DNNA#!#'=9FI'EJ9H,QE<!=CM\:(<"FS;*6D)8CP7)^Y
M9$:08BB>DN*Q'/%11:F2IX%`A%*/F2`$[S*4`9=2D[D8B&2`PGS*E.,2RP2Q
MJ4FIXJQ$)BBX`J#Y!D!">:^D7"U2:/FWBF!ENX%`Y&1>G-T1X3<1(4KHH_';
M^32H!N(1X08L.H>LKY.)^%:XG%&'6LZ\!-+J(ZUC4/FHHG'VE:C$`KFK<1V)
M!"+V:1$Z;[)?)%ZWD,@6;-MBGP650*LE1754V@\K4A5G!@,C=DD<T_,E;_8;
M#1%"F>];MI+D$4)L8KJVK92$&"$6M2QB*GM)$&+[GF4[_IQ^*+2$=QIS'D^*
M10,B7SZNLM>@G[K7A>+-)Y*%G8'Y1#-B/A&-F$]4(V9%-N]";L@6S0E<W-,-
MXRHE(B""D9-:"5&XCD3K2+R.)'<1'&?>C-P0+'H4%&?E?`5$,&.<J:^D6X@!
M1CR'*I4WP@BUI0,H#C$&?)M22W%\@A'B.RXEL^>Q6HC.+;5\&)]C5]EI0`0C
MAU<MJ^$7F.@+3/P%)AD8X7WJF/!ONO>P9MZ5S!%6FPWX_]]"N]I?#8Q8BW@^
MLY2"'B)B0WV+>4J8(H10XBPNKA@1&^JYCJGL)$&(3VS+GW>"5?/69%8]U2_1
ML:"\GG-%7$Y$[FJ(YYG6(K%E8N,09JH;C9`12MA"2HR(#8$:"/5X"F&_E00S
MKD]<\EF]YAW*#;VB<4%ZU0Z+",;KF\D-L:CI$R7[0\Q`,TDM6XE-A!D+TL2W
ME22(,6-;'C"*G00SCNDPUR(SA,/,>Y59]B*Y12N#Y,\.',(M&%_(-[>FXI^0
M((!M706(,&!N%YT(!IRM-ZL9XBR6D(O+G`I8,&]9[@@6'0T2/)^00;#<]5#(
M3#C1\VH]$\(K%*\*XL1[)G'5XAXA`JHR,&01[34K_+6+KW-/N'C-$L\W9=Z<
M\C"_7%HMJU\KN(P9A&T:G5[1GBA_X5#&`[*#-YCE>$1V\-`"X\8T`=["KNDI
M_SUM3D75:I?\"$N96Q=J92.>S<2'KK[VCTG/=0>O8/V?9WC>S.%UQ]P"?*SK
M;OS`%Y@>3!__`P``__\#`%!+`P04``8`"````"$`J-ETB<`#``#1#0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R,5]]OXC@0?C_I_H?([TOB\*M%
MA%6[5?=6NI5.I]V]9Q,,6$WBR#:E_>]O[`F&F&PQ#T#&G^?S?)X9AN7GM[I*
M7KG20C8%H:.,)+PIY48TNX+\_/'\Z8XDVK!FPRK9\(*\<TT^K_[\8WF4ZD7O
M.3<)>&AT0?;&M(LTU>6>UTR/9,L;6-E*53,#CVJ7ZE9QMG&;ZBK-LVR6UDPT
M!#TL5(P/N=V*DC_)\E#SQJ`3Q2MFX/QZ+UI]\E:7,>YJIEX.[:=2UBVX6(M*
MF'?GE"1UN?BV:Z1BZPKB?J,35IY\NX<K][4HE=1R:T;@+L6#7L=\G]ZGX&FU
MW`B(P,J>*+XMR`-=/.8SDJZ63J!?@A_UQ?=$[^7QJQ*;OT7#06VX)WL#:RE?
M+/3;QII@<WJU^]G=P#\JV?`M.U3F7WG\BXO=WL!U3^V64E;`!.])+6P.0.CL
MS7T>Q<;L"S*>C:;S;$SS*4G67)MG8?>2I#QH(^O_$$0[5^@D[YS`9^>$3D>3
M?#J_B_"2XHE<)$_,L-52R6,"Z0&<NF4VV>@"/'<A=.?P08&VI44_6'A!YB2!
MXVJPOJXF=+Q,7T&ELL,\(@;>/89Z1`JTGAOX+KA/%-9J*:R,EO,1#9?^\F%_
MXYX_%\MDZH]N5PL"SORQ)G3B'2$58B87F*E'](X.D(&C6RO<[<7V\3CS#I`"
M,1$4D!D#%-8:1G$^(U(@YLY=SWR:P<N?H1?$K,<0ZF570Z:9=X1,B(D(!C)F
M(!AKO:478B(H;%<]9_(IFZPUC"+4"S&SFWK=]QA"O>QJR#0/]$),1#`4FM%`
M-,Y\2[$.%,-B2_5:,XH5W"^54+0.A*I1EV6_23-J"_C,$NKFED/A[@+A.E!,
M3/TN<,H#BJ7]<6UVH!@6P%S$Y%FL.8SE2CD$=<I]5*#P8W+)XI0;9[ZCN>60
M[3Y4#KM!3$S]?N!CPB*_H5QT)Z##K<"9PUBNE,-F$)-S_6YPI=Q`6\C/Z8O-
MC2(H1KE^9_#*8;G?4"ZZ)^3#/<&9;RG7@2*4R_L](:Q6MQRPY>??=U2N`T4H
ME_=[PTDY9[[5YSI0#(LM_G,'\BS6',1"PYS+$83*?52L.1SD@L0)-SL7JUL.
MR/+S(-,)9WT4)":D?FOP(6&U?YQR=NB,9!EN"3!41PB'(!Q#Z*!R.%GC/%IS
MM>-?>%7II)2'QHW#JZ6W^HG^(7<SN5^`.;ME._Z=J9UH=%+Q+6S-1G.(4>%(
MC@]&MF[:74L#$[;[NH>_3APFS&P$X*V4YO1@AW[_9VSU/P```/__`P!02P,$
M%``&``@````A`(_:7^PX`P``"`D``!D```!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&ULE%9;;YLP%'Z?M/^`_%YN(2%!(55)TJW2)DW3+L\..,$J8&0[3?OO
M=XPQY=+;7D+X^,YWKARSOGXL"^N!<$%9%2//=I%%JI1EM#K%Z/>OVZLELH3$
M588+5I$8/1&!KC>?/ZTOC-^+G!!I@4(E8I1+64>.(]*<E%C8K"85/#DR7F()
MM_SDB)H3G#5&9>'XKKMP2DPKI!4B_A$-=CS2E.Q8>BY));4()P66$+_(:2V,
M6IE^1*[$_/Y<7Z6LK$'B0`LJGQI19)5I='>J&,>'`O)^]`*<&NWF9B)?TI0S
MP8[2!CE'!SK->>6L'%#:K#,*&:BR6YP<8W3C1?L0.9MU4Y\_E%Q$[[\E<G;Y
MPFGVC58$B@UM4@TX,':OJ'>9@L#8F5C?-@WXP:V,'/&YD#_9Y2NAIUQ"M^?*
M)&4%>()?JZ1J!"!S_!@C'SS03.8QFBWL>>C./'^.K`,1\I8J6V2E9R%9^5>3
MO%9*B\Q:$;BV(H'M!>Y"2;QA%K1F<&W-/-\._'FX;)R_80FZ3=1P-98@,C5P
M=+9-E798XLV:LXL%DP?YB!JK.?8B$&G+TRIT!8.VI8I]H^@Q"I$%I1"`/FP"
M=[EV'J`#:<M)IAQOR-@:ANJ"DMT9X%EVMEH,C?:&H[H-P7<90,/^)P-%5QD8
MWXD!GGW[0\];PS`F.P/T3.9#F[VAC*.%R>A%:\JJ4!BX05E70\5$<Z"[7>E'
M/K>&T<5I@%=-]H8Q#A/<],+48Q':,,8F8D5H7I8NFL!S1Q%K3C_BV:BI6TU9
MKGI9S5;A4&?WOL[^'9W!P,"8CW-;N%UBZNDXL='\)IK33RSPQD-C.%TS#/!Z
M,PQCW(S%(&#3`87"S`3/DSQ!MA-D-T'V?610)WC+QW6:P?[5RV6Z&A1]6+A)
M)Q/-F4&BW=CXWGB,.U)7N@D")T:3?+/(==#Z!-"[K23\1+:D*(25LG,%OD+H
M;X?J@R<)VX-GA,.!=..KHH[PQ(M@<4WQ'1Q@+^&)'\'F>('O1[`=IOC-(H)>
M`.YTCN%\JO&)?,?\1"MA%>0(J;AV"/7C^BC3-Y+5S28_,`DG4_,WAR\.`JO5
MM8%\9$R:&^6@^X;9_`,``/__`P!02P,$%``&``@````A`,:3W3]S!@``6AD`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&ULE%G;CJ-&$'V/E']`O`_0
MP/@FVZL!L\E*B11%N3PS&-MH#5C`[.S^?:KI>S7&DWU8CZM/59^Z=%5/S_;3
M]_KJ?"N[OFJ;G4N\P'7*IFB/57/>N7__]?EIY3K]D#?'_-HVY<[]4?;NI_W/
M/VW?V^YK?RG+P0$+3;]S+\-PV_A^7US*.N^]]E8VL')JNSH?X&MW]OM;5^;'
M4:F^^F$0+/PZKQJ76=AT'['1GDY541[:XJTNFX$9Z<IK/@#__E+=>F&M+CYB
MKLZ[KV^WIZ*M;V#BM;I6PX_1J.O4Q>;+N6F[_/4*?G\G<5X(V^,7RWQ=%5W;
MMZ?!`W,^(VK[O/;7/EC:;X\5>$##[G3E:>>^D$T6KEQ_OQT#]$]5OO?:STY_
M:=]_Z:KC;U530K0A3S0#KVW[E4*_'*D(E'U+^_.8@3\ZYUB>\K?K\&?[_FM9
MG2\#I/N9JA3M%7:"_YVZHC4`KN??Q\_WZCA<=FZT\)Z7043"9]=Y+?OA<T5U
M7:=XZX>V_I>!"#?%C(3<"'Q.&)E1C+@B?'+%V%N28!TM8?,9O9CKP2?7HVQG
M%&!U=!,^N<)B;B.?16F,[B$?\OVV:]\=*%F(0W_+Z0$@&[#%P\IWEH&&?!<4
M_4+A.W?I.A#"'J3?]M'Z>>M_@\P5')/8&&(B4H&@V:-F#T*@FUV82IG`T"H!
M\M(#R-'_\8#"J0=B[T0(U-ZAN7,J$$+E(`2:"@I")B"8+10&9AL%,KQT%0I6
M#V^(XI`P#!2*3`':.Q4(R5<([JID`H'IPC8S=.GJS@57)16R7IK!2QAF/=8*
M\1:8*UM>K34;$;9Q,&T0M$7VP(91+5#CV"&R]."PB0JG`-.G,$#UFS#,:L4.
M@!=E3Y'I=<H1IELK$W1@(&`OPX>BDPD$3LOBD1<4@+U`84L8AGM!O&AMTDOY
MNND#`AT8:,X'@<`^0!.9SP0%8!_0]@G#Z-M'Z+RD#&)46!P$IJ^'QW:R!W:,
M*J.W#M15M5-.5Y%C!!%*&$9W#-5&*A#RE#,!SV<`-6WZF/%U/9^Q5MJ&`P#2
M'!!G@TI-XG&`FF7",'/$!4(2%X+[YT`@<`T1N$=H/,?QI05Z7'[43SEHCK&$
M2,I2<I^SA%BDZ213U2&"2]B`,[LI:AD)!XEVBE*<\N583K>#H1!X,3*8Z1I&
M!1`ZP11+=C,P.N6(,,O!;I4<-!M=-BMUTDPB6I/57C-NU3C4T5KY9GI"AYOR
M1,:;S3P]WF$0FV<F(6(PJCS'`6[V$J3*8TH-V<YT-9,P1$LC/!5ZBL"AQ_V=
M,-!LZ`5$,6<2$7J[BW"K*/2J+YN>T`&F0F^=3S;?C!18G1!N^=37NWTM%0!H
M$G*0ZHV-7S'%+%4@='HR;F@L1-,-.L.4&[*"V&C3Z<<!,IH0,?_N[IM*B,K"
M0Z5,5S+)TD&ER%HQ9W,,"E0&*[+NF,2>A\BO5$(4Z8=*F:YDDJ;#29&6$68S
M2X\PT8[YF-F$,!#KB:$7+Y\#[1^ZNZ4<K7<;73_P5D@CTS5,TG0L*=)3YY0-
M+IW_1(L4TTUEQ`JV@*A@,PD_%4MOJ;D,/X83/9-KP(?*O!9,P[70'*PB'Z,8
M]QW4UQ(.TOM.'.!;F01)CZ1$H[=$:ID$@9I)V!RJ$[D([?D:!KAG<I#.'>="
M0A1S9EGVS`6N(*[RL9X90K7@JM+N-.,R2H'5,SE(]DR4HE2LZ[5@MTR.F@E&
M)B%6/N@$5&=#%A`;C)$Z?DEHB5);=+!%F2$RBX$.,;4Y*P;H_^P]Q7[5""G>
MC*GU2VC"01'8D><G).CZFRJ4*@]F'12%*#-0)G4ZIA!UR/Y]ZFRLZ1U&OPBQ
M#DG?DL`_1!U?8Q1*\#S8HLP0F=3-*3E&?3%'W1Z?T5I=)#AU!C*HQ_C8IJ%$
M*>J6*#-0)O7IF7D_ZFS4Z5&W?J=,0@8RJ(?$:B<2I:A;HDS9`I1)W9R<8]1G
M"\8>J=;)3^`E=Z)@4#-.%4I1EXI"1%^%N2U)G;WRLG?(NNS.95I>K[U3M&\-
M'"WXE62_E6+VO`RG#]Z7QZYAK3S#RGBVK)4%K"SHJ;-6EK`RO@%:*RM8&=^Q
MT0H\<+^$4[;(!MXS[3T.\"`^)4_"#3PH3N!#V'A"_A)&L!#1%5]2@@?O6WXN
M?\^[<]7TSK4\0=P"CSXR=^QMG'T9VMOXQ/O:#O#4/?YX@;]AE/#F&G@`/K7M
M(+[0#>1?1?;_`0``__\#`%!+`P04``8`"````"$`N/LZZ]P"```L!P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R,55UOFS`4?9^T_V#YO8`A$(A"
MJG95MTJ;-$W[>';`@%7`R'::]M_O&A,())7Z`OAR?,Z]QY?+]O:UJ=$+DXJ+
M-L7$\3!B;29RWI8I_O/[\2;&2&G:YK06+4OQ&U/X=O?YT_8HY+.J&-,(&%J5
MXDKK;N.Z*JM80Y4C.M;"FT+(AFI8RM)5G60T[S<UM>M[7N0VE+?8,FSD1SA$
M4?",/8CLT+!66Q+):JHA?U7Q3IW8FNPC=`V5SX?N)A--!Q1[7G/]UI-BU&2;
MI[(5DNYKJ/N5K&AVXNX7%_0-SZ10HM`.T+DVT<N:$S=Q@6FWS3E48&Q'DA4I
MOB.;>^)A=[?M#?K+V5&=/2-5B>-7R?/OO&7@-IR3.8&]$,\&^I2;$&QV+W8_
M]B?P4Z*<%?10ZU_B^(WQLM)PW*'9DHD:E."*&FYZ`$JGK_W]R'-=I3B(G'#M
M!<0/,=HSI1^YV8M1=E!:-/\LB`Q4EL0?2.`^D)#06?GA.OX`BVLSZBMYH)KN
MME(<$;0':*J.FF8C&Q\LS$SPSD13O,8(LE(0?=D%<;QU7\",;,#<6PQ<1PP9
M$2ZPCQ*0\!4)$S42QBVC>6\#YWS^=;Y@QH>,ZX$WIF[>0N`LK<`/1R(K93&K
M,\R$F*4.D"NIFVB*(=^Q\B!.%A(6$_7>A605!<'DWTP"&N"*A(DN)!)O(6$Q
M5N(F(($7!M$(F6E$5S5,=*DQ':%URF*LAN^1,/;>.13HE2MEF.A28B*P$A83
MVRX+UZLD?,<I,S:G5EV>NWF[E`I&.ZR4Q0R.19X7QY.G,\.2F=3IJS#1N01)
MEH99S"#ADXB0J=Z9!`RF\W).&GUX+A(DJT4=`\AZYJ_#=1(M3]X.+?NI-TR6
M[`NK:X4R<6BA:PFX/4;'87GG]^-N?`$CK*,E^T%ER5N%:E;`5L]90^-).^WL
M0HNN'R1[H6%X]8\5_)48?-6>`^!""'U:F'DZ_N=V_P$``/__`P!02P,$%``&
M``@````A`!Z0A:GQ`@``*PD``!D```!X;"]W;W)K<VAE971S+W-H965T,C4N
M>&ULE)9;;]HP%,??)^T[1'YOKB2D"*C*I5NE39JF79Y-XA"K21S9IK3??L=V
M2'-!P'@@L?WWG_,[YR1F_O!6%M8KX8*R:H$\VT46J1*6TFJ_0+]_/=W%R!(2
M5RDN6$46Z)T(]+#\_&E^9/Q%Y(1("QPJL4"YE/7,<422DQ(+F]6D@I6,\1)+
M&/*](VI.<*HWE87CNV[DE)A6R#C,^"T>+,MH0C8L.92DDL:$DP)+B%_DM!8G
MMS*YQ:[$_.50WR6LK,%B1PLJW[4ILLID]KRO&,>[`KC?O`E.3MYZ,+(O:<*9
M8)FTP<XQ@8Z9[YU[!YR6\Y0"@4J[Q4FV0(_>;#M%SG*N\_.'DJ/HW%LB9\<O
MG*;?:$4@V5`F58`=8R]*^IRJ*=CLC'8_Z0+\X%9*,GPHY$]V_$KH/I=0[5!M
M25@!OP3?5DE5"P`Y?M/7(TUEOD!!9(=3-_#\$%D[(N0357N1E1R$9.5?(_(:
M*V/B-R9P;4P\W_;CT`NC_W`)&A>XGEP\.P[#211/;X]ETKC`CI/+[;$X)CLZ
MJQLL\7+.V=&"3@5^46/5]]XLA&HF:O)1S>HUR)"`V==E$+MSYQ4*DS2:U5CC
M]Q7KL2*(O;YF,];X85^R'4N",&HU#H"T-%"G,S1J%LJ/K`[-(-:5T4".6\T@
MC/55Q>:J8GM)T0.!8#L@ENKRP&W+HU87",S:8(,X:#.B2[@RFDM`5Q6;JXJM
M4<2Z1;R)"Y\VC!X/Q-'A.;69FAUR3%H#PV$TESB,(M(Q^'$W!.VPN>JPO:3H
M8<"SU\$8ED6M#G$&7;0RFDLX1F%P/#\*/EK=X%QUV%Y2]'"B'LZI*FIVB#$(
M8F4T78QAG.NQ9)"+C5$TI/WFT:C;2Q8]D.E9$#4[!)D.VLMHF@9V`S?\:&`=
MP]H(NJ1#C*L*.`]5(.<]#(<Y[\R;N<9[\AWS/:V$59`,GG'75N<$-Z>=&4A6
MZQ?TCDDXO/1M#G]*"+R]71O$&6/R-%#G:?LW9_D/``#__P,`4$L#!!0`!@`(
M````(0!9TA!W:`(``&,%```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM
M;(Q4RV[;,!"\%^@_$+Q'E.2W83FP';@-T`!%T<>9IBB)L$@*)&TG?]^E:"M6
M'+2YV.)R=G9V=Z3%_;.LT9$;*[3*<!+%&''%="Y4F>%?/[=W4XRLHRJGM58\
MPR_<XOOEYT^+DS9[6W'N$#`HF^'*N69.B&45E]1&NN$*;@IM)'5P-"6QC>$T
M;Y-D3=(X'A-)A<*!86X^PJ&+0C#^H-E!<N4"B>$U=:#?5J*Q%S;)/D(GJ=D?
MFCNF90,4.U$+]]*28B39_+%4VM!=#7T_)T/*+MSMX89>"F:TU86+@(X$H;<]
MS\B,`--RD0OHP(\=&5YD>)7,-T-,EHMV/K\%/]FK9V0K??IB1/Y-*`[#AC7Y
M!>RTWGOH8^Y#D$QNLK?M`KX;E/."'FKW0Y^^<E%6#K8]\BE,UU`)?I$4W@+0
M.7UN_T\B=U6&!^-H-(D'23K":,>MVPJ?BQ$[6*?EGP!*SE2!)#V3#$#F^3Z-
MTNDH&8W_ST*"HK:3!^KH<F'T"8$[H*9MJ/=:,@?F<PMG'5U3,%KFT2L/S_`$
M(Y!K(7I<#B;3!3G"E-@9L[[%)'W$YH+PPP4=G1AH\4K,I::/^II^KE[$.@2`
MI!.1OBEPBQB_:NB5A)[?*>FCL*2K"H/)K%]C'3##*\RHC]C\"]$3`23OB/#1
M#$,K79O30;_".D"F[2+B_AT8WZ>'NV'ZJCY4#J8.5I#<E'S#Z]HBI@\*RJ7`
MV$6[=VF5^AV\B:_A'6N-2KH+L'Y#2_Y$32F4134O@#*.)N!U$]Z2<'"Z:0VX
MTPY,WSY6\#'CL.,X`G"AM;L<O%6ZS^/R+P```/__`P!02P,$%``&``@````A
M`+;?%BN5`P``7@L``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%9-
MCYLP$+U7ZG]`OF_`$"")0E:;K+:MU$I5U8^S0YS$6L#(=C;;?]\Q)H`!L=L<
M(`S/,V_>C`>O[U_SS'FA0C)>)`C//.30(N4'5IP2].OGT]T".5*1XD`R7M`$
M_:42W6\^?EA?N7B69TJ5`QX*F:"S4N7*=65ZICF1,U[2`MX<N<B)@D=Q<F4I
M*#E4B_+,]3TO<G/""F0\K,1[?/#CD:7TD:>7G!;*.!$T(PKXRS,KY<U;GK['
M74[$\Z6\2WE>@HL]RYCZ6SE%3IZNOIP*+L@^@[Q?\9RD-]_5P\!]SE+!)3^J
M&;AS#=%ASDMWZ8*GS?K`(`,MNR/H,4$/>+7#(7(WZTJ@WXQ>9>>_(\_\^DFP
MPU=64%`;ZJ0KL.?\64._'+0)%KN#U4]5!;X+YT"/Y)*I'_SZF;+364&YJW@I
MSR`27)V<Z1Z`U,EK=;^R@SHG*(AF8>P%V`^1LZ=2/3&]%CGI12J>_S$@K*,W
M3OS:"=QK)SB<S?TP7OR/EZ#V`O>;%W_F+T(<1F]S<4U>E1Z/1)'-6O"K`TT&
MS&5)=,OB%7BNA:BS::2!"J4:_:#A"8J1`TE+L+YL@CA8NR^@=5ICM@8#UP:#
M;<3NAM`E`AX-&1"H0^864UMU3"VI)K$UAFX`OQ=@!!$V$"LDY#P24ENAU)T4
M`K^?IL',.Y@V1,5S-X6P2("3$1+:FB!(I=4Q6C19&"D,9E%5`D?A?#&W`3L+
M$,;SL`58%*";1RAH:Y_"THZP-9BHHG"'PSG\;,1N"F&1B$9):*M-8B"#@=0<
MYMCO]X-Y#UHT4@910]*B`*T]HH.VVA3PH.T-QG"(EKA7J5WW=>!A;SR\_L"T
MV_&V`[35#A_$/9&W!M--L=^.4PA+@^4H"6U]:T\8S!2)*81%`L-0'Y&B,O>U
MZ&6ZK4%='D'<%MSLSA%0Z\>FHN?5L"K8C+'I#5J#3%O@R`\&.]1&A!&`QGL#
MZZDV0L,,NRZ-(&PS,7.B6IN@KB(]R&X28NNA!]L($3/OX-KNLL'4Q%-#L2[,
M%,0F`OF,$='F-WO$@+J*!''<*%]3&8):V6PJXP,4#A5]*G@PO6J0F>(!]MK9
M4+,P3NHI[R_[_6&..>:SGE-QHCN:9=))^:6`2F"8S(VU.5X]^-4!J7D!AYZ2
MG.@W(DZLD$Y&C[#4F\406ICSD7E0O*P.#7NNX+A3_3W#.9;"=]F;`?C(N;H]
MZ,][<S+>_`,``/__`P!02P,$%``&``@````A`)(0'+@O`P``-@D``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S`N>&ULC%;);MLP$+T7Z#\(O,=:;<>&Y<!I
MD#9`"Q1%ES,M41(1211(.D[^OD..M3IN?3&LX=-[LW*TN7NM2N>%2<5%'1-_
MYA&'U8E(>9W'Y-?/QYM;XBA-ZY26HF8Q>6.*W&T_?M@<A7Q6!6/:`89:Q:30
MNEF[KDH*5E$U$PVKX203LJ(:'F7NJD8RFMJ7JM(-/&_A5I37!!G6\AH.D64\
M80\B.52LUD@B64DU^*\*WJB6K4JNH:NH?#XT-XFH&J#8\Y+K-TM*G"I9/^6U
MD'1?0MRO?D23EML^G-%7/)%"B4S/@,Y%1\]C7KDK%YBVFY1#!";MCF193';^
M^MZ?$W>[L0GZS=E1#?X[JA#'SY*G7WG-(-M0)U.!O1#/!OJ4&A.\[)Z]_6@K
M\%TZ*<OHH=0_Q/$+XWFAH=Q6+Q$E*,&O4W'3`Q`Z?8U)``H\U45,PL5LOO1"
M/Y@39\^4?N3F7>(D!Z5%]0=!OE5'+NO#`]5TNY'BZ$!A`:T::MK$7P.Q$0\A
M!&3HW(&L)`:],_"8+(D#.`76EVT4A!OW!>)+3IA[Q,!OA_$[A`NRG3;H#;1;
M"6,U$I`SJWF/AB%?\#Y?..)K8VEYS:E-7N=6%$0=$4HA)AJX/N\0(]<!,G!]
M*F5.(8\#FBCHB5`*,5=(06T'4FTTQCJ-9M'YBA*(6=@R+99SS_,ZP"B8Q4AA
M&HPYG2HM.R)40LP5P4#G#(*92IG3_^4-,5=(F?NQ[^PV;\8ZC6::-\1@WF"V
M+N9M]:Z"L4X5;B?Y0LQ)`?@O5<:'41P$8?/E!UX_CN9\*K::B%F2F`Q3%H47
M6L$WP]MG;5H@>SS1"_OIQF8X@89Z??./&L\?WP!G:CCY_YXCRS&.[I*:F>X^
MMK8C?!QZT.HOAK"_84XQ(0@K%IJ6N)1`"/L]$6.&UH:1'*B<W9R(NB9SXUO!
M9FXUZ`L<?9#K;E%8*<:#(7<4]O<?U@67%"Z(BLF<?6)EJ9Q$'&IP.X"^ZZS=
M<MP%1N3,'JUWN,7<[@B664-S]HW*G-?**5D&I-YL"9Y)W'OXH$5C%]->:%AC
M]F\!WR<,%I`W`W`FA&X?S&;MOGBV?P$``/__`P!02P,$%``&``@````A`"EO
MDU=1#P``PXH``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULI-U9<]I8
M%L#Q]ZF:[^#B?6RS>,$59ZHQ:$$KVM$;<4CL:MND@'1ZOOU(2++1D5I_>J8?
MTO;EQ]'"/;K2U4'^].\_7U_._EAO=\^;M_M>__RR=[9^>]Q\?7[[?M\+`^5?
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MKJ5NT5!<A.1G=P^R85HU'`_!8F?,VHPXBBDG&+7%C,1.U=J,.#KK)YAYFQ$=
MP:A,=3YBR@9+-MBRP9$-;M5PM$.O1*]8G&"\$XQ_@@E:S$CLB/`$$YU@XA-,
MTF*NQ0>\/,&DW::6-=GE7U?6Y"_7LJ9H.,H:V3"5#3/9H%0-1]U@*/)*K4S5
M_S39H,N&N6PP9(,I&RS98,L&1S:XLF$A&[RJX6CS+D6O\MN,R(2@,M4N"*N&
MH\!78J",*E.]*98-B6Q8RH;TJ*'65[*+\ZZ^DK^<3?T<7[$,Q'9/"I/US_>K
M&B$>4$Q1S%`H*%04&@H=Q1R%@<)$8:&P43@H7!0+%!X*'T6`(D01H8A1)"B6
M*-(N4<O-;(KF.#>K:86\^;Z770"]Y]OH6F3<I#!=.8EB6HC;PW3<\/+P7_VR
M<88Q%!0J"@V%CF*.PD!AHK!0V"@<%"Z*!0H/A8\B0!&BB%#$*!(42Q1IEZCE
M9'XC[&AFN\K)O%GD9%_F9&&Z<A+%M!#7AYR\N;G*DU+DY+'H'X`0"BY%/8[1
MMA`-0^@HYB@,%"8*"X6-PD'AHEB@\%#X*`(4(8H(18PB0;%$D7:)6DJ.VU,R
M;Q8I>2W.K">%Z4I)%%,4,Q1*(8JT[A=#K<A:%8-H*'04<Q0&"A.%A<)&X:!P
M"U';J?5CY0)C>"A\%`&*$$6$(D:1H%BB2+M$+2G[66G"\4!9W`*^O'J?=C\`
MF9]BFGU2HJX$93)M(:-K,3DQ:T%B`%>8J$PT)GH+&5V+&<AY"Q(K;#`QF5A,
M;"8.$Y?)HH6,;L2ATFM!8L_X3`(F(9.(2<PD8;)DDG:2>O;F=[I;3G/[Q1WP
MVK7GC;A',BE19](6<3K(M(QR6UQ_7I[WQ53:C!>C,%&9:$QT)G,F!A.3B<7$
M9N(P<9DLF'A,?"8!DY!)Q"1FDC!9,DD[23U9\WOA;<E:W".O)ZO(HDE>%I>=
M)G=DX@.3:0L9W8B['+,6)`[+"A.5B<9$9S)G8C`QF5A,;"8.$Y?)@HG'Q&<2
M,`F91$QB)@F3)9.TD]03-K\#WI:PQ9WQ>L)^%+4<ZA4G_0)U)BR2*4>9,5&8
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M3'0F<R9&28JCPV`XS&X\U>^/F!S$8F(S<9BX3!9,/"8^DX!)R"1B$C-)F"R9
MI)VDGK5YJ417UA:E%/6A5MQLF?2[ZBW*K$4RY2@S)@H3E8G&1&<R9V(P,9E8
M)2EROW][-1X.Q72=S5$<)BZ3!1./B<\D8!(RB9C$3!(F2R9I)ZFG;5Y.T96V
M1;E%/6W%+<=)OZLFHTQ;)%..,F.B,%&9:$QT)G,F!A.3B562HYMB8L;!YB`.
M$Y?)@HG'Q&<2,`F91$QB)@F3)9.TD]2S-J^W.,K:JMRP7]1AU++U5IR]34K4
M<=[[P&3*9,9$8:(RT9CH3.9,#"9F2<H1=#R^N1F*>VL61[%K40;#<:.>TT'A
M\F(63#PF/I.`2<@D8A(S29@LF:2=I):L@[:2IZ,O&A]>%S/&M[)XHD1=2<MD
MRF3&1&&B,M&8Z$SF3`PF)A.+B<W$8>(R63#Q2E)=Q+<5?/LUTQ]FCUQJ'&8"
M7E3()&(2,TF8+)FDG:2>N*+:Z3`1-?HH51RT5#W=BH/]I$2=B<M53QQEQD1A
MHC+1F.A,YDP,)B83BXG-Q&'BEJ0<^5MN6"\XB,?$9Q(P"9E$3&(F"9,ED[23
MU+,V._L]/C>6T\?Y@[7D]/&MF.28E*@S:XLX'63*469,%"8J$XV)SF3.Q&!B
M,K&8V$P<)FY)RH&R-6OQ@_9X.3Z3@$G()&(2,TF8+)FDG:2>M7]1^Y0_OJZ1
MK;+VJ40=J?C`9,IDQD1AHC+1F.A,YDP,)B83BXG-Q&'B,EDP\9CX3`(FX3O)
M'UTX$-TV>G_UXQO;8MHN9I(P63)).TD]4[,TZQQ?\]?EY:S8KLF@0)T9BV3*
M469,%"8J$XV)SF1>DF(T&O:S.S#U6Z\&QS"96$QL)@X3E\F"B<?$9Q*4I-JW
M0_FMS[`&1MG37R\;&5OTR3+$[=6EF*:):R&&_1OY)9B$UW/)).TD]6S-*WE:
M9HKSY^PVLE16/I6H,TNQ4FC*469,%"8J$XV)SF1>DJ(;W(RO!^+RP>`8)A.+
MB<W$8>(R63#QF/A,@I(4^[8_OI%/T0QK8#@<CT2OC6I@,+B5#_R,:Z!_W9CT
M2DK0T>^73-).4D]24?%4W<[)'Y'<2%)9Z52BCI5]8#)E,F.B,%&9:$QT)O.2
MY--UV6.C^XTJ)H-CF$PL)C83AXG+9,'$8^(S"4I2[=LKF6(A@8@7$C-)F"R9
MI)VDGJBBR.D]45N*FVYE<=,`*Y<>F$R9S)@H3%0F&A.=R9R)P<1D8C&QF3A,
M7"8+)AX3GTG`)"Q).>1F3Y,6%0,1QXB9)$R63-).4D]64=KTGJPM)4VWLJ1I
M@/5*#TRF3&9,%"8J$XV)SF3.Q&!B,K&8V$P<)BZ3!1./B<\D8!(RB4I2Y//@
M4CZ8,^80"9,ED[23U'/U+PJ:!BT%36-Q>)J4J/,,N(C30:8<9<9$8:(RT9CH
M3.9,#"8F$XN)S<1AXC)9,/&8^$P")B&3Z)WD5RF-D3=^?_DOIX@3)DLF:2>I
MI6I6N52;46H\P>D`Q`3P6$R434K4D9`/3*9,9DP4)BH3C8G.9,[$8&(RL9C8
M3!PF+I,%$X^)SR1@$C*)F,1,$B;+%C(:BP*CM`5]W#2H9VY;/5/V]NK$>-A2
MSS064YN3$G4F+M<S<909$X6)RD1CHC.9,S&8F$PL)C83AXG+9,'$8^(S"9B$
M3"(F,9.$R9))6I+B)#V?@_XXJZTG;5LYT_@H:5O*F<;BOM5DB"4L#RUD-/XX
MD!R^Q3-M08+,F"A,5"8:$YW)G(G!Q&1B,;&9.$Q<)@LF'A.?2<`D9!(QB9DD
M3)9,TDY23]R_J&@:ME0TR;^S."E1-<%^/13S4P\EZ!B&ITQF3!0F*A.-B<YD
MSL1@8C*QF-A,'"8NDP43CXG/)&`2,HF8Q$P2)DLF:2>I)VN62,=E$H>+VNNC
M439_75[3RCNQPP)UY.1#"QF-Q8VB:0MJC+*X*(6CJ$PT)CJ3.1.#B<G$8F(S
M<9BX3!9,/"8^DX!)R"1B$C-)F"R9I)VDGKBBODE6^P];ZIS&8C"=E*@S<;G.
MB:/,F"A,5"8:$YW)G(G!Q&1B,;&9.$Q<)@LF'A.?2<`D9!(QB9DD)2EO`0_R
MKT'4"T^7'"3M)/6L%05/C:QM%CXUYL8GPP)U9BV2*4>9,5&8J$PT)CJ3.1.#
MB<G$8F(S<9BX3!9,/"8^DX!)R"1B$C-)2M*5M9@`:>=RZEDKJI\:6=NL@FI4
M2$^&7`7%9,IDQD1AHC+1F.A,YDP,)B83BXG-Q&'B,EDP\9CX3`(F(9.(2<PD
M*4GQ!RSJ,[^'6=8EQT@[29&T%[NG]7H_7>U7GS^]KK??UP_KEY?=V>/FYUOV
M!R+SF:7WUK/M^MM][[?^W6]7O>R/R8KVA_Z=>O@CP*+=[M\Y;>U>_\YO:P_[
M=]&A_>(]T.[SIQ^K[VMKM?W^_+8[>UE_RU;M\OPF.]G>/G]_>O]EO_EQW\ON
M*GW9[/>;U\./3^O5UW7VI[POSS/\;;/95[]D&W#Q:[/]_;#YG_\+``#__P,`
M4$L#!!0`!@`(````(0`CZZ49F00``!`1```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;)28VXZK-A2&[ROU'1#W$VQ."5&2K8&M:;?4+555#]>$.`D:
MP!$PD]EOW^5#`*]X:'J3@_VS_'DM^W><S9>/NG+>6=N5O-FZ=$%<AS4%/Y3-
M:>O^]>?+T\IUNCYO#GG%&[9U?[#._;+[^:?-E;>OW9FQWH$(3;=USWU_67M>
M5YQ9G7<+?F$-]!QY6^<]?&U/7G=I67Z0#]65YQ,2>W5>-JZ*L&X?B<&/Q[)@
M7WGQ5K.F5T%:5N4]\'?G\M+=HM7%(^'JO'U]NSP5O+Y`B'U9E?T/&=1UZF+]
M[=3P-M]7,.\/&N;%+;;\<A>^+HN6=_S8+R"<IT#OYYQXB0>1=IM#"3,0:7=:
M=MRZSW2=^9'K[38R07^7[-I-/CO=F5]_:<O#;V7#(-M0)U&!/>>O0OKM()K@
M8>_NZ1=9@=];Y\".^5O5_\&OO[+R=.ZAW'*\@E<P$KPZ=2G6`$P]_Y#OU_+0
MG[=N$"^B)0DHX#E[UO4OI7C6=8JWKN?U/TI$Q>A#$%\'@7<=Q*?_.TB@@\#[
M+4BX"/UHN7H`Q5/3DNGXFO?Y;M/RJP-K#,"[2RY6+%T'4(="-#Z+UJV[=!V8
M6@>M[[N(^!OO'3)::$VJ-/`Z:*BIR.X501(/&@\(!@S(C`5#M`H,D4O!E:J&
MZ9B(*K,H(ON0D$?+D*)UZT*4859!,`90%$H33C1(D<TIC'E#$`N$:(6%-AV`
M!,,L%(32S$',*0P(6,@6"-%J9B(B(8)0FEBN$#\("`V0(E,*.Z8!$5LA1*L)
MX:^6"$)I%,13F"01,069$CS```O>D@C1:C)$!!4\51J="']%Z`HGPE"@5!F)
M$$?,N",=X4P!&7:FZ,4PXYY22T-I$ED5LIAL.=F=J>X'TI',DHA>3()+HS0#
M"<I:AKK'>1@)H>#N."-A-&1$=F.0E;D$4BTR)DT24Y391'1<3":4,+?/RT25
M]TU])*+('U,M6LE"Q:MH1<;!5*FTPL`>H$T>87PS/,H731[DG2E5(K6*:4P2
M@JTO,R0(V>01%CCR#`>+<L8I1Q#<%6O./G5BYB0F""3/!B*:_\MCJ1+9TZ]!
MYB0FB-UFX5?'_3Y"YI%JD:Z,OUR2.!AWBR9YV&JIW6ME,]I(%!\[6J3=U@](
MF$RVB"9YV'"IW7%ELTGB8QM+M4B34.('RSO3U1I[`<WJF+8[K%>;WR(;2ZD2
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MW[Z(._/P7\;N7P```/__`P!02P,$%``&``@````A`%F$$*MS!```X`X``!@`
M``!X;"]W;W)K<VAE971S+W-H965T,BYX;6R,5UV/FS@4?:^T_P'Q/@&#;2!*
M4C54LZW4E5:K_7@FQ$G0!!P!,YG^^UYS"?X@S?9E)MC'U\?GWGLPJX_O]=E[
M$VU7R6;MDT7H>Z(IY;YJCFO_G[^?GU+?Z_JBV1=GV8BU_UUT_L?-;Q]65]F^
M="<A>@\B--W:/_7]91D$77D2==$MY$4T,'.0;5WT\-@>@^[2BF(_+*K/012&
M/*B+JO$QPK+]E1CR<*A*\5F6K[5H>@S2BG/1`__N5%VZ6[2Z_)5P==&^O%Z>
M2EE?(,2N.E?]]R&H[]7E\NNQD6VQ.\.YWPDMREOLX6$6OJ[*5G;RT"\@7(!$
MYV?.@BR`2)O5OH(3*-F]5AS6_B>RS*/(#S:K0:!_*W'MC-]>=Y+7W]MJ_ZUJ
M!*@->5(9V$GYHJ!?]VH(%@>SU<]#!OYLO;TX%*_G_B]Y_2*JXZF'=#.UI)1G
MV`G^>G6E:@".7KP/_Z_5OC^M_9@O6!+&)&*^MQ-=_URIM;Y7OG:]K/]#$!E#
M89!H#!(#S7$^6D0I(XS_?Y0`&0TG^5STQ6;5RJL'Y0%[=I="%1M90F1UA#@$
M*4LU^4G-#A@8[F#T;1/15?`&FI0C9'L'8B/R.P@V00+@,9&!(QID;B34*+#R
M/4V"3^L'GEN$4`.B=Q@0^2.$Q0'VN<-!C:Y]"*(Y)`X'A*2#2G&602O&-B(W
M$8R3E/-L0E@<X"`&!S<I:M;ADDYQ4`^$\($+B\,PM.=S<Y[PA%!-U2("U6D0
MN25$C3H$]$&0`$*0``UI/!?#1+`D92F))I(6!VYQ<,50LS:7V#GL%B'(A6?$
MT2HWI^.0Z-46B\1B<5-"C3J[D^D4J`1")B6R+'40N8D`)=(T^HD2ZKVA>_7&
M08W:[1'K]<@!(9#TJ7K=]GB$L'3(+`YN-M2LHX>N+.2"$-0#_"\,73E,0)HE
M(=6.8S$AX->&'"Z58=KAHB,AEQ$SDDD83QUCR6T$(:D6SB9C^^@M-P2]S_2-
M6$<822#&S$X\HX$8)$HH-/1/RI0HGYO7R##LB.'ZUXC!/:*$)1F?T4`7'?5B
M"<V8[B9;C_LV2N8^&NL(HQZ(&3>AE''FU%`^AD$(Y30FJ3Z-S4,YW1T]T`"M
MO+@61A#SD(<)><SCOI/";<%M&*HS.^J!&-AJZMYY?3S$V(K8?CI5*MH@:#_M
M0IW.W!+$F$R<8LX?0FP>MJ,.[4N9OGG,K96ZMD808_*9*_,08S.R_75@Q(V[
M$'JD63/&:W/,%6*P9J*80^W:KX.<6`@29T0WF<W&=MHI3W.+-0QR9&%:*"=A
MR$BB^V/`Y,3$,,X31E*MK\4D>FRTP[3M+=0Y]7;$H"Y/'&X#"26.&^<VB(&]
MQ-2X0]F<[OMM-/=;JO5%=48,<N%P-XD<!\HM!"'@0(9IVS1LNW7?0?#Q,6MO
M)Q';$8/W1K@JW;D@6)#[-P3\1L&;_:4XBC^*]E@UG7<6!^CG<)&`0;3XA8(/
MO;P,%_N=[.&#8_AY@B])`;?^<`'@@Y3][4%]`TW?IIL?````__\#`%!+`P04
M``8`"````"$`01&YX\D"```M"```&````'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;(Q5R6[;,!"]%^@_"+S'VBQY@>4@4IJV0`L419<S+5$6$4D42#I._KY#
MTDM(*VY\L*V9Q_?>#$?DZO:Y:[TGP@5E?8;"28`\TI>LHOTV0[]_/=S,D2<D
M[BO<LIYDZ(4(=+O^^&&U9_Q1-(1(#QAZD:%&RF'I^Z)L2(?%A`VDATS->(<E
M//*M+P9.<*47=:T?!4'J=YCVR#`L^7LX6%W3DMRS<M>17AH23EHLP;]HZ"".
M;%WY'KH.\\?=<%.R;@"*#6VI?-&DR.O*Y==MSSC>M%#W<SC%Y9%;/US0=[3D
M3+!:3H#.-T8O:U[X"Q^8UJN*0@6J[1XG=8;NPF41!LA?KW2#_E"R%Z_^>Z)A
M^\^<5M]H3Z#;L$]J!S:,/2KHUTJ%8+%_L?I![\`/[E6DQKM6_F3[+X1N&PG;
MG:@E)6M!";Z]CJH9@-+QL_[=TTHV&8K323(+XC!*D+<A0CY0M19YY4Y(UOTU
MH/!`94BB`TD,-@_Y:!+-DS!)_\_B&T>ZDGLL\7K%V=Z#\0!-,6`U;.$2F%4)
M<0"M+%7R3F4U!L("HD_KZ7SE/T%/R@,DOX1$-J(8020GB`\^3F:@Q%=FCB94
M%%PA[VQB<5JO?>8&,GT%.2MH1'$-87D`G1$/*IHA(#EY2`+'@X$L=)?"3S>Q
MG2[>3%OJ4,*(NHHZZJ%-GQM(:M0#\[$AQ56(Y0*&<L2%BCHNG*W.#62J73C]
M*<9SEFXZJJNBCJ[3W-Q`QG7'<Y;N;%1711W=J=W2W$#>W/,WTY:ZN@[.K^!Q
MZE7447=F.C<0>\_=KE_'6#X6HSY4U/&1.ETP$.,CBM,D3>;.8!06)(P789J>
MJ[%<P($]U@X==GS,'!\'S%4C-F;<B3GPS3$YX"WYCOF6]L)K20VO?S"9P2AS
M<]R;!\D&?4INF(336_]MX%HF<(0&$P#7C,GC@[I03A?]^A\```#__P,`4$L#
M!!0`!@`(````(0``67>JSD````?>```4````>&PO<VAA<F5D4W1R:6YG<RYX
M;6SLG=MN',F9Y^\7V'=("&PT!10ILGBVNS6@2,F6K0-'I.P=#.:B6)4DTZJ3
M*ZLDT5=^A[D:8!;0L^A1_"3[^W]QR,C,*I+M;D_W`H;;W<6JR(@OOO,I(K_[
ME\^C8?8QGY7%9/S]H^W-K4=9/NY/!L7X^OM'[R]>;!P^RLIY;SSH#2?C_/M'
MMWGYZ%^>_N__]5U9SC.>'9??/[J9SZ>_>O*D[-_DHUZY.9GF8WZYFLQ&O3E_
MSJZ?E--9WAN4-WD^'PV?=+>V]I^,>L7X4=:?+,;S[Q]U=[K;C[+%N/CS(C]Q
M7^UUCQX]_:XLGGXW?WHZZ2]&^7B>`4?V?#POYK?9R[%;`+B_>S)_^MT3#77#
MC[+7D_'\IF3H(!\T?SW/IYO9SE8GZVYM[S1_?#/YN)EM=Y?_>`\8V;\?7Y;S
M6:\__X_FM-\VO_";>)=?%WJ$K;WIC?+FJ&^/^_-B7"Q&V=E-#VSV\\6\Z/>&
M98?M]S>;P_VD)V!JUALR9)!_SGZ?WS;'?;NUQ=8/#W>Z6\V?CD'SP%#]8MB[
M;O[Z[15KMZ`\6<QF+)F]*$I@R_XM[\V$^>RT-V^-_79C8[N[L;/=G#FB]N)V
MVGYH>VOC7U<^<9;/BHG88OF*<>84O!<P5-F<\=ME#-%\W*^V?()_;?&3)\F+
M8IC/LA,0<CV9M>EQ/NH-->!=/IW,H/AU=C(937OCULA`X<EH-!EGY_-)_T,G
M.X<W\C)[NYB;H/)X<V<GDW$Y&18#UA]DSWK#WKB?\QC26&;K[\>]Q:#@E\=\
M/C_-UAXW'S_-^TC,M@E%M_ECH/YQ63+=KUH_]\H;$]N^/N1_7A0?>T.XI87]
MLUD^[16#+/^,^BC9CV1],K\!+7W/8#U;HKG"Q60.U]7!:(XYFZ&49F@-32H@
MIN+Q3C;.Y]GD*NOUT2^+H:%GD*.K^D5OOD2QN*7<3IM+!`!>%;W+8EC,B[R-
MC..^Z;LRF_9N>Y?#W,!A\=D"NH2--R=^T$/91C;+W0:F/3;:G.3-9)Z'59N_
M??OUR]<OS2]/D:J/(.%CG@VK'35'U7&?;'WYP#L&P/"C8BZJ.,KWT>!P,K8(
M1#9G,\:_F0P'V*UOL^?0<W[;XCP8ZBI',PVP7R8G:UN;Z#VP,,O@P47^ZVQ[
MJX,JU/^SWF)^,YD5?V'X5E8ZB2K*4H0Q1KQ+N$P8[UBD6L5/7"WVZZR[T]G?
MV^_L'79MH>YV9^=HN[._OW<W%!WH74YS[,/'?-@B]_$`B8:!$0P3JF*<]7O3
M`D%IHO(TORKZ!98U%8'%3#H(V<L&.=-/3%KD!ERW=+/C@&4$::[D1B8L8/M]
MR),/5E]G*$(,?VY&<J4Z:RC`U5:[Q4&1=9I[:XUL$?JA3SB>6SW:\-4)O#%Y
M*%NNA%QRARGQW'LOV$N'+X?9#_T!`"=&ZGR.,G;:`/W\%N5M"OE!YFKG3O=O
M>W_KSM]3][!E[!*PWM;`6LU$[Y"@\:(E-WY+B%G0^RT%]BXO<:7ZSGPF@AC-
MUBPO1I>+6>D0U>29W^1CL#9T-F8PPH^4IRE]T1QYFI@\-WPD-^0OAO(`7_.A
M5Y.RS."<05%.)Z5I&YG2:%R;XYWXRPPS;;+MYCB;]VHV&65^++Y+<\Q;<PL*
MXI11GJU[!#YN(?#E>)ZC)>>KMO`;0A!M(?\LB!9%>6.>+[L()J^E6$]N>ABE
MC.>N>H6W(]A>#-&#K:7S:9K`-[?X!L]D"(I7?9^!2*(G)[PR5T!QV2N+OA%P
M4`P7>'3-A_^8%]<W\@%[1'PH\VR\&%TR#SM.IX*NE5YYR+PU!9W("/.>R.U[
M,9Q\>I#H)J-?B`4J*5$D]'&%5S7XTZ+TKL-\@EW$=^CC<)MW)QQF?"M/SUS0
MZ6SRL1B`@\O;;'U1\J$8/PZ\!E\2OJU:R%39!ECF(?`E/_5.$:G)E>?2)DF.
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M2DWD1(P2+#H-\>R6G$80K`I#RQZ$>MXN+)O:\-Z;9Y>D>\9C(4ET!EV3EHH.
M0TG#K!YTOIA.AV;UL>]2%FBYA7(`3*OULRL4+O(7,V0M>;5E+#00.@IO*)L[
MJX^:]SXO"<66@R)(QI/QAD%31(%1*%7IJCM4[3.<%P4F[,]QG/*3V57>F[//
ME?KQ166363]2W,=QGXKYC?%L<YL/>,S\XQ_V'$9'/#@=DK8S58#!'<^;<V`Z
MD2?;G:%L#A6790<"B63+E@)S`7>7B*#C_B7*_3;K#\F@%*#562UFDK=&5J3^
M0Q/$T[SLSXJIXDF1]=FB+,8Y5E7$/%^,1KW9K;X_+Z['-CE:SNMK<?H9B:=E
M,?Q/,^L=.=<W4C/;V=_^^I_93[-6'2\S):;?.'Y,L<)Z;B`#],\9_RK_HHP#
MZ?6M1T^>?M>?#)$Y>&-$/GU;W\Q>D.UP0RZ*$1SP)O^4O9N,>F/]>M4;%<-;
M/X.^>&*36OK]5^44]OK^T13ISV<?\T=/S2BMSAE+_8WR&?-]&$\^C;->B1GI
MSQ=E]@>X4TK$Y9:S=3'OW_[ZWRCB*9G(O_WU_W;TI]2@9@]_NX?YZW$'@2M1
M)?W)C"RFY=(69*!MI]FPAP,(FC2I.8CZXTW^L3?HR0-_VY]/Y(CN=[+MHZ.#
MS>R"<7YEF[9'Q)L/A]0F+/D_OT&;NN5L2GCP`P91NJR7L;UKYC)Q[['#J2SJ
MC(P>YC6&'_+?V);/H4.CI'[P=@S'(+2"J'OHTIX=6R>`!!A$%G(=$:)>I@Q^
M*6W&5@+>SLTI?_[960:'H"G!VD+)?I[Z=%,0V@D?8=)>'VG4K-M;6]\$9"W/
M007!+7-RH^85:WR@S?)J0;8N\IV]=*`0P>0>-D.;`-%:EAIF+L/:YX(*#NFE
M[.CH/H#`9Y)'B.F&3$DW<FY@LA1".F%??M..TG5<H8XF<L]`9HL,F\I5'J-[
M<//+Q="RM\93-6P[8CE.=^OZ9*%AZ>PEAKA/N<6PCWF9SR;#H725@9@,3:BS
MF1U#-I`DX!C;R?(>]`.?Z5,*/G(B;)*(FSL[.^XG(A\]"/8#-V3OI(%%B!K9
M4AP:4>I+1((-VL!0/PB8;8!4_NVO_P7?BS>=RHYF$2:$(>%/'"0]5%M>PA48
MA'C1[;T.OX$X1E.%V9&^,'E'B@4>0O<KT0U!TL6\#JFM:)2]`$\-9A`@)"=5
M%`2M)N&._#*;D+#W(9_P\0F8=QG.F+?`(>WK&0(]J0_%R&%'Z"H*"SE"H(T7
MI9R,DJA0TB=:>5'$F$JCN-7%((G_@F="Q<*7:\`C29"\=.SL`?%9.ASZH@\&
M]"SY'+E_F/@@$%EOI*VA2;0P&Q(DL5;C?276*JN$F&`2D,Z!U/3ZPGD;,[)-
M0DO0@>Q(DJ*'V9F"XZLA6+'G6Q@#!NUU-C`E8/I3ZP2D9<K<X#,PV^609`DS
M.JC#:@S,IX@D#\T^R>T>8X('K3(E*._4[022_KO%&&N](V5+1EXDZ667!<_W
M;\;8RVN<%*>QC6F*N=^/3XN)-I>$J1_F-[/)XMKTZ@QVP)0*6\/B2L+.`&(P
MC<5G5DQ;9O)EKK-"18?A]*:GX@#)8V*;8C1:`#X[Z4U)%`#SQ6/Y<G/F&QDM
M71XG5%U$W;+`4%-=B$"S/J*J[<XGU[DF<U9)ZWU"SZ!9L<'@L5Q<PGX%GE0G
M>YT/@B(/IOCU\4O,Z[ICV=X5MD>$=,4-B(I#(:):)4!R5^GY#.$&U5@(8P`-
M[%W*.#,VRZ_8BR"17PS<EM<JL:\4F:4LF#G2VC'<;()EX!]XU%$:.W$7VH04
M05`2)+`4&Z6'0-8)WGCYY"6^/6I7!6TLJ%Q]C4]&M'Z>@QSR)1IZ/ISTQAN_
MSV$$BSI/Q+.S3+5O_K/^^OSW)R>/Z2A`IIDVL[]9^98,6<'?/EJ^-D^8Z>1P
MG<X6A/1.9PD#FTH04!.F&T!:8MA;C/MB>CP,+$^QT7=K17\G(Q&*[)H.,1A-
MGLC#9:-;BBC4-H?YXD,^*GKPT^M7L!.K,X?C$=0T'M+EGQPA9<$<)\NQ6YX%
M1D8@$<[-8-&7E"M_`N?V'2:NE&@0<[L!QG'R."#ND#)7AK6>8,M4(L(C*2YI
M^4`>H,<'MNA\ISII`5S(!D@2AL;+J6=%S`)%!@$D!=!J*[G-ILBP/![QEPFM
MB91)Q@7*Q3%GDQ/,5P3IAA0)/CJ2N6_(6V*[\[$#,.!/WVNGO?Y29(NKJ'"!
MKDMPA(*4CL>BA?GY[T4EVI\*3*DM]$D&(1HQU71O39L,"J4Z;%,T*QBH'N=F
M5.!V"FVBQ'(4,Q9`F(DMM76CLVWWN38G7A>R)[QX.%).BU`0E&3EZ`8^8I?8
MH"A2&VAQ!!X5.\4R5JTE<89$LR)8<Z7*_2[GTJ-6FVF!C^?\VIBUZ_MKI.B-
MO_J%J(6B1WW`/-'IQ?T8DQ1Q.GAL3MGD/D?6$;3,!I,1T@RB+>'CHPE$XI1*
M.(Z(O(YJ)6.E5,\&);O<6^YD!AF\(F7=`NS$!SE2$W))V?@QAGB8;;LVB9W:
MVK6YZE`+PG.99R&FVD+MZ[`?TX\ML&SSRV,X<''W+NLA[?PIVZ#^1>7-0I\]
MUP;E:-AP#'JH6DRE)1,,]K<8LEEY4TS1T3.C:%PZ01;L`%#:7?SUK,9_9;!Y
M5Q#6'(RP^SI&S<$91,]::^8S\ZAM!8B6#Y.(*`5AO9<=[6P>$-$T;"\V5JP5
M(4L?ZLM?,!<J_TPA#;/>EE0'!-8B^+?I!):T\4OBD2:<B;:1:D*KF8!AR[$Q
MP&'>O_-;X8VED^*A+)^R[K[+!ZH%),P75`@:(P9N+KK"JJBCAC$[G:.#K<[V
MSD$(9%;!D4YB<7GP&9W'3D]#M]O9VHL]#:O6K_,C4?F*),<S*EVF>,]D'L?(
MCU3+1A9[F3#=V*IB%!*X["=I&,1#^L_,K:44S3\T2_/T`F:76VWY!FFZ16BX
MDC`8D/?[_.*'X&I"=*Q.90NGZIQRV8B6_Y[$+J@G2D3DC<N,1*1*P[B?_"YY
M-T$32[['5^0OTTC.""-H>&B6/'B_>;Z9_>;X^,SD3$P5-E#%*4G2V4F3.4']
M5E`Q6P@0MZUKM5Y!0%NP#<5YE>30^.<A;0$'CTA9B/(AP#Y_?F*PF?\":ZA!
M1D[2"SGMZB)T`NY]_$/Q."V8?OGL?./_(->FZ*#3$%\<8&XQ,PIDV&M_N,"K
M24+M9+,V\=5D,G?4F2FS*IH@ZA%MYCV($89X0B$/#F=BBGVS@XL?_QX&N5H0
M65I,%D(\P=E+2J/K%N/BW\."['NL]ES%L&20S(-.QC[VV2FSH1!0-)E,<=5`
M-8^2E\1WD`>@ZD^?7+!2P.*'GBN+QPUIM!Z&%+C,+AC3WX%O7`A+..S$F&`Q
M"FYX!!@,_6$AI4*+\<"2V'B#*Q:X6K#[6QQGPRCAQM^#T_)FLAA"0L'?,Q$!
MA7\B"C!M$^/C^Z77`PG#3LDY&J:$!<%'1G,`F\1$5VBS-'YRO,3060X3LX[<
ML$I8_7SFV?3&XX614X&64F>!Y7__H.605:AC)C?N"V$*WMR1\P2\OY=F2Z6C
MGYXF76*H#OS*L-6?/1M^`9X#,)@,DP'<>I#8HQ;4:&Z+SJ_TC*SR#60?"_,C
MU*!5HY1@H9U'2F6`U*["R%FE;"'^2<SI2()^$3BYGVF#OA.GUC@-!;D(;9HT
M32)<=?XV?ER>WG`)$42S3(I%I@Q`L<F&-UC.-"1Y]=3@$<71SJ2,QBKTOW=`
M/4?;*8.M'$CB"9AULY+<F=,[SGWX1=`%38@Q3T,EMO(08FD0*I@@_=:'[XY.
M4O<_SO1[6U8F>E_L/R+SJ@21Q[!$AO+B8N13S19B]RP'ZTV`3P&YA*?9>M?0
M;:HN:?X(V6;)5V"M^S&@]<6J+BDK^;;$JJWCA=8Q5>BWRP8+LWO50X8JW)V)
M$NS4Q$R?.L,%RV,)7.0?^@O$^7'_JSCQ75XOKO[\TJ^X#3,BIL!B^R1R0%;E
M5>(8^'(QN'361^QE'WT_?DQ`5S[X*C18)X%(9!_4L>V/`?S\^$@MA-A,61\X
M15D@4FAX&T-.)9&\BYK)#"192()<.`3]`A^IW=_QZBRWQ(^.'X%>G%Q+B>%#
M6"N$W$*_\TV*Y^3C+MUQ#%;$T5E0@)-;#GF43%>'Y57VXO3E"=^HPX,4(JK/
M,H;S)%(/IYE,DEJN!+:=S2S1T0:1(D7./*B%D^E96`G8R][XPRI2TAX#X?U9
M"E'2=8?_[-KS-?4XO",\4?&9$.T`$UYA9B(0*06Z`.F0LR'QI`??8Y:I$6%O
ME#7=(`LJ'%B,21(S2OD``N6XEE"!%C"A]$J)=/EQ)'%?R`6W_A0!<%5\MG*Z
MT?4?MGXI=R0`\,<;/@>=:KN>6PP"'U)2&K@$2MQ^""?AZZ6'7SS@(ZIK[$;=
MF-*400I<<"=O-LQS+:4BEE?'):Z6CT,\4\$R+L;;S-[IH(]$#"SI%"#Y82LX
MF6+FW`)\[J2!5!=9'=,^/I^)>*Y@2YU%;#=#O,2I*.AW(`$-L5Y-QM<;KZ`8
M.1X[2B3E\S^6!W@=HR90\['(:8@@_7X-LPD@3S8%444%-`GE,12&`R$S\1._
MNOR?>33]8@;I"+8H?>@+"XI4Z/+EVCXM;[<R:K[&..K=6BB%,B*@H0I@66KF
M9#Q%#>*[$4<-722!$AI4]I%D]8PBT9\7E,>`QNL2%U^]I`B$NM*1&N>V&.T1
M/]258[E@)&&CA<D'F6_?X<K.30NI80VBE^5$1Z_X-D8AAACC17,1I0.Q1L:*
MHJ&K$(2-"@CGFQ-AXPLAQH6!E^`4X$LI7C<QP(;(\M9%WY3%E#5@F+@[>?!3
MB`99WSL1!D>H!_15FYA_4B)/X"4-XO4EQ?=**D?R&-0K^)K8*K26J[#W<_<6
M84@PC[[7W4EIJMO2/3LL>/-&`I'3ANC(V*'GD@%)`PO*5QH:)2+L(?!CM(.U
M]0AAS55=%S9J^\\+%9G#4)P:9&$S0Q6B`/WS[DOC(25R%,PKB]#[V*-<:]T)
M%=QN3X/`/M+XDB`_DUM5\]F7DT$^E.!A7'!NX7Y&AMDGER4-6:X.Y+:!/]LS
MI><<:@W^TV)P;=I)6PQBLDK%/37D_<%8'(YZX5I3<4%>CK%<"\WS"V"1BL(R
M`@.Z.)6QP,D058T2?$+A1&F"?US+#&)%TIZDE3=B]`JI;1K72P(?VAM[&%]W
MPI+\',S":)EV=;0EX6*4Q,`"5M>G!N7*K:EPWA28)MI@;JL\/)2`<"Z=)HV<
MZ+;QE*,1;@?7Y@1H6W(4><:YU`K``-CSI><]`4K:"&?!`>2X'U>3TJOJWU[]
MLU;8G1Q*<87F1SDVIZ<YH6*PPJ!RZJMB9<`*.X,2RN]0_D?-^F;@-(LS?_H*
M"T/U"EZR#<HPOA^[E"#D^RDV$\V2B]#$_MH]V%*F1=OT9!7V<#.LQ71N/XPH
MON`5F*0D69?JQ+^#OIM"[S?B*M6L'35%I(BE<TWAA,T;B/(7$]R*_@:<K(TX
M,A`(]LOIG,`<#C!U_3D,R*^RPNZOD'D<R:64DK#L<1V3FCQTC2QG@1;C=!K$
M,(\A\M%#Y@L<&'<KI>BX4Q)E]%^)MOC0@U"4K7M3R[QS-#(R@II4C^G'R1!]
MZ<Y)=Q`<?$)W8(*</3W\E%^Q]%3M9T7Y@;_R>7^39CGAMQ)`4<KL`AP*557=
ML.C)G%7&HI9G$VMW80")>*\+3`_SIW[6F6G+:H>>!E@M^IA-_MI)^>M]6P`M
MTQI,A_A;?%/)HP4,RZEL6(V)>[PI$XQO><):=*NL"MT["R<33%3/M2S1=%[)
M$K2`-U.^`:JE8'@7I-JV*MOM_UUH5Z9*;#:9.%I\7/LM3J*?6KHKB(ITF9=A
M3,$\P8D+O!"84(3@*9T;J+YQ81CD&IJ&DE_(7NJ8330=J@3;6!6Q5X7&5L!-
MJS3'YR?9H=H6JEK6BIV([9+<B(.&PX`B&HGZ6T6.,!R^B:#TNMM!#VC&P/P"
M&M#*:1Y45J[&,`%GTGM.N=?RL"BDLC2=R+1ZLIH,5Y3O0CL;]2TO.,%UKI@R
M70/?Q=SV,OHE+LI3W)!D\BIKR!K)3*O0Y8P8"*)]SA^%N(^*AJW@!U7\Z/7T
M=XW[7MS7K<.Z[NN=YF@[B-K\\C0ZM2G3MH[-2!B.EV5>FO-M-+]8:W[AIVIE
M:^KCK+SRTAUTO=#YFY\_!KB`TSP?*AWB3;=9QU3F4;=T/'(QBUDP*QE(79BY
M<ONQ\T2;N!GH</@7:7!/=.0U^N;&WN=5^L0I?XR*HCS4>Y"Y*AI34X4+QRJ1
MKGP/P2K/76W@K!*#L9`)E?QH4\X+2S69GM3J4:.Y$$$22";#6HXUHQDZ<^'L
M\(-)O#6779HV]F&F(GP3WA1NS:X(T\VEKEUR`&5>TP'ZTI((RY`E+/<2MQ6S
M./ED21:'I\44[<32P(QF,$U$7Z6N^OB@=G]@'5NFP(#6QMJ+$*'CJ[,7E5J5
M!5)"007<XV7KXEA0<@ZU8OY2S=<?L^LI<X1GT%X#PY_`6Y6=7<6STG_R'TUY
MHF1\9D-6?55(_8Y\=6RI3&N7)SH\^_-+6`V^M$AIAWN-]WS^P0(KN%@)>5"_
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MG$:9R2WE%'O<)10EYUYQX'+./I+MD8$)[69F7N+:YN/91NXXM-\`+B+>H.>`
M`)W>_A!4JI$%>KTAT>3$6T,OG09-8"V2GY/9%1&CI;?C,IB].;4DY0"JWYWM
MV,S.I.,GB]+T:\0?G#"-5P\XE2`/#54<XW6P%*()PX8K9C86B,ARCFN@EPLO
M:$L);%,GTZ8:L*RJA8V[M&.Z<_2TI5D)B8,^\;26"B'UX:\C,NJ1T-F`9/Z0
MS"J=\3R<E%E_13WA<78&SZ"7)"*F3GY^+7T!BP/15%EBSY(FM_4K..I'?H(0
M2\CA6P@";RG^Y)-3-%X6O%1)J:,WF1*#Y4X.K:N^PMD!\%&?3<TM(X)C.4,D
M[[G$PCK"17\=G_>^CG\\YCY%DC"/=%PX_>9-P:>_Y\:0I'!0^5MN8YO9J;N:
MI-K0W[N3?^@6IL,%R4N!JIQ=E:6F:`LB56.IB*_TU62,C`9#3,PGW\2<EP8W
MB!)6(&OM6ARA64MZX.-9.'=X@O,NS+X$FFS='[W3V5M_O8&\4\K8Z%AW28-<
M*Y\<IJU/67&4I5)125'/IN:+Y9"AF_JA1?*24W8X_8)4$:\KE;A4;M4ZH/,D
M`5I2_MX<P+ZQ,NZ:WMI1.ID@.R[B=FSG4760PG2X)=H=X+Z7.G2:)$<+NYWN
M(1W+A[OA&:$CXD;&(YQX/.KL[FYWCG:[8>0]1O(';80C0S]N(U^_`-O^8>>P
M>^3A^W6U#9=Q"%4]X-[K'.YO=[9VPZY_7>.`L?4+ATL%6@]O=[;WNIW]HX"(
M7YM?DK(0RLC'8P[Q[2EV.H<T+A[LASF"Z3AQ^K'M<53,TN;&A-]668=W1!+4
M=(^K%B>Z$L:TI;G\PB_`A[](%,1@@E\`%7Q,A_"0_'&E<VU#FL/?-%CM!XN2
M[J<ZE42;0MH[A_WIX^"Y&!)7S-IL88FJ8)YFM,)-759:20JO==Y?A?5S3BF2
M(1+FG[MZ]"_)B3<FJV)$'"#%QV@U=;_(A;,S>432SEF-YT2=[R[5>W^3F>E/
M3RR9;)TG\ABQB5'2X3(6FTV]1&;@EZ!T_O0W$V5$3G28<C:NYWT:/]YWS457
M[E!VYWS'C8X,;5C-'.;`"(Y[=U_W=V7URH6=A%,8$!*XSO2Y?I&*!^%964U5
MO?7!%'<]FZ'I>N:HF!&"(==V.X='.YVCO6U32+*<QK&8'V5N$@Z7MF'TT>X!
M.I-695%&VWN(Q7':3KW`NFX&L4R[81:Q03"-=2D.TN&L-?>W.OL[!YW=[5UE
MM=OFS$Z0!N>WC3ZI!!%`QP'8$LC!H-J17`P5<8.K08(6^VAQND^3E_1C@$]@
M4&J(?F1'"W8@X3273D&6IO1$,`(KNQ&1PZUW&>FQH6J2=);?E$80;/L5&F5"
M?P[-4/PE%J?#A!/$E/XG"VXGF^77Q+^6^Z^4G$O)V,VW5OZ$FRB'TXQA=+TV
M3N<[<;J7A2JM*UT9:G]L2:3SAL-MQ<^4[$9G18@*Z>"2)Z'N'J<`J38I-E&+
M%G<_<1S4:COIB05J*J2AQSAG+LZ$':TNIT5=@.<+0J"6_6N7`UW))O^<$#1F
M]^,9?VM4*95&#(0&45<+RH`\ZBI1S`U#TMY`FZ`=N/7Y2`8X0@*-@\.02DI3
MUD(.Y(*MTRRM=A7"4+E=\)DF3])G>.J)H,F-E%A6K*#A%()F'S2Y!QL:6CQM
M/0-U0;0F(4IP0KUING1?'@4^=[H@R5A=-)NF2`TIH3%,20E5@)BP7,!+WGWP
M)#;&L3-UW/4+$H<DC76"W[?=ASN!Q;8!JY7S8+>K"1I&DZU=D--B#G_"UGXT
MC!D"D;1XPW#(7<888CE/_B#U2!D;4;)S?%.5,TD(B"U[68WYE=DI(O=)2I3F
M4$W4^#[)7DJZDPRT&%37#9823\_6*<H]5OVQ'O+M)(PUQ:524LA$E.[8-@(I
MPAVK@\81)T+:Y#@0W`*$QINN1*5D#OH%QHL@>I4;ZF+^BBE^3V$T8KAZ^*6B
M4LFJC@[Y@S:IX/,[1W;D_)LV>[@RP1$DMD).Q1;/X?*IF+QI79>/NL_,[IB9
M7?[LG2M(;@P.YQ64TO?@1ANN*JE+38AMHU4D6E*84E]CZU[!MU($*+:P?!/(
MKU_V7/-H\X>EO:S-05^_'"Q_VMWUB@M;46(E"*_@@5_5S6YR'6UCR>5=GNO;
M>[M$<[N^E;,R+*V;[-=W.]O=5J&P1M`(J-ULV%B?;CQD6RV*DL`TS0<IOWYY
MB,-A!-6M$BX87]OJ?/TB5EW;)=3#@8]W>K=4TAML0D;^7%+1A"O][3XNWC4N
M3I]HSO9VR<U+=?<%D2*5(#\,\:3.3'..7E/A#!M:_)HV>"M-\S.1)T/6MG?=
M3>MQ+"I#)MWUR_"'L,`-CS!LTF3#"D&M3W63'$V:9ZBV<(N6)"@N5@?1.L=P
M[-1"`0BA4+[&C5ZZ\!U]^;L>9^90/WKO@U;_^B7)-'_]XD%?XP*0_9U]/6!^
MDB5ZT)W#H4TIPY30W7+.B';;&730I3?KAM[(8"A94/N)"#)-G>S/3E9SH5:3
M7*>Q>-U2`,E/]['%GK%%\D!SF0M@"WZ9W/6D#&"*';J9<:_2+8T'?.`DHR<G
M`/WP$0]+OIP]S]]S==Z&%*0Y3[YC6(^Z-F>O-E/O098=<73)";2H[_"ZY-*5
M3\YY"B#A;"0R)A_1W0_JGQ`'0@$,9P(;II2C/RZT=DQ`J=:.G[*FAR:=OSYI
M5<E1/980U$R:[_X8J_%JS*2D;67G1/VDSL+D/8CRWQPER`<;,-J&?>*$,QZ?
M:2"C`D*').+E(3<OCL^?96IEN>"\;C][,]G,#K<=97>WG*,78'65*Y-A626L
ML4UIKIL`"2@/>TPQ?F[E,*P+G(=7*;R92F.,9>AK/P>QK'*2;RPCM0ZCA_*&
M9PU-!"SX%EC(QS:O0*D:1XB\\/;C%@(K*3[9<"E'B)(0+S"6W4<C44T+FMYE
M:A`,K)N_&!<)PY0Y<)SJF;+&=^M,7N6)PR[LGEQ3DOSL%S(6$"SI\X\5SW@L
M:*I+7"S=!*D=ZI5"_ER0Q``.`C5PCF/TY"XQ;K:`75[1+3JC=H0BM</PA@-F
M=V>15-H73N_>M>;7*$4=CFW\&0+Q)-ZA8:AR$05\H@[`F%(+S8O$$KK4Y:92
MX49R%]91>YM"3$%175/N,\$\GB(O1=Q`A@?#9!DUPY-F2'`2N8H`V"B:WL68
MCGL`RC2UYY,:QIJJDZXAI,O=7VX1.+(:+HP/SR>)^O3H16);:"]1VKYM6IPK
M@3*H=_A6CI"N=6C9AA?JQ;=V\B:XS]R9M$[[6'ISY+MX2K"Z5-8,+RS@8\W&
M(RM<N!VN&=GJ[&%G'S9^GUOB#@^W'C;ZZY?FN*<GNG?(:L>5PGW8RMWM_<XV
M[EMC]-.(M#9]FD,O8)MJ6>M8%">UF8++V52Q"1EQJ7E+27!:A_NZK@J^N"S&
M7(-$SJ%JRW/=!5&1)Q$&0A'.Y_Z`:&.)P^%O1R7IW]Q;;??-'U^[DQ"MI@?7
M78&#U6CTSM:W6S[\L=UIP<[K&JRYU-;F[B$WPN`N';;>-K:]N;>EW[J;NP=[
MS0??T7%,XD9]!VG/<K;>;8&RM;F]]0T3;6T>'#2G^:;YQ1]=A8Z`F$!-CH0=
M&VR.VO7)N"<K`K,MTM6WY9/=S6YW^03/0]_8Q]!AS?6%.RW0M[M[@GQ[OX6<
M.(&5D%$YV6V1XP&M[[8F.:.].DG<.0<L7M(N*Z#:.*J.-D#K^O";RM;W6G,Y
M>':WF@B1K/C6YN5L@YJ.W138-HM,\.=PXJ)$M!A8DZJS?&,)G=V!V'EL+%3?
M>+CO).GON2!50V1RFSU3'QRZUYNT*H1K<7,+C&=5-35ZUK%89.DDCD1QZ(ZX
MS]*'N%JN7\12K-'@6AB5-)*$L14'.!>L^MOG>"V@J!I4+E=L-9DZ3N'/.V.%
MR7291V,?Q_H>PDN=J9+-YP$Y/]`DUX[,,>Y^"PW)R<BX)W/$B0WEN$46Q$4F
M+X3(.8*;?Z`0,DW<.F\''U%D&>-@*_P,\U3I;_PO_/S<^6)V*O$NL):%.]HB
M'DTJ`,K46Y]8<(SAS<#7WYC=MV:RQC'*L3+QR4'BI@2<)(E+8?'$4NLXPLNN
M5;]S\'TAX+Z%@'=.T03NN35I620LN.2JMAR-M_3LQ%OEL)X6<(>HP.I/E@1^
M-E%;'6)T:B=H5(+@ADDJ!\J6G7*3S^]I/;@I/F2_HXM$N5:$3M37%<0GG'6Z
MHC/)<O[\Y!)?7`1Z\OSM8Y=@";-N<JD-TBV3*2&/@IOLY#BF+Y1.O\.OZC71
M<6RL">O3<@_/6W@7KN:1&+.[M9T]]T(X7X$(N6A:)/TA6IEY[_I^_5(6GYU)
M0(+&F(Z994R]LB$-07N?]>TY^4I>"*6U0DCN,U7MCOK+Y@:D&<&9F@Y<>R_Z
MM)CK2CJ$SS+Y=I.C>4[2MA'CEY/QPJH2]`R.0G6EF@5(PXDZU(QDQY&;?HR8
MS*FN1'>_N:==&Z%-CV[Q43(@UGJ#-:'._U,-"XF>3]S*@(,O#20M0@!E.HBP
M9&K7TU>7K:IX9@>"$[C<VE$=64?.^Q"/].9*8(2%[&&L'"H%2T&Z-=[B2IY?
M@*W$)]=QZFT=#G5F+D-3A]-T<7EKZ:J09JX=U\[;G:JB,TN3\08&:XM8W]WZ
MAL-2+K\L5>GYL:7A^DWJ'ZNL:FD`43NTRJ#9+;_B6E/]O&B)J<R[XSM4?&'=
MZDX!AOO8?J,F8P6AL:/)OG'*F="64LA<@*X71&IQ;>LZ-7X+$.P?[%G2[BY(
M?LTL3(-C8T,A(!I>D_.?`)V`992&^?<^+AWF-N$Z+3:(01V!F,IQZ%5QE6#;
MY%<]DB$"5$>N7>UUM\":B)L`*X6B`IV[?K%JEY2&^H3\W9+W0:<%\IH-J:WJ
MFO1T8!H5S,4CVF9XDD)0_-INCA8;57K#K6EX"B]A`(&)AO;\(`LXQII:?<L(
MA$I();G%7*_(/_`B5P/F';;6.NZC9FT9B0L)BN<I+69^'&M8\H3$;YQ+=CMV
M[Z=U^9@']E=:5RW1<DI<?JQ2,6$M3/0$S<1-T$['V;5&/E\<71F)MEAI,24I
M218H_@Z@E-#-_^/N;YA`Q#>1F-Q2RD0F7>:YW"07YVX%MDJO2WN:HP0`Q,[V
M8N`,EFV5=GI&HO8;6H\O+R?S.>ZGG=7L3>W=T"4XG$W-C*<(K2&S1VY(=T;/
M">^K"]`$]!EPL+M`N4@L=QO#'0MN9NM"D9W"?L$A+P=6CE*-7\?7C;#X7#?O
MG^9J9,I>]2YI9^5O+G[?D=!;$LUW*9;B>_?*+/V$1%(>4?85'-N=U=QUI0,T
MJ)(_+1P)G6ZTJZOMQFH)ETKODZ*<S"E(00G3X]YR(=W053(1V:?FF>#\#_B-
MJ,UQX!5QH:>I'ES;D;+1_UO\G^+?YC83:NQ5L4I@#W9'14&PKAUT#IR#8`ZC
M058W;/KJ*IZ_K*86!4&$^6#P<EPD'/BNTD&O`ZNVI/#,LVO3,!"'.TQ'L?&7
MRJ-LPH7NV4FXS?W"O"O0$_'&T03'<ZV)N_=/_/+OFWGG`3/_G5/O/I;<\5H"
M:]R/\C*=PB:N-LA=BJ;6=;>^70#ZXO2XM?>]Q]SB,,-RR*ZI%('&QW5L5??6
M]S&/47E?V2-KR<N+D1ZU1^G1%D7?^^-U*QG<>3HPHB3L#AEWS0Q40^"PVXW+
MVPW_41XO.HS$NE=YT'V[^XVD(P*E/^1/>BF*W""UK`X7L30M!J2M)U>_4M*'
M&39#LJ"Y\P:RK)>1Y(SC3\TT-35F82&1Q)V"R8E#BR$<3J/(.'U$DD\R98::
M:!\I1#ZU0#5.?P61L+SG'0C<!$?5DZD2"0*/,OK=@OIB=]<L<#=Z3>W'T*L&
MRAFVDI<I-"5$20P*U?[2*WU>831]9-!"TJ6MW>38^NL7LOM>OZ"FQ)?C[$5^
M.?.%UBTZHU.<-0Q3T+)1%SO+X][>8)%]/**,^XM]\>\&H=I`&P'OAW,1EM>?
M1KBHYSF;HH2479.:7CO5>$@4#Q%;0%IH/(*+UQ+=#(YU@Y,"1.VI`AIQ0"0A
M4;_-??"VUPV2B?'2-T_8;<MO3H^M?`.AR9NH`7^BD'**(B6Q]?6+.,!<P:90
M-8DFV3!4"$B8(N==;A+();.ZAC6-"SK+C)"6^?KEOG5^F*9Q-(7C"8(>I%-^
MO$K9<AG3:I-.ZG]*?>(R41:FZC9=XPL(:5A<AF_81-BF>+J_P;\.7)O?%2%T
MFW/Z2T7R;>]#]JX84,O@971DUS`AN%2*<,4NZV_?O>%-(Q)$7@"A,EWB(:0Q
MWEIWAQ(,?1%B#+E+ZC+#^8J-TPPF][90\ZTX;Y5"(?*7R5.9E;P,P(1*]=PV
M&E97*2MJMZ!`!9U.LEI+_!B/6*^M"3K7-6F$Q$Q+7[G9FJQ_3##[\7RB8SQJ
M,Y#HD$^T#WK12IK9+=UIPBI#6,X7`^MP$X$&]FZ8_D:WN[?QV\7K[:.];%TE
MO5'O<N,8\?(]R1H:=E-_MTW9B6Z2>=I.;;^,.'!W[@.@P04FB"7LX*%YC7:N
MTD0_OI)M;7OS2.9DR,[0(TJN6DNG++&,YS>MSA<!YY:IY@X+:H$(2ZUEIG),
MNSM'%EG+MH0:'T[[@:VN\K]-\':<'2^N%S@U+M&'PH^!)9\USAYXC<-1SP56
M^E,K(`%6[123.K(9WR4-IX%B$>X6#O5NE&JORL9)>U8H[&YV`PJ9I,$L]#)S
MN5=*40LUPJJ*U<3D`^N#$@'2H<[VNL=#>X\WM7*S5DD/TDF/=HNYOWYQ1\*:
M[`VNW7NS7,3^0-L*J-6;BBI(@F@Y`7ZA[J[?+N9R>DHX[$29K5GV+IC$$[/<
MV?J+WYZ\.WGL6@0"Y[N,YJ*@:&1V9^K[/(SN&$S7#!Z"!7OU$^)A>N/9R6&V
M'@U-"/)<^LB6LLNB*BV![O;M\\$12J5+RDQ4J8NB@9$22QEFM51#&)<8`6!2
MG=Z11]G1:5%\M)=B&+!T4J`AY0L2DN+>H-^#68Z\&'"A5$8M9V+GG1IQK8#1
MSL-^#<+`-B-.?X/YOM(,E]S+2IG8HG;H0_[%D!)7-3T!5'Z(;=Z!;#0A&X>=
ML+ZJM>V=BOFU$0P`'K=7*+J"8PI.M$F(+_C<-"A/!>ULRJN;F`0""P;&^QAO
MU++K=W%<W24T2*UI7<LZHG--G^./M6WO?Y$,<TFVX`@[6S[_-/%&7GRPUO6C
MF0D'7A&4P1BB7!?<S[D:@\)#</*TJEO/)<#=151@VX\+88YWX$D?Z9`1&'2@
M>HNNR^%<B==6/%[A^6\'C+,]M]R`,Q-Q,A.?E+\"1[O=RBHYI"LSC2RD0608
MJD&=K`WU5=;TJ):!T-)%5[;@$DU$;9]\3_?`Z?@Z31MN?E,>ZZK'/$-6N8`0
M08P,-,6H:[0<;!_N1;=4P9X[]**>.DE;I1)$R?I2/S#W@QF.;`Y-M+X=QIG-
M-Q;3&&T<''7V$1Y=Z".0?:.4Z(CZ67._6J75C":$LAB/\-V,80O!CJ)+$.P>
MXWR3;.B/P&]=92S%\,[^_B\)P]M'G8/=(\/PZ2*>R:J3-CV*0DB'`T$V!GJA
M!@)?\Q[R"6D\OK"+DEVVAFZZ9:03)XU#OCL^>$F?)K'F;.&4KQ@LX(_QD+NJ
M<X:+QUKTO;'EEM#7NTT/>N-P<^]U"1(;TO*E8J%.+`'71?X9`%]OGM*?+`6=
MF'1GR2,.FAZBF11FP'.WBV!\"J0!`)+2\*WV7%HT5`+].2MYI[K?#;F2OK7R
MNQK?_$LGB1=".+Z]VV&*"%;EQAE`K!>;/NQ]=+)4W=V@#>1XN0.>"AMLDO=2
MD3$9$)1C]#GK\M00?$O:ZC:UJHN<:.EH=[]%W&(5<2O&Z$:_.&6?'Z0A?S>Y
M(9KY[63*F:XRH73$EG>&GKSDK;XU/RO*@B>GA$'QFF(9>VDX`4Z<Y=Y'H2!F
M6-O`K:;S88+##*&:E=XH(LAB6N_%=UKY'L[GGSD7I:@M6W_YYI1RW>'6P>.,
M=X!'A\//&J$-JR2FXA`6VK;^6&\EQ(V3!U@)"5"8K\$+*XQ`M]LYY/RI_$&?
M/9I2@.2]BKSNQV>E>`-:=\\4D@8IO+$*,JA3\DH,'$9*=EI*JJDQ_K2*U=[0
M:N5>X.?>1?AC;(5H6]<D9_EX7-X./_;&A:M,"5?_Y#?OFAP<_&A^"];J`9X'
M\;..LLC&)7%Q;Z"KW*EYXQF1P9$QO)^;WL:P_2%,HQP-NCIJ3W,6W-D=8DL*
M@!G.F&3O!:5RM(N=4>:@DUZS^V]4NCO9FW_S;>71<BE<X,2+RK!(O=(#_EU8
M.YL9T+E`UYR?G;JR;JC.A\&VNW\?;#)I;>"P\LGAJ`I",R^2%J+\PH>.6$U]
MHXTYB*OY>HOY1%?_T-F+DP+(>AT`,ZNQEQ+^QGRR81]"<04*)_D=13GN9UP4
M/!JS9AY]J,QZ-&Y>9X_)2>9I[M3T$N7IQ1\M,_9V_/5+E;4_?`#6L6\A8A8[
MGO-BYJ%KQ3F.2#1+HXXM8C8B%?7%_+#37,)F]2Q'RGROA_&+H@\/J9,(59)Q
M6FIF.WFBLLC^E:UUM/6&I3Q^W3Y>7Q4_(.GUB:TAN@Q`PJAXE(9)%G>WDUFT
M[5V[;9^G48#7.M/9(L)S\GGSVZ;:=]_>U\EW8"G?Y3,<*PE&"2'X0'*1>..C
M&A?/.!K?7/""[;M^+)?D0#Z%$6\>K7.O,4,TR8DL6(^:%X@IJR@5'2F@T,GB
MFNZ./HJ!M(1S1:O#'^9N#.V-%E7;3A.6OF]6LOW$\]U&EMA7A&MA-\NA%\/I
M0X2=5>$7W:!"'L:\^61NWS^B;P+XW5BH=]"T"-A$M"?=2S)I5#U1S3\&W4LG
M<RS\$Z/]EX#K79_(68'IM^8JMFK?%U"KZI200J?3;T0WN6*BKU]":0+?UQW-
M:?7>_-%??]:4"0S:C*-HS:_?Y2HLXLDU?SB^1@FJ/Z7YPYN%>6J3J^8/)[Z1
M@[;%YD\O*<#C]Q?]Y@_XS.XXHYW]:OYZ@8&@^<V?.VCUW_]![Y5H/O.6EQT@
M#<H#/N`PD.6(AT/+FS9G6M\]XBJ75G=_;8&H#[(0/#=G.29'YJA&A=5.>)G8
MIH=JE9:_I+_(WGK#Q1/IC9-V/6PX8<WKZ8D[&8<ZYX!"Z61G,5;JWM]>B"XA
M"UK:AJS)W/K9EMWT\O6+:A9K7,)%W+I[L-O2!?[TQP]CT>ILV6H6Y6R3SB/M
M<OO681-=85'%O<89@^:(]6YG9XNK<[9;E$F>Q:')VT^RU^Y.Y^!PMSDGYTS;
MQV&2O`VA.1&1^2)J\VL<:?/&V.C:3G3%GH8@NRAMLK=J,PT$,LV]=K3'NZN9
M2UI][:"KTB9)T/1X?9:`=.<ANY\(HN[A;F>'\,`@VN9N-S6.U4%J8K)UX=:]
M`^[S"P[-+[AWWN1$AA)A55]Z\\(K9S9=VM7=I&-WL>A2(DQHH$QU*U9++N@"
M[,]H2%"DCWOPS-]68E@ZC[J:6Q<129VZAL['U2UI9[H20-V=Z^%32Z]1%5^@
M$I*YFTA\9OU+##A3,>P'OTR\.5W:5'F>O@RW.1`M'5[(S>(H?%[25N`G@8KF
MT/?T^##F.0I+!7EK+WD1+W)A%7>12VT'S3G>-8YJ-G\_42NZF-,^R+W`1Q09
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MWD_B0OUCW]#4W-=9>OF7G`EW_=GZ_7"2G"(BHVPI`Y^')YOSGQ*T?<17TEGZ
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MJ3OR\.I#7OX*I_CJ)LI4E5R[`@PI!G_+KN229@5B]/#-_V/O6G;J.(+HK\QN
M6%B$"T[D2!$2P685$`(B+[Q"@)5()J#<>)>/SSE5U8^I[IJY%VQB15DA<?M1
M7?VJKJIS1G:WUU<YBK!2C`[#E[$OEX6S;Y\P6_C](/S]"RMX0+X(*:="1:^&
M4\:2UL,[^F_\:/=F?X6;;Q>T"!I4\E61']!BF-+>X80LK<Y#/*3)'R;,6WC1
M?[SCMY$LOA&LZ$F=,R$GP]:2Y)2H1O2U^:A\EU!S/3.?-]"1AK,:OLJ<K!%U
M]J560UH%?I+.X4VDHP3)I+CI0+"(A*+??G\D5A=YEDC]1GP+8('K&]S>5#Z.
M+3SH'P$7]RWQ&L0.T^@3/;J6$221F,R>KB<^&H-5D/N0UA&\[+A+K%5<53<(
M-2,P*;<Q;BT$'26"X,5(CA7R*R$QB4`U&!:^U'C"H$V7MF>\I,NK_YN<V`+'
MTN\<0QMR>Q&0(=(HX2%5F6<6ZJ)>9`3EOLLUX.N\$0*K9NN=8_7"DI"P<M:G
M]-(,YTHRFM'KI+-^V5JC*C2\@I$,RD./6!HRQI&_LW1H:W%L6RT>+;HS0/4"
M`G@_4?`0?KXG8@IKSXC=?9'(/ET25HE%BET:[N`N'^]HF$8OS1@0Z2Y(N7A,
M1_5#'6/U)(K9Y8D#?^IN3M+P0SJ;-!5UB`-:B&,ET%Z.B4F:V&-$+NN[?%M3
MO4JP&*?%VDC!E3W65TG]2S0"[C6^";!W)#&+D?PJ,."K<H`$PG3Y>,VWBR"[
M6<K<W7_,U2A6!!XT2ZOP9Q`I@0T&P2OCD'W%+*W6_>E]OCR81=4(`QH]7U`S
ML]EUV^WT7]R\7E$;"1%7SY+$17JZ&_#:"*Q$()#FK)</J^8-]&&__==!^Z_7
M[;^^;_YUB@CQ/;B2H\M[5(HWK\4Q,</Y'TZO`6B::^^U(2*`=5*;;?6CD,CY
MAD[4'RVE+2[7)*F`=.=_SK+#G^BWJ?P/MEWS<>PU6Q>VDW`F4/<N,?C=3MC/
MVD8GGB.X36HJ,K4<$A>?KSNZ`-\MOD!B'](5E+6DN4P;)/#AA;G-EL_!3?PA
MP]\I/=6#Y'$DMP05X;[,3A,Y],61XM6ZG3@-:'\[>;;L[&5Z>P(K1JCP#0=X
M(G08-%"-0>,28<OG-GHD;!O:-`U/MAF_UC:D14@G/E8D$V'?"J9842@2_TZ_
M^V6U??.X<A/*_Z)P!^1\M),_'^X+PC_JEBI-GU_IN"C]H3?L5`QZL.:5"S!/
M!.R,OLNFZQV#BNS)<2F_/U'&R.Q,#H5$9$6SZ#,22,FET7\`J1BI7A('8B(>
MC70LX3Z;%U7K9M9UI%4(E!*O/,DA]9.^4)SI6/G\]W7'G>-OE.$,Z*,Z53V1
ME/%=C<>YA$[D;2Q)\(E4[1GT9EXSQP%/Y!&3"8QV,B]97QF)(HE*C_GMB24$
MSTQ?$@X2O!X<&^#LE.7\\2VX!<F)*4286+(*'N73/Y$U_MOD@ML='S/F.I*G
M=X<]S<)J?&$7]$-]&DJ2>=J:S91LRWD6-;3=U6#(F.>9'DC%3][`O48#6]X.
M7B^_)&J]G*8?#1P`7TAA^%[?S'&"F5T)]]?R?,SSED0RZ%HP!)V700@<AD+W
M$36"5TWR6^PUO-W`F>P.*5'?][`A*T+4L1$;2&1S#A`?GD"``$,X@P![X40W
MD<]X"N+"O3@/!PTE8-:6.4A\_^K7#^8F@BR&'0'%AM46[/KI:,XK2%K8GJS>
MA-?QHN/I:X"4L#Y&MPAPB>:]VK^K`]]WVH`$_YFSR!>A!2KD;O!/%2*!_`[Q
MQ2O+@&XG!_WWI<?W\-1S\P-TH1AW_)FSO6&Q;,K9!)0\&ONFV>#R\(7_`Q-`
MB?\[Y%3CA2,BY8IX$O%#:@CURXNH1(+\LM*WTTUYEG$!6ZZ]+SO"(R=AE>$'
M\U'Y$E<]KC=?Z*A+[A:40IQ*:62-]\,7.T_O`>Z@'B$6(D7S5%A-BT;NA`>#
M,3L)E)UNYBG26C+82=N!>%#%..7;F[B[(24\0$(>Y=HWN[H#5YDT0#&L!=]1
MOMN5`R9+K7@P6%_H_.,#OO'`5Z+(74-0VVSF$_CF):BUX75*-I:=`4M-79.4
ME`XJY4`IC"]--L#3^D'3QA4S-"UFN`ZI<DD[T@35CNY)9J=.=APD\I@Q\+E1
M>,(N)F41G??3:?=J1UIW(1II5TE8G,PC,D?BZ2?PSA<]`P/#'`&#+V\;JT:T
M-T7@$.OAV7TY.`;6):X[80-(!JBO,DYRF8G(/(4A>@4KY`Y\,!6B4QEHO@H&
M%#U:AR\&_ZS?D(HRM5B301'ESLZ!*H.;>MV=*3X89P"_P2([I^"$N6]S*[XF
MM+Z$@+Y#NEF._QFU#C=FA3]$#_P/O<LO"X'VP^$[L0Q6!"+8G+"3W@ZQ9V76
MSB`0;1QUMS->%Z[34N/K0KS]^,X+-\EU`ALF*B(8C55<LSFR*@Q>,D#E1(=^
M/M459?G8.@.6(,SIJ$3!NL.:4S^(KF$NP0W:2"EU2X'0*CG1PA,*);)\3D"#
MO*+*$2Z1S5=#$\M<K(&<)Y[>%ICTQ1-FE*P'!(GRJR05+'.##A=;V%*`#$LE
MR$C<LOP8QM44#PJ:Q@+V]&,:WS0Q1(80PV*KO11KW'_3C35F0"P88`S-JI^B
MVT`],W7G%6-P-&:NZ(PTV3.+FG].S2Z,,F6$#&""8W1VV._J"]%?-9!!T:=!
MW/V#;D&W<7)(,HJ%I_*1I_S7&@\KKG$C7H)E7W)4<>+S^PQ^/2`,H0S4#[HK
M@V*6TA<^O1V]0%@.@=-$O=$[TZ-FX,37R`59PY(36(&-M%82'T#TN*>?,Z=J
M=0@'O%)$#%/[E`H@'-@&59X\B._6Z[\._P$``/__`P!02P,$%``&``@````A
M`%03:DR$#```QG@```T```!X;"]S='EL97,N>&ULY%UM;]O($?Y>H/^!8-KB
M#J@CB:(L*6?Y$,EF&R!-#Q<7+=`K"DJB;%[XHE)48M^A_[TSR[=92227XDHK
MI&=<;%+:F6?FF9V=79++F^^??4_[[$0;-PPF>N]U5]><8!$NW>!QHO_MP;H:
MZ=HFMH.E[86!,]%?G(W^_>UO?W.SB5\\Y^.3X\0:B`@V$_TICM=O.IW-XLGQ
M[<WK<.T$\,DJC'P[AL/HL;-91XZ]W&`CW^L8W>YUQ[?=0$\DO/$7(D)\._JT
M75\M0G]MQ^[<]=SXA<G2-7_QYMUC$$;VW`.HSSW37F2RV<&>>-]=1.$F7,6O
M05PG7*W<A;./<MP9=T#2[4VP]2T_WFB+<!O$$]W(3VG))^^6$_U:UQ*39^$2
M0/SA/]LP_NYWR:]7?WSUJOOO;[_[YX_.\E\_?;/_V4_?ZIU,#9$)'%3+?-VM
M%`L?)Y([J06W-ZLP((:88`F>N;W9_*)]MCV(A!XB681>&&DQ$`JFL#.![3O)
M-V:VY\XC%[^VLGW7>TE.&WB"Q4#Z/=\%1O!D)]%P7CUS1)/9-$(8G$U]/$-M
M\L$D&T]6VV3_?,`F3M>@7E<;_W&ZF!75=DG3M1\7>SYLHROGBNB)'N<3W;(@
M7?2Z770K)>Q$RL:S+N@[F[+KP=DLZUM]:RC5,BX6]WE#A7U+IBMK%%IOAW=G
M<Z=\9676I6GX7#T`.YQ<+[K0=2OZ]]#"GW/$R9D'-*F,<='!)'.)GW6_(C\^
MN+ZST3XX7[0?0]\.T+ET8&/?/CPNJQ0MJ;00-"%POJ!?VKAAKSU4U/%;SWT,
MDJ)HLUU#B;V(W'6,7SW4">3&)#-F`V2[GI?7J_T!EGEPYO8&2N?8B0(+#K3T
M[X>7-11Y`53YB37L>S7??HSLEY[!2IU.\M6:!IO0<Y>(XG'&2LMT:)]=WUNS
M>Z:7($-.1%"4"+6LV?`$0N^GXYE\I+/Q6+90PX(?R4+?#O!'LE`+_IM)\VG:
MD4Q9('-Y6NSBK*_[>C@>CT>]Z]%H-#;[/=-D3IZG$>T&2^?9P8F@-#?M(Q@`
M@G%_-+XV`$C7'#%59T70!P##P6`TZ(T-$_YG(\GI$<CVZ4!7S2I!H(A5@D`1
MJVPVTI&0^=.>`FLPBOLJ0:"(58)`$:M#R1EXJ)Q5@D`1JP2!(E;9&IK$O@IK
MFXK[*D&@B%6"0!&KTHK/-`./E;-*$"ABE2`X-ZO9M&IV?V^Q%97]RDQ:?9SJ
MPB*^N2XVP8-YZCR,EC!#SJZL]/HP1TS.W=YXSBJ&27/D/C[A[SA<P[_S,([A
MDLWMS=*U'\/`]N#/3M8B^UW1$BYJP?6KB1X_N8M/H(Q;1$E\DZ@XE88\ZYDX
MFS"'9G=H#HSK9,(F2;7O+-VMOV]=KOM@7((;T;?UAA,?!KF2-!R*Q;P.LI#2
M)]B"4<V8%FP`,9&%A&`+&386"]NB-I(68C:2!H(VDA:B-D+7.=2Y,D\NPRU<
M3]TEV+)&W6ZR?BBJIUH@`7X@8@Z#(&WV_5G;Y(!':]LTM17RRU[?F!KXPZKC
M`Y;6M-BWLZ;!`2MK6HC:R,=-QBXG/%^ZP/1\`,F.O[FO'P<#%"4-"1Z2X=/T
MA)<VDHL;PMFNU-I*Z<1F$-!RL-KQ5C-;TM$1!MN%XWD?<?C[QRH?<6$1Z_;F
M>45N.H`[0?!2/=[3@'_"0FSZ9S*Z)@=@4UDCH[219J_7WLN'K3]W(HO='L)4
ML+,6Z"F.IJPL*([9DKKOL&4X/1'S0Q3&SB)FMZ^P!?\R//T2/+U4D`B>-OK-
M$OW@)V%_M-$/RSP'202_*-4/P26L7V8\X(TZ:5`#!32HJ_#(1`"3^0P!D*`"
M`=Y8E/H`PE,%`I@D90@@0`L$`*<B*MKT@Q[)9A`#A4K0?RJ5D&,R*SF5)[2R
M+/V"_@HK+2[]MG(SR;<0Z(6;X:`"0"N592E658HAM$-/*UP`!Q4NL&#4E3/D
M]<IROC*'D*0+&`J/0!JH\HB\J"0Y%W06`*H],I58AY"@P%2D&@+`40*!$-%3
M-/[V*`9%(S"-!D5#,(7`C<%G[!.4"6Z$5(0!\"CI%46=T.-&C#.Z@4!0E2%)
M-!BJ4B3%H"I'%E08JE(D@:`J0U(F5*5(BD%5CB14J$J1!`)X1$F&I$RH2I$4
M@ZH<65#15Y4B"015&9(PT3]QBNS09=-D$96LGXZ[1ZV?:L^KVH747MFD"7C/
MFB>SIV3F"%RPN1292O<`G(VW(^/:J?841NXO,,G$Y[P6<,*)='P$,'87],R7
MR%X_.,\P%4VN\CRORM=Z`4FVOK$;C#S"4DR%?E@QU[4FRJ7[IP66]HZHM9Q-
MZFL7YG<B@U_<KHV06A"XN*,:`_HZQ2`]!"1U$>RYJMT$@Z1R#(2J]CV$<H/7
M3QMF"_1'NN8-6+@:AL]5%C"'R:]!-KT`.+5=EW#1@^)%JB^4*F\9%V6^P$6Z
MJL"8IFN#C0(E&W8ORV%P-;<C.,SW=V>#.RYB*[:-7')$WR&4U>'A^G)RE>,K
M0L=N"FF6!TD>KO-=<RZ/P$-S41T@*60>#/;#=4T-GL/%U1%!)NHV@K*!VTI@
MMG6F*&@R[M#8VUW149U':O"T]5;++'=B=)?&Y1%XN`YQ8G<Q,IODD6H\)1WT
M=.FW+(\<!;-MSVC)->24HI;_/ZK9FBV5D(J)=Q@40SN9E^/SJ"*W>:XC`P,'
M#PYX=*7K2$T*ZO;:6JP4X?4]J7.OEM,?V7":$$%S=C7O@G/R)LK;1T%+SY?U
MR;V@%S2>POEYNXG=U<O14X-J-DI[86L(-")JJF_>*T=4W6WGXOWJX5(]/FZJ
M7C<T\@X\4]XOI_L,<%L6'CS]>"\3/U15\7]*]PH5=_MP2XI0KAJ0$"-'.!UO
M!;F@$5,ZG":#%M=A3I!_Y&`Y0^=M7F.6N^X,<(\(>PXOG\HO/M?4P+W<7%/N
M])JJC$^-I052D_YEP-PLRWNGKH7:=:?J:I$?"$M=0VO'K[$T$Q[%A#R4$-9F
M'GK*Z<?EH6OA*;G$Y3.SBT'4FJROW4'IX'T"PO8KCZ-F!L>DRS+28`/PG8G,
M49":#RC2ZVHZH%P`G$9#?QD[<+YJEBDT=.09Z&(0,78.7D]!/\`4%.^5I/%Q
M>>70.=&)3B;(2D`#>,V+<Z&H$P6MDO%&(7B"V;>\C,4O3M5D#<&Y"T77ELUS
M.*\)F^"A.;N?*]WKHG62/69(IIV4`[1?)O!SJJ-&:+D(]ZH&"0@%!^VR-%<=
M8Y>3YC#C"=V8>JH\2Q<]N+B#@]8=89]$#;=*QEMLDTU]JVX\Q,??,M]<8$H[
MJ>/:SSI."B^O(IM.BS"9936=<.@?[JVE':)198OY0ZC_\2FMD7+V$!$\-D0V
M8>*W8,H?,M+P)0Y8[?Y>N]+>+C!+Y[D5"9UO70\V3L5Q"A\`6\"%WM"?)B?3
M1W:J9.5+QP:NT1)9D"V;R@()27HP\*%`(@ON*6@J"]0GLOI@+9$%^U,UE@4/
M:J:R\)'-`I<)CV4TQ05-4EF\[P>"OC</\8@#/<&%)HO@HK(*'G&8*VR$=STT
MEE7P",1166!R4UP%CX"0R#)!25-9!8_``I4%X=945LZCR?M^(.C[ZX,\\K&*
M3R**X**R"A[Y6.T+QBJ55?#(QRJ:W!17P2-(I;Z'#YK**GCD\X0IF">HC06/
MO.\'@K[?S:A\Q!N"$9](*;B#OXB/<'5"Q$>)E((U/LK[@E&>2"GXXN/;%(SO
M1$K!%,@C%IGP@;A%.4=]WKNFH'>G]C++NGS`X#@C`@/>([38>O"6R!#?,<F>
MM,5E36(0%I9"DIZ<Q2=M!ALGYH+X_H##J(B@^^>U9P=V'$8O&CY=FXOC21\(
MBOM3&.8^XB48<"@"Z,_P1DYXV:<&?DD\Q,<P/EG91$S>%WCWX%8[3<1`ZP0-
M'W]XTV03,=`Z$<,G5:R?1,2\"];;G"$^E^+0+2+BO1M\<I9\Y/`>-@"DB*0/
MSC:.[#S^^"YE"#KF`VZWF<O@4T3RNJQL;]"T_OP`NVMF3L0GCTG?P0)>!/A?
MMS%Q([8B0O#BMHB0!S>&/8BS3LR)0%A"(D)XXCT7L9-1!&7\W8X"["U<U]V)
MT1*+BOT#H/I?/A=;KS*_Q_C.6K8I:SX?`$<MG96]]>*'_,.)7OS]%[:[-P13
M^JT?W,]AS$1,].+O][AM.O1B6`6#=/-^`UMQPV]M&[D3_=?[Z7!\=V\95Z/N
M='1E]IW!U7@PO;L:F+/IW9TU[AK=V7_!9?B"WS?P"MT6+]!E+_J%'01ZYIN-
M!Z_9C5)C4_`?BW,3G1PD\-E>R0`;GD_,C.AL\A<0W_X/``#__P,`4$L#!!0`
M!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q9
M3V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#
MNF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:
M@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%
MFRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F
M)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPET
MB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4
MP2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUN
MM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P
M!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+
M"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%
M353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI??
M?O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O'
M)?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69E
MN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B
M5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAU
MC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(
MS$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!
M^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y
M*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&
M2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N
M0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'
M0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QH
MADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$
M0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[
MF)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL
M&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&
MQR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-
M#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S"R/:=O8U
M+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3IBI=B!F?'
M,4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%[R=P!;$^
MUA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+
MPZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#
MFWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-
M36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U
M,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@7
M2#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[
MM;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>
MF#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`(MO[2Q/!0``(1H``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULE)E;CZLV%(7?*_4_(-Y/B$G(
M34F.)C%NC]1*5=7+,T.<!$W`$3"7\^^[C0W!AN,]?9F9.!\+K^T=L^+9?OW(
M;]X;+ZM,%#N?3*:^QXM4G++BLO/__HM]6?E>52?%*;F)@N_\[[SRO^Y__FG[
M+LJ7ZLIY[8%"4>W\:UW?-T%0I5>>)]5$W'D![YQ%F2<UO"PO074O>7)J+LIO
M03B=+H(\R0I?*6S*SVB(\SE+.17I:\Z+6HF4_);4,/_JFMVK5BU//R.7)^7+
MZ_U+*O([2#QGMZS^WHCZ7IYNOET*42;/-_#]0>9)VFHW+P;R>9:6HA+G>@)R
M@9KHT/,Z6`>@M-^>,G`@R^Z5_+SSG\B&A7,_V&^;`OV3\?>J][=77<7[+V5V
M^BTK.%0;UDFNP+,0+Q+]=I)#<'$PN)HU*_!'Z9WX.7F]U7^*]U]Y=KG6L-R1
MO"05-[@3_/3R3/8`6$\^FM_OV:F^[OS98A(MIS,21K[WS*N:9?):WTM?JUKD
M_RJ(:"DE$FH1N$*+D'`2KB(2+?Z'RD*KP.]69?G9J03*5E,.FM3)?EN*=P]Z
M#"9>W1/9L60#PKH.VDQ7&5B@5-)/$M_Y2]\#SQ6,ONTCLMH&;U#J5#.'$69M
M(L<6D?66NK0=>.@2\Y*X)=I+F!J`G]U4%M/NF@#L=1ZA_#V/K14Y*JVT@@<U
MT!<,.[UFEL<AL;"F28>()1(/"5N$#9&'B.%L-NI,CD*?]BH3$6L%#HJ9]QG+
M+$I0E(A1@KD(PRI,M;>(3:/.IEU?RG=W/M2M:X8H?'1#LWH'Q;@LHP15Q*KI
M?#(E\_ER;I8M1C68BS`LPW;1L]SVK1RUK5I=>%#,HIGF.EHOK?>/_?>7(9E:
MI:+J?9CHHYR6391@+L*P"=O.B$TY:MI</3X$:D$5XICE$26H(E2EPM5\9I<J
M[@-RT[=KQ?K`8C9;S*?+KE:&3]@U1WS*4=/G;!9U`LJH8EQ&48*B1(P2S$48
M5F5,>CQ5VLZ5H]B^I!B7592@*!&C!',1AM7UJ%4Y:J[JH'L5XG**$E01CN[M
M`V2QF@ZZUW4/PR>!C#6RILVPZ30*[0^JAEQ><83B2(PCS(F8CF7"&'8Q4<$#
M'ER/S7'P>-60T['2<2`45XEQA#D1T[$,'B..51[I/UT'W4P4XW!SQ!&J$?5\
M'=V.#6*THYVW,>W*\#%B5V62OMTHG%E;,G$%%Y46<83B2(PCS(F8CF%]QAS+
M86QG)@IRKC"*4%PEQA'F1$S',H:,K+%*)^8:6U'N`%\(95F<CE&$:I6H"6/S
MB"RM[TLQ?AOF1$R_,HX\_-HYF:BT8OJVXX:&G+Z5C@.AN$J,(\R)F,YE.GDX
M;T,'4:$%V:Y=R49_FE&$ZELYBA+C"',BIF,94D8<J^QBKO'"WK]<`4<[1A%*
M%*(#R!+"L1TP8HTXBL*<B.E8QI41QRK%F(X?*5R%:.**.MHQBE!<)<81YD0,
MQ^%X[&J&L1U;0X[2'W&$XDB,(\R)F(['8U>HXI*YQO:.K2&G8SQV:94?[]CX
M;9@3,?V"I5Y/-SOV7-Z[Z<FG4+YM!VSK$7+0D-.WTG$@%%>)<80Y$=/Y>/X*
M5;1R[]@:<M@YX@C%D1A'F!,Q'<-\>VO=K;$<MM?8WK'A.!Q+(SA"-:)V[/G8
MAHV+R)/Y'T]%&58G[^JH.>?EA1_Y[59YJ7@MX&O3#-J[&^U._)]">1AKC1_(
M!HZ+A^.4;.!,&,:#[@(XM[\G%_Y[4EZRHO)N_`RWFDZ6D-%*=<2O7M3BWAQ\
M/XL:3NR;/Z_PKQ@.!]'3"<!G(>KVA;Q!]\^=_7\```#__P,`4$L#!!0`!@`(
M````(0!ZN3GN8@,``'`*```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC)9=;YLP%(;O)^T_(-\W8$C2)@JI"E6W2ILT[?/:`1.L`F:VT[3_?L>8$#!D
MRDT"A]?G/+9?CMG<OY6%\TJ%9+P*$9YYR*%5PE-6[4/TZ^?3S1URI")52@I>
MT1"]4XGNMQ\_;(Y<O,B<4N5`ADJ&*%>J7KNN3'):$CGC-:W@2<9%213<BKTK
M:T%)V@PJ"]?WO*5;$E8ADV$MKLG!LXPE])$GAY)6RB01M"`*^&7.:GG*5B;7
MI"N)>#G4-PDO:TBQ8P53[TU2Y)3)^GE?<4%V!<S[#<])<LK=W(S2ERP17/),
MS2"=:T#'<UZY*Q<R;3<I@QGH97<$S4+T@-<Q#I"[W30+])O1H^Q=.S+GQT^"
MI5]816&U89\4V?V@!4T436'GD*-W9,?YBQ[Z#"$/BLA&H(O(OZ<R#[ZNXG9E
M^M>GDD_-MGT33DHS<BC4=W[\3-D^5U!IH8<GO``M_#HET\:!]2)O!H.E*@]1
ML)PM;KT`^POD[*A43TR/14YRD(J7?XP(MZE,$K]-`O]'\]Q?73TX:`?#?SL8
M^]<2N&8VS8H\$D6V&\&/#O@1>&5-M+OQ.H#E3'3P04=#=`L[$"()T=>MMW%?
M81F35A$9!?QV"CQ4Q">%W@DHUE6$N4]4U%%=42^\1HA,H%_`MPJ,%4&G&%2$
M!>M5=/06!]HZ9J[Z*01Z,YEW:0R*4<Q[BL50$?]/,4"!)#V4$X*.A@CFTRWF
M<E@@,HH^PNU0$8\59\@!`KAU`D%'APAWPP*14?015D-%/%9<0%A.(NCH$`';
MKC.2/@.V;3>67(``=T^L@XY:$);O(B,90)R-US@F'DLN0.BS9_SZZ:@%87O2
M2`80YQ(&8BPY*P:.@!8T`:&C%H3M2B-9-`UBCA=SVY/F>1_R`@&&9C^!T(0M
M!JM&U&KZ1;!EW7A"<PE$=ZWQAF#3S/IO*+;<'[6:/HAO^3>>T%P"T=UM`L0T
MO3Z(;[T!$3::`8CEX7A"<PE$][8SB-T]X4"W;>);;T/4:OI`YV+&JZUDV5C)
M#Y:+Y>+NS&S<:LYS<WJ55.QI3(M".@D_5-`W,0SMHMT'1_LET#V`$[TF>_J5
MB#VKI%/0#(9ZLUMH7<(<_N9&\;HY&W=<P5G>7.;P94?A9/)F(,XX5Z<;?<!U
MWXK;?P```/__`P!02P,$%``&``@````A`%:B3THN`P``.`D``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&ULE);;CILP$(;O*_4=D.\WG"%$(:O-$MI*
MK515/5P[8!)K`2/;V>R^?<<XD`#I9GM#PN2;G_EGC)WE_4M5&L^$"\KJ&-DS
M"QFDSEA.ZUV,?OU,[^;($!+7.2Y936+T2@2Z7WW\L#PR_B3VA$@#%&H1H[V4
MS<(T1;8G%18SUI`:?BD8K["$6[XS1<,)SMNDJC0=RPK,"M,::84%?X\&*PJ:
MD81EAXK44HMP4F()]8L];42G5F7OD:LP?SHT=QFK&I#8TI+*UU84&56V^+*K
M&<?;$GR_V![..NWV9B)?T8PSP0HY`SE3%SKU')F1"4JK94[!@6J[P4D1HP=[
MD0;(7"W;_ORFY"@NOAMBSXZ?.,V_TII`LV%,:@!;QIX4^B57(4@V)]EI.X#O
MW,A)@0^E_,&.GPG=[25,VU<I&2OA27`U*JJ6`#C'+^WGD>9R'R,GFCESW_8#
MQT?&E@B94I6,C.P@)*O^:,H^:6D5YZ0"&2<5V_E_E>"D`I^=2CCS0\NU;Y=B
M:E]M/Q(L\6K)V=&`-0:%BP:K%6LO0/C4B).9OC4PH$S1#PJ/48@,\"P@^KQR
M@VAI/D.OLQ.SGC+^"'GL$-5PI9MT@;.N/53==$27DNH`7/M2`JO/,<%>[Q':
M?^&QLZ*BRDHGN-:!2T&GUVNK?)P2P:C,9(J,1#938BR23I&SR,"9>]69BL8(
MKGUGW/#<FM;*6C/>!>./S-XDDIO$YB:1OD4,K$*I5X:HHO!.7M@(@Z&/M4;F
M[6*]LSW'BFQWB#P.$->R'<_WAD@R0+QYY$;^:/2;`>)[<T!&*ND`":S`#3W[
MS`S\PEYQQ:^*#OVZX:B.M6;@4?WXQZ.]222:"'33O,@+H_%KOAD@;@AFYZ-%
ME@X0+W)]*W#"OK$#N[#W7+&KHF.[YU=!KV3-Z/E.6JK?6XV\T9'DMLCFI@@<
M6*K:?U2BW>H32>_`%>$[\DC*4A@9.]0P+1?ZW4?[@_#!47O4*+ZV%["+3N.)
MO8"M$N)FGP#G68-WY!OF.UH+HR0%/,J:A3`=KH\^?2-9TYX'6R;A(&N_[N$?
M"H']V9H!7#`FNQOU@/X_S^HO````__\#`%!+`P04``8`"````"$`^@Y&P^\"
M``"'"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R,EMMNXC`0AN]7
MVG>(?%]R@'`24!6J[E;:E5:K/5R;Q"$621S9IK1OOV,;TMBPIC<M&?_^\WG&
MS+"X?ZVKX(5P05FS1/$@0@%I,I;39K=$OW\]W4U1("1N<ERQABS1&Q'H?O7Y
MT^+(^%Z4A,@`'!JQ1*64[3P,15:2&HL!:TD#*P7C-9;PR'>A:#G!N=Y45V$2
M1>.PQK1!QF'./^+!BH)FY)%EAYHTTIAP4F$)_**DK3B[U=E'[&K,]X?V+F-U
M"Q9;6E'YIDU14&?SYUW#.-Y6<.[7>(2SL[=^N+"O:<:98(4<@%UH0"_//`MG
M(3BM%CF%$ZBT!YP42_00SS=Q@L+50B?H#R5'T?L<B)(=OW":?Z,-@6Q#G50%
MMHSME?0Y5R'8'%[L?M(5^,&#G!3X4,F?[/B5T%TIH=RIVI*Q"MX$?X.:JCL`
M1\>O^O^1YK)<HN%XD$ZB89RD*-@2(9^HVHN"["`DJ_\:47RR,B;)R60(F*?U
M9)!,TS@=WW8)#9$^R2.6>+7@[!C`]8!WBA:KRQ;/P5D=891"*C.U^*!6M0;"
M`J(OJ^$H6H0OD)3LI%E?:A);L;FB2#M)""`=#9S10Z-6(74HZ-'$G9$F7AO-
MJ*=Y?Y56;'P*"P9>U(,YIT1%EPA,>A#.@==&,]4)2R;I9#8>VYB;OF*83D:S
M=-HI+`@XR14(%74AAIV!R831^#+A4U@0<$E[$.XE4:NWRF(T/AB?PH(96S#G
MLJBHFQ&W+$;3AQBZ=?%*+(S)50P5=3%&3F&,IH_A7E&?PH)0D^3_WUZU>JLP
M1N.#\2DLF)D%<RZ,BKH9<0MC-'V(B\)X)19&#'V\EY0SAPZ[($[BUR=1G\21
M;+P2&^1&;S5M$3I!KY.X[2PV(B^03V(#J=;W?EVZS)B.Z&]I,$=5'7T]S9)<
M;VIFE)H!U.(=^8[YCC8BJ$@!28@&$^@"W`Q2\R!9J^?/EDF8B_IC"3]X"`RG
M:`#B@C%Y?E"CNOL)M?H'``#__P,`4$L#!!0`!@`(````(0``V,"FPPH``.HN
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)2:66_C2`Z`WQ?8_V#X
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MI]OA?;"JI]%P?'>C$_2_7?-^]OX_.+^T[\5I]_CG[MA`MF&>U`P\M.T/)5H]
M*@3*8Z&=ZQGX]VGPV#QMWO:7_[3O9;-[?KG`=,=*9=ONP1/\.SCL5`U`Z)M?
M^O=]]WAYN1V&D]$TC.>+((R'@X?F?,EW2GDXV+Z=+^WA_T8JL+:,E=!:B6"<
MYGHT&\7S2?05(U-K!'[1B+/QB7,8I@X!?JU>L/PMQ9E5A%^K""8^<32W\O"+
MCN:C11Q/9XOYYYJPK/00X?=+H2VM'ORBQ^5H'DR6T16'`52,F5=5.F9*>H<X
M-O6@ZRC=7#9W-Z?V?0"+$R;\_+I12SU8*6NV@FQ^NIJ"TMXJ\7LE?SN$U$"Q
MG('^O`OFRYOQ3RC2K959]\A0B00E5*$JLRD'&0<Y!P4')0<5![4'QA!_EP2H
MZR\E0<FK).#PUPA<5D(6,4J@2LI!QD'.0<%!R4'%0>T!$C&LX"]%K.1OA_"O
MF_;%A(:XMC*PKCNAF(HDG4B7!D$R07)!"D%*02I!:I^0;,"0OY0-)0_9@)76
M12I7@17Z+!V=2)<.03)!<D$*04I!*D%JGY!T0%Q^.G#I*ZRCQM&N+8&-U>5A
M$;`Y[X10+14D$R07I!"D%*02I/8)"1(&W1>DPC1(2Y;=:D\$207)!,D%*00I
M!:D$J7U"(H)-V8](;^6+Y4B=[^:TD[NY4J'16@(GF#>E?#/KA+HI%203)!>D
M$*04I!*D]@E)@.IJO;,,ZU9A&J0EWI0*D@J2"9(+4@A2"E()4ON$1`0-05]$
M"M.(+('MWINVB*W$3JB;-D$R07)!"D%*02I!:I^0(%7;T1>EYC1,1-[,291*
ME$F42U1(5$I425031(-3/8=7E+;!&JG&[O*RV_Y8MS!C@>NO3(\"9PM.TCHP
M*)AV*$&D;RUL!V45X<<K@2DM@<PJ1J:O5ZU7CK9FG?D"D3-?.D7?/#O?*R>%
MHZ_1EC9/4Z.:D\]2\[U]):DQS0Q)C4$D-0*E@55TX602Y18%?AZ$K5(J5A+5
MQ!8-6C4A7M"X206V.?'GW:``=@=O1F=T1A.K&+@ED2):=#.:611&NF6/@^DL
MBA;44HXRKC8*M.2,EXC(J*:B$,S8K;\HGD^7,?-7$W\T2:HUZ4N2;5G\)!D$
MAQQ67`+5H+;'T$UDBLA)98B<5([(Y:U`Y*1*1,Y6A<A)U8BT+1J<:DGZ@K.M
MBK.[AEMY%0FK@#F=MP2EW"2EB%PD&2+8AKUJ8G.26ZF0[")SUM(5SA8FO43D
M/%:(J$=VLUA?\TASIYJ?OMS9ILC/G4$Q'"XNWB6[9TE@M:L,@Q1&DEKD552&
MR,UOCLC%6TA;)4JY<56(G*T:44^MJ%ZG+U[;`SF[Z\`@6BM+-G,)2OFUTBEB
M"C(GY>5NRLZ2W$I!K:!BX101E8A<HBI$I#"6K,FLG7EO$%XITL)0+927J*O'
MK&VY_`0:Y,U[HI+)=Q*#8A=T9J7BL,M#CHHNZ`*1F_<2%9VM"I&S5:-B3W6H
MEDH$#4_DH.15:V'/S_X^0^FRYLH@Y<];,;R)A(-&[TE^!1D4^^>K15-]WH23
M(%Y,V`3GUA*I'V&\M%)@W!N5/&^HOWD\7\[825D3?Z1Z0M:!BNIAG8B6I\E#
MY-*22)1*E$F42U1(5$I425031(-6#:-7/=B)J+V?589%4[J7LOT@<5*X^%.)
M,HERB0J)2HDJB6J":+RJF>N+UW:'WE806N1/ID"IE,HDRB4J)"HEJB2J":+!
MJ7ZK+SC3A_D],_1D>@%[MQ.(W`).+8KA</`V`];F94X*ISQ'6VZ?*Q`Y\Z53
M],VS%5LY*31?HRUMGJ:`-8UB$;,[K5`VDQ9![X;^$D1N["DJJINVGW>PM[&-
M+7,":"9',WY6C'_H@E&J=(K6,MM\*R>`.C6Q3!/"&DV1$+ZKR094/3N"O8`D
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M?6DS#1TI.8-(Y803T848*5)R%D'VO.C9LLC"3@J3FUL$`2$J4,K=,):(J'EQ
ME@GS-3%/LA*QAA2W+LUI,5G$BHEM,(F5\HO)*6)P&2(8JI<HMJAS*W6EF*3'
M$I$[`2KG4;]*CM@*KZ_YHEG[H*.%IYU\"5K$:HEY3ZR47TM.T67-F%?;:I>U
M0-PMHZ)72])\B5)NT5>(/C5?HY3<F"+6]_:<B%J$E97I=VE9!6P[3*PB*:M.
MT27((K-CA&SAY=;(M7HR1CQ7I56$,:*K"A&IX(!MK?4UC[2J/FBMH=T15661
M=]^`4@ZE$F42Y1(5$I4251+5!-'@^IKF,(9'"-V6(]ODR*#91+<SWUAV$[Q,
M#ANO2:8#4"U@S_X/&[_(KD$SWVX@GNA9Q0^EJ'=85+YWO3:BA=\M1DJ$K0V#
M,'[6_B=6@XP@#-PI24?P0<L5R9;+(F*W)WZC^*$4]:X:"B_[.OZY>H+43;]I
M.?QS.#((PW>!Z1=1"5[VIRD,W#%-!Z!.16\`G5MS6A*W!GT8F/5^18IX5P\T
M?.\Z?'BTAZ/0U^G<6X3!N[",>[Q,@W<['G4/4K[[SJWBS*U!5X*?7I&BWM6&
MZJ6^I_:G9L_U9\$BC-]%9N,W&F2<8>!Z(3J"#W96^&)2Q"]W5I3R=E:),HER
MB0J)2HDJB=3'G7JH>A`F./.QIOG([M"<GINDV>_/@VW[=H3V`'J^NYL.FZ]$
MU],(/Q/E5Y8K>&\.IQOGP62E7CKW7`GA"CSTZ[L"'Z.:.TQN+0SABG[DS*]$
M,#(X/:0U^++UOE<#G.B[6&Y)N>BQLU8.>OC]='4/R96.UU/(51^/5_"Q3X_\
M;`6?S/3P^0J^).GABQ5\CR$Y//99J2<[\@H\MEFI)S/R"CP9`9V^4<%S#M#I
MNY*&2]#IFW2XT0"=OBMI$*S4JWTY`GAOOU)OY>45>"L..GU3`N^X0:?O"CP5
MA+'US0H\T(.QZ2OC;N;A`^37S7/SK\WI>7<\#_;-$RR`B?[TX62^539_7,Q[
M_L%#>X$OC]4K_\$+?%/>P-<)$_4RXZEM+_@'!#+NOE*_^QL``/__`P!02P,$
M%``&``@````A`(4@"1IW`@``T`4``!@```!X;"]W;W)K<VAE971S+W-H965T
M.2YX;6R,E%UOFS`4AN\G[3]8OB\.A(0T"JG25=DJ;=(T[>/:,0:L8AO93FC_
M_8YQ2DB3B]P`?CE^SJ>]>GB5#3IP8X56.8ZC"49<,5T(5>7XS^_MW0(CZZ@J
M:*,5S_$;M_AA_?G3JM/FQ=:<.P0$97-<.]<N";&LYI+:2+=<P9]2&TD=+$U%
M;&LX+?I-LB')9#(GD@J%`V%I;F'HLA2,/VFVEURY`#&\H0[BM[5H[3M-LEMP
MDIJ7?7O'M&P!L1.-<&\]%"/)EL^5TH;N&LC[-4XI>V?WBPN\%,QHJTL7`8Z$
M0"]SOB?W!$CK52$@`U]V9'B9XTV\?,PP6:_Z^OP5O+.C;V1KW7TUHO@N%(=B
M0YM\`W9:OWC3Y\)+L)E<[-[V#?AI4,%+NF_<+]U]XZ*J'71[YK<PW8`G>"(I
M_`A`YO2U?W>B<'6.DR1*DUFVB),91CMNW5;XS1BQO75:_@M6\9$5*,F1`N\C
M93J/9MED>@.$A(CZ3)ZHH^N5T1V"Z0"7MJ5^UN)E`A5D7MQX-<<91A"4!?6P
MCK/9BAR@&.QH\QALX'FR&2P(T`<7$.\5%U[U+GRUO,_'((QYR77>]"K/JSF&
MYRF<;#X`@HM@DXYL3DF=A0PF5T+V*KB`CHU\G`C!1S"ZP0=@KOCP:N]CJ$M0
M4K@S1EZS(;.SN.=7F5X]9P8%F'Z\Q[V"EH^"0OU$I_$P%_[W.2DHZ?U9=(L/
MT843%.9.<E/Q+[QI+&)ZKR`G/W:#.AS<3>*#^ZBGRTT_,F3X`>>LI17_04TE
ME$4-+P$YB3(HFPE',BR<;OMIWVD'!ZS_K.'FY#!ZDPB,2ZW=^\)79;B+U_\!
M``#__P,`4$L#!!0`!@`(````(0`*.J6W(@<``(X<```8````>&PO=V]R:W-H
M965T<R]S:&5E=#@N>&ULE)G;;N)($(;O5]IWL+@?P&`,6`FC`9^]*ZU6L[O7
M#IA@!3"RG63F[:?:W>4^E)?)W,3AH^IO5W5UNQH_?/YV.5MO1=V4U?5Q9(^G
M(ZNX[JM#>7U^'/WS-?RT&EE-FU\/^;FZ%H^C[T4S^KSY_;>']ZI^:4Y%T5J@
M<&T>1Z>VO7F32;,_%9>\&5>WX@K?'*OZDK?PL7Z>-+>ZR`^=T^4\F4VG[N22
ME]<15_#JCVA4QV.Y+_QJ_WHIKBT7J8MSWL+]-Z?RUJ#:9?\1N4M>O[S>/NVK
MRPTDGLISV7[O1$?69>\ES]>JSI_.$/<WV\GWJ-U](/*7<E]7375LQR`WX3=*
M8UY/UA-0VCP<2HB`I=VJB^/CZ(OM9;/I:+)YZ!+T;UF\-\K_5G.JWJ.Z//Q1
M7@O(-LP3FX&GJGIAILF!(7">$.^PFX&_:NM0'//7<_MW]1X7Y?.IA>E>,)=]
M=8:1X*]U*5D-0.CYM^[Z7A[:T^-H/AL[L\5R9<\6(^NI:-JP9,XC:__:M-7E
M/VYE"RVN,A,J<$45>[Q83N>=R!W'N7"$JW!<CE>+A>.NEC#Z'4='.,)5.-I3
MY;[O>()N%S%<A2?<]1U[5]C#5=BOQDM[NI[_Y`Z7P@^N>(<?\H,EV-T?7-'O
M@Y&MA2=</Q29#67%)Y_5%Y_7C\5F]V4#_^!=WHMNPLNN*U<_;_/-0UV]6[`'
M@']SR]F.8GM,512JF)"^=&$%[9GY%V;_.(*<0DTV0-\V]F+],'F#M;`7-ML!
M&]UBAQ9L/3!9WP2!"4(31":(39"8(#5!IH`))*3/"E3D+V6%V;.L8#Q;!#)-
M,R,%:($NO@D"$X0FB$P0FR`Q06J"3`%:"F!'^*44,'O8O-3"<*=ZS%MA`WM&
M7ST+W637F_1Y(20@)"0D(B0F)"$D)213B98?".*7\L/L(3^PZ_6QTY4CC.XE
MJ#?I$T1(0$A(2$1(3$A"2$I(IA(M01"IFB#<0!CN\H#WOQ5$VU-<VZB+W@C=
M?$("0D)"(D)B0A)"4D(RE6AAPV-J*&R&];`%<?I-8T>(3TA`2$A(1$A,2$)(
M2DBF$BU&F*JA&!G68Q0$'J6RZ%US)^R-^JDE)"`D)"0B)"8D(20E)%.)%C9K
MSI5G)58TPWK8@JSEU!+B$Q(0$A(2$1(3DA"2$I*I1(L1>A<U1M$/C%FOU9[*
M_<NV@IFT^W:`F>NQ<V(K92T(4^A[!G>NKV]?&,W[E`5"FHWUMIE-;<,C[+_'
MLHF$AMMKQ$0UZ;V$JE&,:?\]JF:JJI8JUK[=S=77ZJ;FJK/7DR60FBV*?(H"
MU)+Y"BF*T%')""(Y/PEU3"G*-$<]#ZR+&E@7K)TTBD,@&\I/J05'KX6=L'*@
M-5&LC$[!1RVYR@)$FKQC.(;":C;G[:L[FZ^,.XC0A)^R6(<:H[8<+D%T=[@4
MM<1P"]<V=\`,3;KA]-RR]FPHM[QM@W8"ZW1K<\1.C4K67#.WW,J!OD:Q6NI6
M/FK)P@D0R1%#@>;3+I%S>VKT>Q'ZK/J[C!%)Y0215$YU97NV-I9IACZ=LIXQ
MUK$-94QT<G*4K<T15",F<4>1CTA.?(!(.H:(I%4DT$PM(C&BM$K046JEB*15
MIFGI\;(&;"A>T9BI\7)D5,A*G_L=;$9LV8(59L5')"<M0"2M0H%$.=CNPJ'K
M2FC+8&,4DMH)(JF=&MJ+I;,PUFR&7IVVGB+6K`VEB'%C0^;(V*",`^X.?LEA
MCDKA^(CDG`6(9+`A(GBFR-6W),N&RT/AJ%9&1QQ++9RG!)$<,45T=\1,6/WO
MB'HZ65\XE$[1+\IIV]H<:17GDH+KC3`0'_UD402(I'J("/R5;!I;1816VBZ]
M)-D4-R%'3-!1CI@BTD9T2"4*K8%*9+VEDKJ?M5>VZ$7E+6P%4FIO1Y&/2"U'
MKN7()W\HK!PI'PFD;5K<T99:"3I*K121U,HT+;V$8#)H'MPQ%'[798K.:;#E
M9&O37+4<:65F+XV&<2<<M8U-.,I9#X25HT\QZ2&XH[/L'GWNVC:*.L+!Y%*,
M$<G!D@\-EJ(5'VP^M8T-(T/E@8)CW>N]@C-[5-[M:GV%0'+Z=U`*W11(Y%,4
M4!12%%$44Y10E%*4:4@K./BM7\L#GMTZKC\"$$&CI.PJQAK?2:M^TZ(HH"BD
M**(HIBBA**6(O=3HIF;&GMX\!?PE!?_5]U+4S\6N.)\;:U^]7B%`V-(V#SWF
M;T>V"P]^X``!D[L>_"@PP)<>G)H'^,J#D^8`M]<>FZR!;V93?#%CC!VL/3CR
M48]D[<&AC7(X(GGL3$2_@0./QTXX]!MX*_2E2YPQ]A;>%G5=G,EG<+,#.MNY
M!S\<#N@[H#\T\-;QX(<T<)CT(\!+HEO^7/R9U\_EM;'.Q1$F:]H=Q&O^/HE_
M:/DATWJJ6G@[Q,Z;U@G>^Q5P9IFR_?1852U^8`/T;Q(W/P```/__`P!02P,$
M%``&``@````A`)B)=(.W`@``&0<``!@```!X;"]W;W)K<VAE971S+W-H965T
M-RYX;6R,55UOFS`4?9^T_V#YO1A(2-HHI$I7=:NT2M.TCV?'&+"*,;*=IOWW
MN[93"@F3\L+'X?J<XWNO+^O;5]F@%ZZ-4&V.DRC&B+=,%:*M<OS[U\/5-4;&
MTK:@C6IYCM^XP;>;SY_6!Z6?3<VY1<#0FAS7UG8K0@RKN:0F4AUOX4NIM*06
M7G5%3*<Y+?PBV9`TCA=$4M'BP+#2EW"HLA2,WRNVE[RU@43SAEKP;VK1F7<V
MR2ZADU0_[[LKIF0'%#O1"/OF23&2;/58M4K370/[?DWFE+US^Y<S>BF85D:5
M-@(Z$HR>[_F&W!!@VJP+`3MP:4>:ESG>)JN[),%DL_8)^B/XP0R>D:G5X:L6
MQ7?1<L@VU,E58*?4LPM]+!P$B\G9Z@=?@1\:%;RD^\;^5(=O7%2UA7)G;@E3
M#2C!%4GA>@"V3E_]_2`*6^<XG479,IXE:8;1CAO[(-Q:C-C>6"7_AB!OO2=)
MCR1P/Y+,%I>2D&#(;^2>6KI9:W5`T!T@:3KJ>BU9I9!!YL"M0W.\Q`A,&4!?
M-DDV6Y,7R`4[QMR%&+A^Q/01!-A["?`[(>%0)^&2Y33O`C#D2Z?Y9I-\#LTQ
M7#_L9/.>($B$F/D@)NLC1I8A9,*R0T$"*C;0.$U+"+I``V@F-!SJ-?J\!"2!
M]`Q4_^-[,<GIT#%G0.:^N8>E@HH//"'7SVD\CY99WQDN8LP5D&2<^<5T7MW@
M.^\VAXXY`W+N[V:T?LJ?BQAS!>3$WW+:7P(C8,*@A\>L1^C<(LR;(87WF*37
M$1ST_G2%HP.-U!?9KX(S.,[B]8G+,(C"^95<5_P+;QJ#F-JWKE(@T*/]`-RF
M3N44GZ^V83"2_@O,JXY6_(GJ2K0&-;P$SMC5'NDPVL*+59T?&SME85+YQQI^
M01S.<!Q!<*F4?7\!9=+_U#;_````__\#`%!+`P04``8`"````"$`T%$U[48/
M```U6P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)3<VV[;2!*`X?L%
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MOQW>R707QR?*UWQS<7,A,WWZ\'4CK\"&_6RW_O;Q_//DMKV:G5]\^M`%Z#^;
M]<]]\/]G^X?MSVRW^5IOGM<2;3E.]@A\V6Y_LUV+KY9D\`5&F^X(_&-W]G7]
M;?7C\?#/[<]\O?G^<)##O;!#[K>/\DCRW[.GC<T!>>FK/[J_/S=?#P\?SV=7
M[Q;7E[/)='%^]F6]/YB-'7M^=O]C?]@^_??8:=)/=9QDVD\B?T<F>67@K!\H
M?_N!T]F[Z\GES>Q:'OV5@?-^H/SM!\K_O=)?9NM>YM70_XT/=-T/E+]O>B!Y
M`W4/)']_[17=]`/EKWN@-T5B(KEQ/((V28Y'9WKY;CY=7+_OCN$K49D,1U_^
MQXU]VP&8N&-N_^?7GK`[Z)/@J+_U";OC/O$'_O4#>7',]^Y]DJP.JT\?=MN?
M9W+RD5>\?UG94]GDUL[6OT/Z)!K>,_+6O;?=/]O^'\\E#>3=L!?]_=-DLOAP
M\;N\">_[/G<C?72/I>MAWXAVVB2&-`830Q9#'D,10QE#%4,=0Q-#&\"%Q'`(
MI!S_7PJD[6\#Z4)PY\!'=AI%S?5P0Y(8TAA,#%D,>0Q%#&4,50QU#$T,;0`J
M:I+[B-I\,62;;993L<JV*QV5N[Z/Y.Z0DE%"+H<N0^0@*<1`,D@.*2`EI(+4
MD`;2AJ*"*"\=091/N9/O8=M?HBH]AHCQ3=QW>BVL0Y<AK)`48B`9)(<4D!)2
M06I(`VE#46&5^(1A=6=`RUWTW*N^ZT4^5(-X7NLT70Z=W+`$DD(,)(/DD`)2
M0BI(#6D@;2@J6/+BQX)E60>KE_EPXEM"$D@*,9`,DD,*2`FI(#6D@;2AJ,C(
M9V48F>X3=KIX)Y$\+DGX&6M'Z*#UHC]VWT<9-G0:,@R20@PD@^20`E)"*D@-
M:2!M*"J.MB8+5BKN[6A9!ZN7(,,@"22%&$@&R2$%I(14D!K20-I05&1DK1Q&
MILNP*UF_OI)B=HB.6B_R(,%)["9*L:'3D&*0%&(@&22'%)`24D%J2`-I0U&!
MM$5$&$F78YWK<#D*LHR4D%*2(66DG%202E)%JDD-J56D`V57P<&;\2TI9ZNL
M*.<<J:2;7D9)YWL-64=*28:4D7)202I)%:DF-:16D8ZK72<'<1T2\+A^EB6;
M"\&=+3AM.,,$!"7LE9(,*2/EI()4DBI236I(K2(=*+L8'@M4OT@.`]633K))
MG&1#+Q?AQ!;F-L+OAZ"G)$/*2#FI()6DBE23&E*K2,?.KGC'8M>OA,/8A8OC
MKE)?VHL$.N\24DHRI(R4DPI22:I(-:DAM8ITH.QJ-PC4&Y9NMNR*3W(]Z?R+
M:WLWT"=;0DI)AI21<E)!*DD5J28UI%:1#JM=*@=A'4YR_1(ZS+]P5=WG'RB9
M@%*2(66DG%202E)%JDD-J56D`V77PD&@NOR;O7]G+TF?JATF_?HY#&)/.@%G
M\0EPZ.5/@*#43>_3U)`R4DXJ2"6I(M6DAM0JTG&52(1Q'1+0>K3,ZRG\E`4E
M$U!*,J2,E),*4DFJ2#6I(;6*=*#L2CE.P#^I+";]ZCI,P)XDG7QM,9W'"3CT
M\@D(2MWT_L*I(66DG%202E)%JDD-J56DXCH]46=TKA/049"`I(24D@PI(^6D
M@E22*E)-:DBM(AVHJ,YP[]0I:PE'.LGB*\&^UY!DI)1D2!DI)Q6DDE21:E)#
M:A7IV)VH)::L)1R%2<9:@KU2DB%EI)Q4D$I21:I)#:E5I`-EU_G!66Y(LG[]
M'YS)ICWI)(MV)):^ET^R8:"CE+T,*2/EI()4DBI236I(K2(=NQ.UQ)2UA*,P
MR5A+L%=*,J2,E),*4DFJ2#6I(;6*=*!^O9:PR[QH.>)(YU^\U>![N61+2"G)
MD#)23BI():DBU:2&U"K28;5+_['W;E\2A.]=5`G+*2@AI21#RD@YJ2"5I(I4
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M%94+;\D_5A*SH2`(SG^S>%?"]_+Y-PQTE+*7(66DG%202E)%JDD-J56DPWJB
MDI`-KGB!XBC,/U82[)62#"DCY:2"5)(J4DUJ2*TB':A?KR3L5[VB19XC??Z+
M=R5\+Y=L"2DE&5)&RDD%J215I)K4D%I%.JPG*HD9*PE'8?ZQDF"OE&1(&2DG
M%:225)%J4D-J%>E`V55^L,A[R_FO+PR"]=^L)YU_\::$[^7S;QCH*&4O0\I(
M.:D@E:2*5),:4JM(A_5$D2';SWCOHJ)8NEX^)1-22C*DC)23"E))JD@UJ2&U
MBG2@;`$0Y)^[7#?K"X,PR7J2>/F-AUF\\>`&^CVMA)22#"DCY:2"5)(J4DUJ
M2*TB%;OYB2*C<UUD./(9M20EI)1D2!DI)Q6DDE21:E)#:A7I0/UZD3%GD>%(
MYU^\)^%[N3-:0DI)AI21<E)!*DD5J28UI%:1#NN)(F/.(L-1F'\L,M@K)1E2
M1LI)!:DD5:2:U)!:13I049'A3G)S5A*.=)+%>Q*^ET^R?BY_WDO9RY`R4DXJ
M2"6I(M6DAM0JTK$[44G,64DXNAF^XK4D):249$@9*2<5I))4D6I20VH5Z4#]
M>B4AO\V)5R,]V7-I\"$;[TGX7C[_CG/)0$<I>QE21LI)!:DD5:2:U)!:13JL
M)RJ).2N)GN2$Z4*P)"6DE&1(&2DG%:225)%J4D-J%>E`V:5\L)+K*HG)HOOB
M^N%A<__;W58R:C+\&FS>+_V#%5Y/\AT^'\"^EWP<!_D8;5\D;BX?^=3-=37,
M97RO<*[H*G7F>[DGD7.NPO<*YII'5QQ+W\O-57&NVO<*YXJN'C6^EYNK57/I
M@V&+BM<.QK^V+^I@V/[1DO%(ZF#TO;K?>!]_ZCD'I3W)-^'<$S7LE9%R#BS8
MJR15'%BS5T-JU4`=P!-UR9QU24_VFZ<^1>?QQ1<W<#I$)2&E;JXP=OTC^H$9
M!^8<6+!72:HXL&:OAM2J@2IVBQ-U2><ZR7JR7UH+8A=?.'"]_`=[XBD<&!6#
M:=]+OE8SI*(?Z"CS],I<.><JW$#][*.*H'0#9]T/K*?7B^N;JVA!5[D^_HG6
M;YJ\<0-?F;QU?;K)]9&*"B.W,%VP^NG);MX'1RIZ'4O7R^=OXBD<B"-U?$39
MC72'Q?B!CC)/K\R5NUY^KL*1_[`I>Y*M*?N[]]GB>GZSB#Y7*C?,SU0[\C,U
M;YBI=<.ZF?0Q.%%%+5A%.?+O@R4I(:4D0\I(.:D@E:2*5),:4JM(!RJJHKH%
MQI]\@7K!"LN1+"R"1(Y7N+Z72[Z$E)(,*2/EI()4DBI236I(K2(=UQ,5UH(5
MEJ-@@49*2"G)D#)23BI():DBU:2&U"K2@8HJK.%LR3)JT9-.LNCTLO2]?)(-
M`QVE[&5(&2DG%:225)%J4D-J%>G8G2BC%BRC'(5)UO?RE+!72C*DC)23"E))
MJD@UJ2&UBG2@;,$3K]S_["S7%TG^,^ENT9-.P*C66?I>+ML24DHRI(R4DPI2
M2:I(-:DAM8IT7&VA$L1U>//V!4P8NYY\MBT7H(24D@PI(^6D@E22*E)-:DBM
M(AVHJ/+I/F;_Y&<B"U9%CE0"+J(">>E[^03LY_*_"4G9RY`R4DXJ2"6I(M6D
MAM0J4G&].E$5=:ZK(D=!`I(24DHRI(R4DPI22:I(-:DAM8ITH$X4)5<L2ASI
M)(NNG"Q]KR')2"G)D#)23BI():DBU:2&U"K2L3M13%RQF'`4)EG?RU/"7BG)
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MQEHDUG+3C+$6B?5Q4R-^!A.)M=SH8&R,Q/JXGQ&/D2&C(V3`Z+&1,(]&68(\
M&F,)\6B$)Q)AN:,/G^MR?G-K=Q;88J3%;AVP1;8*;NW>`%MD+^#67OQGB]SL
M]_-XY.6)C?2_LX=WS.T;:<0_SV\_RT<0'_C.GLM&?#F_EA<^%ES9^),7/M8B
MVWCRPL=:9%-.7OA8RW+^7AYG[&#)-I<\SEB+[&/)XXRUR$:5/$[7<C'DEMS+
M^&7U?=VL=M\WS_NSQ_4W^7B]['92=\?;'A__<3ANXIU]V1[D+L;=[5\?Y/;4
M:[D'ZZ6])=VW[?;@_B&!O!AN>/WI_P```/__`P!02P,$%``&``@````A`%J9
M`^>A!P``51\``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R465UOI#84
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MGXXP[^\L*G=C[.'#+/RIWK5-UQSZ6PBW1:+S.6?;;`N1'N_W-<Q`R[YIJ\-#
M\)G=J8@%V\?[0:"_Z^JM<_[?="_-VT]MO?^U/E>@-JR37H&GIOFJH;_L=1-\
M>3O[]I=A!7YO-_OJ4+X>^S^:MY^K^OFEA^6.]5=VS1%&@M^;4ZUS`*9>?A_^
MOM7[_N4A$/(V3D+!>!QLGJJN_U+K[P:;W6O7-Z=_$#10GX)P$T0`3=//;WD:
MLUC^CRB1B0)_QRC)1ZEL<5J#'*KLR\?[MGG;0(X!\>Y2ZHQE=Q#8Z&`F,RD#
M"[33Z,\:_A`DP0;FW$'KM\<DN]]^`Z5W!I+/(8PBBA&AU=91%3;`[RFJ#*?O
M;('I1!>4=.B.K'2K9C4&S+'!#<BG>,.0Q1PA/9IJ#K%!""E8U@52NA6RQ9E4
M:B<UD,@1`K)/\XX]FE<1:@U!6,(P"RQUZT,`4YTH)))RR!&2#JM]$Z69R&)/
MJH)`XB@%2$2C*`*1H11)Q"R&,(6-Y3`=<C**IQ34O9ZN'IT<(3#B-"E?UZL(
MM88@;"5A.Z:D;J6ZIC9[</41(@==>1J)Q)M&X0)TO0F]_%$N0`HAHS"95"<<
M8<,ZBHX<=:O'44S?1XX(<9447GH4(T07@XA[U4!A+TY2<,DC:64@%+6SVD(T
M4M2ME*),/8H(P1$BQFUXW.C8O38#Y4:(XTB$=@A",5NDJ%LIQ=3F-:J(D#4.
M!4)P%C))&?-D5BX@"_7/I`,AR<`+'2&'W2/":?<,W1Y=;W/D!K/*UV!,]K(L
MX5X411$9EYE=&LI8E__YTC-T!5*:_/0TF'6F&&<-HTP<G,T-EROR:E>P9&?R
MHFFXI%-O)7.&F'$P)AFSRF#2$@A/$QEZ*:4(XB9C<92]D[5,.X1E/.ZLH=FK
MH[9Z8-X:C"N=M\K%=8A:A=!,@)$<JC-Q=3?-76XG;2@C!L5E##S&RYF"$40D
M_/51!)`F[^\T;1$+PJ)S@.J3^Z0SEFON8E+@*D3!`ZO6`^8SC627APJKG<)2
MG0F+1D*RUBOD.7/-YB9.XW"NK`MAB9".P0^34B2(C$4BWJMBVC=6"*.MN(0S
M&\ED`K&>*(I#WU^9B^#,J:B&K=LODE@ZJ4+EU0YBV4Y;#(V%L/0XY,PUGYLH
MBY),>M(7%",2>+CR'R45Q429B$/)[7ZF=+67+-!%BW$3URG91E3$+*?<`"G8
M58A:A1"JG+K9J.S03"M!YNWSW&!<JK-GEP]@E,&8<BVT-3B90MDN.QF?.UGF
MU?/<8,PH:>AL#)25`ECJ>X:B@)0+F=I$HC2U`<W7G^MF3U1;3W#]#6:%)@8Q
M@"6:!"!6>2X[%]?-U+DRWV,-QEU\;RK%=8A:A5!)821'4K_`<MWM26LWIY$6
M,2[E>;Y>QR@S%JZ`C.+4<1_*6=O'0AJ@J\`R3:[B/%H8KH@95SDB6\+DZ]R<
M_.DH_?(#9%D.0[FN&QB?&UAFD]]P1LRZOJZ#21DRZ545949"RK%@&0L==2AG
M;1]6WUE.H+NX.L\L*.?$@B*9"+_.%0:R-B^U&H:2IE8V(SVW-.;[:LY=3Q."
M+Y%V(<M"NX@X81(.R'9)*>=E/^-H1%1@[TD[-Z`Q!25/X=W$=+(RJ8R!#$8P
M.*G/SKDDCLC@A.:D#F$+AS$W+49+&YIIB6"AEWVY`9GLDRR5LX<%"H$7E8F3
MG\-\E(&\DS&4[+*CB;FC,?^(DAL0DO4E064)A,<2?NP:&[(XU'(4RE4[R_O[
M3>AN:ALL]$PA-R!7&@]27(>H50CEO&QQ`BV.IJZ7EKD!1<,+I-A_?5E,W;:.
MSPJPP:"XC#M/])0EZ.$H.Z6L;O93UK<U@2!749]&\0&,6L=0NMI65A(!70<D
MG@R..:]\AK3+Q=R^9HEP%:)6HU#.U.`FB>?&!H9#ZU,N/N!L'\`H@S%;+8$+
M"GNFHF2ILTUD%QR-V1!&6`2MY\-UC!*(&<DF[%VRVDAL-DQDT5_(%F/^Z4P@
M:)VL:U2"I6'J;0%EHB#5.$MC+NP+`2HL=3+??<6"H_GG@-R`UCF[CL;B+(R\
M\X@R49`S9TG(G??7A'-$_<SG/'1[18+YOF9`JYP_@%$&@ZRSE"6.3U/2U-=F
MI!?\S7^9D</]I"Y_>#$"KPQ3_U!>&,3:M/0MIXT"-R><.T:*G/$6$Z_M3E7[
M7!75\=AM=LWK&2H8A_H_M4ZWIY^YO@WSVG-V!Y=OT+Z=.N"N\U(^5[^5[7-]
M[C;'Z@`AP]L$:EN+UZ+XH6\NPV7A4]/#+>?P[PM<7U=P?1?>`OC0-/WX00\P
M78@__@<``/__`P!02P,$%``&``@````A`.\ML2#I!0``81X``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C$N>&ULE)G;CJ)*%(;O=[+?@7`_REDT;4]&.8BB
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MA^DE@=8&G9@";WG^G:'!GH7@YG'G;J]6X*]"VB>'Z/U<_9U_K)+T>*I`;I/=
M$N=G>!*\2UG*/`!5CW[6GQ_IOCK-9=T:F1-%5S53EMZ2LO)2=J\LQ>]EE6?_
M<TAM4O$D6I,$/ILDJCDR-'-B?R:+WF0Q[EFTD6:;JFE]HBQ0ZKI"UCW+].F*
M3)J;H1NTK:%\NC7@<74)X+--`H5YLBE5D)H+PC1O%'E>"?6F)WQI;S=&MFD:
MECWY1)Y64O6NJ?[YI@"+-[5Y$-5^NCAC;M;:Y$Y41:\O1?XAP<@!E2NO$1N'
MU)D*J1M[-QZ]&1[Z7<SP;XR?RZ`N6+F$Z(]7W;!>QC^@!\4-L^`,O#\P$Y%9
MM@SK1RRQ@P,N#SP^215S>"W1YO!Q8(4#`0ZL<6"#`R$.;'D`WA^J9XM%V[4,
M&UF@I6_-#1YX;.ZV55F8M6I;DP4/B,^8BL]8MC?=RZ&)A--#F"+B=A^$DGA=
MPD)"^%T$)5EU"9PDH)$UC6RZ""I*2!+;+J&;R..['L:X"R1H#CVW3W,6%C3G
M`4%S4Q'E6N*;'!QP>[+HR)W>$XS?PYA(]]433-#'($G6?8PNUGS3QQ@B$_8Q
MR/#;/@8-3KMA1A`7ALP^<5E8$)<'^&3/QKLE)AP<</$M'@[X.+#"@0`'UCBP
MP8$0![9MX#[.Z-B7NY;!XQW,DX_-4T\OAGF;3=AE6"<]#J4F,NN",_"`VW"+
M)%V2A$,2+DEX).&3Q(HD`I)8D\2&)$*2V)+$;H@0N@@LV3H>T)6;!]CEN0SC
MZ4U?W;R/I/7B8,&9(0^0A$,2+DEX).&3Q(HD`I)8D\2&)$*2V'+"MNME'AK[
M=\)%9335)\KCZSY?"EZ`Y5S'"P_C`;N,O&"A*7#!F2$OD(1#$BY)>"3AD\2*
M)`*26)/$AB1"DMARHO$"R(UZZ&XH@^``MB_R\(>C70&S,%8>66[!F2'E.3'E
MAG6_H#6$,WS9)?-[).&3Q(HD`I)8D\2&)$*2V'*"MZ8R4I`<NZ$$@N3P][U/
M<A;&DJ.5X8(S0Y*3A$,2+DEX).&3Q(HD`I)8D\2F2^@6Z@=A'X/6TMLN@Y9=
MNR%"T)_MQ#P:`*\"Z^O8">AIBP8RZKZMC'1=?YQN%&2<Y0V_+RM01H=&7!KQ
M:,2GD16-!#2RII$-C80TLKTA;`.(%&-WP_O$$*W"-DYZI@>V&]<9+.YK#+Y*
M;*"AT8)&'!IQ&\2JO3@U#'5J(/]Y`F+:EJH8J(?Y`J)IMJ+:"%D)B#JU;%M#
M$V\@(KJMJQ,+%68M,JJI65.$;!IDH.U"&MG2R&X0$;W`]ECZO,#W7H1_#!;Z
M"[]@NZU@F('Z+&G$H1&71CP:\6ED12,!C:QI9$,C(8UL:637(+P;Z=.)HNIW
M&44KL!V9/BOPG1K1"G@#@6V=4U8@$8?.XM*(1R,^C:QH)*"1-8UL:"2DD2V-
ML!,\IA&W@JIKFF+>IVMN!7Y"QP\OLJ0X)LOD?"ZE.'^_P,X!6Q?<HK>3P6\&
MVU)'<5>=P:9^-[[49K`KUXT[V@PVY]C.UBT1G/M=HV.RC8IC>BFE<W*`(B@C
M=BQ4\"-"_J/*K_41RUM>P8E?_?4$1[D);`#"$9`L'?*\:G^P!]P.AU]_`P``
M__\#`%!+`P04``8`"````"$`%$6C?-H*``";,0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6R4F]MNXS@2AN\7V'<P?#^Q)4O*`4D&L4CN#C`++!:S
M,]>.HR1&VU9@.]T];[_%,W\6[9[MB^[D8Y'\6:*J2I3Z_N?ON^WDZW`X;L;]
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M4OK7V5?-55.WUS=F5C[3S*HVJQ6KT^KQ_C!^F]`6(EW'CY7>D-5=-YVX93JM
M8>'D_[6V?M+F#]/KZ826="3Z];&NKN]G7\F3:V>SY#856O3>0GM3#RMR('.@
M$C`CZ4%__?_IU^9:OY]YZ4&RH$RLM_!=1`YD#E0"0"SMD=S9BWGPK6XU^RCQ
M[0V*63H;VB?!J$63/I@$P8Q(1E1*0#--E6NF^^#L!M'FM`BR"`+Y#G%&EU81
M3,(J&)&,J)3`*DA/L@J_FS4U8OTD2TLZBN*)_-O,P\'(=Q.,2$942D`;W78%
M;9JB-DMLT#.W3<^(8$0RHE("0NBV+@C1%(580D(2)]7SS$G!*#B)$<F(2@EH
MTWDUQBE_`35%;9:D3F)$,"(942D!(;3J1(@)F'5[11?7!ET>,G4'U&A)YK\\
M1@:CX#]&)",J)2"[H@R8Z/8.-!C5.92ZD"/!D>1(`4(].J#'"VK\V%SP8F43
M``46[X^E0RVM.=ZL=9WM0V?548!+K!9H):*5'UX"0NTZOD?MP9<V[(-$B^H@
MNJ]R(AB1*<&)=92.$]MLK6/MN;U7N;">>LVBS&L-^J-W'3L*J(G7LE0CHE7T
MFAV>.A)"\3HX1_'!:RYFIQ(M2KV6$U'E1*8$)]:1-T[L:ARZ'\YZ37?(;@J+
M,J]UN=="Q]1K67TD=/K$X24@%*^C=10?O&:#..RU-*[;_%`Q)#B2'"E`J$='
MZ((>&[A!3XCEJ3.R@J:O@I7?0H(CR9$"A!)U["Y(M"$=)*91WKF,(5$Q)#E2
M@%"/#LI1C]E_BYLK_7AP=@?:.`Y:0VA/W9F7)E6PBNYD2'(K!0CDU^7,83#>
M)`ZEF8,CP9'D2`%"/87,4=W$,KKFF<*ACCP>H]DBKUB<%07HQ"BF912APWB\
MIOZVK&UT3Z^;0^`4:Y4@P:TD1PH0ZBEDALME2<U3@T.D*_5`GE"C5=AB'$F.
M%"!4KX-YP9LVQH,W+4I<U]<,"8XD1PH0ZM$1.NIQ&>/J6N^?]\WZRW*D'5*%
M!S=])V-`7SJDZY]D,V551Q^MHBOM6!U%[J1CEIZEZTA6OJ."L7`U.@M<6,UO
MXP>LQB8-\+I%M!H_75\S)!SJXM.UY$A!1]2)J<7&R>2^YBFFMDBG@L196972
M.RN**%Z]*'6LFJRC]!UK<]!QW<[I#V9\%0>BL7$U.FMD7D\>]FN;5,#+%NEM
MF:PFKS%<1YHXKB9T]$AZJ]L+TM->*%UGC`O2;4(!Z19E%R(K?/K:6L&%"!VC
M=&=EO5X9KS.WI]U`.[GXDG;3C%G+H<SM>9WBK1*W>V1*75,]2(^LVZOBEO$V
MO$)>8&;S2<7@3+/-<9F_\V+`=4S][1!U#/[V5I?\#=W0WY@(\YMVP1.B0^CO
M)KO"O;>*0H5'J;_M\+2Q]%%D>:]`-]2.23/XFV?&A45IVN%(<"0Y4H!0C\YD
M^7UWN5!<V.27WHL.819O8AUCZ]QHY3>"X$ARI`"A?,R:P9T\.Y)<G3#!G0P)
M;B4Y4H!0#^:]H(?GMX5%H(<AP:TD1PH0ZBGEMQ]<7I[S%A9=0V71Y$5:M(J7
M-W3T2'(K!0CEZWP1=V=PITTC=!G\L,N%1>!.A@2WDAPI0*A'YX"HQQ9I)",(
MLSD"A%F$SP%-7I4MG!7%EIB'FUB"@8H&\XV?W&",V0[1V;)W5,^1X$ARI`"A
M'LPA/RI=&_ZPY-`/2M=HY5<C'/I!Z1JM?$<%8^%J"MFE:F,AGI6N#<\V#J6E
M*T?"H;1TY4A!1]19SB0-SR0.@1YKE2#A.YH7G+:TX$C!6*BGD$GH=#7L3IXU
M&HNPHL@KXMY9I15%J2,OI7W'"Z5T'(@V!JX&$XO9T^EJ>(+1)\F48+(:(R^E
MO5528WB4U!@>7:KIO`VOZ9IR$C(XBP\LX_3.*@FD@B/)D0*$OBPDH<L'!0W/
M00[A:[(F+_>CE;_3!4>2(P4(U9=S4,-SD$.)ZWJ.!$>2(P4(]6`."O<73SV-
M2RJD-$DJ^5-&M(HN"QT]DMQ*`0*);3E!&8P;T*$T07$D.)(<*4"HIY2@YC$V
MM3PC.92E[?QIQUE!UF[C8P6*P+SBKUO+\X=#R;N(E."@F`3<HU`\P&AY-G`(
M5];FM;JSPI7%B@]%8.0/*^,1O[4H75E"<-!2`)[?TEO/,#Z/P:U%V=KR8LM9
MX=K.U%IM.98:G&UE&TO3M24$UU8(B%521K8\_#F4K2P[/>J=%:XLIB`448YK
M+8]K#J5QC2/!D>1(`4(]&-=L%9F<L>OW8-F)IT.94_*<X*S0*3$*@HBN'+D,
MQLOM4'*Y4X*#EL+/;=S('0\_#F4KR\./LX*5=6?"3T=6R:.+OXD,SE:F+:F0
MB<\,SL@07%DA_-1T>X71>?C1+\7U<SC=J3$I=7GX<5:XLC/A1[\P+JV,AQ]C
MB2L[%WZTOF10LQMK.N\.*^/!QW1A*\N#C[/"E9T)/OJQ)A$1YK9Q)7W*-)9X
MNL&1X$ARI`#AY2[$K6YA'HW.O56DQYO\KG6(PDFZ`_)0%JU\#2(XDAPI0"B_
M'/%T29D%%H?2B,>1X$ARI`"AGD+$TQ7%65_R"*B=2-KQ9*:+$=\>O$6KZ,O0
MT2/)K?37KFYXLK+:[=>K]GO.W7!X&_IANSU.UN/GGNYG>BAYO`_8?C:[[&[]
M=[-Y2T,M5$;2X'E+.[_3!5VIY89:S(%&WJ?K:![S>HJU7%.+>>1B+30:7:'"
M/`OJ0R=3I1;J0V=$A9:&5-,Y2:F%M-$34JF%YJ&GCU(+S4//`866>G&G7VV6
M6AIJ,8^$^4H7U(?.@0M]%M2'CEA++2VUF%,V-AJMAXX="WUH.<75T&**:Z$M
M4-P!%?G2GD_D<U<T-WTM4IB[HLGM>X:L#YVVW$DZ2^%]Z-R#6DI^H<^]GTH]
MEO09N/F4.IMC69/K"S,LM>,+_*FY>Z(;C$M:TO4H7@ZZ&L6+H?=]89R^JN[T
M)V5\!OK6BEI*HOJJI9;2+**F%LJ`?#1Z"TLM)05T/D?.+2E85K0?Z/L5/MJR
MHAU!GX846FK:$O8<B+E>^][6)Z&)OIC_6+T-_UH=WC;[XV0[O%*`FIML=;`?
MU]M?3O9=].1Y/-&W\N;S]'?Z3Q`#?20^UQ]9OH[CR?]"HF;AOU4\_@\``/__
M`P!02P,$%``&``@````A`*Y8MGMP`@``T04``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3,N>&ULC)3;CML@$(;O*_4=$/<;?,AA-XJS2KI*NU(K554/UP1C
M&\6`!>2P;]_!)*XW<:7<8/-[^/YA&+QX/LD:';BQ0JL,QZ,((ZZ8SH4J,_SK
MY^;A$2/KJ,IIK17/\!NW^'GY\</BJ,W.5IP[!`1E,UPYU\P)L:SBDMJ1;KB"
M+X4VDCJ8FI+8QG":MXMD39(HFA))A<*!,#?W,'11",9?--M+KER`&%Y3!_G;
M2C3V0I/L'IRD9K=O'IB6#2"VHA;NK85B)-G\M53:T&T-^S[%8\HN['9R@Y>"
M&6UUX4:`(R'1VST_D2<"I.4B%[`#7W9D>)'A53Q?SS!9+MKZ_!;\:'OOR%;Z
M^-F(_*M0'(H-Q^0/8*OUSH>^YEZ"Q>1F]:8]@.\&Y;R@^]K]T,<O7)25@].>
M^"5,U^`$(Y+"MP#LG)[:YU'DKLIP,AM-9E$:)Q.,MMRZC?!K,6)[Z[3\$X+B
M,RI`DC,$GF=(.KT70D)"[49>J*/+A=%'!,T!EK:AOM7B>0(%9%Y<>37#,XP@
M*0OJ89E&T8(<H!;L'+,.,3!V,7$708#>64"^`Q9>]1:^6-YS'80^+QGFI8,\
MKV88QBZ=-/J74+`(,>->S&38`D(&4O8J6,")]3RNRQ*"[O``S("'5UN/KBY!
MB?N%2:/_E&8ZR/3J>V90XM#=_;."(^\EA7Q#3^+1;-)UA@]XSPK*8W_':91>
MU35<H=!YDIN2?^)U;1'3>P46OO$ZM;NYJ\0WQ[4^GJ_:IB'=![AH#2WY-VI*
MH2RJ>0'(R">-3+B38>)TT_;[5CNX8NUK!;].#LT7C2"XT-I=)F!,NI_Q\B\`
M``#__P,`4$L#!!0`!@`(````(0#8F%2DP0T``"5````9````>&PO=V]R:W-H
M965T<R]S:&5E=#$Y+GAM;)2;VW+;.!*&[[=JWT&E^[%%R98E59RI6"+%\ZEF
M=Z\568Y5L2V7I$QFWGX;))H-X&>4R5R,X@^-'T`WSB0__/[7Z\O@S]WQM#^\
MW0^]J]%PL'O;'A[W;U_NA__Y(_AM-AR<SINWQ\W+X6UW/_Q[=QK^_O'?__KP
M_7#\>GK>[<X#4G@[W0^?S^?WQ?7U:?N\>]V<K@[ONS=*>3H<7S=G^O/XY?KT
M?MQM'IM,KR_7X]%H>OVZV;\-6X7%\9]H')Z>]MO=ZK#]]KI[.[<BQ]W+YDSU
M/SWOWT^L]KK])W*OF^/7;^^_;0^O[R3Q>?^R/__=B`X'K]M%].7M<-Q\?J%V
M_^7=;+:LW?P!\J_[[?%P.CR=KTCNNJTHMGE^/;\FI8\?'O?4`N7VP7'W=#_\
MY"WJR7AX_?%#XZ#_[G??3\:_!Z?GP_?U<?^8[M]VY&V*DXK`Y\/AJS*-'A6B
MS->0.V@B4!X'C[NGS;>7<WWX'N[V7Y[/%.Y;E65[>*&2Z/^#U[WJ`]3TS5_-
M[_?]X_GY?CB97MW>C2;>^'8X^+P[G8.]RCL<;+^=SH?7_[5&GI9J1<9:A'ZU
MR'AZ=3.^O9O]B@J5UU2%?K7*[.K.&\TG=_^\)E.M0;]:P_OEUM`8:.I!OUIC
M<N7=C*;*(1><,-?9Z%=GN[N:W=[>3&>J_A<R>A.=4_U#9[WY=?=YW';UCZ[Q
M4H/+L;QN^T73GU:;\^;CA^/A^X`&*47^]+Y10]Y;>.02W9-T@[J^15U\J\P_
M*?O[X=UP0+WF1/3/CY/)S8?K/ZFS;K7-`]IXML62+52'5;(K%_@N"%RP=D'H
M@L@%L0L2%Z0NR%R0NZ!P0>F"R@6U`:XI#ETP:(#]4C"4O0H&N_&!@41G['B>
M+3C+R@6^"P(7K%T0NB!R0>R"Q`6I"S(7Y"XH7%"ZH')!;0#+\S0T?\GSROY^
M2&K&,+BU7?W0VDQN#"/'9-F9=.$`X@,)@*R!A$`B(#&0!$@*)`.2`RF`E$`J
M(+5)K.B0"R$Z-[?=G*22:6$S_#R93)U@:)M+P>A,NF``\8$$0-9`0B`1D!A(
M`B0%D@')@11`2B`5D-HD5C!HM8-@T-[CARN&LJ?HT(\Q5NZ<\&@C*K0S<L=*
M9]*%!X@/)`"R!A("B8#$0!(@*9`,2`ZD`%("J8#4)K'"0[L#,SR\;BO<1(&]
M]Z#)O%L]ED!60'P@`9`UD!!(!"0&D@!)@61`<B`%D!)(!:0VB>5AVOST>5AA
MV\,M\6[$P]JF.1FT&Q\@/I!`ZTP[G378A$`B(#'H)"VYI9]NV(WOG*DS[8RX
MZV1`\I;0UI1MBI:TAZ"FJ260"DAMZEA.5R=78Y_*W5IAV^DM,9VN;0RG`_&!
M!%I'6K0&FQ!(!"0&G:0ECM.="3'MC-BA&9`<I(N6F$X'4@&I31W+Z736Z7.Z
MPK;36V(Z7=L83@?B`PFTCN'TECC.<GIHV!FQLR(@,4@GG8W9^6?VPI1V1BR=
M`<E!NNAL3.FY+5UV1BQ=`:E-:2LT'MT9],6FX79P-#*CHY'MUMG(KN!*K+B&
M/J*`Y8V@B979?J>+AV+%\A&B&.43L3+D9\X9,Q4KEL\0Y2A?B)4I[QRD2K%B
M^0I1;<G;`52'0&-&TR?O*W6;<'[>;[\^'&A.]KI-KM<>&FD?Q>4]:&0%5EO1
M3S>C>S/G@+YBK?::1QW`?40!RYN![9$?SR9VOPE1*T(4HWPB5E+[L5O[5*S8
M$QFB'.4+L3+EG7UF*58L7R&J+7D[L.J,>2FP?QS>K<"V9U(KL"VR`JNM)EWX
M5QX@'U&@D;$TK]$J1!0ABE$K0:L4488H1ZT"K4I$%:+:TK*#H<Z41C!XWZ#N
MXIPU3"-U"=8-G?',66J6;"7;YA6C61<:7Z/QI+DA&T\F(\^])0O81@;AFI5$
M/&1DULJ[<?ILQ%;SIKS1U=RI=HR%)9*'^WG*2%J2,6J59U=S9YK-4;F0/*Q<
M,KK8C(JU6K=-9[>SD;,FU6S2>,T.M3JQ]H5:GV3-B;-%=./+%5S26%,=8BR3
MW8J16/F,Q"I@)#Y;,Q*KD)%H18S$*F8D6@DCL4H9B5;&2*QR1J)5,!*KDI%H
M58S$JF;4:-E.5^?0/J?K\ZGH/J@[`O*P,[Z<3<&2K60(K!A)2WQ&M#TRQJJS
M=PNTU=A:#.^<#KP6+>X,(2,I,6(D]8I%GC,F:)4R$JV,D6CEJ%6@5<E(M"I&
MHE5;6G:TU)FV+UKZK&M&JT76$-%(.L9*/8M0HT8R^HS$*F`DU5XS$JN0D6A%
MC,0J9B1:"2.Q2AF)5L9(K')&HE4P$JN2D6A5C,2J9M1HV4Y79]H^I^O3K^@^
M>/KX:\Z2XYES;EBRE81\Q4A:XFO$2]!X-H)]8,`VYA*DJR#BH8C+8.M9@KJ,
MZJ$0+4'.&A5C80DK2V$I(VE)QHB7(,^9,W)4+B0/C\V2D>E<:$;%6NT2Y$U'
M\]'$:4G--CUK$(GWQEIQYU2FD;1]J:9&925HA<A'%"!:(PH118AB1`FB%%&&
M*$=4("H158AJ"]D#3!V2C0'V\V>8[:F:ML_=XC&9.(O'@]<:77Q\(S;<RU:(
M?$0!HC6B$%&$*$:4($H198AR1`6B$E&%J+:0%;"Q<W?1!,QXGM.DTSBPXN/L
M:!_8B/9M712=@;H4FRX^B'Q$`:(UHA!1A"A&E"!*$66(<D0%HA)1A:BVD!T?
M=<K_E0&E=ECM]":QF$R<:?J!K2Y&3"O)G?E*LG$0?40!HC6B$%&$*$:4($H1
M98AR1`6B$E&%J+:0'3%U%6!$C(^Y8WU%8.PQ-*)S%+MSB6C%&649]A$%G%'V
M06M&(A]BQ@A1S!E%*V$D6JE&]L6E^\0B$RMN8\Y:(E\P$OE2HXDTNT)4<\9&
MRX[##ZX;:!?FKO\:J?-L-W]Y<^>XNQ0K;LF*M:2./J*`,TI[UXRDO2%FC!#%
MG%&T$D:BE6KDA,:9!#*QX@;EK"7R!2.1+S6R0J.]*IZH.6-/:-0!OV^(M`=_
M\_IMW**?A::SXI:L=$:CCCZB@.6EO6M&TMY0(\>=SBH8B157(F8MD4\8B7PJ
M&:7[C>^<35`F5BR?LY;(%XQ$OI2,IKQSDJG$BN5KUNH)X`^N&NCP"6-+7S7\
M9&QU5ESZ2FO93G>?B_ABQ1D#C>@4R&C-2+P22D;3*\X0B<2*M6+6$OF$D<BG
MDM&0=Y^+9&+%\CEKB7S!2.1+R6C*.\]%*K%B^9JU>F*J[@^,0?FSAR!T/0>Q
M;M'/!FMGQ;5:L99U.^0^;/#%BC,&&EFQ!OE0,IK><AZ51&+%\C'*)XPD&*ED
M-.6=!SV96+%\SEIFK*'VI60TY9W]=256+%];\O;:J"X(+L7:>2XR;B\4K(E9
MWS'0S'MIS>RLN%8KUKHX(?ABQ1D#C:Q8@WPH&2_4*Q(KEH]1/F$D.^`4,V:(
M<LYH!A:J6DK&"U6MQ(JK6EOR=F!_<.DQQDL/C=19O@L@/F,1*RY]A<C7B%9\
M=>'DC>_N1E/WM;^`C8P;+I0*!4FUX&HH8JON(8LS<<=86,)Y9(N2(LH8M<KT
M<C@]]S#^<T9UCN44K"#EE((N-*IB*_,F?3)Q%NK:*M$.OG/YTIT\]/6)>?)H
MD5H-)/ASIW'+<6<EP0?DLQ7-7(:6,S\%;&5V-P\>`+"55#44)/(]'4+7:]KV
MP*NI4W[,,A*5A)$4EB+*&,E8SAF)5L%(M$I$%2/1JADU6E8X)\[5#(>SX?8%
MID;V6'8?/"[%J@LG(I\1.=0(IS.^`FVECL&=%8:3M<11H2`C(SQ$9:MV%'H8
M3BF?VY)P'BDL190QDHO='+4*MA*M$E'%2+1J2\L.I[I.,=;<+ISZFD5ZSL.D
M1?;HA&</8L4N6"'R-:)ZJ:EY?G/CS6^<?6+`V:2U:T92JU#0Q<CINMNS@7.8
MB5E+2DP828DIHHQ1.\YOKT;.])BS@2@7C$2Y%'2A+96V8M]-/?HVR=DUUJS4
ME&<'_`<70?1*H+MQ9B0;C26B%2(?48!HC2A$%"&*$26(4D09HAQ1@:A$5"%2
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M7*@W#3%EZ9'?Z!TW3*%7^:B<OA1Z,8_*Z4NAU^RHG+Z4Y7Q![V3WE#)?T`O5
MR)/Y@MZ&1E[,%U4?7WHC:D??%+>F%/7R+VK1R[[4CKX4>D^7VM&7LJ3AV3>>
MUC0X^WA"0[./%S0P^_ARMJ`/!K"NZ]F"/@!`GLP6]/8^\F*VJ!I^W4TC].WV
M^^;++ML<O^S?3H.7W1,M)*/FI>!C^YEW^\>Y?8=T\/EPIJ^VU>ND@V?Z'']'
MK_*.KNB`]70XG/D/*OBZ^\#_X_\!``#__P,`4$L#!!0`!@`(````(0#[1K8\
M^04``"<6```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)18VX[;-A!]
M+]!_$/0>RY1\%6P'UJT-T`)%D;;/6EFVA;5$0]+N)G_?H7@1A]0ZFSYTX\,S
MPS/#RXRX^_RMOCFO9=M5M-F[9#9WG;(IZ*EJ+GOWGZ_9IXWK='W>G/(;;<J]
M^[WLW,^'7W_9O='VN;N69>^`AZ;;N]>^OX>>UQ77LLZ[&;V7#8R<:5OG/?QL
M+UYW;\O\-!C5-\^?SU=>G5>-RSV$[4=\T/.Y*LJ$%B]UV?3<25O>\A[T=]?J
MWDEO=?$1=W7>/K_</Q6TOH.+I^I6]=\'IZY3%^&72T/;_.D&<7\CB[R0OH<?
MEONZ*EK:T7,_`W<>%VK'O/6V'G@Z[$X51,#2[K3E>>\>29CY"]<[[(8$_5N5
M;YWV;Z>[TK??VNKT1]64D&U8)[8"3Y0^,^J7$X/`V+.LLV$%_FJ=4WG.7V[]
MW_3M][*Z7'M8[B4S*>@-9H+_.W7%]@"$GG_;NS[,4)WZZ]X-5K/E>AX0?^DZ
M3V779Q6S=9WBI>MI_1\G$>&*.UD()_!7."&SS7*Y6&W6'W<"S$$)_!5.UA]V
MXO&HAFPD>9\?=BU]<V"+@>[NGK,-2\*5ZX@TB%A48F!]"L8^,OK>7;L.A-P!
M^GH(_/7.>X5,%X(3V1R"&;%DL&PSMXD)I":0:8`'TI5^6):?T<_H3+^<.9+`
M&)!OB)4,:9*80&H"F08@L<'/B67T8>-IR=Y@=1'G!+"Q%&F)*;&BJ`@L)+60
M3$=0$#"5F?%@KC8(&X4CHLD)_"T6%`G.(\V*HC1;2&HAF8X@S7!D3,UPV-_=
MY8P.0<`?E=0@F!M1"!+,J4AFYA5%16$AJ85D.H*B@/.I12&/)$,'L7*22"##
M[3F<K]A"$@M)+233$20$SK\F1%P:,W:5]=>J>(XH9(2H+<'86"!'B)XZ/PAP
M?F-%DG$EPA%<!2KC?K#`9JDB2;-,=X3"8+7<NOO&,+[2NQX&8^,P.`)AR*EB
M"TF$5:`XJ85DNA42N+4%^JL9U!VY]HR`-7&$@$LM1^:^%*2M$I5,F)&%899R
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M92TH'3W)`#,$8>FL7AG26:#\\V*B)1<5#R@JPW:W0@3K83"*(V4FHYF$4AO*
M$(2#8;5M#$:=75$$]7/`H0UD3X5!MM8Y$*RA@\<SL=HS,1,O2>AF$]!X_F.X
M"X9=.D*)#:4VE"$(Z?$G*AY9CMV%T20-=%S^!/2#-FEDR15*I*_'C=+(DH89
M\H6CF:B`>C1&K^3;Y5!`>K=D0XDTU/HE&\J0(=;)JHB]"WQ>7/1=(""DA[,T
M*)&&_EB+;2A#OK`>5B%&/<.=&FQ5_P;5Q6S@!(1J6!!8'Z6B\F@;=LK0[N$$
M"_Z\VP>-CF!CX&A8[3"BP7T0/-E8`7$(%;C`ZO:%H5[@)#1>$JET+PK<9".!
MS+A\_@K$WSWJLKV4<7F[=4Y!7QJX:R#5AYV"Q?/3,CSR?6`,1,L0/M`@,2:^
M"N%[:0(G8`#7]]0(F$`9L$>.9!T>(0Q[)((1=MM.C6QA9-@.AK)D'<)'D6V1
M;$+X%IG`_7F8PDTP-4)@9'C9,N?P?1@9#HDQ`N]XQRD\@O>]*4^1#^]^$W-'
M00A/$K:F:!'"9S_@GIH87N_N^:7\,V\O5=,YM_(,BSP?;MZ6/_3Q'SW_OG.>
M:`_O=NQ3S[G"@VP)GPOS&533,Z6]_,$F4$^\A_\!``#__P,`4$L#!!0`!@`(
M````(0`\_EG6JA```()6```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;)2<VW+;.!*&[[=JW\'E^[5%2K8.E60J%L]GLF9WKQU'B55C6RY+F<R\_39$
MM!K`#WN=7,3VA\8/L!L`V8"H#[_]]?AP]N?F9;_=/7T\#RXFYV>;I[O=U^W3
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M[-H3_?-3>#W_</DGS>H[;7.#-H%ML68+-;.5;.2"V`6)"U(79"[(75"XH'1!
MY8+:!8T+6A=T+NA=,!C@DN)P"@:-^U\*AK)7P6`WWC`PHN-XGBVX2N2"V`6)
M"U(79"[(75"XH'1!Y8+:!8T+6A=T+NA=,!C`\CRM&K_D>67_\9S^-Z;!PG;U
MC;:A]>5D=&6;K$\FIW``B8$D0%(@&9`<2`&D!%(!J8$T0%H@'9`>R&`2*SKD
MPE^*CK*GZ-""?O(\KE+:Z*WPG$Q.X0$2`TF`I$`R(#F0`D@)I`)2`VF`M$`Z
M(#V0P216>,C/9GCX5J'P,0KLO9N17--MQHC+TID3)R.N%@&)@21`4B`9D!Q(
M`:0$4@&I@31`6B`=D![(8!++Z?3$X7.ZPK;31[*8GNX2:R`1D!A(`B0%D@')
M@11`2B`5D!I(`Z0%T@'I@0PFL3Q,#SD^#RML>W@DU_2\*\-Z/G&&]<GH-*R!
MQ$`2("F0#$@.I`!2`JF`U$`:("V0#D@/9#")Y71:&WQ.5]AVNB8S&=9`(B`Q
MD`1("B0#D@,I@)1`*B`UD`9("Z0#T@,93&)YF(:IS\,*VQX>B3.LW2?YD]%I
M6`.)@21`4B`9D!Q(`:0$4@&I@31`6B`=D![(8!++Z2JW]7G]R&VW:^3X/726
M$[$Z.1Y1C"A!E"+*$.6("D0EH@I1C:A!U"+J$/6(!@O9<5"IEY'O\K-*,*9D
M],C([KQA9*PPB")$,:($48HH0Y0C*A"5B"I$-:(&48NH0]0C&BQD.UUE73ZG
MC]F8Y?01.8-_Z@[^DQ5'*PH`Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E&/:+"0
M'0>58/GBH!,O<_"/B.+`'EZKG36Z0Q@H0A0C2A"EB#)$.:("48FH0E0C:A"U
MB#I$/:+!0K;35=KD<[I.ITRGC\@9_#-W\)^L.#11`"A&E"!*$66(<D0%HA)1
MA:A&U"!J$76(>D2#A>PXJ$S*%X<QP[(6(8W,P0\HHH.)XQ.36,6($D0IH@Q1
MCJA`5"*J$-6(&D0MH@Y1CVBPD.UTE5SYG#XF79;31V1O#LS=#3.UT:X6H<5I
M78H0Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E&/:+"0'0>5;_GB,.9A5APTDF&]
M5D<4*C<0%"&*$26(4D09HAQ1@:A$5"&J$36(6D0=HA[18"';Z2H%\SE=IV;F
MRC^BF0SKM3J,<4<ZH!BM$HWFP6F*I&B5(<H1%:A5,J)4Q]CMN+9O4I58\4VJ
M1M0PDJZV&AD3O$/4(QHL+3L.*BOSQ6',UJS!/R(K#B,R.A0%@&)$B496'*!B
MAA5S1`5JE8Q(THB#<Q17B97$8>S$7&9SPU9F'*"KG;8R/-$C&BPM*P[A*SGP
MD=LYL$9F'#0R6H\0Q8@2C<PX,+)]YXSA3*S8=SFB@I'XKF1DRSO'0Y58L7R-
MJ&$D\BTC6][91N_$BN5[1`.CH[P=K5<RY1`S98VL:(U6-,B,T;EP]D0C7=$8
MBC&BA)&X(&5DR<^=P9^)%;L@1U0P$OF2D26_<+:^*K%B^1I1PTCD6T:VO+/#
MTXD5R_>(!D:>`*J,V%CV]-'^A?K`R.%^>_?'S8X6CN!TLA^.&;2Y'&ID!7:T
M6M!</BT[P<+)42)=D:RX[S&B1"-K9GKDPX63_V>HE2,J4+X4*^E]Z/:^$BON
M?8VH0?E6K$QYYQFV$RN6[Q$-EKP],YTT'@+[^^[9"BRF]^&(K,".:"'C--)6
M!HH1)1I9402M#"OFB`K4*M&J0E0C:E"K1:L.48]HL+3L8*C4VYAEO*$8CBFY
M-9M&-*<A?IHZX<*YZZQUQ;F<UT6,0F,V::W9^!&<Z7023)U)F'`U><Y,&8EX
MQLCL53!SQFS.5M-C>Y.+I=/M@@VDL9*1-%8QDBNI&8W*BXNEL\PV;"#*+2-1
M[AB]>1D]6XUNNUY<+2;./6E@DV-S=JA5PN\+M=X(D`[>J,\/TL/[_/A9R>,G
MG-:,Y-,Z$2.QBAF)5<)(<H.4D5AEC$0K9R16!2/1*AF)5<5(M&I&8M4P$JV6
MD5AUC$2K9R16`Z.CENWT5W800MQ!T,B97\Y#P9JM9.Q$C&14QHQH(3/FJO,(
ME["5NJ/RQ^&"N3.`4[:2%C-&TF+.2*P*1C*P2D9B53$2K9J16#6,1*ME)%8=
M(]'J&8G5P,@S15[99PAQGT$C:XJ,5G,9&!%:Q8S$*F$D0S%E)%89(QF*.2.Q
M*AB)5LE(K"I&HE4S$JN&D6BUC,2J8R1:/2.Q&AAYIHC:%O"M2^-V@74+&I$S
M19S481UJ*PEYQ$@&1LQ(WX+"Q02>`Q.VD5&7,A+QC-&;:W?.5J=;D'./*MA`
M&BL926,5([F2FA'?@@)GS6C80)1;1J+<,7KS,GJV&MT67$^6DZES)0/;>"88
MY0S>6"ONY-`:29Z_#@%%B&)$":(4488H1U0@*A%5B&I$#:(648>H1S18R+H'
M35_9N#ARV^D:V4<X2^<98RU6G`%$B&)$":(4488H1U0@*A%5B&I$#:(648>H
M1S18R([#*UL24]R28&0<WB.*$,6($D0IH@Q1CJA`5"*J$-6(&D0MH@Y1CVBP
MD.UT6LY\*\Y4<6?PCXBVZ.1Q*'2?Y]>ZHKF1ARA&E"!*$66(<D0%HA)1A:A&
MU"!J$76(>D2#A>PXJ)S:<Y>?CKFV>9?7R%F$G/VEM5C)(C1J&4?\,5HEB%)$
M&:(<48&H1%0AJA$UB%I$':(>T6`A.PZO)/Q33/@9F8N0MA(4H56,*$&4(LH0
MY8@*1"6B"E&-J$'4(NH0]8@&"]E.?R7UIE$/B]"(9L9CC[8R4*21-=+'B@9*
MM)6YM85:&6KEB`K4*E&K8BMZ4#MEE.'<V6RIQ8JG;L-(MN]:E.\T,JZQ1S18
M6G8<7LG&IYB-:V0X?8THTLCH4(PHT<B*P]BB(9]AQ1Q1@5JE1H96Q59V')R\
MH!8KB</8+Z.K+<IW&AF7W2,:6![W]J>OY-E'[MR4QZ3:N+BUMC)0I)'1H1A1
MHI%Q<2EJ96QE^\X9P[E8L>\*1C*&2Y2OV,J6=[9F:K%B^8:1R+<HW[&5+>^D
MR+U8L?S`R!,ME4_[;MUCGDW3C45NIB,R0K-&%&GT]NE:+%8LGS`2%Z0HG[&5
M[0)G\.=BQ?(%(Y$O4;YB*TO>/5VKQ8KE&T8BWZ)\QU:VO//TTXL5RP^,/`$D
M+3.`<.+B'*71)V7@MC0B*["`(EWQ[=.U6*RX[XE&ULP$^4PJ&G<7]W0M%RN6
M+U"^U,BXH$HJFO+.L40M5BS?H'R+\IU4-.6=O9->K%A^L.2M^]G,R>PAL,Y1
MVM'>7E\U,H_2$$4:F4=IB!*-S"BB5H85<T0%:I6H56'%&E&#6BUJ=5BQ1S18
M6G8P7DGO9YC>:^3L8SJWF+58\5"($,6,](9<.)]/KJ>.5,)&LE2GC&0C,1,D
M(Q3/TMCJM)'IK*P%&TAC)2-IK$)4,QJ59Q<S.MXR_CDSL6%S::=E).UT@MZX
MJ)ZMK`.3I7-P/[#5L44[^*]L,\QPFT$C.CF0#H5+Y^+68B7!'[6,(X>8K>@A
M29ZWE\Z:DK"5N;&!YSQL)?OXF2"1]PP(W:_Y\7`UN+AVVB]81LX12D;26(6H
M9B3G"`TCT6H9B5:'J&<D6@,C/).8O;);<>3.`CIN.MASV3U?7NN*9"7A/%5D
M%+.5/0J=^96P%25\IZ![P@GR&5>D>$E%."MGJW$6^L*IE67>E5Q'+J]"5#.2
M0X>&D6BUC$2K0]0S$JV!D6=VOK+I,<--#XWLV;EPGI_78L6QBQ#%&BW"X\18
MSF;!<N8\R"5<3<9SRDC&<R;HS<B-ET,'D&(5+IW4HF`M:;%D)"U6B&I&XSR_
MNI@X7FG80)1;1J+<"9)>PJ+2:ROVW740S":P'.OK]<Q?M1GB25EFXR:)F;(P
MDBVM-:((48PH090BRA#EB`I$):(*48VH0=0BZA#UB`8+V?=`M7?@<_JXIV`Y
M?424K\L8")?.>%K3=W6I/,3(ZB-$,:($48HH0Y0C*A"5B"I$-:(&48NH0]0C
M4E]D)LX9XS!^,=GX_4B/FY?OF_7FX6%_=K?[\43K/7UP\M.'$QZ_$>UF&J[4
MICVM8E`RI9+CZ@HE,RHY3A>W9'9%7[!V7'ZAY)J_>LTM":@.O8'CZ4%`=>B=
M$%_)G$J.-W)7+5RNU$FHI\YT0KT^?J#3K3.EKX6C`R1/'1+S:@6D12_I>FH$
MI$5ODOI*R-/T;J.OA#Q-+^#Y2LC3]$H8EM`WV7WV:U$%C_T-->ZU5T'VV'^>
MK3[3`,.&;ZA'O@[=4!2]0:08>G4H@MX`+E;#<3EW@D1;"RNU<8`]HEV!E<KY
ML802^I5*U[&$<O&5RK2QA#+=54PY'I90WKI2B2J64!:Z4FDGEE!.N5))));0
MCB5=C\\#M/](U^,KH:U#NAY?">WZT?7X2FBOC=KQ>92VR:@=7PGM<%$[OA+:
MG*)V?"5T(D'M^$8`G2]0.[X2.BV@=GPEM-%/[?A*:,>=VO&-*-H_IW9\);0;
M3NWX2F@CF]KQE:S#<*4^\XV12ZE$?5P;2^CCV2OU26LLH4]6K]2'I+%D'4ZI
M'=\43*DD]Y;09XJI'5\=^H0PM>,K68<TKNEM">Q!2B7JQ1`LH1=!J!U?";W#
M0>WX2M9A0.WXEB!ZZ8':\970^PK4CJ^$7C6@=GPE]'[92KT]AKVFM\56ZETP
M+*%WOU;J-2XLH=>V5NJE+"Q9![3NT#M!6))2B7K7"4OHW29JQU?24HEZZ8CJ
M7)X6./IBT.?;[YOZ]N7[]FE_]K#Y1C?KR?$]AY?Q.T3'/P[CQ^+/ONP.](V@
MQZ\^O*?O>MW0]P].+NBY]MMN=^`_5`.G;X_]]#\!````__\#`%!+`P04``8`
M"````"$`]NM5THP)``"/)P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6R46EUOX[@.?;_`_0]!WB>)[3AI@K:+QM_&+K!8[-[[G*9N&TP2%W$ZG?WW
M2UFB))+>9N9E,CT^/!0I2J(_;G_Y?CR,OC7G;M^>[L;!9#8>-:==^[0_O=R-
M__HS_W(S'G67[>EI>VA/S=WX[Z8;_W+_W__<?K3GK]UKTUQ&H'#J[L:OE\O;
M>CKM=J_-<=M-VK?F!%>>V_-Q>X$_SR_3[NW<;)]ZH^-A&LYFB^EQNS^-M<+Z
M_",:[?/S?M>D[>[]V)PN6N3<'+87&'_WNG_K4.VX^Q&YX_;\]?WMRZX]OH'$
MX_ZPO_S=BXY'Q]VZ>CFUY^WC`>+^'LRW.]3N_Q#RQ_WNW';M\V4"<E,]4!GS
M:KJ:@M+][=,>(E!I'YV;Y[OQ0["NH\5X>G_;)^A_^^:C\_X_ZE[;C^*\?_IU
M?VH@VS!/:@8>V_:KHE9/"@+CJ;#.^QGX_3QZ:IZW[X?+'^U'V>Q?7B\PW;$R
MV;4'\`3_CHY[50,0^O;[W3@"#_NGRRO\;S&)E[,H"./QZ+'I+OE>V8Y'N_?N
MTA[_KTF!D=(B<R,"OT8DG`3SV4))?&(&5WO?\&O,@F"R#&:K:/FYX<(8PJ_U
M][-CADKOG<.OU?B!,:^,&?RZ,=_$\7QQ<V70`4QB[U']Q[K\P6%/];3UTYUN
M+]O[VW/[,8(U!!/3O6W5B@S62MA,M$F[G7JHP)VB/RC^W7@Y'L&D=H!^NX_"
M^>WT&]32SG`VDA-01H(,54]*-N5`QH&<`P4'2@Y4'*@]8`KQVR2$/YD$Q5=)
MP.%O$'!9"5G$R$"3E`,9!W(.%!PH.5!QH/8`$C$LUY^:=L7O%[F=]N!F1D/<
M&`XL8DN**26Q%)L&@60"R052"*042"60VD=(-F#(/Y4-Q8=LP"9C(XU"%NO&
MD#Y+AZ78=`@D$T@ND$(@I4`J@=0^0M(!<?GIP*6OX#YJ'.W&("N[$!*!I`+)
M!)(+I!!(*9!*(+6/D(A@H_<C,KO<1.VXE]?][NNFA8D,[":GZ#12C01S%ZE!
M(HNDQ@HV&5L5P0W;&S-+PB3F1J@_S/O-L!#2I;7RI5G!59:$TK4O3?(!^_>G
M^?BS??/SH>@T'QKQ\R&0U%BY#&4"R8V5%[S0*855)9#:UR&1JH;4.]^PEA5,
M(])(`#_>["W8_F5(KN!3:X9)SS021OWA&`?S113=4)G<4'03I,Z_0@B75M@;
MSYQ/.?$5Q<OY*F:^:M\7R0QT($.943#-C$:@%\,0$X.X64L%)Q.<W"`W5J<0
MG%+H5()3^SHD(M6_#(74XS0F`['I7M)Y2I#ES3="+HH,(1B75SIL'G+#"LGV
ML&2-4>&T,-DE0LYCA1#UN**CKZ]YI+E3O='`0@ETSP1G'0YH8Z`8LNWB7;%N
M('$L-$P-Y%52AI`KI1PA%V\AM4IDN7%5"#FM&J%>B\:K.J.A>'7'1.+5$*V5
M%9NY)#`LOU:L(:8@<RPO=W-V2.2&!;6"AH4S1*A$R"6J0H@4QHKUHK63]P;A
ME2)-E.J:O$1=.SL#TV6YB=D8R)OW!"$W5ZF!8A=TAE!H\Y"CH0NZ0,AIE6CH
MM"J$G%:-A@/5H7HC$33<V$+)JW[!G(^#S0,<BGP'-1"KH(BNUP19?@5IK=@[
M0PTKGO?G2S@+XIL9F^#<<$C]:*7`B9>H!!/FUK$X8I!E_"WCY6KACD5:*JK_
M$EF+79O%V@IXH&`RY080A4Z\[X8VR((`[##9.9@X#JZ.5$*9A'()%1(J)51)
MJ"8038QJQ+S$8!<2F);-7RL&<O.4(,M!J80R">42*B142JB24$T@&ISJO8:"
M,UV:'YQIT[PV.C"0J_#40#%<L1,>K-B49XZ%4YZCEML("H2<?.D,?7E6=95C
MH7R-6KT\38%JLKP47-TC=5-&#AD-P6I#?XG:+J`5@UT*H=1`D;I5^78/BY^M
M_,P1T"9'&3\K0KETAD:9[4Z5(Z!R391I0E2/]EE"^$Z@^*Q#TQ!)B(!2V,]Z
M0Y>C3$*Y@:"&<>P%0B[?I32L)%2CH:R"D+6??16$BPF<>[C@>PJ-TT`JEUZU
M\T[4L&*WF-)!0[Y]9\A:]1433`*FG!N"?U9(9R7*D%%R9Q6RT-F"+=J:.",5
MH_IBOV)LQF3_V5/OQI!6/V.LWTX,"[I4G/-TT)`'D2$+-F)O0EASG2/+ZT.D
MQQ)99*C<8X4LWR.\[Z#M08TLV:V$JL_T5IO-G>X__6VFI\*>XL\C;"/456)8
MI-ID+XM:L`1MHD+1BQB6&KW'8KM+(3V6*.\R7"&DZVLVB9A,?<T9+3G6V=JT
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MHH'<34(2"BB54":A7$*%A$H)51*J"42#@VW##TX71PSWV';Q*`:K#0TM9GT[
M\X5E-PG-97+8>$TR'8#J'8>RJW#F5D,+7S<0C[S"*RSB/1KJ%J,;OUOL*70@
M!L+X6?N?X&5_G&'@3DDZ`F`-Q0]W%SQ^`UV)_QJ+>F=-2S_]2_6(!:<_DNV+
M@3!\%UC_J"#!RS1\=TS3`?C'OWI:WVL\1/+T-]"UZ+7AO[*H<W5$8>V!H7KM
M#D^^["#T">8O\$A#&+H+RH1N+M/07:-!O?NGE1>Z/*Q@!*H6_C4HX_P*BSI7
MNRD+G=6]WF])]!K"Z%U<9@#F,HW>]4%Z`/IK%_WYP[$YOS1)<SATHUW[?H+T
M0TMT?VMA_,PF7C_H[VS8%7@LM59/?&#[%U<6<*6_/>17PN5:;8C2!C[G>>@?
M3'(+^,RG?X;)\1"$!G0V$7P6-(`_S-</^DZ:"\W7\!Y8#F@#T0T%!T\@UNHA
M@[2`)PAK]9!`7H&;=+#I#R;F'6ZYP6;H2AI&:]462S7H>=?5X)5TL8;7JP,6
MBS6\&Y5XNES#&TF)E\LUO&&4.#R8@CB&KL`S)8BCOS*U(<)74F_;E^:W[?EE
M?^I&A^89BFS6/PP]ZP^J]!\7_:YU]-A>X/LH]=IU]`H?OC7P6G"F'C@_M^T%
M_X!!3>VG=/?_````__\#`%!+`P04``8`"````"$`WR199"P%``#)$P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R<F%MSJD@4A=^G:OX#Q?L1\2ZE
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M?,YC9^R`TVQR3.`,6.Q63DY3^\GU#F[;=F:3*J"_$W(OM-^MXD+OZSPYADE&
M(&U8)[8"SY2^,&EP9`B*'53M5ROP1VX=R2EZO99_TON&).=+"<O=9R4QO<)_
M@I]6FK`>@%./WJO/>W(L+U.[.VCUA^VNV^G;UC,I2C]AM;85OQ8E3?_A(E=8
M<9..,(%/8>*.'R[NB6+XE,5?/H"A\(#/7_:`(ZZ2@$_E,>KW>X/1\/$D8$U%
MGFS)>%;#UM=M9**N%NDOV'3ET<`O7SX:A[=*U6++J(QFDYS>+;ANH1F*6\3N
M`J[GPK*)YA(=HMH-NCYF\B>FG]JP-M!(!="W6;?3GCAOT+^QT,RQQFTJ%E+!
M>IC9+DVP,H%O@K4)-B8(3+`UP<X$H0GV)CAHP($,59"PN%\*DNE9D#*"N01U
MLATC-:F0)4L3K$S@FV!M@HT)`A-L3;`S06B"O0D.&FBD!KV,4NOU5;>Q/\-=
M3.LVUQTT4YD+#?2N:LE^4[)0$I4<(BM$?$36B&P0"1#9(K)#)$1DC\A!)XT0
MX=11B#`@_O,:9GI(%10JL6['N$3G0O19K$JB8D5DA8B/R!J1#2(!(EM$=HB$
MB.P1.>BD$2ODH\<J[X`,5^G)LYYSTN-SE-W.%H@L$5DAXB.R1F2#2(#(%I$=
M(B$B>T0..FDD,V@F(X9&B\W6\I+$+W-:;3-D8DS>3(P3F#<RPX70P-U5]:3;
M'36OXZ42R;*5,!HH(U]I=*-QTVBM1-)H@XP"I=&,>L:HVRJ1--HAHU!I="/C
M<MLKD30ZZ$:-]&'XZGV)TO]!;VRNR_29O)D^)WKZ0M-5,2X168DJ+6JD62.R
M054!TFP1V:&J$&GVB!STJD9B[$E(V^3(9!AN)L,)VP?57=@SQ[`HZ]1A(;(2
M1EI82+-&9(.J`J39(K)#52'2[!$YZ%6-L&#/_%%8##?#XL0%(RVL;O-*6PC1
MN`Y+$;VLURQ;<5&GOJ7ZJDQ>(&M%/C':(*-`E#4/V]@Q;$59M]KA=H;]X7A@
M[#MVR#E\Q'G__\X'W;FQ-.R)Y*.UJ7AS<01B#W[:ZACGL)"JND^7-=(+S?61
MJI%:5U^BVFM=HT^\-E)5>P42\:=<-E*W`G7;_*&C/^R-^\9\V,FRVBF4J';:
M/^#$GN=9NW<J)[X&_/F</SRE)#^3!;E>"RNFKQDD#`_)LXG"_,7`O._!#(5^
M-?ABY"TK8X/[(P]N"E@?C#RX[#$/1QY<V)C#"XFGZNYD^,_9BXH/]/..!QMT
M[#/O>K#IQ/RIYSU!0/@/\YX'VRG,%P,/9C?F_L"#48QY,/!@LF(>#CP8E)@O
MAAX,+,S]H0<C"?-@Z,'0P3P<>C!6@#LJ.7B_<HO.9!_EYR0KK"LYP6*WJZU.
MSE_%\"\E'[K6,RWAS4KU7'V!5V8$6K?=@HOP1&DIO[!_H%["S?X%``#__P,`
M4$L#!!0`!@`(````(0#_"GA+.A```/E=```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;)3<6V_;2++`\?<%]CL8?M_8U,6.C20+2;S?L#C8<\ZSXBBQ
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MY?].Q,MJW<N\&N+?^$#7_43Y^Z8'DC=0]T#R]WVOZ*:?*'_M`[TI$Y'4QG$+
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MH23G.F0UA`R9@R20%))!<D@!*2$5I(8TD'8L*HGRTI%$.<K]]CULXB6K$C%D
M;'KIY6S9!YU*ZQ`RI!620%)(!LDA!:2$5)`:TD#:L:BT2GZ0ULG\PXG$FAE=
M8FU"EKV,]Y=1]-$KSR'(3HLA"22%9)`<4D!*2`6I(0VD'8O*HYQLC/-HCR2&
M=;)ZF0W[Q!4DAB20%))!<D@!*2$5I(8TD'8L*C-2%N/,=`??*SGQD%0>3U=X
M_#53=-9ZD3.MX=T<13=>B0U!0XE!$D@*R2`YI("4D`I20QI(.Q:52-.OC<YB
M;(D9ULGJ951BD!B20%)(!LDA!:2$5)`:TD#:L:C,R'GT.#-O*3$S16>M%WD0
M5V*32Z_$AJ"AQ"`))(5DD!Q20$I(!:DA#:0=BTJD:3#&F;0UUKE.EZ51E9%B
M4D)*21DI)Q6DDE21:E)#:A7I1)DSY,";T7197EU9TH6%9J&?^'$X+L1NHBVV
MA)22,E).*D@EJ2+5I(;4*M*Y,^?)H=P=SY_EE,V^WJ5I.$TZQT4&BAF5D%)2
M1LI)!:DD5:2:U)!:13I1YF1XE*ANOW;ZY,STV7[]]:3KSV^[[,1Q_0T3[?9(
M&)62,E).*D@EJ2+5I(;4*M)I-2?#H[0..[G^)'E<?^/SYJZ)7YGK![HD8U)"
M2DD9*2<5I))4D6I20VH5Z429L]U1HKKZFW[\8*X6_N[4S;1D?@'VI`MPZAU9
M[<1Q`0X370&"4D[,2#FI()6DBE23&E*K2.?5G"O[>37AOTUJ?W(M(<.YR?32
MOT80#:?@+LIK>%<NQJ8T)B6DE)21<E)!*DD5J28UI%:1SK(YD?:S_$KC$?4G
MW^-=0$_R9\A]-/&N!J[L1'>I*R8EI)24D7)202I)%:DF-:16D<ZKO(^1UY/5
M:R9T)X\N@]/+:_W^7T9]E.Q>ASRC>H<85[V@Q*UDHU)21LI)!:DD5:2:U)!:
M13K+YAQ]5+W#0:H_=Q]7:$^Z0I&[(<IF)8Y`"2DE9:2<5)!*4D6J20VI5:1R
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M`--\>0V6)5VAWN%KY:)L5F)20DI)&2DG%:225)%J4D-J%>G<O;?!FH0:K,B[
M1K>T42<K=&C"7)9!B5O)1J6DC)23"E))JD@UJ2&UBG26I=Z"%6I<7RR>]*0K
MU#M\K5R4S4I,2D@I*2/EI()4DBI236I(K2*=.].VC-[=K^]#^SYGO`^-YEX&
MEY.A&SIQ`C#$N"R#$K>2C4I)&2DG%:225)%J4D-J%>DLFP;'S_+I"ZB3OB<:
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MDC)23BI():DBU:2&U"K2B7I_&S)C&]*3J>713LZ_`^2B;/)C4D)*21DI)Q6D
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MKC7.7?^(;F+&B3DG%HPJ214GUHQJ2*V:J'-G.HM`7S+K.XY17]*3^6S8*'?^
MA0,;=3/*W7$M\\&HT42O&4SZB?+A%%N=*=?*')U8*^=:A9VHG[W7$91VXK3[
M=O7D>GY]<^6=T%4VQCW1^DV+-W;BB<5;&],MKK>4UQ@-!S=V/[,CF1O1HX1[
MKV-EHUS]QH[&$[&E^N5=CY2ZB7;C98Y.K)7;*+=68<F57MF3W)3HOO0^OY[=
MS+WC2F6GN95J2VZEYO1**N%SKV5Z]5YH-Z'KI=PKGD9>]I8V:KP+\LIPY6)L
M.F-20DI)&2DG%:225)%J4D-J%>DL>_U6E^57/LP_9R]F27;`HY+WSX5=E,MK
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MA$:DWN33%Z$1J3?Y`$%@9"9YD[N,H1')V_$>FK]-9Y(=N0'*.8NI;!_Y'"Q'
MY)/6\@R"CS.5QPG.64QE^QSO:/C/0$;,)T%#CR/;)SAG,9'JE6]'!.;(B/G.
M26A$<AV<LYC(NUX^KAZ:(UM!OA\0&I&M$)RSF,@KE6^_A>;(*Y6O&X9&Y)4&
MYRPF4HER@3@T1RI1OO\5&I%*#,Y91/)*Y?I^8(Z,F*^3AT;DE0;G+"92(<?[
M`/XVE1'SU=_`:A.ID/"<2$;D5W\"<R+)F_S,36A$\B:_U!(:D>P<[[/YSRV2
M[,@I-.<L(JDJ^>$"CBQEQ/Q41&A$JBH\Q^QZ0S-DJ>!*LE#PL67#!+>+;);P
MEI3<RR]/\;FN9M>WY@891U(9,7?`.")WO&[-+2Z.R"VM6W,/BR/R@]6+\-:2
M)Q:(7YJW1<C-VS_@"WE+!#?@TAQK`A-6L[F\\-#&D/O7\L)#(W(W6EYX:$3N
M+<L+#XVL9E?R.*&-F\J(N3W+9,GM6'F<T(C<;Y7'Z48NAAJ6W^-^7O_8-.N7
M']NG_=G#YKN<REQV]Z!?CC_=??S'X7@O^NSK[B"_Q-W]A/&]_,3Z1GY'^-+\
M.N?WW>Y@_R%/ZF+XT?8O_Q4```#__P,`4$L#!!0`!@`(````(0!=0S[L_@4`
M`/86```9````>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)2878^J2!"&[S?9
M_T"X/V(KHA+U9!1!<#?9;,[N7C.(2D;$`/-Q_OU6T]WT1YDYX\TP/E:_3;U=
MW90LOG^4%^LMKYNBNBYM,AC:5G[-JD-Q/2WM?WZ$WV:VU;3I]9!>JFN^M'_F
MC?U]]?MOB_>J?FG.>=Y:H'!MEO:Y;6^^XS39.2_39E#=\BM\<ZSJ,FWA8WUR
MFEN=IX=N4'EQ1L.AYY1I<;69@E]_1:,Z'HLL#ZKLM<RO+1.I\TO:POTWY^+6
M"+4R^XI<F=8OK[=O657>0.*YN!3MST[4MLK,CT_7JDZ?+Y#W!W'33&AW'Y!\
M661UU53'=@!R#KM1G//<F3N@M%H<"LB`VF[5^7%I/Q%_3R:VLUIT!OU;Y.^-
M\K_5G*OWJ"X.?Q37'-R&=:(K\%Q5+S0T/E`$@QTT.NQ6X*_:.N3']/72_EV]
M[_+B=&YAN;OYLNH",\%?JRQH#4#JZ4=W?2\.[7EIC]W!9#H<D]'$MI[SI@T+
M.M:VLM>FK<K_6!"AL_<B(RX"5RXRF@Z(._0>T!AS#;AR#6\PFTQ<;S;]^HU`
M9)<-7+D(>5S$XR)PY2+3AQV9<@VX]C?RJ*MSK@'77N-A1PB4#EM@6D-L\1Y/
MA_1E`O_T-_/%A!Q6<EVI!FF;KA9U]6[!_@>MYI;2TX3X=`9>I+S2^K*%W9/1
M\"<:O[3!4BC(!NC;:CP:+9PWV`<9CUGC&*)';$0$+6`J&YA@:X+0!)$)=B:(
M39"88*\`!PSI78%-])`K-)ZZ(O)9"R!M,DS:B`@Q)##!U@2A"2(3[$P0FR`Q
MP5X!F@5P!CQD`8V'@TLI#.(-]65?\QA7"9KH(9L^I/<%D2TB(2(1(CM$8D02
M1/8JT?R!)![RA\:#/W`J*CMGK&>_YD&?&=2']`8ALD4D1"1"9(=(C$B"R%XE
MFD&0J6J0.$`H[GP0][_FQ.UWSP:1`)$M(B$B$2([1&)$$D3V*M%RA,>3FB,_
M/0?T:=F>B^QE777/;9$[#==S9X0HN7-"%<0)2SRC3@(>-.XMVW)ITAW)HR$Q
M1H3]]\+VB&MXO<8.J<;]*'K0@ZIQB"7]]T)UKZIJ5L$CXU.K?E0W^C025M%P
MW2I&5*L0"1#9<AWI5(A(Q$<I3B"=&(U*$-FK.EKNM*-7'K(B1XKU'!DA<%$6
MW]4/B0T+<N'@5H*,<S3@2O-^=;?WM%UC6,B"1N.NC(@W&L^,V2,>P9I/^NS>
MH:GBKTR5Z%--/)A-3W2O3J7Y"=W8/3\IUOUDA';`BE6>/LV&!;EPTBM!4STH
MX$JR1K:]MJC]D)'QD+5%9&@\_B(^8M:OR8Z1&?M10,V,D6JBJ9+1W'1)5=5<
MHFWG/9LZKOO$$12>2&:#42"04E0"R8&A0#(JXFBD%`V.B@626HE`4FNO:>GY
MTF[NSC:C;:U1%QP9A3'3UWPCHX0K@4!*'0@D%S'DB%<"\28NVD9BE$QV)Y#4
MC@62VHFA/9FZ$V.+[L6H3ENWB'9[]RQB72!T)R+3-6'(.(OFID5]E!@8B(%R
MS;8"R61#@:!ZY:Z;FCN&1T'AJ%'&KXF=U!(W$0LD9TP$^G3&_:]FU.VDW>$]
M.WG7J-K)D%9Q'BJX/D@D$A".9%%L!9+JH4#P]%7<-$Z*2$3!N:I$(3?1C+$8
M*&=,!-)F=%$E<JT[E4C[1L6Z7[5.\-Q'FY@A[=!"*.`#B5J.+,J575?(HUR9
M8<21=FAQ>:D5BX%2*Q%(:NTU+;V$:&^)?/`&HH/D;='==A)>)B%/&-+*C$R-
M9G##!T*4K#,^4*TSAEQ]B<V.@6NYT^ZIY\V)4=21F$QNQ9U`<K)8R'PZ62*B
MV&3C(9$'!G.5O8QC;SC*O#[EF_QR::RL>KU"R</!N%KTF+T%7$]\Z._!!X-O
M/1^:9LQCSX>V%_/MU(?6$O-XZD.KB#F\?7P:W>%K^E;R'A_Y\%L=ZZS'/OQ(
MQ?S)]9_`+OS%VO7A1QMPI\\87D;>TE/^9UJ?BFMC7?(CF#7L?L;4[+TE^]"R
M'MUZKEIX#=F]/#K#^^4<&I<AK=AC5;7B`YV@?V.]^A\``/__`P!02P,$%``&
M``@````A`))B[]<R`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$H
MH``!````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````)R104_#(!B&[R;^
MAX9[2VEU&M*R1,U.+C%Q1N,-X=M*+)0`VNW?R[JNSNC)(WE?'I[OHYIO=9M\
M@O.J,S4B68X2,**3RFQJ]+1:I-<H\8$;R=O.0(UVX-&<G9]5PE+1.7APG047
M%/@DDHRGPM:H"<%2C+UH0'.?Q8:)X;ISFH=X=!MLN7CG&\!%GL^PAL`E#QSO
M@:F=B&A$2C$A[8=K!X`4&%K08(+')"/XNQO`:?_GA2$Y:6H5=C;.-.J>LJ4X
MA%-[Z]54[/L^Z\M!(_H3_+*\?QQ&3979[TH`8OO]M-R'95SE6H&\V;'MFVL3
M[YL*_\XJ*08[*ASP`#*)[]&#W3%Y+F_O5@O$BIR4*2$IN5B12UI>T6+V6N%C
M:[S/)J`>!?Y-/`+8X/WSS]D7````__\#`%!+`P04``8`"````"$`CGUV"*0"
M``"]"```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````"<5EUOVR`4?9^T_V#YO77:5--4$5=KDJV3
MMC62T^X1$7S=H!)P`5O-?OTNH4GMC7A:WS#W@W///7!-KIXW,FG!6*'5)#T[
M':4)**Y+H1XFZ=WR\\G'-+&.J9))K6"2;L&F5_G[=V1A=`W&";`)IE!VDJZ=
MJR^SS/(U;)@]1;-"2Z7-ACG\-`^9KBK!8:9YLP'ELO/1Z$,&SPY4">5)?4B8
MAHR7K7MKTE)SC\_>+[<U`L[)I[J6@C.'5>;?!3?:ZLHE\V<.DF1=(T%T!?#&
M"+?-1R3K?I*",PE33)Q73%H@V>L&N0'F25LP86Q.6G?9`G?:)%;\0MK.TV3%
M+'@XD[1E1C#E$)9W"Q^[M:RM,_E/;1[M&L!9DJ%#V-PMN[[=M;C(Q^.=!Z[Z
MGCY#0(*&/L:E<!+L;;5@QD4@C\==S#L4`7$`M.\B16W0N7+(%_VJ0K>%[B(_
MU##5RFHI2N:@I-=,,L6!%KM*Z9UZ0\C9OV,*AZ=YM5FJ*WI;8],.>#S]H9@>
MLG[(E/7:<`B9@>5&U%Y1/O-U8X4":W=T%$WTE"\:!4+Q+`XF7N[+I=H&4I\:
M47OHT60_M`.Z8%NVDO&:9F!$BXIO(5[`5&\VP@5J?`\1ET-\>/OQ3D>/G",@
MMXV:BF9EX:E!L'3>>K:C7L.<Q;LY'',>/2=.(UUZKHXA.Y`UY#;(&8UB":0-
M)1VN<!S-.AQS$8T)\N-!?G0&C@D99^,(?V\/B;>V*^%!/!TI_Z\?C1\=R4B7
M.(H:AO/@<,>[#\3`93ERQK!8XLH=CHEKX45A0]WIN\0J[<V)/R;#-Z$>[5V]
MU#-\2_>CK[])BC4S4.)0V-M?-\@-3CTC?9+IFN$+4^Y]_C;X07T?_D;RLXO3
MT7B$,[BS1[(7;>(;E?\&``#__P,`4$L!`BT`%``&``@````A`'Y/$`K7`0``
MJ!4``!,``````````````````````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"
M+0`4``8`"````"$`M54P(_4```!,`@``"P`````````````````0!```7W)E
M;',O+G)E;'-02P$"+0`4``8`"````"$`FM$*B](!``"-%```&@``````````
M```````V!P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"+0`4``8`
M"````"$`):`@#28#``!B"@``#P````````````````!("@``>&PO=V]R:V)O
M;VLN>&UL4$L!`BT`%``&``@````A`(?M-U#"!0``=14``!@`````````````
M````FPT``'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(M`!0`!@`(````
M(0"HV72)P`,``-$-```9`````````````````),3``!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`(_:7^PX`P``"`D``!D`````
M````````````BA<``'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"+0`4
M``8`"````"$`QI/=/W,&``!:&0``&0````````````````#Y&@``>&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+`0(M`!0`!@`(````(0"X^SKKW`(``"P'
M```9`````````````````*,A``!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L!`BT`%``&``@````A`!Z0A:GQ`@``*PD``!D`````````````````MB0`
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`6=(0
M=V@"``!C!0``&0````````````````#>)P``>&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+`0(M`!0`!@`(````(0"VWQ8KE0,``%X+```9````````````
M`````'TJ``!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!`BT`%``&``@`
M```A`)(0'+@O`P``-@D``!D`````````````````22X``'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"+0`4``8`"````"$`*6^35U$/``##B@``&0``
M``````````````"O,0``>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+`0(M
M`!0`!@`(````(0`CZZ49F00``!`1```9`````````````````#=!``!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L!`BT`%``&``@````A`%F$$*MS!```
MX`X``!@`````````````````!T8``'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+`0(M`!0`!@`(````(0!!$;GCR0(``"T(```8`````````````````+!*
M``!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$``%EW
MJLY````'W@``%`````````````````"O30``>&PO<VAA<F5D4W1R:6YG<RYX
M;6Q02P$"+0`4``8`"````"$`5!-J3(0,``#&>```#0````````````````"O
MC@``>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3
M`````````````````%Z;``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&
M``@````A`(MO[2Q/!0``(1H``!D`````````````````(Z(``'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"+0`4``8`"````"$`>KDY[F(#``!P"@``
M&`````````````````"IIP``>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M`BT`%``&``@````A`%:B3THN`P``.`D``!D`````````````````0:L``'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"+0`4``8`"````"$`^@Y&P^\"
M``"'"0``&0````````````````"FK@``>&PO=V]R:W-H965T<R]S:&5E=#(P
M+GAM;%!+`0(M`!0`!@`(````(0``V,"FPPH``.HN```9````````````````
M`,RQ``!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL4$L!`BT`%``&``@````A
M`(4@"1IW`@``T`4``!@`````````````````QKP``'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+`0(M`!0`!@`(````(0`*.J6W(@<``(X<```8````````
M`````````'._``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`
M"````"$`F(ET@[<"```9!P``&`````````````````#+Q@``>&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L!`BT`%``&``@````A`-!1->U&#P``-5L``!@`
M````````````````N,D``'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+`0(M
M`!0`!@`(````(0!:F0/GH0<``%4?```8`````````````````#39``!X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`[RVQ(.D%``!A
M'@``&0`````````````````+X0``>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+`0(M`!0`!@`(````(0`41:-\V@H``)LQ```9`````````````````"OG
M``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`%``&``@````A`*Y8
MMGMP`@``T04``!D`````````````````//(``'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"+0`4``8`"````"$`V)A4I,$-```E0```&0``````````
M``````#C]```>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M`!0`!@`(
M````(0#[1K8\^04``"<6```9`````````````````-L"`0!X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`#S^6=:J$```@E8``!D`
M````````````````"PD!`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M+0`4``8`"````"$`]NM5THP)``"/)P``&0````````````````#L&0$`>&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0#?)%ED+`4`
M`,D3```9`````````````````*\C`0!X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L!`BT`%``&``@````A`/\*>$LZ$```^5T``!D`````````````````
M$BD!`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`
M74,^[/X%``#V%@``&0````````````````"#.0$`>&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0"28N_7,@$``$`"```1````````
M`````````+@_`0!D;V-0<F]P<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0".
M?78(I`(``+T(```0`````````````````"%"`0!D;V-0<F]P<R]A<'`N>&UL
64$L%!@`````J`"H`6`L``/M%`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1PAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements Of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of reimbursements</a></td>
        <td class="nump">778,232<span></span></td>
        <td class="nump">1,677,301<span></span></td>
        <td class="nump">2,373,200<span></span></td>
        <td class="nump">2,723,459<span></span></td>
        <td class="nump">28,793,719<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">830,730<span></span></td>
        <td class="nump">722,037<span></span></td>
        <td class="nump">2,730,233<span></span></td>
        <td class="nump">1,520,221<span></span></td>
        <td class="nump">27,235,208<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">112<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">429<span></span></td>
        <td class="nump">3,262,462<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,122<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">1,608,962<span></span></td>
        <td class="nump">2,399,450<span></span></td>
        <td class="nump">5,107,555<span></span></td>
        <td class="nump">4,244,109<span></span></td>
        <td class="nump">59,845,697<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(1,608,962)<span></span></td>
        <td class="num">(2,399,450)<span></span></td>
        <td class="num">(5,107,555)<span></span></td>
        <td class="num">(4,244,109)<span></span></td>
        <td class="num">(59,845,697)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,299)<span></span></td>
        <td class="num">(318,623)<span></span></td>
        <td class="num">(2,508)<span></span></td>
        <td class="num">(952,241)<span></span></td>
        <td class="num">(1,967,215)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">260,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value - derivative liabilities</a></td>
        <td class="nump">189,348<span></span></td>
        <td class="num">(294,381)<span></span></td>
        <td class="nump">216,112<span></span></td>
        <td class="num">(287,604)<span></span></td>
        <td class="nump">915,498<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="nump">188,049<span></span></td>
        <td class="num">(613,004)<span></span></td>
        <td class="nump">213,604<span></span></td>
        <td class="num">(1,239,845)<span></span></td>
        <td class="num">(791,717)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,420,913)<span></span></td>
        <td class="num">$ (3,012,454)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (3.76)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (6.84)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
        <td class="nump">23,601,895<span></span></td>
        <td class="nump">801,799<span></span></td>
        <td class="nump">22,401,711<span></span></td>
        <td class="nump">801,799<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivatives [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivatives</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 5 &#8211; Derivatives</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company&#8217;s common stock at prices below such warrants&#8217; respective exercise prices and these provisions could result in modification of the warrants&#8217; exercise price based on a variable that is not an input to the fair value of a &#8220;fixed-for-fixed&#8221; option as defined under FASB ASC Topic No. 815 &#8211; 40. The warrants granted in connection with the issuance of the Company&#8217;s Stock Offering and 2012 Common Stock Offering, the Convertible Notes (previously issued and converted) and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a &#8220;Lower Price&#8221;) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time.</font></div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Activities for derivative warrant instruments during the nine months ended September 30, 2013 were as follows:</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Fair Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,146,338</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt;
 display: block; margin-left: 0pt; margin-right:
 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Reclassification to paid in capital</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3,130,536 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(600,880 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td width="76%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Change in fair value</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(216,112 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family:
 times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom:
 black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance, September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,015,802</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at September 30, 2013 and December 31, 2012.</font></div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30,</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display:
 inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline;
 font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Market value of common stock on measurement date (1)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.17</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Adjusted exercise price</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.48 - $0.81</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.50 - $2.475</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Risk free interest rate (2)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.10% - 0.77</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.33</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrant lives in years</font></div></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4 months/5 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0 days/4.22 years</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected volatility (3)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">125% - 161</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">%</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times
 new;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">139</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr><tr bgcolor="white"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expected dividend yield (4)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="76%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Probability of stock offering in any period over 5 years (5)</font></div></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td><td width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">25% - 40</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The market value of common stock is based on an enterprise valuation.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</font></div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">Management determined the dividend yield to be 0% based upon its
 expectation that it will not pay dividends for the foreseeable future.</div></td></tr><tr><td width="4%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td><td width="96%" valign="top"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;
 </font></td></tr><tr><td align="left" width="4%" valign="top"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5)</font></div></td><td width="96%" valign="top"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</font></div></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708775-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5708773-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41635-113959<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5618551-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80748-113994<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624181-113959<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668309&amp;loc=d3e80784-113994<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624177-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5580258-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41641-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTextualAbstract', window );"><strong>Property and Equipment (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 429<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PropertyAndEquipmentTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodLineItems', window );"><strong>Milestone Payments Milestone Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4) Biological License Application filing with U.S. FDA</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div
 align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(5) First commercial sale</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(6) after the first $10,000,000 in net sales</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td></tr></table></div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">MSKCC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodLineItems', window );"><strong>Milestone Payments Milestone Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock', window );">Summary of milestone payment</a></td>
        <td class="text"><div align="left"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></div></td><td width="93%" valign="top" style="text-align: justify;"><div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div></td></tr></table></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval </font>for each licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">(2) upon the receipt of regulatory approval from the U.S. FDA for each </font>licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentsMilestoneMethodLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentsMilestoneMethodLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentsMilestoneMethodTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payments milestone method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentsMilestoneMethodTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EW5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MarketValueOfCommonStockOnMeasurementDate', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 1.17<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">0.33%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">139.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.48<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0.10%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">0 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">4 months<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">125.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract', window );"><strong>Summary of fair values of derivative warrants on basis of valuation model</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Adjusted exercise price</a></td>
        <td class="nump">$ 2.475<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">0.77%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Warrant lives in years</a></td>
        <td class="text">4 years 2 months 19 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">5 years<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">161.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Probability of stock offering in any period over 5 years (5)</a></td>
        <td class="nump">40.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value of common stock is based on an enterprise valuation.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the Treasury Bill as of the respective measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">For the year ended December 31, 2012, because the Company does not have adequate trading history to determine its historical trading volatility, the volatility factor was estimated by management using the historical volatilities of comparable companies in the same industry and region.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[4]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[5]</td>
              <td style="vertical-align: top;" valign="top">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MarketValueOfCommonStockOnMeasurementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market value of common stock on measurement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MarketValueOfCommonStockOnMeasurementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfFairValueOfDerivativeWarrantsOnBasisOfValuationModelAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bbb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsProbabilityOfDefault</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract', window );"><strong>Schedule of derivative warrant instruments activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsUnits', window );">Beginning balance, Units</a></td>
        <td class="nump">5,146,338<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital', window );">Reclassification to paid in capital, Units</a></td>
        <td class="num">(3,130,536)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantsUnits', window );">Balance, Units</a></td>
        <td class="nump">2,015,802<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Beginning balance, Fair Value</a></td>
        <td class="nump">$ 3,574,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue', window );">Reclassification to paid in capital, Fair Value</a></td>
        <td class="num">(600,880)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangeInFairValueOfDerivativeWarrants', window );">Change in fair value</a></td>
        <td class="num">(216,112)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Balance, Fair Value</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangeInFairValueOfDerivativeWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ChangeInFairValueOfDerivativeWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantsUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative warrants units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantsUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification to paid in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantUnitsReclassificationToPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification to paid in capital, fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeWarrantUnitsReclassificationToPaidInCapitalFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ScheduleOfDerivativeWarrantInstrumentsActivityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVKAM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="5">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Aug. 01, 2012

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Rental Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>After First Net Sales [Member]

</div>
          <div>Product Development and Patent License Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Abbott Biotherapeutics Corp [Member]

</div>
          <div>Phase I Clinical Trial of a licensed product [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2002

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>License agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>License agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2012

</div>
          <div>Memorial Sloan Kettering Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Oak Ridge National Laboratory [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 06, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Aptiv Solutions [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 15, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>license and sponsored research agreement [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 19, 2012

</div>
          <div>Fred Hutchinson Cancer Research Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Aug. 28, 2012

</div>
          <div>University of Texas M.D. Anderson Cancer Center [Member]

</div>
          <div>Clinical Trial Agreement [Member]

</div>
          <div>Installment</div>
        </th>
        <th class="th">
          <div>Sep. 26, 2012

</div>
          <div>Johns Hopkins University [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 21, 2012

</div>
          <div>University of Pennsylvania [Member]

</div>
          <div>Clinical Trial Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013

</div>
          <div>Former CEO [Member]

</div>
          <div>Separation and Settlement Agreement [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfLicenseFee', window );">License fee payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,750,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Net sales in milestones payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfRoyaltyPaymentToRelatedParty', window );">Description of royalty payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">We agreed to pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of up to 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">We agrees to pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Royalty payments of 2% of net sales will be due to FHCRC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RoyaltyOfNetSalesPercentage', window );">Royalty of Net Sales Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FirstCommercialSalePeriod', window );">First commercial sale period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 years 6 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TechnologyServicesCosts', window );">Technology access fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Annual maintenance fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ResearchAndDevelopmentArrangement', window );">Annual research funding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PurchaseOfRadioactiveMaterial', window );">Purchase of radioactive material used for research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">233,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProjectEstimatedCost', window );">Project estimated cost for clinical trials of drug Ac-225-HuM195</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,859,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DownPaymentOfProjectEstimatedCostPercentage', window );">Down payment of project estimated cost percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DownPaymentForProject', window );">Down payment for project</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,997,732<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="nump">239,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration', window );">Clinical trial cost for approval of food and drug administration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,500,000<span></span></td>
        <td class="nump">13,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear', window );">Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FundToRelatedPartyUnderAgreementAfterYearTwo', window );">Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfPatients', window );">Number of Patients</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountPaidToEachPatient', window );">Amount paid to each patient after Completing clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,185<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,366<span></span></td>
        <td class="nump">481,204<span></span></td>
        <td class="nump">38,501<span></span></td>
        <td class="nump">31,771<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpFeeForClinicalTrial', window );">Start-up fee for clinical trial</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">79,623<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,749<span></span></td>
        <td class="nump">33,946<span></span></td>
        <td class="nump">22,847<span></span></td>
        <td class="nump">16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartUpDueCostPaidDate', window );">Start-up due cost paid date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 10,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NonRefundableInstitutionalFee', window );">Non-refundable institutional fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PharmacyFee', window );">Annual pharmacy fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,025<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmendmentProcessingFee', window );">Amendment processing fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AgreementConsideration', window );">Consideration pursuant to agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company paid Mr. Talley $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid Mr.Talley a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PerformanceBonusPayableUnderAgreementForService', window );">Performance bonus payable under agreement for service</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">60,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">This agreement terminates on Decemeber 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Rent agreement termination date</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AgreementRenewalDescription', window );">Rental agreement renewal description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The agreement automatically renews on a month-to-month basis and requires a two month notice of termination.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfAggregateAmount', window );">Payment of aggregate amount in installments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfFinalInstallmentForServicesByCompany', window );">Outstanding payment of final installment for services by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">125,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentOfPerformanceBonusForServicesByCompany', window );">Payment of performance bonus for services by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AgreementConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AgreementConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AgreementRenewalDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding renewal of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AgreementRenewalDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmendmentProcessingFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amendment processing fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmendmentProcessingFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountPaidToEachPatient">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount to be paid for each Patient that has completed the clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountPaidToEachPatient</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical trial cost for approval of food and drug administration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ClinicalTrialCostForApprovalForFoodAndDrugAdministration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfRoyaltyPaymentToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of royalty payment to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfRoyaltyPaymentToRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DownPaymentForProject">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Down payment for project.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DownPaymentForProject</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DownPaymentOfProjectEstimatedCostPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of total estimated project cost required for down payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DownPaymentOfProjectEstimatedCostPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FirstCommercialSalePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>First commercial sale period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FirstCommercialSalePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FundToRelatedPartyUnderAgreementAfterYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement after year two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FundToRelatedPartyUnderAgreementAfterYearTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FundToRelatedPartyUnderAgreementForFirstTwoYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fund to related party under agreement for first two Year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FundToRelatedPartyUnderAgreementForFirstTwoYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NonRefundableInstitutionalFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Non refundable institutional fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NonRefundableInstitutionalFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NoticePeriodForTerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice Period for termination of agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NoticePeriodForTerminationOfAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfPatients">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of patients.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfPatients</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfAggregateAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment of aggregate amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfAggregateAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfFinalInstallmentForServicesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding payment of final installment for services by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfFinalInstallmentForServicesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfLicenseFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License fee payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfLicenseFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentOfPerformanceBonusForServicesByCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment of performance bonus for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentOfPerformanceBonusForServicesByCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PerformanceBonusPayableUnderAgreementForService">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Performance bonus payable under agreement for service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PerformanceBonusPayableUnderAgreementForService</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PharmacyFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pharmacy fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PharmacyFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProjectEstimatedCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Project estimated cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProjectEstimatedCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PurchaseOfRadioactiveMaterial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of radioactive material.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PurchaseOfRadioactiveMaterial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ResearchAndDevelopmentArrangement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ResearchAndDevelopmentArrangement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RoyaltyOfNetSalesPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty of net sales percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RoyaltyOfNetSalesPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpDueCostPaidDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up due cost paid date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpDueCostPaidDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartUpFeeForClinicalTrial">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Start-up fee for clinical trial.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartUpFeeForClinicalTrial</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaintenanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MaintenanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TechnologyServicesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 605<br><br> -Section 25<br><br> -Paragraph 76<br><br> -URI http://asc.fasb.org/extlink&amp;oid=22169047&amp;loc=d3e132428-111767<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TechnologyServicesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Note Payable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotePayableTextualAbstract', window );"><strong>Note Payable (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_KeymanInsurancePolicyPremium', window );">Premium paid by company pursuant to premium finance agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 140,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InsurancePolicyDownPayment', window );">Down payment under insurance policy</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InsurancePolicyInstallmentPayment', window );">Premium monthly installment for nine months</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment of notes payable</a></td>
        <td class="nump">$ 103,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InsurancePolicyDownPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of down payment of insurance policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InsurancePolicyDownPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InsurancePolicyInstallmentPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of monthly installment payment of insurance policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InsurancePolicyInstallmentPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_KeymanInsurancePolicyPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Company took a policy for its top management employee and mount of policy premium paid by company on behalf of its director and president.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_KeymanInsurancePolicyPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotePayableTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NotePayableTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the total principal payments made during the annual reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentAnnualPrincipalPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 1 &#8211; Description of Business and Summary of Significant Accounting Policies</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;<font style="display: inline; font-family: times new roman; font-size: 10pt;"></font></div></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Basis of Presentation - Unaudited Interim Financial Information &#8211; </font>The accompanying unaudited
 interim
 consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Impairment of Long-Lived Assets &#8211; </font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family:
 times new roman; font-size:
 10pt;"><font style="display: inline; font-weight: bold;">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font><br />&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"
 colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;"><font style="display: inline; font-weight: bold;">Income Taxes &#8211;</font> The Company uses the asset and liability
 method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&#160;&#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase 2,280,184 shares and warrants to purchase 9,441,942 shares of the Company&#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase&#160;1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 3 &#8211; Property and Equipment</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment consisted of the following at September 30, 2013 and December 31, 2012:</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">162,384</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">3,100</font></td><td width="1%" nowrap="nowrap"
 valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,292</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property and equipment</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">165,484</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Loss on disposition of equipment</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman;
 font-size: 10pt;">(4,122</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment, net</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,918</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Depreciation expense for the&#160;nine months ended September 30, 2013 and 2012 were $0,&#160;and $429 respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 6 &#8211; Commitments and Contingencies</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Employment Contracts</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On September 16, 2013, the Company&#8217;s Board of Directors appointed Dr. Kaushik J. Dave as its new Chief Executive Officer (CEO)&#160;and Director. Material terms of the Employment Agreement are as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="3%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">a</font></div></td><td align="left" width="74%" valign="top" colspan="3"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">A base salary at an annual rate of $350,000, which will be re-evaluated upon the&#160;six month anniversary of the start date and reimbursement of certain expenses.</font></div></td></tr><tr><td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="2%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="4%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="68%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="3%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">b</font></div></td><td width="74%" valign="top" colspan="3"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The CEO shall be entitled to participate in an executive bonus program, which shall be established by the Board pursuant to which the Board shall award bonuses to the CEO, based upon the achievement of written individual and corporate objectives such as the Board shall determine.&#160;&#160;Upon the attainment of such performance objectives, the CEO shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary</font>.</font></div></div></td></tr><tr><td width="3%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="2%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="4%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="68%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" width="3%" valign="top"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">c</font></div></td><td width="74%" valign="top" colspan="3"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">An option to purchase common shares of the Company and restricted stock (the &#8220;Grant&#8221;).&#160;&#160;The Grant will consist of (i) an option grant to purchase 675,000 common shares of the Company; (ii) 125,000 shares of restricted and (iii) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work.&#160;&#160;An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date.&#160;&#160;As of October 25, 2013, the option has not been granted by the Board.</font></div></td></tr></table></div></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div style="text-indent: 0pt; display: block;"><div><font style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">License and Research Agreements</font></div></div></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make payments in the form of upfront payments as well as milestone and royalty payments. Notable inclusions in this category are:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">a.&#160;&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt;
 display: block;"><font style="font-family: 'times new roman';
 font-size: 10pt; display: inline;">Abbott Biotherapeutics Corp &#8211; The Company entered into a Product Development and Patent License Agreement with Abbott Biotherapeutics Corp. (formerly Facet Biotech formerly known as Protein Design Labs) in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000.</font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="right"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(1) when Company initiates a Phase I Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2) when Company initiates a Phase II Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(3) when Company initiates a Phase III Clinical Trial of a licensed product</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display:
 inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display:
 block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(4) Biological License Application filing with U.S. FDA</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(5) First commercial sale</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(6) after the first $10,000,000 in net sales</font></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,500,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Under the agreement, the Company shall pay to Abbott Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.</font></div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company met its first milestone in 2012 and upon reaching the milestone the Company paid Abbott Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012.&#160;&#160;The milestone payment for the Phase I Clinical Trial was recorded as research and development expense.</font></div><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div><div align="left"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">b.&#160;&#160;</font></div></td><td width="93%" valign="top" style="text-align: justify;"><div style="text-align: justify; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Memorial Sloan Kettering Cancer Center (MSKCC) &#8211; In February 2002, the Company entered into a license agreement with MSKCC that requires a technology access fee of $50,000 upon execution, an annual maintenance fee of $50,000 and annual research funding of $50,000 for as long as the agreement is in force.</font></div></td></tr></table></div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div><div align="right"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent:
 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Milestones</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left"
 style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Payments</font></div></td><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="#cceeff"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1) filing of an New Drug Application (&#8220;NDA&#8221;) or regulatory approval&#160;</font>for each licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">$</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr><tr bgcolor="white"><td align="left" width="88%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">(2) upon the receipt of regulatory approval from the U.S. FDA for each&#160;</font>licensed product</font></div></div></td><td align="right" width="1%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td><td align="right" width="9%" valign="bottom"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">1,750,000</font></div></td><td align="left" width="1%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div></td></tr></table></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">The Company expects to file the NDA for regulatory approval in the 2016-2017 time frame.</font></div><div align="left" style="text-indent: 0pt; margin-right: 0pt;
 margin-left: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block;"><div align="left"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt;
 margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">c.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">Oak Ridge National Laboratory (ORNL) &#8211; API is contracted to purchase $233,100 of radioactive material to be used for research and development, with a renewal option at the contract end.&#160;&#160;The Company is currently negotiating the 2013 agreement.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">d.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">AptivSolutions provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company clinical trials, Phase I and Phase II.&#160;&#160;The total project is estimated to cost approximately $1.9 million and requires a 12.5% down payment of the total estimated project cost.&#160;&#160;The down payment totaling $239,000 was paid in 2007 and 2012.&#160;&#160;On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services.&#160;&#160;The total project is now estimated at approximately $2.2 million.&#160;AptivSolutions bills the Company when services are rendered and the Company records the related expense to research and development costs.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;e.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (FHCRC). The Company will build upon previous and ongoing clinical trials, with BC8 (licensed antibody).&#160;&#160;FHCRC has currently completed Phase I and Phase II of the clinical trial and the Company intends to start preparation for a pivotal trial leading to an FDA approval.&#160;&#160;The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC.&#160;&#160;The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA.&#160;&#160;Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $150,000 per year for the first two years and $250,000 thereafter.&#160;&#160;Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year.&#160;&#160;A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug.&#160;&#160;Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">f.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On March 27, 2012, the Company entered into a clinical trial agreement with MSKCC.&#160;The Company will pay $31,185 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up fee of $79,623.&#160;&#160;The amount due of $79,623 was paid on July 10, 2012.</font></div></td></tr></table></div></div></div><div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><div align="left"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">g.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On July 19, 2012, the Company entered into a clinical trial agreement with FHCRC.&#160;&#160;The Company will pay $31,366 for each patient that has completed the clinical trial. Upon execution of the agreement, the Company is required to pay a start-up
 fee of $19,749.&#160;&#160;During the clinical trial additional fees apply and will be invoiced when applicable.&#160;&#160;The amount due has not been invoiced but accrued by the Company as of September 30, 2013.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%"
 valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">h.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center.&#160;&#160;The total estimated cost of conducting the clinical trial is approximately $500,000, which includes a non- refundable institutional fee of $14,500.&#160;&#160;The estimated cost is based on treating 24 patients through 2013.&#160;&#160;Upon execution of the agreement, the Company is required to make a payment of $33,946.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">i.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On September 26, 2012, the Company entered into a clinical trial agreement with Johns Hopkins University.&#160;&#160;The Phase I/II clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $38,501 per patient, who has completed the clinical trial. The Company is required to pay a start-up fee of $22,847, an annual pharmacy fee of $2,025 and an amendment processing fee of $500, when applicable.</font></div></td></tr><tr><td width="7%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td><td width="93%" valign="top"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="right" width="7%" valign="top"><div align="right" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">j.&#160;&#160;</font></div></td><td width="93%" valign="top"><div align="justify" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On November 21, 2012, the Company entered into a clinical trial agreement with the University of Pennsylvania.&#160;&#160;The Phase I/II clinical trial will be conducted with Actinium 225.&#160;&#160;The clinical trial will be conducted under the protocols established by the Company and pursuant to an Investigational New Drug Exemption (IND 10807) held by the Company.&#160;&#160;The Company will pay $31,771 per patient, who has completed the clinical trial. The Company will be required to pay a start-up fee of $16,000 and additional administrative fees, when applicable.</font></div></td></tr></table></div></div><div style="font: 13.63px/normal 'times new roman'; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">&#160;</font></div><div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On August 1, 2012, the Company entered into a rental agreement for office space at 501 Fifth Avenue,&#160;New York, NY. The agreement terminated on May 31, 2013. On June 1, 2013, the Company entered into a rental agreement for office space at 546 Fifth Avenue,&#160;New York, NY. This agreement terminates on December 31, 2013. Upon the expiration of the term, the agreement automatically renews on a month-to-month basis and requires a two month notice of termination. The Company paid a one month refundable deposit.</font></font></div><div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><div style="text-align: justify; text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On&#160;February 28, 2013, the Company entered into a Separation and Settlement Agreement with its former CEO. Pursuant to the agreement, the Company paid the former CEO $125,000 on March 8, 2013 and a second payment of $125,000 on September 1, 2013. The Company also paid the former CEO a performance bonus of $60,000 for his service from August 15, 2012 to December 31, 2012</font><font style="font-family: 'times new roman'; font-size: 10pt; display: inline;">.</font></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable</a></td>
        <td class="text"><div align="left" style="font: 13.63px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font size="2" style="font-family: 'times new roman'; font-size: 10pt; font-weight: bold; display: inline;">Note 4 &#8211; Note Payable</font></div><div align="left" style="font: 13.63px/normal 'times new roman'; color: #000000; text-transform: none; text-indent: 0pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">&#160;</div><div style="font: 13.63px/normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-right: 0pt; margin-left: 0pt; word-spacing: 0px; display: block; white-space: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;"><font size="2" style="font-family: 'times new roman'; font-size: 10pt; display: inline;">On December 28, 2012, the Company entered into a premium finance agreement to pay a $140,000 premium for its director and officer liability insurance policy. Pursuant to the agreement, the Company paid a down payment of $28,000 in January 2013 and&#160;is required&#160;to pay $12,636 in monthly installment for nine months. As of September 30, 2013, the outstanding balance related to the premium finance agreement was $0.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivatives (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativesTextualAbstract', window );"><strong>Derivatives Textual [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfProbabilityOfStockOffering', window );">Description of probability of stock offering</a></td>
        <td class="text">Management has determined that the probability of a stock offering is 25% - 40% for each quarter of the next five years.<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfProbabilityOfStockOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of probability of stock offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfProbabilityOfStockOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWIAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">2,330,134<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancellation</a></td>
        <td class="num">(49,950)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="nump">2,330,134<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.95<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">8 years 2 months 1 day<span></span></td>
        <td class="text">8 years 10 months 28 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">$ 685,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">1,609,035<span></span></td>
        <td class="nump">685,800<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Summary of stock option activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Beginning balance</a></td>
        <td class="nump">12,770,636<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">warrants exercised</a></td>
        <td class="num">(2,304,910)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Warrants expired</a></td>
        <td class="num">(1,023,784)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Units, Ending Balance</a></td>
        <td class="nump">9,441,942<span></span></td>
        <td class="nump">12,770,636<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning balance</a></td>
        <td class="nump">$ 0.97<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, exercised</a></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, expired</a></td>
        <td class="nump">$ 1.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 0.77<span></span></td>
        <td class="nump">$ 0.97<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Outstanding</a></td>
        <td class="text">5 years 1 month 2 days<span></span></td>
        <td class="text">4 years 5 months 23 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
        <td class="nump">6,114,768<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
        <td class="nump">$ 9,611,403<span></span></td>
        <td class="nump">$ 6,114,768<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>29
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U
M,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U
M93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S7U5N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U5N,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED
M871E9%]3=&%T96UE;G1S7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R
M:7!T:6]N7V]F7T)U<VEN97-S7V%N9%]3=3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D=O:6YG7T-O;F-E<FX\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M
M96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T
M95]087EA8FQE/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1&5R:79A=&EV97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5Q=6ET>3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E
M;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5S
M8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<V-R:7!T:6]N7V]F7T)U<VEN97-S
M7V%N9%]3=3(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y0<F]P97)T>5]A;F1?17%U:7!M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7U1A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE
M;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D5Q=6ET>5]486)L97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97-C<FEP=&EO;E]O9E]"=7-I;F5S
M<U]A;F1?4W4S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1&5S8W)I<'1I;VY?;V9?0G5S:6YE<W-?86YD7U-U-#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D=O:6YG7V-O;F-E<FY?1&5T
M86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R
M;W!E<G1Y7V%N9%]%<75I<&UE;G1?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?
M1&5T86EL<S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7U!A>6%B;&5?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D1E<FEV871I=F5S7T1E=&%I;',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$97)I=F%T:79E<U]$971A
M:6QS7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$
M97)I=F%T:79E<U]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N
M8VEE<U\Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT
M:6YG96YC:65S7S,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,S$N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y%<75I='E?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D5Q=6ET>5]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z
M17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R
M:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z
M06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z
M4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\
M+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM
M;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES
M('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!8
M4"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B
M8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T
M.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970P,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15%!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DYO=BX@,3(L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N
M=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@
M3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)T%C=&EN:75M
M(%!H87)M86-E=71I8V%L<RP@26YC+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X
M($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P,#$S.#@S
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,S$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M
M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES
M8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<R,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A
M=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4VUA;&QE
M<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H
M87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S+#8U-BPU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y
M7S1E8SA?835B8E\U,#%E,C9C,65B8S@O5V]R:W-H965T<R]3:&5E=#`R+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4%=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%5N875D:71E9"D@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0W5R<F5N="!!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I
M=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#DY
M,"PP-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#4L-C$X+#8V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@
M8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$V-RPQ-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PP-#,L,#8S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PW.#4L.#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970@;V8@86-C=6UU;&%T960@9&5P
M<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DQ
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#`T.2PY.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#<X."PX,C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0W5R<F5N="!,
M:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3(L,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DW
M+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<R`M
M(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,W-2PV.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,2PQ.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO=&4@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I
M=F4@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-S4W+#DV-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-3<T+#DU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E;G0@3&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#0U+#8U,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-C0S+#$X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-#0U+#8U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C0S+#$X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@
M86YD(&-O;G1I;F=E;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@)#`N,#`Q('!A<B!V
M86QU93L@,3`L,#`P+#`P,"!A=71H;W)I>F5D(#`@<VAA<F5S(&ES<W5E9"!A
M;F0@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL("0P
M+C`P,2!P87(@=F%L=64[(#$P,"PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D
M.R`R,RPV-38L-3@R(&%N9"`R,2PS.3$L-C8U('-H87)E<R!I<W-U960@86YD
M(&]U='-T86YD:6YG+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(S-BPU-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,3,L.3$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60@
M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L
M,#`U+#$W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4V+#8W-2PQ.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9FEC:70@86-C=6UU;&%T960@9'5R:6YG
M('1H92!D979E;&]P;65N="!S=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U-2PW-#,L-#8S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(%-T;V-K
M:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,#0L,S(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ-#4L-C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3&EA8FEL:71I97,@86YD(%-T
M;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0L,#0Y+#DX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2PW.#@L.#(R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B
M8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E
M=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139.04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5;F%U9&ET
M960I("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"86QA
M;F-E(%-H965T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K+"!S:&%R
M97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA
M<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M-C4V+#4X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Q+#,Y,2PV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@<VAA<F5S(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPV-38L
M-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$L,SDQ+#8V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`T-64Q-6,Y7S0R-#E?
M-&5C.%]A-6)B7S4P,64R-F,Q96)C."]7;W)K<VAE971S+U-H965T,#0N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$4Q4$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O
M;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%5N875D:71E9"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,38P($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1A
M=&5M96YT<R!/9B!/<&5R871I;VYS(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY/<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT+"!N970@;V8@<F5I;6)U<G-E;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W."PR,S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8W-RPS,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W
M,RPR,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#<R,RPT-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR."PW.3,L-S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES
M=')A=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,P+#<S
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<R,BPP,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#<S,"PR,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4R,"PR,C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPR,S4L,C`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I
M871I;VX@86YD(&%M;W)T:7IA=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L,C8R+#0V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34T+#,P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&]P97)A=&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PV,#@L.38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPS.3DL-#4P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ,#<L-34U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR-#0L,3`Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3DL.#0U+#8Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8P."PY-C(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS.3DL-#4P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,3`W
M+#4U-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T+#(T-"PQ,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3DL.#0U+#8Y-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W1H97(@:6YC
M;VUE("AE>'!E;G-E*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#(Y.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,3@L-C(S*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-3`X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DU,BPR
M-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PY-C<L,C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V%I;B!O;B!E>'1I;F=U:7-H;65N="!O9B!L:6%B
M:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92`M(&1E<FEV871I=F4@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X.2PS
M-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R.30L,S@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Q-BPQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R.#<L-C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDQ-2PT.3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE
M<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ.#@L,#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-C$S+#`P-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,3,L-C`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR,SDL.#0U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Y,2PW,3<I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,2PT,C`L.3$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,RPP,3(L-#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PX.3,L.34Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PT.#,L.34T
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!C;VUM;VX@<VAA<F4@+2!B
M87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,RXW-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V+C@T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@+2!B
M87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C,L-C`Q+#@Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@P,2PW.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,BPT,#$L-S$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`Q+#<Y.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q-6,Y7S0R
M-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B
M8S@O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0E!"1SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O
M9B!#87-H($9L;W=S("A5;F%U9&ET960I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ-C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!/<&5R871I;F<@06-T:79I=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PX
M.3,L.34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-2PT.#,L.34T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J
M=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('!R
M;W9I9&5D(&)Y("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(X-"PS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3(L-3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS,S8L-#`W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R
M96-I871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L,C8R+#0V,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!D:7-P;W-I
M=&EO;B!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U-"PS,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O
M9B!D96)T(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C<X+#$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O
M9B!D969E<G)E9"!F:6YA;F-I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3DL-S(U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDR+#8Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I
M;B!O;B!E>'1I;F=U:7-H;65N="!O9B!L:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,C8P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H86YG92!I;B!F86ER('9A;'5E(&1E<FEV871I=F4@;&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-BPQ
M,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C@W+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#DQ-2PT.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/BA);F-R96%S92D@9&5C<F5A
M<V4@:6XZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L,30S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L
M,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN8W)E87-E("AD96-R96%S92D@:6XZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4X-2PP-#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<S+#8Q-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8U,RPW
M,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,@
M+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-#0L-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-S4L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($-A<V@@57-E9"!);B!/<&5R
M871I;F<@06-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-"PY-#<L.38Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,L-SDU+#0X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T.2PS-3`L-C(W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G0@
M;6%D92!F;W(@<&%T96YT(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`P,"PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#`S,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Q,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X,C,L-C@Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!#87-H(%5S960@26X@26YV97-T:6YG($%C=&EV:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,#,P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#$R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L.#(S+#8X
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($9I;F%N8VEN9R!!8W1I=FET
M:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y";W)R;W=I;F=S(&]N(&-O;G9E<G1I8FQE(&1E8G0L(&YE="!O9B!O
M9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#4L.#@X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!O
M;B!N;W1E('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$T,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$T,"PP,#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE<R!O9B!#;VUM
M;VX@<W1O8VLL(&YE="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V,"PQ-C,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPQ.3$L
M,#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]C965D<R!F<F]M('1H92!E>&5R8VES92!O9B!W87)R86YT<R!F
M;W(@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT-C<L
M,SDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L-#8W+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%!R;W9I9&5D
M($)Y($9I;F%N8VEN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,R-RPS.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-C`L,38S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L,38T+#,W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C
M:&%N9V4@:6X@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PV,C@L-C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L,3,W+#$R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#DY,"PP-C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@8F5G:6YN
M:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PV,3@L-C8Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PW,#,L-SDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A="!E;F0@
M;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DY
M,"PP-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#4V-BPV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#DY,"PP-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L
M(&1I<V-L;W-U<F5S(&]F(&-A<V@@9FQO=R!I;F9O<FUA=&EO;CH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P
M86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C0S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R('1A>&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N
M=&%L(&1I<V-L;W-U<F4@;V8@;F]N+6-A<V@@:6YV97-T:6YG(&%N9"!F:6YA
M;F-I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA;"!C;VYV97)S:6]N(&9E871U
M<F4@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<R+#@U,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O
M9B!W87)R86YT<R!I<W-U960@=VET:"!D96)T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W-RPQ
M-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',@:7-S=65D('=I=&@@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,3@L,#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PY.#4L,C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S(&ES<W5E
M9"!T;R!T:&4@<&QA8V5M96YT(&%G96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34Y+#`T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3<P+#(X,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R<VEO;B!O9B!N;W1E<R!P87EA8FQE(&%N9"!A8V-R=65D(&EN=&5R97-T
M('1O('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDX,2PW,CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&9R;VT@
M9&5R:79A=&EV92!L:6%B:6QI='D@8VQA<W-I9FEC871I;VX@=&\@97%U:71Y
M(&-L87-S:69I8V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8P,"PX.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#@S,BPR,#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
M/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q-6,Y7S0R-#E?
M-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL
M93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@O
M5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC
M;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H
M=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*
M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E
M<V-R:7!T:6]N(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@
M;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/DYO=&4@,2`F(S@R,3$[($1E<V-R:7!T:6]N
M(&]F($)U<VEN97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD
M:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z
M(&)O;&0[)SY.871U<F4@;V8@0G5S:6YE<W,@)B,X,C$Q.SPO9F]N=#X@06-T
M:6YI=6T@4&AA<FUA8V5U=&EC86QS+"!);F,N(&9O<FUE<FQY(&MN;W=N(&%S
M($-A8W1U<R!696YT=7)E<RP@26YC+B`H=&AE("8C.#(R,#M#;VUP86YY)B,X
M,C(Q.RP@)B,X,C(P.T%C=&EN:75M)B,X,C(Q.RP@)B,X,C(P.T-A8W1U<R8C
M.#(R,3LI+"!W87,@:6YC;W)P;W)A=&5D('5N9&5R('1H92!L87=S(&]F('1H
M92!3=&%T92!O9B!.979A9&$@;VX@3V-T;V)E<B`V+"`Q.3DW+B!4:&4@0V]M
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M/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S
M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/D]N($1E8V5M8F5R(#(X+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M(&EN=&\@82!T<F%N<V%C=&EO;B`H=&AE("8C.#(R,#M3:&%R92!%>&-H86YG
M928C.#(R,3LI+"!P=7)S=6%N="!T;R!W:&EC:"!T:&4@0V]M<&%N>2!A8W%U
M:7)E9"`Q,#`E(&]F('1H92!I<W-U960@86YD(&]U='-T86YD:6YG(&5Q=6ET
M>2!S96-U<FET:65S(&]F($%C=&EN:75M(%!H87)M86-E=71I8V%L<RP@26YC
M+B`H)B,X,C(P.T%0228C.#(R,3LI+"!I;B!E>&-H86YG92!F;W(@=&AE(&ES
M<W5A;F-E(&]F(&%P<')O>&EM871E;'D@.3DE(&]F('1H92!I<W-U960@86YD
M(&]U='-T86YD:6YG(&-O;6UO;B!S=&]C:RP@<&%R('9A;'5E("0P+C`Q('!E
M<B!S:&%R92P@;V8@=&AE($-O;7!A;GDN(%1H92!3:&%R92!%>&-H86YG92!C
M;&]S960@;VX@1&5C96UB97(@,C@L(#(P,3(N)B,Q-C`[)B,Q-C`[07,@82!R
M97-U;'0@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@9F]R;65R('-H87)E
M:&]L9&5R<R!O9B!!4$D@8F5C86UE('1H92!C;VYT<F]L;&EN9R!S:&%R96AO
M;&1E<G,@;V8@=&AE($-O;7!A;GDN($%T('1H92!C;&]S:6YG+"!E86-H($%0
M22!S:&%R96AO;&1E<B!R96-E:79E9"`P+C,S,R!S:&%R97,@*'1H92`F(S@R
M,C`[17AC:&%N9V4@4F%T:6\F(S@R,C$[*2!O9B!!8W1I;FEU;2!C;VUM;VX@
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\
M+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SY!4$DL(&EN8V]R<&]R871E9"!O;B!*=6YE(#$S+"`R,#`P+"!I
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M04DI+"`H:&5R96EN869T97(@<F5F97)R960@=&\@8V]L;&5C=&EV96QY(&%S
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M($YE=R!$<G5G($%P<&QI8V%T:6]N+B!);B`R,#$R+"!!4$D@;&%U;F-H960@
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M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V
M,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY/;B!-87)C
M:"`R,"P@,C`Q,RP@:6X@86YT:6-I<&%T:6]N(&]F('1H92!#;VUP86YY(&-H
M86YG:6YG(&ET<R!N86UE('1O($%C=&EN:75M(%!H87)M86-E=71I8V%L<RP@
M26YC+B!A;F0@:71S(&1O;6EC:6QE(&9R;VT@3F5V861A('1O($1E;&%W87)E
M+"!T:&4@0V]M<&%N>28C.#(Q-SMS('-U8G-I9&EA<GDL($%C=&EN:75M(%!H
M87)M86-E=71I8V%L<RP@26YC+BP@8VAA;F=E9"!I=',@;F%M92!T;R!!8W1I
M;FEU;2!#;W)P;W)A=&EO;BXF(S$V,#LF(S$V,#M/;B!!<')I;"`Q,2P@,C`Q
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^3VX@4V5P=&5M8F5R(#(U+"`R,#$S+"!I;B!A8V-O
M<F1A;F-E('=I=&@@82!#97)T:69I8V%T92!O9B!/=VYE<G-H:7`@365R9VEN
M9R!!8W1I;FEU;2!#;W)P;W)A=&EO;B!I;G1O('1H92!!8W1I;FEU;2!0:&%R
M;6%C975T:6-A;',L($EN8RX@*&9I;&5D(&EN($1E;&%W87)E+"!T:&4@0V]M
M<&%N>2!M97)G960@*'1H92`F(S@R,C`[365R9V5R)B,X,C(Q.RD@:6YT;R!I
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M.R8C,38P.T$@=&]T86P@;V8@,RPY-S`L,3,W('-H87)E<R!O9B!!8W1I;FEU
M;2!#;W)P;W)A=&EO;B!C;VUM;VX@<W1O8VL@=V%S(&5X8VAA;F=E9"!F;W(@
M,2PS,C(L,#4U('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C:RX\+V9O
M;G0^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/&9O;G0@<W1Y;&4],T0G9&ES
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/D)A<VES(&]F(%!R97-E;G1A=&EO;B`M(%5N875D:71E9"!);G1E<FEM($9I
M;F%N8VEA;"!);F9O<FUA=&EO;B`F(S@R,3$[(#PO9F]N=#Y4:&4@86-C;VUP
M86YY:6YG('5N875D:71E9`T*(&EN=&5R:6T-"B!C;VYS;VQI9&%T960@9FEN
M86YC:6%L('-T871E;65N=',@86YD(')E;&%T960@;F]T97,@:&%V92!B965N
M('!R97!A<F5D(&EN(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG('!R:6YC
M:7!L97,@9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H92!5;FET960@4W1A=&5S
M(&]F($%M97)I8V$@*"8C.#(R,#M5+E,N($=!05`F(S@R,C$[*2!F;W(@:6YT
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M('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!A<R!F:6QE9"!W
M:71H('1H92!314,@36%R8V@@,CDL(#(P,3,N/"]F;VYT/CPO9&EV/CQD:78@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF
M(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^1&5V96QO<&UE;G0@4W1A9V4@0V]M<&%N
M>2`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!I<R!C;VYS:61E<F5D(&$@
M9&5V96QO<&UE;G0@<W1A9V4@8V]M<&%N>2!A;F0@:&%S(&AA9"!N;R!C;VUM
M97)C:6%L(')E=F5N=64@=&\@9&%T92X\+V9O;G0^/"]D:78^/&1I=B!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P
M.SPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4]
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[
M/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R`F(S@R,3$[/"]F
M;VYT/B!4:&4@0V]M<&%N>2!C;VYS:61E<G,@86QL(&AI9VAL>2!L:7%U:60@
M86-C;W5N=',@=VET:"!O<FEG:6YA;"!M871U<FET:65S(&]F('1H<F5E(&UO
M;G1H<R!O<B!L97-S('1O(&)E(&-A<V@@97%U:79A;&5N=',N(%-U8V@@8F%L
M86YC97,@87)E('5S=6%L;'D@:6X@97AC97-S(&]F($9$24,@:6YS=7)E9"!L
M:6UI=',N($%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@1&5C96UB97(@,S$L
M(#(P,3(L(&%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-A<V@@=V%S(&1E
M<&]S:71E9"!I;B!O;F4@8F%N:RX\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
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M/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S
M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^3&5V96P@,2!);G!U=',@)B,X,C$Q.R!5;F%D:G5S=&5D('%U
M;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A
M<W-E=',@;W(@;&EA8FEL:71I97,@=&AA="!T:&4@<F5P;W)T:6YG(&5N=&ET
M>2!H87,@=&AE(&%B:6QI='D@=&\@86-C97-S(&%T('1H92!M96%S=7)E;65N
M="!D871E+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`R
M($EN<'5T<R`F(S@R,3$[($EN<'5T<R!O=&AE<B!T:&%N('%U;W1E9"!P<FEC
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M86YS+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN
M<'5T<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2X@07,@<F5Q=6ER
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M>2!L979E;',N/"]F;VYT/CQB<B`O/B8C,38P.SPO9&EV/CQD:78@86QI9VX]
M,T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/DQE=F5L(#$\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#)P>"!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`R/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@
M,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.T%T(%-E<'1E
M;6)E<B`S,"P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
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M9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y
M)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(L-S4W+#DV
M-CPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[070@
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
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M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/B8C,38P.SPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY3:&%R92U"87-E
M9"!087EM96YT<R`F(S@R,3$[/"]F;VYT/B!4:&4@0V]M<&%N>2!E<W1I;6%T
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M/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S
M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M<V5N=&5D+B!"87-I8R!E87)N:6YG<R`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R
M92!I<R!C;VUP=71E9"!B>2!D:79I9&EN9R!T:&4@;F5T(&EN8V]M92`H;&]S
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M1F]R('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,L
M('!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E<R!I;F-L=61E9"!S=&]C:R!O
M<'1I;VYS('1O('!U<F-H87-E(#(L,C@P+#$X-"!S:&%R97,@86YD('=A<G)A
M;G1S('1O('!U<F-H87-E(#DL-#0Q+#DT,B!S:&%R97,@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VLN($9O<B!T:&4@;FEN92!M;VYT:',@
M96YD960@4V5P=&5M8F5R(#,P+"`R,#$R+"!P;W1E;G1I86QL>2!I<W-U86)L
M92!S:&%R97,@:6YC;'5D960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S928C
M,38P.S$L.38X+#@R.2!S:&%R97,[('=A<G)A;G1S(&EN('1H92!A;6]U;G0@
M;V8@-2PX-C$L,#0T('-H87)E<SL@8V]N=F5R=&EB;&4@;F]T97,@<&%Y86)L
M92!I;B!T:&4@86UO=6YT(&]F(#$L,34R+#8Y,B!S:&%R97,[(&%N9"!C;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VL@:6X@=&AE(&%M;W5N="!O9B`Q,RPX
M,S$L-S8R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!H879E(&)E96X@97AC;'5D960@9G)O;2!T:&4@8V%L8W5L871I;VXN
M/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V
M,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^4W5B<V5Q=65N="!%=F5N=',@)B,X,C$Q.SPO
M9F]N=#X@5&AE($-O;7!A;GDF(S@R,3<[<R!M86YA9V5M96YT(')E=FEE=V5D
M(&%L;"!M871E<FEA;"!E=F5N=',@=&AR;W5G:"!T:&4@9&%T92!T:&4@8V]N
M<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E<F4@:7-S=65D(&9O
M<B!S=6)S97%U96YT(&5V96YT(&1I<V-L;W-U<F4@8V]N<VED97)A=&EO;BX\
M+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T
M96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970P-RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D=O:6YG($-O
M;F-E<FX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY';VEN9R!#;VYC97)N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O:6YG($-O;F-E<FX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$
M:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
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M>2!H87,@82!N970@;&]S<R!O9B`D-"PX.3,L.34Q(&%N9"!N970@8V%S:"!U
M<V5D(&EN(&]P97)A=&EO;G,@;V8@)#0L.30W+#DV.2P@9F]R('1H92!N:6YE
M(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3,[(&%N9"!A(&1E9FEC
M:70@86-C=6UU;&%T960@9'5R:6YG('1H92!D979E;&]P;65N="!S=&%G92!O
M9B`D-C`L-C,W+#0Q-"!A="!397!T96UB97(@,S`L(#(P,3,N($EN(&%D9&ET
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M)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S
M-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?-#(T
M.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C
M."]7;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O
M<&5R='D@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A
M;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^3F]T92`S("8C.#(Q,3L@4')O<&5R='D@86YD($5Q
M=6EP;65N=#PO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4')O<&5R
M='D@86YD(&5Q=6EP;65N="!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R!A
M="!397!T96UB97(@,S`L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R.CPO
M9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$
M<FEG:'0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-C<E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.TQI=F5S/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(P,3,\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$P)2!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]F9FEC92!E<75I<&UE
M;G0\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.S4@>65A<G,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI
M9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-C(L,S@T/"]F;VYT/CPO=&0^/'1D
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX]
M,T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-38L,38R/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O
M;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8W)2!V86QI
M9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M="US:7IE.B`Q,'!T.R<^,RPQ,#`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`-"B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXQ+#(Y,CPO9F]N=#X\+W1D/CQT9"!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8W)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,38U+#0X-#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DQE
M<W,Z(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;CPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M.B`Q,'!T.R<^*3PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
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M:7IE.B`Q,'!T.R<^*#$U-"PT-#0@/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M3&]S<R!O;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
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M#0H@9F]N="US:7IE.B`Q,'!T.R<^*#0L,3(R/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXI/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0<F]P
M97)T>2!A;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M1&5P<F5C:6%T:6]N(&5X<&5N<V4@9F]R('1H928C,38P.VYI;F4@;6]N=&AS
M(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@,C`Q,B!W97)E("0P+"8C
M,38P.V%N9"`D-#(Y(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T
M,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E
M8F,X+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@4&%Y86)L93QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&4@4&%Y86)L
M92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.;W1E(%!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q
M,RXV,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R
M9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&1I
M<W!L87DZ(&EN;&EN93LG/DYO=&4@-"`F(S@R,3$[($YO=&4@4&%Y86)L93PO
M9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT.B`Q
M,RXV,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)SL@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!T.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R
M9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L87DZ(&)L
M;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V
M,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S+C8S<'@O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S
M-G!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM<FEG:'0Z(#!P
M=#L@;6%R9VEN+6QE9G0Z(#!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&1I<W!L
M87DZ(&)L;V-K.R!W:&ET92US<&%C93H@;F]R;6%L.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^3VX@1&5C96UB97(@,C@L(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A('!R96UI=6T@9FEN86YC92!A9W)E96UE;G0@=&\@<&%Y(&$@)#$T
M,"PP,#`@<')E;6EU;2!F;W(@:71S(&1I<F5C=&]R(&%N9"!O9F9I8V5R(&QI
M86)I;&ET>2!I;G-U<F%N8V4@<&]L:6-Y+B!0=7)S=6%N="!T;R!T:&4@86=R
M965M96YT+"!T:&4@0V]M<&%N>2!P86ED(&$@9&]W;B!P87EM96YT(&]F("0R
M."PP,#`@:6X@2F%N=6%R>2`R,#$S(&%N9"8C,38P.VES(')E<75I<F5D)B,Q
M-C`[=&\@<&%Y("0Q,BPV,S8@:6X@;6]N=&AL>2!I;G-T86QL;65N="!F;W(@
M;FEN92!M;VYT:',N($%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RP@=&AE(&]U
M='-T86YD:6YG(&)A;&%N8V4@<F5L871E9"!T;R!T:&4@<')E;6EU;2!F:6YA
M;F-E(&%G<F5E;65N="!W87,@)#`N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?-#(T.5\T
M96,X7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C."]7
M;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$97)I=F%T:79E<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F5S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E<FEV871I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^3F]T92`U("8C.#(Q,3L@1&5R:79A=&EV
M97,\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE($-O
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M=&AE(&9A:7(@=F%L=64@;V8@82`F(S@R,C`[9FEX960M9F]R+69I>&5D)B,X
M,C(Q.R!O<'1I;VX@87,@9&5F:6YE9"!U;F1E<B!&05-"($%30R!4;W!I8R!.
M;RX@.#$U("8C.#(Q,3L@-#`N(%1H92!W87)R86YT<R!G<F%N=&5D(&EN(&-O
M;FYE8W1I;VX@=VET:"!T:&4@:7-S=6%N8V4@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!3=&]C:R!/9F9E<FEN9R!A;F0@,C`Q,B!#;VUM;VX@4W1O8VL@3V9F
M97)I;F<L('1H92!#;VYV97)T:6)L92!.;W1E<R`H<')E=FEO=7-L>2!I<W-U
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M>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.T%C
M=&EV:71I97,@9F]R(&1E<FEV871I=F4@=V%R<F%N="!I;G-T<G5M96YT<R!D
M=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M,R!W97)E(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P
M.SPO9&EV/CQD:78@86QI9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY"86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M)SXS+#4W-"PY-3@\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXH-C`P+#@X,"`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
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M;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=VED=&@]
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXH,C$V+#$Q,B`\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M"B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C
M8V-E969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D)A;&%N8V4L
M(%-E<'1E;6)E<B`S,"P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG
M;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
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M.B`Q,'!T.R<^5&AE(&9A:7(@=F%L=65S(&]F('1H92!D97)I=F%T:79E('=A
M<G)A;G1S('=E<F4@8V%L8W5L871E9"!U<VEN9R!A(&UO9&EF:65D(&)I;F]M
M:6%L('9A;'5A=&EO;B!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP
M=&EO;G,@870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q,BX\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M86QI9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.@T*(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DUA<FME="!V86QU92!O
M9B!C;VUM;VX@<W1O8VL@;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+V9O;G0^
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M.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,2XQ-SPO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
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M,3!P=#LG/C$N-C4\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-S8E('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
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M,3!P=#LG/C`N-#@@+2`D,"XX,3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
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M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C$N-3`@
M+2`D,BXT-S4\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4FES:R!F
M<F5E(&EN=&5R97-T(')A=&4@*#(I/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M="US:7IE.B`Q,'!T.R<^,"XQ,"4@+2`P+C<W/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,"XS,SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N
M=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M;VYT:',O-2!Y96%R
M<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXP(&1A>7,O-"XR,B!Y96%R<SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^17AP96-T960@=F]L871I;&ET>2`H,RD\+V9O;G0^
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M86UI;'DZ('1I;65S#0H@;F5W.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ
M,SD\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>'!E8W1E9"!D:79I9&5N9"!Y
M:65L9"`H-"D\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O
M;G0M<VEZ93H@,3!P=#LG/E!R;V)A8FEL:71Y(&]F('-T;V-K(&]F9F5R:6YG
M(&EN(&%N>2!P97)I;V0@;W9E<B`U('EE87)S("@U*3PO9F]N=#X\+V1I=CX\
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,C4E("T@-#`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B4\
M+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[
M/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0^/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$I
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.38E('9A;&EG;CTS1'1O
M<#X\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
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M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\=&0@=VED=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^
M/'1R/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH
M,BD\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y-B4@=F%L:6=N/3-$
M=&]P/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^5&AE(')I<VLM9G)E92!I;G1E<F5S="!R871E('=A<R!D971E<FUI
M;F5D(&)Y(&UA;F%G96UE;G0@=7-I;F<@=&AE(%1R96%S=7)Y($)I;&P@87,@
M;V8@=&AE(')E<W!E8W1I=F4@;65A<W5R96UE;G0@9&%T92X\+V9O;G0^/"]D
M:78^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$.38E('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-"4@=F%L:6=N
M/3-$=&]P/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#,I/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.38E('9A
M;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M:78^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L@/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$.38E('9A;&EG;CTS1'1O<#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T
M9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L969T('=I9'1H/3-$-"4@=F%L:6=N
M/3-$=&]P/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^*#0I/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.38E('9A
M;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SY-86YA9V5M96YT(&1E=&5R;6EN960@
M=&AE(&1I=FED96YD('EI96QD('1O(&)E(#`E(&)A<V5D('5P;VX@:71S#0H@
M97AP96-T871I;VX@=&AA="!I="!W:6QL(&YO="!P87D@9&EV:61E;F1S(&9O
M<B!T:&4@9F]R97-E96%B;&4@9G5T=7)E+CPO9&EV/CPO=&0^/"]T<CX\='(^
M/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#DV)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L-"B`\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#4I/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$.38E('9A;&EG;CTS1'1O<#X\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/DUA
M;F%G96UE;G0@:&%S(&1E=&5R;6EN960@=&AA="!T:&4@<')O8F%B:6QI='D@
M;V8@82!S=&]C:R!O9F9E<FEN9R!I<R`R-24@+2`T,"4@9F]R(&5A8V@@<75A
M<G1E<B!O9B!T:&4@;F5X="!F:79E('EE87)S+CPO9F]N=#X\+V1I=CX\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q-6,Y
M7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C
M,65B8S@O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G9F]N=#H@,3,N-C-P
M>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&QE9G0[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!B86-K9W)O=6YD+6-O
M;&]R.B`C9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&1I<W!L87DZ(&EN;&EN93LG/DYO=&4@-B`F(S@R,3$[($-O;6UI=&UE
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M8F5R(#$V+"`R,#$S+"!T:&4@0V]M<&%N>28C.#(Q-SMS($)O87)D(&]F($1I
M<F5C=&]R<R!A<'!O:6YT960@1'(N($MA=7-H:6L@2BX@1&%V92!A<R!I=',@
M;F5W($-H:65F($5X96-U=&EV92!/9F9I8V5R("A#14\I)B,Q-C`[86YD($1I
M<F5C=&]R+B!-871E<FEA;"!T97)M<R!O9B!T:&4@16UP;&]Y;65N="!!9W)E
M96UE;G0@87)E(&%S(&9O;&QO=W,Z/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\
M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&1I=CX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
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M('-A;&%R>2!A="!A;B!A;FYU86P@<F%T92!O9B`D,S4P+#`P,"P@=VAI8V@@
M=VEL;"!B92!R92UE=F%L=6%T960@=7!O;B!T:&4F(S$V,#MS:7@@;6]N=&@@
M86YN:79E<G-A<GD@;V8@=&AE('-T87)T(&1A=&4@86YD(')E:6UB=7)S96UE
M;G0@;V8@8V5R=&%I;B!E>'!E;G-E<RX\+V9O;G0^/"]D:78^/"]T9#X\+W1R
M/CQT<CX\=&0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#(E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@
M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$-"4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0V."4@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1L
M969T('=I9'1H/3-$,R4@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE
M.R<^8CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS1#<T)2!V86QI9VX]
M,T1T;W`@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&1I=B!S='EL93TS1"=T
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M=&AE($)O87)D('=I=&@@82!T87)G970@;V8@9F]R='D@<&5R8V5N="`H-#`E
M*2!O9B!T:&4@8F%S92!S86QA<GD\+V9O;G0^+CPO9F]N=#X\+V1I=CX\+V1I
M=CX\+W1D/CPO='(^/'1R/CQT9"!W:61T:#TS1#,E('9A;&EG;CTS1'1O<#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$,B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W
M:61T:#TS1#8X)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0S)2!V86QI9VX],T1T;W`^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M<W1R:6-T960@<W1O8VL@*'1H92`F(S@R,C`[1W)A;G0F(S@R,C$[*2XF(S$V
M,#LF(S$V,#M4:&4@1W)A;G0@=VEL;"!C;VYS:7-T(&]F("AI*2!A;B!O<'1I
M;VX@9W)A;G0@=&\@<'5R8VAA<V4@-C<U+#`P,"!C;VUM;VX@<VAA<F5S(&]F
M('1H92!#;VUP86YY.R`H:6DI(#$R-2PP,#`@<VAA<F5S(&]F(')E<W1R:6-T
M960@86YD("AI:6DI(#$P,"PP,#`@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O
M8VL@82!S:6=N+6]N(&)O;G5S(&]F('=H:6-H(&9I9G1Y('!E<F-E;G0@=VEL
M;"!V97-T(&%T('1H92!O;F4@>65A<B!A;FYI=F5R<V%R>2!O9B!T:&4@<W1A
M<G0@9&%T92!U<&]N('-T87)T:6YG('=O<FLN)B,Q-C`[)B,Q-C`[06X@861D
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M+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQD:78@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9&EV/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^
M3&EC96YS92!A;F0@4F5S96%R8V@@06=R965M96YT<SPO9F]N=#X\+V1I=CX\
M+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I
M9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/E1H92!#;VUP86YY(&AA
M<R!E;G1E<F5D(&EN=&\@;&EC96YS92!A;F0@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%G<F5E;65N=',@=VET:"!T:&ER9"!P87)T:65S('5N9&5R('=H
M:6-H('1H92!#;VUP86YY(&ES(&]B;&EG871E9"!T;R!M86ME('!A>6UE;G1S
M(&EN('1H92!F;W)M(&]F('5P9G)O;G0@<&%Y;65N=',@87,@=V5L;"!A<R!M
M:6QE<W1O;F4@86YD(')O>6%L='D@<&%Y;65N=',N($YO=&%B;&4@:6YC;'5S
M:6]N<R!I;B!T:&ES(&-A=&5G;W)Y(&%R93H\+V9O;G0^/"]D:78^/&1I=B!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C
M,38P.SPO9&EV/CQD:78@86QI9VX],T1L969T/CQT86)L92!S='EL93TS1"=W
M:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<CX\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#<E('9A;&EG;CTS
M1'1O<#X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/F$N)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D('=I9'1H/3-$.3,E('9A;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$:G5S
M=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L-"B!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL-
M"B!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D%B8F]T="!"
M:6]T:&5R87!E=71I8W,@0V]R<"`F(S@R,3$[(%1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(%!R;V1U8W0@1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E
M;G-E($%G<F5E;65N="!W:71H($%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R
M<"X@*&9O<FUE<FQY($9A8V5T($)I;W1E8V@@9F]R;65R;'D@:VYO=VX@87,@
M4')O=&5I;B!$97-I9VX@3&%B<RD@:6X@,C`P,R!T;R!S96-U<F4@97AC;'5S
M:79E(')I9VAT<R!T;R!A('-P96-I9FEC(&%N=&EB;V1Y('=H96X@8V]N:G5G
M871E9"!W:71H(&%L<&AA(&5M:71T:6YG(')A9&EO:7-O=&]P97,N(%5P;VX@
M97AE8W5T:6]N(&]F('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY(&UA9&4@
M82!L:6-E;G-E(&9E92!P87EM96YT(&]F("0S+#`P,"PP,#`N/"]F;VYT/CPO
M9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD:78@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/E1H92!#;VUP86YY(&%G<F5E9"!T;R!M86ME(&UI;&5S=&]N92!P87EM
M96YT<R!T;W1A;&EN9R`D-RPW-3`L,#`P(&9O<B!T:&4@86-H:65V96UE;G0@
M;V8@=&AE(&9O;&QO=VEN9R!A9W)E960@=&\@86YD(&-O;G1R86-T960@;6EL
M97-T;VYE<SH\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SY-:6QE<W1O;F5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T;VTM
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M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L
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M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^
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M9&ES<&QA>3H@:6YL:6YE.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E
M969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXH,RD@=VAE;B!#;VUP86YY(&EN:71I871E<R!A(%!H87-E($E)22!#
M;&EN:6-A;"!4<FEA;"!O9B!A(&QI8V5N<V5D('!R;V1U8W0\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
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M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
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M<&QA>3H-"B!I;FQI;F4[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#<U
M,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
M:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXQ+#4P,"PP,#`\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\+W1R
M/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#@X)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[(&1I<W!L87DZ(&EN;&EN93LG/B@V*2!A9G1E<B!T:&4@9FER<W0@)#$P
M+#`P,"PP,#`@:6X@;F5T('-A;&5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L
M:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$
M,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM
M;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/C$L-3`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/E5N9&5R('1H92!A9W)E96UE;G0L('1H92!#;VUP86YY('-H86QL('!A>2!T
M;R!!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@;VX@82!C;W5N=')Y+6)Y
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M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M9&EV/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M82!M:6QE<W1O;F4@<&%Y;65N="!O9B`D-S4P+#`P,"!O;B!*=6QY(#(T+"`R
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M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0W
M)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SYB+B8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!W:61T:#TS1#DS)2!V86QI9VX],T1T;W`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3LG/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I
M>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/DUE;6]R:6%L(%-L;V%N($ME
M='1E<FEN9R!#86YC97(@0V5N=&5R("A-4TM#0RD@)B,X,C$Q.R!);B!&96)R
M=6%R>2`R,#`R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!L:6-E;G-E
M(&%G<F5E;65N="!W:71H($U32T-#('1H870@<F5Q=6ER97,@82!T96-H;F]L
M;V=Y(&%C8V5S<R!F964@;V8@)#4P+#`P,"!U<&]N(&5X96-U=&EO;BP@86X@
M86YN=6%L(&UA:6YT96YA;F-E(&9E92!O9B`D-3`L,#`P(&%N9"!A;FYU86P@
M<F5S96%R8V@@9G5N9&EN9R!O9B`D-3`L,#`P(&9O<B!A<R!L;VYG(&%S('1H
M92!A9W)E96UE;G0@:7,@:6X@9F]R8V4N/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\+W1A8FQE/CPO9&EV/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.@T*(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/E!A>6UE;G1S/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
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M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T
M<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^,2D@9FEL:6YG(&]F(&%N($YE=R!$<G5G($%P<&QI8V%T:6]N
M("@F(S@R,C`[3D1!)B,X,C(Q.RD@;W(@<F5G=6QA=&]R>2!A<'!R;W9A;"8C
M,38P.SPO9F]N=#YF;W(@96%C:"!L:6-E;G-E9"!P<F]D=6-T/"]F;VYT/CPO
M9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXW-3`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^*#(I('5P;VX@=&AE(')E8V5I<'0@;V8@<F5G=6QA=&]R>2!A<'!R;W9A
M;"!F<F]M('1H92!5+E,N($9$02!F;W(@96%C:"8C,38P.SPO9F]N=#YL:6-E
M;G-E9"!P<F]D=6-T/"]F;VYT/CPO9&EV/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/C$L
M-S4P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED
M=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z
M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M;"!T:&4@;&%T97(@;V8Z("@Q*2`Q,"!Y96%R<R!F<F]M('1H92!F:7)S="!C
M;VUM97)C:6%L('-A;&4L(&]R("@R*2!W:&5N('1H92!P871E;G1S(&5X<&ER
M92X\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY4:&4@0V]M<&%N>2!E
M>'!E8W1S('1O(&9I;&4@=&AE($Y$02!F;W(@<F5G=6QA=&]R>2!A<'!R;W9A
M;"!I;B!T:&4@,C`Q-BTR,#$W('1I;64@9G)A;64N/"]F;VYT/CPO9&EV/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.PT*(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQD:78@86QI9VX],T1L969T/CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1R:6=H="!W:61T
M:#TS1#<E('9A;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[#0H@;6%R
M9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^8RXF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y,R4@=F%L:6=N/3-$=&]P/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/
M86L@4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2`H3U).3"D@)B,X,C$Q.R!!
M4$D@:7,@8V]N=')A8W1E9"!T;R!P=7)C:&%S92`D,C,S+#$P,"!O9B!R861I
M;V%C=&EV92!M871E<FEA;"!T;R!B92!U<V5D(&9O<B!R97-E87)C:"!A;F0@
M9&5V96QO<&UE;G0L('=I=&@@82!R96YE=V%L(&]P=&EO;B!A="!T:&4@8V]N
M=')A8W0@96YD+B8C,38P.R8C,38P.U1H92!#;VUP86YY(&ES(&-U<G)E;G1L
M>2!N96=O=&EA=&EN9R!T:&4@,C`Q,R!A9W)E96UE;G0N/"]F;VYT/CPO9&EV
M/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$-R4@=F%L:6=N/3-$=&]P/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@=VED=&@],T0Y,R4@=F%L:6=N/3-$=&]P/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/CQT<CX\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#<E('9A;&EG
M;CTS1'1O<#X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/F0N)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M<W1U9'D@;V8@=&AE(&1R=6<@06,M,C(U+4AU33$Y-2`H06-T:6UA8BU!*2!U
M<V5D(&EN('1H92!#;VUP86YY(&-L:6YI8V%L('1R:6%L<RP@4&AA<V4@22!A
M;F0@4&AA<V4@24DN)B,Q-C`[)B,Q-C`[5&AE('1O=&%L('!R;VIE8W0@:7,@
M97-T:6UA=&5D('1O(&-O<W0@87!P<F]X:6UA=&5L>2`D,2XY(&UI;&QI;VX@
M86YD(')E<75I<F5S(&$@,3(N-24@9&]W;B!P87EM96YT(&]F('1H92!T;W1A
M;"!E<W1I;6%T960@<')O:F5C="!C;W-T+B8C,38P.R8C,38P.U1H92!D;W=N
M('!A>6UE;G0@=&]T86QI;F<@)#(S.2PP,#`@=V%S('!A:60@:6X@,C`P-R!A
M;F0@,C`Q,BXF(S$V,#LF(S$V,#M/;B!!=6=U<W0@-BP@,C`Q,BP@3V-T;V)E
M<B`R,BP@,C`Q,B!A;F0@36%Y(#$V+"`R,#$S+"!T:&4@86=R965M96YT('=A
M<R!A;65N9&5D('1O('!R;W9I9&4@9F]R(&%D9&ET:6]N86P@<V5R=FEC97,N
M)B,Q-C`[)B,Q-C`[5&AE('1O=&%L('!R;VIE8W0@:7,@;F]W(&5S=&EM871E
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M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DS)2!V86QI9VX],T1T;W`^
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M9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[92XF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y,R4@=F%L:6=N/3-$=&]P/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/
M;B!*=6YE(#$U+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!L
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M;F=E(&9R;VT@)#$S+C(@;6EL;&EO;B!T;R`D,C,N-2!M:6QL:6]N+"!D97!E
M;F1I;F<@;VX@=&AE('1R:6%L(&1E<VEG;B!A<R!R97%U:7)E9"!B>2!T:&4@
M1D1!+B8C,38P.R8C,38P.U5N9&5R('1H92!T97)M<R!O9B!T:&4@<W!O;G-O
M<F5D(')E<V5A<F-H(&%G<F5E;65N="P@=&AE($-O;7!A;GD@=VEL;"!F=6YD
M('1H92!&2$-20R!L86(@=VET:"`D,34P+#`P,"!P97(@>65A<B!F;W(@=&AE
M(&9I<G-T('1W;R!Y96%R<R!A;F0@)#(U,"PP,#`@=&AE<F5A9G1E<BXF(S$V
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M86QT>2!P87EM96YT<R!O9B`R)2!O9B!N970@<V%L97,@=VEL;"!B92!D=64@
M=&\@1DA#4D,N/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H
M/3-$-R4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y,R4@
M=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#<E('9A;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/F8N)B,Q-C`[)B,Q-C`[
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M(S$V,#LF(S$V,#M4:&4@86UO=6YT(&1U92!O9B`D-SDL-C(S('=A<R!P86ED
M(&]N($IU;'D@,3`L(#(P,3(N/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\+W1A
M8FQE/CPO9&EV/CPO9&EV/CPO9&EV/CQD:78@<W1Y;&4],T0G9F]N=#H@,3,N
M-C-P>"]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<[('1E>'0M86QI9VXZ(&QE
M9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!B86-K9W)O=6YD
M+6-O;&]R.B`C9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S+C8S<'@O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!L969T.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&1I=B!A;&EG;CTS1&QE9G0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT
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M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SY/;B!*=6QY(#$Y+"`R,#$R+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE;G0@=VET
M:"!&2$-20RXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!W:6QL('!A>2`D,S$L
M,S8V(&9O<B!E86-H('!A=&EE;G0@=&AA="!H87,@8V]M<&QE=&5D('1H92!C
M;&EN:6-A;"!T<FEA;"X@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N
M="P@=&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M=7`-
M"B!F964@;V8@)#$Y+#<T.2XF(S$V,#LF(S$V,#M$=7)I;F<@=&AE(&-L:6YI
M8V%L('1R:6%L(&%D9&ET:6]N86P@9F5E<R!A<'!L>2!A;F0@=VEL;"!B92!I
M;G9O:6-E9"!W:&5N(&%P<&QI8V%B;&4N)B,Q-C`[)B,Q-C`[5&AE(&%M;W5N
M="!D=64@:&%S(&YO="!B965N(&EN=F]I8V5D(&)U="!A8V-R=65D(&)Y('1H
M92!#;VUP86YY(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,RX\+V9O;G0^/"]D
M:78^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0W)2!V86QI9VX],T1T;W`^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DS)0T*('9A;&EG;CTS1'1O<#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0W)2!V
M86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@
M,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SYH+B8C,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!W:61T:#TS1#DS)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU
M<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/D]N($%U9W5S="`R
M."P@,C`Q,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8VQI;FEC86P@
M=')I86P@86=R965M96YT('=I=&@@5&AE(%5N:79E<G-I='D@;V8@5&5X87,@
M32Y$+B!!;F1E<G-O;B!#86YC97(@0V5N=&5R+B8C,38P.R8C,38P.U1H92!T
M;W1A;"!E<W1I;6%T960@8V]S="!O9B!C;VYD=6-T:6YG('1H92!C;&EN:6-A
M;"!T<FEA;"!I<R!A<'!R;WAI;6%T96QY("0U,#`L,#`P+"!W:&EC:"!I;F-L
M=61E<R!A(&YO;BT@<F5F=6YD86)L92!I;G-T:71U=&EO;F%L(&9E92!O9B`D
M,30L-3`P+B8C,38P.R8C,38P.U1H92!E<W1I;6%T960@8V]S="!I<R!B87-E
M9"!O;B!T<F5A=&EN9R`R-"!P871I96YT<R!T:')O=6=H(#(P,3,N)B,Q-C`[
M)B,Q-C`[57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@=&AE($-O
M;7!A;GD@:7,@<F5Q=6ER960@=&\@;6%K92!A('!A>6UE;G0@;V8@)#,S+#DT
M-BX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<CX\=&0@=VED=&@],T0W)2!V
M86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DS)2!V86QI9VX]
M,T1T;W`^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY/
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M=R!$<G5G($5X96UP=&EO;B`H24Y$(#$P.#`W*2!H96QD(&)Y('1H92!#;VUP
M86YY+B8C,38P.R8C,38P.U1H92!#;VUP86YY('=I;&P@<&%Y("0S."PU,#$@
M<&5R('!A=&EE;G0L('=H;R!H87,@8V]M<&QE=&5D('1H92!C;&EN:6-A;"!T
M<FEA;"X@5&AE($-O;7!A;GD@:7,@<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M
M=7`@9F5E(&]F("0R,BPX-#<L(&%N(&%N;G5A;"!P:&%R;6%C>2!F964@;V8@
M)#(L,#(U(&%N9"!A;B!A;65N9&UE;G0@<')O8V5S<VEN9R!F964@;V8@)#4P
M,"P@=VAE;B!A<'!L:6-A8FQE+CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R
M/CQT9"!W:61T:#TS1#<E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.3,E('9A;&EG;CTS1'1O<#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D
M(&%L:6=N/3-$<FEG:'0@=VED=&@],T0W)2!V86QI9VX],T1T;W`^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SYJ+B8C
M,38P.R8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS1#DS)2!V
M86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/D]N($YO=F5M8F5R(#(Q+"`R,#$R+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@82!C;&EN:6-A;"!T<FEA;"!A9W)E96UE;G0@
M=VET:"!T:&4@56YI=F5R<VET>2!O9B!096YN<WEL=F%N:6$N)B,Q-C`[)B,Q
M-C`[5&AE(%!H87-E($DO24D@8VQI;FEC86P@=')I86P@=VEL;"!B92!C;VYD
M=6-T960@=VET:"!!8W1I;FEU;2`R,C4N)B,Q-C`[)B,Q-C`[5&AE(&-L:6YI
M8V%L('1R:6%L('=I;&P@8F4@8V]N9'5C=&5D('5N9&5R('1H92!P<F]T;V-O
M;',@97-T86)L:7-H960@8GD@=&AE($-O;7!A;GD@86YD('!U<G-U86YT('1O
M(&%N($EN=F5S=&EG871I;VYA;"!.97<@1')U9R!%>&5M<'1I;VX@*$E.1"`Q
M,#@P-RD@:&5L9"!B>2!T:&4@0V]M<&%N>2XF(S$V,#LF(S$V,#M4:&4@0V]M
M<&%N>2!W:6QL('!A>2`D,S$L-S<Q('!E<B!P871I96YT+"!W:&\@:&%S(&-O
M;7!L971E9"!T:&4@8VQI;FEC86P@=')I86PN(%1H92!#;VUP86YY('=I;&P@
M8F4@<F5Q=6ER960@=&\@<&%Y(&$@<W1A<G0M=7`@9F5E(&]F("0Q-BPP,#`@
M86YD(&%D9&ET:6]N86P@861M:6YI<W1R871I=F4@9F5E<RP@=VAE;B!A<'!L
M:6-A8FQE+CPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\
M+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0Z(#$S+C8S<'@O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG.R!T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
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M<F]M86XG.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S-G!T.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^3VX@075G=7-T(#$L(#(P,3(L('1H92!#;VUP86YY
M(&5N=&5R960@:6YT;R!A(')E;G1A;"!A9W)E96UE;G0@9F]R(&]F9FEC92!S
M<&%C92!A="`U,#$@1FEF=&@@079E;G5E+"8C,38P.TYE=R!9;W)K+"!.62X@
M5&AE(&%G<F5E;65N="!T97)M:6YA=&5D(&]N($UA>2`S,2P@,C`Q,RX@3VX@
M2G5N92`Q+"`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!R96YT
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M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#,V<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V9F9F9F9CL@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]D:78^/&1I=B!S='EL93TS1"=F;VYT.B`Q,RXV,W!X+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)SL@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,S9P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!B86-K9W)O=6YD+6-O;&]R
M.B`C9F9F9F9F.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`S-G!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^3VXF(S$V,#M&96)R=6%R>2`R."P@,C`Q,RP@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@4V5P87)A=&EO;B!A;F0@4V5T=&QE;65N="!!
M9W)E96UE;G0@=VET:"!I=',@9F]R;65R($-%3RX@4'5R<W5A;G0@=&\@=&AE
M(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<&%I9"!T:&4@9F]R;65R($-%3R`D
M,3(U+#`P,"!O;B!-87)C:"`X+"`R,#$S(&%N9"!A('-E8V]N9"!P87EM96YT
M(&]F("0Q,C4L,#`P(&]N(%-E<'1E;6)E<B`Q+"`R,#$S+B!4:&4@0V]M<&%N
M>2!A;'-O('!A:60@=&AE(&9O<FUE<B!#14\@82!P97)F;W)M86YC92!B;VYU
M<R!O9B`D-C`L,#`P(&9O<B!H:7,@<V5R=FEC92!F<F]M($%U9W5S="`Q-2P@
M,C`Q,B!T;R!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^+CPO9F]N=#X\+V1I=CX\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q
M-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E
M,C9C,65B8S@O5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^17%U:71Y/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^17%U:71Y(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
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M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)SY.;W1E(#<@)B,X,C$Q.R!%<75I='D\+V9O;G0^/"]D:78^/&1I=B!A
M;&EG;CTS1')I9VAT('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
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M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R.30W.3DX<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W
M:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN
M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-F9F9F9F8[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^5&AE($)O87)D(&%P<')O=F5D('1H92!#;VUP86YY)B,X,C$W
M.W,@,C`Q,R!3=&]C:R!0;&%N+B8C,38P.R8C,38P.U1H92!E>'!I<F%T:6]N
M(&1A=&4@;V8@=&AE('!L86X@:7,@4V5P=&5M8F5R)B,Q-C`[)B,Q-C`[.2P@
M,C`R,R8C,38P.R8C,38P.V%N9"!T:&4@=&]T86P@;G5M8F5R(&]F('5N9&5R
M;'EI;F<@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T
M;V-K(&%V86EL86)L92!F;W(@9W)A;G0@=&\@96UP;&]Y965S+"!D:7)E8W1O
M<G,@86YD(&-O;G-U;'1A;G1S(&]F('1H92!#;VUP86YY('5N9&5R('1H92!P
M;&%N(&ES(#(L-S4P+#`P,"!S:&%R97,N/"]F;VYT/CPO9&EV/CQD:78@86QI
M9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V
M,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^5&AE($)O87)D(&%P<')O=F5D('1H92!#
M;VUP86YY)B,X,C$W.W,@,C`Q,R!%<75I='D@26YC96YT:79E(%!L86XN(%1H
M92!E>'!I<F%T:6]N(&1A=&4@;V8@=&AE('!L86X@:7,@4V5P=&5M8F5R)B,Q
M-C`[)B,Q-C`[.2P@,C`R,R8C,38P.R8C,38P.V%N9"!T:&4@=&]T86P@;G5M
M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S
M=&]C:R!A=F%I;&%B;&4@9F]R(&=R86YT('1O(&5M<&QO>65E<RP@9&ER96-T
M;W)S(&%N9"!C;VYS=6QT86YT<R!O9B!T:&4@0V]M<&%N>2!U;F1E<B!T:&4@
M<&QA;B!I<R`T-3`L,#`P('-H87)E<RX\+V9O;G0^/"]D:78^/"]D:78^/&1I
M=B!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R.30W.3DX<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/&1I=B!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R.30W.3DX<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)SY/<'1I;VYS/"]F;VYT/CPO9&EV/CQD:78@86QI9VX],T1L
M969T('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V9F9F9F9CL@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,RXV,S8S-C,P,CDT-SDY.'!X
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M:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!T97AT+6EN9&5N
M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y
M(&]F)B,Q-C`[;W!T:6]N(&%C=&EV:71I97,Z/"]F;VYT/CPO9&EV/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F9CL@
M=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V
M,S`R.30W.3DX<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[)SX\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P
M,"4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0S/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M+W1D/CQT9`T*(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT-"B!C;VQS
M<&%N/3-$,SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#,^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY!=F5R86=E/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A
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M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY796EG
M:'1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^06=G<F5G871E/"]F
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY.=6UB97(@
M;V8\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^
M/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I
M9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^079E<F%G93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY#;VYT<F%C='5A;#PO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.@T*(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<CX\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY5;FET<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0S/CQD:78@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5&5R
M;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS
M1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
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M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$
M;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L
M($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
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M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
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M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^,"XY-CPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R
M:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#LG/C@N.3$\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS
M1#DE('9A;&EG;CTS1&)O='1O;0T*('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/C8X-2PX,#`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^0V%N8V5L;&%T:6]N/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-#DL.34P/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+V9O;G0^/"]T
M9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ
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M.B`G=&EM97,@;F5W(')O;6%N)SL-"B!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.@T*(#$P<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L(%-E<'1E;6)E<B`S,"P@,C`Q,SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,BPR.#`L
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M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C`N.34\+V9O
M;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C$L-C`Y+#`S-3PO9F]N=#X\
M+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,RXV,S8S-C,P,CDT-SDY.'!X.R!F
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M97AT+7-T<F]K92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F
M9F9F.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R.30W.3DX<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[('1E>'0M:6YD96YT
M.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^06QL(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!A<F4@8F5I;F<@86UO<G1I>F5D(&]V97(@=&AE:7(@<F5S<&5C
M=&EV92!V97-T:6YG('!E<FEO9',N(%1H92!U;G)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@870@4V5P=&5M8F5R(#,P+"`R,#$S)B,Q-C`[=V%S
M("0Q+#`Q-"PT-S0N/"]F;VYT/CPO9&EV/CQD:78@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N
M="US:7IE.B`Q,RXV,S8S-C,P,CDT-SDY.'!X.R!F;VYT+7-T>6QE.B!N;W)M
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M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C
M9F9F9F9F.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
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M+6-O;&]R.B`C9F9F9F9F.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,@T*('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^5V%R<F%N=',\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,RXV,S8S-C,P,CDT-SDY.'!X.R!F
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M,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!T97AT+6EN9&5N=#H@
M,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y(&]F
M('=A<G)A;G0@86-T:79I=&EE<SH\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,RXV,S8S-C,P,CDT
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M92UW:61T:#H@,'!X.R!B86-K9W)O=6YD+6-O;&]R.B`C9F9F9F9F.R!T97AT
M+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R.30W.3DX<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'0[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-F9F9F9F8[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQD:78@86QI9VX],T1R:6=H
M=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,CX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G
M93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5V5I9VAT
M960\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(-"B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.@T*(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ
M93H@,3!P=#LG/E)E;6%I;FEN9SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^3G5M8F5R
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M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^0V]N=')A8W1U86P\+V9O;G0^/"]D:78^/"]T
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^26YT<FEN<VEC/"]F
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M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY5;FET<SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P
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M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>&5R
M8VES92!0<FEC93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&1I=B!A
M;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9`T*(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(^/&1I=@T*(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
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M969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^,3(L-S<P+#8S-CPO9F]N=#X\+W1D/CQT
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M(&9O;G0M<VEZ93H@,3!P=#LG/C`N.3<\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/C0N-#@\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^5V%R<F%N=',@97AE<F-I
M<V5D/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/B@R
M+#,P-"PY,3`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^*3PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@
M,3!P=#LG/B0\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^,2XV-3PO9F]N
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M,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H-"B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS
M1#(-"B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
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M.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@Q+#`R,RPW.#0\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^*3PO9F]N=#X\+W1D/CQT9"!A;&EG
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M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^,2XV-3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P
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M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY/=71S=&%N9&EN9RP@4V5P=&5M8F5R(#,P+"`R
M,#$S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS
M1#$E('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)SL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)SL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
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M>3H@)W1I;65S(&YE=R!R;VUA;B<[(&9O;G0M<VEZ93H@,3!P=#LG/C`N(#<W
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M("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+C`Y/"]F
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M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^.2PV,3$L-#`S/"]F;VYT
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M/3-$:G5S=&EF>2!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG.R!F;VYT+7-I>F4Z(#$S+C8S-C,V,S`R
M.30W.3DX<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&)A8VMG<F]U;F0M8V]L;W(Z("-F9F9F9F8[#0H@
M=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
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M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#L@8F%C:V=R;W5N9"UC;VQO<CH@(V9F9F9F
M9CL@=&5X="UI;F1E;G0Z(#,V<'0[#0H@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<VEZ93TS
M1#(^1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,Q
M+"`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O<F1E9"!O<'1I;VX@
M86YD('=A<G)A;G0@97AP96YS97,@;V8@)#DU+#DW,2P@86YD("0W,BPQ,#`L
M(')E<W!E8W1I=F5L>2X@1'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(')E8V]R
M9&5D(&]P=&EO;B!A;F0@=V%R<F%N="!E>'!E;G-E<R!O9B`D,C@T+#,W,2!A
M;F0@)#$V."PP,#`L(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T
M,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E
M8F,X+U=O<FMS:&5E=',O4VAE970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q
M=65N="!%=F5N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S
M='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R
M9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL
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M.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E
M8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O
M<FMS:&5E=',O4VAE970Q-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135$044^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L
M:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M871U<F4@;V8@0G5S:6YE<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M;F]W;B!A<R!#86-T=7,@5F5N='5R97,L($EN8RX@*'1H92`F(S@R,C`[0V]M
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M:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C
M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V
M,#L\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SY/;B!$96-E;6)E<B`R."P@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&$@=')A;G-A8W1I;VX@*'1H92`F(S@R,C`[4VAA<F4@
M17AC:&%N9V4F(S@R,C$[*2P@<'5R<W5A;G0@=&\@=VAI8V@@=&AE($-O;7!A
M;GD@86-Q=6ER960@,3`P)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN
M9R!E<75I='D@<V5C=7)I=&EE<R!O9B!!8W1I;FEU;2!0:&%R;6%C975T:6-A
M;',L($EN8RX@*"8C.#(R,#M!4$DF(S@R,C$[*2P@:6X@97AC:&%N9V4@9F]R
M('1H92!I<W-U86YC92!O9B!A<'!R;WAI;6%T96QY(#DY)2!O9B!T:&4@:7-S
M=65D(&%N9"!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D
M,"XP,2!P97(@<VAA<F4L(&]F('1H92!#;VUP86YY+B!4:&4@4VAA<F4@17AC
M:&%N9V4@8VQO<V5D(&]N($1E8V5M8F5R(#(X+"`R,#$R+B8C,38P.R8C,38P
M.T%S(&$@<F5S=6QT(&]F('1H92!3:&%R92!%>&-H86YG92P@=&AE(&9O<FUE
M<B!S:&%R96AO;&1E<G,@;V8@05!)(&)E8V%M92!T:&4@8V]N=')O;&QI;F<@
M<VAA<F5H;VQD97)S(&]F('1H92!#;VUP86YY+B!!="!T:&4@8VQO<VEN9RP@
M96%C:"!!4$D@<VAA<F5H;VQD97(@<F5C96EV960@,"XS,S,@<VAA<F5S("AT
M:&4@)B,X,C(P.T5X8VAA;F=E(%)A=&EO)B,X,C(Q.RD@;V8@06-T:6YI=6T@
M8V]M;6]N('-T;V-K(&9O<B!E86-H($%022!S:&%R92!E>&-H86YG960N($%T
M('1H92!C;&]S:6YG+"!A;&P@;V8@=&AE($%022!S:&%R96AO;&1E<G,F(S@R
M,3<[(&]P=&EO;G,@86YD('=A<G)A;G1S('1O('!U<F-H87-E($%022!C;VUM
M;VX@<W1O8VL@=V%S(&5X8VAA;F=E9"!A="!T:&4@17AC:&%N9V4@4F%T:6\@
M9F]R(&YE=R!O<'1I;VYS(&]R('=A<G)A;G1S+"!A<R!A<'!L:6-A8FQE+"!T
M;R!P=7)C:&%S92!!8W1I;FEU;2!C;VUM;VX@<W1O8VLN)B,Q-C`[)B,Q-C`[
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^05!)+"!I;F-O<G!O<F%T960@;VX@2G5N92`Q,RP@
M,C`P,"P@:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A;GD@8V]M;6ET=&5D('1O
M(&1E=F5L;W!I;F<@8G)E86MT:')O=6=H('1H97)A<&EE<R!F;W(@;&EF92!T
M:')E871E;FEN9R!D:7-E87-E<R!U<VEN9R!I=',@86QP:&$@<&%R=&EC;&4@
M:6UM=6YO=&AE<F%P>2`H05!)5"D@<&QA=&9O<FT@86YD(&]T:&5R(')E;&%T
M960@86YD('-I;6EL87(@=&5C:&YO;&]G:65S+B!!4$DL('1O9V5T:&5R('=I
M=&@@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I87)Y+"!-961!8W1I;FEU;2P@
M26YC+B`H34%)*2P@*&AE<F5I;F%F=&5R(')E9F5R<F5D('1O(&-O;&QE8W1I
M=F5L>2!A<R`F(S@R,C`[05!))B,X,C(Q.RD@:&%S(&EN:71I871E9"!C;VQL
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M871I;VYA;"!.97<@1')U9R!!<'!L:6-A=&EO;BX@26X@,C`Q,BP@05!)(&QA
M=6YC:&5D(&$@;75L=&DM8V5N=&5R(&-O<G!O<F%T92!S<&]N<V]R960@=')I
M86P@:6X@86-U=&4@;7EE;&]I9"!L975K96UI82`H04U,*2!P871I96YT<RX@
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#,V<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^07,@82!R97-U;'0@;V8@=&AE(%-H87)E($5X
M8VAA;F=E+"!T:&4@0V]M<&%N>2!I<R!N;W<@82!H;VQD:6YG(&-O;7!A;GD@
M;W!E<F%T:6YG('1H<F]U9V@@05!)+"!A(&-L:6YI8V%L+7-T86=E(&)I;W!H
M87)M86-E=71I8V%L(&-O;7!A;GD@9&5V96QO<&EN9R!C97)T86EN(&-A;F-E
M<B!T<F5A=&UE;G1S+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I
M=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#,V<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M3VX@36%R8V@@,C`L(#(P,3,L(&EN(&%N=&EC:7!A=&EO;B!O9B!T:&4@0V]M
M<&%N>2!C:&%N9VEN9R!I=',@;F%M92!T;R!!8W1I;FEU;2!0:&%R;6%C975T
M:6-A;',L($EN8RX@86YD(&ET<R!D;VUI8VEL92!F<F]M($YE=F%D82!T;R!$
M96QA=V%R92P@=&AE($-O;7!A;GDF(S@R,3<[<R!S=6)S:61I87)Y+"!!8W1I
M;FEU;2!0:&%R;6%C975T:6-A;',L($EN8RXL(&-H86YG960@:71S(&YA;64@
M=&\@06-T:6YI=6T@0V]R<&]R871I;VXN)B,Q-C`[)B,Q-C`[3VX@07!R:6P@
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQD:78@86QI9VX],T1J=7-T:69Y('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]N(%-E<'1E;6)E<B`R-2P@,C`Q,RP@
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M86YG960@9F]R(#`N,S,S('-H87)E<R!O9B!#;VUP86YY(&-O;6UO;B!S=&]C
M:RXF(S$V,#LF(S$V,#M!('1O=&%L(&]F(#,L.3<P+#$S-R!S:&%R97,@;V8@
M06-T:6YI=6T@0V]R<&]R871I;VX@8V]M;6]N('-T;V-K('=A<R!E>&-H86YG
M960@9F]R(#$L,S(R+#`U-2!S:&%R97,@;V8@0V]M<&%N>2!C;VUM;VX@<W1O
M8VLN/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N
M("T@56YA=61I=&5D($EN=&5R:6T@1FEN86YC:6%L($EN9F]R;6%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=T
M97AT+6EN9&5N=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE
M9G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F
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M(S@R,C`[52Y3+B!'04%0)B,X,C(Q.RD@9F]R(&EN=&5R:6T@9FEN86YC:6%L
M(&EN9F]R;6%T:6]N+"!A;F0@:6X@86-C;W)D86YC92!W:71H('1H92!R=6QE
M<R!A;F0@<F5G=6QA=&EO;G,@;V8@=&AE(%5N:71E9"!3=&%T97,@4V5C=7)I
M=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C.#(R,#M314,F
M(S@R,C$[*2!W:71H(')E<W!E8W0@=&\@1F]R;2`Q,"U1(&%N9"!!<G1I8VQE
M(#@@;V8@4F5G=6QA=&EO;B!3+5@N($%C8V]R9&EN9VQY+"!T:&5Y(&1O(&YO
M="!I;F-L=61E(&%L;"!O9B!T:&4@:6YF;W)M871I;VX@86YD(&9O;W1N;W1E
M<R!R97%U:7)E9"!B>2!5+E,N($=!05`@9F]R(&-O;7!L971E(&9I;F%N8VEA
M;"!S=&%T96UE;G1S+B!4:&4@=6YA=61I=&5D(&EN=&5R:6T@8V]N<V]L:61A
M=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&9U<FYI<VAE9"!R969L96-T(&%L
M;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N;W)M86P@<F5C=7)R:6YG
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M;GD@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"!N
M;W1E<R!T:&5R971O(&-O;G1A:6YE9"!I;B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&%N;G5A;"!R97!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,BP@87,@9FEL960@=VET:"!T:&4@4T5#($UA
M<F-H(#(Y+"`R,#$S+CPO9F]N=#X\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E=F5L;W!M96YT
M(%-T86=E($-O;7!A;GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^1&5V96QO<&UE;G0@4W1A9V4@0V]M<&%N>2`F(S@R,3$[
M/"]F;VYT/B!4:&4@0V]M<&%N>2!I<R!C;VYS:61E<F5D(&$@9&5V96QO<&UE
M;G0@<W1A9V4@8V]M<&%N>2!A;F0@:&%S(&AA9"!N;R!C;VUM97)C:6%L(')E
M=F5N=64@=&\@9&%T92X\+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP;&5S(&]F($-O
M;G-O;&ED871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S(&EN($9I;F%N8VEA;"!3=&%T96UE
M;G0@4')E<V5N=&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#,V<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&1I<W!L
M87DZ(&EN;&EN93LG/E5S92!O9B!%<W1I;6%T97,@:6X@1FEN86YC:6%L(%-T
M871E;65N="!0<F5S96YT871I;VX@)B,X,C$Q.SPO9F]N=#X@5&AE('!R97!A
M<F%T:6]N(&]F('1H97-E(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M
M96YT<R!I;B!C;VYF;W)M:71Y('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S
M(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R!O9B!!
M;65R:6-A(')E<75I<F5S(&UA;F%G96UE;G0@=&\@;6%K92!E<W1I;6%T97,@
M86YD(&%S<W5M<'1I;VYS('1H870@869F96-T('1H92!R97!O<G1E9"!A;6]U
M;G1S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@870@=&AE(&1A=&4@;V8@
M=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@=&AE
M(')E<&]R=&5D(&%M;W5N=',@;V8@<F5V96YU97,@86YD(&5X<&5N<V5S(&1U
M<FEN9R!T:&4@<F5P;W)T:6YG('!E<FEO9"X@06-T=6%L(')E<W5L=',@8V]U
M;&0@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA=&5S+CPO9F]N=#X\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8VQA<W-I9FEC871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^4F5C;&%S<VEF:6-A=&EO;B`F(S@R,3$[/"]F;VYT
M/B!#97)T86EN('!R:6]R('!E<FEO9"!A;6]U;G1S(&AA=F4@8F5E;B!R96-L
M87-S:69I960@=&\@8V]N9F]R;2!T;R!C=7)R96YT('!E<FEO9"!P<F5S96YT
M871I;VXN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX]
M,T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`S-G!T.R!M87)G:6XM
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M4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,BP@86QL
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V%S:"!W87,@9&5P;W-I=&5D(&EN
M(&]N92!B86YK+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N
M/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^
M4')O<&5R='D@86YD($5Q=6EP;65N="`F(S@R,3$[/"]F;VYT/B!-86-H:6YE
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N="!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#L@9&ES<&QA>3H@:6YL:6YE.R<^26UP86ER;65N="!O9B!,
M;VYG+4QI=F5D($%S<V5T<R`F(S@R,3$[(#PO9F]N=#Y-86YA9V5M96YT(')E
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M=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E<FEV871I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
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M/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^3&5V96P@,2!);G!U=',@)B,X,C$Q.R!5;F%D:G5S=&5D('%U
M;W1E9"!P<FEC97,@:6X@86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A
M<W-E=',@;W(@;&EA8FEL:71I97,@=&AA="!T:&4@<F5P;W)T:6YG(&5N=&ET
M>2!H87,@=&AE(&%B:6QI='D@=&\@86-C97-S(&%T('1H92!M96%S=7)E;65N
M="!D871E+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG
M;CTS1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`R
M($EN<'5T<R`F(S@R,3$[($EN<'5T<R!O=&AE<B!T:&%N('%U;W1E9"!P<FEC
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M86YS+CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[/"]D:78^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`S($EN
M<'5T<R`F(S@R,3$[(%5N;V)S97)V86)L92!I;G!U=',@9F]R(&1E=&5R;6EN
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M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#!P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M;V8@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2X@07,@<F5Q
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M<F-H>2!L979E;',N/"]F;VYT/CQB<B`O/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,979E;"`R/"]F;VYT/CPO
M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P
M>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV
M(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&5V
M96P@,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<@8V]L
M<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/E1O=&%L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z#0H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`-"B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R8C,38P.T%T(%-E
M<'1E;6)E<B`S,"P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS
M1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+V9O;G0^/"]T9#X\=&0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C(L-S4W
M+#DV-CPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[)B,Q-C`[
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L
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M.B`Q,'!T.R<^,RPU-S0L.34X/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
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M<W!L87DZ(&EN;&EN93LG/DEN8V]M92!487AE<R`F(S@R,3$[/"]F;VYT/B!4
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M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO
M<&UE;G0@0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M0F%S960@4&%Y
M;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L
M:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX\9F]N
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M+CPO9F]N=#X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5A<FYI;F=S("A,;W-S*2!097(@0V]M;6]N(%-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG
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M:6%L;'D@9&EL=71I=F4@<V5C=7)I=&EE<R`H;W!T:6]N<RP@=V%R<F%N=',@
M86YD(&-O;G9E<G1I8FQE(&EN<W1R=6UE;G1S*2!W97)E(&5X8VQU9&5D(&9R
M;VT@=&AE(&1I;'5T960@;&]S<R!P97(@8V]M;6]N('-H87)E(&-A;&-U;&%T
M:6]N(&)E8V%U<V4@=&AE:7(@969F96-T('=O=6QD(&AA=F4@8F5E;B!A;G1I
M9&EL=71I=F4N($9O<B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R
M(#,P+"`R,#$S+"!P;W1E;G1I86QL>2!I<W-U86)L92!S:&%R97,@:6YC;'5D
M960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S928C,38P.S(L,C@P,3@T('-H
M87)E<R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA<V4@.2PT-#$L.30R('-H87)E
M<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@1F]R('1H
M92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(@,S`L(#(P,3(L('!O=&5N
M=&EA;&QY(&ES<W5A8FQE('-H87)E<R!I;F-L=61E9"!S=&]C:R!O<'1I;VYS
M('1O('!U<F-H87-E(#$L.38X+#@R.2!S:&%R97,[('=A<G)A;G1S(&EN('1H
M92!A;6]U;G0@;V8@-2PX-C$L,#0T('-H87)E<SL@8V]N=F5R=&EB;&4@;F]T
M97,@<&%Y86)L92!I;B!T:&4@86UO=6YT(&]F(#$L,34R+#8Y,B!S:&%R97,[
M(&%N9"!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@:6X@=&AE(&%M;W5N
M="!O9B`Q,RPX,S$L-S8R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&-O;6UO;B!S=&]C:R!H879E(&)E96X@97AC;'5D960@9G)O;2!T:&4@8V%L
M8W5L871I;VXN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT($%C8V]U;G1I;F<@4')O
M;F]U;F-E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N
M="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV
M(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@
M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E
M,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q
M93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<V-R:7!T:6]N(&]F($)U<VEN
M97-S(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$97-C<FEP=&EO;B!O9B!"=7-I;F5S<R!A;F0@
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U;6UA<GD@;V8@<V5T(&9O<G1H(&%S<V5T<R!A;F0@;&EA8FEL
M:71I97,@;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!A
M;F0@;F]N+7)E8W5R<FEN9R!B87-I<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I=B!A
M;&EG;CTS1')I9VAT/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L
M:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^3&5V96P@,3PO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
M=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY,
M979E;"`S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C
M;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^5&]T86P\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY$97)I=F%T:79E(&QI86)I
M;&ET:65S.CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W
M:61T:#TS1#4R)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V,#M!="!397!T
M96UB97(@,S`L(#(P,3,\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D
M/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,BPW
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#LF(S$V
M,#M!="!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXM/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M="US:7IE.B`Q,'!T.R<^,RPU-S0L.34X/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXS+#4W-"PY-3@\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q
M-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E
M,C9C,65B8S@O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N
M="`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/B8C,38P.SPO9&EV/CQD:78@86QI
M9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0V-R4@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[)SX\9&EV(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[3&EV97,\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,3`E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,C`Q,SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N
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M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/C(P,3(\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0V-R4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T
M:#TS1#DE('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
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M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,3`E('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
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M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('=I9'1H/3-$
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/D]F9FEC92!E<75I<&UE;G0\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.S4@>65A<G,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ
M-C(L,S@T/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#$E('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ-38L
M,38R/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#8W)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/C,L,3`P/"]F;VYT
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M"B`Q,'!T.R<^,2PR.3(\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ#0H@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#8W)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,38U
M+#0X-#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ
M-3<L-#4T/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI
M9VX],T1L969T('=I9'1H/3-$-C<E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
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M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^*3PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3&]S<R!O
M;B!D:7-P;W-I=&EO;B!O9B!E<75I<&UE;G0\+V9O;G0^/"]D:78^/"]T9#X\
M=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
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M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXH-"PQ,C(\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
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M.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E#0H@;F]W<F%P
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M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L
M:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0<F]P97)T>2!A
M;F0@97%U:7!M96YT+"!N970\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`T<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE
M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'@[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#$E('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B
M7S4P,64R-F,Q96)C."]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$97)I=F%T:79E<R`H5&%B
M;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E<FEV871I=F5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&1E<FEV
M871I=F4@=V%R<F%N="!I;G-T<G5M96YT<R!A8W1I=FET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1L969T('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD
M:78@86QI9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^56YI=',\+V9O
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M)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
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M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C
M8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY"86QA;F-E+"!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-2PQ-#8L
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M-3@\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!W
M:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#,L,3,P+#4S
M-B`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H-"B`Q,'!T.R<^*3PO9F]N=#X\
M+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24-"B!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH
M-C`P+#@X,"`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
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M93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
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M:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXH,C$V+#$Q,B`\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#)P>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$
M<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P
M>"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P>#LG/CQD:78@86QI9VX],T1L969T
M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0F%L86YC92P@4V5P=&5M8F5R
M(#,P+"`R,#$S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P>#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$
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M:R`T<'@@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^,BPP,34L.#`R/"]F;VYT/CPO=&0^
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,BPW-3<L.38V/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O9B!D97)I=F%T:79E('=A<G)A
M;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M;V1E;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@86QI9VX],T1L969T('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/B8C,38P.SPO9&EV/CQD:78@
M86QI9VX],T1R:6=H=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O
M;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
M:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY397!T96UB97(@,S`L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#)P>"!S
M;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXR,#$R/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M
M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^36%R:V5T('9A;'5E(&]F(&-O
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,2XV-3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^061J=7-T960@
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO9F]N=#X\+W1D/CQT
M9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^,"XT."`M("0P+C@Q/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W
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M.R<^,2XU,`T*("T@)#(N-#<U/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0W-B4@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^4FES
M:R!F<F5E(&EN=&5R97-T(')A=&4@*#(I/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M9F]N="US:7IE.B`Q,'!T.R<^,"XQ,"4@+2`P+C<W/"]F;VYT/CPO=&0^/'1D
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXE/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^,"XS,SPO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO
M9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T1W:&ET93X\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN
M+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#LG/E=A<G)A;G0@;&EV97,@:6X@>65A<G,\
M+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-"!M;VYT:',O-2!Y
M96%R<SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXP(&1A>7,O-"XR,B!Y96%R<SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^17AP96-T960@=F]L871I;&ET>2`H,RD\+V9O
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^,3,Y/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^17AP96-T960@9&EV:61E;F0@>6EE;&0@*#0I/"]F;VYT/CPO9&EV/CPO
M=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^+3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E9F8^/'1D(&%L
M:6=N/3-$;&5F="!W:61T:#TS1#<V)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA
M>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY0<F]B86)I
M;&ET>2!O9B!S=&]C:R!O9F9E<FEN9R!I;B!A;GD@<&5R:6]D(&]V97(@-2!Y
M96%R<R`H-2D\+V9O;G0^/"]D:78^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXR-24@+2`T,#PO9F]N
M=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)3PO9F]N=#X\+W1D/CPO='(^
M/"]T86)L93X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT
M+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P
M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N
M/3-$;&5F=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,2D\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@=VED=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQD:78@86QI9VX],T1J
M=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^5&AE(&UA<FME="!V
M86QU92!O9B!C;VUM;VX@<W1O8VL@:7,@8F%S960@;VX@86X@96YT97)P<FES
M92!V86QU871I;VXN/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('=I
M9'1H/3-$-"4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DV
M)2!V86QI9VX],T1T;W`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$
M;&5F="!W:61T:#TS1#0E('9A;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@R*3PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!W:61T:#TS1#DV)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS
M1&IU<W1I9GD@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH,RD\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^0F5C
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M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0T)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-"D\+V9O;G0^
M/"]D:78^/"]T9#X\=&0@=VED=&@],T0Y-B4@=F%L:6=N/3-$=&]P/CQD:78@
M86QI9VX],T1J=7-T:69Y('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^36%N
M86=E;65N="!D971E<FUI;F5D('1H92!D:79I9&5N9"!Y:65L9"!T;R!B92`P
M)2!B87-E9"!U<&]N(&ET<R!E>'!E8W1A=&EO;B!T:&%T(&ET('=I;&P@;F]T
M('!A>2!D:79I9&5N9',@9F]R('1H92!F;W)E<V5E86)L92!F=71U<F4N/"]F
M;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D('=I9'1H/3-$-"4@=F%L:6=N
M/3-$=&]P/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[(#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DV)2!V86QI9VX],T1T;W`^
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M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#LG/B@U*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!W:61T:#TS
M1#DV)2!V86QI9VX],T1T;W`^/&1I=B!A;&EG;CTS1&IU<W1I9GD@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SY-86YA9V5M96YT(&AA<R!D971E<FUI;F5D
M('1H870@=&AE('!R;V)A8FEL:71Y(&]F(&$@<W1O8VL@;V9F97)I;F<@:7,@
M,C4E("T@-#`E(&9O<B!E86-H('%U87)T97(@;V8@=&AE(&YE>'0@9FEV92!Y
M96%R<RX\+V9O;G0^/"]D:78^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C
M.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V
M8S%E8F,X+U=O<FMS:&5E=',O4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14=&04,^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I
M;F=E;F-I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DUI;&5S=&]N92!087EM96YT<R!-:6QE<W1O;F4@365T:&]D(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W5M;6%R>2!O9B!M:6QE<W1O;F4@<&%Y;65N=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N
M/3-$<FEG:'0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P
M<'0[)SY-:6QE<W1O;F5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@<V]L:60[
M)R!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^4&%Y;65N=',\+V9O;G0^/"]D:78^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG
M:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N
M/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B
M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L
M87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P
M=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^*#$I('=H
M96X@0V]M<&%N>2!I;FET:6%T97,@82!0:&%S92!)($-L:6YI8V%L(%1R:6%L
M(&]F(&$@;&EC96YS960@<')O9'5C=#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@
M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXD/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$<FEG:'0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG
M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^-S4P+#`P,#PO
M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
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M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT
M9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
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M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXW-3`L,#`P/"]F;VYT/CPO9&EV/CPO=&0^
M/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\
M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+V1I=CX\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E
M969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0X."4@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^*#,I('=H96X@0V]M<&%N>2!I;FET:6%T97,@82!0:&%S92!)24D@0VQI
M;FEC86P@5')I86P@;V8@82!L:6-E;G-E9"!P<F]D=6-T/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$L-3`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
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M)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F
M=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[#0H@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@]
M,T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=@T*(&%L:6=N/3-$<FEG:'0@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I
M;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+#<U,"PP,#`\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS
M1"-C8V5E9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX]
M,T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
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M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G
M:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!W:61T:#TS1#$E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$.24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$L-3`P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS
M1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS
M1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO
M8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O
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M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXH-BD@869T97(@
M=&AE(&9I<G-T("0Q,"PP,#`L,#`P(&EN(&YE="!S86QE<SPO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE
M9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE
M9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[
M(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]D
M:78^/"]T9#X\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#DE('9A;&EG;CTS
M1&)O='1O;3X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA
M<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXQ+#4P,"PP,#`\+V9O;G0^/"]D:78^/"]T9#X\=&0@86QI9VX]
M,T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI9VX]
M,T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT
M/CPO9&EV/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^35-+0T,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M36EL97-T;VYE(%!A>6UE;G1S($UI;&5S=&]N92!-971H;V0@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!A;&EG;CTS1&QE9G0^/'1A8FQE('-T
M>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1R:6=H="!W:61T:#TS1#<E('9A
M;&EG;CTS1'1O<#X\9&EV(&%L:6=N/3-$<FEG:'0@<W1Y;&4],T0G=&5X="UI
M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
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M/3-$<FEG:'0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<CX\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,G!X.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY-:6QE<W1O;F5S/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#)P>#LG/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT
M.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D
M:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,G!X.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I
M;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SY087EM96YT<SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I
M;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C
M:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO9&EV/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M,T0R/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T
M.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M<&QI8V%T:6]N("@F(S@R,C`[3D1!)B,X,C(Q.RD@;W(@<F5G=6QA=&]R>2!A
M<'!R;W9A;"`\+V9O;G0^9F]R(&5A8V@@;&EC96YS960@<')O9'5C=#PO9F]N
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M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Y)2!V
M86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^-S4P+#`P,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A
M;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A
M;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN
M+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]D:78^/"]T9#X\+W1R/CQT<B!B9V-O;&]R/3-$=VAI=&4^/'1D
M(&%L:6=N/3-$;&5F="!W:61T:#TS1#@X)2!V86QI9VX],T1B;W1T;VT^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R
M9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L
M;V-K.R<^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
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M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]D:78^/"]T
M9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
M(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y
M.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED
M=&@],T0Y)2!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1')I9VAT('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^,2PW-3`L,#`P/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#$E('9A;&EG;CTS1&)O
M='1O;3X\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[)SXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/"]T86)L93X\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B
M8E\U,#%E,C9C,65B8S@O5V]R:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%1T9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%<75I='D@*%1A8FQE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@3W!T:6]N<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R
M86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-U;6UA<GD@;V8@;W!T:6]N(&%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,S9P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^)B,Q-C`[/"]D:78^/&1I
M=B!A;&EG;CTS1')I9VAT/CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0S/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^/&1I=B!A;&EG
M;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV
M(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
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M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\
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M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D
M/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4]
M,T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL
M969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)SY796EG:'1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/E)E;6%I;FEN9SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
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M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#LG/D%G9W)E9V%T93PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T
M.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3G5M8F5R(&]F/"]F;VYT/CPO9&EV
M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM
M;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^079E<F%G93PO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.@T*(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.@T*(#$P<'0[)SY#;VYT<F%C='5A;#PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/DEN=')I;G-I8SPO9F]N=#X\+V1I=CX\+W1D
M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=T97AT+6EN
M9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@
M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
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M9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R<'@@<V]L:60[)R!C;VQS<&%N/3-$,SX\9&EV(&%L:6=N/3-$8V5N
M=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K
M.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^17AE<F-I<V4@4')I8V4\
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M(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I
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M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SY686QU93PO9F]N=#X\+V1I=CX\
M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^/'1R/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM
M<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^/&1I=B!A;&EG;CTS1&QE9G0@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA
M<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R<^/&9O;G0@<W1Y
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M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\
M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0S/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ
M(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F
M;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#,^/&1I
M=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@9&ES
M<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR:6=H=#H@
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A
M;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!B9V-O;&]R/3-$(V-C965F9CX\=&0@86QI9VX],T1L969T
M('=I9'1H/3-$-3(E('9A;&EG;CTS1&)O='1O;3X\9&EV(&%L:6=N/3-$;&5F
M="!S='EL93TS1"=T97AT+6EN9&5N=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SL@
M;6%R9VEN+6QE9G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#LG/D]U='-T86YD:6YG+"!$96-E
M;6)E<B`S,2P@,C`Q,CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I
M9VAT('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^,BPS,S`L,3,T/"]F;VYT/CPO=&0^/'1D
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M,T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
M/3-$,24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N=`T*('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M9F]N=#X\+W1D/CQT9"!W:61T:#TS1#DE('9A;&EG;CTS1&)O='1O;0T*('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXV.#4L.#`P/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG:'0@=VED=&@],T0Q
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M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^/'1D(&%L:6=N/3-$;&5F="!W:61T:#TS1#4R)2!V86QI9VX],T1B;W1T
M;VT^/&1I=B!A;&EG;CTS1&QE9G0@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P
M=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[(&UA<F=I;BUR
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M86X[(&9O;G0M<VEZ93H@,3!P=#LG/B@T.2PY-3`\+V9O;G0^/"]T9#X\=&0@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$<FEG
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
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M;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I
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M;F1E;G0Z(#!P=#L@9&ES<&QA>3H@8FQO8VL[(&UA<F=I;BUL969T.B`P<'0[
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N
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M97<@<F]M86X[(&9O;G0M<VEZ93H-"B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO
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M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R!M87)G
M:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z(#!P=#LG/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T.R<^3W5T<W1A;F1I;F<L(%-E<'1E;6)E
M<B`S,"P@,C`Q,SPO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1')I9VAT
M('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H
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M9F]N="US:7IE.B`Q,'!T.R<^,BPR.#`L,3@T/"]F;VYT/CPO=&0^/'1D('=I
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M)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M93H@,3!P=#LG/C$L-C`Y+#`S-3PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CPO9&EV/CQD
M:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R!M87)G:6XM;&5F=#H@,'!T.R!M87)G:6XM<FEG:'0Z
M(#!P=#LG/B8C,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A
M>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&]P=&EO;B!A8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!T.R!M
M87)G:6XM<FEG:'0Z(#!P=#L@;6%R9VEN+6QE9G0Z(#!P=#L@9&ES<&QA>3H@
M8FQO8VL[)SX\9&EV(&%L:6=N/3-$<FEG:'0^/'1A8FQE('-T>6QE/3-$)W=I
M9'1H.B`Q,#`E.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT
M+7-I>F4Z(#$P<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
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M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
M;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[
M(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SY796EG:'1E9#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O
M;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P
M.R`\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[
M(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;3X\
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M:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA
M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN
M;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
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M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ
M(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G
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M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CX\
M9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
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M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R/CQT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M;6)E<B!O9CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA
M<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R/CQD:78@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I
M<W!L87DZ(&)L;V-K.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI
M;F4[)SY#;VYT<F%C='5A;#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W
M(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE
M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R/CQD:78@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT
M.B`P<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SY);G1R:6YS:6,\+V9O
M;G0^/"]D:78^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.R`\+V9O;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
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M>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M
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M="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`R<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
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M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
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M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
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M,CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^5&5R;2`H:6X@>65A<G,I/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#)P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P
M=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R<'@[
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M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(^/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y
M.B!I;FQI;F4[)SXF(S$V,#L@/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/B8C,38P.R`\+V9O;G0^/"]D:78^
M/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P
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M('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T
M.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ
M93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+V1I
M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
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M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
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M>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F
M=#H@,'!T.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[(#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
M97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN
M93LG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E
M969F/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T
M=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P
M<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T.R!D:7-P
M;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE
M.R<^3W5T<W1A;F1I;F<L($1E8V5M8F5R(#,Q+"`R,#$R/"]F;VYT/CPO9&EV
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
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M.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO=&0^/'1D('=I
M9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXP
M+CDW/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M
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M;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT
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M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@
M9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L@-BPQ
M,30L-S8X(#PO9F]N=#X\+W1D/CQT9"!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M
M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO<CTS1'=H:71E/CQT9"!A;&EG
M;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M/CQD:78@86QI
M9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[(&UA<F=I;BUR
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M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Y)2!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I
M<W!L87DZ(&EN;&EN93LG/B@R+#,P-"PY,3`\+V9O;G0^/"]T9#X\=&0@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q
M)2!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@
M;F5W(')O;6%N.R!F;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG
M/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C8V-E969F
M/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N/3-$8F]T=&]M
M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P<'0[
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M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M=VED=&@],T0Q)2!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q
M,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXH,2PP,C,L-S@T/"]F;VYT/CPO=&0^
M/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXD
M/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D
M:7-P;&%Y.B!I;FQI;F4[)SXQ+C8U/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
M;FQI;F4[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I
M9'1H/3-$,24@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES
M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
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M<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I
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M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[
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M>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@8F=C;VQO
M<CTS1'=H:71E/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0U,B4@=F%L:6=N
M/3-$8F]T=&]M/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`P<'0[(&UA<F=I;BUR:6=H=#H@,'!T.R!M87)G:6XM;&5F=#H@,'!T
M.R!D:7-P;&%Y.B!B;&]C:SLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@
M:6YL:6YE.R<^3W5T<W1A;F1I;F<L(%-E<'1E;6)E<B`S,"P@,C`Q,SPO9F]N
M=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=VED=&@],T0Q)2!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@
M,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('=I9'1H/3-$.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[
M)SXY+#0T,2PY-#(@/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL
M:6YE.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N
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M/C`N(#<W/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@86QI9VX],T1L969T('=I9'1H/3-$,24@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N
M97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$,24@=F%L:6=N/3-$8F]T
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M(&9O;G0M<VEZ93H@,3!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^)B,Q-C`[/"]F
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M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
M.R!D:7-P;&%Y.B!I;FQI;F4[)SXD/"]F;VYT/CPO=&0^/'1D('=I9'1H/3-$
M.24@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA
M;CL@9F]N="US:7IE.B`Q,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SXY+#8Q,2PT
M,#,\+V9O;G0^/"]T9#X\=&0@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R!F
M;VYT+7-I>F4Z(#$P<'0[(&1I<W!L87DZ(&EN;&EN93LG/CPO9F]N=#X\+W1D
M/CPO='(^/"]T86)L93X\+V1I=CX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF
M>2!S='EL93TS1"=T97AT+6EN9&5N=#H@,S9P=#L@;6%R9VEN+7)I9VAT.B`P
M<'0[(&UA<F=I;BUL969T.B`P<'0[(&1I<W!L87DZ(&)L;V-K.R<^)B,Q-C`[
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U
M8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970R,"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P141+044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^1&5S8W)I<'1I;VX@
M;V8@0G5S:6YE<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W5M;6%R>2!O9B!F;W)T:"!A<W-E=',@86YD(&QI86)I;&ET:65S(&UE87-U
M<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@86YD(&YO;B!R96-U
M<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<U-RPY-C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3<T+#DU.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5V
M96P@,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!F;W)T:"!A<W-E=',@86YD(&QI86)I
M;&ET:65S(&UE87-U<F5D(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@
M86YD(&YO;B!R96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQE=F5L(#(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@9F]R=&@@
M87-S971S(&%N9"!L:6%B:6QI=&EE<R!M96%S=7)E9"!A="!F86ER('9A;'5E
M(&]N(&$@<F5C=7)R:6YG(&%N9"!N;VX@<F5C=7)R:6YG(&)A<VES/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A
M=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,979E;"`S(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=6UM87)Y(&]F(&9O<G1H(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R
M960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!A;F0@;F]N(')E8W5R
M<FEN9R!B87-I<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L-S4W+#DV-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU-S0L.34X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T
M,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E
M8F,X+U=O<FMS:&5E=',O4VAE970R,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I(0D<^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE<W,@
M86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#@^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#(U+"`R,#$S/&)R
M/G!U<F5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/E=A<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^5V%R<F%N
M=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CY/<'1I;VYS(&%N9"!787)R86YT<R!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/D]P=&EO;G,@86YD(%=A<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^0V]N
M=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^0V]N=F5R
M=&EB;&4@3F]T97,@4&%Y86)L92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/DUA8VAI;F5R>2!A
M;F0@97%U:7!M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1G5R;FET=7)E(&%N9"!F:7AT
M=7)E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#(X+"`R,#$R/&)R/D%C=&EN:75M(%M-96UB97)=/&)R/G!U<F5S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,C4L(#(P
M,3,\8G(^06-T:6YI=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5S8W)I<'1I;VX@;V8@0G5S:6YE
M<W,@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI
M8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@;W=N97)S
M:&EP(&EN=&5R97-T('1O(&)E(&%C<75I<F5D(&)Y(&-O;7!A;GD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS
M+C<P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N(%-T;V-K(&ES<W5A8FQE(&EN(&-O;G-I9&5R871I;VX@
M9F]R(&5Q=6ET>2!I;G1E<F5S="!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VLL('!A<B!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17-T:6UA=&5D('5S969U;"!L:79E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)T9I=F4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4V5V96X@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F5S(')E8V5I=F5D(&)Y(&5A8V@@05!)('-H87)E:&]L9&5R(&]F($%C
M=&EN:75M(&-O;6UO;B!S=&]C:R!F;W(@96%C:"!!4$D@<VAA<F4@97AC:&%N
M9V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,S,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!O=&5N=&EA;&QY(&ES<W5A8FQE('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT-#$L.30R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX-C$L
M,#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPR.#`L,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PY-C@L.#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L.#,Q+#<V,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,34R+#8Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&]F(&-O;6UO;B!S=&]C:R!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3<P+#$S-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-T;V-K('-H87)E<R!E>&-H86YG960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S(R+#`U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?-#(T.5\T96,X
M7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C."]7;W)K
M<VAE971S+U-H965T,C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4U3D%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D=O:6YG(&-O;F-E<FX@*$1E=&%I;',I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$V,"!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D=O:6YG($-O;F-E
M<FX@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,2PT,C`L.3$S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPP,3(L-#4T*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PX.3,L.34Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-2PT.#,L.34T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-C`L-C,W+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@
M;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M+#DT-RPY-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,RPW.34L-#@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0Y+#,U,"PV,C<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D
M969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P+#8S
M-RPT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V,"PV,S<L-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-C`L-C,W+#0Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?-#(T.5\T96,X
M7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C."]7;W)K
M<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$583$%%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U;6UA<GD@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,38U+#0X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,34W+#0U-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S<SH@86-C=6UU
M;&%T960@9&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-30L-#0T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$U-"PT-#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&1I<W!O<VET:6]N(&]F
M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PQ
M,C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,3@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3V9F:6-E(&5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!P<F]P97)T>2!A
M;F0@97%U:7!M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&EV97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38R+#,X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-BPQ-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9U<FYI='5R92!A;F0@9FEX='5R97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@<')O
M<&5R='D@86YD(&5Q=6EP;65N=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQI=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('!R;W!E<G1Y(&%N9"!E<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPQ,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L,CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U
M8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14A(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R
M='D@86YD($5Q=6EP;65N="`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@97AP96YS
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,CD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q-6,Y
M7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C
M,65B8S@O5V]R:W-H965T<R]3:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0D%!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY.;W1E(%!A>6%B;&4@*$1E=&%I;',I
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*86XN(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`R."P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E(%!A>6%B;&4@*%1E>'1U
M86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5M:75M('!A:60@8GD@8V]M<&%N>2!P=7)S=6%N="!T;R!P<F5M
M:75M(&9I;F%N8V4@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$T,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O=VX@<&%Y;65N="!U;F1E<B!I;G-U
M<F%N8V4@<&]L:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R96UI=6T@;6]N=&AL>2!I;G-T86QL;65N="!F;W(@;FEN
M92!M;VYT:',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV
M,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I;F-I<&%L('!A>6UE
M;G0@;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q,#,L,#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C
M,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?
M-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970R
M-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13-&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&5R:79A=&EV97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!D
M97)I=F%T:79E('=A<G)A;G0@:6YS=')U;65N=',@86-T:79I='D\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN
M9R!B86QA;F-E+"!5;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-2PQ-#8L,S,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y296-L87-S:69I8V%T:6]N('1O('!A:60@:6X@8V%P
M:71A;"P@56YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M,3,P+#4S-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)A;&%N8V4L(%5N:71S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`Q-2PX,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!B86QA;F-E+"!&86ER
M(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-3<T
M+#DU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5C;&%S<VEF:6-A=&EO;B!T;R!P86ED(&EN(&-A<&ET86PL($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8P,"PX
M.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C$V+#$Q,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4L($9A:7(@5F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPW-3<L.38V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P-#5E,35C.5\T
M,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E
M8F,X+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15<U044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV97,@*$1E=&%I;',@,2D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CY397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O9B!D97)I=F%T:79E('=A<G)A
M;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M;V1E;#PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL@;VX@;65A<W5R96UE;G0@
M9&%T92`H,2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S="!R871E("@R*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS,R4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,ET\+W-U<#X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@*#,I/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SDN,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S-=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y:65L9"`H-"D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U
M<#Y;-%T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;-%T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8F%B:6QI='D@;V8@<W1O8VL@;V9F97)I;F<@:6X@
M86YY('!E<FEO9"!O=F5R(#4@>65A<G,@*#4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CQS=7`^6S5=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@
M;V8@9F%I<B!V86QU97,@;V8@9&5R:79A=&EV92!W87)R86YT<R!O;B!B87-I
M<R!O9B!V86QU871I;VX@;6]D96P\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&IU<W1E9"!E
M>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VL@9G)E92!I;G1E<F5S
M="!R871E("@R*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@;&EV
M97,@:6X@>65A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<P
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!M;VYT:',\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T
M:6QI='D@*#,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]B86)I;&ET
M>2!O9B!S=&]C:R!O9F9E<FEN9R!I;B!A;GD@<&5R:6]D(&]V97(@-2!Y96%R
M<R`H-2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P
M/ELU73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!F86ER('9A;'5E<R!O9B!D97)I
M=F%T:79E('=A<G)A;G1S(&]N(&)A<VES(&]F('9A;'5A=&EO;B!M;V1E;#PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D:G5S=&5D(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N-#<U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C<W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT(&QI=F5S(&EN('EE87)S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R<R`R(&UO;G1H<R`Q.2!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI
M='D@*#,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38Q+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]B86)I;&ET>2!O
M9B!S=&]C:R!O9F9E<FEN9R!I;B!A;GD@<&5R:6]D(&]V97(@-2!Y96%R<R`H
M-2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELU
M73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X]
M,T0U/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN
M97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D
M/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/E1H92!M
M87)K970@=F%L=64@;V8@8V]M;6]N('-T;V-K(&ES(&)A<V5D(&]N(&%N(&5N
M=&5R<')I<V4@=F%L=6%T:6]N+CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG
M;CTS1'1O<#Y;,ET\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L
M:6=N/3-$=&]P/E1H92!R:7-K+69R964@:6YT97)E<W0@<F%T92!W87,@9&5T
M97)M:6YE9"!B>2!M86YA9V5M96YT('5S:6YG('1H92!4<F5A<W5R>2!":6QL
M(&%S(&]F('1H92!R97-P96-T:79E(&UE87-U<F5M96YT(&1A=&4N/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E
M/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELS73PO=&0^#0H@("`@("`@
M(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^1F]R('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!B96-A=7-E('1H92!#;VUP86YY(&1O
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O
M;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELT73PO=&0^#0H@
M("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^36%N86=E;65N
M="!D971E<FUI;F5D('1H92!D:79I9&5N9"!Y:65L9"!T;R!B92`P)2!B87-E
M9"!U<&]N(&ET<R!E>'!E8W1A=&EO;B!T:&%T(&ET('=I;&P@;F]T('!A>2!D
M:79I9&5N9',@9F]R('1H92!F;W)E<V5E86)L92!F=71U<F4N/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*
M("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELU73PO=&0^#0H@("`@("`@(#QT
M9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^36%N86=E;65N="!H87,@9&5T
M97)M:6YE9"!T:&%T('1H92!P<F]B86)I;&ET>2!O9B!A('-T;V-K(&]F9F5R
M:6YG(&ES(#(U)2`M(#0P)2!F;W(@96%C:"!Q=6%R=&5R(&]F('1H92!N97AT
M(&9I=F4@>65A<G,N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q
M-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E
M,C9C,65B8S@O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$)!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$97)I=F%T:79E<R`H1&5T86EL
M<R!497AT=6%L*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY397`N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1&5R:79A=&EV97,@5&5X='5A;"!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@9&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5S
M8W)I<'1I;VX@;V8@<')O8F%B:6QI='D@;V8@<W1O8VL@;V9F97)I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=-86YA9V5M96YT(&AA<R!D
M971E<FUI;F5D('1H870@=&AE('!R;V)A8FEL:71Y(&]F(&$@<W1O8VL@;V9F
M97)I;F<@:7,@,C4E("T@-#`E(&9O<B!E86-H('%U87)T97(@;V8@=&AE(&YE
M>'0@9FEV92!Y96%R<RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@8V]L
M<W!A;CTS1#4^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1I;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ
M73PO=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^
M36%N86=E;65N="!D971E<FUI;F5D('1H92!D:79I9&5N9"!Y:65L9"!T;R!B
M92`P)2!B87-E9"!U<&]N(&ET<R!E>'!E8W1A=&EO;B!T:&%T(&ET('=I;&P@
M;F]T('!A>2!D:79I9&5N9',@9F]R('1H92!F;W)E<V5E86)L92!F=71U<F4N
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S`T-64Q-6,Y7S0R-#E?-&5C
M.%]A-6)B7S4P,64R-F,Q96)C.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@O5V]R
M:W-H965T<R]3:&5E=#(Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2$=!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H
M1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E
M<ET@?"!0:&%S92!)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O
M9'5C="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O
M;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R<"!;365M8F5R
M72!\(%!H87-E($E)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O
M9'5C="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O
M;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET@
M?"!0:&%S92!)24D@0VQI;FEC86P@5')I86P@;V8@82!L:6-E;G-E9"!P<F]D
M=6-T(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N
M97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=
M('P@0FEO;&]G:6-A;"!,:6-E;G-E($%P<&QI8V%T:6]N(&9I;&EN9R!W:71H
M(%4N4RX@1D1!(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;&5S=&]N97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-
M96UB97)=('P@1FER<W0@0V]M;65R8VEA;"!386QE(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@
M;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N97,@<&%Y;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06)B;W1T($)I
M;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=('P@069T97(@1FER<W0@3F5T
M(%-A;&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S
M=&]N97,@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^365M;W)I86P@4VQO86X@2V5T=&5R:6YG($-A;F-E<B!#
M96YT97(@6TUE;6)E<ET@?"!.97<@1')U9R!!<'!L:6-A=&EO;B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M=6UM87)Y(&]F(&UI;&5S=&]N92!P87EM96YT/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-96UO
M<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;365M8F5R72!\
M(%)E8V5I<'0@;V8@4F5G=6QA=&]R>2!!<'!R;W9A;"!&<F]M(%4N4RX@1D1!
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U;6UA<GD@;V8@;6EL97-T;VYE('!A>6UE;G0\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N97,@
M<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW
M-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X7V$U
M8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970S,"YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P141'044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@
M86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',@5&5X='5A;"D@*$5M<&QO>6UE
M;G0@0V]N=')A8W1S(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@3W!T:6]N<R!;365M8F5R
M72!\($-O;6UO;B!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@0V]N=&EN
M9V5N8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@9W)A;G1E9"!T;R!P=7)C:&%S92!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET@?"!297-T<FEC=&5D(%-T;V-K(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A497AT=6%L*3PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!G<F%N=&5D('1O('!U<F-H87-E('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N(&=R86YT960@87,@
M<VEG;B!O;B!B;VYU<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N(&=R86YT960@87,@<VEG;B!O;B!B;VYU<RP@1&5S
M8W)I<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<H0RD@
M,3`P+#`P,"!S:&%R97,@;V8@<F5S=')I8W1E9"!S=&]C:R!A('-I9VXM;VX@
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M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&EE9B!%
M>&5C=71I=F4@3V9F:6-E<B!!;F0@1&ER96-T;W(@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"87-E('-A;&%R>2!A="!A
M;FYU86P@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#,U
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!E<F9O<FUA;F-E(&]B:F5C=&EV92P@1&5S8W)I<'1I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/E5P;VX@=&AE(&%T
M=&%I;FUE;G0@;V8@<W5C:"!P97)F;W)M86YC92!O8FIE8W1I=F5S+"!$<BX@
M1&%V92!S:&%L;"!B92!E;G1I=&QE9"!T;R!A(&-A<V@@8F]N=7,@:6X@86X@
M86UO=6YT('1O(&)E(&1E=&5R;6EN960@8GD@=&AE($)O87)D('=I=&@@82!T
M87)G970@;V8@9F]R='D@<&5R8V5N="`H-#`E*2!O9B!T:&4@8F%S92!S86QA
M<GDN/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\P-#5E,35C.5\T,C0Y7S1E8SA?835B8E\U,#%E,C9C,65B8S@-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#0U93$U8SE?-#(T.5\T96,X
M7V$U8F)?-3`Q93(V8S%E8F,X+U=O<FMS:&5E=',O4VAE970S,2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P159+04T^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',@5&5X='5A;"`Q*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#4^.2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#`Q+"`R,#$R/&)R/E)E;G1A;"!!
M9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY296YT86P@06=R965M96YT(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^06)B;W1T($)I;W1H97)A<&5U=&EC<R!#;W)P(%M-96UB97)=
M/&)R/E!R;V1U8W0@1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E;G-E($%G
M<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/D%B8F]T="!":6]T:&5R87!E=71I8W,@
M0V]R<"!;365M8F5R73QB<CY!9G1E<B!&:7)S="!.970@4V%L97,@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CY!8F)O='0@0FEO=&AE<F%P975T:6-S($-O<G`@6TUE;6)E<ET\
M8G(^069T97(@1FER<W0@3F5T(%-A;&5S(%M-96UB97)=/&)R/E!R;V1U8W0@
M1&5V96QO<&UE;G0@86YD(%!A=&5N="!,:6-E;G-E($%G<F5E;65N="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/D%B8F]T="!":6]T:&5R87!E=71I8W,@0V]R<"!;365M8F5R
M73QB<CY0:&%S92!)($-L:6YI8V%L(%1R:6%L(&]F(&$@;&EC96YS960@<')O
M9'5C="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y&96(N(#(X+"`R,#`R/&)R/DUE;6]R:6%L(%-L;V%N($ME='1E<FEN9R!#
M86YC97(@0V5N=&5R(%M-96UB97)=/&)R/DQI8V5N<V4@86=R965M96YT(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^365M;W)I86P@4VQO86X@2V5T=&5R:6YG($-A;F-E<B!#
M96YT97(@6TUE;6)E<ET\8G(^3&EC96YS92!A9W)E96UE;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`R-RP@,C`Q
M,CQB<CY-96UO<FEA;"!3;&]A;B!+971T97)I;F<@0V%N8V5R($-E;G1E<B!;
M365M8F5R73QB<CY#;&EN:6-A;"!4<FEA;"!!9W)E96UE;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY/86L@4FED9V4@3F%T:6]N86P@3&%B;W)A=&]R>2!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#`V+"`R,#$R
M/&)R/D%P=&EV(%-O;'5T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D%P=&EV(%-O;'5T
M:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/D%P=&EV(%-O;'5T:6]N<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`W
M/&)R/D%P=&EV(%-O;'5T:6]N<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$U+"`R,#$R/&)R/D9R960@2'5T8VAI
M;G-O;B!#86YC97(@4F5S96%R8V@@0V5N=&5R(%M-96UB97)=/&)R/FQI8V5N
M<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G0@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CY&<F5D($AU=&-H:6YS;VX@0V%N8V5R(%)E<V5A<F-H($-E;G1E<B!;
M365M8F5R73QB<CYL:6-E;G-E(&%N9"!S<&]N<V]R960@<F5S96%R8V@@86=R
M965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,34L(#(P,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!2
M97-E87)C:"!#96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@<W!O;G-O
M<F5D(')E<V5A<F-H(&%G<F5E;65N="!;365M8F5R73QB<CY-87AI;75M(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,34L(#(P,3(\8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#
M96YT97(@6TUE;6)E<ET\8G(^;&EC96YS92!A;F0@<W!O;G-O<F5D(')E<V5A
M<F-H(&%G<F5E;65N="!;365M8F5R73QB<CY-:6YI;75M(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,3DL(#(P,3(\
M8G(^1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#96YT97(@6TUE
M;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,C@L(#(P,3(\
M8G(^56YI=F5R<VET>2!O9B!497AA<R!-+D0N($%N9&5R<V]N($-A;F-E<B!#
M96YT97(@6TUE;6)E<ET\8G(^0VQI;FEC86P@5')I86P@06=R965M96YT(%M-
M96UB97)=/&)R/DEN<W1A;&QM96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,C8L(#(P,3(\8G(^2F]H;G,@2&]P:VEN<R!5;FEV
M97)S:71Y(%M-96UB97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N
M(#(Q+"`R,#$R/&)R/E5N:79E<G-I='D@;V8@4&5N;G-Y;'9A;FEA(%M-96UB
M97)=/&)R/D-L:6YI8V%L(%1R:6%L($%G<F5E;65N="!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R
M/D9O<FUE<B!#14\@6TUE;6)E<ET\8G(^4V5P87)A=&EO;B!A;F0@4V5T=&QE
M;65N="!!9W)E96UE;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY&;W)M97(@0T5/(%M-96UB
M97)=/&)R/E-E<&%R871I;VX@86YD(%-E='1L96UE;G0@06=R965M96YT(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,C@L(#(P,3,\8G(^1F]R;65R($-%3R!;365M8F5R73QB<CY397!A<F%T:6]N
M(&%N9"!3971T;&5M96YT($%G<F5E;65N="!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQI8V5N<V4@9F5E('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6QE<W1O;F5S('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T('-A;&5S(&EN(&UI;&5S=&]N97,@<&%Y;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97-C<FEP=&EO;B!O
M9B!R;WEA;'1Y('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)U=E(&%G<F5E9"!T;R!P87D@=&\@06)B;W1T($)I;W1H97)A<&5U
M=&EC<R!#;W)P(&]N(&$@8V]U;G1R>2UB>2UC;W5N=')Y(&)A<VES(&$@<F]Y
M86QT>2!O9B!U<"!T;R`Q,B4@;V8@;F5T('-A;&5S(&]F(&%L;"!L:6-E;G-E
M9"!P<F]D=6-T<R!U;G1I;"!T:&4@;&%T97(@;V8Z("@Q*2`Q,BXU('EE87)S
M(&%F=&5R('1H92!F:7)S="!C;VUM97)C:6%L('-A;&4L(&]R("@R*2!W:&5N
M('1H92!P871E;G1S(&5X<&ER92X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U=E(&%G<F5E<R!T;R!P87D@=&\@
M35-+0T,@;VX@82!C;W5N=')Y+6)Y+6-O=6YT<GD@8F%S:7,@82!R;WEA;'1Y
M(&]F(#(E(&]F(&YE="!S86QE<R!O9B!A;&P@;&EC96YS960@<')O9'5C=',@
M=6YT:6P@=&AE(&QA=&5R(&]F.B`H,2D@,3`@>65A<G,@9G)O;2!T:&4@9FER
M<W0@8V]M;65R8VEA;"!S86QE+"!O<B`H,BD@=VAE;B!T:&4@<&%T96YT<R!E
M>'!I<F4N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=2;WEA;'1Y('!A>6UE;G1S(&]F(#(E(&]F(&YE="!S
M86QE<R!W:6QL(&)E(&1U92!T;R!&2$-20RX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@
M;V8@3F5T(%-A;&5S(%!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3(N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FER
M<W0@8V]M;65R8VEA;"!S86QE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,3(@>65A<G,@-B!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y496-H;F]L;V=Y(&%C8V5S<R!F964\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06YN=6%L(&UA:6YT96YA;F-E(&9E93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;FYU86P@<F5S96%R8V@@9G5N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M=7)C:&%S92!O9B!R861I;V%C=&EV92!M871E<FEA;"!U<V5D(&9O<B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(S,RPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;VIE
M8W0@97-T:6UA=&5D(&-O<W0@9F]R(&-L:6YI8V%L('1R:6%L<R!O9B!D<G5G
M($%C+3(R-2U(=4TQ.34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PX-3DL,S,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]W;B!P87EM
M96YT(&]F('!R;VIE8W0@97-T:6UA=&5D(&-O<W0@<&5R8V5N=&%G93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXU,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;W=N('!A>6UE;G0@9F]R('!R;VIE8W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DY-RPW,S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C,Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(S.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@=')I86P@8V]S
M="!F;W(@87!P<F]V86P@;V8@9F]O9"!A;F0@9')U9R!A9&UI;FES=')A=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(S+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,RPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5N9"!F;W(@1G)E
M9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C:"!#96YT97(@;&%B("@@4&5R
M('EE87(@9F]R('1H92!F:7)S="!T=V\@>65A<G,@*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1G5N9"!F;W(@1G)E9"!(=71C:&EN<V]N($-A;F-E<B!297-E87)C
M:"!#96YT97(@;&%B("@@=&AE<F5A9G1E<B`I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@;V8@4&%T:65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G0@<&%I
M9"!T;R!E86-H('!A=&EE;G0@869T97(@0V]M<&QE=&EN9R!C;&EN:6-A;"!T
M<FEA;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,2PQ.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,2PS-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT.#$L,C`T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L-3`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L-S<Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&%R="UU<"!F964@9F]R(&-L:6YI8V%L('1R:6%L/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#8R,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+#<T
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,S+#DT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#@T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A<G0M=7`@9'5E(&-O<W0@<&%I
M9"!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/DIU;"`Q,"P-"@D),C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S
M,"P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.;VXM<F5F=6YD86)L92!I;G-T:71U=&EO;F%L
M(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@<&AA<FUA8WD@9F5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06UE;F1M96YT('!R;V-E<W-I;F<@9F5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G-I9&5R871I;VX@<'5R<W5A;G0@=&\@86=R965M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B=4:&4@0V]M<&%N>2!P86ED($UR+B!486QL97D@)#$R-2PP
M,#`@;VX@36%R8V@@."P@,C`Q,R!A;F0@82!S96-O;F0@<&%Y;65N="!O9B`D
M,3(U+#`P,"!O;B!397!T96UB97(@,2P@,C`Q,RX@5&AE($-O;7!A;GD@86QS
M;R!P86ED($UR+E1A;&QE>2!A('!E<F9O<FUA;F-E(&)O;G5S(&]F("0V,"PP
M,#`@9F]R(&AI<R!S97)V:6-E(&9R;VT@075G=7-T(#$U+"`R,#$R('1O($1E
M8V5M8F5R(#,Q+"`R,#$R+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F9O<FUA;F-E(&)O;G5S('!A>6%B;&4@
M=6YD97(@86=R965M96YT(&9O<B!S97)V:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYO=&EC92!P97)I;V0@9F]R('1E<FUI;F%T:6]N(&]F(&%G<F5E;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&ES(&%G<F5E;65N
M="!T97)M:6YA=&5S(&]N($1E8V5M96)E<B`S,2P@,C`Q,RX@57!O;B!T:&4@
M97AP:7)A=&EO;B!O9B!T:&4@=&5R;2P@=&AE(&%G<F5E;65N="!A=71O;6%T
M:6-A;&QY(')E;F5W<R!O;B!A(&UO;G1H+71O+6UO;G1H(&)A<VES(&%N9"!R
M97%U:7)E<R!A('1W;R!M;VYT:"!N;W1I8V4@;V8@=&5R;6EN871I;VXN/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;G0@86=R965M96YT('1E<FUI;F%T
M:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S
M,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N=&%L(&%G
M<F5E;65N="!R96YE=V%L(&1E<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)U1H92!A9W)E96UE;G0@875T;VUA=&EC86QL>2!R
M96YE=W,@;VX@82!M;VYT:"UT;RUM;VYT:"!B87-I<R!A;F0@<F5Q=6ER97,@
M82!T=V\@;6]N=&@@;F]T:6-E(&]F('1E<FUI;F%T:6]N+CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y087EM96YT(&]F(&%G9W)E9V%T92!A;6]U;G0@:6X@
M:6YS=&%L;&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!P
M87EM96YT(&]F(&9I;F%L(&EN<W1A;&QM96YT(&9O<B!S97)V:6-E<R!B>2!C
M;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F('!E<F9O<FUA
M;F-E(&)O;G5S(&9O<B!S97)V:6-E<R!B>2!C;VUP86YY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`T-64Q-6,Y7S0R-#E?-&5C.%]A
M-6)B7S4P,64R-F,Q96)C."]7;W)K<VAE971S+U-H965T,S(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5724%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5Q=6ET>2`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI
M=',L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC96QL871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0Y+#DU,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',L
M($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#(X,"PQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#,S,"PQ,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+CDU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+CDV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!497)M("AI;B!Y96%R<RDL($]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG."!Y96%R<R`R
M(&UO;G1H<R`Q(&1A>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<X('EE87)S(#$P(&UO;G1H<R`R."!D87ES/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R
M96=A=&4@26YT<FEN<VEC(%9A;'5E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#4L.#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G
M871E($EN=')I;G-I8R!686QU92P@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C`Y+#`S-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X-2PX,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A8W1I=FET:65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(%5N:71S+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-S<P+#8S-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/G=A<G)A;G1S(&5X
M97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS,#0L
M.3$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S(&5X<&ER960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L,#(S+#<X-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@56YI=',L($5N9&EN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0T
M,2PY-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPW-S`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC92P@97AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$N-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!E
M>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-C4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%;F1I;F<@0F%L
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C<W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+CDW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!4
M97)M("AI;B!Y96%R<RDL($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Q(&UO;G1H(#(@9&%Y<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S
M(#4@;6]N=&AS(#(S(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L
M($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+#$Q-"PW-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!%
M;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Y+#8Q,2PT,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8L,3$T+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?-#(T.5\T96,X7V$U8F)?-3`Q
M93(V8S%E8F,X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S`T-64Q
M-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C."]7;W)K<VAE971S+U-H
M965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5044)'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D5Q=6ET>2`H1&5T86EL<R!497AT=6%L*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ-C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@*%1E>'1U86PI/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M56YR96-O9VYI>F5D('-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP,30L-#<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E8V]R9&5D(&]P=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY-2PY-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,BPQ,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(X-"PS-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,3(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS,S8L-#`W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%<75I='D@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C@T+#,W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$V."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I
M='D@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R.#0L,S<Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^,C`Q,R!3=&]C:R!0;&%N(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I='D@
M*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AP:7)A=&EO;B!D871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/E-E<"`Y+`T*"0DR,#(S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3,@4W1O8VL@
M4&QA;B!;365M8F5R72!\($5M<&QO>65E<R!$:7)E8W1O<G,@86YD($-O;G-U
M;'1A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY%<75I='D@*%1E>'1U86PI/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K(&%V86EL86)L92!F;W(@9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPW-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3,@17%U:71Y($EN8V5N=&EV
M92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY%<75I='D@*%1E>'1U86PI/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO
M;B!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`Y
M+`T*"0DR,#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(P,3,@17%U:71Y($EN8V5N=&EV92!0;&%N(%M-96UB
M97)=('P@16UP;&]Y965S($1I<F5C=&]R<R!A;F0@0V]N<W5L=&%N=',@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D5Q=6ET>2`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@879A:6QA
M8FQE(&9O<B!G<F%N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S`T-64Q-6,Y7S0R-#E?-&5C.%]A-6)B7S4P,64R-F,Q96)C.`T*
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M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C4N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Y
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M,RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?,#0U93$U8SE?
?-#(T.5\T96,X7V$U8F)?-3`Q93(V8S%E8F,X+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>186</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Consolidatedbalancesheetsunaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Consolidatedbalancesheetsunauditedparenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Consolidatedstatementsofoperationsunaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Description of Business and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Notes11</Role>
      <ShortName>Going Concern</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayable</Role>
      <ShortName>Note Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Derivatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Derivatives</Role>
      <ShortName>Derivatives</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/StockOptionPlan</Role>
      <ShortName>Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Notes13</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Derivatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesTables</Role>
      <ShortName>Derivatives (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Description of Business and Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/GoingconcernDetails</Role>
      <ShortName>Going concern (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/Propertyandequipmentdetailstesxtual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/NotePayableDetails</Role>
      <ShortName>Note Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetails</Role>
      <ShortName>Derivatives (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Derivatives (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetails1</Role>
      <ShortName>Derivatives (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Derivatives (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/DerivativesDetailsTextual</Role>
      <ShortName>Derivatives (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Commitments and Contingencies (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/CommitmentsAndContingenciesDetailsTextual1</Role>
      <ShortName>Commitments and Contingencies (Details Textual 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cactusventuresinc.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element fil_PercentageOfOwnershipInterestToBeAcquired had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_FairValueAssumptionsExercisePrice had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -6 0.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 12, 2000'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>fil-20130930.xml</File>
    <File>fil-20130930.xsd</File>
    <File>fil-20130930_cal.xml</File>
    <File>fil-20130930_def.xml</File>
    <File>fil-20130930_lab.xml</File>
    <File>fil-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">23,656,582<span></span></td>
        <td class="nump">21,391,665<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">23,656,582<span></span></td>
        <td class="nump">21,391,665<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5DAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Nature of Business</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Nature of Business &#8211;</font> Actinium Pharmaceuticals, Inc. formerly known as Cactus Ventures, Inc. (the &#8220;Company&#8221;, &#8220;Actinium&#8221;, &#8220;Cactus&#8221;), was incorporated under the laws of the State of Nevada on October 6, 1997. The Company was a shell entity that was in the market for a merger with an appropriate operating company.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 28, 2012, the Company entered into a transaction (the &#8220;Share Exchange&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (&#8220;API&#8221;), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.01 per share, of the Company. The Share Exchange closed on December 28, 2012.&#160;&#160;As a result of the Share Exchange, the former shareholders of API became the controlling shareholders of the Company. At the closing, each API shareholder received 0.333 shares (the &#8220;Exchange Ratio&#8221;) of Actinium common stock for each API share exchanged. At the closing, all of the API shareholders&#8217; options and warrants to purchase API common stock was exchanged at the Exchange Ratio for new options or warrants, as applicable, to purchase Actinium common stock.&#160;&#160;The Share Exchange was accounted for as a reverse takeover/recapitalization effected by a share exchange, wherein API is considered the acquirer for accounting and financial reporting purposes. The capital, share price, and earnings per share amount in these consolidated financial statements for the period prior to the reverse merger were restated to reflect the recapitalization in accordance with the exchange ratio established in the merger except otherwise noted.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">API, incorporated on June 13, 2000, is a biotechnology company committed to developing breakthrough therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform and other related and similar technologies. API, together with its wholly owned subsidiary, MedActinium, Inc. (MAI), (hereinafter referred to collectively as &#8220;API&#8221;) has initiated collaborative efforts with large institutions to establish the proof of concept of alpha particle immunotherapy and has supported one Phase I/Il clinical trial and one Phase I clinical trial at Memorial Sloan-Kettering Cancer Center (MSKCC) under an MSKCC Physician Investigational New Drug Application. In 2012, API launched a multi-center corporate sponsored trial in acute myeloid leukemia (AML) patients. API&#8217;s objective, through research and development, is to produce reliable cancer fighting products which utilize monoclonal antibodies linked with alpha particle emitters or other appropriate payloads to provide very potent targeted therapies. The initial clinical trials of API&#8217;s compounds have been with patients having acute myeloid leukemia and it is believed that API&#8217;s APIT platform will have wider applicability for different types of cancer where suitable monoclonal antibodies can be found.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As a result of the Share Exchange, the Company is now a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 20, 2013, in anticipation of the Company changing its name to Actinium Pharmaceuticals, Inc. and its domicile from Nevada to Delaware, the Company&#8217;s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation.&#160;&#160;On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. (filed in Delaware, the Company merged (the &#8220;Merger&#8221;) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company has been cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company common stock.&#160;&#160;A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.</font></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation - Unaudited Interim Financial Information</a></td>
        <td class="text"><div style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Basis of Presentation - Unaudited Interim Financial Information &#8211; </font>The accompanying unaudited interim consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements furnished reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2012 and notes thereto contained in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2012, as filed with the SEC March 29, 2013.</font></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DevelopmentStageCompanyPolicyTextBlock', window );">Development Stage Company</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Development Stage Company &#8211;</font> The Company is considered a development stage company and has had no commercial revenue to date.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Principles of Consolidation &#8211;</font> The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Financial Statement Presentation</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Use of Estimates in Financial Statement Presentation &#8211;</font> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Reclassification &#8211;</font> Certain prior period amounts have been reclassified to conform to current period presentation.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Cash and Cash Equivalents &#8211;</font> The Company considers all highly liquid accounts with original maturities of three months or less to be cash equivalents. Such balances are usually in excess of FDIC insured limits. At September 30, 2013 and December 31, 2012, all of the Company&#8217;s cash was deposited in one bank.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Property and Equipment &#8211;</font> Machinery and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives of five years. Furniture and fixtures are recorded at cost and depreciated on a straight-line basis over estimated useful lives of seven years. When assets are retired or sold, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in operations. Repairs and maintenance expenditures are charged to operations.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Impairment of Long-Lived Assets &#8211; </font>Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#8217;s carrying value to determine if an impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Derivatives &#8211;</font> All derivatives are recorded at fair value on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices. Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Fair Value of Financial Instruments &#8211;</font> Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2 Inputs &#8211; Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3 Inputs &#8211; Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of September 30, 2013 and December 31. As required by ASC 820, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of fair value assets and liabilities and their placement within the fair value hierarchy levels.</font><br />&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></div></td><td nowrap="nowrap"
 valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td></tr></table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Income Taxes &#8211;</font> The Company uses the asset and liability method in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and income tax carrying amounts of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will be fully realized. A valuation allowance, if necessary, is provided against deferred tax assets, based upon management&#8217;s assessment as to their realization.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Research and Development Costs &#8211;</font> Research and development costs are expensed as incurred. Research and development reimbursements and grants are recorded by the Company as a reduction of research and development costs.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Share-Based Payments</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Share-Based Payments &#8211;</font> The Company estimates the fair value of each stock option award at the grant date by using the Black-Scholes option pricing model and value of common shares based on the last common stock valuation done by third party valuation expert of the Company&#8217;s common stock on the date of the share grant. The fair value determined represents the cost for the award and is recognized over the vesting period during which an employee is required to provide service in exchange for the award. As share-based compensation expense is recognized based on awards ultimately expected to vest, the Company reduces the expense for estimated forfeitures based on historical forfeiture rates. Previously recognized compensation costs may be adjusted to reflect the actual forfeiture rate for the entire award at the end of the vesting period. Excess tax benefits, if any, are recognized as an addition to paid-in capital.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"><font style="font-weight: bold; display: inline;">Earnings (Loss) Per Common Share &#8211;</font> The Company provides basic and diluted earnings per common share information for each period presented. Basic earnings (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus dilutive securities. Since the Company has only incurred losses, basic and diluted net loss per common share are the same.&#160;&#160;The potentially dilutive securities (options, warrants and convertible instruments) were excluded from the diluted loss per common share calculation because their effect would have been antidilutive. For the nine months ended September 30, 2013, potentially issuable shares included stock options to purchase&#160;2,280184 shares and warrants to purchase 9,441,942 shares of the Company&#8217;s common stock. For the nine months ended September 30, 2012, potentially issuable shares included stock options to purchase 1,968,829 shares; warrants in the amount of 5,861,044 shares; convertible notes payable in the amount of 1,152,692 shares; and convertible preferred stock in the amount of 13,831,762 shares of the Company&#8217;s common stock have been excluded from the calculation.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Recent Accounting Pronouncements &#8211;</font> The Company does not expect that any recently issued accounting pronouncements will have a significant impact on the results of operations, financial position, or cash flows of the Company.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">Subsequent Events &#8211;</font> The Company&#8217;s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DevelopmentStageCompanyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Development Stage Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DevelopmentStageCompanyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2303973<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PriorPeriodReclassificationAdjustmentDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBPBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">284,371<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="nump">6,336,407<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">429<span></span></td>
        <td class="nump">3,262,462<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposition of equipment</a></td>
        <td class="nump">4,122<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">554,308<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">678,116<span></span></td>
        <td class="nump">900,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">219,725<span></span></td>
        <td class="nump">292,692<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(260,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GainOnChangeInFairValueOfDerivatives', window );">Change in fair value derivative liabilities</a></td>
        <td class="num">(216,112)<span></span></td>
        <td class="nump">287,604<span></span></td>
        <td class="num">(915,498)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">114,143<span></span></td>
        <td class="nump">14,386<span></span></td>
        <td class="nump">87,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
        <td class="num">(585,043)<span></span></td>
        <td class="nump">173,614<span></span></td>
        <td class="nump">653,730<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued liabilities - related party</a></td>
        <td class="nump">344,501<span></span></td>
        <td class="nump">2,100<span></span></td>
        <td class="nump">375,686<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(4,947,969)<span></span></td>
        <td class="num">(3,795,480)<span></span></td>
        <td class="num">(49,350,627)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payment made for patent rights</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(3,000,000)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(8,030)<span></span></td>
        <td class="num">(1,812)<span></span></td>
        <td class="num">(823,689)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(8,030)<span></span></td>
        <td class="num">(1,812)<span></span></td>
        <td class="num">(3,823,689)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Borrowings on convertible debt, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">645,888<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on note payable</a></td>
        <td class="num">(140,000)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(140,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sales of Common stock, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">660,163<span></span></td>
        <td class="nump">53,191,098<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from the exercise of warrants for cash</a></td>
        <td class="nump">3,467,393<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,467,393<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">3,327,393<span></span></td>
        <td class="nump">660,163<span></span></td>
        <td class="nump">57,164,379<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash</a></td>
        <td class="num">(1,628,606)<span></span></td>
        <td class="num">(3,137,129)<span></span></td>
        <td class="nump">3,990,063<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">5,618,669<span></span></td>
        <td class="nump">5,703,798<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">3,990,063<span></span></td>
        <td class="nump">2,566,669<span></span></td>
        <td class="nump">3,990,063<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for interest</a></td>
        <td class="nump">561<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,243<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">372,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedWithDebt', window );">Fair value of warrants issued with debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">377,150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedWithStock', window );">Fair value of warrants issued with stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">318,087<span></span></td>
        <td class="nump">5,985,238<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to the placement agent</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">159,044<span></span></td>
        <td class="nump">2,170,282<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock', window );">Conversion of notes payable and accrued interest to stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">981,729<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification', window );">Transfer from derivative liability classification to equity classification</a></td>
        <td class="nump">$ 600,880<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 4,832,204<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of notes payable and accrued interest to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ConversionOfNotesPayableAndAccruedInterestToCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of Transfer from liability classification to equity classification.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfTransferFromLiabilityClassificationToEquityClassification</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedToPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued to the placement agent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedToPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedWithDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedWithDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOfWarrantsIssuedWithStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued with stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOfWarrantsIssuedWithStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GainOnChangeInFairValueOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on change in fair value of the derivatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GainOnChangeInFairValueOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeBenefitsAndShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12317-112629<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 50<br><br> -Section 40<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6850294&amp;loc=d3e12355-112629<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainsLossesOnExtinguishmentOfDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromDebtNetOfIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 3,990,063<span></span></td>
        <td class="nump">$ 5,618,669<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">53,000<span></span></td>
        <td class="nump">167,143<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">4,043,063<span></span></td>
        <td class="nump">5,785,812<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
        <td class="nump">6,918<span></span></td>
        <td class="nump">3,010<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">4,049,981<span></span></td>
        <td class="nump">5,788,822<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">312,001<span></span></td>
        <td class="nump">897,044<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related party</a></td>
        <td class="nump">375,686<span></span></td>
        <td class="nump">31,185<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">140,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">2,757,966<span></span></td>
        <td class="nump">3,574,958<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">3,445,653<span></span></td>
        <td class="nump">4,643,187<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">3,445,653<span></span></td>
        <td class="nump">4,643,187<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 authorized 0 shares issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 23,656,582 and 21,391,665 shares issued and outstanding, respectively</a></td>
        <td class="nump">236,565<span></span></td>
        <td class="nump">213,916<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
        <td class="nump">61,005,177<span></span></td>
        <td class="nump">56,675,182<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(60,637,414)<span></span></td>
        <td class="num">(55,743,463)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">604,328<span></span></td>
        <td class="nump">1,145,635<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 4,049,981<span></span></td>
        <td class="nump">$ 5,788,822<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(1),(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph 1, 5<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Memorial Sloan Kettering Cancer Center [Member] | New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Memorial Sloan Kettering Cancer Center [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MilestonePaymentAbstract', window );"><strong>Summary of milestone payment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LongTermPurchaseCommitmentMilestonesPayment', window );">Milestones payments</a></td>
        <td class="nump">$ 1,750,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LongTermPurchaseCommitmentMilestonesPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Long term purchase commitment milestones payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LongTermPurchaseCommitmentMilestonesPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MilestonePaymentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MilestonePaymentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
        <td class="nump">$ 165,484<span></span></td>
        <td class="nump">$ 157,454<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
        <td class="num">(154,444)<span></span></td>
        <td class="num">(154,444)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LossOnDispositionOfPropertyAndEquipment', window );">Loss on disposition of equipment</a></td>
        <td class="num">(4,122)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">6,918<span></span></td>
        <td class="nump">3,010<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
        <td class="nump">162,384<span></span></td>
        <td class="nump">156,162<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture and fixtures [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Summary of property and equipment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
        <td class="nump">$ 3,100<span></span></td>
        <td class="nump">$ 1,292<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LossOnDispositionOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss on disposition of property and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LossOnDispositionOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>37
<FILENAME>0001213900-13-006378-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-13-006378-xbrl.zip
M4$L#!!0````(`&Y4;D.7S+@E_Y8``&AQ"``0`!P`9FEL+3(P,3,P.3,P+GAM
M;%54"0`#O^V$4K_MA%)U>`L``00E#@``!#D!``#L75ESXSB2?I^(^0\:/^Q3
MRR)XTU-5$RX?W:YVV1K;U4?L;CAH$I(039%J'BZK)V)_^P(\)%+F35"B)/;#
MC$LDD1\ROTQ<">##O][FQN`5V@ZRS(\GX)0Y&4!3LW1D3C^>?'NZ'LHG__KT
M][]]^,=P./@1FM!67:@//`<_'US]-?SM\\-M]/E`.F5.N5-N\-\`C``_8AG`
M#1CYC!7/`#,X__J_@^$P*NJSZN!B\#=^`>PI6#_S?[FT-&\.37?P%4.9(/SN
M=^3.B,0K';F6/?@EE(D1GXJG,BGJ:>;9CJXN?QC<6:]P_@+M`>!_&*Q@*&<<
M@1%*>GNQ#71&_G>`56`Z9Q-D?#R9N>[B;#325,WUG%<,P+,AKJMVJEESOT*,
MPF$5!5\8R/QC]<GW[]]/26FGECW%;S+<B#Q^P?6,7B=/=;3Z(/ZR.`H>KEY]
M5_1WSG\7*(HR\I^N7G50VHNX4##Z[>OMHS:#<W6(3,=532V!!>5@WWP?.1;/
M`BGOB^"-Z`/-\DS77B9KZT#M=&J]CL*'OD*'#!AR8/699]N8?UG?A4_)AVSR
M0QVB]&_P@Q0Y.ES84"-<SJR2,E)MS;8,.)I@-@SAV\)0315S;WF-_QT5!-^T
M6;I@\B1%,C)?H>.F?Q(\2_G(5)'FI'_C/R*?@(U/H)M3-;]>^)75VY9I>O/T
M#W37'KG+!7[?,H?X+6@C;?5=\4?)#VPXR80ECO#3Z$4':>D5Q@]2JNNX"SOC
M??PDY0//&4Y5=;'Z9J(Z+SZ0\$&*%<(G0]5ULS_##VWTXKG0B7U&-.&D?N,_
M29/EVCGFPT\34<5-C2I"$%7<=53)\=_?;DE0(9&11)<SQX\;#W`R\*/-6>@+
M^3%IM+"M!;1=A*L4BWY^`:2B'T\<-%\8J]]F/AMPX!U&H?7TS=%/1E$K<6&9
M+GQS!X]0<TFP3X1N+7R(L`N'+SZ?.\_WD^=G'!R^>"8NE&%.UA_@:([<Y?K?
M2">_X,;%'OBU358NHL_%S<\GGW!!@)-ECF4^C#8_)@6.TB5@72!+CTGTHZJ+
M?R#0AHPX!.SZZ_73Z)?U]Z-$G?.5<.$YKC5_QG2ZAB]$">PS*Z__?H`&B7MC
MU7:73[9J.JJO7.?S,O[D_`TYSU_AW+*1:CP:EFK^#%T7XS&G%Z1AL"]P9:']
MU6]GG\^G-H2DO?8_NT4:-!VX^C%X:3N6"'YSX)0(CG[0L4@<OI&&0BP#'>'G
M09\G=-RS\GHY^80I>U96.1]&J1!*82-R$KH-1*<K.$?0Z)U:2C(6,])V+W'M
M`\[B1I>TN[$28\]7QM4W/F#EN,#H:3.27_]^]?S,@>$EU`BMI2JT/E^XZ/71
M,CS_A<-D9UH=MT`0B;1B50@BX1"(FSWZ!`F;@A5%`.AL4X"[)AM*H-44A$I@
MI>%7U29*V$;XO\!M.])4XXE\VS<";34">6INP],3C,5QG1NR4FN,!4+8@ZO&
MV&L;ZC]YKC;#<"PS,,,#="#NO<Y*=%A,_7&!"[9P*=%7&XI]?IRI-O1G+RZL
M^0)_I1(L_J_.N>?.,!O^@OHW4X?VHVMI?]POR/,Q'CIBO%=OT-:0`\=X0`0?
M5',*`S]3W]#<FQ^FAY0U28O=I&*S-A$>*:8%9IQ\B@I/4&0;WHV')D+OW52\
M&X?IWKM[[\[S[CA%>N]NR;M[W^N6[W6<S>$T&N#7;.Z9W3-[B]-M(;?YTK,I
M[YV!]FP*LW*`[LZF^$K@F/;:-P4KP=A6%#BFV90=^OVN9U.D(5!::\-8><U8
M!@S/O6GP=Y)I#_B/O:%8AAE3Z["=2"TEUCE*1&HY,5%.*U)'JW_"VLPX'*[^
M[I=).K!,$EI?J$H7L;6&'4>(.A3Y9B(_^<M=WD^>X)OJ?+T\)T/@5?3N&S:?
M9I7T=("MFYR(C;1;-VG-W9['/8];#MOQ5:]28;N-](<H;(O#1[BH3/<OULQT
M?K(6?V!/7)OTZ-F=IY8#(/-F4%:&K-A>4!;6S.Q9VK.T0<C%/*W64TX2FU;(
MY;Y>^1-@$94[-0&6-ARMD(85:"T^9T9+:\I^::U2\MKVM/9\CFNB(S),?86/
M4/-L1)*LK]XTP].A?FU;<[(LZ;G^JN3]Y$JU361.G3&T@X7+97H!?O#\5;5Q
MV-F3:-FB(M;KL0F-;"?('2/Q@C5R!X\@0H7OR213JQPD;6Z68GHJMD5%+/25
M;%QY,>"=Y4)GK"Y5_'?/QU5,S-503\PM$'-LPPFT;:C["48]-=.HF::C(R?G
M=]76GY:+(!GQ:KXPK"6$L1RU/2%2O!IKTV?6IS?ZVNC[U<%/-_3Q=LG7J3>=
M'$._GU5L,?6&!<,[Z[71\LX8FJ:S-%Y5$ZE'/Y>8KY@#F$W<8"<`0[;%;79R
MM->PTRX*V%968]\KX?D63E7CRD<79)1@-IJHZWLA=(C.-I"'R2()^-N@:SN6
M6J^;KRS56XUFUX'8K=(J,=C&)OF.1:7F':Z6=HYO:JW/F>M*SEQ7"=*/L8_>
MZ/T8^Z",>_3;_/=[-_N1$VV?=ISO]\;JSA+MW?%'W>K\OQ_HMGC\4=]5V])D
MQ4YLV/>\NFRKOB.UUQVIP^)-WR_:T8$SV^/-M8KL7U3#@Y^7JS]_PL8@6\B7
MM_`5&L%F_.C9C;GP7,=_P.X',<K5<&WKG*KVE@_4P1V/Y;D#M/PX.'5\28*?
M>V[J5W]Z:$'`?UZN>HGWDPD.A:LG^V'P$A5;6SNUAD=GYVO/-A&YM0,_OT9O
M_OT=!VCL[&H>E,4;Q'2P'U:G$=/!X5C^B^J?+L5U=[(JO*>C-26LKFH`7)6%
MYXL9@A/<[=?\3.F@+4@_K^`1+E3;'TR00\Z@ZQK!L\/-=%OEB6?K*,=W"B%E
MI+J5TW/K3LMMWL!`_YJ1\&QYCCCPZN^>NSUWFR^H<.2<^2H+*OX'+2ZHK,\U
MX/I$N::!*;FSGWY@6EDJ9K5.]2S>LUVIRO:D#ELZ[*#K6JMVV`&WI7TX7==:
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M[9OG#KK$+GLRJ7UH'I)EA]Y!NC"*">)7/XKIG-M4L\YQ.U.95<ZO*ME-`.UE
M_/E^4+O2,F=./8^;)&WL4ZP;>N_@]TO;FQ[\2'<;>QJI1-LL@_0NTQ67>8`:
M1`OW?O(`IQX6CE_#UK*M5]4@J>_?'J]UM7>BG3I1>1/U;D6I[Y_,N@F[A)?D
MF#'+;_AQ)V",2S3=X]A#WV*G/B,!I[+*>^IW=%ZH]Z7]&B#7F%?JG;QK3GZO
M_O&`]"F\\_O<JG&KOEBVWW,X3*<JJN]Q$^<)N0;$#F_JZ!7IGFID9QUC![Q$
M-M2PZE+#=["OD?R32+.Q6?9D^C]5!^%US*4403G^)3>*IBCTN"E;DG5E=Q$_
M/[H8)BF`S-VY2[)MRC+Q/X.MZZ2!M$S_JVZSF3*12GL/Q5W.I67FFBRV,6#3
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M3&<GKI(3?@PS9,0AX+HSX0?8X9WUVCV];1`)@"%@ZQ+I'\/AX!L.?X-'Z*<[
M#@;#8?3[W_]V\W_@?ZY_&?\$W^"E($KR[P_P3_3I9O8'?+WZ`]EOW\6/&L_S
MFB`(VM-_9I^^?/SXY>SZZAI<B](7(%]]X,'5!^$,"+PL_U/XD>>%FP^A@`")
M1T03U3O^8.SD4_C['*H.CL.?0B+X#R/TT;/HWZ2,E!*_/5Z^*PXY%L\"Z0P_
MJU[:\X+DIA`HJW+]137X*?;RG3>'?A9H3='OOB<_7D+3FB,SK=BR"DH4,4JB
MSZ_YPHM5."F6/*JH1_+)>S.310?_2<72;@C7#8,$XM0R8\^+2B:$OPJ.7$WX
MP@=R;>^5[Y$/<(H<ETPNDN620>A%#W"2=Q%I=+GO8(QM-%<U/_E>-9P?!C>F
M=OIAE%4\P;1^1C:'V:IQ8^KP[6>X+"D['F\RRXH$G>.JZZ3ZUX8Z+2E@@BL"
M@[(3GT=E7GBV37Y"#J[R[U"UKX((7;+X(0YL0PX$`K+*BF1=6II'Y),.7LGR
M`3/\=U!X_./-`L=^^*R&?-TZ)<M/E+4I:%VU:_R+4T%44LA&.>EB`B15!/T[
M54RLG"1EKY$![6CK1TD1CW/LK;@A?8`+R\9^,QV0"3O57,;YFRAXPTW6B9G!
M[-X][M?AUE`G1:5!2&GI!R0B^"^%;=)`AQK"P!P<;^ZNL<(Y41`%F4WX5(Y@
M`G&5.:HZ,Y)E@?^/C$E>5<-/D',O5-M>XG?][F@!TJA?%T-*VKK!FX/.3&1\
M/'%M#YZ,J(KEP/`2:D1!8%/L6CO,R2=!8CA)D3^,*DFF"Y4)-0387*B\P#""
MQ.X8:LC]?*BL(.+_E)U"71$@'ZH@`GG74&,1)0\JIR@,(W(-H(YMN%"1?O6V
M".\9O2<;[,X=![I.V%S1T"D0)<#'<)802Q-E274*'(Y)M4%25YH@R8(,8NY-
M071)3?`,SR6(E6.:C'FJ.TA%"1P#$B;)ED8%54G]B`J0JZ,*E$B)&K+,OJ-&
M16'ER:`H,L@5IFF6AR/-6%VJ+P;Q%?P+;L/U6Z2^(,._VC$D#WYV9YD:/3>1
M%8GA^1BZFEA:KT_9H`YPUPBT6I_8=M#UQU2\%0!9R(2>*I8JS+(JE@11%NOC
MO+-<&+U,LY7DF40#E"*F"8ILY>3TNR_QX.A5);FS[^E&A3&"Q"M"+)CF":0"
MK"1'6$F0%%&L#JP=/?$BSP%96L.A"J*LW_`\'C=R-4"TK8(Z8BE4.M'K7YT7
M$>Y"(*-_:&KU:Y\W'*XIK%8,P!WA"<36#;:[-1EH4112JR:Q20YJXT46<`J(
MQ8E-&;7EEPU4_F1..?GGNHZ"LQ[&>&1S8UZH"^2J!IUALR@)0([W2=.%-<53
MMHL.&$8`DE0)3^Q0E4=7G<(K+-I>V,B!EW!"%E%Q3\&;>W[WX-(C)Y]M?D%%
ME;A-Y/CX\*LYKBW6LJR!\`!3X@'?5BU]#YA9A@YM)]@&1*6/!G!KP,7<[;V8
M!B!*JX[G6+DLAEA[1>[E:T4M[P:D14*I`:P[B*T",-DVX7'!O>UO%=?]`#N&
MMC]C7DN/L279&&"R\G6:&`66@T`9=)9NMP5Z,[^YNH8S%D``$_R7!753,"6(
MJ?K<$L0;Q_$H:K``5R"-`J8J*J."J>1Z&TUE9:RT-4%'46U9ZX#K;F:=V,+*
M*_T]W\*I:@2KD,&AB&'"09BS5R+TL'[H`:F=X#)AIV%E&D?W+<-M&M?KPVT]
MHC.I*/."95UT=8(Y!724XW@P>LT8/V;%S3J@JJAKG9_0!%0;D;R$NHKC97NA
MO(3B,N#Y9Y8^X.&4Z<&L13(NF>U297:G3/%*N\5SF[DZK:*G77Q!4G1Y80_0
M@22=G!S5N!X]AXO<M<R^N=(O<?&V(E=>,V!%A-F8SV<Y7E"V`JR(:@E@DB2S
M'+L+A17-*TH<&V^Q6@16C=U)F+*D<!*H8]@?H0EMU2`KJOH<]SA)ZBI9WZ'F
M#!++,EQL!K)`8%-LE?P!""S#LF!KX"KYA,PQ$L?L2G%%"X,<PW+<UL`U\0T<
M\["9Y5I8+^'"QH7Y&\W)^W.2S_J7_T\*S40\KRE'4A-`E=R!9Y76`37H@32L
M>YNB&O"38T66%ZLSX4<5F;>6X]R;E\A96(Z_K',_"?*2`.V^:PUI#;JRS>M6
MQ=C-ZY9OX2$/XJL"^>(:`FM`Q*$@\%PB3I8&>K\@NYWP:"H,H>GK[Y6"(\LI
M"B_$FK]W,JH#J!@,>1XP"E4`E=I_(#*R$@\,]#50D`H,&$D0!*H`&O!34&1>
M$!6I*IX;4[/FD!"Y.2N'V;1<BZF#HA(UA]G<;(:B$C^'V02EJHNBJ)7)TF8H
M&D72;*JF@[HAJ_S0H3<%P0%99&/]\PT!5657HJ<BL"P/J,FN%C1916FKU@7C
M#"'>=C:4W(!\0!$E%@BEH)`6WB%<A+B1OWHC_/20,R-3!?>32_A"?0JTGL"&
M/<G&-:S:F6Q<P_8%-AE0B\E%G$(`Z1G+L=[EZK>ZD^X;;;3"<_$LET*9S0%6
M:[Y961(9?JL`JP516>'XU'3T;2FP@(%`W)@[:1U?`W]1@,`K=;5Y9YE6LNM`
MK8LP%`''Q&F8*:L^H&I^`7#O&G><6D54T1%DAE>VJ:$BXG-BRQ9KTNV5%"`!
MJ2H\Z%(=H7'X#5Z(*RDNH)KD:O05>)E3*$FN.!+C648!7!MU+IK:PDV%(@`J
MDIM0[WTB=2:0*]4V,2&=*$OGL^H@S;^TS_#<C`2.?`IFYF,-N5,IMBNB0')3
MD/ELS08IGLK\UD#F$SL;)'/*[$R3%4#&)WHK@/P5HND,_W;^BL/E%-YY).GO
M?N)_%DM6:4C5]PDS9)F1`5)\S%P/2DN5R:'T_E4FA_JIE6%Q8X^[XD)'JY/C
M).G587EL'0!H5B>ZW>$S-.$$^?L`TT\);]Z\<X`5XL/>TJ+;PUOZZH[\90:9
MZ7:]DM=9[%==BO)V>$X"G<)+A5/=KU=Y3G6@+@TZQB+'B3PC-80?3TG`?QMP
MN^DG62+;@%@W2Z22S+;21<HH*OY[,#][B1S_Z(^Q#>?DB,O&AA0E&<1W@Q>*
MI(ZOBA7K"6PR(;BQ"Z*!>JZ1J9H:[B-=6$[&04?5$H2!(K%"%K2D-)JHZMNK
MA*PF:QT**RIL>7V0TVK)K.Z]>3$C=\S<F*O3R8EEHTE>&K--T2)"69&TX96;
MHM\:.@H3]%6PKA=7-1NJ9'-^\/\W9GABWF6XB3#UY#P:<^4\%S^]J1Z.[=2D
M:/(2\(ES$3M5E29SDK*4"/-MU*O,N6@4TN0E3HQ/K=;#L9V:%&7FR`*33[8=
M5J5)/U_@$IL%ME"OY`EQ-/H>^=Z2*[YEY,6G8S&@,]B;C"XV#@5L4),[Z)(C
M>,>V1:XGT#\OO^$!YHVY2H0C&]Q?*06H(2<I`B\SB=6?DM+;PURT=*;PDA(_
M8WDGF)LT<+S""8S(2DVK@+GDG^+V9)UK?WK(QC1S<0<,D3!5O[^4=\X:#8&5
M3H^K);")([\[.*4(02[<S--]*70N$L<[EY?<'MZ";7D,EZ?6;>!MP`N9Y419
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M]/N*@@O9-N=?:$R5`$X";.'53NGRV\1=N-N4E<5X#NC.<#>))N4NJRJN1)#:
M_*2^D5X%JI,/G!O^:Q1?X"QB<GXT7GI5P4VZ:.S&Y'\VCF#39#O*K59VE?Y/
M8=G4SE`CHPUR,:OMWR*)BW^%MDNFDX+,(@VI1O`CN=W[&JKD0G;:FFP+PT[T
MT&C:GI7CAQ+4P12MP,?6O*-.37#.Y*_(G='<HDM-6!EKU1?6R"P2(&8I);P4
M2DJC/P[(#+E$IIP\NLBH6*N=49LB"RPG4U/+DS4V5,V_B_I\2F>N7%#\:]XJ
MB6T%9V,KEA+:)',+2`PKLS5UM8Z.R:F;]:IYU-`^6;'396F&QA8AE#4>30A-
M\K-D()$!2P-(*71\PC1P)M`FX_@H!6)Y8:B.@W`+Z6?X/5G!-1C)7UMJ_UK%
M4W25"B/+[]NIVHA:KUT#,O$RQ[+,^QC:J+)1O^O>GJIFF!Z*L3J6@?3H'+\Q
M)B6.,,G44=7PCXWW)XE)TJ]A.;@K1G+RT=3T19ANF'&!S.D8ET=N-WO".OAL
ME';V3_]EN/_4T>M`-7"I_]_>NS:WC2,+P]]3E?^`-SOSK%-%*Z*N5K(S58Z=
MG,UNG/B)G=UG/TU!)"1Q0I%:7NSH_/JWNP'>)$JF;-FF),PYLR-+)-!H]`V-
MOOSVRA6CZ!4+H[DK@![AE6/'LP&"MZPYB]XQVPEG+I^_94.<XAV;\F#L>,?X
MEGI"?1-@]I;\ZM7_&4?O<)H1`)$,G0[D>*[CB7<,?SP>\:GCPI>1,Q4A\\0M
M`XQS3_T:.O\KWC*3IJ$O;H6<9>B[MIP&V9Z9[/_PZ>S=7TY:IOF.G8O0"AS*
M3F'^B+V/0Y@O#!GW;'853P'>.7Z?0RK+L,H2M"+\;W#29#%O`&G)9\1?591)
M;!!\9J]9.I3:BC^!D)W1O'PWVKTZ;<<&8Y;LF3SVY/<FMW\%Q+.D\P6[G/!@
M"MHYCF#+W-!@<%YOP`S!5`3NG/WP_%N/\9"=<2N*0_8O0!I,DCQW%$U$.DFK
M^0YS6[@W3[\QWQGYGY-95_TN)\G]^MI@MS"YXUE^,/,#C(("N6.+@.'$+K\-
M<;GXF5@<__@B;KC-&1#I5RORA_!HSV#F8-!OL&MX3D%(PW(63H3K,D$=06`8
M'JGI:$C8\A\B0ES`DX".,8QU"X8I4#SCLUG@SP*')DT";T!2T."-.XG\*2AS
M'UGCJP=BR*)\,M8Z,1A:`09M5K*O@BP3&R:)?-BV"#4.4!4*K45BE>U+/ORT
M*!"]2'6S.,!;AXC!*+<3QYH4)N$RC,,&R)J_)A3HR-84*`[]7,<%(3N+A<**
M`^DBA^?O8+^C/,]<?BJ"!M0I%,Q$F\G<>$>"8Q-I_@1E'`E@X,'@+@`MLN!@
MEV![8>$\8#?4,?(7;'3#@+8991H;R3`*"9*=BCADJ%MA"K]DFQHY@DP_G2(3
M@CB)W2AEY,*(<G.E.))PJ-YIA,7+3VPH+#X5]!3JZ<!W75S4XJ,%P$\C^3P`
M"\\:3'#87QPL]Q9`90GG!A;3;+3;;?E3N$1#Z<J_H<V1WZC"-N=Q3)M6G#+=
M4'L9.`X"2BU@`<144)K]=R"$D,:E-KY-KNF`>(&08>A0OEP``R5=.B_C<MKB
M>@A4Y,ED=/@S&=Q`K0"T!FH=SP9&<;*RA9=20`D1D6B6E@,`1N)7D@D>2F"K
M^0_AP\<WL$.RL6:2!2A&(V'A.\,YR?8\9D&13$`P`/,@(ARZJ`H=FV0%+ERQ
M="#GR^P6Q.<HL2,!AAGF)L'WL-09T'HHV4`!8JA)03%8,".^*U1]BHR1&)_B
MX$K+R.L/9<2*_%QA:K2F;#ZC*PL<'K_PZ;L$+8F"@A4A1U&C)'PF$",7L**>
M7<`8P(!K#6P2'J3<\+E4O@1$!3C:T'5`6=JI;I2SP8-B!JR+J12W#D#A@=UH
M:_WW6/H/:-<H6D.PB7`\`UN]C6*VV320MCD;.K`1UL3S77\\3^P2XD8G4H1A
MRY852,S#0/`?T23PXS$10`!4(B39N<X(I2L\$`DD9,0'WI.%#&W,,7.`/+D[
MFW#4'*#$7-`STVGL^7*8.3L"F*]?,UAZA&)<JA_\$:B1PMKIF]`!-(#J28%V
MD+5HN9$_%O0\D2?.=POR#U0;6*;P=A@/@8\=.'T8[$+8B>1)-.G%Z2?0F4>2
M]_DHHGEE/`@BP8*1!-X8HZ[D(5NM>-F$+$-0X5P6ZW!=/O1E4P.4/"`70@DB
MK`-8Q_&`M*)8RLTHQT22DP,?A#K\/S"_9*'1>C0BDA"",)ZA"**=%V@^`--]
M>O/)!84!P($-`28/2@]"<_;$TL\1(&OJT^<KU^?>\3\%$`:VN@53'T`*V!F9
M4H#!JW^>G;U69C>8OO0WC#L/\8[#8RI$<<QERV,PP&_9>1"/V:E4#OAU`YY2
MQAJ*7Y?'GH72!.QJ4/W.L27G2NF:A3,4BK1)!",)JAA^F,Z!:!V;N2+^(:8.
M!_JZ^`SD!=.@J"2:R>E%4%G#/^4&HRDA*3Q0?5L(27;6N85X!]58X-NQA>+2
M=60,F\3("#F<A#\]0)2(IB%L,DA4@,WW?-#;'J$_<H:^C5P$B/\!ZY`GA^(6
M"^+&@/2JY(G\N6+&Y[`S=@(2ACLPD/5S-@/>1M,4Z2R2^DMRK%1&DD@7*2*Q
MF`K(0<$`R@CFF'`@XZ$0G@0TP2=^3VJP'/F(0"="M`T!5^*&@`':6IP'94`F
M`FX=L&EHPEO'EHLF*X+<021U;&=$(5JPR/E,FLQJ#TB+`Q<X$>U,.<KA60`(
M1H*E:67T:,JHFO&>')J`2#S_%EY!ZS5W6LZ=GQ,&);G/4P(^#JD5..BT6>&X
ME(Z04V5`(Q$'::'()4+%14;4W72@/4]PO+X@P=AJTJ&M3:=-9"S+F?'$\Y??
M5-KHQ`[PZ"3FWW6ZE4(C9+8_A7&!B4<`4^*W@=?/P2ZXI1-G;J:".,GK_/63
M&2PYX)0">*84#JJHLM,)(.04I+'+3#-!R-+J1=EJREQ2RF!/OT[620A9`I.&
M*?>ZW8GBIR3UQW%Q[S8378%%I[P?W3PC+1RU.-A88`G0)0=1Q%>P:(-PXLS`
M.`N(K<HH5?JVR"%PAQMI!/1(1[92EI*'.'O)IW%!9[N"[4LS`FD*=U0.TA%G
M@W:C_^N24?Y:'H-+7[+P($%FN/CIA!'8;LL:10)CE`\@'1ERRN&\L#:TE<F<
M(47@NNJ<07X7>0SW5RP%;.[R(8L.$S13"JXA&.\L=\Y:Z_4XA47#,1S?:1N#
M?M,PV_W<..786NV\05A,H]UJ&<UN]TYXMF$//9##"Q+E,>Y/5BYP3S3U?>^(
ML,PCD4;^II0=L^\>CVT'#Q-TM>],67IY"M^@U2Z?S%\(%O!\33XT99"AY(J3
M$5^^0/&!8\*GNWU=R*6)9P"]2?FCR0QK>4CO_K(PS7QVH+%AV)D+[XYE&T(\
MW%MXSLX\6-\]6BYI8\ET(`Y!>A:<[]\;5PWV/Z>GEP5IB.RFEI1;@Y.A2<J\
M%<ZU($;`Y#+'L<N59W54`M55=FF`SZ<>4@RZ<,*P]%+CPUD!5IH6]GI&/D"?
M?<0#F-D\_K]2+*N#Z`G._RT%AUT=_[\&W=X&:*F[<](;8&?[)!T!NVX,A]&<
M:SJW>.DR]?U([EX@U%T)2-,4G81")!87#K"E=""/LBD1I?BNX"R-`T_Z*A/7
M)\+);61Q^<01^7XIK1+A]Q!R].T"LLD!DGOVM3KBD^Y4E(,'#64*`X/"R43Z
M#CQAB3#$6W!Y8SCB3I#!E2!*:K?,I9NL2[IV0R1QY$N\"4@X,7D%E1:B/YD(
MQ`6\;I.+Y4:LFF`4P^KG@@>$T?!^.`TG?NS:>*:&\Q11-KSS9^S)B[64M.\>
M:.'XD`")\#$!XM;.+H[:TN1N$3U)6D)'AR"OG8>'O(R9RPX)W//BU&6/?M*$
M]/]9:5JZWY`&5+H^8*[D@#20=IT^53Z>KLKU5$:!.,[(9F58PW71WY"[X^%Y
M1Q^3#H7$?9#X5B<<"8VL)1&H^Q[JE4[N<J!AO=N/M]N7F=(FRS47V+5^O^\6
M.HF^6BDI5+D=(H1HXH=B04X5GBZ_?9#W%2!JPUS\$PG8E,H*LV1Q"7D#1[C.
M%%90Z0Y-D]I]2>V[W.`/L-HIV5F@13)S-PT6+-K(:VE0&J9Y#UFE>UVI1]%R
M0L?W=LU897>%.1L%Q=B4_Q!X%Z56CK3(PS">J@M^\MYSND=7UH2Z;9*7UC0#
ME\5T\%4W5VQ-11#8RI=1S1Z0'%<^CQ*^\B&1-#RUXT"ZBD7^-IZL)S19(ZGS
MI0UDD=4B+Q,2OQQR=[I^?3E0-][\)JQB:/)*OCM3GGX9#:%"(Q+RR41JD`Z8
MW/@2P]%'L/>1+=*PBHS=Z^<E.7"ZP.1=$@3T(9?&6\T83"S!D`Z#$Q@=9*GK
MP#!VIIA)`/N`!0?O$Z<83IM&[&$(!%TW1A.ZKG4QO!9H:(BWPP"1R"!JL*L8
MC@A#[N+!7Y[;XC`F\2V#]_!=&//C^:<SC!.(T4!%S4_WUU'.?=Q6]S"T\K(C
M2G8"+S-5"#)T%=J"6HM+M8%A`4/NU=`3>.`TGI0%D\Z>M#K92@*_X-8$Q@OD
M"R)]@5,(&#IO9&"?Y8>1BG509>QEX!`'``..4!PC7$`4Y!R\P<`NI2%MH%PQ
MBET@SQO)""/T->#!&6CU([I:*.A<ALG]I%NJQYT_1*L@`>#?$^&E]@C-&I&O
M"1@4#`_;4%:(FCX-.+*L>!K+SW:NLK\:8NIC'$-ZC9>(!^G40V&2C#-&]8.R
M`)NM.6'B;U)<)F^U0>XT&!8I<@)IR$PYG@H\\@F246,[&=:L":<K&1`LN?>U
MD5(S1OTTQ?U,W'J??6]\_)EBA56=R95>\HO,%@?KUA&W(1`/O.W2VXJ0R;V<
MS7`+-"Z()VZD"RU0E\7R_.`$0,P8S&W1%[:\3"0[GHB?!P'YXU74Z93/R8DH
M77D8"(IA-.BPC#`:R_&<:3Q5OC/05SEK>^3'`>C'_\8\P%@MI7:D9_'3""/#
M!`:.JRO*S/$KF3!CZ%%,$B,&4,,DR)<4U<CU`1^`!%^)B-3O1HB1#():3L7N
MI;\LZ#RU8!G%3H&.`.\4!8Q#8#J%W0M15\L),$(E<>)*_[.,**9##WJ4<IN2
M^$/I\E)V^J33CPI<LM#ZC&[1`"7<H2]8`E2<,HF%*$*M#_^/Z57,>ARL3H\"
MN\K./;BHT?+[*7=867N8420BT(SI`Y*?<^D?H/+L[/P.8MY+,HVDBBS..N0J
MH>*_,896)X]2A+E4@($H?IG>$Z"K'N\(^`UW7!FC/\J!A8^EK&&K<%XUDIP5
MQZ,O?5NX^2PL_#(9W1^&(KB1P7CR93CN<Z5O40+@PW_&]EB:)FBHZ-/WO9GC
MY8MU[`&_/IQ!B'3_E<BJ_#5P4NMD#>-D=(_2U!8CHBT>JJ!GH$^59I?=)ZDT
M&Q"D(2;C<670&:B4L',#B7J5.`PJ*G$YS55L&D.FQ%3%?*I7(GL3QJ"`6V?&
M981PGGTG#IA9@37)18SDTQV0=W-:S9O%D7*2C8E%<5EXFH1WI"."$@G]A%L5
M1])-,%W228"4CD?RH3A&I?@IW#[G4%.^,5"+B\/'7H[M)%12896N##,"<$H7
M%>S;NNF66N5#TYB?\::(F4#QM-UY:^Z[)R^'86^WL<6IF9:Y,E4RZD3Q3!(5
MC=F,%CD.U!M3P=%Q0%*UEG=3==W75MF^JJ]D$#[LBK>TO72%1&H[(0_I*\=(
MLHP7DYME:=WE=AO$E7!H=!N,8BM"S1F0O2[_2F[GIXB'],:J"`09$BI1IIR>
MEJC0*!DB(\HJXR7DG*X630NN,BJ<.]"V&8K8D;*,Y<49"CU,!H%%W/@8F"*!
M,N1MRUQ>Y,ZP3*C!+#@3./"X$_Z`OT1D-5Y+_&8"6]H[`2D;=;5"1QPZZ%,X
M2A#X0Y56-9P7K)GAG'X6*CPF3=<`)JQR/M><1RS3+I>H2ZI,IH`HTS0]?N9,
MU^P2JDR>IF$_GA*F?PV9K&*0W7/QH1]'"1D6;[]*;`9EKL0A0IB:Q2D1+X)1
MV:Y]M"(AE2.V"9"W3)'3.U9S.BJ+I7V\3V10D=5$VXT4&K)0EH2()JON095B
M+CDG\GR,&04U`=;2;Z3W$R2-2\R"S@]GR7N0&76<V.#NJP**JLX'X9U>G;$3
M3/#(+F17W>BBPR6[/)/0.`%Q52!`7J>'TYR9*J$'T(B7)4O!NO)A$<IWDUM6
MSI@IE.DHAFD`E&&8#Z;+!E6E#Q37QJC1U/SKYLHNR9,#JJ%\M//\)7AV`$#_
M=S;2*K1)NQT>FR5US^[<3<):B>`8!NQ-9:5`')CRGDR04\QWZ]C1Y"W5J]B8
M\1C&SX<SCD(/RSO1WS-NV^KO=,(@_607)=R-^FOH1Y$_326>&N-8?OV6M68_
M2S-`=J264IGH71F&'MDY9*W`SY".MBEZAD!-/Q!)C((J<&-\W!=XL56&-IE4
MNRN(4U;U!ECS_-N`SWY[)?^[DLKR>@Z7]HZMI;NG)`A-!.4G-$T$F@C:F@@.
MF0BN,3_N0$G@3<Z2JFI3':+9M-;&7,\,>X^;^_+#\TL_O:MZ5_6N/M&NOGSQ
MB/M*^;YZ9W>/7P_0`,G"@O*^O/67Y5K"[3D?Z%W5NZIW5>^JWM5:6")L.(9=
M](/?7OW%LH08C5ZMVGRZ[OKM5;?UZ[[9*:75I,I2QC:W7.3U88([<S7JGHW!
M%6B#9=#*Z)?6\W@[<5P-6,3CCC*?)@U-&I46\>Q`_[)+U-$R^MV^,>CU-)5H
M*M%4LLK&NYTXD=`67F+A+67_:P-/:W%MX&G2.`C5O9MDTC:Z_8XQZ)YH<JDW
MT)I<GLWD>T-QZF4VS+,GRM0M^;OZ[7VE44OJFGB6/Q7LFO]<5QPA7U<K#E42
M=%;.(DWG`^BF(IKX:25L5==0EL^FF2*<J<&^JY:N3JC>,#!U7#7IXC_7Y:?D
M*ABDV2A9$8XPS00OZ^$GBW0G@"R62EE;ZQ`K`04BR_61U1.HT(G'J000CABD
M-1:I5:W,?,?F1T-*)%/51;#`RT+Q$+DV+"QBI6W\J,U?L8EM4D.F#%FR"'66
MNL(QCXD2922>XAE6;I[(UFJRA]/4#_#V^P?V0J-D3DSU3%.4ER=)UX(UIN>J
MG@SUL"R;U\#R*VE]%>JUI;I:`2ZQE%(8E2W$R,.;U;)<E1G$0Y7RXP1)@1M=
MSZ^&95B^Y7NPY2L]G_GAN@(3WU;T;J,J7QG;>*$L.P'LC44>[<;J%P/A3(<Q
M\%96D70LVZ<6JKXL-`-1+4FQ#9Q*#%O554Y"IFN=U(T"J5?9\7L2+I<RG;RB
MTLO*YR[7=I(-9F1?FID4@+<\2/OK$F7)&KG#>4YKO,=@_N,K:^)3`6SY9J'^
M#I%5.DW2T46V>BGF8?(P*C:+R82Q3;4?D9(=@`F3)>>Y7Y%Q@FAM0<G\L&J^
M?,%?V5F'%KE4CR2GJ0.A:JV&68&^M"R`1!>JYI"X;^RA4I%E`2D;4X2YFK])
MA3+5I@$6,9VY_ER(?`FR?`=%S#7',C1E;;1I;DJ8I84<2[QBS3$0*!F.L-A7
M$;AT`VB$D&%32]6`.Z_$$?1B"R:2((J0DJ&I/W16+LT/1D*5"$RG`4LI\@.J
MX9#]+LV-!I:MOG'\."25G()86(44EICF"MH[K6BRT"V8RV+*"Q.DR))9P$7R
M%MAU=%2R30UL7D(E4T&Q#X4G1@ZJ=BK(!K9`(FD5K"A<`9>V[1"TN'O<L8^I
MK1_U+];2M&[2]$/2Y_KHLQ^&K]DE=I"5TD(VA:PD6163$J4[EM2DCALC<18:
M:>?%'\OWGDE[JQ=K.J,!\)Z&3(<Y<@G.Y=%D5]1850&!K73L1$I[(DH.#.KU
MM+::+"V=2<>D][PR&R3"D+1!C&'O"2\F9_Z2*/?C"(LYTI1K2YV?WXV7:BMY
MU"7,W#B46XB1M5D5O`:[<CRKT)*!2A[Y'A5)ED8;%585\@2P0`T(/Y5=75HU
M_DNJB$_%RH[SLH.N(TM<+D/'CE3#>R-M=R^;-/K>#7;LDZ5*TG)HKV77=5`G
MLD906CHV@;8<4I#>5M)P:2@L'LL:DEA@01T,J>I(5LH<&W$FT#:PG8W<2JQL
MJ0I3RUXVR\%`1F'%3AC&LCB`W+"TN%'>;I%MAV,P:+&!=,MHG30-\Z23O(/H
M2'&3?W)@=#JF,>BT<GWHJI@3&RVH]=`%9>0`L/9.C)/60+W\+EN6*MB@*J?"
M.KK&2<\TFIU.^FR>(F2/HAF?JU(V"R^;AMEM&;U!*WUYD:1F:6=R"??R$&WC
MI&T:_=ZFR,VW&%FBTAP=:KU:-[WZ36#>+O5B4^ZSR\#WX+,E-CBQV#Z"Z$?*
M&E4%L<C^Q.$5"PF[V'ZD,$_6M)L7>]S`#%:4'`:2SAO8W#XM8)TO-4-UZ*E%
M'I;<RLK^%@E9TV'=Z/`J'H9PFD):_'!3F?`*`FFZ6/P:Z<VE1@L".]0G!:Z3
M+N#IX;):*QG2P8J,J5)>!C$-C/M@@2:.`Y&V@[A#Z/WM31P>CSF?O?T:C+FG
M?(F%WE2GGIUO$_1UE!9,3?L(A>?IQ/#T5<8[&5-?PG@6&![70#WOD4I^?_GB
M;R/'??L_/OP*$UHB\-(?J?\=_/%-C'Y[=28__S&X^/#''^WF,>C*8U3YKWY_
M0L_F=@EU%0U^`07+6H7J<80?IA!TI]"HNO+]9?_3A2X%28.#M&WKG7QF+-GL
M84S7%G:NNIDTW%5IQ50/@-Y`F]^1+=D$667%"XT)N553XQZ4PB\=XV30-@9=
M4Y9,@Y](:\3A8IL%]?2@@U%S`R/U4U2QCZ4MQJE@L>5$Q0X1V2ELN84@SMEK
M&KUVW^B8'72#+`^.G3Q39\8R^E`M)ZU093%X,/_AL$?V:EJ+F)IED&&983GT
MP9H5A599N!<H2625-8N<9CBD0A-M<)CK#NH!O;+H5K@W"8Z20J0CT.H^G/X"
M[L!?*$PC3O8V&!/Q$$7XF`?I>;*T7EM6NA8%EN-1R318R-A7E(9,JU7]8_'Z
M=:Y\\$+?U?R6Y,@#N8C*=F-;$JJS)R5$&%/I8>S#(GX"^257'IE&_VN(Q>[H
MP$R.V'S+16ESI@7TD*#(NR&&5/X5?;1I+4'EWS-D[X>0_!.*<]`5&4NO@I0K
MLNALP+.?I;A*.0,=C`0'4:D(IO*(9C!4NJYLPX"HE.8P#IZ[DAS.\UC!\WJ1
MM_!Q.*$'/XB6)=B)PSG7P3C!./7=$-+)2D9*?ET*!>H^.@[RO^6OG54S9RF7
MJ-2A("D1`F7R-:UPQ4\GC*@I!7>C"1E7JL^IHUHBHSQ(L)N=%:?<%JI2)=5)
M#>C^&$P7=!O3CX0Y0F1^M.1>.'4MU:Y$;EW9=2-57-89G<J,%@2L+"R:,":9
MCJ!LTNNKW"7Y0L"#]*)%3CCBZ27G0G%H4B&R?3:8LH'LJSG$:RT0%ZDF*0-]
ML94X7JGF6G3+4LO(MKZ"DG39O%CZEPX&Q7:!"S#*BKY44WLH<BVZ54/KO$P<
M4FOLU`]Z#X7UMS<K37:TYY.S1-+FZ]+%,X!GIYV^LG."-O71U&\73/WR[FA:
ML-PI6`J(R[K$T1F8[OV4<9"5.BXU8\M[$-[=3J(.(7RUK8RK0CE[_=4!J+I*
M;N58W;LJ))9@;;>J(F9XPWYSX>;(6Q.=7<-"B#FXF_??];VJB[EA:O\60L7K
M6"%3$_0^$?0FJ8Q[2M"5*JZM,18.T1XHPTV)<:!14]^DSE(XRR3C@5=OVOV,
M+TV4^TR4.T*$#ZLFMH=Z]RO>:(C,*;25T_C.FZ09,76IO_DFY^Q=JZ=0"^[=
MJ<(\9J]EM$\ZU=&[\QI;$_/^$G.W9P!![STQ/Z3&U![J_8]QX,F4+KS4&3D_
M\;-6_D5ZZFOE7Q\&?C[!N:K(1MLPF\U["TX8=7<PK^EZ#^EZA4%@M`8':PX<
MKB-`.^`?!35:8NZ_Q+P/JG=4;&K"UH2]EX2MW0/+S7<Q%:(D;E3;!]H^J#4O
MUTV,FKVNT='W!9JJ]XNJNWVCT]U_JM:>@@6T?19A^+:8((W5_"R'\J^T=:"M
M@UKS<]WDZ)'9[1B=3H?ML"1]K<V"YP=:D_.3D+/V%!2M`2K3XA%0JK(754'6
MW@)M#SP'&[]\L4,B=%5DP5'',%N[?`FK#8(:`%T/@V#_.Z5MWT.0K$%G_F]F
M&FB\W5/.5D+<<\NS-7#?D3#-ZB8RME',@NWI37`=L[,U*VE6TJQ4RTB+5?S6
MV0.=7UZXR\`BN$]G/.T#(I_%>.H\/[/=7^(#\%3GUQ5/*?(?GCJWT6(>6=3W
MC('Y!*U\EZ1\/0A/LX]FGP=VPVZ:]\^OVFGVV:GVV*LGKV$MU/-<K$JAX6(T
MR?6$JM(R@(PR+%XF&X_\TC2R]_&G7SJM`;;#P=KGSHUPU_2TR=J,;%(:.%]2
M^%P,MU<]N+"A""\@L-WHM6<_WZA:SW]=0/9?L1$6V/%OV5^:](\2%%'`O1";
M\[T%]O02\5&@35=$$4@<543UK:HF7483)81S"^(J>[4)C+M$;72PH&=$-O@0
MQ-HX\&///D[@'M$_[]CQK1C^<`!TA#2,`O^'.%8E8IO+@@&H"ZO_Y)&5$F0)
MDA9)4GY1J'[,%JF<9J1RR)U".63ZZE(V&UMKU>J=W6!GUPJ\#1&75S6J9O2]
ML"G%Z$ZB<VN,4LH57[VL'G7K)&D,F*_I3I4'J%%,Y#..5?*G3CQ5%>D%X^-`
MR(94U&(6#MKL%[/3-&!GLF=]V4'%=D!Q1/`'IQZW6#<I2$O-8\_*I#W"#'LY
MS1OL,@["F,NQJ<U.,ED11.QLBYUG_%L/02!HL*L,+`C!<#SV#^[%6+,^T3H9
MD>9:'&=?JJ7\`KCHM7LX`&DRZJL91MQU:0I<5D[-4=-CF+:L=21"F^_I.>0N
M+31I1*'6MQJYMSP$_5A%_ZW08T55%S@W'%7JIZP#)ZC*OPL;B'Y\BMJ6:O\_
MCCZLKZ>C1)EDNJ-;T!T9#M=7MZB+B;EK%?<76UKE6I]30PH0'=2O)6N@NO""
M:F.'Y(K/45.:4/8PQ??A[PC;."8=>JD?SBBF@B[4"]6S-N@-2@,Z^,90N/ZM
M;.>2@)9[+6?-8AN@P,+&4.I-U2^$ODAAM:C'AFP)*>6076C405V%2^8I#IYK
MK@Z'NL"1+3H0#8YLGL4]&'P6IX(VUW,>NX6DE-]JOALY/X5]#++OF#ZEOP!/
MR":QC'9K1%L%6@_DX,?3J_?L].J,7?LSQP*SJ\%.S"([=9JRUT^ZG6/\C^Q/
M!EOH"=D^A;KW((#)%JW;H2O:FJ_868TZ,B2'C:2G=N'G1*-DK62_4"_:HUG6
M"CYI\)GUG!7VZ[3/"Y"\;/0)8EN*;+64A`2Q]]>Q;#[LEQ(D=DTBK<)E4WMZ
M3K6(6=A06':!QM+'J$VC:L84R3Z-.3H]PJ:.68_F8C-FV'OL)24G(A)!6/+O
MOT9Z45C`H88"VU_+%0:RUWVNE?!K9`NN`,;6S;)G\U&!G#[[</9CE_A,CI1>
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M?DB:PU;TWLL7FVH^>*-^AH^6"0>CZYXR,^KY%Z$)6Q/V_A&V/O`MH.V;L%P>
MAEG8"T7G.3(TA,^<B+M:&]:!<NLF-([:AMEN&MUV;V]+J6F"/BB"[C6;QLE)
M<V_)N>J1KX*R>SR*V0#[F@7WC04/R!#5I*Q)>4](69^I%M!V-N'>&&.^<Y'^
M^A!5!U*MFY38_^*3FIX/B9Z/6F;/,,W6P9^AJFHZ'?ZNRQCJ,H8U6-6^E3%\
M-E9Z^>*YF0D@T.RDV:GF9]Q57+</Y2S3*-+E;,HG-`5J4"=MUPKT/;;P>J9*
M?2VC:7:-D^83M"RI8[4^S4NZV.7#6:C?[1N#7N\P66@W"EZ68#2MZ[8+)8DR
M=WE:#F2YED,H"S)8W+54?]<XI`HTJGP/?#%T/'_J<)?&DF%-\)MPL[HCLI8#
MO1:&\91*ZX18KV-%'<VE=)@=J>>Q*V4@=MS@O9>KJV[N[\U2&G<KZ3W/OQML
M4>V<T_?=S+K!LU?$5=`9^T]=]ZF?H.\Y=-F4W6;R#7.@]\GYJ<EU)\EU$U_K
M/I&KKN^SD7]=%UO9M8W;4;M1D]S62.[EB_TBNJ31_&Y<W=:``!ZR_1<\^"&B
MK`!YH6PRNDH%QZ8$5'O9YI%@1V9)3-Q*0M$!GOM7%\5LF/WJN-U=_:1I=Q]I
MM]?=>]I]]G(^]5)QI]2&0-@+]?FU%CMH2=!L=$[8,79Z.C'W7B)H&MY+&C8;
MW2;2<*O1Z1^L6CO<L]LW)_S!1H&@CD(B$&'$`CJBM?01[=F!KH>$:#;,YJ\@
M(IJ-_BZ?V7[5RNV0:;A=<GNU'[1[KZ/:?FFQ?ZNN7"XV^,0Z"7/!@TUZZ-2-
MX_<YNJFC&J2]Z6Z\3;5C3!T^5T,":S*;S\,WG4:K=2@4IL\U"VC[\!,;]PH@
M=-_ED>Q8?M369YIG![H>]J#9ZN*1QNSMG-_NY0M]IMD0:$`9@+W3Y-H>[!J=
M/NKIY0#T%L#O`)`VFSO"M=E11^NN9P>Z'L+@(&J\:0K6%+S#%*S/8PMHNPS\
M(1_*<Y@_2F(#1R,18,ZTXS'NS=D,_O)MYM^(@"GG$#OJ:L7W[$#70VRT=OE^
M6A_5#IIRT=O0:>XK_>Y&-9/\Y"G6ZU/!0NU^)T>QD3_;=<5_KUC_0>]N)*A"
M-+N"!RQ',UV7*.&$;,A#./G[:`PQNG&9!1AJFA:=65\CID+&XATD]GC"NF+]
MYI7[_DR05<K\W%.^O4\`V)[R+7#AC^.2(+E;'C);P#=3&-UFPSD`YO&QS'22
M1:2P-M1U0`E0<_;><5W&TU)4,!`Z^[`4U6**E.9TS>E/QNGWN1;=0TY_+RP>
M@[I%UCSSIS/T2-@^ONA';,*!2[DM_ALCXT<!1[N.31S0W<#8D9_)`>9$H?K!
ML;B;/IM=1!LT1>YB>L0M>)K$"<@69TI%Z%9)D]S0Z1".K&]G(=0!6;3TT7-D
M-!2^%O(IBB\;]@0`QA)T@1AKFT)+FJ>4-/>YQ'IF27.1\6!.U5,ER>(-'<B`
MH6#-7Y45'\_`C@=1\/(%$W2GI[KA3G@$7\/BP!1`P3+C\W2D$-`6J'*28!P(
M0:P\BB,P#1J:-;<!&6R'9LYRYKR/HWT/S8`<PT^*]CWQ+G+GK'B9P9>N,T*6
M>/Q^)986W)HP,!T"&"NQ_CU``QNA\4\7'??1PS7TM?WM31P>CSF?O3U/"^U^
M\L#FB!&CX:EG_UW8,-SX%`\^9+F<.Z'E^GC\N0;HWB,8O[]\\;=D'##%IDZ4
MO'T&"(*WA6>5OPF&CX>+_"9&O[TZDY__&%Q\^../=O/X2LR.L8[5J]\3'"FT
M(-J!!MJ-7GOV\XWG!U.PKOZZ0"]_+2GVS>AB[RW[2Y/^44^`R>>%L._3MR#B
M/;%0*[DY^_D.WHZ`%HZ5PQ"?PSG?L5L_L+-OZ5$*A:'O1/9<2KK'G%*3DYGD
M]U$@(FN2/3WDUH]QX,>>?9P`/*)_WK'C6S'\X0#,""*\Z/\0Q\H/VKQ?+<5E
M>BDAJ@6R*^7F`O.6[,8B^\HO;H6<>.B[=FX>)1%HHB\^V/`])BGXI&6:[UB.
MRL@X+M#96M9<K).]CKNJ.ZGO%IKU1_.'Z<SUYR1)$9T!G'(T*HNH+,7;5R]7
M-=SLR:KA1OY<FE)N_UW(WOL\L%&KG#N!P(,D4/!LYJ.KRF;G08/]$XZU$^<'
M^T>#G=,Q-J0S*@)V-G'$B'WX*:R8_%!?1R/'@EF/SCY\?9UAERJ6J]$;[`+.
MIP%60T?-F'JS<KM].@Z$U*`\H.ED=?3P[5/N_F9#R9=2`Z?:K5"%'=[>O5#[
MP>9F_24&W\`"+0V<6;3)L[R6]DXAK!0[IW2T9"%W.;IP(KPFXIX7`R>2.QH8
M\9=VMVF`(6*@U0`V)QTSA^AJ/A;R&BDYF@++9OP3.C]E4A:.!W(@"'$&Q=AA
M!':K+-PEW4;.=!@'H61P]#J)(.*.1\=<+Q3WLF3+CJVK"'[[B-TTJ*!56\BJ
M'/6?![+>2<U`V^2H?PBR=[CYZ7]3<?O(EMA&'6OJ*.`?9U2\P01SCH43+I4!
MK-^)7$$NRQG(=L=R9BC='1EXD!J#0]^+0W1VC`,^331*-DJ(5I(33N1=!6H*
M:8G.0#G$F(T-P\MWLM_DV_P6/]/PL")X+)(@&GG?*7['+;!/;U)-<QLX<&KV
M\!H#/::H^%`C67XP\Z4&'/XI+U1#%L8P,9B>BW.G_IQ&3DRDG[ZG,T>HTY*)
M:;"9"/!,CXT(<Q,9"?#E^.7,XN%$H5(BF$_A(!XI?W'Q^C@#EAH+<0:J=RP(
M!)@ZH@A9S,5E1YWFKZ\3!9VS"@H\?(<BUDI9*V6ME.NME*V=5\J/<`SRF#^3
MEVD^*AMK@O(OB:6;\"!K]I9<X\MS2Q@%#N7627?]$3Z1>%):S7?_@R5$TK_-
M=Z]+-01J4WI2GJTLWPN=D"3TD?,:Q;N";1PH%9A"V.MW\6BV%M)W,`H,8[;D
MH]DS.>AQ,?`4/M9LKGY,+I*S$';Y&.:3*@BU*.GDD3/*Z1-:RPT&-JDK#M^3
M]Q)W'`A)4]/?>.]QZP<_2I$&6X8>#T0,NHUN8<KY,=U])`#0#4D!"F(.(3Q5
M+826G;SIQT'Z]0CO5(I@E<-`B_]J13ZZU0#!.;>:VC.\[\$[V2%.2QNXH):W
M>TE3,^?7@SQF3R(-/SL6>AB(%+Z)$,@3B"9U-MY1YN-I$+^K0O4Z)RV1#2C\
M&*C?\4"$N3F\!PG>\0\;C'/7GTE7;[H/25=,!P\#*!H`HAC6'N2.`\E<#G`E
MG"+&Y)B"J:;\A\"8"#F0BEU"LQN9-YZ-`EQY^CO'WITRIA+6#X(#Q19!Z<^Y
MB_)-/=E@7WSIU'4\RXU#ZLY)HP,`%DP^QC`ND*)/ZJ)^0$+"8[N>BXV=^W>;
M6NJ%7:%W7JHCUAFI=X9"5+!'MR,67K[8!J*2%AEWVUM#3#IB[QT?>#'@,Q%'
MCA4"!P>SPA5J7H04Q`=GEX%OQU;$SO/R`MCT$C@//B9R/;LW(@FR9N(&.T*A
M(`)WSCYR2\BG!-HUR=<_//_60\D`DT<">/U<H"G$/O-A^!IYO]5LME'DA,**
M`SBU_R3!<"-D,E@H3^\8H>V,'`O`C9RA;\]!AH%Q`&;?G[$46O*D[LXFG(FI
M$Y$AA"&?OA/Z0`8"9`]Y%91?!3XI,RH5F(6K/=AN&WY+9>Y(I/)0.OC)O0__
M;C]@Y(G5H&Q77#.YD"=BVJ!,*V4:)M4_$2@5%S?\E[[1ES<O:0C?@N]JH4ET
M.K1T8,G;<?@FG>1I+TL+0KQFJN@I^G_6C`HO4BK80`\=+KKNI;:K-'5,HJ6H
MM>,[5OQ-<02B<.$7&NKMMMI`U@S9ETKX:<I\%,I\FF:3.X\FC9%-^>Q!#0?W
M'3L'B)&'E2@ZR=\<[0L2C\S7\GB7>J<\)W+@E!?B&9:<^)_8&3Q/V7?7%`-)
M\?_JL&;C93D>=#>GRJ*_94T5F-UUN3R<:3?"SFZ17DG/H,U(IJ30S>Z3C#I3
M:WIY/'E?J=#J?DK[UMW27HM[+>[KAAPM]S7A:#O_09*_74'R:]&O17_=D+.?
MHO_EBP*"3*/;W$WQ#PNI(?EHPW]1_'=>8[B`ZX])NJ?1![,92'=9IF7DT+4N
MW>U_;UPUV,?S4RWJM:C7HGZ+Z#$-;>=K._\Q!7WW-?OH!&%$,?<BL-",#[DK
MM"C7HER+\JV*\EVUV>M(.MIB7Q3DO=>Y1)\1B?1?S&82"HO1O)Z(2+3?(RY)
MRW;-H%JV:]G^U+*]5M'X=<3N=TH:6Y,K(4LN8`G=R%^7+D(]->`0$'M1,#\>
MSH_51RR=X*#3/\D7\T?,;/V*_TGU"?G]899%SS_FM$6.2_"X7!;V?,LPA,AL
M-9+N98M*:^$<8C`_8.D]-)46I8R8$(LI.<$=;0">:&OWDK0J,N[.EY3)Y[-,
M142%_R0I9NDLE`MEMB@5A1*Z`\S&3NK-9\_E.6_&'7M]@A9?3IBA!*8D3P;F
M^4?LSEFK0YG8K979]LO#)"DV*T+RL(Y^("P,R;<9?5Z1LJHJENT,E^E$T:=G
MH&%YHFAU4VA5>N@ZN?)J;^3/A9CZQ)17KL\]]D\J>XRBY0SK*`7LC+)?V-'%
MU3_/SEX7\DD_>>RC&`8Q5IYH-9NMHNI?R#!-4]2+*:0TK"S<'8C_QDY`5_R8
M*.KA_<^<<<L284A9EBB<E&R*"PF;1J[0XI1C756/BD`MO(32)2G'F$B<4>Q1
M\X_<8RB\0"BY/J8!AD7K!M/A01K#(]:]6@!MHR#XXXJP`\PP?/FBGIQ9BQQ#
M0,ZN:`*=9:BS#.N)+)UE^$1.4(T1G66HZ44+&DTXSXT1+6@TO>Q7^-/N[M6C
MC&J^3H)P\?[%8U]@A/,@'A?"=(]RY5N_G)_FB[?BS4H@QK'+J4,KG\T"'S9X
M!6&E3=HVR^_0D04ZLD!G=>OLOMJIO5T)%=O=G7J443$4(&U^$0A+.+-(EO5>
M4F1L!$/3<TE^2MII=`45:=6F55L]D',`.D[GMNQ)T-QNH7:SB#EY.[Y!;-S#
M0^.:*C`NU5Z/%!=WZ(10*,;]<R8L6=`:CM0RCNN+LA?*+`M5=;_5-'O8+KM/
MC=-AQ_BT>JC4QMAZ^6(K80:;[7L)S*D\KD=HPA.$5U7'_*-0JO58`58ER-FY
M,-6O_`?[YMAC8%BNNN=\YD-L=H<<>_3UVY?/Q:"IT\M/&$24JRB>;T'T2ZO=
M-DP,OAS)&O6<FMC!$I..SM24+D99+J5#>>2DD?2G"P2L"6NCR`8ZJGE0,CL3
MGKTRK#/7`<2*`Q@H<N>`H;&/E5B2X%-LT9.ILFUUEEW%1D]KZFQ$Q,\%VAWW
M=_L>_5E.OEHXT:BGP/0W5[Y+09+4*/3&L05]P.Z8`)O'QS*N,13!#1B)81JZ
M'4:QG384L\FO;QVW6MWCO\<7YJ#+CDY!,DWY\/CTM11'RBA)I(:5A'Q'*+="
M(XT%I[8BJH332ME#?1M2.$$"B1!G4^+2\K$#&5I#/^E+D$N_F(T!!J*[).6H
M#5(:38KI'K\R&[N-Y.+<HW2:;.QD0IQ@)6R%@;(&$ZWV@,)',;B=@N]E!Y,^
M0;,R?OZKQT[C,1`6Z\DH>R/K@-8RLK#_"S@0F+U\2[1<("W,"*:?9RME(K=9
MQK%F3=V2':Z.<\^_S>&&+Z&\U6@E*,\-ND!T0W@@+%`&'1E2>N,!.M+P5*0Z
MY^4?E4D"H?*VN02'R@G`E:[,&\#]VUJ;<ZV,M#+:%$GE'0ZU6I(V,R86>8*9
MW43D5<D;`!8/9R!1?/PQX_QB.L%'_/'O<83942%H`I7$D/8B3+(9/O[][-O9
MZT:A)18UMQS&CJN2K&:!N''\6#:V]+VQCV)^2:W1M._/3MA1ZF1).E&5]R>E
MJ:F%7V956P""*U"ZE6G)1%L5YUX2EI3W8),707;:A`7,>*#J9:$R8#/GAH2\
M',`5G'(?J,D175`D'H8[SP0(?J$)9UES+NK*"9A).W-)O2S%^)2'N!-XTF9#
M[OU(Y+=LZ$E(6@D%Z7^80+TB5;G,+,,]!)#&0CJP?C';F9+"5T!--[K)%P:,
M`,I$)H!XN6%LV8F,4M/(C$B[C`*6RON2IWX];!>>=HU=1[%%LB?(,1M%3D-$
MXO*AI*]?3)6;,H-)J.MK8J9)[UQTZR?YK##`+RWU-";]"<IP+84Y">%FU-$L
M\JGI>Y(0(UV#0\45@'-8A"/M+WINL8$C\V^E^2%!5];@&"C"(]#*6[ZN2$$T
MTRU+IK=CD0U.[)FGU[1_%V$#K=75S>,7/)EY$]<H6=6R3[4,)&UK:%OC:97H
M2%L8:RV,"Q*VK7X%$V-1KY9D*#;*U2")`KRK^:5M&N9)-[WAQ^L0A\Z'F-E(
MRCY5\<NJ?,,&E$Y.+>%Y#^;G4N4?Q[,TZ;$_,'J@[%;I4#[%6R028MG3V>$U
M2?XVFTGR]S9O`BOT>L:I8(_;C5Y[]O.-YP=3P%8)0>2S;I'6WC&5K/67)OVC
MGHC`*`BQ]>A;.-8"F2PFYOY\!V]CZNNQN@?`YW#.=]@TW<Z^I4<I>H>^$]ES
M*6D><QLY)IE)?A\%`JS2[.DAMWZ,`]@#.\DN^\N(_GG'CF_%\(<#,".(\*+_
M0R199LTT':K*)8O&X7H<ZMNEYQ;4Y7::UF+9.1EE\.#!2FS]>:I4G;5[O1JH
M,VR"K10:H*'?&90NXCP.DC/+(AXR!RB,$^*)P94'T<2,=[P;'T[NMO1+<AF\
M#LQ?17,B)CP_DD?A=*!A'&'9@B#.CHUIQV(Z45R)622FZ.-M2_7:/HSS`VQF
MG8`[\!/$1,O>M;)7W<NT3AXL?5%J?/><&Q&$CHS3NA8_011<-,X;[!0]1SE?
MI711WG%+DUW+D"\,1K1\#R.[5HA!)UR\O%$E`PVTPT#`.Y[EQC9=EX'%=0P2
M&1U!9`0Y'DP6Q9D4E=*X@U4'5X*Y`"#,/^3H&T4W6R!D_$"KD^@5O.$!.VX\
M4<)PE>_FGBJ%NL/S@H>IW38&G=YAB-U:@7;@0M?10G>MT,U,HU;OP7+W'_[$
M"]G?_=D/D&$Y";Q2:JD;ES>?/BV.G+K!I9A%<Q%GP"`(SXFGK-7JKKZNN&NH
M.+T\`!$=^9@YC0(4I*\33DJ,2+!>9W$0QIP"$/#RYI-W@Q)WG,2@I<F8'WZ*
MJ0S].OKTY1R0?]+LOV83X2Z.NLGAX`1$OTEW$4I^HQ;Q*YP+KC?V8K5:QDFG
MGR_P-9MP./U;\^P1H]GJJN)>,@Z"*`!0B97#4-%D=<!(WRV8^5H%:!7PE%+N
M3ZT"UJJ`+_Z-T@#F@S5`M&1Y7PK/"^?N#?<<KO7`P_2`:?3[#]8#"1HJ*`.S
ME]5QS/PZW)["Z&&$D0XW5/0QW(J4KW9]H=WMF[C;GU;E;&^;TGJN]]BI=@^!
MUUOUZ)Z:*NH"`ZX*:@)=W/YHY%@8K`,8QSA7M&X_.B.4ZS?"BX61$1D*U/_X
MP0^#??F/E&/94!CYXWCD]/`]BMAMF\J]R]*8MWP([X-@[/2JPHC.GV4@0P3R
M7%C*$9U"^CU);Z=,/I[WMN"[B\''/(Y@NR*4[NY<IIN$,F-Q"MLW.8[\8_J0
M9"L60[,Q<$G^[/D1K@]G4A!B6'%!4]#%-&<8+"3?R3FI;#'S0<67R'DM$6I]
MWWQH>'27TR`7,5&RQMI9Z;EXUK0$^$D%V7:5A:2B*+B"O7.E(#DM6N[4!P%P
MCA[Q#U\;[#)GZ*[Q_)*,H%#`]%VP&UO=I*.!#`M2D$I+DH4"3?!B`&+V1N:1
M2D5D7BAQ-_1+9^5H&./?5(I\Z'LQW?W]TLNJC*-D5HD0,EPU460J,!K7NBBA
M6TM";?O;>X>UK#[_[4T<'H\YG[T%7$R=B`(F3SW[#-X#EA.>Y8CPW`DMUP_C
M0%P#5;]'POS]Y8N_)6]F/W\=(4:%%Q)Q?)-1PF>8QW$UX8%XC[<'2<!J.A0E
M,L(?W\3HMU=G\O,?@XL/?_S1;A[#QF%V=/O5[V6!'@G&%L7.)AA$08?_UVP-
M.OW!X`1%C)(:5/FY(&%N.)Q]O&CAVULA63KY<I4PP\TYGBP\[`>S"<C'MZ2$
MRWH-E,O04BD(@LJ_38<JD9UW2+=U@G%!,)6(KF7YMB"]`.%823+9M46RW3@J
MIXC]H>_:<L8O?B18OY"Q^P&LE6A^IRU1ZHS2U%5GZJIBT^S;#A;\#GNXIYOZ
M/W=(-ITN9#N0"7,5H1Z\=+E754(])DZVTXJLAGN2UFQY[V/VBTP\$84$K%1G
M]-^%BWNS.DXB.V3;8/$D6PO`>GA#EAJ?9>]36&"K7?93DALFHT6\F"Q(&)L\
MS.X<+\5"-*O21*6R-6"F#,`5TBKX#7=<.FJCY4II7VB>BNG,]>?D<K7A3&]%
MODI"`LLLC-V(JR2:O(V><W.K9;:28EP*JBTV_*HA+57E;VEXL$\>]@9!U[;F
M\CIR>>DVR4/B$W-WG5BZLP%#:].KOJ;7,\G"S:]U-+4<+K5\I:OM];VHM`.H
M-E2R95-CK[?S^3>OY#JBSJ;;R'==_Q9/.%0<-8RG4[R=\$<9+27%\+"VGA,Y
M(GRK)<?^D5H5T7$HWMJ?==GBNB78;JD[4UT%XKWB2ZNU]6H?.IH\_S;@L]]>
MR?^N[&BZ9,P_]X+RBWCY8NUNP\]ZO_=IOS=DYSN;$M=U@_]-VE'8A[:]6G0?
MR%X_3=O6O=ITS1L'PAMZKP]JKP_$I#F]$0$?BT/;7<W)![+7VJ+1%HWFC4/7
M<H=Z<#^0[?TFIMSQ'&^L]W<O]_=T/`[$F$>'9:9JTV5CG7P@_/`EB<T\*'XX
MG/T]T$/Y@>PN9I1BF\R8NWJ']W*'/\$&.U[H6(^ZOR]?//(.PP1/8;,DD*K8
MFF/Y]5O66E=1?_>(8BL&C8)HZ`>V"!2FDF"HH<MQO<7?5`Q4B^*G"K^H"++0
M=QW[W=ZRXG?/B=9'<&]'S+*UU%M'V:M):4-,?_B)#;Y"P2X#QWH*XTS3U-[3
MU+4(INS(D<WLPM>:J#11/1S3_^)NK.63]I_IJS]]]:=#(/1>Z[W6>ZWW>N_V
MNF#?L.&83.+?7OW%LH08C5ZM(@E5Y[_;^G6/K9^O<11&G'J.&Q6*7=YI$16[
M1YBK4??L5)%U<BB!<@>H.M>)HAK\M#5/LH"6T6XW#;/=J8[_W9<RF@>V"?\O
M.TKZS<:@IZE>4_V!2OZ3QL#4Y+_#Y/_RQ8Z*_7+`GX[R>R==XZ39/"3B7W&N
MHIHF#SE5/?O"]HZK=X"8:JS4[K,!N\_=F@DT$V@FT$R@F4`S@68"S00'S@3Z
M$FE-H@;V6'-=JK2_C$-]950_^&LG5(XZ`V/0W1/W24EXJB;\>L!?.\(_3&VJ
MF4`S@68"S02:"0Z="1[K$FGW3U4/24S0`N6@!,K+%WLL4NZ17:\9X4`988_9
M0#/!;N!<,T'-UJ.90#/!83.!OKNJF`"5=H1F[29E0+7UT:N^9%UC.=,R6B=-
MPSS1&5":!^X)_PYG0'4UU6NJ/U#)?](P^YK\-?D?EM`WC5YS8#3;!R7Y<\>J
M-]1/N>R,<"C=RPN'O7HTNW[DYN5_QF'DC.9[NZ//OW];[4?_N!+CU'69/\,`
MV)`Y81@+4(N>S?S,N\!X(-A0T*>I'T0P`/Q^(P(6P6X$+!#A3%B1<R/8C0#*
M@N=F(G!\.VRPZXE@L1<(RQ][])[E3V?""RGBEHF?^%DP'I4Y,%)2ON4A^\4T
MFF;'Z/0[C;6>#23S/27KO"[9&=%572KMBY)Y^>(`U,RB3,J2V!\LE8H[,/1=
M6\[Y;QX`PNXH]:VUG-9R95H.]=#(=UW_%M63$S+.PG@*L,R9/V*WDK081RWF
M1(X(WVHJVTLJ6ZN(]G0+=])NV$QRY!A2.G/2DSN>;I.-59"8S>:O]Q`C##/%
MU')_>]64?ZOZV/AW=E&9<QO4V)&T.Z!E-4U;M0)S]QU!F@PT&>P#&>Q#3P?=
MP7@7*:\.8.X^&:QJY+$[M%%CT#39:C+09*#)8+_-)]U1>0<)KPY@[CX9:.M)
MD^T.DNW.D\$^J,UG]SIL\>98T]XB[0%R:TU]W\24.Y[CC;795E?0]E7PG8['
M@1CSZ+!.#-I4U*RR,3Z^Q!28Z8\.BE4TZ=6`]+171Q/>\U2&AB\#;D4Q=S7Q
MU16T?26^3T![CA<ZUD&17D7;-`%-A=X=RZ_?LM;L9XT6LW]P#_W`%H$".PG?
M'+H<&:?XFXJS;%'$9^$7%04;^JYCO]M;]OWN.7>D*6R'==FNDM*NPJU9H"JF
M/_P4@>6$@ET&CO44YKOF!<T+->6%:Q%,V9'CL;G@05C28D,S@V:&0V&&?W$W
MUOI@Y5FGD`M=XX/X/L!Y!XOM:%G(=:A9Q64O7^R!^V"_J1*VZ/#H4E-E7>#4
M47":0+0R/12AI<MN5RR[?2XL5;3*I*)5K0W(I`QUNO;D4\!?OR*4+:/?;QJ]
M=J_Z!NR^E-$\L$7X=[7^:K,Q.-"JPYKHM>#O-#HGFOHU]1^4R,_PSGJ&:7:,
M?N^@F$`WCEV9C*9*?#*AP@<V24O3@D6K537\4<MH-SO&P&SNAUPIB1G0I*]U
M:MZ#T.@=5`<+3?1:WC]L`VK'`P_J%JZY8!>YX-EJ']29#_1MU>.<J&9.H,]3
M-2;C&NO7(]-HMMI&?U^ZPNKSE#Y/Z?.4)OJ:P%\[ZC],.U+S@.:!0^<!?3=5
M*>ZOI%NE/EC5E:9K+&0&1J=C&H-.2=SH_LH8S0+Z@/6NV6!]'?BGJ?Y`!7^W
MT1QHZM?4?U`R?V#T3-/H-$N,Y?VE_-R)Z@UU(RT](.CFPL_2=?;EBR=L+ZPW
M]6DVM61+89^WYU?`+\_C`!N)1Q,!_P9"L"D\,0F9@%GMO'M`Y@6V&?=L2A`T
MZ)TS?SKCWIP%PL(:,#;S9Y'C>_14THQ<_)P)+X3-]T?LET'7&/1A+'S@EW[+
M,)M-`]X.9P);E@MWWF`YD#S8J\>&J'72,=I]4T)D]DZ,YA)(*WTB?WL3A\=C
MSF=OSYW0<OTP#L37$8(`XW.<]YMP>23L,S^,PJL)#\1['@K[DL^GL*GA-6SP
M>]S&WU^^^%LRU%4\#,5_8_C]PTWA(68!"/#'-S'Z[=69_/S'X.+#'W^TF\>`
MF&-$QZO?G]Q-5447+;#_LB8J,O'0=VTYS1<_$NR$28ETTC+-=RQ#$),86NNS
M>@I45!&7#YE<BO.GV0@:\X)[?"R01MF$`^^!N1(C';,PP[T@W!/?X#-`G)8;
M(\=Y?O);PG!VRAU5>&DE`^2YY'T<PN+"$)AMZ'C$:^&E[SK6_'YLLJC-MJI.
M'V&'JHU9PD\\@FU`R9=@,,];A=UAIR``/2>>LDN07%-0>W'D6-P-#?;)LQH,
M=:,(W#G[`58M2-B0G6&AZ9#]"Y`&DR3/':%<3B9I-=\I$9U^8[XS\C\GLZ[Z
M74Z2^_6U`806PL)!XL_\@.@4U"GH")S8Y;<DZ/'S500_XA]?@*)MSD`O?+4B
M']5)SV#F8-!OL.N<$L%A.0LGPG5!_T1.-(=A>*2FHR%ARW^("'$!3P(ZQC#6
MK1--@"\8G\T"?P;&"DXZ$P`9*C9+#KZ:$YZ2,N]CZ-6=-;YZ63V#UHE18AQ0
MT3F@$L>+?-@VLO2`JM!.6"164MKLPT\+[,.Q*%+=+`["&.4;C`+&H34I3,*M
M_\88J@:0-7]-*-`)PQB^0J'I9Q<Q#,0=$E<H+#!^(D>:)G>PWU&>9RX_%4$#
MZA0*9J+-9&[N6<0`1)H_G2F0)C#P8'`7@$"T8(?!+L'VPL)Y@"?86+!?FHVF
MR8"V@4L`448RC$*"9*<B#AFJ`C3,2K:ID2/(]-,I,B&(D]B-4D8NC"@W5XHC
M"<<$Y)T()!8O/[&AL/A4T%.H'`+?=7%1BX\6`#^-Y/,`+%V5"0[[BX/EWD(K
M4X"-:+-FH]UNRY_")1I*5_X-]51^HPK;G,<Q;5IQRG1#[67@.`@HM8`%$%-!
M:?;?*5LXS!O#(1(O$#(,'<J7"V"@I$OG95Q.6UP/@8H\F8P.?R:#&Z@5@-9`
M+Z/+P"A.5K;P4@HH(2(2S98%YR84]R1^)9G<P)IAJ_D/X</'-[!#?.9$(,K^
MEXP$)D8C,.SAG>&<9'L>LZ!()B`8@'D0$0X9-:%CDZS`A2N6#N1\<G8D),3G
M"*P0SW*X"S"`%J+O8:DSH/50LH$"Q%"3SK"BL#P)"1Y@\[`P8R3&ISBXTC(A
MT2U5U"3MELT5HD:CLT3*YC"&X]LX/'[ATW<)6A(%!2M"CHIH-'@F$",7L**>
M7<`8P(!K#6P2'J3<\+E4O@1$!3C:T'5`6=JI;I2SP8-P:F,^?!7<8BUE#VQZ
M6^N_Q])_0+M&T1J"3?Q'#$=ILXUB%L^W#C++T(&-L":>[_KC>6*7$#<ZD2(,
M&PC']6=(S,-`\!_1)/#C,1%``%0B)-FYSDCZ#V`V)&3$A^!XPD8;<\P</">X
MLPE'S0%*S`4],YW&GB^'F;,C@/GZ-8.E1RC&I?K!'X$:Z0!-WX0.H`%43PJT
M@ZQ%RXW\L:#GB3QQOEN0?Z#:P#)5QQ;'=G@P-]B%L!/)DVC2B]-/H#./)._S
M443SCD002"18,%+B#$`QLUKQTDD(AHX<`AI?Y$/<!'@7)0_(A5""".L`UG$\
M(*THEG(SRC&1Y.3`!Z$._X]G*V*AT7HT)F>Q,)ZA"**=%V@^`--]>O/)!84!
MP($-`28/2@]"<_;$TL\1(&OJT^<KU^?>\3_)J89;>H;"(&!G9$H!!J_^>7;V
M6IG=8/K2WS#N/'1`3GF`YQM8FS,FB0+#?0$:/@_B,3N5R@&_;L!3REA#\>OR
MV+-0FH!=#:K?.9:U@EE*URR<H5"D32(825#%\,-T#D3KV,P5\0\Q=3C0U\5G
M("^8!D4ET4Q.+X+*&OXI-QA-"4GA(!Y!+%L30I)B`Q2TQ#NHQ@+?CBT4EZZ#
MN@W$.V%DA!Q.PI\>($I$TQ`V&20JN;-\T-L>H3]RAKZ-7`2(_R%L=7(H;K$@
M;@Q(KTJ>R)\K9GP..V,G(-V`MF(@Z^=L!KR-IBG2623UE^18J8PDD2Y21&(Q
M%9"#@@']DR'0%I#Q4`A/`IK@$[\G-5B.?$2@$R':AH`K<4/``&TMSH,R(!,!
MMP[8-#3AK6/+19,5`5@$2QFECNV`*@]HD?.9-)G5'I`6!RYPZ*)B!<KA60`(
M1H*E:67T:,JHFO&>')J`2#S_%EY!ZS5W6LZ=GQ,&);G/4P(^!M$)$A5TVJQP
M7$I'R*DRH)&(@[10Y!*AXB(CZFXZJ.K`V]\=A>/U!0G&E@H9I-,F,I;ES*3%
M6#Q+,=KHQ`[PZ"3FWW6ZE4(C9+8_A7&!B4<`4^*W@=?/P2ZXI1-G;J:".,GK
M_/63&2PYX)0">*84#JJHLM,)(.04I+'+3#-!R-+J1=EJREQ2RF!/OT[620A9
M`I.&*?>ZW8GBIR3UQ[E^V&TFRJZR6MT\(RT<M3C86&`)C-!((HKX"A9M$$Z<
M&1AG`;%5&:5*WQ8Y!.YP(XV`'NG(5LI2\A!G+_DT+NAL5[!]:48@3>&.RD$Z
MXFS0;O1_73+*7\MC<.E+%AXDR`P7/YTP`MMM6:-(8(SR`:0C0TXYG!?6AK8R
MF3.D"%Q7G3/([R*/X?Z*I8#-73YDT6&"9DK!-03CG>7.66N]'J>P:#B&XSMM
M8]!O&F:[GQNG'%NKG3<(BVFT6RVCV>W>"<_:,/"E*YO5MS&%.QL>.N'7T6GJ
M.)&/R/^][S7G2M&RS,TE+%\JRC86+0^:*B]:-KPS791$J\<L7`25OT>[@P1Q
MB4<?+Y($=<R^>SRV'3Q"?,+SES-E'U/WTR</;77Y9/Z*MD`^U^0Y4V88RJLX
M'=%1(][MW4*^3'P!Z#_*'T9F@8#3DA1B2^(S\]*!CH9A9RZ\.Q8@0SGZ!^!W
ME,.ISPI[WF&<`<XLV0P$(,C+@KO]>^.JP?[G]/2R(/^0P9(%96MP,A1)*;?"
MG1;$")A<YCAVN?*ECDJ@NLJN"?#YU"=ZAIZ;,"R]QOAP5H"5IE5!#BA;/^*1
MRVP>_U\IB-71\P3G_Y:"PZZ._Q_(7P(>$.K.25.`9>V3/'3D!7#>&9U;O'22
M^GXD=R\0ZG8$Y&>*3D(A$HH+1]92.I"'U_L0T"@./.F=3)R="">WD;WE$T?D
M[0V)5@!^&>&#[M`X()='[MG7ZE!/VE)1#AXME/$[3:_/#>!?"P0C*#EU1SCB
M3I#!E2!*ZK/,B9NL2SIS0R1QY$GT_2=<F+R":@K1GTP$L@->M\FI<B-633"*
M8?78R(LP&MX/I^'$CUT;3]%P@B+*AG?^C#UYE9:2]MT#+1P8$B`1/A7XLU2A
MG.A)TA*Z-@3YZ3P\UF7,7'8LX)X7ITYZ](PFI/_/2M/2C88TF=+U`7,E1Z*!
MM.0VUI^5-"/J4ICZ[7GFC;K"0Z]:YL/TZ(X:TO>-@\CAD!$24^);&0YQ7?13
MY.Z&>-Y!R*0C(G$[)#[9":?(&+2RL"8DD>"-\&(Z:R)KK`N-J;[K>7OK+.4[
M8$=-'1M0QV5F*I"%G,/C>OJX6]0E6G*E?)(R0*KV:.*'8D$Z%IXNO^60]R(@
MX$/8-3HZTE4BB/64*@NS9/$/>;-*N,X4C?EU=W69"%M';'FB_!Z*KZ,/0$93
MLF4>BPSWPB3_+C<_PQ;HM<SXODJ-B(+%OI8^I:F<]])5NEN6FAUM.72^;]>P
M5I9@F+.:4"1.^0^!]V%JY4BG/`SCJ0HRH!L$3G?YRKY1-U[RXIQF@.>%(G&\
MH\&;`[*9Y1NV\J=4LU`D-Y;/HP2Y?"@-+K:S..9<1`#9<VA$1](*D5:917:4
MO-!(?(/(^>GZJW!@D;/R/'>)L0"7-/4W8;F`%^E/`DR>ID;MN0BMP)DI-X)6
M#BN5PR(*5W/<F;IGD+$8*C`C(9Q,T`;I@,E],[$:?82S!S)$&M21,7H5DMAT
MXPO6`P\GIYZ-__D`''K#762$IS(C]D)^(^Y(*-"''!:K&9F)A1G2474"TX%<
M=1T8QLX4.`EC'_#DX/WF%,-[TPC"0DH'QFE@N"]0U1!OJP$BD4'48%<Q'&"&
MW$6WA#Q5QF%,HEP&$^*[,.;'\T]G&+<0H^&+%@+=IT<EI21HY64'J,P_4&;2
M$&3HNK1!:H;J1$IA"D/NK?%,YDR1*I1;E(]XO1C-+V'Q$;R);Y&AK:E]`VI/
ML"B=4@D*5Y/Z!;<F\'(@7Q#I"YR"TU3Z#BAKRP\C%84!\L]RDI`F#@`&',$Z
M1B"`/,B!>8,A9TH+VD##8A2[0*@WDB5&Z!.A!N8-]A%=0A0.+P/X?M+]V>/.
M'Z*MD`#P[XGP4BN%9HW()P:L"N:(;2C;1$V?AD)95CR-Y><4)/*PT1!3'R,L
MT@O&1%!(YZ-,C9+OCE$UH53P@;.=,/&+*7Z3]^T@@1KL&]B,3B#-FRG'<X1'
MODLR=6PGPYHUX719!"(F]WXE/56-`?-,^VF*4.%#7X-SH$<_Y.[7T6??&W_&
MD-Q30JMFX`T8.,,H4BIB\IA0R20N5WOX<^E"8`L[XC8$HH*W77I;$3BYQ[,9
M;H'V!?&*S!5"SR^YL>5IPPF`R#'\W*(O;'G]258_,04/`KI+4'&R4SXG)ZAT
M16+H*@;^H,,UPO@QQW.F\53Y_D"CY6SSD1\'H$'_&_,`H\N48I*>T4\CC&53
MV4]TJ9HYKB5S9HP^BDF2Q!XF.ZFP9%)E(]<'?``2?"4Z4K\A(48R#NI!%6V8
M_K*@%=6"9=P]A68"O%,4/`Z!Z11V+T1M+B?`F)K$"2W]YS(&FHY(Z,O*;4KB
MSZ7K5CK(R+.2"K6RT&*-;M%H)=RA+UL"5)PRB=XH0EU%$MR'J_-2X1R,W1OR
M?&O>WX3W<WA;DQ`&EIN=>W!14^;I05*(LB<QATI$H''3!Z0\R"6\@"JU,V\!
MJ`,OR:V2JK<XZY"K%)+_QAA,GCQ*,?52L0:B^&5Z3X)7%7A'PF^XX\JLA%$.
M+'PL92U;!3"KD>2L.!Y]Z=O"S>>=X9?)Z/XP%,&-##^4+]L\XDJ/HP3!A_^,
M[;$T>=``VN2LOYK,\\R`Z/X7+NOK*'4;??+`:HFGF46L#_OK#OM$L?]*1%S^
MYCM%XVI^R<@=A;`M1D12/%31W4"6*I\PNT93^40@?T/,.N3*/C10EX%DE!J"
M*A-@3&SJUYJK(#R&O(@YF?F<MD1D)_Q`D<7.C,M0Z#S73ARPV@)KD@N-R>=U
M(,OFE*$WBR/EB1L39^*R\)@*[TB?!V5,^@F3*D:D"W"ZFY0`*=,`28<"-I6]
M0'D%.:^=<L"!-ET</O9RW":ADGJN=&68^H!3NJB7W]8MX+-62?DTYF>\=V(F
M4#QM=]X(_.[).W'8VVUL<6K=9?Y2E74[43R3A']CVJ9%'@GUQE1P]$B0,%U_
MF:;WM;"OK;)]55_);`/8%6]I>U6J/^QS0A[2(8\A<QDO)A?JTBC,[3:(*^'0
MZ#;8TE:$"C,@,U_^E00E3!$/Z959$0BR'U1&4#D]+5&A43)$1I15QDO(.5TM
M6A1<I8XX=Z!M,Q2Q(V50RYL[%'J8]0*+N/$Q'D<"9<@KG;F\>9X)8<-7%APE
M''C<"7_`7R*R&J\E?C.!+<V<@)2-NK^ADQ'Y#2@*)PC\H<H?&\X+1LQP3C\+
M%164YJ4`$ZX[[FO.*W!>NURB+JDRF>NB+-+TU)JS6+.;KC)YFD8[>4J8_C5D
MLEQ#=IG&AWX<)618O&(KL1F4N1*'"&%J#:=$O`C&=G)K'K-"2TGQ-07+0@VF
M^I%26=SPXWTBFXH,)]IQ)-*0A;+\1319==^J='/)"9'GH^LHG`NPEGXC_:D@
M;%SB%W2;.$M^A\RNX\0)=U]#4`1Y/OSP].J,G6`R2W;QN^KF&%TUV56=A,8)
MB+$"`2([/9;F+%4)/8!&["RY"M:5#\U07I_<LG+V3*$D23%4!*`,PWP883:H
M*O.@&#=&I:;F7S=7=AF?'$T-Y?6=YR_;LS,`>M2SD5:A39KN\!C0NR4GNFLW
M"6LELF,8L#>5]0)Q8%;NG82J8CY5@@UK<VS,>`QS!525M]]>->7?,V[;ZN]T
MPJP&_4+9T!7E']48Q_+KMZPU^UD:DKXC-;WNK"ZYLK3\"OP,Z72;HF<(U/0#
MD<0H>`,WQL=]\9+J=@MHDPG$NX(X95AO@+7[%AEE:^GN*0E"$T'Y(4T3@2:"
M35IS:"+8.R*XQES``R6!0C>?BC;5(9I-:VW,]<RP][C94@7V9Y!^>E?UKN[6
MKE9N`5]U7V%`O;-UV-D#Y=<#-$"R").\+V_]?;GF@SWG`[VK>E?UKNI=U;M:
M"TLD:VS\%\L28C1ZM6KSZ];:^'%OP$O3T3:W7.3U8>4>?\_`X%OHD+<]J(^K
M`;O%=GC/)U(U:6C26+.(9P?Z"5IK;@_8EM'O]HU!KZ>I1%.)II)5-A[UG]06
M7F+A+546T`:>UN+:P-.D<1"J>S?)I&UT^QUCT#W1Y%)OH'>(7.YL3)]E35?*
MAR[4&/$L?RJN^4]=2V"3.B*$-09H6U=,(%_I*@Y5]G!6/B++@YN*:.*G=;-5
MS4%9;)OFB7">!ONN6KXZH7K#P(QKU<2+_UR7TY'+]T\S.+*2%V&:0%W6XT^6
M]$X`62Q,LK8.(=;C"426'R-K#5!9$8]3(1X<,4CK'U(K6YDPCLV1AI1_I6IY
M8#F5A5(=<FU8QL-*V_Q1&\!BD]ND8DL9LF3)ZBS=@V/N#R672#S%,ZSS/)&M
MUV2/IZD?X(WQ#^R51CF0F"&99O8N3Y*N!2M2SU7U%NIQ63:O@<5.TFHFU(M+
M=;T"7&)!HS`J6XB1AS>K,[DJFX:'*DW&"9)R,E4K[JV2&'FI\DVU%COU[%Q1
MWP^RWHHNRK`X9ED%QEQOMGPEYS,_7%>/X=N*GFY48RMC%R^451J`K;'\HMU8
M_6(@G.DP!I[*JH2.95O50FV4A28AJE4IMH=3252KNLU)R*H07@6B*M:&GN(O
M1-??9$$P0IY6=!LH.NID=OR>1,NES,&NJ/"RPK;+=91D^QG9M4:68\6V/&GW
M7:(O6;UV.,_IC/<8_GY\94U\*ELMWRS4JB'B2J=)^KW(1C#%S$4>1L56,IDH
MMJD2(]*S`S!A>N$\]RNR3Q"M+>^8'U;-ER_%*_ONT"*7BGCD]'0@5"W4,"N2
ME^;22W2A8@Z)!\<>JA19FH_R%T68J\:;5`-3+1U@$=.9Z\^%R)?[RO=7Q`1M
MK-U2UF2;YJ844UK(L<2KE>.VM+!6$;AT`VB$D&'+2]6>.Z_"$?1B@R:2(XJ0
MDJ&I>W16FLP/1D*5Z4NG`3LI\@,J?)#]+HV-!A:4OG'\."2%G()86(44F9@8
M"KH[+0.RT$N8RS+'"Q.DR))YLT7R%MB3=%2R30UL=$(%3$&M#X4G1@XJ=BI^
M!I9`(F\5K"AB`9>V[1"TN'O<L8^IZ1]U-ZY6T[R2D,S+U0^JE?.E"$@Z:'FZ
M@3Q-D,>./OMA^)I=8H=9*2]DT\A*LE6Q*=&Z8TF-ZK@QDF>AT79>`!8ZU:2]
MUXM5E]$0>$]#IL,<N03G\FBR:VJLBF?`5CIV(J<]$24'!O5Z6HE,%G_.Y&/2
MFUZ9#Q*#2-P@R+#'A!>3`WQ)F/MQA*43:<JU9<C/[\9+M94\ZA)F;AS*+<1H
MU*QF7(-=.9Y5:*5`E8)\CXH62^.-RIL*>0)8H`:$GXJ?+JT:_R5EQ*=B94=Z
MV6'7D04EEZ%C1U('P]0@WY11B$T<?>\&._K)"A^I\^&U[,H."D66UDD+N";0
MED,*\MM*VC,-A<5C6;$1BQ*H@R$5Z\B*C6.CS@3:!C:_D5N)=215H6C9^68Y
M@,8HK-@)PU@FU,L-2VL"Y2T7V98X!K,4U$Z&O9;1.FF:)YWD741+BJ/<&VQ@
M=#JF,>BT<OWJJA@6&RVL]="%,0"Q=V*<M`;JG7?9:E2-`U6F%,#O&B<]TVAV
M.NFS>8*0#8UF?*X*P"R\;!IFMV7T!JWTY46*FJ6-RR6XRT.TC9.V:?1[F^(T
MWQEDB4AS9%A%L=ZA)?,*]8NXS;5%"GP//LH:$N$VV@<>W,D9LUY9AE%61&DU
M#6O["*(?*<M4590B6Q2'5TPD[&*3D,(\67MO7NQ2`S-847(P2/IC`(EF!:7S
MA5JH0CRUUL.:55FYW2)-5R')3>DL3Z-7\3"$<P*>MV\T8=Z+,#,4,HG#2I18
M$%;3Q2K42(`N]400V-P^J32=-!!/3Y[5.L"0>E9T3;7G,HAI8-P'"Y1T'(BT
M<T-E@5B)@DI+NW[./,H7RI'\%0XKJHC2J6=_\;VTIA+UF;M&W7)?LGRJ6EFZ
MO,_.!>=4#[_1]1QT>1]-!&-=WD<3P5B7]]%$,-;E?3:UJ0[1;-+IG'N7SJEW
M5>^JWE6]JWI7M?&A2_O4#5&'Q`=Z5_6NZEW5NZIWM1:6B"[M4T";+NVCTWOW
M,O.[<JG<[1('3*O)8W?3>77A%DTEFDIVE$IT>1]=WJ>.''@06ER3AB:-'5#=
MNTDFNKS/C@"MR>793+[*-8H>&MB?SQ:X##!])II?NMR+X-4/_XT=J@^QC32`
M[?1PKVTPOZ*^7G\US^C`_LKBY:Z@SA*L[58@9X:WS\Z-"#='WAJ%4L/8S1S<
MS?OO^EZ%\FYX([$%[5;'H%Y-T/M$T)MX7_:4H"L%BJTQ%@[1'BC#38EQH%%3
M7S]4*9QEDO'`@TYV_Y"JB5(39>V(\F%!47NHA[^.1EA[4"0>G*V<SG?>1,V(
MJ<OF@@>;G+MW[4JH%A[GG8HM,'LMHWW2V7LWLR;F0R#F;L\`@MY[8GY(F,P>
MZOV/<>#)$KI8\F_D_,3/6OD7Z:FOE7]]&+AN@K-MF,WFWHO-QZ=I3;A/0;B%
MQ`#3:`T>5>/#;'7`O#[M:Z_[4Z!&J_L]E9H/1+76^9JP-6'7!_7:![!<)!`K
MJ5,P)SD"[G,/H.T#;1]H,6KVND9'7PIHJMXOJN[VC4YW_ZE:>PJ6JDB'X5ML
MN!)/8^I4QVQLD6@YU(-"6P?:.J@U/]=-CAZ9W8[1Z738#DO2U]HL>'Z@-3D_
M"3EK3T'1&L!FD=BM&<92+=*HM;3V%FA[0`O0^PC0CF&V=CGH2AL#SPCTRQ?U
MHN;J]5P`\MJ1\G-Y")(UZ'3_S4P#C;=[RMI*B*NQ(+XC2YK5361LHX(%V].;
MX#JF9&M6TJRD6:F6D1:K^*VS!SK_LC0`PX#W'L&OLL^(?!;CJ?/\S'9_B0_`
M,]N/AZYX2I'_\/RXC1;SR**^9PS,)R@YN"3EZT%XFGTT^SPPC:IIKDVCVJ#8
MY=UU*?-5+*^LB;!C5WP=91WL/GEA%,3X2GC?6I:/K3AWNOJE=N6LMT9VZIBI
MB]E%[[Y[3K1)@O`^'?(TO>X>O6(]:$8%H0^4:`^P0>_#+V/J=FF[UJ8X\")M
M.WJ_JDE.DUP]G-05K_3[O;V+6GO/X>!L">.@NF7M5.1/O>)^NH;9Z1GM]OYW
M7-%T?0"E\`ZR@=#&U[-[J/=TM':]R+-N@N$IHSF>?Q&:L#5A[Q]AZ\/>`MJ^
M"<OE8>B,'(MRNEGDLQEW;!B367SF1-S5VK`.E%LWH7'4-LQVT^BV>SN7_EFH
M@GG?%"88I(RHBWNI:6Z[--=K-HV3D^;.4=RV$XXKZ*/'HY@-L*_%_KZQX`'9
MBIJ4-2GO"2GK8\\"VLXFW!L+/.2,,!3F9L-0&'W..1@I43VK?5>%@Z;G0Z+G
MHY;9,TRS=?!GJ*J:3D>GZ^QHG1U=@U7M6W:T9B7-2IJ5:GJ^7<5Q^Y`AGP9X
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M.!#H064VCP0[,DLBF5:2B0[+V[]B$V;#[%?'[8X*"DV[>TJ[O>[>TZZND5)`
MVJG]9QQB'W#Q4P26$PHV"QQKD]0)+0GV3Q(T&YT3=LQ^:39.S+V7")J&JR?7
M/QH5FXUN$V8"FFLU.OWN/M*9/EXMEBIQPA]L%`A,VXM$(,*(!72*:NE3U+,#
M71=%9#9_!:G0;/1W^5CUJ]8_ATS#[9++I?V@W7N=IO9+BZF@2.8Z-_"TX[&Y
MX,$FO4/JQO'[''S485/X>A*^Z6Z\3;5C3!W=5D,":S*;S\,WG4:K=2@4IL\U
M"VC[\',F+/2IW?@NCQS7B>;LJ*W/-,\.=#WL0;/5Q2.-V=MEUYH^T1PR!;<'
M^TJZ^GJH7)4!_`X`:;.Y(UR;'76T.GMVH.LA#`ZBGI:F8$W!.TS!^HBV@+;+
MP!_RH3R:^:,DHF\T$H'CC=&)Q[TYF\%?OLW\&Q$PY2]B1UVM^)X=Z'J(C=9N
M!$N]?/$H)[@GK(L/*SA`XD(?0:>Y$R3VL'-6>>F*IU(N5>I"T.0IUNM3%D+M
M?B='L9$_VW7=?*\@^D'O;B1@I*,SFN\*'JXG`J=;G8'@A&S(0SB<^VBO,+HG
MF048PWF3U&5I5,7DJC3`.TCL\2R!BN5L5^[[,T%6*9UR3_GV/F%;>\JWP(4_
MCDM"VVYYR&P!WTQA=)L-YP"8Q\<RA2@.\?`1P>O7`646S=E[QW49O`.LC]_#
M0.B/<V[$4NZ1YG3-Z4_&Z?>YS-Q#3G\O+!Z#ND76//.G,W0:V#Z^Z$=LPH%+
MN2W^&R/C1P%'NXY-'-#=P-B1G\D!YD2A^L&QN)L^FUT?&S1%[CIYQ"UXFL0)
MR!9GRJ,UTB0W=#J$(T)E3\QX0!8M??0<&<.$KX5\BN++ACT!@+EG@_@9:YM"
M2YJGE#3WN6?:0TESD?%USGQ`+EVXF`.Y,A2L^:LZ&<0S.!N@>!%TD:<Z@DYX
M!%\"NL"X0%$UX_-TG!``"&AD^*\(A2#A,(HC,#8TYVO.?S+.OX^C?;\Y?U(\
M/!`;(Z/.BI<9?.DZ(V2)._%7XF[!K0D#NR2`L9*CA0=H8",\6=!%QWU8?54-
MVNW4DTTJTUXX+I@\OB<N^9QJUZ9?7(AHXMOWJ$+[QS?AH@5U"1B97P-((9A7
M`$7X?I[_Y?2G$_YQ(:9@2W'WRO6Y]T\1183C,ZR_'IR1"^:"JAN65[:ME1.Q
M6)VZ?S?KJ!=6,LXR6Y3PS@)WE3+.9DA@BWQVMXB]4Y"T%[!1YCY7DN1=`55K
MGF/;Q-A*O_7C.=D?`=@=++Z<`+6EXIRUXIE4E&X2MGZHR+I7::@JU1:/*3Q#
MU5Q\QXJ_*5Y`!"[\0D.]W59]QEJA.E'UFBH?@2J?I@+DCB-)XV,S#GM0!<#]
MQLW!X4,+&$TT6L!H6GD:`;-Q>//)R3;"FQ^$PEW=J4<8TWS-1HZ+;DMT97KL
M"PQP'L1C=CJ;N8XE;S".)(V<M%K-=U_.3]._S'>OF1_@/67L<KIGY;-9X,/F
M%GU`J1,41A0>7I3`4W9L1>LI[L&M$_?'IW9?4;41;G:)%THJHVU&+B5QQ[M.
M+OUNTV@V2V*8#YQ6MJ;A*J6E:OU6)_UVU'HM;^5E/)\EG%F$JJY,9XU@9'KN
M>^.JP3Z>GV:W=P7"T5I,:['G1\W>JS/3V`N%MI6;0WFKO]E=?$UN\$^'B/3W
MC@^2->`S$4>.%9[YP6SQXKYJ@(B^X]REP**ZWW'6"EF/=L>Y[QWEZGUC62M4
MU?5"8<>1I/'QA!<*^XV;@\-''2X4:H7"(_,UNYT(+TUS<CPG<L"N#AEGEQ,>
M"O:)G<'PE&5TC0&R,A1Y,]?$4[DC:H7;>KDC:H6:FCC5:X63&OD@:H67772J
MUPJ!Z)F^2\9K(:^%?)U0HZ6])AIMT]^[BL/=\EX+?"WPZX2:O1?XIM%M:I&O
M#?S'$/B=U^R]`S@8DSS_+(5X(;!2A5[>.M$D#3K1PET+]TT*RSZ5>(?Y=Y%V
M:A5%4BO,:)M^&U53V$<G"".J%(H=W4'0A]S=I*&[%N*:$[6%KBUT;:$_O?CN
MO69\A%69J``;"?)?3"(V_!<K,WHB(H%^C\@B+=$U:VJ)KB7Z4TGT[4:.Q^'Q
MF//9VRMK(NS8%5]'5Q,>B/=8YQ(]V,(+R8=QA<7OOLXH^OL4:V4[T?P^$>6G
MMSRPK^<S04'C'Z8SUY\+D1M]79VWTNUM]QZVO_L487YP?%$Y_+!]D+BI7?>:
M=:O0N[KWN[K91NY6;L*_!4XB[(/82,V>>[>K.OU#VQL'2OIZ5_=T5_?9WCB]
M$0$?;W(%M;O[J+ES[W95FQO:W#A0TM]SQ710!^%]WLAO8LH=S_'&>B=W?"=/
MQ^-`C'ET`-:BMBNJ;>\^D_N7&.\0F3_:?W+?\YT\I$-NW??QY8N-T0"O9(C`
MF("`6U',7;V?-=C/AR#A$VREXX6.M?\[>1^#(H%2%Q9;P0L*GNK%Z_:`9[Y[
MSD:5Z^[++VPMU=5&'!XB"7SXB<DCH6"7@6,]A56C::&VM'`M@BD[<CS9&7B3
MMLR:&/:.&*B)\X&2@/;8Z)N@P[T)TKNJ=U7OJMY5O:O/;WQL7.N@V]J[W+2O
M<11&W$,CT6#GPJ)T+-8V#=9JFJW-S97*Z;'/QM6K0:LKT69`EZ2-E@%-F_!X
M4+>,=KMIF.U.=4SOJ+C0=+VUDM/U)>=F8]#3E*PI>8\D]$EC8&J2WB.2?OFB
M'N(Y@^,)J;EWTC5.RNI*[!E!/Z2.S[JCB69/K7$>FT?O@^H=95--V)JP-6'7
M!]N[@UU-V)JP-6%KPM;7&8^%MC/N85$UJF&WC#A]>:&EPU%G8`RZN^Q,*(D=
MU,1\F,1\0*I.$[8F;$W8]<'V[F!7$W:M#B</OL[8T:/)0X+`M630DF&/)(,F
M[/LFU>\0:3\(;DW<AT'<NTG:FK`U86O"WAO"UK<HZY)"KL0L4EDA3<H*:>OS
M2QVHMFX"HV6T3IJ&>:*S0C1=;SOL^'FR0KJ:DC4E[Y&$/FF8?4W2FJ1W7SB;
M1J\Y,)KM_9?0=W8"?:IC1FG?S+^]V5Y#T>=O3_IO'@3<BQ9;DJZB#+:,WF7D
ME6!X80_*#HMU:D!:06AN!@9;Y)YTS.I5PQX-B@=7>VT]/VQ;%77/B=6ZP:-W
M^5!W>9-*@P]2`MM&PG-W9]&$I<7'-B%?53WRR;>>:5H\=%K4NZQWN0[P[)7!
M\LPM8#1=:>FA[15-B_M(B[NYRSNKR?31NS[P[!5A/7NC5DU9>TI9S]XX5AMF
MFOZ?D?Z?O9.LEJS[0UE9`]4G<VS`E)JV#H&V"DBH0:==35M[2EO/WOFW=A9A
M`ECEUGK/:BX^,[3W`[;0"_*8TK%41\AWK/B;BH;#U2S\0D.]7>X>N0<\6;_.
MPG4@FIT"5E/X6O36N'%R':AGIX#5I+X6O77N"UT'\MDI8#6MKT7OOVK7]OKY
M3Q>%O)W:.9^?%[H'`'<'W]R1)E4KKEF[6_MV"-<TIVFN9MM::^!T7)3>?RUS
M=H_FZE!SJE:[O^U&Y`5\52S^\*1<O:WB#\\!],.K0&P#:K-E]/M-H]?NW76,
MJ5X'HKS!:4VPOX*T`69-W*N!?K+*)ML`MMD8/%>-GCJ0LB;DO9/2G4;G1%.T
MINB=%\VY\TG/,,V.T>^=;,_PJ"ME/W\7CUH=4U2-J)`)=46]27J/%A&'HO2.
M6D:[V3$&YG,U&MS&(BHV&M3DO*\:SVSTGJO"HC;=:D[(NRF7[X-J3=>:KC5=
MUP;U^N9D]9%DY@3Z0%(+*JV;@#@RC6:K;?2?K3V'/I#4DYSU@:2&HD,3\J'(
MY0,RW)Z%KA>2\`^%LI=#`C1MZUN2YPGFVD8#0:T)]UX3#HQ.QS0&G=;^WZEJ
MNM[_HTJSP?HZDDM3\AY)Z&ZC.=`4K2EZYV7SP.B9IM%IEABBNT/-U4XCJYL&
MKF@@^&<<1LYH7G[2:/<>=M1XTB:"YR)P;N"]&_'9X4/'=2('$%W6%_`T_./K
MZ(\_VN;QN;"P,V#K%8L]1S[T_>K\%;.%Y4RY&V*7O-_;W7YGT#W)X"Z=:5N@
M_/&1.P%ESK^?IQ__[HB`!]9D_EG<")>Z%Z:_??)F</RB'UJJE^'":GZ&SEO/
M<6%S@UB\>E,'2-OED.XHWLTGP'O6QG(MTEK];G_0ZSTJTG(=-6M.K-N!M`JQ
M[@[>JQ/KR''?7HH`BX[P,4CIK[>>",*),_N$54A$&%W[[\6I]=\8KZ'70=XZ
MR=CLLQAS]X,7@2PG$%&P>TX\78)J%@<BC^36J]_-1K/YMS<;@;7==72S';CW
M.MJO?F\V!NW^/1<""G*J5..G,(Q1'7[R`,[0L6'[45=^](,/\$XT3X:A(4('
M?RM=W1G8`/[TCU8_VZ5M[1BL="`7^C"X\XQS&?@S$43S2Y=[T:EGXTNS*2#Q
M`Y@R4QX)^WLH1K'[&5BKG*&6&@.O'/+]/&T7_#$.8*&P1/C]H_,3/X5)[^`K
M8"Q5TBF3`!O!68,%7G!K`O9F,,__GJSP(\SUX`4B'9"I%W[X:4VX-Q;?<.<?
MG2C#)?YKM]N2+$O`N2>D33-#=TY0/!B4!-NGL%C;<6/4&%?"B@-2&/"X&]O"
M_@BG";2=XXAXZ>OH`P^P9T0(`H8&/IWZ,1Q)*E!+ZX\'3O5^7CY`2=?M##DA
MK3Z/G4]?/K[ZO7O2,YN=3D9T6T'#'N(U.2=Y=A(@5A7%YJ!W<M(::!3?A6*8
M]`;DG0.JZXL?B?"2SU&-5<:SV6WU!BV-YPWP?!F(D0C`_"'#H3*FVR=ML]_;
M"U2WZR2-!YV..>AHO#ZB-&ZU3IKFR6,H/+0QKOV(NU]'.6-<6AU;/_6L6%U[
MT(=AU-EG%3`)L(DI9.-!X9D`-MNM5K/;E0"O`RA/Q-]$Q,&2MI.].+6L>!J[
M:!&?BY%C.>44NJ&KI]?LM?L=,T<J=\];Z9B16.TCL;W#Q=<1S"^6CA67W?]4
M.$]D`#T;_.M.?Y?]1UC$_P1^N!7WM=GM=[J="@#2C%N'[0'4L7Y5/3.OX.NX
MJC4TLW9IK<%3+ZRBQ#%[W<[)4Y/25@3-^E6UVG5?U3U)J6VBPW3SA144QRR`
M(<FZ@,^NP`_P,M@58*+_+WV_<N#MR*].I^``V!)L3[[>JDSVB.M%(^8S[/57
M[]P)9[[TK7X=)>]L8>M67"-L8]**^.N8K98TURI.6KR4R3!<Z2"\'I2\5R4_
M]$.F7+_ZYNH)$27_%/,I]SYY80R'$DM<^JYCS>&0/063N.(-SGKB[32;R1W-
MNKD2>!9^/?=OO4L^KT!__^!>A<O0DQ28U1.M``7^A-.)BT]L$2*SU6OW2B%:
MGJ](),,(GPAB_.74\V+N7@:.9SDS^%`!OJK"I]EN=@LT=/>\"0*S"\WDS$N=
MBS87),M',8"L:W9Z[?:)Q-V*J1X"22F"2B&!9[HGS=;](*%?OPG+Y6'H@*5"
MW'GM7W('#Y5\Y@`1;"H%2J$\;INPE0FQW0N.\MOJ]$[YZRC[\HO8BJY?$_*Q
M:MHM`OGP$(MU0-Y[&])!'ZX=CGO-YLE)\P$TD0*3WD>31^235[KT-%?]X9"W
MS)YI*J:K-&<"X`4/?HA(/99SVWSU+@0'$2Q0AIV#>74O`OX#S(D_R`-4O/EF
MCOW;JX^^'WE^)([-/TR,7C"5XZLR2-M=PRI45UT#16#TNO=80\(IZ8:=AF$\
ME3[2I/D7]?ZJ>OQ>$3!(@O`TCB9^X/ROL+][M@AR481H$X?OYX49OR$IJ?OO
MG\ZTQ#.X!D._-QLG9B8([ES>[N#"\>Z!B\[)L^`B=Y:N!5VT04<T.OWN7B+C
M'H1A-O(FY8-Q\<T)?WP,A$C"A+ZMDGL?__/A^:3&8C!49T&<ME`E-!O-9K^_
M'C=ER]TQ%*V@F;M1U)(H,N\@GT=%T1HSY>X%M.4",,1GVPOX\',FK$C8U%&P
M)N1?O,^Y"^H=66&!>G^_[%P\X0J7[JJ>8@\[_VE=F(/SO5OFPD8V'V&%__)=
M@-1UHOEN:*5%([\M#RJ].XW:LN7N')(JZJ5E))%1T[K3P'MD)&V@F9:7T,8E
MM`>/N81SY\:QA6=7WN6E!11O$XI+Z`"IOMD:*'?B<CTHK16@R+R+R\`?RA2/
M.7HJ1CQVRSU1=R)D]8YVI3U92I2KH=@&T,^@HS9!BSR9EEF0^X"6>XJPKK1,
M[T$MTG,86H$S2Z_4L@<EX*.1"!QO7(W1?K_@'A^3NXA->`A`@PT\Q3`F%DUX
M!/\CV"R;@_DCQEF(\\!'-9$3LE;W5W;,.LU?V<@/F.#6A/TWY@&,A6_@(!Y,
MST9I'D,C\8)66DMVD>F-T2"XC`,+H!7H^7(BBC1P7+#<?8_B@E?>QRQ1Q3=!
M5[N7`.K\.H"]YA9)KO?S_"\R=FV(Z<?O'1]6$_"9B"/'"L_\8":W_X_5L+V?
MG\%08S^`97V*1/J$3>->XL<K`>#:9RX0E,7=Z\#!T+S/0&P>/`9XL6.K2C!%
MOYM=`&Z`J[U'[_7$"1Z.79.PJ]&;1R^,Z/IC1*O"Y^ELYJK+BRHHU12[A-*/
M3A!&^##J'.Y>\9(D!TV<53!Y.@(%1.C\(B+$8Z4`0(W(<B$JZ?*`512LSL=E
M7[D^]_XIHHALDS.,(@G.!#H/'XCF+^+V/(C'FXE0C=#5"/TF+`'6Y=?1-S'&
M(#YX#)`;^#?<Q=2-[U<?;7[@6NIT'`@R_R6C2SX^QU(%_DQ&'<%@$7Q(]'OR
M?!72?`#>DH.1C"@.PORIK1J2KIT(J]M\\FQT/\1<%F4XFSAB!.<YBU)ZU.BP
MR',G$!802"E:/DQGKD^@X6P!8+M2_*]:_;JEY"HDP,EIBJ3_=?BGP'H[(G<X
MJM&*?U<UC+":T/<9@(:G.QYA[@L1,)SWPAC.?[-L1<Q/EA0:[#QHL',.Y\!P
MPEV7#043F"#DXHG3A\.EQ<,)&_I>'#+'8QS^7V:5P8_P;.Y\.IS3U.]]'F#U
MJ&@"+T<\&`N"`>:&X^I,%GA@1W`T?9T<18=`?2SD+@_FC6)MI`H[D:?-<I_"
M*4;`R"/U^WGVB*+MTUL`-ZFTD(3VA5^1.Z\GW%.I:_]#032?/`#&\<NK8BQG
MU%7;P#\(@C2V73XG1,[IH9Z[BH#OJ:``08M+!!X%L%2::!IT4C6;JT?B(%>!
MZHG0I[<L5-H0@'?0(;M9/F]+;]M"SHC+O2]\*G?C^M:_GOAQR#T;W0R1$)(K
M\"&U+>5R.=G&,!'$F+`*<X:Q&VV4L]I?T#-Z@^[:H&12U`T@WI]LJSK/N%.H
MV^2/])NPK_W$%%->\/#*&7M?O?>D>_=(?N7.\]41L#G*-C;7ZH"]WX_.7C/`
MD`$H8A*!:"8%Z</*V<]9""L]AJ5)TPR>N9TX8.:-G%'.SKIUP*0#,R]BZNX`
M`""'/QAR'G!:$(+1E=AA(5AK$;/Q4C!&0Y+^Q@N%6S_XT6"G8/K9-J4.<9=%
MMS#^_)AN$)+9Z)ZA,*7`,IG`X`QLDV@2PJQV^J8?!^G7Z!A:@&%3`EFP"<ET
ME!R:ND4^BHHYT#MRGFLW<ZQ4LMAB%OZ-\&(!)W!_[-$FIL>\"Q%-?+OXP/^N
MJ/VFRCN9G>-_Q)X,1C"[V><-$/<Q$/;?XPBK;(6^)YT,P!,"B_85G`U%#"9H
M\NPKH-'0AU&2MRJC[KB72*&<[-\<08^`WCHZ&U=Y;1^5M-7V/'A_EBXUO_ES
M[D9SQ2W7?AZ-S^=0*Z?Q!7S]_F\XV.-W(1Z^9WR._[FX^N?9&8AU/*GCN3R8
M'P_GQ^HC'JT=$*\LD*M&2=_Z%?_7@U-YB'M)-\@@L5WE.<;;9=S'$'8G<EP2
MRK@JO#A^RXY,U$[RRIB-`G]*OX^0.&#ZY(J$1C:8'["CUFO02T(Z)69$#$FK
MQK(;YW6;\_R[^?@2ZW>U'MQ<,B/+-HP4++I>8H$$\/'O9]_.=@^9CZTW4V:Q
M<\PB)V4+LS*<=A,6BF<XF/EP3FHUNHJ7,@OH29E)/?-UE(CVK`+KSNWX':57
MDW2Y-4M.L%)RX[O):;=&./G]TFS]IW<A5[YR67E#YEI8$P]C".97(KB!40&<
M<$7.8E;K\Z,8PMJ;5)4T_?QLBG*=8;%PXE^QW#Q&+K@#`'@(RUZC8G&=J8Q(
ME)5GYRDO<XKL&T(J+3H]8RI;&>0MMQV?T_W$!8IYIV+N^B:X^,I_?'/LL?C"
MY3'\,Q_Z`=VC5JG*WI85<.X$.UU;X..%2UK`&,EB^R(0U-7-E8\E_>"!*D>#
MD^X@+1-<!F)JW&1E+2B8<>G!QU1VZU=56@;=;*ELX@T`+UGK1S]0[U2(JF[V
M'W6O6NU!RE*E(&X.?R)8NL>G\5AZ'9J][/.C4MY@T.^W6UM=SE)N1RVVHQ!6
MA!0'CZ21&G[PT?=ME(P8'&-/X=$P"E9'`JADW+KZB9XZ3;K@B>KBIN0CW.Z+
M>;USCY_3O;AS9KNUQ9W[&'MV\91&@*=KQC'0@K^^]?^#'OP=W+`*@9[JJ+(9
M+JJBD%R9^`*\MW?X:VV`OSPB$N1]B7$*,#B`*L6J,C59(XI4XX)9?Q_M^UW>
M/U%RR;7XR<.+\U.$,<7<&HP56&TUCG)5Q)9OZ3L24XNK3K`A*T5CM9]K_P.W
M)NKWM67A^L<7/-@8$?<\WU3$05D93+"@Y>)7+/(!.#`'P#GN4W'.`W#0[O4>
M"P?U98B2HHPG9JO9>31,]+(>"1M@XA_^Q`O_[L]^`#5D6-DR!9QTF^:CK=L\
M_N+?/(@"+H7GA7/WAGL.WS;M]_O55GZ%E_'?9Q^%`'U;F&\/Q&!_T&LEO896
MKO-AF-@186@.^IW!XV)BET1BNSWH]!X9'?65BZW62:?_R*NOLW0T>ZD177G]
MYS%YS%&.WE5VL$;"$4NWMHZ;_6.SN-Z%U=Q_K342?[C6]G%S<-Q^I+763<!M
MN.`OO@>K@D.C[$091DX4RQN&53%S.W40+"O-W4W8?.W:TZN0"0^FW)K?A8YN
M)MCK+.2;R55#;EV9O2L\&P>Z#'Q+A"$(FOU8=;KCY2M,UY\,>9;OQ[KU&Z+2
M-+#2!</H7`*!+B(0_J[\;9'EKR>"H1^4>QA`Y-CL(FBP:^ZZ8LY^,5M=BBF&
ME5R@)&4G!D.0*227LY`*7B1Q1QC*DG\#((AH$F;*MV#<W&2`8#^=44W("PEG
M:9#R+ST9VHQE229."//2K;N,)0/I`03%S"Y-TL(@FW-AR8G;<N:6BG0IWZ22
M[#V*#5:]"9=\B.K._P[!+B^MGWEWU_>^RJ*`-UMY)O\C^$M&@\"OUY33IWJH
MI:_=)XK^&UY3+FNG:]Q[G@X<J?DPB,J3>RYRFP[DEF8V4KR3Y$@5MHXO&S+K
M,1V0QR"7X"D0$^Z<!<(3MZ&,\**(\^/(/Z8/2707D'X@J+4TAGI%M[Y\CGF$
M%YHI0TDCT1L5<)8/)/DL>"@^I/"C_C77BM63S'YJFIENK81ATO]@W[5SQ>O*
M`%B2>M\06=Q]8/;$RGU_ZEU:LZZE-('3,3P\!JRL:9R8Q;4H.[Z-M[?IY[J*
MB"1I<-UZE_#Q$5#IYISHF=R`]23"?]^15`4)2YA;%,/[CKF\!MH$!UM)650I
M=E_C"#;)L\&:DY<Z54O&5\SGJI#YV6[#)G6VD$^X:DDUQ->&37/-5K_?I+8_
M>XBDO#K<&E$MML`]!'P]M!-SK7$$@G`DJ'_AIN4)MD53QYW!(-^%X!%65$`8
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M'`2Z'GKZ60[O&S3;CW/LV1G45:>T`9):L[TKZ"K>;3]R;4H*HZ(8N^9@&R4D
M"[#7%AT+M50?'0EXI?C="]*B7N5#8V<S+]Q"3WBS:78Z?9404WG>_&Z=NJYO
MX57LYI"VBY"VUN<OM,R\QJPV[>,`NAZE@^Z@;]X#4`#U_SL^9DF7+G8EZ*Z;
M'1_C*ES'^_%VI'[[#'^PG_15!$+NMU<`I/!L8;]2WP:^"]].HFCV]LV;V]O;
MQL]AX#;\8/RFU6RVW^#/;_#!5^G0`&1A1`+:#Y(!)P$N]B^%GO;J)Y</A0LO
M\.$?A9_?+(%]&A3GX(&5#`(?[X!9/?%F!';A<3+B*^8'M@A^>V4VFLE0D9_O
M6Y]\BP%W:X'<&`&M]0AH[0("6O='0&L]!;3J0@&M-0AH/80"6NLIH%47"EB/
M@`=10'L]`MJ[@(#V_1'07L\"[;JP0'L-`MH/88'V>A9HUX4%UB/@`2S07L\"
M[;JPP'H$/(`%.NM9H%,7%NBL04#G(2S06<\"G;JPP'H$/(`%NNLIH%L7"NBN
M04#W(13074\!W;I0P'H$/(@"U@K!;EV$X'H$E`%9@#`0H1\'EMCDC)7!]G/J
M`G:\,9S5O./O5PL(RYGKE#,PY<$/$;$;\GGY(RJ/2QT*L!>"$U(+*9M2!SQL
M7R6"6>#`V16?3Y(!"@NIP<I:<F4`YX_C42`$P^J;V.>!!>BLN2TV?Q[.`0=I
M9^@84]8HY>4Z$#R,@SE[CU6A>9@DQ<!`,]DKBTWI"?DB-E:H(2[:KW[_Z,OR
MQ]2<@L[NR[E?!AL*B\>PL5$N^\SV18@I(&R"7<RX+?X;(P*C@*.7$;/,L#XF
M)I.E^&1.%*H?,/DD??;&=X%<L.&U3"C*_F;(6@`B;HM(2C&NW)7<T.D0CJP0
M;2'4`>9DR8\>?N_(W*:03Y$,[#C$PM,RW65<3^KM%#J5%[J4"T:]>F`/V=P1
MKJTZQ35_55Q*O44<6;H:2%3F<E%S<T<U+,'-Q(K=R3@AI0M2<6P?5B<$H6\4
M8\!I#7'3?<XN[DO(*'[S&?Z@;W&ASEO\7_CS_P=02P,$%`````@`;E1N0^_K
MS<*O!P``VEX``!0`'`!F:6PM,C`Q,S`Y,S!?8V%L+GAM;%54"0`#O^V$4K_M
MA%)U>`L``00E#@``!#D!``#M7&USVC@0_MZ9_@<?_5H")+U>DFG:(9!TF$D#
MDS2]?NL(>P%-;8E*<A+ZZT\R)N7%EL1+C)RYZ4P#9E?:W6>E7:TD?_CT&(7>
M/3".*3FK-`[J%0^(3P-,AF>5NZ^7U>/*IX^O7WWXJUK]?GYSY;6I'T=`A/=%
MT@PP!-X#%B/OXG?U(L"",N_;M"U/-G7P_N#8DQ^_CF+&`S1YZUW3>XCZP+S&
MN[?>8;UQY-6/3P]/3H_J7O.+5ZVJGD),?O81!T]*1OA9923$^+16>WAX.'CL
ML_"`LF'ML%X_JLT(*U/*TT>.%Z@?CF:TC=KW+U>W_@@B5,6$"T3\/URJF2R^
MQLG)22WY59)R?,H3_BOJ(Y'8RBB7ETNAOE5G9%7UJ-HXK!XU#AYY4%$V8#2$
M&QAX2?>G8C*&LPK'T3A48B?/1@P&9Y4!#JO*C/63H[IB?M.BA-,0!TA`T$>A
M4I2/``2/"8HE0!!4/-7XW4WG20,?^2+F]Q+4F`''Q#_P:5135#6+YFI*7A^%
M?APFAKF2TBW(#8\"2*`ZGCY5#>^H[\1=J+_07:@`HFS13FEO"0H#Q/L)%#&O
M#A$:UY0!:Q`*/GN2F+1:;Z2(O$D?_VAR+KMOQ8Q)>6<=A*@/8=+MCVRZ6L%2
MMA`?-4F@_ES\BO$]"J44O"E:B+&)'-;?4!B#1GH[_F78FVQ10<3\61_RXP+F
MJ^,AI:CQ.(J2UJH2WFC&/V`TTAEXUB_=1`^/L@"8G/GDQ!=S*20=*P%06/$>
M``]'0OY4.(0]!F.$@XO',1`.4HFN&`&S=3\;;O?AL[)!"MZA2^!-131.#U*N
M/0.09_EL&QL&2+'#@XZ!B4E/!@4A/4,-[[%*2JY!/RXT;,ZBH5?6;@`4"<X5
M1GT<8H'!8JK*("Y6VJ;OTUB&A1Z:H'ZHIAGYA,40K$HF?[NFQ#='_TV;W*,+
MYH.V,CEL;##WYI$E76X@5+EF#S$[Y[5B+R.H.89P;ZZYI@)F0IOQRJ(N!3R9
M:J9H'+F#1AN8S+(%OH>U8H"6K13XZ!5/@7KG#E"W@OH_1S24<G&53HB)!IX,
MXJ*S/1B`M&602&):O691[]&)\DV=L=Y95=.]F-FB442)%10KI*7`855!]^)>
M,PCP5(:>7")W2`N-L5`"Y><J.1RE@"1771=CX#V$-%F?W0HTA`LB@(T9YM"&
M`?:QD*E6',5)?M6.&2;#90YMI-RZ\5+@O0LCFJ-N=8\K8[DT6BL(&UG=R).T
M:BVCK,F53/&N;*IF45I&E=K2ULK'UZ]F_W:S2\2%_%\-'$X'JM*4]+2#[2)3
MNX7L&YF$*+@TW)V*0(9I55M7)5ZE+;J0?0,<Y`A1FRAS\VLJCD9R/=]>=QYR
M`5@>L0;=7=PT^@Q$*A>JBEP088*Y8,F:U`R8B;,<D!GU=W&SJ`UC!CZ>FE5*
M'E$F\._DJS81S.<J!UA:O>W2^H)'%\+DBG+>)6W,QY0G"Y+N8+IWT]`-+CUC
M.>`R:6^9;>\IVG:(3`Y`R6\3;^>H"R[+H1#XC8PV)`;]3N8RY1Y38HV15[+@
M9?T<S_;74"UC()FC3>$+T&M*Z*).YMP@GZ=8V3NJ!@#<(OU<IMRC!QD-ONQ'
M*UJ:ATCA7J1B`5>#`60XN'A4NL68CU1^W!VTH:^;N,R\94++PA+NU8[_;%;-
M!?6G9_JX8^8M$WP6EG"OP"S%LDIG%NGV"4N6P+GQ<Y[4\?3`2C&-4VY;`-Q-
M^>_VJ4+6':BCLI<A?>!W6U?_#,T64OPSR%#P:D2ZBQ*BQ^@]EHJ=3^XX!!WR
MY/E-7\XZ26E9/ZIM&REZM;7IQ+3'Y>_ZD*P,[T6E72P+7L@)@4X`SH'``(MD
MXV*$&)PCJ6R+1FHV,M6;[-LH.9YK&,OU:J+\',+F9<5<]I(C;&>B_RN0I0&T
ME*7)>6^;+A6E\,D9W!Z#",>1!DXS;\D1M3!."NK?+HW/1;$O,4'$E_JV*-??
M!M*QO2@DETV2@OC>)1"?N[A5:CCMZUW_[&BV75FZR@>)&%W2&B$RA`ZY1)@E
M!S65"+/B3=:`LV8M*4KVIDE!.G8J),IU%`.DCOA-_W9(>@.TG9Z+SKP)JMT'
MV*C!DJ*_K1E3GSAQW"=LKI^MY1-6#;XXG[`SXU,YPZ4(;51F\?;:-LZPU-)+
M]X)EP\W@=ZJ<E6.'#I&1;=LR:E8C!=]U0I.D8/V5-OU?,682)"%C.59CU!3O
MS+S[W2Q9$[:5^U%FTSBX6;XB=>YU_G60S6_D94&L,9:+QVNR#?"T[-UF:LIJ
MI/"7;O@``;^4P*NUGA2T.^AP'JL7,YF*'!;,[GFN!KB,EW08C>/>7<X;N3"8
MI!ND\W?,-4#FLI0:OGQ#.#C-S/O:S,6Z@\7KPW*NG#X`^6/RQ')PKM%@J1'?
MU(CN'0C*UN1?Q)B,F;9S<@;C"X3WCU'<>R=#]MOJ>L`P#997;AI0UVIFCQ!O
MHF[&X0OK);'C9\F>T1R9^;?EV;,7:([,2<1R5G^&HWBS%0Z:6]RT02`<\K7.
MWNG:>;;#=KI."W]CYG.\$M`1'3XS_9$Z`^->ZY8VP%B_\C`UA(O'[.9?26%Q
MQ&B3,M#.NBB=0^S.N);KN:WVIS-.(\TD,B"]#G=I0%S+).9(/,,G(QA_>'KU
MNOSR'U!+`P04````"`!N5&Y#5+,<AA$>```XV`$`%``<`&9I;"TR,#$S,#DS
M,%]D968N>&UL550)``._[812O^V$4G5X"P`!!"4.```$.0$``.U=6W/;.+)^
M/U7G/_AD7]=Q),?.)+5SMN3;K'?MR"4K,WN>4#`)23BA"`TOMC6_?@%2HFZX
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MGT^*O]*F*?Z2%OWO2`"S0E9*NHZ$+=C_CI?-CMFOCCO=X]/.^]<TK.BB;<*L
MFF9]@+.3\H_OF+A@$B0D0@,T.EK\^&UPN]L-Q]E)B*<GBS8G,(KH3(R&+]E\
MAGY^E^+I+$++WTT2-!*RN)R?47[&:/X+&^UD#VKHSRAFR^8X1".81YE!VG;'
M-D0IF4(<VR&T''HO.HLACJ?%YV:2R(UQ]Z%P0HE)@OP)'5>,&Z23-_H^U,8D
MZQG]9!8#%C0M"5(-/L+1,=LU/WP^_5`,<DFF4YRQ_3B%<7A)XHSNVW3_QB@=
MPJ<(I>^.MCD,8)#EZ3/MDB<HQ7'P/B#3DX)']6C[47O]>XZS>0/"-CKN1\,5
M2H,$S]@63D87.9T'I8S;QWPZA<F<C![Q.*8'6P#CK!<$)"^$\$`BS,1PA3*(
MHWK$FYG1&-?]BH9>14-?BX8A>LUR&#5E?O^)]Y/!0T+HEI#-J>C9>IJQ==X$
M3]DX^Z*4X&>J73Q7G'=J"GNWO[7]I8GH-(8S1F^//T&31:P_ZH&HK[<L:@QK
M8G]OLC`V>QJDH@G<W`$*FJ@"B6/,-K,[2L`&:;09BD,4+HEC(YDY<PN;B`0;
MLT7,"B&)0A+T%^`>TS$R$J,'."]FJ7YQC[()"2DCZ#9#TW0Y5@2?4%3,`&KU
M!Q]*&=DCM9!'0S*+OJ"S#6,OV226:GO+"1:*7RU+:I20:3/1+:D@]5DZ(DF(
MDI_?T4'RE-)+BM.6K?E2Y?P2T$5%E^=UA-@P]"M"8_;#ZN\125'X\[LLR5$-
M#-?E,H+I4R&</#T>0S@[8>">H"A+E[\IX#[^T%E8N7]9_!H,4`0S%#Y`>J(.
M$QBG]%.AY*<7\_6_]%XQ;X'6'P1T;2P!B2E3;TE4F&XNAT9\"M>%2XBO-HQF
M!91E8W!J`S*1';_"JYG0U<!57/TX`(&K=<^*-:`V74.'0ZIBSP!BW).O]_1$
MLNP"DVR"$CA#>8:#])(DL_L-]\W6F:?H!3Y:@8/G5Y)#L5KPNX><F@=;,J<3
MD`3#Z#$B,/X7RC)J/,7C2^8:3B[IUHP2J?!UNX.S%J!0@YDE'!WC>.@<C4P;
MOZ!C?M]'#:P&`><.L#F49KC.I0*TDTV[QI*EL^'$._`)]SB!";J`5,VE]M:,
MGB>P1)L>$N-"*[Z8KYHLI-I[@8G4/#(W>"W;R9!$@@D*\PCU1TKR4Q'](H/,
M^!P'--R,@BK0,4S*I=W67\D*G45AX&VT<VC#64&0OTBV6?;&6FC.\8JE.'R(
M8/P53I'2WK`QG6N3<@=;P3YAA_6WE612G)[8ODZ7E$D#V<S2NI[.(C)'Z#&C
M&G"_H$)HSBG[.+6D;6T"_/4ADX$WX/X&&?>9$M"-=DX-\<."N,VW"9O],%;'
MVK)+>T&&GY<6H\SP-S>X$X>`#Q:'EFB\\"*8B:8Y\+*_@3CY%48YZJ4I*F[A
M[S!\PA$5#4KO$4PIFV$_'J`@3YCGC3;X2N)D^5\*%TYU/!%&YW'@E#!!O\HI
M86P.!TX)T_@*=@N3(FJW?Z*2Q,6\^O$?&"44K<G\#CVC2.&XT!O``X^&4<P5
MRTHE"V\4S8K,A0`*36V7=J7E66L<U\X)?9@4,&LR^V='VQ,'PH%A]\]E4-%Z
M&\_R+"U8[BAM3$DOIVZ#VE^A`E4N>UYCUVV$7=<#;X%%[+H>.@5X=)XV`F_1
MRZD9;Q&\%7M+\+JFHS"JO`R9&MC+*NIV-,+!AD;8>TJSA!KS@G`-2[.!3S[@
M;\=&LRLV?S:%52[+&F^2[8#;'OSD*,#'(D+\[4+$OOR$/KC+;O\<L/VVM_U(
MD;G@#(Z^?R;%?H3(\BP,C'S@+`QSH'!V8C/B\,%'EJ+@_9@\TQT!EYLT_6%[
M;Z:_`G=H#*-KRH8P*8/3RG'6A2&4-N'GLVG8(M)%I:1!Z)G8;N+*Q220V:Y@
MMXAMBU0=NW(:BM=^>D-`OR><3^79#!N-G/A.>"MO=\_?(=0;+\@R,YW%"62]
MM?3TB[E&C*5&;SM>$;?[>#WV_3&0A/0R:I4^:HW>EKPHVO<0FH#41'.#/_^_
M7'-@>G+-8!]5_VX6[F$PH7M5,E\G6>G@E/1RZN#2_+3X",J9\@:QFSRA<LT3
M%G5W@U\+GX;:(RWLY,0/900O*4_^'(8]>M*'.,J9`^R1N<X*_]?U:Q#E(0IO
MJ$Q8M%N>P5)WN(:4JWB</J"DC(>;\P=09:78FQ5\_G$U+;MB,W$U8G-1:J4J
MJ+J"S@?'&2QV,:RS<#:EXLT18A=]3[0Y7Y>!?SJ@V824CA4?NJ9"H?49\J&3
M<N0-5LWR2SI6G-SV,=GAPEJ)AV6"01PNYA3KU++FH&/'?6U-TBIF_%%9+DG\
M3&T%3/6W!SHL2A(4%M^J\EM0]`0=E\%P>WP=&GPMX3OU";ZO)$/I`YPS5;P.
M>+O]0,=E+)P9Z/A<+8'[:'JCV]-\*D,=%+%31N<`'5>E<'R^GM^5D;6CD6K$
M`8HS.$;]4?\E1DDZP;-;5GD)I=F07*!>\'N.DU7PS=9JT.X/.BY\AW;`V`6\
MEAAL77>RDJZ+E,K;-,W9GG,;T\THQ72ZPA*Z(4E9#6E)6D%66J`A`'B_04''
M523<(5#?7S;^>#+7>'F`23]YS%@%MR)(<&DU2P]R96_0L>):]&`IU!2"/UJW
MT$-_G69XRHC_EJ)1'MVQRNY-[@%YXX"N'1>B/^N@MCA,*/+\J'JVYIA;;,)R
M^0=L2Q)L\YR6H.O"V7.HO5O`L`G5W(NKI=Z4B<7>)5(Y/NBZ<#X=\F,V)J;E
MRCHS_9$/20:C_FCM]"G7MN!+%S4'71?>K4-][C*NE\B<FT9FN;N$3"O40T?6
M!71=^+(.A9"*\R5*GURFE,C>X/%%>;N39(OH=W9:&E8<.J)=^54^A(,:*EHB
M%QQ"-=CR(:?#YTAB]Q5/ZH!9T\#8X-.;:TW[0::.*Y=HXE$3S`W^_DQ@>A)C
M8A]5_Z)%^B.JQ"']6&%N>Z?U1S0_)SYJ(G:\P<=T?+#+&]:]D)+RY(]77<CC
M5[3<1L2WK?4'<5J`9!\%MQ:++8!WZ>`=R8P5C=Y^)EQP0:D)[`:/WNRO0G)_
M24C:R/0H.OJ9AV$"QB5[_GR3O2#(IWGQ_M05FB4HP(5KEOX<H4+R<=B;DB3#
M?Q2_%W(F<YT;FL).LL4!EX5!05BK+'5'%V@_OL+IC)3W[BN[6P%WC=ZV\B+L
M0UF327]B#F5,-U2FW(:W6]VG%]PIKC</59=I][EXAU6^U-YR3FL'[O$5%2HO
M^%9+!\YNOL0$BW:7W'8[L05/'10W6;T\FY`$_X'";_332=;R4=@GFU[,KU]1
M$N`4/20X0`-V(:9P>EN8S0,G.6=-"*Y&K+#OC4%2$*7T\*RU<NT+MX0''_Q-
MOML,FB<^;W?H^><+OZ<03"7%H[CMW#Y^O?DY\*6^3:X_\H:O>O)>;^?VF6LM
M>6^1:RV5HPK&655W':V.T67V7S\N*KOV1ZQ%\77?DQ"IDGZ,C.W4.ZVED9ID
MU=Z#Y3#YCK(%96NA4OUXK?+W%<Q$I52U^SMQ/AN%8!?=.LQ[LS.NE_;.IV5"
M[\9A*[O\4_5U7ZO:+,IU&/?':\VC=H#3[S<)0LO<H0'_FZX[A!.OLR/`!?S[
MDX+#7Z4S%&0H'*)D6OO+7G5UXY-V]F5O,NZ/GUI&[:\DHHQ'.)LW^+;Y@[CQ
M83M&?5<$_N3QR.B^PL\X1'&X!_KK0[@I!>,8^VT!F,BSL?*^T$-"GLHG,N9,
M.!N>&/4[0[S>;@K2'!)O.>^*Q)W#W&8Q(P)GQ6M+,`XO29'Z@F*'K_[>D7C,
MSL&'/`DF,$4K"G4NNS1Z.[C\$E.EN@Q3]'1P.:8G8<&GH6:GW9=G`U2$DSS`
M))L/Z2Z2TB^/;?<7\_6_*.[$]`?QX*I+`U&!_[P.E]XX,]9I4^8+[#9V?;]5
M3^AJX/S+\-@;($_NLFPA9?_9DJ<GDF47F&03E,`9RC,<I)<DF<G?,9'W<GLQ
MQ5WPN]Y9-0^V9$XG(`F&T6-$8/POE&6(/8)W">,`)9>(>8^DPM?M[O:Z2A.%
M&LSXXT`5GZ(7\TO*]I@P<X4I5\L6H4*):#BBG5NNPV@4S5ENPT(0<*`\XQJ.
M:.GZ3%M3V0/,NJM#)0=O=!N/%H<G6I(_J\2Z7O7`IKO!29I=TJ8X@-&0'7/]
MT1T.J+CHR9B0,`_$6:_U!W&:^+/'][JK%-3FVRJ*CR@@<;@OC/JC.,W4,8]C
M+<;MU9YEI`PG.-D;2.U!W.;IF`>R%N/64JRHP1:1,2-A,7=O-HOH?PN/OPP\
M=4>W*3E&`=-CUEHMR'+OI@RP$!AJW$%)?79I>[</3AB%1,JCM2KMO1$UH8NI
MOZ*,S2E_CD+4W.US%$9QD+%HK6[B5_1RE>1CW;U*U-SM"Q-&89"Q:*U(X@`%
M",^R_FB`QBR5F)),"4C(,XQ8=<UOCS<AE`*C/X#;%R6,0E6/:47MQ#W<IIA^
MJQF)T0.<,TX48>2BYFZ>@=CK/E;%CC6M64QM14ZZH$>`0HT1W+W:()7M+A0U
M>9(;IP</'.GQ`T<6A5/UXT>$ST((YKF3Q(/H=JT5#%*70%%PATZW`T9VU)`5
M9^UJ,-+NF(XASEBYR]LX9+%ZK!2P_.:%V]YAI(8N2'R'J(@;;YSB.P3^AK-)
M<5G(KLLG>#8DUY1=C6B`FB.YCN40(J,)I)*[-XB]B0:QC;7UVXO+"4:CZU<4
M%$\1E)4J$[H57>$$!70(J8VDU]EIC$B#KXMSE.KR:2UV9YR@X@@6''$[;>Q$
MA%@\UG@<6#-VJHF$^Q*GE:4\8^6QPI6,1'@5M=878SWI.=ZQFXK1OPH2Y:O3
MA8>'?EC,>E47ZQ7V<9:-S5FO_#-31KHWF/1>8!(NZW=+<-AH9^<:_P"VQS87
M_B2^\BO-]%CBT+A8;>G%?-5FZ01B[*QXBD-6>6;U)J\$3AO360H*T#9?=L#E
MKP%+K'OS1?\0*\D3*\GIDO+U`$=HK=:5Y@'.Z>,V]L36+B!3!01"\`;>XH%6
MQF?Y1B\3#(F+4U91<E'6SU+$R@&4!25;_A15V*)0N6ESV]L*9-&OE:@4N.#K
M$G'CS9=E"A]/CD730/EWTJV5PE*><#MMW48BB;\&/BA<\KT!8H#2+,&LL(4>
M&-SV;F.2Z@(B9,&:6U%V1FX^5MK@[GG[M5,7,4?V+J1WN?,G]6OA[T_7-5S)
MI\-K[B82J8'0^9^2B"5;'F9F+#S""";LH8@'E(Q(,F5YHA<DSM.U5X,%GY%N
M=W=A2'NA4I=%BR5#BQJT`X2G3WF2%JI,?S1,X#.*6!VE.!4^2*W3%71<U9#<
M&QY=]JSE3DAG5G]!NMU!QU75Q[TAJL.BM>R)M2^W__3_*&#7RVIT%+U`UU6%
MQKU!T>#,GQ)\2M^7R/55:K*W,15%7@BKSPI3#"<P+GU:Z2]%G;/;F(H#DU"B
M:QR*!-!U5?[1B/YR2#%92RPI9RPF1.&0+$.2%Z\HI(]X'/?CXOP7;!OZ`X"N
MJXJ/>^\@]9BTEGZB3X9ZNV\T%NBZ*N)X0`BW^+66C[+E2BA(HU]\0'F$8Y3V
M8U$PN;HCZ+KPJ1C2H'286X+RTV%!&;Z01IC0?J#KH6_%!"0+WI:(?#X$(CJV
MAK07Z+;2=:+)V<HV-PW&KW1R2N]C,$%A'FE8%>(.H-M:/XF<J4KZYE_-::IQ
M]JLRU#@I^@C*]9N?!'1;ZVXQ+XAJ91CWS*S"&=E<Q9MG52BD`&=9%]!MK0=&
MQ5:%@<#MXED^98W79M\2*M\2*CU,J/SS%,G>+Z+IK4+V6X5L'P'R)*SIK4+V
M6X7LMPK9#5`X<(5LON,:?A_@<(R^PG*\._A$DJ(0D!0'53>GC[3JRE^#"6L7
M]CTZSO,CB?)BJY1O.)RF3M+X:N\R?,+MU29,4/B//`LF.$Y)7'Y'`Y0BRMY$
M8V_1[>ZT&J^N[&LP8ZU"85%;])8JV[=XH[CH#4EZ5$68PJ?;^#JB<T?S7I!G
MZ'Z.(H+#.Y1_1U,L+]=F9&RG]7AUD33%J;6+ZF\Q?D9)6CRK-D2O,+V_ZC'G
M3K7N-+Z]6F.X38'2Q:TV2]8NI_]))G'Z#S+[3O>"%552/&1=W!;3U16_B@-K
ME\=W$(<1?"E\#%(9[S9T6Q-75[)\NJW=^ZY_1P\HCM-Y]`QCQ?$@[^0VTZ3)
M!L+GP=K-[C_A%*7I)9SA#$:_)"27F\2BYFX32+1W"@GU1NYK#>56\8H2J;.L
MQ+W<UK'504>3"2/7NC_:^U%V,E`.X&W?@V%_<HC\>2'(4LZ+]?>C=@OT&I"$
M-[Y_G]:')]<(/BT4^U</IAYO:./+4)V:KS=8?@7JP&]Y.4FAL@-9?<[MEWC4
MKIAI)VOJH"4SU]*CS%]0-*KZ:"EOJ$'1S"XWIH=#KU]E,[L=[^IFZDK2_LN+
MY6YRA9Y11&8%?3$U(#/$GM@HW\):$B7?L.N.XRX_BK=>.?MP$X9LH50+"A%Y
MKI*9].0MIMK>>RV+*>/P<4;BE"0H7%[GU9.T>@!W*4KUI*_'B;4#<D/ET<-`
MUL5=%I*>U%6TV\N9CV!0'D;CXA^M'5[6QUV&D>9NKB+>VH7]6O3>/8SA>$&%
MCL1UNKK+*](3O"X/UF[2!RQO3W,OX;9UE].C)V$AT=;NOA_1#):I/NR\0%D6
MU5C4>IW=I>3H"5V?"Q-WXC9K;2Q2PO-L0A+\!PJ+'**UXK"LKFQZ,;]^90^Q
MIN@AH9K"@.6$J2JQFI\-G+;-O6!9&/Y4?2W(4E=$7+4"IXZ\&K8AX2^`+<Z]
MN3-I@ILG=QLN`?2O2NRB6IH2RHUVX-1I;-36-\$7_`[!_HB<BDQ+Y.OMP*G3
M,"D]D6\3_$-4>SWUL$C,G;%JKZ<6:_(NLOVK*Z@;),I3YK0$IRVH!,.DQW$:
M\+FQYN0]Z//1IRTH"<.'I2:7_@0P#=`SBG,T0`$9ER*O"+Y'5&$)-QO\@61E
M"^L/!DY;4()F%_+]&+;FJMY^!?T*9J)=D=<4G+:@4@S_^Q.Q8\U;O59QJ#\:
MD#F,LOEB[B%9CWD5R%^[/SAM02$8/BBU>+3F[%Y,W!\MPXU6A=-$+E=Q#_"Q
M!35X^6@HN++F["[CABCUS+J%$9M:6/]6VAY\;$&Q6K[LI3R9\(D;>O<;!9.8
M1&0\?T3),U4PTTN29C*/JJ`'^-B"0K/B8UW"E3^N\WLJB@S%+,50A=)V4_"Q
M!45DQ?#PV+%9CK0,.8C#];B;50TZX;V=HA_XZ*'QKWF4Z/!F+6EM:6-1G0*&
MF,"BFOP]9%4U8"1`0]H'?&RO.T#%E[U"I`\)897\KU.6FYXQCW<J^A9X3<''
MUAK[(G;LE1V](B]QY?GA3:_4:6N,`#ZVTB9OP*6]:J!KA-R09$&)&II56_"Q
MM;:XD!]5X4]#,7H,9U8T8S9+R'-1/^.&D)"=54D^[H53VI31GV%AR>2FPX&/
MK;75]V&YPM6X[7Z3Q^&FJV"SG"RCC)E6PQ?R?U0C$5F4]48!9ZVU\1MP6H%G
MWO!7$%,D@C$RQ#7]ZPP!SMKK'JC)9H69>Y?!PJNT>&!+=C>PT1"<M=I!L,M,
M!8GQ.C-?<\8,56?H?LNH%GPJV\W`62MM?!$KE7R-&_B]*<GC[`%B^@E>PV"R
MF%4@9D%K<-9:8U["425TXS;\8T9WN6^S&X3HD;2A>PCD+NX`SEIKO<N96ET3
M6I+^55[XSQCTDIM"?F-PUEKS7<Q0)7'SX2J%MQ\'%.H!"A!^1N'%?)5\0)4R
MT6,@&CW!66L-=DWN*F",&^HKAT!_=)-'T?P*1SES%I1EHHHHS>O?*2-#LO82
MO!BK!H.!L]::^LT9KA`U[@OX#3(_=+:(IF4Q\%])AH/%A9OZO23M_N"LM=9^
M+1XKJ(R;]QL!`HLHZ6>(*2`XPME\%1+='RTHUHFFT!H(G+?6R&_&;(6B<3M_
M$0U=ZI']43]GOE?ZF:-,[[%P24=PWEJ;7H^Y"A7C"7%?23Q`HSP.V=?-7KK%
M65Z.+`Z5E?8!YZTTV;7XJF`P;KT_T.]S"H.Y)#YYU0*<M]9FW^*B$J@%<QW%
M(2/T(2$!2E-*IUBV_,;@O,7&NHBA2N+&;?7*#4GI33&=1'9UPF\,SEMKHXL9
M6L66VG))S<O]BNU8,(H*)K0>%M3N#\Y;:\77XK&"RKAAO_15KL^O\-"N-P7G
MK37=1>Q4LK9AJX\(/67B`!7/A"_`W[GB6@3MB8WT.J.`\S9;YW4YK<`S;I:O
M&YAT3I8L@V-8&C&J_4RK+SAOK3FNS5\%SSZFN*'*M@BF:/7`+G.A=CCPR9J#
M3ZVTP54L52`9M[2KM3!`,7J!D=J9)>D!/K76ME9P50%@W*BN8LMZ8TK"F")>
MJB&BHT;0''QJK2DM8ZF2NWDK>CGK#=T7HS6-8W5ZI1=S5G,!QJ*,JUIC@$_M
MM<3K\EG!9MQ67X5B;FDB36#3&0-\:JUE7YO/"C:!P7^89]2O?\]Q-E^\F*[_
M4KK-ZE%K>0@7\U63A8![+S`)[R0/KYL;O-;3[(8D$DQ0F$=H<3$@(S\5T2]Z
M]-WX'`=\(=XHJ`)]T*1<VOW@?,D*G451CVVCG<-GXZT@R%\DVRQ[4SFH.<<K
MEN*0E;+Z"J=(^8R)C>E</V6_@ZU@G[##^MM*,BE.3PK*.5U2_E64NY[.(C)'
M:*UXGK+4F;`/</EHH:U-@+\^9#+P!MQ%L(H2T(UVP.7;AH<%<9MO?XI(-=:J
MRZ68]O,LS6`<4I-Y0"*6;\;^:,,VDTX(7%R&'L0RL26N'W()EA>;AUE]Y5S`
MQ26P_<5A?3%6TO/F#-N7.2J]$<*%F^TV%I9)LC@;</G08-N6(E]^'FV*3-V[
M3=,<A5=Y0J52TEC&#*_I@NDR8EBZV&H/!ER^@'CPM=1$/"8J0?JQ<:WNP0^Q
M<7%F`QT7P01MW;D$`O3G\0:#`OT-X?$D0V'O&25PC#;*[!]&RY-1`#HNPC#:
MNFYK"-5$05'7#M&M(Z/Z5FTM::.$@([+EQR\6]G&96NB8JLW"WSG.'*WQ&N1
M`CHNW\YHX2*O+5U_RN,6G#VII?U4^_`:(`8W_3T+'&)!0BQE&B73KFJE'Y8:
MT/'ZRL3&8C^\@/VI,&Q0X+>43QRG./@51OF!M.[-.4''ZYLB?_7L73$J:BT[
M"#Q<A%B^Q1^^Q1^^Q1^^Q1\N;]05X8?KS?X<T8=;''MS;:8=[.57P-^V..5"
M]R]2K['8/8F.:R9_DV%MW+27X0L93DB>4OUI.,%)AE!9]XH1(GV'7-W1:<R:
M*E!)FX4#"KY4$V]C5J8,/Z,F$`B'<!I[UA`,&3,>75QS#\"]WE&NK6GO]VJS
ME5`RW]0).X+S9QG6?XG<3B"7TP?DA3Z&3;Z]46H:@.:).N,./?\B_9L]9.XR
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M%?/I%;_57:L_Z+HJ8JX+6VUV_+EFZD7%X/4AK#<`Z+HJ<U[WT]/GQQ^GT%)5
MOT`Q%6]1&)Q/O89#7CD&Z+HJ?5X7REHL*;+X.;E&)VQ2EI-'__,?4$L#!!0`
M```(`&Y4;D-)DH!B[%@``&]>!0`4`!P`9FEL+3(P,3,P.3,P7VQA8BYX;6Q5
M5`D``[_MA%*_[812=7@+``$$)0X```0Y`0``[;UY<^1&DB?Z_S/;[Q!/N_:F
M9$;6H6JI)<U,KR4OB=,L)I=D23LF6VL#@4@2+220`I`L9G_ZC0B<F4"<.-S9
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M\,,//[P3?V5#L_#'3-!?);Z7B[G2OA>1CN#_.JZ&'?-?'7_XYOCCA[<O6?`5
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M[[[]X8=OOOOYVV^_^X^/?S/F\^XO%?R]MTUIEFQ3GUI!+[[`_HMY#W_[_L\?
M/OSI^__X\Y^_O_K6_,6X4V-<N/.F\?'GNZ_^4CML+PY(04A:E.2WBO;__%OQ
M+N-!8V'%0U*KP#\CPJ!\M'@0',2WA\`6Z;X:>:E?O1W[48.L'/'.3UB8M,F/
M]R1TE2;K(9I3O58R9(+>&9N*$J0`F%'_[6/R_"Z@X3MN/O@/PHX<O_]0!E__
MG?WJ;\5S;^ECR!\7Y]?>FO98CK_^Z4]__?#3Q4\__?G[O_YP\?';BX_???B;
ME'X&B_'IN^\^?;S\^?+RA_>?/OS\[9]__O;[C_(7Z@I9*5?-.,('SFT5YD$Q
MAX+8"<B!8MA-PQP*<<JT,O6B2^;;7_Y*=SI?*B><VWFJ($BDIQQ(Q$C"AH+Z
MQBD`S.XAM(+4ZQ)T4C25R"^8#PJX'[J(O$<;X[]/"&GU#R$<2DK]=\('H#'S
MPUX;U*[W"HW6H/=)S%1B?;I-4_ZD,/.]Z#^IEY['P1E;<9H8<RDMA#U7`#D4
MF'(H*<82/IB%T`'AP\'-^D0X0*R[3KBD!EXC65,I0[74N&=L;4S\'AVDA3\`
M(%TT\K^CL>]#7AK4NO>)B]:X]\C*U.)<)[Y-#7L_(815ET&0"DDQ$(\Y'QL`
MB!U7"I+4B*ND:&J1;SS'!?M-YF+,#UE@L.M=6%(Y:@<%8C`Z>S\F&!1^0")T
MQBZA7^+F495"267*(K4(76)(+]$'12=3I;T%49'9@(!Z#:F`:3V'3+JF36M>
MA!%-3YFO>DS2OJ2F)HN[3PZ?Y3^$(\D/BF&D&H?&68R(`4&&OU>T#!/\?7(U
M<7X_6:^3^"Y/_-_OGCSVU9?;G)=*\5(PBV2_B@M@YE\-3I9%%U1$D!V1@I"T
M*,$]R)S@('<,#$13MWV@ETM;]5IYV8-`N,V.'SUO4^@8C?*L^LVALI6__MM=
MSA2;N[SEZB*,O=@/F=]+LE!3J])K;JQX0ODG2^"'$GOB1;QDDPDII7D&6+(R
M!;B:C"0K4A.2BE*!%LS%N<BQTN\Y"/%\VKK(,B9UIC5D$JJY79_TY3O[:6(`
MEC(PR]<&]U%J&>GU24H!F5NJRZT75Z?3SP3:R\B@]<O0$:EVUI#Z%5,X%8QB
M_(_HO(52XHS<@TK<YM.<4R][6L0!_\_Y']OPV8O8VV2+_-1+TQT+)W_QHJUV
MX\6.&93W,(7:$45&(&I5Q0\MTB.RR$E%300Y"G\S&*C/?Z`-Z>BH-IV3)7,@
MR\D#?0SCF'\M%IX6+S$1MN:DSSS(*/ML4DQ@D825=5$&&#:F93[K>9/2C1<&
MYR\;&F>4O=\R?Z+IGF6WC4),6$+')&:P#T6UI"(EF;`T@I`<Q"ZH`I9A6&E!
ME@FPB0#KEY&-!Q;T#Y8_FS#'7)Z!E@MV:^`955"QT)(+'K`J.;VS.'6IT8O!
M+YZW#H6.^=K["Q4TGE>IL`9PY_>D"8M=\MT-FV)Q7HHY^0U/GEU3!Q>JX`7O
M.Y5`NXZD&'Y$!$%Q9JXB.2*,")FW=$(G8-$&5DQ%`MGS_>UZ&_%3Q"2@FY3Z
MH3@[-Z]QF`DPPDA`KY*&(8!6'^?V_79.']C;&V>,`;V[U#\B<^?2]T3IORT<
M]^R*=!5Z#V$4YB'-F$Z+S>BG)`IHFG']SG>N:7ACOM">W&("#D6N15I[=.84
M)LS9YZW^'?/!O%R<7%Y=WE^>WY'%]1FY^WEQ>_[S\NKL_/;N7\CY__I\>?^?
MJ,*7$3]IF_A?R@^,SL7;ZK"1N[=48!"+I=\J[+7*"@Y0(8(2E$)(9]DI5%J=
MX7`J!%%#A"(D<@+1(@+9[K05>)/01*LO,\;]OI]LXSR[\7;>0\03D>PWZ98&
M/>\8!]=LKMSR]\[/@0YG!DQ09W52LB(E+^$02VYM.4?E^Z?`OVGA]TK\U98`
MNF!@J(:853T,4P\P>W%+11KJQDM;;VB<13#A!99C,`.JT_$C4E*2DA39'L1`
ME"I-)L<D+;%O&$/X]C0N,JQ.,9@+\'P:>IWDM'HCQ\WV/A;0?K@?UJ%@\E&5
MZB%*%IB_?*U2J((`B\F7O#ZX&U>HA9&'ENO$?*I]1M/PV<O#9]H-"TR=KI('
ME+/5`.L<E*V'D[ZE.PK/Z@Y)L6P'<YDFDJ=TE09B!YGQ&I"-Q^(@C<0,@[H,
M1[%?&3-EFLM]!]P"2$^J"YW[U*N][6P`*KU#7AM#(ENMSRB\GOIM"W$'%G/M
ME[;,X,Y_-B59K\-\+0J]X^`TB?,P?J2QWR_82JU6L8+V9VJ8G>V"9G1Q**4]
M'I6'&X;+5^$"]Q(&HFGD+O1R.>=!?HL2CE[C`ENLT6N_K/;P13.%>L_^C*Y"
M/QP_:K3?%!T`(I@(A(O/M(/14S^!9U_4O%3"=B8`CC"M*`M4BT(-V7%/W9&1
M#@MHI]H/J^>83C&JZASSX?W[H_?%_U==9-Z^_\"W-,ABFS\E:?@/&AR1]Y,V
MSG%/O]JBSKJHLP+U_^"P-PRVMP<[@>L7-`7P__'^[?L2YS.G^5<V%?5,-,A)
M/2UAEO&='W&:"[:[D+5&VH0E<HV>-_HOFQS9'4(_I`,[;]X%T!?T-FVKQ*@C
M<BED#$'880Y`:D>.^@W)AP]''[[]EHW['M*BC`.ZSX9TS&D#_E_)-Q^/OOOV
MNZ-OO_]&V)%O/AQ]_.'#T7???:LV,D>$_6U#?9Y:CO#L,<O45'V:NU]'9ZSN
M"`+1A\F+;KPPN(Q/O4V8>QTAT9;,2-A`1S]R>)T"AWHDX4/)94S*P:C\NQ,@
M<0([C(D_$2#WG+DYG!LU!O!(0Z-(9C5A2BV:<]>96=9$G$R[R[U'>AXSG[E)
MPXR6J8!%<Q[Q;)LRFWQ(8;XW/?A)<#O8(TQ2=U.X'D+$&-*P/:H2,:3%F12L
M28<010PQT1P5L[!W*+:8A:`U"]FXL]!W93;26<B?J'XF``L+QC(NFO*#D2P+
M9-[9-@SKX0`=@?6",LEQDD6>I^'#-A?EIO<)SSU-4;O@GF2RA?8O66G!:>SC
MZ,YNA:38R\WVLNJT]S@?8$!I@<3D8.)@)`8-WH;C.:F[N94]E>?OY38<Q+E8
MW,L0@,?W<N-LV`-98IGQG%-WJ)'IYX.@<$8&T.S\.8K8V0%-8=>B`TSP%GM<
M?%@/F+LIBTDL:ZAQ4'NE+#!;IJ+)>R"2F#<T%5N&P[9/I5RA(UIC\-I-5KZ;
MNDQ)05WL>O`KH(H-5U0!X@B8RUV">GL`G8>W$VJ'[4.-1$.I;[&]W^SJF\8!
M&BY048`6G%8MRWJ'A@A%/#``5ZEZG2TX-%[23""5/M)(&F%5K-C/'N85]SCA
M\H0'($W5;*)=_O&\G3&N?34+>W$A\W)]@NG@V7JD$E;5+&ZY,V6#R9^IKX*3
M:1I8J=Y(N*Z3M[P9:C$4K4^V_#:EM0`NHG/2"%>W#'E)7ZO@9JQEJPE+:$]M
M!EM=E3?O:M5]6V805MTJ%30N&149OR*EL#[H8A0+)34^7&2FH2"&R'4!KF*!
MH-;78(G:>ULMLG6W$R+T*VX#\3,M7`5?:W?>Q6VA+6.#R'=KEJ)]Z@131C\N
M().%-1;';('HH,P]C`E]\9_8:,J7.<5&'<FHOTV+S2[V2S]9;[P87_]DC0K:
M>FG0?(+)O>36KAE#)L'R1OE^:S)E$F$4]VP#"O'BVT0*[3PTY++[,F:6B]87
M@;M>B2!C`^VBY?"D]\)G9+DB2[8&$Q?Y0%[5/1*R8B1I+KY'?,6]1AR-W)5:
M%F>L&O8BFMW29QIO:?\=8?T']P_(P/I2=%Z_HS)\!`I?HW_7\H]HO(A$.-0]
M&7HE8SZ!+HUB_%A>E9FY>@LY(VA_H8+8J8N5M$D'=0LV`.JQ=9]H?+?8:V7.
MR"7H!&X^';JE&67SPF^*;AUK*5_+U$6HF4`Y#!VTKDDNQHM:T?8QN9($A6<9
M!*IUUJN^,3*EX?IAFV9%K(G&'QG)I=([F0CE?'KV$XV9RD?\]H9@'<8A5W?>
MET"N:4HSI&,'[;?T<`\%M:0H+C[9HX'2OPD!>GLTZ)R<H;`:N3HS29WSR'IS
M*RY_J762YN$_Q#]-W9V*!=PA<Q6L[IG@9C0_+;Z)*/^Q4+X6Z1&Y3N)-F@1;
M?Y);A-V.BKLB+52O-;Z*,]%X/0/AU)QEUDGFC![/"^.K),N6\5F8;9),-*Q8
MKHJ[5S]8.SPU-W!_IP/;\0:,@+SA)%\3)H@M*AZ43719L?M.G#4^/I@#"_:!
MU1=XXW+F>-&9=9.`10<?KQB9&K-PQ<3.`*:X3&.4+B%49-('09[Y@4IB.;]Z
M<=14=D7A<)-M?5S6_*633KX-32`DE7ME^",3>@!]+39]N"5Q3D:W6$"'-_VP
MY%K,!Z#R\&8`KFE.(N[\N'16ZI'$F.Z.,0-R90`"W&LK=,4NB=Y1E#EO5(R3
M_=<H38_M10!Z1E#^VP1BQQ+D3S0EY4;_FW+\URA\NCN<L(13.LNO\?36-Y9"
MI?<T%<$YBX'8BI5FBNTH3?'&/CFT%^W"Z9;&%"-0IKPM7E^25P-=!@]_?7"/
M*=$'PRJD/F68-QV8<1]-V=KZ_(4;F6V8/?%\PG)U1A^,/:6>$92G-('8EP?,
MBD0@S;XFRYCL$_+B/TZ*X!RN*SPB$NU[H))5W7P*1P\M]-@&=)6="1M8]&-L
M6931CZE9@;C2N964K'_77\&I=!]ZAM`1D@ED^?7(1Z2]J\),:?M/C!C1?HH+
MT"HM7Y[\84A77EB=T66:671SKGC@RK^XX#WMPWG<@CC-];XCA)HN:/G(=]&P
M3PP>H!J;+*.0U=1>(4CW#$[SX$OO].5'6V-?679'DNWMS^P@V,6Q`5+NYAA!
MP9>C&I:;FM\$T-Q];V>?&#K:.H32IR"5EHN8"E$`9?+N$;9=*).7KA0XFF;"
MG3>>7"<</";I55BC^*-/6^<S-.=>RCOU9U7CF1,O"WU>S!Y&V]R\]XN.#53<
MH8?7N_[A?:2JH]D0S8]'PE+O-//>2G[9ZH&3L@7.`Z<NSFL4]&A\N*%(*CVY
MF3S.IV:_TO#QB3UXP3Z\]TBOM^L'FBY7XMU:!^'UVJ<T0HY/@8X0G"?G4-XK
M1J3D1`I6/+O=[3EY1$YJ%3CK5P%0-S[^K'CEK,3%K!3]6VJ;L-=W`HN!F$+<
M;9SS((V:\ZJN\MC_<G7J94\74?)%=4RY_VRVB@?8<7PU,&D["Z[RG(`("L!N
M%N.B2@Q1P1WP-Q!$]6E_O13.N@KG+W&3)L]A0(.3W>>,!I=Q71*VX)<^%_>@
M./8$<'@"M+=VFI2^R%1(<L6&G.S(&\Z)7,9?DZ;&L^$VI1(/RA`,GXV63E_P
M<LH^^)TZ,.@<PPBP%W<_DXNKY:]WY.)V^8DL;\YO%_>7US^1Q>G]Y2^7]Y?G
M=_AZ,[@;!=-T@)M%F/.2]K]OLUR<Y+]/;BF?S#"B>WF,^V2XX>QU,),\&RJZ
MF6@BNU>OUX_A%Y?6#R*=U"O_\VLQRUAF-$](6L]H7&5<V&_YSSZ?S$TUF0]L
M,K>9Z*WY=>M<C`=GY%_/));S9C9M8/'OE*91&3=/:!=G3$:O-U&RH_2$QG05
MYN)VP3)[1X/39,WWXF0]%)0^VYPQ='1M,P6=UEPE+:F(B_LH.?FQH"=M!JCB
MR2&P14_1XP<!T&\-15M@;2WF1H&CK8S#-$.INX",T!5%R@M#>Q0%4-<^*2B"
M@Q$PHFZ(HA-0X\XH&NF<<;G6>GA19'P69GZRC?.;E*[#[=K6F^H90GM1$\B=
M<+3=LJ<\#T$J,O*F),14G>*$,@A^W.].E*QX"PY!ABHD&/P-.3#^#67HP.,`
M8\4T\O^F6@EE>"["V&.+DOCQ-,ERXPXC2AY@>1LU,)UEJ0F(H$#AUH=`$HI6
M7B.XJK'Y?=C@%N8&LJA>8.L%T42S5F$DU.7]#Q_?"V5AOQ"G@I9Q<1+A,K[P
MPE1<!L:UN*["-W72QOR@?+0%X-[S8LN8E&<V+F/"2<N[_X3+QG4N92A4P&,X
M0>)O>3:I=W$&C_<MBI,X`_#V'CLR.W0$%K?8FBIEV&)IIV:]&R:E7D;/:/'?
M5HKTU-N$N1?9[EE9<(2*:*Q`]URU(HC(FXK\:VZ;F]VBD@6V,IQ!H`NIS0ZV
M)$0#/Y&X:2DPGNT)>]E6QD36@HU"BXLNBP/N?#)D#)T$L9D":Y4N.""^)LH9
M^IN*^&OFC\M9"&-\=2C6$FYZC925>$-J]$U*-UX8G)5KSZJ/5!R(\Y;%Z[K[
M:"/N>/RUX608*GK)K>H0)3Q:<8IUHJ;1X_AOQTFHT%8-2@7<XJ2KOV6,XKST
M["@ZK<##1A2_V-@`RUC&P@"@B&NNFHAS@N"FCSOB"*=_,JS#G!:;5QCKV$Y"
M4$_"*PMX%*(_-.J1RSVDTB]\L;.3W7@[[R'B1HG])MTR3]*\KGOH8\0=3^AC
M.!F&RE]Q(R6[H@RC8-BV!TA#(,?)J%%O6JB]$C5P,G),J74+!2P4`I%5N*41
M#RYOO%1B#BS-K9H]OF!`-QV.!N&(E)Q(R0IY.&`[#::F@!R3M)R(#6,&TJIQ
M5`D>%C&8:`?&HXNF88(%1[`N8S:@C8XD]IUX07#,93#0OB,54UQ!X=1=;0IP
M>^=%,'1>&T54RY-91F(*UY/-VA2IF[39VB%PHWL9/]-LTO/BJB=`QV5.D](-
MS<K14]KA"0Y$VZ$\/`?>AQI?7L9=ZH<<B-:+_'QZST*^\N3=PO]C&Z8L&LS9
M=PWY4M%J%TK/""JT,H'8V5\H:?BIXI**-&28=I(&H"-K+Z!DE:1L$93S?Z>\
M8Q".G:+I88$%%<8JIXPE3/4-T)0PN\<BFWQWP[Y2OHB#\^I^5-O0P8(S=,A@
M-0DF5J>B/R*"PY%(:9RCO"5X&';VID\>W\I-5KSM0`EZPTD%9IQW!X^"N0U9
MC14\8K)7<J-(R5K#,:Z,!J:C^C@B2T?U@[;LD#7+@FBTQ)0YY+W<35B#G#!W
M,V**RA#F^3T1K:\^WYV?D<MK]G^_G-\=]+W"FZ*R%-\J164BL-A25`KSY)*B
MDMLF<$-<GV>;+$6E>@)TO.DT*98&NSGTB:!WUO2S<9C*ZH/_*EH:6L(^:&EX
M<7F]N#Y]I2T-#8S"D`R>WB+,N.Q.$Y_2(..RRH_.LU=>KBZS;,O>D%H=6#?@
M!);#,P'9+1(NB`HUYF3BECM^W+8B172,W0GB29*FR1=^78`X@9HP-YWF(D49
M"+B\!QU;7":K%4WQG6PW%UUU*LQ4;N=3RENZ*5>TR]5UDM.JM,(V(I'R@8X[
M%``/9;09RC5/#*[JD5!Y40M(=:*.*5W,AE;U1JA24Q/@`7?W.KTR<NH:I8)Q
MW96]6JYNTO+8AN@.N(B#XA>4_5'\QL6=6W#'X.*M)D/M]FM/SVQ/S8P(6I%J
M;?@5OT20B1IM)NZ\J,BGEQ="97R<85``'@.-(P/<KI"PD@&19Z]D(.O[W"AB
M(7M;8!P?61L":&OXJY>F7MR[B%%O5*BY0<=/6K!JB;YL271%A"J8&HB/]\RA
M+S3UPV)W[$M)*+;U>:(=761B)KUFFV$FHHLQ[SIP`ZR/([(-L'[0(^134;C?
MP:`[=P8T/?5>0PGS@*]K\DVQ[1$I--AECTBNOO/9*OY>+)3A_^$5`\\L`.;G
M6EB<FP2'YUYL(PHKWM#QA>5$].Z!\.61^*'%X8@4/$C/B3-$&T$#X9?W3/><
M+>\-/D`CK8%0+Z]/;\\7=^=\-U]L`2VNSXH?SO_7Y\M?%E?GU_<S;^E/_66;
M1HTH(TD7&V845SH8L!GO`=UN-I&X/M&+JNL3+V,6[J_%^2[K*T$-V8'=#FH,
MMY/4:5$V5VJ2%C&V9H4C8>7-T*,DVZ9%3DO$FBL./6QXX>E7:"G/ZIM%K81Y
MUF/\R9K>>R\\A1Y:W_E]2`X=,W7A]!RSYS?.B2&$CT$5">C?7Y@+T3B+YU'"
MF`58-,-79"R1*]/3[3U"-:=.%),J40A)0Y`6#5QSFKT7[XI^\6<0L7=YX7U9
MS[E`H'$.?4*BZ>O2D9!Y%]7<Y5PSI.S'IA8T#GK6_&>UFW8MPQS\/&A',L*$
M28L2CTC)M566S!?JO46:#6NL+>`FF"I)T,ACQCB)C\7<A7MSUY>EQ%?J.)8:
M&J\51]#!.6_J>\@O8_9P<??#:5,)5UPJZ(<L=!:_S%C$?$&]G+VLJ7]VX@UW
MDY_31'1OO7O@-RQ7?(Y(B],1:7B1AADIN:&(#D::AA90OP&Z*L:#WL\UGJ2:
M!"`#5,#Y;J'6K1K5YB??#J7!KV'^Q%_(-+`P8P9YJY`)U$/1W+]`J"(C!1WA
MA*+F&86['X2QODFGK@(("XQ?.,9@"HS.=PA-"+)S<1#H;3K&RJF]2L=4,Z>Q
M(T8EE89<YG;YQN`<3,<TQ9`VGGP8.K4^]=;^36XUYH4'8B]<U$85?UAIWO@6
MXCZYB3Q?+"87CQ:=2^R8HHP\>J#;F9'[A-0<B&"!/Q0Q!2U5OSP1M8N;&K@W
M"?#QXY.)D+^2H$6FY^[!BT3)G4U4L[K:/[32-/2N<L3W25'N;QS9N+*&"'?<
MIZ&346V6\X?'TO;ZYM<;'\R>E><H<,1&DTR%2)+RJ>CKH%UM&')=1Q)!P4Z"
MWSI7@R/<&F@FI#'8,!LQ1F!VSXQKMJ(IKXJO[B[8G49>EH6KT!<"<Y_PNJ;#
MWSK&;.[/0Q+.#9DP=:17<2Y.V-6\R3X;;C`+]@=_0%`G.N%4U9,C#K+TW(N\
M(_[^/#%#0HMY\J>=IQ'"Y>EFRGIZCEI7J*,,L$=7P#KV'CAS:(/RP3;>)EX?
M:N#GV]M<IH]>'/Y#/)PYXBR)PJ"H_!.G-K-*3I>K<F_6B^[8;\3B0]4,JW<+
M:9R'0>U^CC55W>W0S$_#35Z&AR?;+(QI5MP[>;==K[UTQW]_%S[&0DYXRJ.X
M5867%=RPU_!A+^*;=;;:?,7.<<.Y.G1?\^;35G,G#7O%7(%MKXZJB,K]UC&U
M\)48JE8121RT%*G1HTJ-[NE+?A+U9S>4)32SOQ]T)1K`!QED"Y826]`J9!,6
M5V=F^0L1\4:XRMT0?(]Q/!F:"!+:]!A5TP'9'>>TRT\)XWK*OT9J?/)*2@>1
M)I8`.-0%,8R4X[`$9Q.\/T@J4B5$TCRC0H)&D6;KT$'.`#+-)X.D$1!L;M$9
M"IY\C]N7\+)LN][@R\4H546;7%'IR:Q]I/JOCK#-A.@9`?;*TT+L:;#47#!2
M$V!Q>F,@*Z_(,08(V>O-3$)U;=V,Q!.!YC4AK//2W8HW]++;<B+L!+I]J`N;
M0Q]Y`M2778&O.5WDW;0#G*VPSWO2RNB0I_2$"LR13>FY%J-3A;SHH:X/0N8T
MC4&(0UU&AT)!3S#ISR[:3`.L?C@[/!D;:-\FAZ>5-JS>RAQ2VPJ@<T<:P3/R
M/&JIFU.)JKJ9YM1AQCSASS1XM&\W(+$T[H^`<U=#IJ6KH!4W=#O34P%M'6DN
MMCQ*AM9=$P`=Y&#-T'C1H6J!VDH,\,<#G@7OM`=-U'CZA#<$F&B"\.V4CJ$T
MAK'$8(V9L<E1LEZ'>?6*IXG86*6Q/RC$L&,*%5380N^>G*CIBY[!;0[8`HMI
MP>(.'9QD7!DLN`@X,IUV#@@LN4.'`-:3X2[Y6)W\M%.`SM&[B;]9>S`7V9]Q
M75"_PW+%7G5#XTQL[-_2B%^G)^Z$O'OR4OK@932H;K^S3B`,>PI8#F'HY!QJ
M17G("YFC'QUFR\(55ZK5+$G)L[A-]H@(ML>"+ZFO5D08#XRC)NILPA@Z@M!P
MG+1?USVG,/!QT#'%\.E2*-G21,E.#I0,:^@Q_DP55A==T#&2!IDE&$91GSGO
MN'C(Z!];]A+GSRX!AY0>[A8+*:!N5]YJ*"G&8HL7)L(">`&%6M@T-TXH)0U.
M99Q=K9P1M!-50320/*P>;Q`L=&Y-*X=&#DLGA//I577LB[G-AS`67C,3QXAV
MILY(P0'*'2E!=3H[5P??VJ.+\VUL+5O^%U"YAB.\+II4MP[YH7%.>O%3NB>M
M[,VH2%X69LO5P6&\7?&_SM[*D"NTZS(&WU$^3LA7>`WI$2+=FQ(T4\>](\_'
MY'/L;8,PKWK-A>O6&>C6-5_H?**=Z!LY2"NY=SX0>$:?:92(@NJ[W'ND?.WH
MQ08ZVSGC:,@)X@BL,<AN[4)-2`0E*4DQ:.8,,.&;&HZ/"4=S0CN]DYX1ME*Z
M.7>;6P?[!_I_)2]HKZ\!VM-8LQG^:KR\)<B;-&0.>Q,5=Y/N$:/SVR:":K@+
MK)72^=3O<T:7J_,L#UFTU%QDKUO%'E!!K5P[+W\H7VP`#Y?K(9CTR!U1TD+$
M[^/NZ?VS%RR#>S&UL"G7K+V2-N?9W#!)B[N^;^E^.\A%\/=M)HHY6KV!;#V6
M-7]H+^8P(8<B?$B'22GGQH[.R[D*O.$!72=IG_?.5EZ9Q?[#-XJ?O8CGFRU7
MN';,P,J7#:'V7JDJJOCX#RU23&H\#V(T?M5*;-65R18RBZ!#QL#UHC%?>*]K
M/`%673$PZ>S4$_!:NV(,66I:"OA\&GVYWGAARM]DF9Z%V2;)O&BYNDKBQZOP
MF0:++*/.?M>)-Y0;=IR(0R%OV)!E2BI&?.W+61T+7J1@ADGG9YJ2I&<:T#CO
M(:J@].4#]`#B++*!NAL>T(10;L,CG09RVQJ,254G`8C."^O%T?(,+[B"M:[N
MJ/.$K8/%=M5+9LR@?*DI5/4U3>TJ@IH6DR9.A3V18$?C*:U$6>D:;>1XQJ`X
M]I,UO?=>!GI"*1]H/Z@`V(G>Q%#"QF)2O?'1(?2!.C$T\H`:&9Q/J6YI1MFL
M\*Q6JP+B_(4?>Z%VWL^$%93O,X/9W8XHJ$1NI%T&4Q)BTKTY8(NS3VC\G87H
M*KV=N=S.VF2B]^#9X`H@,[;0GM`<?D\S!>GA3CS*.A'XOM.KZ/RGI6B;=HZP
MD.OYU/C<2^,P?LQN:"J^C6/*5L<&RJOJX77.%Y<4A)$4AZTQJ>78(-]<)5GV
MM<!:7?+..:#QH(;BJ?2>9K(YG\I=TR^M0O\TB=F//FVM6P>Z4&O^T+[484(Z
M9[[HE[WKVO:88%+@J2?BEOKTX.JZ/3[HG*VK-AAY74=5@#OG;6H`C(Z^@VF[
MT=EZ4XGN')+&I,[3(D7CAJW$U*K#`@XUK-/)U87H(<T^48^W6`F6+%[WMVG*
M6[?&P742I]4_Q:F]>]X3W]E7C_=@:"<^YA3*]SB.2(L]J?B3)5])ERQ%3JC]
M#%(<0/U-/`:M[Y]R_EKWVV8T)ZLDS9_X77RT[.<8M>9T7<VIQP;R>7\N]I9B
MXI%T;X[C)#YN?O/`WP1==#&Z8AN%'6-K-8)"3>M@Q(`3NFL$G<LP$1B7\9"V
MK,6F77I)(4LO767,)"8Q%M49UP7^$PVV$5VN>KO)N[>#,N4+'4Y83$!'?DM2
M7@LBN;$!7ETG!\^T-VC`?_'2E%NML'UM17$1`;Y>BK;";]:#RD[RG9MLM"I3
MF@?]6DQ_MHS+3A]\A-@+^)0$--*N(3HM!49X"D1SCE$F1UW]U=+XBC%?'M2=
M=VKF1'!'8`KFF:665V_"^JS?3&0\W'^HVO8\US.VYD^"[Q,RG10]5W5TEG."
MH\_(>*9'VH-D-+OC;%\_A1'-\B2FU?9Q_8M/-']*`O$TT[#(G"%4/&0#^5"D
MZV%-H^CF5P5I:?YPA#^O%:O.@$T(=E.!7=>_6@M2$(LT4,=,PCE;C9VS3E%4
M==QX;"5YS^QAQN/K),Y.=NV_+%Y"XR8M%ASAJA8M0'?W*HOB)S&&_,9'X4B;
M3(X*L"+15D@UA8F6$@JCCF?)V@NM6[OT<(#.BO2"T@A@,0Z'AY\`!WBV0BYH
M1GD)J90Y1\B+AX<DST_")'^BJ;>AVSSTL],DW7RBZP>:ZKR/"0N(W($>UJ$`
M%13D@(1P&O);006_V'\EL*P7Z<ZX'@YP^8P&Q_K:4+&DBV<SK7)?&=-UDH9>
M=!<E7OQ7FO.>RO'CJ<=`IJ>4MUB6&@!YX&[*$W1];`Z\LY(J28F@)34Q*:A)
M03Z=6C'F+HODUPO8.2\P`/+=7T]/X2SCI%\Q$U_Q]_HK^L57]`4YLAR`I7G2
MIP'L;--D&<>K,*:7.5UKU_5VS"!B+!NH3ADXSH`(#O"1UZL&:QV/C8,65[YQ
M@';I8C5;/9UV/\.ZWL.!,_H=#M7NG7GZ'UW1QRCX6[N[ZT-E113QC/>9<1FB
ML71PU!T0#-5KS36D[0.P"[Y?_%B<PSG9=:XJ77SQ4ND^;O_YA-$>"'8Z9L0I
M4Q7$M0]@[YU$;S^`G.SZ[ADFXBE06\9PTY:L]JXVET_;PZ[O#G3UM,&=Z1E;
M2=7G?D;6T/F,6?%H]A3)UJUR<V"?&'K[Z!!*)P,K!)4/`-J-G?;MP;>*>D7)
M:)>H3XYF].?.*MN\=QSP\OIK;TVEN[']9FJ*9X-Y^6DFLM/>X8]MF.\JOP.T
M`0PY`6U3`+AO/)]`&[G@Z31IQGXUZTV4["B]R]G"9BDN&;';U=(S@O;2*H@=
M32_'$C&8%*-Q[=ZXP&JCR:1PP/VY5AB-?+M.$N=3KK*0VZQ.I)\(RK,>OOJA
M1)5_!]K)=7KE!9G\I5U<N.%,PZJM@:2:N,P^V484=LO\M6I'4GWR;O@3H;WG
M*).F:ELH2_]HDF:`.Y]0\Z5.EVFR98KY`O?[XRFFV='5L;02SPY`*];)%N4Y
M9+M3L",^"6O.WVB27)+]1WO+A>R(5-P1[)'..%/-GFE2K)O*$_$A3$_WJ<1[
MC/2\L18!].PJ[D%:Q(%CMQW;(&F\!T/'2F-.H>)4?LFI[,6I:-2%Z3#J*YLC
M\)AH='6TZ[0UDBX"F*^37?WCSR%->9__W17O\F]S5-20&_C%3CJPJLY_-0&F
MHZ*S((._L,E(2,UN;#*14``U;!O@[@NZG2"U8XXF&C"<"I5$[[NSEI]KB3K&
M@ZE(Y@"/-[=1"SN/;:$3`.;@,MYL\TS8I0]V^R$J%N#^MQ>62H@+@B,B2,@'
M7%L1=K!T$."]K%SHS%RK5.)@%>@;MQUZ%2LTOK(7IKE"?8-SK]X.G@X*'F\F
M%TH[WR652%A%^SC<4WU$Z*D^.BC61_R>2@Y+!P&5I_HXT%-]A%:@`:DCYXWV
M<1^.QAN.-)4J-5\TUQ:X7P6!=3,>TT0F`R<2C]<?4\%GRTJ[[-WW'C`NMSF7
M*]7++/*FL^OA>]WNO=?B(<M3S\]U0<:4CX9HC3#=-,KVI9<KK8XN\G9>J<_T
MM7Y3JFSU9/@&#/-/*6]^/=KE-ZW?@%U^,YO*J:*[Z55]OJBPZ6K=>G_;Z*Z?
M"724)H-VJ"RM#OK5P,X=$:!1D@.02`8$/$I1"IQ1M*&2-N>HX8QF?AJ*@I_E
MZF2;L6@DXUI=Z_E=^!B'J]#G5^8T5VSR>_S8TXT.[X_U&(AH8)SIZ0ILS95[
M_XJO<#BMJ*#%>^^BUY([B@/Z_V4GR;HQT_2SQ**>A_8L9:WK`%NSY#6SM"FY
MHPAI1C1%TO!E/#MD&ZIDU'_[F#R_"VA81"GLA\/@A/WJ;U?TT8O.V6.E/>1[
MW4P?*50@T@^CF_QD(T@Q!%,;@M'>'BSD4(B1,M"0R]!4PEX\R*Q10&?\W/%`
MSPMWCNF6\H#A*/[PUYW="\A$HM><2^3!O9VZSTQ]N%W;-T\^H(1LL-<!T3EL
M6@[`M1^-Y-6=&]X9OSL:'R&7>&U3NEYQ1W!U\<E.T;W)[E[9%BMTEQ?OP;2Z
MO?@(LN43"I!@&^H60NMVA7%'8A$H)'\CMX)J$Y;0:58SV$ZRB[%B>GZXX"E;
M"\$V2N":2_5\ROO)\Y_"F*:[]OO8E9>I6$!Y3S6L3KOA:O2^?.(J+1L"B6HA
M@7E&`P%4>D2]],U8:K9-XS#?IKQ_VD7XPG_*'&NBY9R@_9X29*<0J1HLQ+`:
MCFOQ.0*PE0X8N"_3BZ99Q9-.+F?LUQOG81!&6[XA>L>+"L1^Z/F+'VT#&ERP
M:>&-#;;%8GZY.O?8F\>/V0U-B]8'NWX&-NO'*5\!RG-..ZV=O$AK,&E&8UJC
M8IX0,*\]@_(IO?[TF@=MR)0=E-7=IW7\H",(`\"&:G%$.!7.!?-L*,%C"U,!
M-NN`;B:]SML\57.C.*@:6)I?ERNEA2A-4@`YE*NJP2X;2[1M.V=ULHY`O%F`
M6)?X."+Y4@[&<;>:3D&DM34:[9C/H9XF,9/!/'R(Z`UC2].4!J*QF=M:7,<.
MVIWJX1X*7XN"U"1EKT"42_-Y((([4D/!-?*C9E(+HI3724ZS&V_'J^GL4LUJ
M)E!+9ATTE6P*`E)2X,O.&GTUY4K-Y),!5:]?V9[J'?.1D%5"XTW;5$7;5\@.
M[O[_L^9<&S7/M+G7ON.Z2'1DBZ8MYAK7G$$=0Z(O^=:+;(XLC_O`5W@TJ3-E
M$QFE\D&8SB//.7.)9.82_<R]*9_T-7@T.)F&3G5.IU<]G8W3#64"R3S?(UVN
MEE]BFF9/X>8RSBD3UOP^.:$+_X]MR-97-G&D.5/(2-$&>J?VJZ;E=J*F)A4Y
MN4_("245AWEO:IH:,;]LH$8<5HCSA#Q0%H04'/C-*'ZRWG@QCG/7_T3PG:-5
M&/RX8E!K>Z>-,FV-G;.I/DW6Z_(6B\LLV_),PV5\FL19&-!4",-%DA;7IE:/
M%X_.PCY!Z?.#`Y\`$2D.GI1N`HLS++.I%4MFU\D>4\*XDO**VMKFMQB#QX'3
MSDM8S4L8,S5OS\N*S0LMYJ4V#=Z$\V*]CX5T8G#LCXUC8J21[RCV!<'AC_,L
M#]=>3H//&5UMHZOPV;Z_CAUSZ'TXVZFP/"M1<R$%&R+XH`@<QYJ!!N*V@!CU
M003?IG.2^6$G1!0"[]XPD%?"\9JY)WZ_X"VW+28!4!\92*.^WM?OO:$R(]4P
M(L:!1QY6[YY2G[+O+=8+U/.?R.+FDF3\;T])Q)P"7VS49Z/]PM-FPM,*?[I'
M06CYS/&7V]91AM4D5.]-A`_$$0DH%$C>/T^J/=`%I\;%LXLU3[>-4Y5J^U!H
M'S_6U)F6?5><"6=-6KQY2JWB3AC[X@[0(U(\`554,-6<W20Y,S>A%T6[9DTA
MK!R^D&%4E1M01^NF;\XAQGV2>]%RU5K3%/;/),Z0TD($&PH@AV(IAG+UW%OT
MWO7*Y>R!AS4.%EOLA13]^C5_\#`2$!R!A$Y-I-&$1D><];:*3P*>>M#KKC23
MK.0#N:^E`=A9F%;#BR0GN%Z/A>NTJQ&`*X194.'::C%1-.WNBH&6.5N"GQ(6
M%9QR=&GL4&:C(H?PXVHXAX(D1I-R.,9*EB%P<)67&,B9U`OJA6R^M?4MS;TP
MID$53R]\9O.V$4_=G=%5Z(?6"V<#CM"K8B/0A])8$37+V#<M.E(2=J03H"QD
M$,PVIJ`8A2):P`OJAP)43!\Y?U2@P/,(YN;%*$E@;%OF,Z!W_A,-MA%=KN3M
MLDQN';#F!W5ZR`)P)S=>DO)L@W+W$,55`6,"3AP!@QVDLA5KY9DJ2YF>3WF7
M*V8TJ+Z/G-+&]3.!CG%DT#H'N\4X!$WDQD2#HW^<@]38.$.5W"$HJ+E2G%:T
MZSE[%<YX"-&NC>V5XKB7QN!?P1T9Q(`17VOCCL"Z=38^E%8$JGA-JW[+\E28
M6P51ES.TW[.:!,N2-L;BB)SLJH[=4&FUZ?"W3GMM2C[[_5C1N5%[F1]6V"83
M>`1:7I7:K8S7FB:LT+G</9B6"EQ7HJXH;I^K!-E;2(O/GW;ET<VA=H01@:[]
ME";9>.7A!3>TGK,":ZEL@@Q1.MP:7U&(L:E1;FJ44G^(T_6;`7RMGGY/%X=Y
M][8BSEC?VLYB;U+JAZ+B@/T<4?X#>\/%.DGS\!_B]]*W-W7[HST/K.?S>!.F
MVE1I\SXB-7>A)VW^1X>YW:-]4X@BU)APSMY<T2S[FNSO1S6/F'NG;6[X'/V/
MO%./$7JX%M@C6QEUO^MQ38QS.=`5L^?+^"S,-DEQX+#9@M!83FD)E"E+R')!
M<]@=86:49!F3%FU[MP[6L$V%EV$,6GB3U80!GG-1X>@8^^.^3KTA2&'$O!\5
MM*32TD1IJROM[)-[DZ$>G@X%ER9L(`HOS>#)5L0'^R`(*S%'Q8>K---",J4E
MFN9B.=\RL1U(V::>]FBA$TT'0+KMZ*98.XR07[%X;T)?-C3..EEF\"Q*GQ`9
MY4QZ),C9=_#&RF5?90>7H:"&\!1*,(<RP@?7W;,1N@5W,+A\@%["I*9?*U[.
M8O]7NEM[\66<;5./P1'='W<W*5V'V[7-"E3)!W+9J0%X*#_%<%*/+UJ)[DA)
M@<+V.\`J_T(V7MCNF4<VVS3;\AV$/&%KKV+,*HP%<N\QI137>M,2]6F),D^2
MWXE7=*O>B8X>89ZQWVX(X^8]"I"$KC=1LJ/%993BY+98D!8T&\G\,:_Z0)^\
M:,7'<J9!R#P24SW!A5'QEE,]"UC0U9V)SFN7=`8*[VR4#KB>)5]B9OU,MA,T
MU!"^6`GF4&([=H</)^5X<$]L!46\^:;X,]G&O,E.6*,KU`K^"+P5HD5M%8(V
M-J[Y!\!P'(G7JY$TX-#JT%BZS?Z9>U'$.<M57&K)],P@0P\3J%H#T**"L@.C
M`JPBD742YT^\ZTP+'_?,,2_/%7^<OT/&J$`;:]$'%9OQ&*!BIA&#J;+.F;UZ
MR/EKI$(J%G',%E8W:1C[X8;]8!9Q6/&"*DXP!-K-'CWDI*$[(@4EJ4E11"8#
M039@6CH9BRO%-L62&]R9N\BK<BO<0EC=6V/6!^S.:!H^>[R)5GFI9?/HC#==
M?`[SG>TI@`%/@`P)G"=%=6RU855=Z-I2VHQ4W+"=#IAF/GATWLQ'>2VL<+W5
M?'@E-SSA!>0LX(HVAAD-;0@RR&(,N)CKX%G9YSC,C1KXR4AA+LN2P>C&#8<&
M*2-B+'@&`R.&G%<\3X"@J*2N+L86[3TG:$BV8>^3!'>YE^838#BACV',VVJ0
M!R_B:X>CB3Y"`>,\-JO@M`0Q[:M;)[V<E*"6HRT?BR/!I3&LBIO15%9U/#LO
MN-Y2/_*R3%RTQK_0?7+CA;S-G+<)F8+:!+QN#X"])==M2O36N%"F(W+(B]^(
MQKF)+I,%/S31[EBST<',=^\X9GX;3$$%96PP8,<5T@ZR"@9WS[J;A#D3;=5;
M7GAA^HL7;?="\&MJD6;3<H)+LAF`E!NV(\+)B*`3Q_J1)-60@[*-/P<!ZPE'
M&WS`,>DP8'HX@%E/4^.AR7D:6HYYX[_Z928/!)LGO;J(L#U)HX:&D^KOK&&B
M:HJ,XL4))V+>H''P3*SX3#QS#O\$D63'ODP34AX:%_?;9T4;]LNXUTA7RW63
MU*D9(Y"[9`TA=LH9B]N[F/5J=+5__P<^T3H0(U/'1@OA,V9CHNG?FT&24;/2
M/OG]JQ:J![$(E34_UIQ2V2>'/[%T"$<1&0'U+IX<`(*S2[U"97A\J4^B9FP3
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MOEDX`MAZ:\UO7US.%;<%-F`LR)L/X]^':[VA."=B'#N+UKHKW5VT5=SY5@"U
M;5QDV78MLJW97I[5=EFL9PB]5#:!?"C`K<"E175$]K<X4(0E0V`N@K]O,]YZ
MG5:X-GVXP-?;QE)KM`8W%5E8K;P-L]\O4DHOXYPR6<IO#8(&:WY0*W@+P*:J
MR<D)IR<5`W(+'3F,`%?`6G%8804K%3'"-_`M(UW%5YD<L)1=:->YH3XSH/<T
M->Y%:<P/I^/<`VSN-PLRPND076[E`)'_FL>T23'Z%<0`2CA507K$;\?C98`[
MZJ4@U^0-4Y;A`4!'\W"8EE^2B*W9HC#?#8T`)!PQQ0!2T-:&IN&`.PPP1EPC
M>VZ0O?F(.PA0R[!U&*`48!S:>A8^\W:Z@417G6W<'E_,@<'!!%CK;44_C=9.
M$REH,-?8@@K;+J31^'U.IHH<W."1-W\",4[CJ-A8X42/W@(8JLMXL\VSFS1Y
M\!Z$W>0[(RMO&QD?:C=A!1Y(*&$J+%%!)^ZCK"AYA%_2SFN$1D1X`*?,OJ]6
M-.7'PT-^(^>.%">X2<*,!_FV"/[)FV\1AA5Z&3:+)[0"/,+AZDQ_/XO!$<H.
M%QR'HGO`R0M7LCFN:QGA\*XEJ+P8C?7PK4S^+`[62H1O@')D?AINZIOU&NTK
M=L9*LV2R+6[*"J8#H2G,KGC5E.75H;7Q9O\L=\9+<O#M\'%@%K=IRGT4_";X
M/#AQ;'];:JBB=9V->LX7#5\E\2//[MTPJ7GR,LKWY<-<7%'H<MA6QPYZD:Z'
MV[W_-7X\%NGMBH8T1"C/YSIBS"TQ@B];#477:+5J)K<8U/)D=\I6S8\)K^GC
M1<+5B,#F&*\K>ZC%K/MT=#H[E*-Y^,#'UQ(?8#J4.P'>Q!`OV)IVH,@KU[G#
MY!V#VDO>LCCA.9Z75C\&K_?638^55S\B*BN!\33PR!,C"P5:$]-C3K">-AZH
M5`/C!Q.-<LX?W'!>%V&:Y:=L:.A[T7T:>M%R=17Z_,KH@*TT@JV?FYU:=N`(
MD4VP!MU)`0NQ%AQ(Q8(('ES?*RZD9(/C6/2(P"\/03-=]DA4P=Y,#=LZWS`2
M[I7XX'Z%/9=CQY%Z<%-N:0;"2;.'6:8[RC`'CJ9)FM&U90VY06`_#?VR6[#`
M;*TFGX)+['9K\AG("B'H6C`4]FLT?37=EG&S`\,LVOU3F+H:M'X#;\X1+-:R
M`=TON8(#9NLU%?!+]%9K2N1(+=50132*M&SUVMDNG81)E#SRIY3L%YM-5#9[
MM@^N#+A!QE-&8#N7)-1$E<$A+3)\$=,4(!E?7M_T)<R?R.>W=V_)Q=D"8:@T
M%'II7XC7D.$*ALRU51O_&*NJLVDI5HO)>LV/@7K1G1?)6SYVC*J<&"*044'I
M%$$6F:%Z,.&C\80FB*%8!QOV6/P&2\9&XP@@M(HBC15T6N*LNXM53E/!_9KF
MG&UF'PQ(>4"&``I@G9/\?&B9Z&6#A?!G^/P]7D3.?MP:4I&<C1DDKM4PMRK8
MZX&IJ]8HDK.27],O9^GVT23B[]@L*2V$>U8`.907-I3PL2AB^-<#Q-HU6R()
M.!+HL-M<R'5^6:,=SAI[2WT:;O+EZI8^;B-.M&//2)-G+[I@,#[?702>O:.V
MX`KINJW`]UP!QHEYVK`A)Q4]X0S(9W)'&`]\+GX4Y(D*.=XU_5C8TP:[5V%?
MM;'C"AKL-5T;1EBK.8;*M2O;ILHFK/`5HEXI6A9K:LBOD/5A'@!27D2N`(FP
MY+0CM([EI8<2Z]Y"-62+ACR)Z8VWXXQ=#E%*>4#&!`I@W2L?RJ&D'(NQ&;(%
MGE9_XW4-;5.0H7)E.N'3.BZ-Y#EKA5SQZB=FY2--EL0V["!6R79P^PPTD7JA
MAD.E7>!KZ6%P6X!*G1J_+9GUHGJ$+RA<[*;Z@G[S!=<=P#C6X`Y**EV6VVNH
M^X7&->ML$0>G29R'\2.-_9!F5D<CC7A!>F`#H)U310T)\7A=8IL(U:'(5P70
M>8D]`D*_381K)6VJB=HPQ%`-YULUWX=Y1)>KRUATB>*-)2P.<?830ZV,95`Z
MG4+Y.'%\J!Z)Z>3E^##`5K=*X5*N9U62!:@<OX;YTRV-A'7,GL+-?7+.-#C?
MN1V"M&4/??C1?CJZN=1F,,D34@S'>:)Q.-H^#17E;Y;3`'Y^T5$/C,XMNBF!
M>TS]%-+5^0OUM[R;TG*U"GV:,E=\%J;49RS,=Z\-.4&LTHU!=D(R3DAJ2E*2
M$D9+*F)$&\3..'\.'Y^*EOWQ[[PHE=:(DX+)$?GRE!"VOB/;*`_7O+/_VHN]
M1RK*R!FX#1/.L&P<M&*3DC]10@LUYK$LIT[I)DE9;,L4G/_U(?'20%P=5KX=
M3(SK*L>Z=;&5.KC7E#VF5-S2(PE3Y04T>X2@U6,'$#K52-7?@8)2O"_N7@MF
M^N:X5IV]PJZO].J1].'Z)HUP._;DD`3"`79?6R&L0,$GSI>V]L$6;XW#WTE$
M6NK8^N5YOD7H^7H3)2*?S--%?,_*LHY:SPAZ8:F"V&EK7H\E]6"\-Y)K/Y[1
M&DGWY>83QCMF&(0RG/^Q9;'N:;)F@;#(9EJD#=5,H-*'.F@=013#2#,.6_;-
MZ%LILW`F'VI&0[C_$FXYMWXFX`90`DTG<WA31LJ/96;T%%]J/J%KW1)KEAJ2
M$T(9MCX(?7MQ]47/D-[4<"Y-K)?L"\PG/+<TR].0WS>B%B"E)O4S@;98,FC=
MC'\U#H%P.<RSC<52?:DIBD"N3.N:C?F`)*O-`%K61UPAJ6A^G0CM,_'C0(0O
M`7'3&VURW%SY)JD6<[_VQH(KU@HR[0TR:D5[4S+X&F.M]QRXT7AJ-RD?5)/E
M?-G..`%DN8V6\540C;-><RP+FGMIH=8@$B"'$ED-^Q?2'HC@IC?#]S\131*]
MB)^I\'*F5#&O^4A[KLP$6TNI1$JYG%+(DWOG,-X_44P7T[P;FJZ2=.TQ3"=)
MO,U:%];8>"QCGJ!=Q,R!]\I802OJ,EK41)"3%CT:1S44<*54#/"F!?B!DQ]-
MBMB]DY@[Y/8M5:FHA>+'+A+BTT1,055"0AYT<X-K1]M6W_4=R.R4W?WPH_<2
MKK?K6QJN'[;,>7"!6*[N4^^91OQ.V3BC1JMP(SX0JW!#@)TC3@49V:/C#1(*
M2E*1@J_!!^)+]_")@J\"("UIN>:1-8L=G^`7XXY8][_AV@NH`%I1D##VMVE*
M@S;\8"LNK>7U;<6-M3@6[3;J*EVT6^CJ@&8L"N:.`9`Q3]A&+,;`U7+:M34H
MXY_1\":K0].#-/P9@/C@DLY4,P&H0AQ;C39HN6*ESN[=Y9OH:?GP=Q9>AL]4
M;8&Z7:PU+$#ZQVMA=;J'MV+HFF12'3//1PQ'E%0DL&9C!%3[BZ1'+PUX*)+2
M]3:FJ5<9C]/SY?Z2:;MA?^`!BY?G7AA7-F73-T<XHAE#S91W@S=2RQF+R)Z\
ME/*56]#.)2W2E'U=8>5.=LV0JE_'%_9]BY*0RSC+4R%<V9)]Q_3^R8N7`DGV
M$V.19Y?QC8A%;7?:9WLOZ,W[&3]`I^,,YWO\(.[K:S^<M)Y.'G:D/:[JM2->
MX8B415"MMR#B-9A2>S$I7^2(%*_"5BVD>)EYK3;6^2\+?8J+SKUG+XSXL7.Q
MI'ODM"@"9@3S5(XK)H7)8)XT'4\R_DP\42>4636JB9G9ICI'OP73GXJO?9]4
MW5W$NV6+["Y\C)>QR"J:!,(6W"!B8BNP_9I!2FIRGS3-G`H&9)$1SH(LXV)#
M`CSY-P;>RA!X&<DX./:KATG`64?.8Z+KFCDM8)"0V%Y=I=&QM:[.8&,<,W]N
M#X!,`[I.R7"CA#)+./)TR&P6THSA1.@-;!H)&H:X=DP'V0QM;G&(P1BPY[%7
M)BV>SH(XGXO,(\V6<5]CNXX',.`"$5H9@=,6R0LRTJ)C9JM30C1[&#446['H
M%&K)TVT5W=$DX*S#J(G0,1N#)(UHKG?26,E8Z28R#O=?$KN=4!TSV"U0/51K
M2T$8'9IPQ@5A"XK8^NO3+QH<38)SP%ZG/=`B9VD&%U=,8JRC!GN;9@HZJCFQ
MW-34L<`29>B*"'H-!^`B:%Q0+75!MK$Y'BSH18JU:KB$$R,N-'YA[,/X\<Y_
MHL$VTA0S2*V=@@MD]*`$=RA1Y6!2C4:9_'!"E)6CD:8TK##)JKZ?#[#BB@;T
M6J8-`[0JYFP"G+>?RDVF\Y=-6-22\)[_)N'"R$^$B"Y&G[3>(@!RHBX"."F+
M`,IQ>T4`U2X_:1XE[A4!CV$FG[JJO&$2M-:QS4R24I2!^&U)\?;+1;+6N/+J
M$>(5Y2))51!"&UGA-YC@"*&F,5#2B&L2Z^1LG9N^9IS;YSB@:=UMSR9$4_*!
M#-(T`!6][<0M28*`U!1XPAI+7`),LB(>SCZK)F*HC6$,9-!]X]C[_38,'NFU
M^%!>Q-Q1DHK+-\W;E6MY@!2BZ(%U'*#W.Q$TI"(B#16>6[A?#S+[>A,W:*F`
M%E?0HIH*AR,VU3%Y'8F9@KFW8F8>^/DNB;;"$=O?T-U+#]H(O1]0IWTP'T;J
M<?ANUL:&P[U-N@V0K!J'RY>KM$3?.EVN(LYJ>Y'2X.=M[C^%<9;$I_P01GI+
M,\J`/IVRKT0MKAPQY@7ARRV`'DH4)R4-+2F(245-"G(\SOT50[7V]D.Q/C58
M_0)K6F'U!3D.]V^KIM(PP%)'W8]K\D*MRT4<7(:G;&SH>]$]OYSF(DD7/K^R
MYN$R/H_8*B3:+?QM3C_M:)2$P17=_D[7H6<?/XSS0,B`8ZPIZY0LB-+"2W',
M\#(D%6\BF!/&G93LR65,R@<0\012/H)4S\`7W4P\:>\N+Y%.F',8-8N871*_
MFK5<S!H_P>65LQ;&A):SYHE96Y>S%I7/P!6SC6K*M$'>F';,V7I_CD.FD%F8
M[Y:K>_KB99_.%CQE5+L,V]#0CB%$?&@+^5#\&WK1\X-S()_(&:F85*$4MF!Q
M1-Q)C?OMV=O9@5N'CN,BSQOD7H6\C"@Q!9).FBV-)EW4VMDH_4?R%&<_)YO?
M6>C:/-@^4E3R@0P`-0`/Y4\,)^5XTI)&=$$:>F#.P903LJ<2V;8FP!7PF"B:
M-HXQT#)G2W#EA4'D?1'MD,UCD!XJB$"C]^4/!:4<5/:]QA,M6+W\_^>M-_\Z
MZ>M;^WSKR>=5'5Z,9!-(+O=2#RT5^E'6!C<TCK-=].S%+BD;#2=(5ZP%J0[_
MVR3XW/$0<,E<X)Q=\D!TFQ8)+K=LIGA:QVRD=>Y!NK>F67;J;<+<BWY*D^W&
MW$%+:2'<M`)()ZH30TDYEHC!>%SV4"!75Z>('+@]&K]$\\@'X_#C.B61>G.-
MALQX[^!32%?G+]3?\FY]Y=T+;A?(J5A!=Z)3P^PT+^.C23V<E.-Q!0!NT"Z2
M=,US>.=+O#?D&<BD44\PO4"Z[XJF2;#U\S/Z3*-D(ZJ7X^#&R]D/5^PI<4;K
MHDQSMVG/%*31K0/TSA93P8.TF(A%6L&&E'Q(ZQYZ-'YK3/C!`?Q-`3\JX<.6
M,8\@GCHOZ"KP[ODF4]V4QNYPBBA=!QB+W8QJY;JBM<;BP9N("<#@6J^::;?M
M-(RDRG%PMTGB+$EI4)4_.;A>"VX@J68;L%+I8AZF)F\J`>&MP;APHQ;<K(9;
M%P,B,!C3?5X57AQ!A+W:RC/BMCKK?N5MU*K?&1`\*/F`7FNK!MA9'T=[A73P
M%N3U`G,.+ER1%55\2",-$T73W[.KUS+W=7_D^8+=XE'\C_T:7\D`9#VO@=19
MO%;CB2!`H/VO$9)]WL$9D_=8_"^J.,!(D>2)`P,M<M;Q^]2+,U[BG,2?O-A[
M+!_D[/6-^$%Z?T/`G=/V#1EIZ!#8@RF!KAN@"%82<R/%%2W8**HV:K#0T@%=
M(MFG-%A`]#3`ZR.$Z0C9#Z';6Y"/0V`,7@$"AU:/5A"0N7ZE%BAZ.,I5P+UM
M&]UX19LAGD6@>1X-=?:&'"'=O3'H3I.LFK#()=:D"-3\GPRML^.?$BXN[V^G
MNUK_;Z6X[OF#HM79<E4F+R^HT244?60@N8+>U^\L/<O&>,M5O9//!H([?K.7
MK]YX16G5X0_>X3N_.@Z/KY!Z^1)?*O+S%<?=TF<:;^DM]9/'.!1+@S"B69[$
M]!/-GY)@?\`_J/55L`Y/@"ZE<YJ4;F0JQI`6ER-2\R$%HR-R,(SQ0A%7C#H5
MUS0GF<?(^''Z=46?R8P/>'6>NU(8%>TY:X2S3Z[YER;GS,N-G'(O'817E@`X
M%+1&O2H'S0>"NV7KMZ_Z[@93O+VU:Q[T^CC<LTH!I/Y9(?W.FMAJR+Y<W28[
M+\IW)?O[Y)9WJN?-@M-\9[,B-V<*N2BW@:[JY\]B[I*ZUO+[A)0,B."`PH6.
MB9E?:%1BAHK8`3#R&QO2\KMN.`=<RW-K7=:NT&T5V3U-7_!>KEAH=L<CL^:J
M**-DO8(<)&6OA-.)S$LI8X:$1Z:"H'5[&'BXX(8FF0F-?2K?%4Y<+QN:2R!Q
MA!,&ZB//\FMUQ[U!:IAF^6FR7C..H1=Q[HQYF!BOV=5,((,'%;3.`3`^EC2#
MA4Z08CB:R,`>D-\`XEK!E6(*0,YQP%B(<#EYK4YIG;I.H>9+]MU3_RE.HN1Q
M=T?3Y]"GV6F2Y9G.X^O(Y_;X>CC=6S.JD:0:2L184%\_"(?G^_S$^*J[ZS"[
M1S04KUZ/:"9;\ZG()R^,<QKSAG`RW5"F#COTT+GL'D"=Q$TS!$8KA@)8Q/&6
M^9!U"P>07MC)ADW26")80Z[S+<Z1Q$'[<&IS?971.E#+!.A*7RVTGHMBR\-$
M<;!W9KM%!K\P=`!6ZD9]6&JUC8,P?D2P+!SZE?:.EC=D2%:(INJENM'72+?<
M"S78)^8-G)>K6R\($UX8^DP_>3GEATIL5HQJ1J!MZC40.V4=Y7B18VXH2$6"
MPC$.`L:3K"U@ZY*$;/EUC[SQ>2I1,3SKS+&QXUIO&FFEOC.[@4H.Z0SS=^KG
MYQEO\9[S^R\SHVBAEPZHOTL?@)X>)GP8J<>)Z!@\"K!\>UJ_O<\&"AW?O^\@
MXXH1I-M'LO"/O_GFV^.?MY\^_/`M?(0P""B.,$"E*JJ>,3(]<=]W3K[$=;U9
MWP.4&T#R+3`+MJ![SU;P.[N4C)JT2C[[#0/@%M*4N*N]6-YOM-^D;.`VFR8"
MWOQ17)>0\",F#>AJ&@3XE/ZQ#=,R>`I:$X8KK'#0?_UNM;7RCV&^+I*T?)9)
MS-%/"!%TR"`HC0V_P*D<"AYW6`&HK`;7BLU$`*P#BJ$(<,042EV0!A4J11BG
M:PS7>'[STX;-UK.X!.HB20*>OF"QY2)8LZ%9GO9^+..&&3;/0--MQFYB-`U;
M1*0A[G4KV8E_<(9%ZE+$\7L\T00C4TQ*T>NE7MEXU:0PM[VJYD2L;;QIYV2<
M)C>PDX(K8AEJ6^R:Z-@;%O<JG6T<[%?S?>;W4-7'\/BS><G`_9?D/ZEG=INQ
M)4N02XVM87>*1AB'3JDO$5Q:!U:%.13E)8P3X:S`(Z>1H'-=-KSTF+T&><,7
MI&3'?B\H\R=*5F)><C8O_-<9^1H^)AMI;@XKA<E6B$73P(1/00.?L\(1S3E:
M`_FER4ZF8#)CME@Q<>0/8L^SB?JL^((6)MI-@)M-$TR$T'*CAB:@&P.[M5%C
M=BREGIB0^<W7I%.AM6$%:F'1F1'#%:ZY&`)]Z:2]%9CQZ'11R'W^LN&'MW5A
MFH0*JG:R\_*R.OQR!(I"2>.7;N=N>-S3*C3>%AO!?/G3J7,#JYSL%R5EP62O
M'#F[\>LM;_VQ7-TPP\<FSKCLL9<6TAWW`.F<1A=#Q#Y..6ATX696R<&=FK][
MTKP[H3%[9(2D;8`S##R>W.KU-^4@7+Y8ILU:?RM196>SLE@GVSB_\4+FQ<\]
M_ZGD:Y+2D)%"I"[D,#K5EF(DX4-Y5,\'5R(.GH6P1K'A*%A02CF*4M++&/0T
M66\BFH?QXT$Q"7Q"P1HF0_A`"[`\7J"M;\:"!R\G3UXF[M9E@%EH+N*)/<PX
M$@D:79,F#-2*YMYW,&?A^N?-!:472;J7:K6)+11<0/L+JL!UVL[QP>3SAG<(
M$]G)_1T=-'[;'M3Q=B,Z<75KRO"X\S%1X?+R>@W3=P34J==0]3_;BM,JW+J8
M]AR24$+X?2D(J8JSH64M&'<GDS0?4JXMW"'P-^?]>GA4F[74`#QLL?L(_*V#
M+2T+T_A'P-%#:0P4..(,M69+PPRE6KN7HHN#U*'/+-@M]6GX3(.37=/<_"),
MUS;AA@D[T/,L1G![JAD%E0A`*CIRLFM?:<!)T40B;C`_)7'^%.V$[TXKE`^[
M=I?_U10HW0^R#/N:&IRX@A4+1=4?;C'6TB%VI:Q<7:XNME&T.PNC+:]J+:XS
MO\L3__?S/[8L6$IX9X<D%K\Q"6\<.8,<DW&=!$4Y]7)%!"M2\B(E,R)HB6#'
M,R<%P^*WX"'(%!/!:['$1`3E1/CE1&1B(JB8B#P16Q=L(K)))L+^2`Z2F<`1
M"@VS$O+S/T-,A+/)^U6<H<[/7_A&6>8]1/0ZR4._[%73ZDQG$U"9,X4,JVR@
M'PIR24M:Q*2@+CM.D18]F@AK#,2TA3@N$!<-G$@P(6+G:&LVR+@"+VNUUH9?
MMCH]3J_<NR>/B<OBV0O9RX51F.].=N4K,#-9OI-)`.;`%>2XD`MX3=O<@@UI
M\^'+P(H3'U+R`@^Y1H?/-VL+5>4)KF(BO/9$L!44K2:"#?DRT438'UJ:8";,
M\>,(M-PM@?P\E*L9<&_"[[V$Z^VZV&];KI9;?FJ2!6XT+XMXK*IN#+A!AE1&
M8+N-R`01*3=FF3EB=*)01U!6M6@X^I,-1ND5*)FN)=OB>'6!DDZ%TCETFA0F
MKG#)7$FU<9*QAKI7[27Q+>4-O7@0=AEG>9AO^;?U(L-+M]0,(,(>':1.*19S
M:`T!V:-`<267`Z#CM`$4[@&:8C_..B!Q^40J1#A"#"-=DD83)HKDGHQFT<G:
M\W?]2BU/N;?(0#>M]EZ_DP@L_PJAK(ZO7+94W%1O#J&50V<;2N^,I-5X(Z@C
MX0,J56D<\`F_21/>6#F,'PU]J(02IDY5`J);^5@.),U(%-[2`<&F08#"/0Z&
M@,,?JA5"44VJT`9W[:P.?)TF<18&U+Z+B(0#I%^4@NH(2GT`<&\D&F]I#&3O
M[V2S3;.M5Q1@UV<<\3A21U0'9S9Q.5FU'FG]K5*)!A\2V16Q,X^>O2CBC\GV
M3WN:>6-39I`'24R@2H^6[,J5+FF3'QX91^#)!T/=E%##6"P::Z@'*H;!Y<^%
M%4ML8*FQVL,GINHZ^(!K^PDV\4,O/8:#K@>`Y(==VP/1A`YV*)+5GG+@B14&
MP<`5(J@4Q?C\:(^6#"G%7"5LF<_@G"3Q-BN-1:>K37EOD$F08,L2J/C2$G9/
MB5W%@0@6=>S0US*KY`,>-XR+^T'@KIQK7T^H;"+<+J65$,!Q1!2.2JXJH730
M\`$;<4T!%.-Z3]-U&'M%;8%J^2*WPD8,0>,/0\C=W:!V;22W/"U2'J>`+6&F
M@EJ6'8E>-"VH+`I`F/48Y[.JL"(+=VPT5Q__6*CM?(VJKJB7T?.735CD:_BY
MNP^Z,$E)"]6T2@+D4!;%,-*,F^8<KDL#*T,`MZ+11NVMVYK4=YH5K&V52K"4
MS:L44C5\CX#-'OWB18XG%E1L4.P6],*3;QF4PU&>0K##Q+6"`6GT(BVAH3QN
M8(>M79^;TD<OY7<TU@#QND\#I3/?59!JG'ONH+J=9/'XR*<UIT7"T2A)(*,%
MR0;(@716@<T]1?7@LJ(6?G%O#T/(?@6CK"4]2)(C6+N/@@O<KYNHC'S)K=:7
MX3I\P6*@J)59;);OV<F.-R3SXIV-I[=C#%I!9SD%AS*WW.:,1-S[V[[&3'!K
M[PNT$X$9/QE4LD03,(PY$:U[S59B(EHFI9T@R_C)&'^BB7`O\P.>"5QAB).-
MT)<7.AB(X6;N,'5I:.;DAMR((6A08PA9$>ET]SJ0F++)0!?G&0_R_5C,%AQJ
M)-L9+LJLCZPL-'F^[*(X.WGB9?S*QS4_UR2$HG5/_<FN&5)"67QA*]RE6.)E
M+4]TFT3\YB7^1]-`;N*W@(KZ)I_<3MLYSN58L"'M1Y'6L[@9;8^KE%(\\(B4
MCSPB[=CB-_Y84C[W_R!HM#[_S&[7:R_=M<Y49T3<QQ[F(9*CK)!S4C3Y28K4
MEWQ>P,++><R<,A:=Q<:]2H=1U!N9[F6-_V"HC;`IIG`FCW!$BB>BV(^;;QX?
MU//X4,WC`_@\%N4*HETKNKEL"B@_QV'.)N2$/H9QS`.-!R_B<?%$TW$>!_@G
MX[P(N4[Z9P)LEW@R>Z_<8I[*V+\>/\G\^XJ&^99)_65<U*3,O:KJ>X77OJ3J
MG]8IK7[KB7SKJWCF/]7"P6Q.Q;604=1[^/'5KP\4VCK+XD"NJC-:/+X6O,RR
M+0W.MBFSO,5[%-VYQ!_+EZUZ<_49M'X?9,\9++9WF80IS4_U'$#C,]U$E4/J
MUG<C0ONA@!:+O7#+\'$,:'6V28H-+B1T5G1US.>JY:\GJ&N*)L&"NKY7>.U!
M7?^T3FM5ZR=.85?-C`^".?VUL5)L.(R-FEU=Y@SLY.KZ>JQ>:S'^*PT?GYA(
M+UC(X#W2RI+?I`9G/^=^G7^"]+!FNF=+&E?O0<H7:9I6BU?!$9`"3_L$.>:Y
MIQU!\MERZC4S]%\B13WVE/WS)[)-O-A<Z6T#%X8H4LBTX4Z9K:B"'<N`85@L
M..[;H5]5C?TQ7/Q:-B"/A2ZNP/TYM(8;--.$27-'7>!-851>E47O+&!G602.
M_5YH5X/C?X")[7A/Y@R=)<?Z*0QL.%@>#H>>CA)^3V,\9K;:#_KUQ8/U^N*6
MKKV0KX=/DSA//3_G%UG2=/V-4S`^\RNBB,AG_RQP6;[ZK4CKM43'*'R1.?AG
ML9@]\H9YSAWUTNSKO4^`,VZ'L4/FP3N($4(4P9OGFBX9E##.0O\7+]I"[-<<
MO`#:F'S`E,YFK>LG$_'HUQ%ACSZQ$^RZ3#VQ"'99M)/;]*XYF(W_$CLJ0Z;G
MGW_WI-^+S+5?TNM"YO/&-^RS7GMKNG@)C3O8]])"KV4.@'2._+-_$?YW\AL?
M,?[9X2$!_\!W!P^K^X3(*-[MD:#Y1?\LX:&Q:?1X0`45\G5>7B$TQ9C917ZJ
M]P;S.?T"HW04O=+BW-7G_DMR_Y1L,^8Y[I_"-*<T%G7(_"F?J.3PLK3-D0$W
MR#9E1F`/I8<1D8J*5&1$T!$A6;\5I#CLOS-,+AFSH'+N*.;\]?+JZ^75URMZ
M.FS82%QMPLRU4=L;S%@5QS0=YW]LPWQWR<#'>?A,E4:DTY/(BA]$.S!+P&:&
MI.!`:A:P-F5LS,*JS`S1NO?7"-^U:V)H`3JL08-9FV&*I@I)'+76V>*<KS=1
MLJ,T.PM3ZC.:;!$'_*K';93S(QKV`8LA1\B@Q1CTH5S6A*2F)(R4M&CQQ2ZC
MHO7F0NL<TPR'>T2"/;Q^"R^NX,9.>[4!CI7J#C<YAI:F8VS5#"#"&!TDN6;-
MID^V4<HK@&0=E0S#U#(#.((.(T621ADF6N2LXX,B"%S!@HF@S"+N]GTO35__
M(DG7-*V]/!JCA/^;.$<IE@APA1WN$<;XP818&-W3%UXJLWC(1-6,41#12P@2
M/$@@=+Q1L?PM!Y+?JJ$(8@4[!&_*D5_C\*(J"9)[3X7XO((JK?U[V&RWE,=Z
M+/1N]'C3-T&9$/!=AD`3UT(-=>WA+*)OL_\^KKHYN]K/,0L/D\<X_`<-^E^)
M/8_]:'0=NSDS")=L`_50@MNTA7Z3GCK,DA[<=8^&-!-("TOFMY'2B9!:K_YG
M@XHC.V"MKM)8QU97YXM_%I%@;F^/E#;>D"MT]&(,OE-'6A'NE7_/8I[<[^YP
M1GOAA2EYYF6;>]=Q<)%.`X;;RXK:A>,9;=>0V,MY(FXKQ.7%&Q)PX"&6G5(;
M15`V&EU,QQ7C_1?V,_L/EPOVA_\+4$L#!!0````(`&Y4;D.J+&NU>3$``$M9
M`P`4`!P`9FEL+3(P,3,P.3,P7W!R92YX;6Q55`D``[_MA%*_[812=7@+``$$
M)0X```0Y`0``[7U9<^.XDO7[1,Q_\%?S.K5(KJ6K8WHFO'9[KFTY;-7MF2<&
M34(2IBE"S<55ZE__`:1(41)6$E22;+_<ZU8!($Z>Q);(3/S'?_U8!B<O*(HQ
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M)6G\0LNG$8IQZ+WSR/(]*_5>VM#[1GV\(&%,`NR["?*?W8"1$2\02N(T=%.J
M1,@WZJE&<VWW=^5&M&<+E&#/#2QW?K=M>TCH*$@08S@F,[)"4<:L!0I4[=I#
M\%1^:3*[<./%=4"^Q]\:`U`TVZS_ERCV(KQB,IG,SE/:"Q3'=(P]I<NE&ZTG
MLR<\#^F\ZKETZ'D>2>G8"^</M&\>1K'9"&[VJ68X[TF"XM'(J,-%G69??HB8
MUB5K-G']F>(58]*H&]P&FDOCP5V[SZRDH42*>DWU+L(O="B^&"O1ME[3D;M<
MXB0;5U2R=,`Q;:-;#5.UEK73K(=/"?'^F&0#YH'.Q$:]VJ]K8_2<UA@]I_;F
M)U).&FXY:1#YI-%TGFKR24C<4S9"CXEZ\T$[,Z5;F>AJ()$T8VW.JB7@_=K6
MYB]W;]ZIT3MU:\UZRYA(UC4ZME,1<DQ=HL3%P3$'5?%%R!W>I@]3]"-)#8\2
M5C_<3`:_$MJR1^AA)@KK\,BK;W^NJ],S63O6>HB*EOV\9;JPFZN#3GO6=K5U
M1,FI;FV]J#=Y'%2WW1^S\Q"OONT>U9MH1*VTML+6X5.CN=9.-`VDJ]_JD7IO
MIK0&S=K8X=11C-V:%GM1AVYN`T9]XEF9@RC*FP_1G-FTF(WY*[,QCSYGW=[\
M?.L^(TYW]PW67W?:RBN]_\^38_3P@<XUQ+\*ZW5UK_91^_R4N%'2H->5^D?J
M]Y0D;E"KQY6:1^KK/:HGV[+>L62*HAC5D^FVIL6^)H?]-!;D5H)TEEK1"8W.
M:YF5_Y9V8Z>#=#I#=/OI%UUD#32^?,KN"(FW\Z&`W<J12#%9TQ\<6=-GSW$2
MT5X5S00,9]:XHUO5^9!/WEH=W`@B$W*,O'=S\O+>1_@]ZS3[(^O]VP^CS<W@
MO]&?G/S+CVB.V0?#Y-Y=(DY_146=S;);I>TLVNVK&WE%B_3/'<X.KS(W)=[G
MUU1OO04.2KIG$5D:BZ_H"E$".2&1CZ)?WM`Z:4S[2+*S;[%\MLS`!442N<$-
M5>\?_T!K*05[99UQ;SDX1%*0,#HR"V<4AL^@7`?N7"#]G3+.:0^EOH^@D/;X
MR-*^2",&\AK'GAO\+W(CNJ>ZI*N40/"BXL[''G(@`5/0<7ID.@HP4]JL@()J
M$>=3#\6^!Z`0]4<@49='"8G:<\LZGWLL_'TD!0N?@%C8#L)K^DNLX&&OM/.E
MQTP<8BFX^`S*1:XA^FQ4RCL_]9Z/730%(U]`=J37.$#1!1VG<Q+)]Z,[)9VO
M/62!CZ.0_T\P)P*R7)(P<P1Y6E#L\21-F*LI<Z65'P\D%9W1A][2H\)5T/65
M3]?[?=/"OABLF1LT/$AKZ<_,C9\SP:?QV[GKKG(E0D$2%[_L:]/F9Z?T09S,
MKG%(.X3I7$-BK+!2F%2O;:FHC^HLCJE0-?J_6Q#(9F$HS+UA((0BM%J<4'PS
M1,\:N;5:TO^L\R\H>B9;"R$$DYN3D3:A>^6!["!B9F0,'O9]$$0R!V=V3T?_
MC]U$O;A!=G.77+A1M*;S]#_=(.4==XSJ`YE>E`3R^=:%-`C^'R*T<K%_]6.%
MPAA1V)-D@:(=B4G8UZ@-9/*IR;T>(+'-LT_4ZY*\BQ[&E%23SOVNB\VGAL0E
MU0O/8X_8W*^+N9DGU1B%>R0?JN)J0"8JTX58`6%(HU(Y'(%L6?7V3A5C59]'
MWBUVGW%`]_TH<ZMEY]H%"2BL.'?BT=@'ZS8!9!JS<^0Q`#F,,5L!K'\D$E<"
MLLC5H4^I`(?0!K%MWOC/QQO_92HG^DN4TJX?0@_]>Q)ZZFU6S2:A+(1Z9`N6
MA098AZ@_CRC('/_<J()<7U>XU9T1K-G,@EX(<0UCV<@B-C=0U9QS2CLC6`M:
M'8H%,*SM#T$9W49&'(I&0JVLFC."-9[5X5B%1^PVTR>RC2CF"0+6,E:'6#X*
ML6M.+\]V>BPZ(UA+F-5=.@,SC#55FF5"?(LAKN6,8(UCS7E6@!O&REO+&B.1
MY@C6OM:<=3FV8:S`#T57,["JJTI.:6<$;6>3DB2\H^+A&,2YN.(RI+QYWBOJ
MC&#-9K6XY($8QD)\YOLX[_:#B_V;\,)=X81A$!LU^#6<,:Q]JQ:O$BS#6&\O
MT0L*2';[]I2X<W05)BA:13A&EVB&/<PRC*3+-+/?7*81W7'LUY">AYLV[HRA
M?<9J*(T=V,V7=GZX-_1^SF@?YXQA+6.U^.?#&-CIFKN=;7!CZHP[8Q]K?@X7
M(FQ-";KD9+V;Z?;5X]KZ">G!C291UE,_VVT^H"ASS-<^-(D:Z+6'MC;$09RP
M=M'F<1EG:;(@$?YK.ZB5FK!?$=B7VZ8&<*`-XTC&@WD3QZDQ[7DE8*]N^Y27
ML(9Q1.-!E(>D:=8$=NFV3_PNMF'81BN6I1K+OD9M8$_P9EJ@A\_>KKN:RPE,
M#PP6>TDM8&=Q:[QS<(FS&_1TY&NN\8(:P#[FEIDN,8GS)O1X5.LM[-*(;.BK
M,*ML[P(3)V9H/+!A#"BJ1W:.K(XW(>TE*BG4L)<(:@"82)[<`,6/B(H\1?(0
MJKV2P$8/L01%YN6#[@_"H#')U3^<;X(V=?(+".L`FS&,.94!&8;1XI$2087(
M(K(KMUT;N!**I?6`31=2UOA$J^`,8BC_BD(JF("%@_A+'&;9/ID7L9IM14U@
MBT4-OM6`AC&\+Q'M+-WK98Q0L$L2)?BOS7.5$@<!82U@LT0-JN5@AF&+_-7%
MX2V)XTEXB>/59EL_F>7AP2/9P)96!+9%U!G7*CS#<-\XD(S)9@S8[E"#51Z$
M(?AME+CRC2E37!TBMZ6!C0KU]],[$(:0O.">A&077)'D1GU<4M8%CE@WIED'
MT#"N@6Z8#R&*-0Y,>R6AP\JU*.*SRT'2^'C4A465[1UB-B4ANGVX^L$DD^)X
MD1M-+]&S;`@KZT*'BS?@6PO;4(Y+161M92-9_B8W7RKK0H>3-U`!+6S#.$H)
MI51G`8>.+F]`N123M<4;<L>&$JUM]TXYZ*AR\ZW8?N^'<&ZZ<J.0JF5<^)*<
MNS'VF.D6!VDBO8I7U(2..C>F5P//,+PN?D=XOJ"(SF@OW#FZ3Y?/*)K,,M"5
MRVA]3:C7('2XNK&"U(=IS8^C*Y?ZI=3BR8QE'[X.R/?X6P=2T)>=,0N$.*@&
M<+M/EQ?6C8>(O&!*S_GZ6XS\F["T\YQY=(.8Q]YHV$&,&^M.8`2/#/&2;`[3
MU@4DH%-5O0T7\)FI%E<Z6S%[">X!*3WS_R^-\]PG4_*(/!)Z.$`[0*?$W@31
MQN>`?15L*EA+XK%FV@%4U*OE*B!KA,Y1B&8XR]13[)>1?T&6[&2KNA77;@,Z
M)W]+:B`X@1A(91!>-%5_`OIW@.K[5HBJ0[\"<%0%TA3(,`S,PW34.*[":/MX
MU#=$=^$ZJJK_^3T+A9OE[WV(T!*G2]E&2547^GV#HRJ,CC2&<1V]BW03Z!'.
M+T@L?_-"4@W8Q0124PX$8<UV#KX&M7?/#>NJ<OR52"6-YN;W9HO1#`>9(GSX
M>OHA4P/V]"CK^"2\6+CA'-V$URZ.LMA<UNGB4I<W7^A6A79N.8X6F$BCN3&]
M"UL2*KX(N2Q?6O[_%8%M,O#IA:9I-@+M,W/<R<1,+BV&7'9#H;0?L]5N`]K_
MQI!@8RTY1#L(>\LAXH?\%<G+#03N:Y)&"J/3(+0KCQGQNLJCBWP0#IX2$5:3
M!#::<C@-=<!GJ-5Y1P!Y&`:[0]PZCVL9Z8Y.@QUP3#*E7U>/=.$/=#&3OLG5
M1(]V6^J`X]*1%.@0]S!F(OV;8BLN-M!/=%CVO#!`/8AP-#[BF_`%Q;;\LB2-
MP3_\8=$Q2X%S&+,+G3PWAHXS[\\41W1>3=QPCMF*K#I0*>M"OQU2DUB^EFBA
M'<1YZ0"I\(5X$^40-@+]$DF[6B*%W7P.Z8*^Z`O0RF(#_0B)57TQ@SW@+4IY
MZ6ICBR)I#/X)$XM;%`5.>^H"Y\%)(7L(^?$UE22[6J62F,Q8TE'VTH7*P4%=
M&?J=DYK$"A8?+;B#,*@\HM5FI9W,JF]?2Y1!5,49P]IIK:J`#.0P=AM5)2]T
M>S+;S3]/]UGY#XC^8_:+YB2AWZ`SAK7,MC9QF(E@:$O,%OWO;A31+;ON\G)8
MT1G#FEZ/H"%5J,/PI-07FI5=J3/NI+6UGHZ8P1Y"0@(&ESW^3?^/G>M?W("M
MO`\HPL3?O["0Z(M),\ZXCR964X1#2#3"QWQ&QT@4K>EP4+[$K%/?&4,_SVQ/
M'3C0K$T2JTS5:&^C9,C:<`K]J'-[VG#ZP5Y*DUP;KD*H5WC3U2K(Y.0&A9QN
MPAF)ECEA&ND@]%IP3ON8*,$`7(O)2H[K'4*6:.K^8,=U+,M>LU?2.04V9AHP
M)73KV`<T"/M4D2Q3R>>VF',*_/*C!3)WT0SCBKR0Q3T)/?KG]FHF]#E'&Q9B
M&)`XC70R`#=MVCGMS)N1ANM]4]3#B(-@1OJ;D*)*F1`O")5$E#"/@CRK`GNL
M*_\QIMBND<L274G4J4YSSBFL'=.*,O#UK*XX@!<@;N1>)<2L,+KE+^_]CI.%
M('A3JYYS"FNE;(%_;=S0ZY,YTZ*[#+V*SBFLM1&"ZQ(X=)IB,[*GY"%PO3S9
MXYSO:654WSF%-1L>FWH>?N@;"JX&;%>@W0O;;3Q$L:N>DLISG`)]J-F:<PIK
M16Q).QI(`SKE@VJVF%)=CVDWV'U<$4BQO@C<.,9T9Y/Q-R7,FK;_JWHBJ=VT
M\Q'6^MC^'--(--:LE_M7Y<=+JWN)8B_"JSQ-RGE*_Q'%6>:W=+ETH_5D]H3G
M80::3KMY>`Z5^0,)Z&8;Q<=.M3N)YFZXR>JR30B<9QE[J(BG\C3R-E>PSG.G
M-MH'2-[;J-^584-YE]$]I5IV'LA];X[=%>#$P;8T1G#@!9!F>V?EX\UJV=9@
M--*?GOBY=4B6,2KT4"2[P1$5-9H'E!V0C3UA6:#!(9$(9S46]7P(BEC$BNR$
MV!S?&8X?KZ*Q("KK`BQVPCYMYSN=A<JD&>!%1H<%P0)BB'((8XY-_H7O.(#U
MW^BZB%\!8%#M=D1G_`AJ``\5H4`E-PK#'0K5)(!@#_!M+VS8P?(WY,_K7Z\V
M:!5D4!GW5F_DU6\6?'@VX4\XAAO)8P@#G=DZ<5(`IYMI=KI#(82-1M(5,T\*
MDW8`!K=6_W2&LUE#P`/8E!61PX@IYB$,TNPJ8I)UG&W'C[XBEX*=S*K/>6S2
M+&71I-F#'\_LP8\B[8'.HMRH88AU6;?#Y]4.:RW-S5J&7IV;$BE:H!M+90C#
M/S=*GA[]><+T.49_IK1'5R^:`UI4!6"H[G=%9Q`*ZT`_,B@6JV#@R)`,84A4
M;A])>?OHEK>/1'[[^'H+V:U;R()`.L4_TXZQ+N8<K25@Q96&?;,GQ3V(@`GV
M$G$\F>V-VW7^OSKSN%X#P.^*MJTFNC+HI.?K)7I!`<GN&RCH.6*;/S?44`']
MRL"O?K9$OQ%^:#]86_:4BO3T)PE9->#G.UN>&A3(H7UC[6C%MYB>&:_B!"^I
M8&09.G8+`K^[V3+S!UBA?5MM7>QC$N49)!Z1M^-MN7W`IW)DD%[NFS4%_.QF
MR_I20QK67%O!`STY24KT%Q>=^L`O<+:]RFB*8!AQ^T)W&7V=T6T"^#G.UJ<<
M;2D,(_#WAF[.<91%3D?Y:\9N,)G=$O8JQ@OR\X3B^EI4ISG@%SM;UJB:$BFT
MZZ=>:U?%D4=?A\25H)_U;%E5Y,`+C?C::XVHQ#"5,JJXORCMKEKUH=_M;%E/
MM&6P-:[U6F?*U#P&ZY"@"O03G&TO-A+8I3+T.PG.(Q42E3G;W%<LC9MW(Y73
MAT9MZ'<V6U8130F4VM)WZRS?;</$4*O5`O0;FZT;;;6E4&I.ORVX5VX4XG#.
M4L-F/C[Z&J.H"?V29LN:HH&^U)!^VWWOT??*_69$0OIGGN@C-KTR-FT*^C'-
MEG6HCCA*I>JWZ7??=<I4D[3J0S^MV;+Z:,N@U)D6K+]]\4:;LH##5U^TCOBB
ME4?[RIO$=\AE/LC^A.Z\O#2*\D0R]R2,BO_,O&TR(G6F"&O?&+:GFTTQ#<'I
MM;@:<2NW(C"3Q]\F,T"C>[NN#-,VL@`,;6Q5+/\P0^HU[)EN&[T%\M,`36;<
M?FOMOC6;@`Z8:B.<V0![Q_,:;_M?I/*<A!N'9E8B8^N.^"A0;KGL-`SL*FY5
M6ZQ)I$7'<9#X=W<OGAAF'>A^%#QW\-YA*JN$A*@(PBQ_N$/)@OA3P8NLVG7[
M';YN`M/6W!P`W0YF=Q,/+MTU9CE2J3Q8B-+YNOHO9S^PS"=;OQ&@F=F(3]$U
MH`'&X>C$)5FZ6.:!?5@8.%+'C"@UV24H*%*Y$_C9\S-)DG-,D@6*W!5*$^S%
M%R1:W:'E,XH$4[>B%G`<#5_JAS.S&D47]\NT<R1B)K6`N.$_4)(@9OZZ8,_Q
M1A>(93.74J=;'3@B1I=#`SB=C'A4K29TQXMN$K3D+9M&]8$B5AJLF*;P>LFO
MUDG6K!&@^!)CNFINE7E!)'T^BN:/!0!9'U]3/!T8T;:)A:H=/V-&DGE^A76^
M/D@^=/;=C82'7>O?@+9BMI3VR:9\^GURRJ'0KR@.S#OE@*V55MGC*\@^W'Z3
M7%],6SF$/KNBNW>72'G`;N-SP$?T`WT0S"OM(.^W]ETM5P%9(U1),BD\-RKK
M`!_XVR*8KTXR*0PB$=/F1DBI#COE@.T%QU6!?>301\\C+4@B$<J,%/8:!\ZY
M<83]C149#407%=*N3+[QYB)\K>V(V;QQX!P>=A2EWBE,2SA#,,PT<^^^1(F+
M@U?_[J[Y=^=Y'VAO:WH7Z_AW-_W&W\2_VX*8^GT&*R5QOB[__`VCB(4)KV]9
MD+#"_J/7`+!AR"K?"I52R6$@^K*16C;@#@$K34%&[0#;>/2I5:B&)M:!:,A-
MN$J3.)//2'F0E]0"MNP8LZ=0`B[`01AM>!#'M9@?=\*@TR+SXX'9;7@83VM1
MOZD%;&EID?HMP&$DP;:QM]*QWEG]#K#QY)C[44OB@IZGN*Y-&SO(9"8#>99L
M@T[V\3[NX%6\F-[2UX"SJEI7E$.GJO8$-XA]TS80JB(6F6<3KSQ0)M66Z>7/
M;2(!#,SD.RE-OF>ER7>B9?)E=O"4XGZU_#:T_`J>B&E"D2P>S4++PS3<VA-.
M%XPK,?+>S<G+>Q_A?'#1/_;'%/W)N45S-[BB,(1A:YQ2@'%IEAC:I9X/44AC
MNXSD?1!:-_>+`!DN!2([E.M>7RT(E1_AY5&><;J4!W3M%`(R^O&$<C@3'71U
M$-M08<:5\[6&'[!&;2!S7FLSDQET:P=H&+.^.!\/_;+RND>C-K#%3Y-$0PW8
M@=>%K4=]!;ASJ01#%*VK^)0F7DDM8!N<)F=\PN6P!K$<7*=1B-GYE$*\QC^R
MDZK:HB^L!&SE:L2V%!6T8=12N`]=\'P<I,RH\L3,,9E-Y>J'%Z0^\J^I/)D#
M7EH<WO8S/9^O^0VH@H?:^RJ@/:S5S4:[(K-V)044M,;%IA6;I*H*_?Y0R[R;
M*-NN4/J]J[$;@P3\]I`677RFI9@&L9^I%U($_&90`T8/<$!O5+BFH<*+/_2+
M)(!2(Y&H./3#/35X4L$9AG?(!0GI]Q-,]S0/1:^S.48Y#A4UH1_=:3`R-9`-
MXR7T"M![DJ#XP5VSS:T)]8?UH-_0L4,\'Y>U1]&M)&9K=HZY5:2-LM0ZU',X
MK1WT+,L&>B9IXP8]]VY0>&M9_0;4JSFVE<'ZK?JAF+J8L)">@CW&VAQ-9I/O
M(8KB!5[=L-1\*$ZFY!R=>7^F.-IZZ^SIDG9]9P1CYFR'R4-M,1)$%S6!95/>
M!!#?Q''*IN";S%$%TZYF;%V3*,^'5L#*(,68_9M`/9HUZHQZ:ZK4TIGFTH$^
MN=K+K[Z1PX,;3:+,[\G//"(+*YUT3ZRL[8QA3)3'4"1#,0SC\"R\M+J*$[QD
MP+_%:)8&M^SQF#JW[[QVG#&,$?.86F0LD$[NHC-M9U<`"Y9SXY$1)8I<."SI
MC'OK)ZBUZ@@@6SMA]_FV]FS)1-K>O6S>OC.&L<D><R*Q)JA"+Z%>L.5.,%.2
MN$&68+58<_-1)9AE1,6=,8RI]EA3C0QWP6L+K\S6Y[68%7VV#]?C5E;%&??6
ML5.+7Q7V@N,O?8X[^I50N7B$/5H0&B>.XFI9UN)%WJ+"5L<KVCQ.I]JJGLU0
M4@,HKD8B'8ZFROL_B&O\>Y3<A%1KT2V)96>>G7*`,3$*2OC;BOW.VV(N01$@
M;Q=NO*`GKQ=,IZ?S-3UAT0EULLIL0-6G!.6D:C8"%'G3A'%]9-;L88#Z\,C6
MF!#YQ9:8+L[I,LVR]U\BNEYCV?E$71DH?J@V_UJ(K%FU]GF'?4D<*$_ET)X2
MWV9-%3N[:S\/(F^BO\^*&R#LMV-K^]%\77GK0TVDH1%X!^-`M<!:U!ZLWZ4F
MAX8*L`.OWPHPF='-`]*/U^.6!\[`J,D3GV01H$$<AFW'Z,%Z5C;B68IJ&`X$
M0OG<:J3/4U?NS.,6UA?T*L2!J\(]*I:^!H>8@T:Z&JJ]0ZRA4O!`#F)1$"(N
M?!IFLB.@1NVNAG)S&374BAV4PU:'7R.Y!5U>$2B^^BA*4``<QEJQ8TJD_?9P
M1A;].T";S&QG2Q(EFZQM0JG(_$4L?0(ZR-J&5MF417.#[]=<`4,T9QVRXCW`
M[J0FX26.5R1WT=WNV!3J8E`;.I2ZB288PFSN6]B,Y/9WI#7WH-#!UZVN,1M\
MUOP1$^:$!'VE@PIT?GZEDZ`8)!%M=ZYV^.%(G)E`ST%%HV;_[F;T@0UB0U[=
M%4CTL%H,T']%DQC^[+>'80CYN5G@]B9N&^C>^A(])W1CX06$)5;7F-'X%9I/
M8Q51Z,U>X@K`DY900IR92@JBBR&/_T#KI1O>A!2:&WHH\WU=/T1HB=.E@"A9
M%<"Y2"[Z0ZH4,+I(UEYG+\GW</-XKH`J<05`%SA3HJ0@H*TP.CS1_Z3;[X#U
MV(BNPWJ`CFL-6>-B&48@9C5;RT4:17)K&*<T8.IK$U;E"*P%00*ZG;*5GBEJ
ME&9GDC"D\GB(Z`X/K^@?PJ%K4AWH'K4NUYJ06@R</.;C.L7#05"/HV][L)4Y
MBU?Z#?GS'3=OPQU^[5:;'P.V%_?;;FS2V55[D_=AK7ICK59CX,>')N+GK*RU
MI=#%+>T!A/A;B!-Q6C!N:<!31WTR#HD5H[/%W(I^@?A/B1LE[;"7=?@1>8$;
MQUE@)>OGE#RXF,5'NBN<L$[K<:O3%N`QIE7F-;%W\O1C9TC#G72.,:0MGGWR
M,7T5`EWM;1%NGW"L"$Y^P:>N#'@VLJ4'1F"M':,Z,=670&W.^66C@&<I\,F_
M*@3HM#7\7'I95H2;D*OKQ60H4`NMND!NI[;9U\4*G0.F'ZL%7()-@-5BZX/:
M.($,;Q,!:7D9O9I>CA\CO.VM*A1XK^20+"QBB/V.]<L?^G%CY+.D8RB,,Y;R
M/$5G:;(@$?X+^=_H\(TJS[PP1YWX?'WU`T4>CM%#A#WTR!8L18AP"U\##BGF
MZ`-?<=J!WF_ERY`H8P\KI8`CAUOBD*\PN[#[3?0=#O%2\I8SMQQP!/&>_/DD
M[7=X$,Z&=^X//;:JY8#C@/78VNLPM)W4]O[L5B.FEU,:.(A7>PGE=QV:1/[]
M9I%*4GI^GX1T,<'Q9,9*9&*_(SY2>41::1LX.E=`)>=6TQ+8+EYRWKG1'RC9
M@*ID"9V$=\AEQY$LT96;B,RDVO4A[1^V^#M4#1/X@UB72Q&>Q7&ZS)\!W-E5
M2J9]95W`MX];TA$3Z-"+2'L*\HCC/ZXCA(IG4A[Y\XEI$U!1MT#Z(A+!,%Q5
M^2-DA;P$^5,4\3S^=:M"Q>2"S2N[T*'?`&E?/_Y)`BJT`"?K&C,+OQ&H&%Y@
MG3D4`O0-;OO:<XE9ZN+0;Z`[U2:@GG0&UIQ]$0SC4KA$?!.NTB1^B,BS^YR-
M#R;8F9L&LCLVC=I0ST$?4UODZ*U=%,,EASZ\)-Y$,;Q>%3?VTJ_(5O?]7%&%
M(=T%*Y'V^[+FF.LUY'MR,@(;KL'`KV^HW\_>61!RJ]F,]HH.!>'(UJH-Z'AO
M0J@9HA:-0\=;)YF!%"?9O.>&_@7)WK1"(7O1"BBLK=*CL_T>F2R11NT`^$_=
MDG#.[`$/:>0MW!AM^ZORIU+4!%Y33>4NF%35(/N]G#ZB+*_?@QLEZRG=U<=4
M&FSA.%]7_T7A.*7?"+`_E`:;`G<7$X3#T0CE>PJ'A8&=H,R(4I,-_F@"=[=T
M]OQ,DN0<DV2!(G>%T@1[\06)5D*O&(U:T!Y-7*D?[HS4*#IYFXZ6),)N\!00
M-_P'2I)L^W;!<HU$%XC=VTBITZT.[>>DR:$!G"&\#"=>=L[7%U1@<\)L;<S/
MI"CA*U;<FBT"^U+57G[KP[6F/C"+L1BX`+9RQ:[9(K!'5@,%,-4HE1@ZM1%X
M8'V[QE&<7-"BV'.#*9M7)[-;[*&0=OLA(G[JB5]),F\$^*V$!L0=KD/&R+NX
MM<A`/"&/T&-N0R70;P7XL03[6F`$'=HA2ZP'TP6.&JN!=B/0KQO85P,CZ-#^
M55PUH">C@,Q9]S?]/ENM@DT\OI1Z=47H)PRLTJT'%]I%BDMQOF)1\,Q-E)ZB
MW$`<IR8M#_T>@55"I2BAG97X9IP9/91FW;Y'">NO^*E#67$HOZ)66)2!A/8<
MXN<,1]\OHW2N.\N*BD.Y^[1"H@RD-:\>FR0^(@_A53*9/:(Y>^F(PJ6=C\B+
M&UQ347U[NO9=*:WZ#3@C6!N=5:+-8!?4?^FUYY]8@+<:$8X:M9W1X,QT.]@Z
MN6V^PW2I24B(-@F"%;YDHN+.J*N&LET*.#9Y":(NFCW$2$LDL3QSO4$+S@@N
M2%%*S"&/AJB&\(*-S-<#U.NV^TY$_#1XXL^)G()TJO7;(T@38;^=/Z8X8=G@
M;D*?.8PR+T7Y/22W/*#?K`Y!_+V+",G`^/P=)XOLEIXYQ2SP:DJNJ(PT/'T,
M6P)V`Q*RJ4F^$ERG;@$O%AC-KGX@+V4.QI/9#'LHHOI_B2/DT2:D)U>]RL#.
M034(XLS>ND@[1>[9/$)9L@C!5'Q0!C#[M/GTR^L]F,^&7/["*9)3"C#+\X$T
M)0(O.]OO5>YJN0I(=J)A*L>V;V)#NK(.8(IF#B_\]4K6^7Y3>?;=C?PI_8IB
MX[E3#C"#4/T-YSX":U8Q&.+XV2?/6*3P/-/I^'R]+5.8,I@,MH((?9:-\MY=
M(N5VM(W/`?NT'"@$7V]:0M[O:2.?$!&J)#;57`$X=:"]6MIB6+:6",0PB,QD
M3Y3!3&[LN>]DS81*PFS&5N2#EM6#3!U4?]%10K+F[P(T#^S"4BXCW/+07C%J
MD@0C602FWW-[)7FB<DX_*`OM&R/FA,\A%T"_^7M$<1)AEH5`CT-N>6CW&%,>
MA2"Z9=R0K"2W$F<&W:I0OB[U;5&ZJ*SY$[9-HUYJ'/T&H)Q3C,@QN[D[!#B(
M;>_&P!U7#Q&2:9=7',J;I09C_&E8!*I["7#86>[)#=QHS<YN*)J1:,GB8<])
MF,:5;#`BYWW-ZI".+(T8-079R1"=S1,/CP@OGU.J.4P6D]DT<E]0P%(UA3$2
M+;<Z59T17)KLQN3J`NRD]Z"TU^K1JUO=&</EM6Y,L`G(3H;=5&:<R?/_(9:5
M#ZFY5=1RQMVT(VE1JH'-VD89,'^#TB`KLL?FI\9*4L<)2UHR7;AA;FB-?\T2
MJ=Z$#]E3EDWN.RQUP1EWTWE+>\=W3$%U,AXI[VW66>1/2>$&O'D'+G["\W`2
M9CLFP82EWX`SADNHV'CN,H/9R:@E?0CJ9:I66\X8+D?U$15@#S%T&)-@![IC
M<,Q@T9G*8ZS,43P)15[;ZHK.N)M6/,U=IPZ\@M*?^D/I]#NIQ2BMYXP[:<.S
M0>@&7<'GUZ[SJ7,VE-9RQCTUT6EBV]IQND3E/VG'*=8G;X'\--`X!8HK..,>
M6^3DL$KN.F6$JWU"F)0YU7&4U1&\/F7_(\ZXQX8]^Z(H]:I3-L"M4R[K9_;.
M=NG0*]`2617GM,>V/A6PDD&;?D8=##@=O4:<OD:<:@O1\-YZ$!&G?X\$],V\
M-E^SSZMI[T38Z6OV^=?L\UW,E?*:?;Z7V>?Y1G_WCT?LS]&]F_>$-DJB+/.6
ME$-5->#4\+K<:<#HI(/(&>W#RQ,)TFP]D$^4G*+`Z=>U9T=^USOIS7%-/_I;
MFE#D84S"?/0_4NE2R2PTYD3=ZL#ITG69,X#3R52J6?+F&[JOOL$[V9NO2<2>
MSURZSS?A54#[':S/O#1!=VL4$.S?HO0/M,3RW(Y6V@8.+M75`UM8.^D:\2W$
MM+DX>T9QBGZX\=WE&3--E1JO,>Z-VH".)-5EW1A4)]TA_ILLPO@WLOJ#SF%;
M1%(V956@LYWKDJ?"T$EWA5L7^X'[/3.$2!DZ+`@=GJG+"[_GG?0TJ([_!Q2&
M\3IX<4/%LBBO!!UX66?JXZ/HI"_!?[M+%,<7[@HG;O!K1%*Y\454'#JL4GN.
MD_0?W$/`TLT-+SN9.N!97`LZT;@.MYHPP!T)VLX<?NQW`+L9Q-G2*X"CUV<`
M#11'_@I`9].;JU7`5*F4@NC6I8RMMV3Z^;P?/Q>Z#&47[VD@GG,$BAEMAW!S
M[)V,$S;/^=K1P%#=I*^5D,^CYS^4,V"4]14PEO-0GA*9;[O;J35L,S@OT0L*
MR"H#$]+S0X+8ZR7Y&WT%`OD,:-H.9-0CCQ3.Q%8'4J?(-6)0A`DNWE"/)G&_
M.[G.%-T-_:<5"6-"^U!<^IGQI&X`,E30C#L]+)WT,MC9].@Q**L"&?BGQYFJ
M]YWT/'@(7"]?JN?9_V@M:;(ZD/%\FLN7JON=="JHN'#>N:$[WR#0X4NG*F3H
MGAYMNB@Z>=O_R$2J.0MRRT)&YNGQ(^QV)^_GGQ#%G0N1KK$H20*#`:57&3)0
M3H\R?1S0]_9MYL[9)%E(DP6)\%_(SR+$*AG(6?+R^'Q]]8.]Y1VCAXCNS1Y9
MO*`J9;?]KW4U#D^1Z+L=0?0\/7B&19V`>%O*.87U`6J+1K[2[`'O=R31)I^@
MDNV=<LXIL&_1'@-\G@ZZ/(A\M7?T**=%6+6<<PKL9J1'V'Z7.VD-:CL9^&DW
MDT4U3`9^^K&;A]=CY@0_[62"J%V.C.CE`.SD?7&>+:.\WKQ&HDAY3DGGM)M.
M0!S1<PQ*?#Q=).FX#]6?]B(=%)]40YS0BZBMB/<7%*;H$7ED'N+,U%:`O4-T
MA^_O%OAKFZV$&Q%OVIASVHOT4X<*TPQR)Z]ORHYOE/S2343S.:^H<]J++%'\
ML2\"U,D;G$J>L\GLD:S=(%EO^CTE5;]G`7O:]9V/W30^:5%JA+*3>^A-IR>S
MPGUPFVA2=)$@KN%\[$6F=SZ7"ER=O`#*_0`I<F8&<P/6;6&>=6EYYV,WLP9I
M,2=%!7U/9&<+-47>(B0!F:^?4/1"#P3Q!8D3V3V!H(;SL1<)S<6;(0FN85PG
MW;DX3%#(@I)5'.\7=3YVT_ZD32X/4"?#24NWJ="O.BQN,WX*;^$5]9R/G30T
M:2ZA.N@Z&6Q:G,?I+L[U,7&S=U[N7)8WB76,;W"2U7$^]MGTI$(&'I`J<JYF
M+_1<Q2R+1\(N%&/1..05=3[VV+`D`@0>5\H_79+O86G?Y'5=>0HQ:,'YV%/[
M3PV<W<P;70%Q3:(-"C6QV[+.QQ[;?82([*6(;LW#FFD82XRT6D7D)<N1=$V(
MS];W*)V?^4M:E&%GO=;QOC9HSOG48[M0$]"E5G3*3G2=AOZN26LWY3E#Q8[A
MT^_D?^D>4&1_,&O%^=1C>U(-K"7UW3(R*8!D(<@,@OB]'I,FG$]]-D49`BT9
M[[=Y:F,[W3QU*KN]VRGH?.JY,>H03DEHIW*1W:?,+8MN(*F$&6+!,-TOYGSJ
MJ3U)!*9DIU/&I+,E2</DP<5TZKARO<6FQP*2!*6=3STV'$DPE91URE[TE-"Y
M_=OJ&B&ZC._L]@2LB2LXGWIL*9+#VKH@=)"[RS2S,3.EDW@A\`L[GWIL*A)#
M*OGJE+$HO\O#'E6R1^0A_(+\\_4V6(]NHD5/E&G4=#[UV#BDB:^DM5-&H:WA
M:C*[3H-@?8F#E!FU\A2(6;#'U9]4"%/"!$7"[!<QTS4:<S[UV*Q4'W*I#YVR
M._WNLGNB9!/2PUS6[TF"O<U5OOK]2>WZSN<>6Y:,4)9$=\J4M.,TM0GT>G$Q
MI1,'.%EOH[HFLPU:'1\SK8:<SSTV*-6#6^I`IVQ*F_BN?-\_F4U2=KM!IR>4
M;,[2HB.JNJ+SN<?V(SUX):>="GZ_)^$CFJ6ASV:EFS!.<)+FO1(';4CK.)][
M:A[20E:2V"E+T0.=5Y:NMY;$V6Q+.)][;!_:PU'2T3'3$`I]!O(A(AZ*8XI1
MS`R_L/.YUX8A$:22KT[9A4I#/\4:8]I!V=4HO[#SN<?V(#&D;91#I_C:&![7
M^2S-YFDW"#(!:#UOK5W?^=QCBY$1RI+H3AF1BMN`:M\5MR#5HL[G'IN)1(!*
MIKIF%YH1NC*''CHG81IOU.[@\GSC_BTV")FTXGSNMR7(%&M)?:=,0%53!NTO
M"Y3%H9L?>%4SL59=YTN/33_:"$MRH<P^EIZ$0&Z,Z+$7YYL(=DDQXI`O*^Y\
MZ:F]1P6JI+A35IU2"Q]1B+Z[@=IH*ZGA?.FQ'4>!JZ2O4P:<TL_X;$Z[/Z>Z
MEF_\1$NLH+CSI<=F&QFHDK5N66R*'E_3U2"H[/&V*WY\OF;)U=Q0%*UMU(;S
MI<]6'U.D)>F=L@MM0P+V]GYU2-=IP_G28RN2,=*2]!:,2^^K$KRE7=V7*OMM
M1ZP4(Z)[^5(Z.X+U*.PT?J&54]H&#KUW'EGFW[[Z,\7)^A(E+@[B-T?>O5WB
MV`M(3#LUF54S.VY\8[/PSNP2ZYGE?MPP%$L2=MEIV/EP_/RPW@+Y:8`VEW8'
MN2XK\9%4"[=E-ET_^^Y&?I;"32(4:]]P8+.!-B97L(^V*9]^)PW-H="O*/(,
M[Y1S8'.&6F6/KR#[</M-<GTQ;>40^BS)[KV[1,JG%MOXG`.;]?1`'P3S2CO(
M^ZU]5\M50-8(5?(U*U/>"NLXL,\WMT4P7YUD4AA$!N2-8Y)2'7;*.;"O/!]7
M!?:1#R,%I%*&(A'>2M(RVVO<@;ER/^+^QHJ,_N:ZF$_(\21-XL0-?1S.'TG`
MXKG9/[:AG](/.K#O5-M1*,O*JA+8(-90B]+)/0..H[KYMQS8Q[?;TZS6-;F4
MGRTE7F4WR5DT6#\5F4I_AG!F][P)A7DO6_R:`_NP>-^4F2_!@6PJV(GM)HY3
MY%^F$95HCB\/TZ@<Y^(B2$.JJL:-.2,8QQ8P5:PEH>8IT;_FJA9F-\-^/Z?-
MK3O),:9-SM><41>?'.ONO"D08?.\\4/09MC=[`CX8J1GFLP5H+6\^/F&]BKL
MOR;_CO!\08?D&=W3N'.T\\SA<?1;U@-G!'LWTV.M5XG5VBL#W3_<"2V9>SNW
M<LUK:U!8[8@SZOA]U;''AG7I#N-!!PMR.]@4P@T0HZXXHX[?YW5OB!C+=QA/
M8?R-=E3`%Y!=&Q+VQ&KM^9`NG"Z>U2)[-A;9(V(>"?1WYEG-W"A9SB@4+<>J
M<7'<WCBCGEYX-ADCQQ<Q]/,LG5LY;JB,<!AC[Y]ND!YIK=C]IC-ZO32U)DA[
M3]=T_XC=+R5_O4RU)DA[K_[P=CU`$4R;6*_70*;70*;70*;70*;"H5H1QU0M
M-OPPICVTPV!8&7_4J<BA?0KD1(&'_'##RZ??R71!TICN+Z8+'"4(Y=FC6:^%
ML1MZ%8'C>51A&-H@@%V)=6G+=U`W(4L5CE]0'0*%30#'Y=2D4@9G(+Z(W-4E
M]XT[2Y,%B?!?R,_2@U5<Y9@@XFT2Z<R`^LC6(\4"V\+7_J[A.$V%9DU]8=;[
M#(HR-+!2JI,A,(U)Y&O,+NQ^;^SN<,BRG"NIWBD''#FR)W\^2?L='D2\T28G
MO9JM:CG@T`@]MO8Z/(S5OUZ"#^CX@6-G^+`2#?":XZ-A%#QP(,"A2MCVX)%C
M[_<J;C?-1]<]Z>M2S-<HJ1P&L6NHE^FCZY[E=K7@`'O/#W!3G+`E_";T\0OV
M65Y&^1:$6Q[<@[K]K8@0=_.0KF[Q_SM.%MF-%[NQ7N#5E%R%";O15>TV#%N"
M=BD6$ZJI`&IXG;H?*):O^!)'R*-U-HE9XS1(Z(062TW,>I6A76+K4'1H?];'
MVL7[A++W==CE`X6UV%DF5001VI#`)5.70`XB6,N;'=*XL*R9`!(4=>NVISNI
MU:#]^GJ16ZWBL]>IMWKSR]*]+.NBF9]7UAGW-#')+C><14"$=A"G]]IB*V[7
MJ3S2;$Q-D@6*I@LWW/BM_LI.O*TF'C'L@C.&>R-(K$269YH:,K&EQWU<&G=?
M7&I%27>^X(SAWCHZG@X>0.[D/OE;2$]J9!ZRNWL^ULU3W()E4+N^,X9[)TF7
M=&-`UG;4L'>H0=:XN0*8->",X5Y2,AWV^HBL&3%!5:`XY)^C$,UP]O(0'[G&
M;9>R#6<,][J2J2(8@6KQ4,.-0GK/NLQ"*NA__']02P,$%`````@`;E1N0T@7
MO$;K$0``(K@``!``'`!F:6PM,C`Q,S`Y,S`N>'-D550)``._[812O^V$4G5X
M"P`!!"4.```$.0$``.T=77/CMO&],_T/K)_2F<HZG9,TY\FE(W\H<6M;&EM.
MTZ<.1$(2>B2@`*!L]==W`9(B2((49<EW4'4O-S*QN]@/8+%88'$__NTE"KTE
MYH(P^O&D=_KNQ,/49P&ALX\G3^-!YX>3O_WTQS_\^*=.Y[>+AUOOBOEQA*GT
M[@!F2G#@/1,Y]Z[_V[D.B&3<^S6AY0&IT^]/?_#@YW@><Q&@U5^\>[;$T01S
MK_?M7[SW[WIGWKL?SM]_.#][Y_7OO$Y']23\.8Z0)Q&?87F/(BP6R,<?3^92
M+LZ[71_Y,A9+8"'F6!#JG_HLZBI:[SZ<*>Y#K/@;,!Y=X2F*0_GQY/<8A9K9
M$P_$I>)\2L+6!#7&&OKY^?GT^>R4\1F`O.MU?[N[?=0,9Z1#0C\5H%\F/,S@
MS[JJ>8($SL!5:R#7"";P=]VD<0T:-M#][18(FT1)`S"A0B+JYTQ4F$Y%['WX
M\*&K6S-0BF=(XJ"6^(<N9R'NIF`9EL]B*OFJ**;`_NF,+;MIHU9YYUVO<]9;
MH\6<PVBLPTM;%>+[(F*`B1T'&BS]!'C!L;]!+L1]+=H4QDL'ORQ"1!$,^-4`
M_LX(X1=_;N]8M5AZ)G2)A;2C)&T6)(J(+^PXNDFA]$HHC-(XLDL72-Z5JP48
MC=$.0&%._#7>9J0B`L?36AU^WX76#%`0WRX"-%@$$'+!:^"AQ8(0B\X,H<4:
M9XK$1#.2-ECTFK9TD)3U:-#(R2266!AH2A/"BJ-;S+Z4BT.4,HDDN,F??D2+
M!:%3ICZK>7:NQM@8D#SUX^GA9H.?TD,R<\I]&EQ32>3J!BCR2/=PXA$8U8T0
MZ[X#/"64:+[`MWF=W-L;/Q$-O(2&9Q#YL5NFD!&-!0Z&]"?]&Z:9`!H:0SFL
M%"L%L6'D!-O!^RCTX["^@VY!R3MI_9)1P4(2*+\Q0:%RJ&*.L10Q13$LALK]
M*=VW@+-;X#VH_1&4A5,3F(2\BX22]ZA)>=\\9<3^_-44%A4O$*P5<HXE`;;:
MVJ6(9#?2V>N,Y'TS,HD?N]%$ID'!IFR!N6:@:2)M0K`;Z]LF8ZT;A,>FWG!-
M].O<6NLH5]%P>HG$?!"R9_%4;Z4-\'8C?=?>2(JFIXD>N9&NL/`Y6:BNAM.+
M&!JQ$+#8/\91A/AJ.'TD,PI;(!]!#.#KB!MV>"-0JT]4)*-CA-UHV(WYO0H=
MB/!#)H!I]4?>B[)@UH\.*]*>U'>C+R_OS,MZ.T(3WS.(.7N]Q%;9'W:E_[6L
M])^94AY,)!_S8PS51ERM$7*EPM_?8[)0#B11I+7%KM4?REK-<).0.,,^0O6J
MT3A"*S0)<3X\LP]V97XH*U.A>"G.$:KP"C;12^AIF7OC_(-5A;UW5=>Z1CE"
M#5ZR*")2AP8PF<'7J04#TWQ]:P*P:[A7UK!!0D_Z`I$CU/FC9/ZGH5[,1[#3
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MY$3!;[2`LUN@LLW>D,4X8L_2<-!IFPOMP:V6.:MLH]M9YNML::'RWI8FJEDI
MSK8[R:[8Z#C7D"215W!?Q4]V7=><;!^U2RKHK>!]K"UVQ59VIB7%_K]X%/6/
MJA%[P%-/%U^=JRJ2CR>"1`MUPRKY-M>E-E,2=K):M7^#1*<O49A!*,(-56#:
M,&4EI/UF)-*BI^;:,""BMZ;@.;H9[R?=W<4!=6\K3M%"+@D3HLFVP@`*#EV3
M`\;TMG*4IL%^I>EF!53P*R^K@@80A''IT4H%:6,E6%)]>LM\3:=8<69%[.)0
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M1'N$!6.-%\0\K66G)`S5F4P&*V)`)C)6K3]S%B^R3@B0!^&\BG0_(T*']'*.
MZ`S?T`$B_%<4QG@XK51@*.G:09O210S6.,17-OFF*!0;!$S:TG+DCR<^QP&1
M^Y#;X/V?B'-$I;@1(L;!/XF<7^&)8=(6H`<OL2Y2:"ER"GO0,H_9*`2_HF?J
M;%W]UBAZ%>40-'#):/J<T7"JBRG24USP3WW?!Z+!#968PR(T9BH)RFAI*+R:
MP"%HQS#V&$PMII@/.(MN"9J0$)SW98B$T%>:%,TQ2S)LQ:_6H;,#M;?36X`G
M^U&;OG"4EL]6ET![JT-+GL&?2I%>A(4!7].<\)\\''0NL^^O-,SN0ESA)0Z9
MOO/R*-$,P]1;(+K2=^U6%JG:PCLFIC7$R/SRD%X@0<1PJB!TEW<LP*&^:&Q1
MP3YH.::>.Q*"XP4G`4Y9'UZM/]QA.8<>\QIDI8&6X)]YJ@;R?`Z8W(\G^*9.
MTOYDPJ2\($S.,4<+#$1\<<GXXDZ_H)?+N!&P8,*`11#2?CG[X8AQ@L+'D"'Z
M#RQA(57.1[EK?HG5NEH6KSV&4W)N&'BWA&K3B_9CU4!Q9VEI-<$LKFE;/,?<
MT/KN>5\(K,_DLYB'8'&'D3J?#/HR=\#T`:O$$U@*8.]9_J=VPM60XLTZ<&?H
M[':OO^3H]T+,R67`!T9)'%6\?NF[2\XOJ?U7ZL^"C3+W]1`MY7!_@%H\_-X(
M_M],XN2^AB6IN%^R[NAK!--=7;>804P^?*:8BSE9Y/F$"]SW88_,L[?4E"ZV
M0$DG#\R<18*TE0M(3F[WE(19YT54+DD1NZ'J'3<2I*_J#1A/L@&9)%H*08H)
MAEWI[*:0O48,<P3<7;_X.I7\H.@:J[VMT1RT`?9)A,(OQOV8210.IX8Y$I9S
M$>HA"I-/?_M2HS)3<*#&4*TDS5#N2%-.VU@=:2.0.V[QE@DQI%=$+%@R=8?3
M^B?;E%RM$79.+JXM]F8Y61OCM09M!>R.88T*K%J1FF#<D>0?>!4A>D-AYZ4&
M0))'''$<01">R](,]6:#<6^)[A+G5^R9ICOT7,8FF(.3\$;U%X8*8).@-E#W
MY57_.T40A[8<L!*(QTE5`6PGEQ!%63(1K\1W9^96<]]/E,C"OJP&P)W%OL*B
MYO`!^Z43MA$B*FY!"R*S"_96"=NA[RC_FQJQC03K]-B.FC#H',!A9>-ME6R$
M&WNL=N"'<+J]3@^\YN2K(0F[&SEW/.$=XI^P3"4Q-C=#FJ:4]>L02)HG:.U1
M"IMMO5_Z\MZR*<54#^..Q0J),(C])^G-BN$TL<)TJH_#:C)G30CM9/PLOGTT
M1P(/"!?R,B14_7<88W7B-YS>$A]3@0.0(XA]6<XB;XOG4HY<\_Z(?4:#5PB]
M#:)S4H_GA+]&Z"WP7)+Y@K"0S13/*;/]Q2),XXRRG&U@79(MF7RP*F#NJS-Z
M%.*R2`T@+DG2GTK,-:_W6"HF*V=6]1`NR7&/GZ]X/&L88_40+LD!$3F&96PX
M?<`S53O(^`HXYFP)T3AGT=/C($!ER;;!<4G6\F6(:K!2#^%.J'++Z&R,>32*
MN:_<=?["P)I[44FQ;(5T"'NO^H<:2C<6-D.Z>!WA<D[P]/H%^[&*G"&:A&6*
M`_]7A&,?)EQY2K:%=^C8OS_C.+GT_D*,;7+I\^<W3D"@=W4MO?ZN2,;BE5:@
MA?>LP27OUS`1+'<HVD&[XQ6;IGG=UG0;''<DO5#[$G"H7)U-C3#756#@72\8
MC86Q+36BW=88#FU6[]`+B>+H`9-H$G.AFW3YPQ*'UR\+%;2;ESI;01_`PM8H
M@=6Z[3$<LJXQ"H>3_V!UJH&MTFT$=$BHY+;=SRI;J:NZTE@KN=+0%^HNU9#J
M25>^H=<.QZ%C@O9L6ZWZ2G2';/V`%0.^_K\WF?])BY+?(!-#BLT9NAG6G1M4
MS=R.GUE;P32HVW+5.-0-@`X-PU^!5^@_.SRVRM,$XY`H>O*K4"50)62P>B6E
M[>KP9Z;A+E8Y2+8_?T8\2"\YPY)'$F[41K=TZ6^/=$V59?)_,:5=1XN0K9++
M23QZH@'L^K)-B''5KA'**8&&Z-,#"6;X7E-$X2V:,*Y33)6[[1LA7=I]]6$P
M+1]9J%&J.4]KJTO\#S@.?HFE/R=4,)J4A8&CQ`A6;GM!67L,E^34)R`WL$^Z
M(84CD`'CZNY-A"8W]#J$"12N^GXL\=T*AXP$MSC^A"-2297NB9Q+&GJB1-?M
MJ[-.V"8C<7?55QYE;63[<-@2S26)_\[F5/S"%I]@).=BE`5LAG))GEM$@A`]
MZYQ'60I;FTN\F\-HA"D5JW"):'7B;8)S2::_J]>(1'H'2J-4QE8MA$MRI(?#
MQHL`*M^$)/S(CEFSJ*/B)[='=4GR3>(=D@PT>%Q`$,)@^<Z6ZXURM<%Q2=;"
M6EPK73.42_(4'Q"JGV7-8"Y)I-^Y@>[4L3FB:):R72-8.VB7Y'M0.9+ZH5?3
M[-#QW2->H(2:FOU8RK#91&WA73)2F@U87W\:8".K9VT\@!.&\AV'TCU4:VLA
M10!?ON#U=./:Y0-;H5"N4D['[`&'ZLG=$>)R57-3LQG%H6Q8RNAPFEV"RO.J
MAI=H`G(G\VJYFC;2737>7LM`G$I/K:,;&IBQ:IY,+*21-X$>@+?(CF9@ZJ"`
M,*0/X.Z0>AW(+'S9`'8(@G*FCA>OA<K*2)4L%L5R4$OK`8AE5`WJ>^H5*6Q^
M92LD=_R,P?:`\91OJU1F\P$8L;`14?I7Z</LQB7C`\8"Y674;=,@`E#%<O$,
MZ/44=E;/FU=>#F(:%%?RX@F'DD\M+^-G]B_PR,:BLRWBX>M"7ZY6PA3.<;?#
M<E\+][':2X#K@C&,"T5XU193&D(EGF'^Y0Z)(O7"CBJ)'+-KY,]3+HUSHCH`
M]VWR""S)IP7LDF!:%=R1L4=L@#D8":]BK)=(,%)Q:U77OM/F:H_5?$G`37Q0
MO[[AO\3!Q2I/IX`K-$[56P&_W=*ZQU=!C&>?!G$8KJY(&*LP)TFVZRL@U[_'
M,`[MSUB_%M^=L"DML+U^47LOH6C=,TG\=`-FO5*R!8I#>^I")B"]:[9$)$Q+
M-R]6J3SY"^TU6826N`Z)GMZ/3=:/X708J\`>QB&6M7=I&V$/(&C6CW-.(;))
M7C-;8T/`:Z;Q-H`=@*`C&(T1\E?%[*3Y\0"$Z,/O0/T-^S(?"P&3I2!/7?LA
MB):%T84']2Q5(Z5VA]Q'%G>NDDEBO-`CZNZ<;8'R9J'=_J*$;-]@BE'=511;
M7=I9E*L^4KM4]KN/F"^)CPOAS7:(AV!,(U8!UM6=2$)1LK1;1G)+<)>F:\;5
M`Z;X&876&*X1R"%AUHG(_@PX5O^I8N):+"=Q%8@#6!W6S`]@4(6&!\DGE;A8
MI?^KAD7F=FB'I(BRRVFIB'9H!Z"(\3,;SUDL$`W44QP2XV3/.(*.*A<?6L`Z
M=&G`PF[VJK#:`I,E;BED`Y9#XB;W[C$661EV6F<JXE#:GFMO"^^BB"TEVTF@
MSU0G72N%XYPGDZ*VW+FFN=U2_SG&TA.%4<]FE/P7!_:JG30!85[S;8WBI.?O
M)O^SZ$]__,/_`%!+`0(>`Q0````(`&Y4;D.7S+@E_Y8``&AQ"``0`!@`````
M``$```"D@0````!F:6PM,C`Q,S`Y,S`N>&UL550%``._[812=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`;E1N0^_KS<*O!P``VEX``!0`&````````0``
M`*2!29<``&9I;"TR,#$S,#DS,%]C86PN>&UL550%``._[812=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`;E1N0U2S'(81'@``.-@!`!0`&````````0``
M`*2!1I\``&9I;"TR,#$S,#DS,%]D968N>&UL550%``._[812=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`;E1N0TF2@&+L6```;UX%`!0`&````````0``
M`*2!I;T``&9I;"TR,#$S,#DS,%]L86(N>&UL550%``._[812=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`;E1N0ZHL:[5Y,0``2UD#`!0`&````````0``
M`*2!WQ8!`&9I;"TR,#$S,#DS,%]P<F4N>&UL550%``._[812=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`;E1N0T@7O$;K$0``(K@``!``&````````0``
M`*2!ID@!`&9I;"TR,#$S,#DS,"YX<V155`4``[_MA%)U>`L``00E#@``!#D!
8``!02P4&``````8`!@`4`@``VUH!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 8 &#8211; Subsequent Events</font></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Management has evaluated subsequent events and has concluded no events warrant disclosure.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (Employment Contracts [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member] | Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted to purchase shares</a></td>
        <td class="nump">675,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member] | Restricted Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options granted to purchase shares</a></td>
        <td class="nump">125,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonus', window );">Option granted as sign on bonus</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription', window );">Option granted as sign on bonus, Description</a></td>
        <td class="text">(C) 100,000 shares of restricted stock a sign-on bonus of which fifty percent will vest at the one year anniversary of the start date upon starting work. An additional twenty-five percent each will vest at eighteen months and twenty-four months after the start date<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Chief Executive Officer And Director [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Base salary at annual rate</a></td>
        <td class="nump">$ 350,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PerformanceObjectiveDescription', window );">Performance objective, Description</a></td>
        <td class="text"><div>Upon the attainment of such performance objectives, Dr. Dave shall be entitled to a cash bonus in an amount to be determined by the Board with a target of forty percent (40%) of the base salary.</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommitmentsAndContingenciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option granted to purchase shares as sign on bonus</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionGrantedToPurchaseSharesAsSignOnBonus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Option granted to purchase shares as sign on bonus description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionGrantedToPurchaseSharesAsSignOnBonusDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PerformanceObjectiveDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description regarding remuneration of CEO and director upon the attainment of performance objective.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PerformanceObjectiveDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OfficersCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><div style="text-indent: 0pt; display: block;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid;"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Lives</font></div></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="10%" valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" width="10%" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Office equipment</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;5 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">162,384</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">156,162</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixture</font></div></td><td width="9%" valign="bottom"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;7 years</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,100</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">1,292</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align:
 left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total property and equipment</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">165,484</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">157,454</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(154,444 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Loss on disposition of equipment</font></div></td><td align="left" width="9%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(4,122</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td
 width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%"
 nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="67%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="67%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment, net</font></div></td><td align="left" width="9%" valign="bottom" style="padding-bottom: 4px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">6,918</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom" style="padding-bottom: 4px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,010</font></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
        <td class="text"><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Note 7 &#8211; Equity</font></div><div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Approval of the 2013 Stock Plan</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Board approved the Company&#8217;s 2013 Stock Plan.&#160;&#160;The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of underlying shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares.</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Approval of the Equity Incentive Plan</font></div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The Board approved the Company&#8217;s 2013 Equity Incentive Plan. The expiration date of the plan is September&#160;&#160;9, 2023&#160;&#160;and the total number of shares of the Company&#8217;s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares.</font></div></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">&#160;</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Options</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The following is a summary of&#160;option activities:</font></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td
 align="left" valign="bottom"
 colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align:
 left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,330,134</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.96</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.91</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom"
 style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom"
 style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">685,800</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Cancellation</font></div></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(49,950</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman';
 font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">2,280,184</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.95</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">8.17</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1,609,035</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at September 30, 2013&#160;was $1,014,474.</font></div><div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block;">&#160;</div><div align="left" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal;
 orphans: auto; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt; font-weight: bold;">Warrants</font></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">The following is a summary of warrant activities:</font></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0pt; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; display: block; margin-left: 0pt; margin-right: 0pt;"><div align="right"><table style="width: 100%; font-family: 'times new roman'; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent:
 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Remaining</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Aggregate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Number of</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Contractual</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Intrinsic</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Term (in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td
 nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div
 align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, December 31, 2012</font></div></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">12,770,636</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0.97</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">4.48</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160; 6,114,768</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Warrants exercised</font></div></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(2,304,910</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size:
 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2"
 style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Warrants expired</font></div></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">(1,023,784</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">)</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">Outstanding, September 30, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,441,942</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">0. 77</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">5.09</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">9,611,403</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font size="2" style="display: inline; font-family: 'times new roman'; font-size: 10pt;">&#160;</font></td></tr></table></div></div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;
 text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="color: #000000; font-family: 'times new roman'; font-size: 13.63636302947998px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-indent: 36pt;
 display: block; margin-left: 0pt; margin-right: 0pt;"><font size="2">During the three months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $95,971, and $72,100, respectively. During the nine months ended September 31, 2013 and 2012, the Company recorded option and warrant expenses of $284,371 and $168,000, respectively.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Going Concern<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernTextBlock', window );">Going Concern</a></td>
        <td class="text"><div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Note 2 &#8211; Going Concern</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As reflected in the accompanying consolidated financial statements, the Company has suffered recurring losses from operations since its inception. The Company has a net loss of $4,893,951 and net cash used in operations of $4,947,969, for the nine months ended September 30, 2013; and a deficit accumulated during the development stage of $60,637,414 at September 30, 2013. In addition, the Company has not completed its efforts to establish a stable recurring source of revenues sufficient to cover its operating costs for the next twelve months. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The ability of the Company to continue its operations is dependent on the successful execution of management's plans, which include the expectation of raising debt or equity based capital, with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements. The Company may need to issue additional equity and incur additional liabilities with related parties to sustain the Company&#8217;s existence although no commitments for funding have been made and no assurance can be made that such commitments will be available.</font></div><div style="text-indent: 0pt; display: block;">&#160;</div><div align="justify" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of assets or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Going Concern assumption.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPQBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UnrecognizedShareBasedCompensationExpense', window );">Unrecognized share based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,014,474<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recorded option expense</a></td>
        <td class="nump">95,971<span></span></td>
        <td class="nump">72,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">284,371<span></span></td>
        <td class="nump">312,500<span></span></td>
        <td class="nump">6,336,407<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">284,371<span></span></td>
        <td class="nump">168,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 284,371<span></span></td>
        <td class="nump">$ 168,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Stock Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep.
				09,
				 2023<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Stock Plan [Member] | Employees Directors and Consultants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Sep.
				09,
				 2023<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2013 Equity Incentive Plan [Member] | Employees Directors and Consultants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EquityTextualAbstract', window );"><strong>Equity (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Common stock available for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">450,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EquityTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EquityTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UnrecognizedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized share based compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UnrecognizedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeBenefitsAndShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date the equity-based award expires, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Aggregate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display:
 inline; font-family: times new roman; font-size:
 10pt;">Contractual</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Intrinsic</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Term (in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="3"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="3"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,330,134</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.96</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.91</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom"
 style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">685,800</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cancellation</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(49,950</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding, September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,280,184</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.95</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8.17</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,609,035</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of option activities</a></td>
        <td class="text"><div style="text-align: left; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;"></font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Weighted</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Remaining</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Aggregate</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Number of</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display:
 inline;">Average</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align:
 left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Contractual</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Intrinsic</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Units</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Exercise Price</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Term (in years)</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td valign="bottom" style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2"><div align="center" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Value</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></td><td align="left" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; </font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Outstanding, December 31, 2012</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">12,770,636 </font></td><td width="1%" nowrap="nowrap" valign="bottom"
 style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%"
 valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">0.97</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">4.48</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160; 6,114,768 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Warrants exercised</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">(2,304,910</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">)</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Warrants expired</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">(1,023,784</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">)</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">1.65</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display:
 inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%"
 valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; display: block;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">Outstanding, September 30, 2013</font></div></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">9,441,942 </font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">0. 77</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">5.09</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td align="left" width="1%" valign="bottom"><font style="font-family: times new roman; font-size: 10pt; display: inline;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="font-family: times new roman; font-size: 10pt; display: inline;">9,611,403</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="font-family: times new roman; font-size: 10pt; display: inline;"></font></td></tr></table></div></div><div align="justify" style="text-indent: 36pt; margin-right: 0pt; margin-left: 0pt; display: block;">&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of set forth assets and liabilities measured at fair value on a recurring and non-recurring basis</a></td>
        <td class="text"><div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div><div align="right"><table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"><tr><td align="left" valign="bottom" style="padding-bottom: 2px;"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 1</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 2</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level 3</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td valign="bottom" style="border-bottom: black 2px solid;" colspan="2"><div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left; padding-bottom: 2px;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr><td align="left" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Derivative liabilities:</font></div></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="left" valign="bottom" colspan="2"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div></td><td nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At September 30, 2013</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size:
 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font
 style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,757,966</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr><tr bgcolor="white"><td align="left" width="52%" valign="bottom"><div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;At December 31, 2012</font></div></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td align="right" width="1%" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">-</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="1%" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td><td width="9%" valign="bottom" style="text-align: right;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,574,958</font></td><td width="1%" nowrap="nowrap" valign="bottom" style="text-align: left;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td></tr></table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Going concern (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">160 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,420,913)<span></span></td>
        <td class="num">$ (3,012,454)<span></span></td>
        <td class="num">$ (4,893,951)<span></span></td>
        <td class="num">$ (5,483,954)<span></span></td>
        <td class="num">$ (60,637,414)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,947,969)<span></span></td>
        <td class="num">(3,795,480)<span></span></td>
        <td class="num">(49,350,627)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="nump">$ 60,637,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,637,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,637,414<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GoingConcernTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GoingConcernTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract', window );"><strong>Summary of forth assets and liabilities measured at fair value on a recurring and non recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump">$ 2,757,966<span></span></td>
        <td class="nump">$ 3,574,958<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringAndNonRecurringBasisAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20225523&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28370219&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 12, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Actinium Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001388320<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,656,582<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZHBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Description of Business and Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="8">9 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>pures</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Options and Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Options and Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Convertible Notes Payable [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Machinery and equipment [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Furniture and fixtures [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 28, 2012

</div>
          <div>Actinium [Member]

</div>
          <div>pures</div>
        </th>
        <th class="th">
          <div>Sep. 25, 2013

</div>
          <div>Actinium [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Description of Business and Summary of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfOwnershipInterestToBeAcquired', window );">Percentage of ownership interest to be acquired by company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="nump">93.70%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition', window );">Common Stock issuable in consideration for equity interest acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Five years<span></span></td>
        <td class="text">Seven years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesExchangeRatio', window );">Shares received by each API shareholder of Actinium common stock for each API share exchanged</a></td>
        <td class="nump">0.333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially issuable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,441,942<span></span></td>
        <td class="nump">5,861,044<span></span></td>
        <td class="nump">2,280,184<span></span></td>
        <td class="nump">1,968,829<span></span></td>
        <td class="nump">13,831,762<span></span></td>
        <td class="nump">1,152,692<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalOfCommonStockShares', window );">Total of common stock shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,970,137<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExchangedInCommonStockShares', window );">Common stock shares exchanged</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,322,055<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock issuable in consideration for equity interest acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockIssuableInConsiderationForEquityInterestAcquisition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExchangedInCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares exchanged.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExchangedInCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfOwnershipInterestToBeAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of ownership interest to be acquired by company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfOwnershipInterestToBeAcquired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesExchangeRatio">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares exchange ratio.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SharesExchangeRatio</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalOfCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of common stock shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalOfCommonStockShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
